# [CL-AcroMetrix] Version string: 2.2.0.12/0.3.2:22-06-07/1.0.0/1.0.0/hg19/T
# [CL-AcroMetrix] Variants included in this table satisfied at least one of the following criteria:
# [CL-AcroMetrix]   - "absent_in_normal": (only applicable when a matched normal sample [MNS] is available) the variant site had non-zero coverage in the MNS and the VAF ratio between the tumor sample and the MNS was >=5.0
# [CL-AcroMetrix]   - "ClinVar_classification": the variant falls into one of the following ClinVar classes: Pathogenic, Likely_Pathogenic
# [CL-AcroMetrix]   - "CPSR_classification": the variant falls into one of the following CPSR classes (based on refined ACMG criteria): Pathogenic, Likely_Pathogenic
# [CL-AcroMetrix] - Required variant class (as determined by the Illumina TSO500 Local App pipeline) - any of:
# [CL-AcroMetrix]   - "SOM": the variant wasn't included in any class based on TSO500 LocalApp filtering, it was therefore deemed to be of somatic origin
# [CL-AcroMetrix]   - "GL_P": the variant didn't pass the AF-based "germline variant proximity" filter, which looks for (5+) known germline variants with similar AFs located on the same chromosome
# [CL-AcroMetrix] - Required variant tier (as determined by the PCGR annotation) - any of:
# [CL-AcroMetrix]   - "TIER_1": variant of strong clinical significance (a PCGR-assigned tier)
# [CL-AcroMetrix]   - "TIER_2": variant of potential clinical significance (a PCGR-assigned tier)
# [CL-AcroMetrix] - Required protein change effect (in any gene transcript overlapping the variant); the format of this inclusion tag is "protein_changes:X", where X is a comma-separated list of variant-associated high-impact coding consequences from the following list:
# [CL-AcroMetrix]   - "frameshift_variant"
# [CL-AcroMetrix]   - "start_lost"
# [CL-AcroMetrix]   - "stop_lost"
# [CL-AcroMetrix]   - "stop_gained"
# [CL-AcroMetrix]   - "splice_acceptor_variant"
# [CL-AcroMetrix]   - "splice_donor_variant"
# [CL-AcroMetrix] - In case of PCGR reporting an "intergenic_variant", protein-coding variant effects reported by LocalApp's Nirvana (except for "synonymous_variant", "stop_retained_variant", "start_retained_variant", "transcript_variant", "coding_sequence_variant" or "intron_variant") will be labeled with the following inclusion tag:
# [CL-AcroMetrix]   - "intergenic_PCGR_coding_Nirvana"
# [CL-AcroMetrix] The "Inclusion_criteria" column lists all the inclusion criteria satisfied by given variant.
# [CL-AcroMetrix] Please note that variants present on InPreD's small variant blacklist are recorded in a separate table despite fulfilling at least one of the listed inclusion criteria.
# [CL-AcroMetrix] The variants might be flagged by any number of the following custom filters, which point to properties potentially relevant during the quality control process:
# [CL-AcroMetrix]   - "normal_origin": the variant was seen only in the MNS (more details below)
# [CL-AcroMetrix]   - "germline_population": the variant was seen in at least one of the 1000 genomes/gnomAD (sub-)populations with allelic frequency >=0.001
# [CL-AcroMetrix]   - "recurrent_germline": according to the variant InPreD recurrence information, the variant was seen with VAFs >= 0.35 in at least 10 % of investigated normal samples (requires at least 20 callable normal samples)
# [CL-AcroMetrix]   - "recurrent_artifact": according to the variant InPreD recurrence information, the variant was seen with VAFs >= [VAF in the processed sample] in at least 10 % of all the investigated tumor samples (based on recurrence table VAF tiers, not exact VAF values; requires at least 20 callable tumor samples)
# [CL-AcroMetrix]   - "LOW_TUMOR_DP": the read depth at the variant site in the tumor sample was <20
# [CL-AcroMetrix]   - "LOW_TUMOR_VAF": the variant allelic fraction in the tumor sample was <0.02
# [CL-AcroMetrix]   - "HIGH_TUMOR_VAF": the variant allelic fraction in the tumor sample was >0.98
# [CL-AcroMetrix]   - "LOW_VAF_RATIO": (only applicable when a MNS is available) the ratio between variant allelic fractions in the tumor sample and the MNS was <5.0
# [CL-AcroMetrix]   - "HET_VAF_RANGE": the variant allelic fraction in the tumor sample was within the range of 0.5 +/-0.15
# [CL-AcroMetrix]   - "NO_NORMAL_COVERAGE": (only applicable when a MNS is available) no coverage data was reported for the variant in the MNS
# [CL-AcroMetrix] The "Filters" column lists all the filters failed by given variant.
# [CL-AcroMetrix] The "Class_judgement" [CJ] and "Class_judgement_comments" [CJC] columns are pre-filled in order the speed up the manual QC process, but their values should always be checked. A variant can be auto-excluded using the following rules:
# [CL-AcroMetrix]   - filters "germline_population", "recurrent_germline", "recurrent_artifact", "LOW_TUMOR_DP" and "LOW_TUMOR_VAF" will serve as exclusion criteria (also, any of these filter values will be copied to the CJC column when encountered);
# [CL-AcroMetrix]     - [exception] if a matched control is available and does not contain given variant, encountered "germline_population" and "recurrent_germline" filters will not be used as exclusion criteria; the CJC column will in that case instead contain value "known_germline_variant_absent_in_matched_control";
# [CL-AcroMetrix]   - "no_recurrence_data" flag in the CJC column is displayed for variants absent in the input variant recurrence table;
# [CL-AcroMetrix]   - if a matched control is available and the "LOW_VAF_RATIO" filter is being applied; the CJC column will include value "variant_in_normal";
# [CL-AcroMetrix]   - if a given variant has exactly the coding status combination of "synonymous_variant"and "splice_region_variant" in the primary transcript while no RNA support has been observed for the variant, the CJC column will include value "synonymous_splice_region_variant_with_no_RNA_coverage".
# [CL-AcroMetrix] CPSR is run on matched normal samples when possible. Variants not 'found' in the DNA tumor sample (e.g., not fulfilling the required variant class criteria for that sample) will still be present in this table as long as they fulfill any of the following inclusion criteria:
# [CL-AcroMetrix]   - "protein_changes:X" (as described above);
# [CL-AcroMetrix]   - "intergenic_PCGR_coding_Nirvana" (as described above);
# [CL-AcroMetrix]   - "ClinVar_classification" (as described above);
# [CL-AcroMetrix]   - "CPSR_classification" (as described above).
# [CL-AcroMetrix] The following filters are applicable to the normal-only variants (in addition, the "normal_origin" filter will always be applied):
# [CL-AcroMetrix]   - "germline_population" (as described above);
# [CL-AcroMetrix]   - "recurrent_germline" (as described above);
# [CL-AcroMetrix]   - "recurrent_artifact" (as described above).
# [CL-AcroMetrix] In case of normal-only variants, all the listed filters also serve as exclusion criteria. Normal-only variants will always be auto-excluded (they should not contribute to the TMB).
# [CL-AcroMetrix] The CJC column comment "synonymous_splice_region_variant_with_no_RNA_coverage" is replaced by comment "synonymous_splice_region_variant_with_unknown_RNA_status" in case of normal-only variants.
# [CL-AcroMetrix] The "Coding_transcript_consequences" field has the following format:
# [CL-AcroMetrix]   - the transcripts are grouped by sets of associated coding variant consequences (e.g., a group of transcripts with "downstream_gene_variant" consequence and a groups of transcripts with "splice_region_variant,synonymous_variant" consequences);
# [CL-AcroMetrix]   - the transcript groups are separated by semicolons and prefixed with a comma-seperated list of the associated consequences;
# [CL-AcroMetrix]   - individual transcript records within each group are separated by the pipe symbol ("|") and contain the following elements separated by colons: a source tag ("R" tag for RefSeq, "E" for Ensembl), gene symbol, the "Canonical" tag where applicable, the transcript ID and the cDNA and protein change codes;
# [CL-AcroMetrix] Size of the target coding region (in millions ot bases): 1.28
# [CL-AcroMetrix] Specified tumor purity (as a fraction between 0 and 1): not specified
# [CL-AcroMetrix] The "TNC" tier corresponds to PCGR-assigned tier "NONCODING".
# [CL-AcroMetrix] The "TNA" tier is assigned to variants seen only in the MNS (these haven't been annotated by PCGR).
# [CL-AcroMetrix] ID of the matched normal DNA sample: NA
# [CL-AcroMetrix] ID of the matched tumor RNA sample: NA
# [CL-AcroMetrix] "Gene_CN" column format: [High_confidence/non-High_confidence]_[Tumor_CN]/[Adjusted_Tumor_CN]_[Normal_CN]
# [CL-AcroMetrix] "Gene_predisposition" column format: [category]_[note]_[associated_tumor_type]
# [CL-AcroMetrix]   - category 1: any age, any tumor type
# [CL-AcroMetrix]   - category 2: any age, associated tumor type only
# [CL-AcroMetrix]   - category 3: age < 30, any tumor type
# [CL-AcroMetrix]   - category 4: age < 30, associated tumor type only
# [CL-AcroMetrix]   - note a: Renal tumours to be excluded.
# [CL-AcroMetrix]   - note b: MUTYH should be included for germline-focussed tumour analysis but reporting and germline follow-up testing should only be performed on detection of two pathogenic variants.
# [CL-AcroMetrix]   - note c: Brain tumours to be excluded.
# [CL-AcroMetrix] "TSO500_recurrence" column format: [tumor_recurrence_summary]|[normal_recurrence_summary]|[any_sample_recurrence_summary]
# [CL-AcroMetrix] The recurrence summary values are written in format "X:A+B+C+D=M/N"
# [CL-AcroMetrix]   - X: sample type, one of "T" = tumor, "N" = normal, "A" = any
# [CL-AcroMetrix]   - A: number of samples of type X, in which given variant was seen with VAF < 0.01
# [CL-AcroMetrix]   - B: number of samples of type X, in which given variant was seen with 0.01 <= VAF < 0.05
# [CL-AcroMetrix]   - C: number of samples of type X, in which given variant was seen with 0.05 <= VAF < 0.35
# [CL-AcroMetrix]   - D: number of samples of type X, in which given variant was seen with 0.35 <= VAF
# [CL-AcroMetrix]   - M: number of samples of type X, in which given variant was seen with any VAF
# [CL-AcroMetrix]   - N: number of investigated samples of type X, in which given variant was callable (i.e., the variant site had coverage >= 20)
# [CL-AcroMetrix] Information regarding genes interrogated by the FoundationOne Liquid CDx assay (F1LCDx targets):
# [CL-AcroMetrix] - retrieved from F1LCDx Technical Specs (document version from July 2021; section "Information Provided as a Professional Service")
# [CL-AcroMetrix] - the following optional elements (separated by a semicolon) might be included in the target information string:
# [CL-AcroMetrix]   - a gene alias not compatible with PCGR (e.g., "aka[FAM123B]");
# [CL-AcroMetrix]   - a list of introns and/or a list of exons (in any order, separated by a comma) investigated at base sensitivity (e.g., "all_exons,introns[7-10]");
# [CL-AcroMetrix]   - a list of introns and/or a list of exons (in any order, separated by a comma) investigated at increased sensitivity - jointly prefixed by "IS:" (e.g., "IS:exons[20-29],introns[18-19]");
# [CL-AcroMetrix]   - other, special tags, as listed in the source document (e.g., "ncRNA" in case of the TERC gene, or "IS:promoter" in case of the TERT gene).
# [CL-AcroMetrix] - E.g., the target information string of BRAF states "all_exons,introns[7-10];IS:exons[11-18]", meaning that introns 7-10 and all exons were investigated at base sensitivity, while exons 11-18 were investigated at increased sensitivity.
Sample_ID	Gene_symbol	Ensembl_transcript_ID	RefSeq_mRNA	Genomic_location	DNA_change	cDNA_change	Exon_number	Protein_change_short	Protein_change	Change_summary	Coding_status	Depth_tumor_DNA	AF_tumor_DNA	Depth_normal_DNA	AF_normal_DNA	Depth_tumor_RNA	AF_tumor_RNA	COSMIC_ID	dbSNP_rs_ID	ClinVar_variation_ID	Global_AF_gnomAD	Global_AF_1KG	NFE_AF_gnomAD	Germline_population_AFs	Mutation_hotspot	TCGA_frequency	ICGC_PCAWG_occurrence	TSO500_recurrence	Putative_driver	Signaling_pathway	Gene_predisposition	Gene_CN	Tier	CPSR_ACMG_class	CPSR_ClinVar_class	TSO500_LocalApp_class	Functional_domain	Drugs	Coding_transcript_consequences	Inclusion_criteria	Filters	F1LCDx_targets	IGV_QC	Run_QC	Class_judgement	Class_judgement_comments	Reporting_judgement	Reporting_judgement_comments
CL-AcroMetrix	BRAF	ENST00000288602	NA	7:140453136	A>T	c.1799T>A	exon15	V600E	Val600Glu	c.1799T>A:exon15:V600E:Val600Glu	missense_variant	778	0.15	NA	NA	NA	NA	COSV56056643|COSV56065204|COSV56080151	rs113488022	13961	4e-06	NA	0.0000000	NA	BRAF|V600|0	Thyroid_Carcinoma:_58.3%_(287/492)|Skin_Cutaneous_Melanoma:_42.9%_(201/468)|Colon_Adenocarcinoma:_12.3%_(49/399)|Cholangiocarcinoma:_2%_(1/51)|Lung_Adenocarcinoma:_1.4%_(8/567)|Glioblastoma_Multiforme:_1%_(4/393)|Kidney_Renal_Papillary_Cell_Carcinoma:_0.7%_(2/281)|Rectum_Adenocarcinoma:_0.7%_(1/137)|Bladder_Urothelial_Carcinoma:_0.2%_(1/412)|Head_and_Neck_Squamous_Cell_Carcinoma:_0.2%_(1/508)|Brain_Lower_Grade_Glioma:_0.2%_(1/509)	MALY-DE/Primary/1/100/0.01|MELA-AU/Metastatic/16/60/0.2667|PBCA-DE/Primary/3/230/0.013	T:7+0+15+12=34/463|N:5+0+0+0=5/104|A:12+0+15+12=39/567	BRAF:p.V600E:ENST00000288602:CTAT_POPULATION|CTAT_CANCER|3D_STRUCTURE	RTKRAS	NA	[HC]_1.804/1.608_NA	TIER_2	Likely_Pathogenic	Pathogenic	SOM	Protein_tyrosine_and_serine/threonine_kinase	Sorafenib_Tosylate|Vemurafenib|Sorafenib|Regorafenib|Regorafenib_Hydrate|Dabrafenib|Dabrafenib_Mesylate|Encorafenib	missense_variant:R:BRAF:XP_005250104.1:p.(Val600Glu)|E:BRAF:ENSP00000419060.1:p.(Val208Glu)|R:BRAF:XP_005250103.1:p.(Val600Glu)|R:BRAF:XP_005250102.1:p.(Val600Glu)|R:BRAF:Canonical:NP_004324.2:p.(Val600Glu)|E:BRAF:Canonical:ENSP00000288602.6:p.(Val600Glu)	CPSR_classification|ClinVar_classification|tier|class	NA	all_exons,introns[7-10];IS:exons[11-18]	.	.	include	.	.	.
CL-AcroMetrix	BRAF	ENST00000288602	NA	7:140453154	T>C	c.1781A>G	exon15	D594G	Asp594Gly	c.1781A>G:exon15:D594G:Asp594Gly	missense_variant	667	0.115	NA	NA	NA	NA	COSV56065695|COSV56224199|COSV56283955	rs121913338	13972	NA	NA	NA	NA	BRAF|D594|9.79e-70	Adrenocortical_Carcinoma:_1.1%_(1/92)|Brain_Lower_Grade_Glioma:_0.2%_(1/509)	PACA-CA/Primary/1/140/0.0071	T:14+1+0+1=16/463|N:3+0+0+0=3/104|A:17+1+0+1=19/567	BRAF:p.D594G:ENST00000288602:CTAT_POPULATION|CTAT_CANCER|3D_STRUCTURE	RTKRAS	NA	[HC]_1.804/1.608_NA	TIER_2	Likely_Pathogenic	VUS	SOM	Protein_tyrosine_and_serine/threonine_kinase	Sorafenib_Tosylate|Vemurafenib|Sorafenib|Regorafenib|Regorafenib_Hydrate|Dabrafenib|Dabrafenib_Mesylate|Encorafenib	missense_variant:R:BRAF:XP_005250104.1:p.(Asp594Gly)|E:BRAF:ENSP00000419060.1:p.(Asp202Gly)|R:BRAF:XP_005250103.1:p.(Asp594Gly)|R:BRAF:XP_005250102.1:p.(Asp594Gly)|R:BRAF:Canonical:NP_004324.2:p.(Asp594Gly)|E:BRAF:Canonical:ENSP00000288602.6:p.(Asp594Gly)	CPSR_classification|tier|class	NA	all_exons,introns[7-10];IS:exons[11-18]	.	.	include	.	.	.
CL-AcroMetrix	CTNNB1	ENST00000349496	NM_001904|NM_001098209	3:41266101	C>G	c.98C>G	exon3	S33C	Ser33Cys	c.98C>G:exon3:S33C:Ser33Cys	missense_variant	1062	0.043	NA	NA	NA	NA	COSV62687839|COSV62688300|COSV62688644	rs121913400	376231	NA	NA	NA	NA	CTNNB1|S33|1.3e-144	Uterine_Corpus_Endometrial_Carcinoma:_1.7%_(9/530)|Liver_Hepatocellular_Carcinoma:_1.4%_(5/364)|Prostate_Adenocarcinoma:_0.2%_(1/496)	GACA-CN/Primary/1/32/0.0312|LICA-FR/Primary/1/5/0.2|LINC-JP/Primary/1/28/0.0357|LIRI-JP/Primary/3/250/0.012|PBCA-DE/Primary/1/230/0.0043	T:4+0+1+0=5/463|N:0+0+0+0=0/104|A:4+0+1+0=5/567	NA	WNT	NA	[non-HC]_2.002/2.004_NA	TIER_2	Likely_Pathogenic	Likely_Pathogenic	SOM	NA	NA	missense_variant:E:CTNNB1:ENSP00000400508.1:p.(Ser26Cys)|E:CTNNB1:Canonical:ENSP00000385604.1:p.(Ser33Cys)|R:CTNNB1:XP_005264944.1:p.(Ser33Cys)|E:CTNNB1:ENSP00000412219.1:p.(Ser33Cys)|R:CTNNB1:NP_001317658.1:p.(Ser26Cys)|E:CTNNB1:ENSP00000379486.3:p.(Ser33Cys)|E:CTNNB1:ENSP00000344456.5:p.(Ser33Cys)|E:CTNNB1:ENSP00000411226.1:p.(Ser26Cys)|R:CTNNB1:Canonical:NP_001895.1:p.(Ser33Cys)|R:CTNNB1:NP_001091680.1:p.(Ser33Cys)|R:CTNNB1:NP_001091679.1:p.(Ser33Cys)|E:CTNNB1:ENSP00000379488.3:p.(Ser33Cys)|R:CTNNB1:XP_005264945.1:p.(Ser33Cys)|E:CTNNB1:ENSP00000409302.1:p.(Ser33Cys)|R:CTNNB1:XP_005264943.1:p.(Ser33Cys)|E:CTNNB1:ENSP00000401599.1:p.(Ser33Cys);downstream_gene_variant:E:CTNNB1:ENST00000433400.1	CPSR_classification|ClinVar_classification|tier|class	NA	all_exons;IS:exons[3]	.	.	include	.	.	.
CL-AcroMetrix	CTNNB1	ENST00000349496	NM_001904|NM_001098209	3:41266113	C>T	c.110C>T	exon3	S37F	Ser37Phe	c.110C>T:exon3:S37F:Ser37Phe	missense_variant	1077	0.042	NA	NA	NA	NA	COSV62687856|COSV62688281|COSV62689256	rs121913403	17586	NA	NA	NA	NA	CTNNB1|S37|2.59e-157	Uterine_Corpus_Endometrial_Carcinoma:_2.1%_(11/530)|Lung_Adenocarcinoma:_0.9%_(5/567)|Esophageal_Carcinoma:_0.5%_(1/184)|Liver_Hepatocellular_Carcinoma:_0.5%_(2/364)|Stomach_Adenocarcinoma:_0.5%_(2/437)|Skin_Cutaneous_Melanoma:_0.4%_(2/468)|Bladder_Urothelial_Carcinoma:_0.2%_(1/412)	ESAD-UK/Primary/1/97/0.0103|LINC-JP/Primary/1/28/0.0357|LIRI-JP/Primary/2/250/0.008	T:37+1+1+0=39/463|N:2+0+0+0=2/104|A:39+1+1+0=41/567	NA	WNT	NA	[non-HC]_2.002/2.004_NA	TIER_2	Likely_Pathogenic	Likely_Pathogenic	SOM	NA	NA	missense_variant:E:CTNNB1:ENSP00000400508.1:p.(Ser30Phe)|E:CTNNB1:Canonical:ENSP00000385604.1:p.(Ser37Phe)|R:CTNNB1:XP_005264944.1:p.(Ser37Phe)|E:CTNNB1:ENSP00000412219.1:p.(Ser37Phe)|R:CTNNB1:NP_001317658.1:p.(Ser30Phe)|E:CTNNB1:ENSP00000379486.3:p.(Ser37Phe)|E:CTNNB1:ENSP00000344456.5:p.(Ser37Phe)|E:CTNNB1:ENSP00000411226.1:p.(Ser30Phe)|R:CTNNB1:Canonical:NP_001895.1:p.(Ser37Phe)|R:CTNNB1:NP_001091680.1:p.(Ser37Phe)|R:CTNNB1:NP_001091679.1:p.(Ser37Phe)|E:CTNNB1:ENSP00000379488.3:p.(Ser37Phe)|R:CTNNB1:XP_005264945.1:p.(Ser37Phe)|E:CTNNB1:ENSP00000409302.1:p.(Ser37Phe)|R:CTNNB1:XP_005264943.1:p.(Ser37Phe)|E:CTNNB1:ENSP00000401599.1:p.(Ser37Phe);downstream_gene_variant:E:CTNNB1:ENST00000433400.1	CPSR_classification|ClinVar_classification|tier|class	NA	all_exons;IS:exons[3]	.	.	include	.	.	.
CL-AcroMetrix	CTNNB1	ENST00000349496	NM_001904|NM_001098209	3:41266124	A>G	c.121A>G	exon3	T41A	Thr41Ala	c.121A>G:exon3:T41A:Thr41Ala	missense_variant	1097	0.039	NA	NA	NA	NA	COSV62687862|COSV62689580|COSV62714770	rs121913412	17580	NA	NA	NA	NA	CTNNB1|T41|1.16e-135	Adrenocortical_Carcinoma:_1.1%_(1/92)|Liver_Hepatocellular_Carcinoma:_1.1%_(4/364)|Colon_Adenocarcinoma:_1%_(4/399)|Uterine_Corpus_Endometrial_Carcinoma:_0.9%_(5/530)|Pancreatic_Adenocarcinoma:_0.6%_(1/180)|Cervical_Squamous_Cell_Carcinoma_and_Endocervical_Adenocarcinoma:_0.3%_(1/289)|Bladder_Urothelial_Carcinoma:_0.2%_(1/412)|Lung_Adenocarcinoma:_0.2%_(1/567)|Prostate_Adenocarcinoma:_0.2%_(1/496)|Skin_Cutaneous_Melanoma:_0.2%_(1/468)	LINC-JP/Primary/2/28/0.0714|LIRI-JP/Primary/9/250/0.036|PRAD-CA/Primary/1/110/0.0091	T:6+0+1+0=7/463|N:2+0+0+0=2/104|A:8+0+1+0=9/567	CTNNB1:p.T41A:ENST00000405570&ENST00000431914&ENST00000396183&ENST00000349496&ENST00000396185&ENST00000450969&ENST00000441708:CTAT_POPULATION|CTAT_CANCER	WNT	NA	[non-HC]_2.002/2.004_NA	TIER_2	Likely_Pathogenic	VUS	SOM	NA	NA	missense_variant:E:CTNNB1:ENSP00000400508.1:p.(Thr34Ala)|E:CTNNB1:Canonical:ENSP00000385604.1:p.(Thr41Ala)|R:CTNNB1:XP_005264944.1:p.(Thr41Ala)|E:CTNNB1:ENSP00000412219.1:p.(Thr41Ala)|R:CTNNB1:NP_001317658.1:p.(Thr34Ala)|E:CTNNB1:ENSP00000379486.3:p.(Thr41Ala)|E:CTNNB1:ENSP00000344456.5:p.(Thr41Ala)|E:CTNNB1:ENSP00000411226.1:p.(Thr34Ala)|R:CTNNB1:Canonical:NP_001895.1:p.(Thr41Ala)|R:CTNNB1:NP_001091680.1:p.(Thr41Ala)|R:CTNNB1:NP_001091679.1:p.(Thr41Ala)|E:CTNNB1:ENSP00000379488.3:p.(Thr41Ala)|R:CTNNB1:XP_005264945.1:p.(Thr41Ala)|E:CTNNB1:ENSP00000409302.1:p.(Thr41Ala)|R:CTNNB1:XP_005264943.1:p.(Thr41Ala)|E:CTNNB1:ENSP00000401599.1:p.(Thr41Ala);downstream_gene_variant:E:CTNNB1:ENST00000433400.1	CPSR_classification|tier|class	NA	all_exons;IS:exons[3]	.	.	include	.	.	.
CL-AcroMetrix	CTNNB1	ENST00000349496	NM_001904|NM_001098209	3:41266137	C>T	c.134C>T	exon3	S45F	Ser45Phe	c.134C>T:exon3:S45F:Ser45Phe	missense_variant	1106	0.047	NA	NA	NA	NA	COSV62687872|COSV62688307|COSV62689938|COSV62711475	rs121913409	17588	NA	NA	NA	NA	CTNNB1|S45|2.67e-111	Adrenocortical_Carcinoma:_1.1%_(1/92)|Liver_Hepatocellular_Carcinoma:_1.1%_(4/364)|Colon_Adenocarcinoma:_0.8%_(3/399)|Skin_Cutaneous_Melanoma:_0.4%_(2/468)|Uterine_Corpus_Endometrial_Carcinoma:_0.4%_(2/530)|Bladder_Urothelial_Carcinoma:_0.2%_(1/412)|Lung_Adenocarcinoma:_0.2%_(1/567)	LICA-FR/Primary/1/5/0.2|LIRI-JP/Primary/3/250/0.012|PACA-CA/Primary/1/140/0.0071	T:39+1+1+1=42/463|N:1+0+0+0=1/104|A:40+1+1+1=43/567	CTNNB1:p.S45F:ENST00000405570&ENST00000431914&ENST00000396183&ENST00000349496&ENST00000396185&ENST00000450969&ENST00000441708:CTAT_POPULATION|CTAT_CANCER	WNT	NA	[non-HC]_2.002/2.004_NA	TIER_2	Likely_Pathogenic	Likely_Pathogenic	SOM	NA	NA	missense_variant:E:CTNNB1:ENSP00000400508.1:p.(Ser38Phe)|E:CTNNB1:Canonical:ENSP00000385604.1:p.(Ser45Phe)|R:CTNNB1:XP_005264944.1:p.(Ser45Phe)|E:CTNNB1:ENSP00000412219.1:p.(Ser45Phe)|R:CTNNB1:NP_001317658.1:p.(Ser38Phe)|E:CTNNB1:ENSP00000379486.3:p.(Ser45Phe)|E:CTNNB1:ENSP00000344456.5:p.(Ser45Phe)|E:CTNNB1:ENSP00000411226.1:p.(Ser38Phe)|R:CTNNB1:Canonical:NP_001895.1:p.(Ser45Phe)|R:CTNNB1:NP_001091680.1:p.(Ser45Phe)|R:CTNNB1:NP_001091679.1:p.(Ser45Phe)|E:CTNNB1:ENSP00000379488.3:p.(Ser45Phe)|R:CTNNB1:XP_005264945.1:p.(Ser45Phe)|E:CTNNB1:ENSP00000409302.1:p.(Ser45Phe)|R:CTNNB1:XP_005264943.1:p.(Ser45Phe)|E:CTNNB1:ENSP00000401599.1:p.(Ser45Phe);downstream_gene_variant:E:CTNNB1:ENST00000433400.1	CPSR_classification|ClinVar_classification|tier|class	NA	all_exons;IS:exons[3]	.	.	include	.	.	.
CL-AcroMetrix	EGFR	ENST00000275493	NM_005228|NM_001346900	7:55241708	G>C	c.2156G>C	exon18	G719A	Gly719Ala	c.2156G>C:exon18:G719A:Gly719Ala	missense_variant	1160	0.194	NA	NA	NA	NA	COSV51769339|COSV51771914|COSV51779524	rs121913428	45225	NA	NA	NA	NA	EGFR|G719|1.16e-45	Lung_Adenocarcinoma:_0.4%_(2/567)	NA	T:10+1+0+0=11/463|N:0+0+0+0=0/104|A:10+1+0+0=11/567	EGFR:p.G719A:ENST00000275493:CTAT_CANCER|3D_STRUCTURE	RTKRAS	NA	[HC]_1.916/1.832_NA	TIER_2	Likely_Pathogenic	Pathogenic	SOM	Protein_tyrosine_and_serine/threonine_kinase	Afatinib|Lapatinib_Ditosylate|Cetuximab|Panitumumab|Necitumumab|Neratinib|Icotinib|Afatinib_Dimaleate|Zalutumumab|Nimotuzumab|Dacomitinib|Vandetanib|Osimertinib|Pyrotinib|Tesevatinib|Rociletinib|Brigatinib|Naquotinib|EGFR/FLT3/Abl_Inhibitor_SKLB1028|Depatuxizumab_Mafodotin|Neratinib_Maleate|Amivantamab|Abivertinib|Abivertinib_Maleate|Avitinib_Maleate|Lazertinib|Aumolertinib|Mobocertinib|Erlotinib|Lapatinib|Gefitinib	downstream_gene_variant:R:EGFR:XM_005271748.1|R:EGFR:NM_201284.1|E:EGFR:ENST00000344576.2;missense_variant:R:EGFR:XP_005271803.1:p.(Gly674Ala)|E:EGFR:ENSP00000415559.1:p.(Gly674Ala)|R:EGFR:NP_001333826.1:p.(Gly674Ala)|R:EGFR:NP_001333827.1:p.(Gly719Ala)|R:EGFR:NP_001333870.1:p.(Gly452Ala)|R:EGFR:Canonical:NP_005219.2:p.(Gly719Ala)|R:EGFR:NP_001333828.1:p.(Gly674Ala)|R:EGFR:NP_005219.2:p.(Gly719Ala)|E:EGFR:Canonical:ENSP00000275493.2:p.(Gly719Ala)|R:EGFR:XP_005271804.1:p.(Gly666Ala)|R:EGFR:NP_001333829.1:p.(Gly666Ala)|E:EGFR:ENSP00000395243.2:p.(Gly666Ala)	CPSR_classification|ClinVar_classification|tier|class	NA	introns[15];IS:introns[7,24-27],all_exons	.	.	include	.	.	.
CL-AcroMetrix	EGFR	ENST00000275493	NM_005228|NM_001346900	7:55259515	T>G	c.2573T>G	exon21	L858R	Leu858Arg	c.2573T>G:exon21:L858R:Leu858Arg	missense_variant	1351	0.138	NA	NA	NA	NA	COSV51765161|COSV51854030	rs121434568	16609	NA	NA	NA	NA	EGFR|L858|0	Lung_Adenocarcinoma:_3.7%_(21/567)	NA	T:2+0+0+0=2/463|N:1+0+0+0=1/104|A:3+0+0+0=3/567	EGFR:p.L858R:ENST00000275493:CTAT_POPULATION|CTAT_CANCER|3D_STRUCTURE	RTKRAS	NA	[HC]_1.916/1.832_NA	TIER_2	Likely_Pathogenic	VUS	SOM	Protein_tyrosine_and_serine/threonine_kinase	Afatinib|Lapatinib_Ditosylate|Cetuximab|Panitumumab|Necitumumab|Neratinib|Icotinib|Afatinib_Dimaleate|Zalutumumab|Nimotuzumab|Dacomitinib|Vandetanib|Osimertinib|Pyrotinib|Tesevatinib|Rociletinib|Brigatinib|Naquotinib|EGFR/FLT3/Abl_Inhibitor_SKLB1028|Depatuxizumab_Mafodotin|Neratinib_Maleate|Amivantamab|Abivertinib|Abivertinib_Maleate|Avitinib_Maleate|Lazertinib|Aumolertinib|Mobocertinib|Erlotinib|Lapatinib|Gefitinib	missense_variant:R:EGFR:XP_005271803.1:p.(Leu813Arg)|E:EGFR:ENSP00000415559.1:p.(Leu813Arg)|R:EGFR:NP_001333826.1:p.(Leu813Arg)|R:EGFR:NP_001333827.1:p.(Leu858Arg)|R:EGFR:NP_001333870.1:p.(Leu591Arg)|R:EGFR:Canonical:NP_005219.2:p.(Leu858Arg)|R:EGFR:NP_001333828.1:p.(Leu813Arg)|R:EGFR:NP_005219.2:p.(Leu858Arg)|E:EGFR:Canonical:ENSP00000275493.2:p.(Leu858Arg)|R:EGFR:XP_005271804.1:p.(Leu805Arg)|R:EGFR:NP_001333829.1:p.(Leu805Arg)|E:EGFR:ENSP00000395243.2:p.(Leu805Arg)	CPSR_classification|tier|class	NA	introns[15];IS:introns[7,24-27],all_exons	.	.	include	.	.	.
CL-AcroMetrix	EGFR	ENST00000275493	NM_005228|NM_001346900	7:55259524	T>A	c.2582T>A	exon21	L861Q	Leu861Gln	c.2582T>A:exon21:L861Q:Leu861Gln	missense_variant	1365	0.133	NA	NA	NA	NA	COSV51766344|COSV51766618	rs121913444	163380	NA	NA	NA	NA	EGFR|L861|7.9e-32	Lung_Adenocarcinoma:_0.4%_(2/567)|Lung_Squamous_Cell_Carcinoma:_0.4%_(2/492)|Glioblastoma_Multiforme:_0.3%_(1/393)	NA	T:11+0+2+0=13/463|N:3+0+0+0=3/104|A:14+0+2+0=16/567	EGFR:p.L861Q:ENST00000275493:CTAT_POPULATION|CTAT_CANCER|3D_STRUCTURE	RTKRAS	NA	[HC]_1.916/1.832_NA	TIER_2	Likely_Pathogenic	Likely_Pathogenic	SOM	Protein_tyrosine_and_serine/threonine_kinase	Afatinib|Lapatinib_Ditosylate|Cetuximab|Panitumumab|Necitumumab|Neratinib|Icotinib|Afatinib_Dimaleate|Zalutumumab|Nimotuzumab|Dacomitinib|Vandetanib|Osimertinib|Pyrotinib|Tesevatinib|Rociletinib|Brigatinib|Naquotinib|EGFR/FLT3/Abl_Inhibitor_SKLB1028|Depatuxizumab_Mafodotin|Neratinib_Maleate|Amivantamab|Abivertinib|Abivertinib_Maleate|Avitinib_Maleate|Lazertinib|Aumolertinib|Mobocertinib|Erlotinib|Lapatinib|Gefitinib	missense_variant:R:EGFR:XP_005271803.1:p.(Leu816Gln)|E:EGFR:ENSP00000415559.1:p.(Leu816Gln)|R:EGFR:NP_001333826.1:p.(Leu816Gln)|R:EGFR:NP_001333827.1:p.(Leu861Gln)|R:EGFR:NP_001333870.1:p.(Leu594Gln)|R:EGFR:Canonical:NP_005219.2:p.(Leu861Gln)|R:EGFR:NP_001333828.1:p.(Leu816Gln)|R:EGFR:NP_005219.2:p.(Leu861Gln)|E:EGFR:Canonical:ENSP00000275493.2:p.(Leu861Gln)|R:EGFR:XP_005271804.1:p.(Leu808Gln)|R:EGFR:NP_001333829.1:p.(Leu808Gln)|E:EGFR:ENSP00000395243.2:p.(Leu808Gln)	CPSR_classification|ClinVar_classification|tier|class	NA	introns[15];IS:introns[7,24-27],all_exons	.	.	include	.	.	.
CL-AcroMetrix	EZH2	ENST00000320356	NM_004456	7:148508727	T>A	c.1937A>T	exon16	Y646F	Tyr646Phe	c.1937A>T:exon16:Y646F:Tyr646Phe	missense_variant	1057	0.193	NA	NA	NA	NA	COSV57445929|COSV57446008|COSV57446054	rs267601394	76768	NA	NA	NA	NA	EZH2|Y646|6.87e-69	Skin_Cutaneous_Melanoma:_0.2%_(1/468)	MALY-DE/Primary/4/100/0.04	T:6+0+0+0=6/463|N:3+0+0+0=3/104|A:9+0+0+0=9/567	NA	NA	NA	[non-HC]_2.096/2.192_NA	TIER_2	Likely_Pathogenic	Likely_Pathogenic	SOM	SET_domain	Tazemetostat|Tazemetostat_Hydrobromide	missense_variant:R:EZH2:NP_001190178.1:p.(Tyr590Phe)|R:EZH2:NP_001190176.1:p.(Tyr641Phe)|R:EZH2:NP_694543.1:p.(Tyr602Phe)|R:EZH2:NP_001190177.1:p.(Tyr632Phe)|R:EZH2:Canonical:NP_004447.2:p.(Tyr646Phe)|R:EZH2:XP_005250021.1:p.(Tyr598Phe)|R:EZH2:XP_005250020.1:p.(Tyr640Phe)|R:EZH2:XP_005250019.1:p.(Tyr649Phe)|E:EZH2:ENSP00000417062.1:p.(Tyr590Phe)|E:EZH2:ENSP00000419711.1:p.(Tyr641Phe)|E:EZH2:ENSP00000223193.2:p.(Tyr602Phe)|E:EZH2:Canonical:ENSP00000320147.2:p.(Tyr646Phe)|E:EZH2:ENSP00000443219.1:p.(Tyr590Phe)|E:EZH2:ENSP00000419050.1:p.(Tyr590Phe)|E:EZH2:ENSP00000419856.1:p.(Tyr632Phe)	CPSR_classification|ClinVar_classification|tier|class	NA	all_exons;IS:exons[4,16-18]	.	.	include	.	.	.
CL-AcroMetrix	FLT3	ENST00000241453	NM_004119	13:28592642	C>A	c.2503G>T	exon20	D835Y	Asp835Tyr	c.2503G>T:exon20:D835Y:Asp835Tyr	missense_variant	1086	0.04	NA	NA	NA	NA	COSV54042116|COSV54042636|COSV54045151	rs121913488	16276	NA	NA	NA	NA	FLT3|D835|1.03e-41	Acute_Myeloid_Leukemia:_4.9%_(7/144)	NA	T:24+1+0+0=25/463|N:4+0+0+0=4/104|A:28+1+0+0=29/567	FLT3:p.D835Y:ENST00000241453&ENST00000380982:CTAT_CANCER|3D_STRUCTURE	RTKRAS	NA	[non-HC]_2.368/2.736_NA	TIER_2	Likely_Pathogenic	Pathogenic	SOM	Protein_tyrosine_and_serine/threonine_kinase	Sorafenib_Tosylate|Fedratinib|Sorafenib|Crenolanib|Linifanib|Gilteritinib_Fumarate|Gilteritinib|Famitinib|EGFR/FLT3/Abl_Inhibitor_SKLB1028|Pexidartinib|Pexidartinib_Hydrochloride|Dovitinib|Sunitinib_Malate|Quizartinib|Midostaurin	missense_variant:E:FLT3:ENSP00000241453.7:p.(Asp835Tyr)|R:FLT3:Canonical:NP_004110.2:p.(Asp835Tyr)|R:FLT3:XP_005266375.1:p.(Asp835Tyr)|E:FLT3:Canonical:ENSP00000370369.4:p.(Asp835Tyr)	CPSR_classification|ClinVar_classification|tier|class	NA	all_exons;IS:exons[14-15,20]	.	.	include	.	.	.
CL-AcroMetrix	FOXL2	ENST00000330315	NA	3:138665163	G>C	c.402C>G	exon1	C134W	Cys134Trp	c.402C>G:exon1:C134W:Cys134Trp	missense_variant	1072	0.068	NA	NA	NA	NA	COSV57725321|COSV57730318	rs1057519865	376348	NA	NA	NA	NA	FOXL2|C134|4.38e-31	NA	NA	T:7+0+1+0=8/463|N:0+0+0+0=0/104|A:7+0+1+0=8/567	NA	NA	NA	[non-HC]_1.61/1.22_NA	TIER_2	NA	NA	SOM	Forkhead_domain	NA	missense_variant:E:FOXL2:Canonical:ENSP00000333188.3:p.(Cys134Trp)|R:FOXL2:Canonical:NP_075555.1:p.(Cys134Trp);upstream_gene_variant:E:FOXL2NB:Canonical:ENST00000383165.3|R:FOXL2NB:Canonical:NM_001040061.2|R:FOXL2NB:XM_005247443.1	tier|class	NA	IS:all_exons	.	.	include	.	.	.
CL-AcroMetrix	IDH2	ENST00000330062	NM_002168	15:90631838	C>T	c.515G>A	exon4	R172K	Arg172Lys	c.515G>A:exon4:R172K:Arg172Lys	missense_variant	1083	0.054	NA	NA	NA	NA	COSV57468734|COSV57468971|COSV57472976	rs121913503	375987	NA	NA	NA	NA	IDH2|R172|1.2e-117	Brain_Lower_Grade_Glioma:_2.4%_(12/509)|Cholangiocarcinoma:_2%_(1/51)|Acute_Myeloid_Leukemia:_1.4%_(2/144)|Liver_Hepatocellular_Carcinoma:_0.3%_(1/364)	NA	T:40+0+0+0=40/462|N:2+0+0+0=2/104|A:42+0+0+0=42/566	IDH2:p.R172K:ENST00000330062:CTAT_POPULATION|CTAT_CANCER|3D_STRUCTURE	NA	NA	[non-HC]_2.102/2.204_NA	TIER_2	NA	NA	SOM	Isocitrate/isopropylmalate_dehydrogenase	Enasidenib|Enasidenib_Mesylate|Vorasidenib	missense_variant:E:IDH2:Canonical:ENSP00000331897.3:p.(Arg172Lys)|R:IDH2:XP_005254950.1:p.(Arg120Lys)|R:IDH2:XP_005254951.1:p.(Arg42Lys)|R:IDH2:NP_001276839.1:p.(Arg120Lys)|R:IDH2:NP_002159.2:p.(Arg172Lys)|R:IDH2:Canonical:NP_002159.2:p.(Arg172Lys)|R:IDH2:NP_001277043.1:p.(Arg42Lys)|E:IDH2:ENSP00000438457.1:p.(Arg42Lys)|E:IDH2:ENSP00000446147.2:p.(Arg120Lys)	tier|class	NA	all_exons;IS:exons[4]	.	.	include	.	.	.
CL-AcroMetrix	IDH2	ENST00000330062	NM_002168	15:90631934	C>T	c.419G>A	exon4	R140Q	Arg140Gln	c.419G>A:exon4:R140Q:Arg140Gln	missense_variant	1182	0.059	NA	NA	NA	NA	COSV57468751|COSV57469541	rs121913502	14716	3.18e-05	NA	0.0000527	NA	IDH2|R140|1.58e-48	Acute_Myeloid_Leukemia:_6.2%_(9/144)|Head_and_Neck_Squamous_Cell_Carcinoma:_0.2%_(1/508)	CMDI-UK/Primary/2/30/0.0667	T:153+1+0+0=154/463|N:5+0+0+0=5/104|A:158+1+0+0=159/567	IDH2:p.R140Q:ENST00000330062:CTAT_POPULATION|CTAT_CANCER|3D_STRUCTURE	NA	NA	[non-HC]_2.102/2.204_NA	TIER_2	NA	NA	SOM	Isocitrate/isopropylmalate_dehydrogenase	Enasidenib|Enasidenib_Mesylate|Vorasidenib	missense_variant:E:IDH2:Canonical:ENSP00000331897.3:p.(Arg140Gln)|R:IDH2:XP_005254950.1:p.(Arg88Gln)|R:IDH2:XP_005254951.1:p.(Arg10Gln)|R:IDH2:NP_001276839.1:p.(Arg88Gln)|R:IDH2:NP_002159.2:p.(Arg140Gln)|R:IDH2:Canonical:NP_002159.2:p.(Arg140Gln)|R:IDH2:NP_001277043.1:p.(Arg10Gln)|E:IDH2:ENSP00000438457.1:p.(Arg10Gln)|E:IDH2:ENSP00000446147.2:p.(Arg88Gln)	tier|class	NA	all_exons;IS:exons[4]	.	.	include	variant_in_more_than_10%_of_tumor_samples_(33.05%)_with_VAF_under_0.01	.	.
CL-AcroMetrix	KIT	ENST00000288135	NM_000222	4:55594258	T>C	c.1961T>C	exon13	V654A	Val654Ala	c.1961T>C:exon13:V654A:Val654Ala	missense_variant	1054	0.076	NA	NA	NA	NA	COSV55389496	rs121913523	375921	NA	NA	NA	NA	KIT|V654|6.35e-16	NA	NA	T:8+0+1+0=9/463|N:2+0+0+0=2/104|A:10+0+1+0=11/567	NA	RTKRAS	NA	[HC]_2.044/2.088_NA	TIER_2	Likely_Pathogenic	VUS	SOM	Protein_tyrosine_and_serine/threonine_kinase	Vatalanib|Sorafenib_Tosylate|Pazopanib_Hydrochloride|Sorafenib|Dasatinib|Masitinib|Regorafenib|Regorafenib_Hydrate|Semaxanib|Anlotinib|Famitinib|Pexidartinib|Sitravatinib|Pexidartinib_Hydrochloride|Avapritinib|Ripretinib|Pazopanib|Cediranib|Dovitinib|Sunitinib_Malate|Motesanib|Quizartinib|Midostaurin|Imatinib	missense_variant:E:KIT:ENSP00000390987.2:p.(Val650Ala)|E:KIT:Canonical:ENSP00000288135.5:p.(Val654Ala)|R:KIT:NP_001087241.1:p.(Val650Ala)|R:KIT:Canonical:NP_000213.1:p.(Val654Ala)|R:KIT:XP_005265799.1:p.(Val651Ala)|R:KIT:XP_005265797.1:p.(Val655Ala)|R:KIT:XP_005265798.1:p.(Val655Ala)	CPSR_classification|tier|class	NA	all_exons;IS:introns[16],exons[8-9,11-13,17]	.	.	include	.	.	.
CL-AcroMetrix	KRAS	ENST00000256078	NM_001369786|NM_033360	12:25398284	C>T	c.35G>A	exon2	G12D	Gly12Asp	c.35G>A:exon2:G12D:Gly12Asp	missense_variant	851	0.069	NA	NA	NA	NA	COSV55497369|COSV55497419|COSV55497479	rs121913529	12582	4e-06	NA	0.0000089	NA	KRAS|G12|0	Pancreatic_Adenocarcinoma:_26.1%_(47/180)|Colon_Adenocarcinoma:_12.3%_(49/399)|Rectum_Adenocarcinoma:_8%_(11/137)|Uterine_Corpus_Endometrial_Carcinoma:_6%_(32/530)|Uterine_Carcinosarcoma:_3.5%_(2/57)|Lung_Adenocarcinoma:_3.2%_(18/567)|Stomach_Adenocarcinoma:_2.3%_(10/437)|Bladder_Urothelial_Carcinoma:_1.5%_(6/412)|Cervical_Squamous_Cell_Carcinoma_and_Endocervical_Adenocarcinoma:_1.4%_(4/289)|Esophageal_Carcinoma:_1.1%_(2/184)|Kidney_Renal_Papillary_Cell_Carcinoma:_1.1%_(3/281)|Thymoma:_0.8%_(1/123)|Acute_Myeloid_Leukemia:_0.7%_(1/144)|Glioblastoma_Multiforme:_0.5%_(2/393)|Liver_Hepatocellular_Carcinoma:_0.5%_(2/364)|Skin_Cutaneous_Melanoma:_0.4%_(2/468)|Prostate_Adenocarcinoma:_0.2%_(1/496)|Breast_Invasive_Carcinoma:_0.1%_(1/986)	BTCA-SG/Primary/1/12/0.0833|ESAD-UK/Primary/2/97/0.0206|ORCA-IN/Primary/1/13/0.0769|PACA-AU/Primary/32/90/0.3556|PACA-CA/Primary/44/140/0.3143	T:43+2+4+2=51/463|N:2+0+0+0=2/104|A:45+2+4+2=53/567	KRAS:p.G12D:ENST00000311936&ENST00000557334&ENST00000256078&ENST00000556131:CTAT_CANCER|3D_STRUCTURE	RTKRAS	NA	[HC]_1.89/1.78_NA	TIER_2	Pathogenic	Pathogenic	SOM	Ras_family	Adagrasib	missense_variant:E:KRAS:ENSP00000308495.3:p.(Gly12Asp)|R:KRAS:Canonical:NP_203524.1:p.(Gly12Asp)|R:KRAS:NP_004976.2:p.(Gly12Asp)|R:KRAS:NP_203524.1:p.(Gly12Asp)|R:KRAS:NP_004976.2:p.(Gly12Asp)|E:KRAS:ENSP00000452512.1:p.(Gly12Asp)|E:KRAS:Canonical:ENSP00000256078.4:p.(Gly12Asp)|R:KRAS:XP_005253422.1:p.(Gly12Asp)|E:KRAS:ENSP00000451856.1:p.(Gly12Asp)	CPSR_classification|ClinVar_classification|tier|class	NA	IS:all_exons	.	.	include	.	.	.
CL-AcroMetrix	MAP2K1	ENST00000307102	NM_002755	15:66727455	G>T	c.171G>T	exon2	K57N	Lys57Asn	c.171G>T:exon2:K57N:Lys57Asn	missense_variant	1010	0.077	NA	NA	NA	NA	COSV61068581|COSV61070413	rs869025608	223140	NA	NA	NA	NA	MAP2K1|K57|1.73e-43	Skin_Cutaneous_Melanoma:_0.4%_(2/468)|Head_and_Neck_Squamous_Cell_Carcinoma:_0.2%_(1/508)|Lung_Adenocarcinoma:_0.2%_(1/567)	NA	T:14+0+0+0=14/463|N:0+0+0+0=0/104|A:14+0+0+0=14/567	NA	RTKRAS	NA	[non-HC]_2.014/2.028_NA	TIER_2	Pathogenic	Likely_Pathogenic	SOM	NA	Selumetinib|Trametinib|Selumetinib_Sulfate|Trametinib_Dimethyl_Sulfoxide|Cobimetinib|Binimetinib	missense_variant:E:MAP2K1:Canonical:ENSP00000302486.4:p.(Lys57Asn)|R:MAP2K1:XP_005254598.1:p.(Lys57Asn)|R:MAP2K1:Canonical:NP_002746.1:p.(Lys57Asn)|R:MAP2K1:XP_005254597.1:p.(Lys35Asn)	CPSR_classification|ClinVar_classification|tier|class	NA	aka[MEK1];all_exons;IS:exons[2,3]	.	.	include	.	.	.
CL-AcroMetrix	NRAS	ENST00000369535	NM_002524	1:115258747	C>T	c.35G>A	exon2	G12D	Gly12Asp	c.35G>A:exon2:G12D:Gly12Asp	missense_variant	1195	0.038	NA	NA	NA	NA	COSV54736383|COSV54736555|COSV54736974	rs121913237	39648	8e-06	NA	0.0000088	NA	NRAS|G12|3.67e-130	Rectum_Adenocarcinoma:_2.2%_(3/137)|Acute_Myeloid_Leukemia:_1.4%_(2/144)|Colon_Adenocarcinoma:_1%_(4/399)|Testicular_Germ_Cell_Tumors:_0.7%_(1/145)|Uterine_Corpus_Endometrial_Carcinoma:_0.6%_(3/530)|Skin_Cutaneous_Melanoma:_0.2%_(1/468)	MALY-DE/Primary/1/100/0.01|PACA-AU/Primary/1/90/0.0111	T:56+2+0+2=60/463|N:2+0+0+0=2/104|A:58+2+0+2=62/567	NRAS:p.G12D:ENST00000369535:CTAT_POPULATION|CTAT_CANCER|3D_STRUCTURE	RTKRAS	NA	[HC]_1.918/1.836_NA	TIER_2	Pathogenic	Likely_Pathogenic	SOM	Ras_family	NA	missense_variant:R:NRAS:Canonical:NP_002515.1:p.(Gly12Asp)|E:NRAS:Canonical:ENSP00000358548.4:p.(Gly12Asp);downstream_gene_variant:E:CSDE1:ENST00000339438.6|R:CSDE1:NM_001242893.1|R:CSDE1:NM_001242892.1|R:CSDE1:Canonical:NM_001242891.1|R:CSDE1:NM_001130523.2|R:CSDE1:NM_007158.5|R:CSDE1:NM_001007553.2|E:CSDE1:Canonical:ENST00000438362.2|R:CSDE1:XM_005271178.1|E:CSDE1:ENST00000358528.4|E:CSDE1:ENST00000261443.5|E:CSDE1:ENST00000530886.1|E:CSDE1:ENST00000369530.1|E:CSDE1:ENST00000534699.1	CPSR_classification|ClinVar_classification|tier|class	NA	all_exons;IS:exons[2-3]	.	.	include	variant_in_more_than_10%_of_tumor_samples_(12.1%)_with_VAF_under_0.01	.	.
CL-AcroMetrix	PDGFRA	ENST00000257290	NM_001347828|NM_006206|NM_001347829|NM_001347830	4:55152093	A>T	c.2525A>T	exon18	D842V	Asp842Val	c.2525A>T:exon18:D842V:Asp842Val	missense_variant	1137	0.04	NA	NA	NA	NA	COSV57264120	rs121908585	13543	NA	NA	NA	NA	PDGFRA|D842|1.11e-20	NA	NA	T:10+0+0+0=10/463|N:1+0+0+0=1/104|A:11+0+0+0=11/567	NA	RTKRAS	NA	[HC]_2.056/2.112_NA	TIER_2	Likely_Pathogenic	VUS	SOM	Protein_tyrosine_and_serine/threonine_kinase	Vatalanib|Pazopanib_Hydrochloride|Olaratumab|Masitinib|Regorafenib|Regorafenib_Hydrate|Crenolanib|Linifanib|Orantinib|Famitinib|Avapritinib|Ripretinib|Pazopanib|Cediranib|Nintedanib|Dovitinib|Sunitinib_Malate|Motesanib|Quizartinib|Midostaurin	missense_variant:E:FIP1L1:Canonical:ENSP00000423325.1:p.(Asp602Val)|R:PDGFRA:Canonical:NP_006197.1:p.(Asp842Val)|R:PDGFRA:NP_001334757.1:p.(Asp867Val)|R:PDGFRA:NP_006197.1:p.(Asp842Val)|E:PDGFRA:Canonical:ENSP00000257290.5:p.(Asp842Val)|R:PDGFRA:XP_005265800.1:p.(Asp842Val)|R:PDGFRA:NP_001334758.1:p.(Asp842Val)|R:PDGFRA:NP_001334759.1:p.(Asp855Val);downstream_gene_variant:R:PDGFRA:NM_001347827.1|R:PDGFRA:XM_005265744.1	CPSR_classification|tier|class	NA	all_exons;IS:introns[7,9,11],exons[12,18]	.	.	include	.	.	.
CL-AcroMetrix	PIK3CA	ENST00000263967	NM_006218	3:178936074	C>G	c.1616C>G	exon10	P539R	Pro539Arg	c.1616C>G:exon10:P539R:Pro539Arg	missense_variant	550	0.031	NA	NA	NA	NA	COSV104381411|COSV55876380	rs121913285	376243	NA	NA	NA	NA	PIK3CA|P539|0.0128	Pancreatic_Adenocarcinoma:_0.6%_(1/180)|Uterine_Corpus_Endometrial_Carcinoma:_0.4%_(2/530)|Breast_Invasive_Carcinoma:_0.1%_(1/986)	NA	T:7+0+0+0=7/463|N:1+0+0+0=1/104|A:8+0+0+0=8/567	PIK3CA:p.P539R:ENST00000263967:CTAT_POPULATION|CTAT_CANCER|3D_STRUCTURE	PI3K	NA	[HC]_1.812/1.624_NA	TIER_2	Likely_Pathogenic	Likely_Pathogenic	SOM	Phosphoinositide_3-kinase_family|accessory_domain_(PIK_domain)	Buparlisib|Taselisib|Alpelisib|Copanlisib|Copanlisib_Hydrochloride	missense_variant:R:PIK3CA:NP_006209.2:p.(Pro539Arg)|E:PIK3CA:Canonical:ENSP00000263967.3:p.(Pro539Arg)|R:PIK3CA:Canonical:NP_006209.2:p.(Pro539Arg)	CPSR_classification|ClinVar_classification|tier|class	NA	all_exons;IS:exons[2-3,5-8,10,14,19,21;coding:1-2,4-7,9,13,18,20]	.	.	include	.	.	.
CL-AcroMetrix	PIK3CA	ENST00000263967	NM_006218	3:178936082	G>A	c.1624G>A	exon10	E542K	Glu542Lys	c.1624G>A:exon10:E542K:Glu542Lys	missense_variant	578	0.026	NA	NA	NA	NA	COSV55873227|COSV55894248	rs121913273	31944	NA	NA	NA	NA	PIK3CA|E542|0	Cervical_Squamous_Cell_Carcinoma_and_Endocervical_Adenocarcinoma:_7.6%_(22/289)|Bladder_Urothelial_Carcinoma:_4.4%_(18/412)|Breast_Invasive_Carcinoma:_4.3%_(42/986)|Head_and_Neck_Squamous_Cell_Carcinoma:_3.5%_(18/508)|Colon_Adenocarcinoma:_3%_(12/399)|Uterine_Corpus_Endometrial_Carcinoma:_3%_(16/530)|Lung_Squamous_Cell_Carcinoma:_2.4%_(12/492)|Stomach_Adenocarcinoma:_1.4%_(6/437)|Kidney_Renal_Papillary_Cell_Carcinoma:_1.1%_(3/281)|Prostate_Adenocarcinoma:_0.6%_(3/496)|Lung_Adenocarcinoma:_0.5%_(3/567)|Brain_Lower_Grade_Glioma:_0.4%_(2/509)|Glioblastoma_Multiforme:_0.3%_(1/393)|Liver_Hepatocellular_Carcinoma:_0.3%_(1/364)	BRCA-EU/Primary/1/76/0.0132|ESAD-UK/Primary/1/97/0.0103|LIRI-JP/Primary/1/250/0.004|ORCA-IN/Primary/1/13/0.0769|PACA-AU/Primary/1/90/0.0111	T:13+2+3+2=20/463|N:3+0+0+0=3/104|A:16+2+3+2=23/567	PIK3CA:p.E542K:ENST00000263967:CTAT_CANCER|3D_STRUCTURE	PI3K	NA	[HC]_1.812/1.624_NA	TIER_2	Pathogenic	Pathogenic	SOM	Phosphoinositide_3-kinase_family|accessory_domain_(PIK_domain)	Buparlisib|Taselisib|Alpelisib|Copanlisib|Copanlisib_Hydrochloride	missense_variant:R:PIK3CA:NP_006209.2:p.(Glu542Lys)|E:PIK3CA:Canonical:ENSP00000263967.3:p.(Glu542Lys)|R:PIK3CA:Canonical:NP_006209.2:p.(Glu542Lys)	CPSR_classification|ClinVar_classification|tier|class	NA	all_exons;IS:exons[2-3,5-8,10,14,19,21;coding:1-2,4-7,9,13,18,20]	.	.	include	.	.	.
CL-AcroMetrix	PIK3CA	ENST00000263967	NM_006218	3:178936091	G>A	c.1633G>A	exon10	E545K	Glu545Lys	c.1633G>A:exon10:E545K:Glu545Lys	missense_variant	619	0.032	NA	NA	NA	NA	COSV55873239|COSV55878227	rs104886003	13655	4e-06	NA	0.0000089	NA	PIK3CA|E545|0	Cervical_Squamous_Cell_Carcinoma_and_Endocervical_Adenocarcinoma:_12.5%_(36/289)|Colon_Adenocarcinoma:_7.8%_(31/399)|Uterine_Carcinosarcoma:_7%_(4/57)|Bladder_Urothelial_Carcinoma:_6.8%_(28/412)|Breast_Invasive_Carcinoma:_6.4%_(63/986)|Head_and_Neck_Squamous_Cell_Carcinoma:_4.3%_(22/508)|Uterine_Corpus_Endometrial_Carcinoma:_2.8%_(15/530)|Esophageal_Carcinoma:_2.7%_(5/184)|Lung_Squamous_Cell_Carcinoma:_2.4%_(12/492)|Rectum_Adenocarcinoma:_2.2%_(3/137)|Stomach_Adenocarcinoma:_2.1%_(9/437)|Cholangiocarcinoma:_2%_(1/51)|Testicular_Germ_Cell_Tumors:_1.4%_(2/145)|Lung_Adenocarcinoma:_1.1%_(6/567)|Glioblastoma_Multiforme:_0.8%_(3/393)|Skin_Cutaneous_Melanoma:_0.4%_(2/468)|Kidney_Renal_Clear_Cell_Carcinoma:_0.3%_(1/336)|Brain_Lower_Grade_Glioma:_0.2%_(1/509)|Ovarian_Serous_Cystadenocarcinoma:_0.2%_(1/436)	BRCA-EU/Primary/7/76/0.0921|ESAD-UK/Primary/4/97/0.0412|LINC-JP/Primary/1/28/0.0357|ORCA-IN/Primary/1/13/0.0769	T:31+1+10+2=44/463|N:4+0+0+0=4/104|A:35+1+10+2=48/567	PIK3CA:p.E545K:ENST00000263967:CTAT_POPULATION|CTAT_CANCER|3D_STRUCTURE	PI3K	NA	[HC]_1.812/1.624_NA	TIER_2	Pathogenic	Likely_Pathogenic	SOM	Phosphoinositide_3-kinase_family|accessory_domain_(PIK_domain)	Buparlisib|Taselisib|Alpelisib|Copanlisib|Copanlisib_Hydrochloride	missense_variant:R:PIK3CA:NP_006209.2:p.(Glu545Lys)|E:PIK3CA:Canonical:ENSP00000263967.3:p.(Glu545Lys)|R:PIK3CA:Canonical:NP_006209.2:p.(Glu545Lys)	CPSR_classification|ClinVar_classification|tier|class	NA	all_exons;IS:exons[2-3,5-8,10,14,19,21;coding:1-2,4-7,9,13,18,20]	.	.	include	.	.	.
CL-AcroMetrix	PIK3CA	ENST00000263967	NM_006218	3:178952085	A>G	c.3140A>G	exon21	H1047R	His1047Arg	c.3140A>G:exon21:H1047R:His1047Arg	missense_variant	824	0.079	NA	NA	NA	NA	COSV55873195|COSV55873401|COSV55888015	rs121913279	13652	4e-06	NA	0.0000089	NA	PIK3CA|H1047|0	Breast_Invasive_Carcinoma:_12.2%_(120/986)|Uterine_Carcinosarcoma:_7%_(4/57)|Uterine_Corpus_Endometrial_Carcinoma:_5.3%_(28/530)|Colon_Adenocarcinoma:_4.3%_(17/399)|Stomach_Adenocarcinoma:_3.4%_(15/437)|Head_and_Neck_Squamous_Cell_Carcinoma:_2.2%_(11/508)|Rectum_Adenocarcinoma:_1.5%_(2/137)|Bladder_Urothelial_Carcinoma:_1.2%_(5/412)|Adrenocortical_Carcinoma:_1.1%_(1/92)|Lung_Squamous_Cell_Carcinoma:_1%_(5/492)|Sarcoma:_0.8%_(2/237)|Cervical_Squamous_Cell_Carcinoma_and_Endocervical_Adenocarcinoma:_0.7%_(2/289)|Brain_Lower_Grade_Glioma:_0.6%_(3/509)|Esophageal_Carcinoma:_0.5%_(1/184)|Ovarian_Serous_Cystadenocarcinoma:_0.5%_(2/436)|Lung_Adenocarcinoma:_0.4%_(2/567)|Prostate_Adenocarcinoma:_0.4%_(2/496)|Glioblastoma_Multiforme:_0.3%_(1/393)|Liver_Hepatocellular_Carcinoma:_0.3%_(1/364)	BRCA-EU/Primary/11/76/0.1447|BRCA-UK/Primary/4/44/0.0909|LIRI-JP/Primary/2/250/0.008|PACA-AU/Primary/1/90/0.0111|PBCA-DE/Primary/1/230/0.0043|PRAD-CA/Primary/1/110/0.0091	T:13+0+10+5=28/463|N:1+0+0+0=1/104|A:14+0+10+5=29/567	PIK3CA:p.H1047R:ENST00000263967:CTAT_CANCER|3D_STRUCTURE	PI3K	NA	[HC]_1.812/1.624_NA	TIER_2	Pathogenic	Pathogenic	SOM	NA	Buparlisib|Taselisib|Alpelisib|Copanlisib|Copanlisib_Hydrochloride	missense_variant:R:PIK3CA:NP_006209.2:p.(His1047Arg)|E:PIK3CA:Canonical:ENSP00000263967.3:p.(His1047Arg)|R:PIK3CA:Canonical:NP_006209.2:p.(His1047Arg)	CPSR_classification|ClinVar_classification|tier|class	NA	all_exons;IS:exons[2-3,5-8,10,14,19,21;coding:1-2,4-7,9,13,18,20]	.	.	include	.	.	.
CL-AcroMetrix	RET	ENST00000355710	NM_020975	10:43617416	T>C	c.2753T>C	exon16	M918T	Met918Thr	c.2753T>C:exon16:M918T:Met918Thr	missense_variant	1228	0.16	NA	NA	NA	NA	COSV60685905	rs74799832	13919	4e-06	NA	0.0000088	NA	RET|M918|3.89e-14	Pheochromocytoma_and_Paraganglioma:_2.2%_(4/179)	NA	T:5+0+0+0=5/463|N:4+0+0+0=4/104|A:9+0+0+0=9/567	RET:p.M918T:ENST00000355710&ENST00000340058:CTAT_POPULATION|CTAT_CANCER	RTKRAS	1_NA_NA	[HC]_2.206/2.412_NA	TIER_2	Pathogenic	Likely_Pathogenic	SOM	Protein_tyrosine_and_serine/threonine_kinase	Sorafenib_Tosylate|Sorafenib|Alectinib|Regorafenib|Regorafenib_Hydrate|Vandetanib|Sitravatinib|Selpercatinib|Sunitinib_Malate|Motesanib|Quizartinib	missense_variant:E:RET:Canonical:ENSP00000347942.3:p.(Met918Thr)|R:RET:NP_065681.1:p.(Met918Thr)|R:RET:Canonical:NP_066124.1:p.(Met918Thr)|E:RET:ENSP00000344798.4:p.(Met918Thr)	CPSR_classification|ClinVar_classification|tier|class	NA	introns[7-8],all_exons;IS:introns[9-11],exons[11,13-16]	.	.	include	.	.	.
CL-AcroMetrix	TP53	ENST00000269305	NM_000546	17:7577120	C>T	c.818G>A	exon8	R273H	Arg273His	c.818G>A:exon8:R273H:Arg273His	missense_variant	1153	0.04	NA	NA	NA	NA	COSV52660980|COSV52664805|COSV52676050|COSV52728930	rs28934576	12366	1.59e-05	2e-04	0.0000264	EUR_AF_1KG:0.0010000	TP53|R273|0	Uterine_Carcinosarcoma:_5.3%_(3/57)|Rectum_Adenocarcinoma:_3.6%_(5/137)|Colon_Adenocarcinoma:_3%_(12/399)|Esophageal_Carcinoma:_2.7%_(5/184)|Uterine_Corpus_Endometrial_Carcinoma:_2.3%_(12/530)|Ovarian_Serous_Cystadenocarcinoma:_2.1%_(9/436)|Brain_Lower_Grade_Glioma:_2%_(10/509)|Head_and_Neck_Squamous_Cell_Carcinoma:_1.4%_(7/508)|Stomach_Adenocarcinoma:_1.4%_(6/437)|Breast_Invasive_Carcinoma:_1.2%_(12/986)|Mesothelioma:_1.2%_(1/82)|Pancreatic_Adenocarcinoma:_1.1%_(2/180)|Glioblastoma_Multiforme:_0.8%_(3/393)|Lung_Squamous_Cell_Carcinoma:_0.6%_(3/492)|Liver_Hepatocellular_Carcinoma:_0.5%_(2/364)|Sarcoma:_0.4%_(1/237)|Lung_Adenocarcinoma:_0.2%_(1/567)	BTCA-SG/Primary/2/12/0.1667|CMDI-UK/Primary/1/30/0.0333|ESAD-UK/Primary/4/97/0.0412|MALY-DE/Primary/3/100/0.03|OV-AU/Primary/5/60/0.0833|PACA-AU/Primary/3/90/0.0333|PACA-CA/Primary/4/140/0.0286|PRAD-CA/Primary/1/110/0.0091	T:103+3+2+3=111/462|N:9+0+1+0=10/104|A:112+3+3+3=121/566	TP53:p.R273H:ENST00000359597&ENST00000269305&ENST00000455263&ENST00000420246&ENST00000445888:CTAT_POPULATION|CTAT_CANCER|3D_STRUCTURE	TP53	4_c_NS	[non-HC]_2.45/2.9_NA	TIER_2	Pathogenic	Pathogenic	SOM	P53_DNA-binding_domain	NA	missense_variant:E:TP53:ENSP00000352610.4:p.(Arg273His)|R:TP53:NP_001119587.1:p.(Arg141His)|R:TP53:NP_001263626.1:p.(Arg114His)|R:TP53:NP_001263628.1:p.(Arg114His)|R:TP53:NP_001119589.1:p.(Arg141His)|R:TP53:NP_001263627.1:p.(Arg114His)|R:TP53:NP_001119588.1:p.(Arg141His)|E:TP53:Canonical:ENSP00000269305.4:p.(Arg273His)|R:TP53:NP_001263625.1:p.(Arg234His)|R:TP53:NP_001119590.1:p.(Arg234His)|R:TP53:NP_001119585.1:p.(Arg273His)|R:TP53:Canonical:NP_000537.3:p.(Arg273His)|R:TP53:NP_001263689.1:p.(Arg234His)|R:TP53:NP_001263690.1:p.(Arg234His)|R:TP53:NP_001263624.1:p.(Arg234His)|R:TP53:NP_001119586.1:p.(Arg273His)|R:TP53:NP_001119584.1:p.(Arg273His)|E:TP53:ENSP00000398846.2:p.(Arg273His)|E:TP53:ENSP00000391127.2:p.(Arg273His)|E:TP53:ENSP00000391478.2:p.(Arg273His)|R:TP53:XP_005256835.1:p.(Arg253His)|E:TP53:ENSP00000425104.1:p.(Arg141His);upstream_gene_variant:E:TP53:ENST00000576024.1;downstream_gene_variant:E:TP53:ENST00000514944.1|E:TP53:ENST00000508793.1|E:TP53:ENST00000604348.1|E:TP53:ENST00000503591.1	CPSR_classification|ClinVar_classification|tier|class	germline_population	IS:all_exons	.	.	exclude	germline_population,variant_in_more_than_10%_of_tumor_samples_(22.29%)_with_VAF_under_0.01	.	.
CL-AcroMetrix	TP53	ENST00000269305	NM_000546	17:7577538	C>T	c.743G>A	exon7	R248Q	Arg248Gln	c.743G>A:exon7:R248Q:Arg248Gln	missense_variant	1211	0.04	NA	NA	NA	NA	COSV52661091|COSV52661580|COSV52675468|COSV52802300	rs11540652	12356	1.19e-05	NA	0.0000264	NA	TP53|R248|0	Uterine_Carcinosarcoma:_10.5%_(6/57)|Esophageal_Carcinoma:_4.9%_(9/184)|Rectum_Adenocarcinoma:_4.4%_(6/137)|Bladder_Urothelial_Carcinoma:_4.1%_(17/412)|Colon_Adenocarcinoma:_3.3%_(13/399)|Ovarian_Serous_Cystadenocarcinoma:_2.5%_(11/436)|Pancreatic_Adenocarcinoma:_2.2%_(4/180)|Glioblastoma_Multiforme:_1.8%_(7/393)|Uterine_Corpus_Endometrial_Carcinoma:_1.7%_(9/530)|Head_and_Neck_Squamous_Cell_Carcinoma:_1.6%_(8/508)|Brain_Lower_Grade_Glioma:_1.6%_(8/509)|Stomach_Adenocarcinoma:_1.1%_(5/437)|Liver_Hepatocellular_Carcinoma:_0.8%_(3/364)|Lung_Squamous_Cell_Carcinoma:_0.8%_(4/492)|Prostate_Adenocarcinoma:_0.8%_(4/496)|Acute_Myeloid_Leukemia:_0.7%_(1/144)|Sarcoma:_0.4%_(1/237)|Breast_Invasive_Carcinoma:_0.3%_(3/986)	BRCA-EU/Primary/1/76/0.0132|ESAD-UK/Primary/4/97/0.0412|GACA-CN/Primary/1/32/0.0312|MALY-DE/Primary/1/100/0.01|OV-AU/Primary/2/60/0.0333|PACA-AU/Primary/3/90/0.0333|PACA-CA/Primary/1/140/0.0071|PAEN-IT/Primary/1/34/0.0294	T:108+2+2+8=120/461|N:8+0+0+0=8/104|A:116+2+2+8=128/565	TP53:p.R248Q:ENST00000413465&ENST00000359597&ENST00000269305&ENST00000455263&ENST00000420246&ENST00000445888:CTAT_POPULATION|CTAT_CANCER|3D_STRUCTURE	TP53	4_c_NS	[non-HC]_2.45/2.9_NA	TIER_2	Likely_Pathogenic	Pathogenic	SOM	P53_DNA-binding_domain	NA	missense_variant:E:TP53:ENSP00000410739.2:p.(Arg248Gln)|E:TP53:ENSP00000352610.4:p.(Arg248Gln)|R:TP53:NP_001119587.1:p.(Arg116Gln)|R:TP53:NP_001263626.1:p.(Arg89Gln)|R:TP53:NP_001263628.1:p.(Arg89Gln)|R:TP53:NP_001119589.1:p.(Arg116Gln)|R:TP53:NP_001263627.1:p.(Arg89Gln)|R:TP53:NP_001119588.1:p.(Arg116Gln)|E:TP53:Canonical:ENSP00000269305.4:p.(Arg248Gln)|R:TP53:NP_001263625.1:p.(Arg209Gln)|R:TP53:NP_001119590.1:p.(Arg209Gln)|R:TP53:NP_001119585.1:p.(Arg248Gln)|R:TP53:Canonical:NP_000537.3:p.(Arg248Gln)|R:TP53:NP_001263689.1:p.(Arg209Gln)|R:TP53:NP_001263690.1:p.(Arg209Gln)|R:TP53:NP_001263624.1:p.(Arg209Gln)|R:TP53:NP_001119586.1:p.(Arg248Gln)|R:TP53:NP_001119584.1:p.(Arg248Gln)|E:TP53:ENSP00000398846.2:p.(Arg248Gln)|E:TP53:ENSP00000391127.2:p.(Arg248Gln)|E:TP53:ENSP00000391478.2:p.(Arg248Gln)|R:TP53:XP_005256835.1:p.(Arg228Gln)|E:TP53:ENSP00000425104.1:p.(Arg116Gln)|E:TP53:ENSP00000423862.1:p.(Arg155Gln);upstream_gene_variant:E:TP53:ENST00000576024.1;downstream_gene_variant:E:TP53:ENST00000508793.1|E:TP53:ENST00000604348.1|E:TP53:ENST00000503591.1	CPSR_classification|ClinVar_classification|tier|class	NA	IS:all_exons	.	.	include	variant_in_more_than_10%_of_tumor_samples_(23.43%)_with_VAF_under_0.01	.	.
CL-AcroMetrix	AKT1	ENST00000554581	NA	14:105246551	C>T	c.49G>A	exon2	E17K	Glu17Lys	c.49G>A:exon2:E17K:Glu17Lys	missense_variant,splice_region_variant	1307	0.046	NA	NA	NA	NA	COSV62571334|COSV62576849	rs121434592	13983	4e-06	NA	0.0000089	NA	AKT1|E17|1.15e-288	Breast_Invasive_Carcinoma:_2.5%_(25/986)|Uterine_Corpus_Endometrial_Carcinoma:_1.5%_(8/530)|Cervical_Squamous_Cell_Carcinoma_and_Endocervical_Adenocarcinoma:_1%_(3/289)|Colon_Adenocarcinoma:_1%_(4/399)|Thyroid_Carcinoma:_0.6%_(3/492)|Prostate_Adenocarcinoma:_0.4%_(2/496)|Skin_Cutaneous_Melanoma:_0.4%_(2/468)|Bladder_Urothelial_Carcinoma:_0.2%_(1/412)|Head_and_Neck_Squamous_Cell_Carcinoma:_0.2%_(1/508)|Lung_Adenocarcinoma:_0.2%_(1/567)|Stomach_Adenocarcinoma:_0.2%_(1/437)	BRCA-EU/Primary/3/76/0.0395|BRCA-UK/Primary/1/44/0.0227	T:27+0+4+4=35/463|N:2+0+0+0=2/104|A:29+0+4+4=37/567	AKT1:p.E17K:ENST00000554581&ENST00000407796&ENST00000349310&ENST00000402615&ENST00000555528&ENST00000554848&ENST00000555926:CTAT_POPULATION|CTAT_CANCER|3D_STRUCTURE	PI3K	NA	[non-HC]_2.278/2.556_NA	TIER_2	VUS	VUS	SOM	PH_domain	Ipatasertib|Capivasertib	upstream_gene_variant:R:AKT1:XM_005267402.1|E:AKT1:ENST00000544168.1;missense_variant,splice_region_variant:R:AKT1:NP_005154.2:p.(Glu17Lys)|E:AKT1:ENSP00000451828.1:p.(Glu17Lys)|R:AKT1:XP_005267458.1:p.(Glu17Lys)|E:AKT1:ENSP00000384293.2:p.(Glu17Lys)|R:AKT1:NP_001014431.1:p.(Glu17Lys)|R:AKT1:Canonical:NP_001014432.1:p.(Glu17Lys)|E:AKT1:Canonical:ENSP00000270202.4:p.(Glu17Lys)|E:AKT1:ENSP00000385326.2:p.(Glu17Lys)|E:AKT1:ENSP00000450688.1:p.(Glu17Lys)|E:AKT1:ENSP00000451166.1:p.(Glu17Lys)|E:AKT1:ENSP00000451824.1:p.(Glu17Lys);5_prime_UTR_variant,splice_region_variant:E:AKT1:ENST00000555380.1	tier|class	NA	all_exons;IS:exons[3]	.	.	include	.	.	.
CL-AcroMetrix	ALK	ENST00000389048	NM_004304	2:29432664	C>T	c.3824G>A	exon25	R1275Q	Arg1275Gln	c.3824G>A:exon25:R1275Q:Arg1275Gln	missense_variant	1118	0.08	NA	NA	NA	NA	COSV66555567|COSV66558183	rs113994087	18083	NA	NA	NA	NA	ALK|R1275|6.65e-28	NA	NA	T:92+2+0+0=94/463|N:3+0+0+0=3/104|A:95+2+0+0=97/567	NA	RTKRAS	NA	[HC]_2.14/2.28_NA	TIER_3	Likely_Pathogenic	Pathogenic	SOM	Protein_tyrosine_and_serine/threonine_kinase	Alectinib|Entrectinib|Ceritinib|Lorlatinib|Brigatinib|Ensartinib|Crizotinib	missense_variant:E:ALK:Canonical:ENSP00000373700.3:p.(Arg1275Gln)|R:ALK:Canonical:NP_004295.2:p.(Arg1275Gln)	CPSR_classification|ClinVar_classification|class	NA	all_exons;IS:exons[20-29],introns[18-19]	.	.	include	variant_in_more_than_10%_of_tumor_samples_(19.87%)_with_VAF_under_0.01	.	.
CL-AcroMetrix	ALK	ENST00000389048	NM_004304	2:29443695	G>T	c.3522C>A	exon23	F1174L	Phe1174Leu	c.3522C>A:exon23:F1174L:Phe1174Leu	missense_variant	1186	0.082	NA	NA	NA	NA	COSV66555460|COSV66556325	rs863225281	217851	NA	NA	NA	NA	ALK|F1174|1.97e-27	NA	NA	T:30+0+0+0=30/463|N:2+1+0+0=3/104|A:32+1+0+0=33/567	NA	RTKRAS	NA	[HC]_2.14/2.28_NA	TIER_3	Likely_Pathogenic	Likely_Pathogenic	SOM	Protein_tyrosine_and_serine/threonine_kinase	Alectinib|Entrectinib|Ceritinib|Lorlatinib|Brigatinib|Ensartinib|Crizotinib	missense_variant:E:ALK:Canonical:ENSP00000373700.3:p.(Phe1174Leu)|R:ALK:Canonical:NP_004295.2:p.(Phe1174Leu);downstream_gene_variant:E:ALK:ENST00000453137.1	CPSR_classification|ClinVar_classification|class	NA	all_exons;IS:exons[20-29],introns[18-19]	.	.	include	.	.	.
CL-AcroMetrix	ATM	ENST00000278616	NA	11:108218045	A>G	c.8624A>G	exon59	N2875S	Asn2875Ser	c.8624A>G:exon59:N2875S:Asn2875Ser	missense_variant	781	0.078	NA	NA	NA	NA	COSV53726848|COSV53730217	rs587782451	142418	4e-06	NA	0.0000089	NA	ATM|N2875|1.7e-06	Rectum_Adenocarcinoma:_0.7%_(1/137)|Prostate_Adenocarcinoma:_0.2%_(1/496)|Breast_Invasive_Carcinoma:_0.1%_(1/986)	CLLE-ES/Primary/1/90/0.0111	T:4+0+0+0=4/463|N:3+0+0+0=3/104|A:7+0+0+0=7/567	ATM:p.N2875S:ENST00000278616&ENST00000452508:CTAT_POPULATION|CTAT_CANCER	TP53	NA	[HC]_2.122/2.244_NA	TIER_3	Likely_Pathogenic	VUS	SOM	Phosphatidylinositol_3-_and_4-kinase	Iniparib	missense_variant:E:ATM:Canonical:ENSP00000278616.4:p.(Asn2875Ser)|R:ATM:Canonical:NP_000042.3:p.(Asn2875Ser)|E:ATM:ENSP00000388058.2:p.(Asn2875Ser)|R:ATM:XP_005271619.1:p.(Asn2875Ser)|R:ATM:XP_005271618.1:p.(Asn2875Ser)|R:ATM:XP_005271620.1:p.(Asn2875Ser)|R:ATM:XP_005271621.1:p.(Asn2527Ser)	CPSR_classification|class	NA	IS:all_exons	.	.	include	.	.	.
CL-AcroMetrix	ATM	ENST00000278616	NA	11:108218089	C>G	c.8668C>G	exon59	L2890V	Leu2890Val	c.8668C>G:exon59:L2890V:Leu2890Val	missense_variant	648	0.068	NA	NA	NA	NA	COSV53724786	rs587779874	127462	NA	NA	NA	NA	ATM|L2890|0.00687	Stomach_Adenocarcinoma:_0.2%_(1/437)	NA	T:6+1+0+0=7/461|N:1+0+0+0=1/104|A:7+1+0+0=8/565	ATM:p.L2890V:ENST00000278616&ENST00000452508:CTAT_POPULATION|CTAT_CANCER	TP53	NA	[HC]_2.122/2.244_NA	TIER_3	Likely_Pathogenic	VUS	SOM	Phosphatidylinositol_3-_and_4-kinase	Iniparib	missense_variant:E:ATM:Canonical:ENSP00000278616.4:p.(Leu2890Val)|R:ATM:Canonical:NP_000042.3:p.(Leu2890Val)|E:ATM:ENSP00000388058.2:p.(Leu2890Val)|R:ATM:XP_005271619.1:p.(Leu2890Val)|R:ATM:XP_005271618.1:p.(Leu2890Val)|R:ATM:XP_005271620.1:p.(Leu2890Val)|R:ATM:XP_005271621.1:p.(Leu2542Val)	CPSR_classification|class	NA	IS:all_exons	.	.	include	.	.	.
CL-AcroMetrix	ATM	ENST00000278616	NA	11:108236087	G>A	c.9023G>A	exon63	R3008H	Arg3008His	c.9023G>A:exon63:R3008H:Arg3008His	missense_variant	862	0.084	NA	NA	NA	NA	COSV53726175|COSV53741856	rs587781894	141634	8e-06	NA	0.0000088	NA	ATM|R3008|1.75e-09	Colon_Adenocarcinoma:_0.3%_(1/399)|Lung_Adenocarcinoma:_0.2%_(1/567)|Uterine_Corpus_Endometrial_Carcinoma:_0.2%_(1/530)	NA	T:116+7+0+0=123/463|N:7+0+0+0=7/104|A:123+7+0+0=130/567	ATM:p.R3008H:ENST00000278616&ENST00000452508:CTAT_POPULATION|CTAT_CANCER	TP53	NA	[HC]_2.122/2.244_NA	TIER_3	Pathogenic	Likely_Pathogenic	SOM	NA	Iniparib	missense_variant:E:ATM:Canonical:ENSP00000278616.4:p.(Arg3008His)|R:ATM:Canonical:NP_000042.3:p.(Arg3008His)|E:ATM:ENSP00000388058.2:p.(Arg3008His)|R:ATM:XP_005271619.1:p.(Arg3008His)|R:ATM:XP_005271618.1:p.(Arg3008His)|R:ATM:XP_005271620.1:p.(Arg3008His)|R:ATM:XP_005271621.1:p.(Arg2660His)	CPSR_classification|ClinVar_classification|class	NA	IS:all_exons	.	.	include	variant_in_more_than_10%_of_tumor_samples_(25.05%)_with_VAF_under_0.01	.	.
CL-AcroMetrix	BRAF	ENST00000288602	NA	7:140453145	A>C	c.1790T>G	exon15	L597R	Leu597Arg	c.1790T>G:exon15:L597R:Leu597Arg	missense_variant	710	0.134	NA	NA	NA	NA	COSV56072463|COSV56121113|COSV56136756	rs121913366	13968	NA	NA	NA	NA	BRAF|L597|3.7e-08	NA	NA	T:0+0+0+0=0/463|N:1+0+0+0=1/104|A:1+0+0+0=1/567	NA	RTKRAS	NA	[HC]_1.804/1.608_NA	TIER_3	Likely_Pathogenic	Likely_Pathogenic	SOM	Protein_tyrosine_and_serine/threonine_kinase	Sorafenib_Tosylate|Vemurafenib|Sorafenib|Regorafenib|Regorafenib_Hydrate|Dabrafenib|Dabrafenib_Mesylate|Encorafenib	missense_variant:R:BRAF:XP_005250104.1:p.(Leu597Arg)|E:BRAF:ENSP00000419060.1:p.(Leu205Arg)|R:BRAF:XP_005250103.1:p.(Leu597Arg)|R:BRAF:XP_005250102.1:p.(Leu597Arg)|R:BRAF:Canonical:NP_004324.2:p.(Leu597Arg)|E:BRAF:Canonical:ENSP00000288602.6:p.(Leu597Arg)	CPSR_classification|ClinVar_classification|class	NA	all_exons,introns[7-10];IS:exons[11-18]	.	.	include	.	.	.
CL-AcroMetrix	CDKN2A	ENST00000498124	NM_001195132	9:21971017	G>A	c.341C>T	exon2	P114L	Pro114Leu	c.341C>T:exon2:P114L:Pro114Leu	missense_variant	1310	0.173	NA	NA	NA	NA	COSV58683051|COSV58690307|COSV58692178	rs121913386	77637	0	NA	0.0000000	NA	CDKN2A|P114|6.37e-18	Skin_Cutaneous_Melanoma:_2.1%_(10/468)|Lung_Squamous_Cell_Carcinoma:_0.4%_(2/492)|Head_and_Neck_Squamous_Cell_Carcinoma:_0.2%_(1/508)	NA	T:41+0+0+1=42/458|N:4+0+0+0=4/103|A:45+0+0+1=46/561	CDKN2A:p.P114L:ENST00000304494&ENST00000579122&ENST00000498124&ENST00000446177:CTAT_CANCER|3D_STRUCTURE	CC	NA	[non-HC]_2.044/2.088_NA	TIER_3	Likely_Pathogenic	VUS	SOM	Ankyrin_repeats_(3_copies)	NA	downstream_gene_variant:E:CDKN2A-AS1:Canonical:ENST00000441769.2;missense_variant:R:CDKN2A:XP_005251400.1:p.(Pro63Leu)|R:CDKN2A:NP_001182061.1:p.(Pro114Leu)|R:CDKN2A:Canonical:NP_000068.1:p.(Pro114Leu)|E:CDKN2A:ENSP00000307101.5:p.(Pro114Leu)|E:CDKN2A:ENSP00000464202.1:p.(Pro114Leu)|E:CDKN2A:ENSP00000467390.1:p.(Pro63Leu)|E:CDKN2A:ENSP00000418915.1:p.(Pro114Leu)|E:CDKN2A:ENSP00000467857.1:p.(Pro63Leu)|E:CDKN2A:ENSP00000464952.1:p.(Pro63Leu)|R:CDKN2A:XP_005251398.1:p.(Pro114Leu)|E:CDKN2A:ENSP00000394932.1:p.(Pro114Leu)|E:CDKN2A:ENSP00000466887.1:p.(Pro63Leu)|E:CDKN2A:ENSP00000468510.1:p.(Pro63Leu);3_prime_UTR_variant:R:CDKN2A:NM_058197.4	CPSR_classification|class	NA	IS:all_exons	.	.	include	.	.	.
CL-AcroMetrix	CDKN2A	ENST00000498124	NM_001195132	9:21971036	C>A	c.322G>T	exon2	D108Y	Asp108Tyr	c.322G>T:exon2:D108Y:Asp108Tyr	missense_variant	1227	0.188	NA	NA	NA	NA	COSV58682998|COSV58690035|COSV58690777|COSV58726216	rs121913381	182423	0	NA	0.0000000	NA	CDKN2A|D108|5.41e-17	Lung_Squamous_Cell_Carcinoma:_0.8%_(4/492)|Bladder_Urothelial_Carcinoma:_0.5%_(2/412)|Head_and_Neck_Squamous_Cell_Carcinoma:_0.4%_(2/508)|Liver_Hepatocellular_Carcinoma:_0.3%_(1/364)|Ovarian_Serous_Cystadenocarcinoma:_0.2%_(1/436)	NA	T:36+3+0+0=39/453|N:1+2+0+0=3/103|A:37+5+0+0=42/556	CDKN2A:p.D108Y:ENST00000304494&ENST00000579122&ENST00000498124&ENST00000446177:CTAT_CANCER|3D_STRUCTURE	CC	NA	[non-HC]_2.044/2.088_NA	TIER_3	Likely_Pathogenic	VUS	SOM	Ankyrin_repeats_(3_copies)	NA	downstream_gene_variant:E:CDKN2A-AS1:Canonical:ENST00000441769.2;missense_variant:R:CDKN2A:XP_005251400.1:p.(Asp57Tyr)|R:CDKN2A:NP_001182061.1:p.(Asp108Tyr)|R:CDKN2A:Canonical:NP_000068.1:p.(Asp108Tyr)|E:CDKN2A:Canonical:ENSP00000355153.3:p.(Arg163Leu)|R:CDKN2A:NP_478102.2:p.(Arg122Leu)|E:CDKN2A:ENSP00000307101.5:p.(Asp108Tyr)|E:CDKN2A:ENSP00000462950.1:p.(Arg122Leu)|E:CDKN2A:ENSP00000464202.1:p.(Asp108Tyr)|E:CDKN2A:ENSP00000467390.1:p.(Asp57Tyr)|E:CDKN2A:ENSP00000432664.2:p.(Arg122Leu)|E:CDKN2A:ENSP00000418915.1:p.(Asp108Tyr)|E:CDKN2A:ENSP00000467857.1:p.(Asp57Tyr)|E:CDKN2A:ENSP00000464952.1:p.(Asp57Tyr)|R:CDKN2A:XP_005251398.1:p.(Asp108Tyr)|E:CDKN2A:ENSP00000394932.1:p.(Asp108Tyr)|E:CDKN2A:ENSP00000466887.1:p.(Asp57Tyr)|E:CDKN2A:ENSP00000468510.1:p.(Asp57Tyr);3_prime_UTR_variant:R:CDKN2A:NM_058197.4	CPSR_classification|class	NA	IS:all_exons	.	.	include	.	.	.
CL-AcroMetrix	CDKN2A	ENST00000498124	NM_001195132	9:21971111	G>A	c.247C>T	exon2	H83Y	His83Tyr	c.247C>T:exon2:H83Y:His83Tyr	missense_variant	1234	0.209	NA	NA	NA	NA	COSV58682852|COSV58685578|COSV58690009	rs121913385	376307	0	NA	0.0000000	NA	CDKN2A|H83|1.31e-75	Pancreatic_Adenocarcinoma:_1.7%_(3/180)|Esophageal_Carcinoma:_1.1%_(2/184)|Bladder_Urothelial_Carcinoma:_0.5%_(2/412)|Lung_Adenocarcinoma:_0.4%_(2/567)|Lung_Squamous_Cell_Carcinoma:_0.4%_(2/492)|Head_and_Neck_Squamous_Cell_Carcinoma:_0.2%_(1/508)|Skin_Cutaneous_Melanoma:_0.2%_(1/468)|Stomach_Adenocarcinoma:_0.2%_(1/437)	ESAD-UK/Primary/1/97/0.0103|LIRI-JP/Primary/1/250/0.004|PACA-CA/Primary/2/140/0.0143	T:47+0+0+0=47/456|N:5+0+0+0=5/103|A:52+0+0+0=52/559	CDKN2A:p.H83Y:ENST00000304494&ENST00000579122&ENST00000498124&ENST00000446177:CTAT_CANCER|3D_STRUCTURE	CC	NA	[non-HC]_2.044/2.088_NA	TIER_3	Likely_Pathogenic	VUS	SOM	Ankyrin_repeats_(3_copies)	NA	downstream_gene_variant:E:CDKN2A-AS1:Canonical:ENST00000441769.2;missense_variant:R:CDKN2A:XP_005251400.1:p.(His32Tyr)|R:CDKN2A:NP_001182061.1:p.(His83Tyr)|R:CDKN2A:Canonical:NP_000068.1:p.(His83Tyr)|E:CDKN2A:Canonical:ENSP00000355153.3:p.(Ala138Val)|R:CDKN2A:NP_478102.2:p.(Ala97Val)|E:CDKN2A:ENSP00000307101.5:p.(His83Tyr)|E:CDKN2A:ENSP00000462950.1:p.(Ala97Val)|E:CDKN2A:ENSP00000464202.1:p.(His83Tyr)|E:CDKN2A:ENSP00000467390.1:p.(His32Tyr)|E:CDKN2A:ENSP00000432664.2:p.(Ala97Val)|E:CDKN2A:ENSP00000418915.1:p.(His83Tyr)|E:CDKN2A:ENSP00000467857.1:p.(His32Tyr)|E:CDKN2A:ENSP00000464952.1:p.(His32Tyr)|R:CDKN2A:XP_005251398.1:p.(His83Tyr)|E:CDKN2A:ENSP00000394932.1:p.(His83Tyr)|E:CDKN2A:ENSP00000466887.1:p.(His32Tyr)|E:CDKN2A:ENSP00000468510.1:p.(His32Tyr);3_prime_UTR_variant:R:CDKN2A:NM_058197.4	CPSR_classification|class	NA	IS:all_exons	.	.	include	variant_in_more_than_10%_of_tumor_samples_(10.31%)_with_VAF_under_0.01	.	.
CL-AcroMetrix	EGFR	ENST00000275493	NM_005228|NM_001346900	7:55211080	G>A	c.323G>A	exon3	R108K	Arg108Lys	c.323G>A:exon3:R108K:Arg108Lys	missense_variant	1162	0.168	NA	NA	NA	NA	COSV51766433	rs1057519828	376207	NA	NA	NA	NA	EGFR|R108|5.53e-24	Glioblastoma_Multiforme:_1%_(4/393)|Brain_Lower_Grade_Glioma:_0.4%_(2/509)	NA	T:64+0+0+0=64/463|N:0+0+0+0=0/104|A:64+0+0+0=64/567	EGFR:p.R108K:ENST00000455089&ENST00000342916&ENST00000344576&ENST00000420316&ENST00000275493&ENST00000442591:CTAT_POPULATION|CTAT_CANCER|3D_STRUCTURE	RTKRAS	NA	[HC]_1.916/1.832_NA	TIER_3	Likely_Pathogenic	Likely_Pathogenic	SOM	Receptor_L_domain	Afatinib|Lapatinib_Ditosylate|Cetuximab|Panitumumab|Necitumumab|Neratinib|Icotinib|Afatinib_Dimaleate|Zalutumumab|Nimotuzumab|Dacomitinib|Vandetanib|Osimertinib|Pyrotinib|Tesevatinib|Rociletinib|Brigatinib|Naquotinib|EGFR/FLT3/Abl_Inhibitor_SKLB1028|Depatuxizumab_Mafodotin|Neratinib_Maleate|Amivantamab|Abivertinib|Abivertinib_Maleate|Avitinib_Maleate|Lazertinib|Aumolertinib|Mobocertinib|Erlotinib|Lapatinib|Gefitinib	missense_variant:R:EGFR:XP_005271805.1:p.(Arg108Lys)|R:EGFR:XP_005271803.1:p.(Arg108Lys)|E:EGFR:ENSP00000415559.1:p.(Arg108Lys)|R:EGFR:NP_001333826.1:p.(Arg108Lys)|R:EGFR:NP_001333827.1:p.(Arg108Lys)|R:EGFR:Canonical:NP_005219.2:p.(Arg108Lys)|R:EGFR:NP_001333828.1:p.(Arg108Lys)|R:EGFR:NP_958440.1:p.(Arg108Lys)|E:EGFR:ENSP00000342376.3:p.(Arg108Lys)|R:EGFR:NP_958439.1:p.(Arg108Lys)|R:EGFR:NP_958441.1:p.(Arg108Lys)|R:EGFR:NP_005219.2:p.(Arg108Lys)|E:EGFR:ENSP00000345973.2:p.(Arg108Lys)|E:EGFR:ENSP00000413843.2:p.(Arg108Lys)|E:EGFR:Canonical:ENSP00000275493.2:p.(Arg108Lys)|E:EGFR:ENSP00000410031.1:p.(Arg108Lys)|E:EGFR:ENSP00000413354.1:p.(Arg55Lys)|R:EGFR:XP_005271804.1:p.(Arg55Lys)|R:EGFR:NP_001333829.1:p.(Arg55Lys)|E:EGFR:ENSP00000395243.2:p.(Arg55Lys)	CPSR_classification|ClinVar_classification|class	NA	introns[15];IS:introns[7,24-27],all_exons	.	.	include	variant_in_more_than_10%_of_tumor_samples_(13.82%)_with_VAF_under_0.01	.	.
CL-AcroMetrix	EGFR	ENST00000275493	NM_005228|NM_001346900	7:55221822	C>T	c.866C>T	exon7	A289V	Ala289Val	c.866C>T:exon7:A289V:Ala289Val	missense_variant	1472	0.185	NA	NA	NA	NA	COSV51765841|COSV51768139	rs149840192	376209	NA	NA	NA	NA	EGFR|A289|5.81e-116	Glioblastoma_Multiforme:_3.6%_(14/393)|Brain_Lower_Grade_Glioma:_0.8%_(4/509)|Breast_Invasive_Carcinoma:_0.1%_(1/986)	NA	T:86+0+1+0=87/463|N:4+0+0+0=4/104|A:90+0+1+0=91/567	EGFR:p.A289V:ENST00000342916&ENST00000344576&ENST00000420316&ENST00000275493&ENST00000442591:CTAT_POPULATION|CTAT_CANCER|3D_STRUCTURE	RTKRAS	NA	[HC]_1.916/1.832_NA	TIER_3	Likely_Pathogenic	Likely_Pathogenic	SOM	Furin-like_cysteine_rich_region	Afatinib|Lapatinib_Ditosylate|Cetuximab|Panitumumab|Necitumumab|Neratinib|Icotinib|Afatinib_Dimaleate|Zalutumumab|Nimotuzumab|Dacomitinib|Vandetanib|Osimertinib|Pyrotinib|Tesevatinib|Rociletinib|Brigatinib|Naquotinib|EGFR/FLT3/Abl_Inhibitor_SKLB1028|Depatuxizumab_Mafodotin|Neratinib_Maleate|Amivantamab|Abivertinib|Abivertinib_Maleate|Avitinib_Maleate|Lazertinib|Aumolertinib|Mobocertinib|Erlotinib|Lapatinib|Gefitinib	missense_variant:R:EGFR:XP_005271805.1:p.(Ala289Val)|R:EGFR:XP_005271803.1:p.(Ala244Val)|E:EGFR:ENSP00000415559.1:p.(Ala244Val)|R:EGFR:NP_001333826.1:p.(Ala244Val)|R:EGFR:NP_001333827.1:p.(Ala289Val)|R:EGFR:Canonical:NP_005219.2:p.(Ala289Val)|R:EGFR:NP_001333828.1:p.(Ala244Val)|R:EGFR:NP_958440.1:p.(Ala289Val)|E:EGFR:ENSP00000342376.3:p.(Ala289Val)|R:EGFR:NP_958439.1:p.(Ala289Val)|R:EGFR:NP_958441.1:p.(Ala289Val)|R:EGFR:NP_005219.2:p.(Ala289Val)|E:EGFR:ENSP00000345973.2:p.(Ala289Val)|E:EGFR:ENSP00000413843.2:p.(Ala289Val)|E:EGFR:Canonical:ENSP00000275493.2:p.(Ala289Val)|E:EGFR:ENSP00000410031.1:p.(Ala289Val)|R:EGFR:XP_005271804.1:p.(Ala236Val)|R:EGFR:NP_001333829.1:p.(Ala236Val)|E:EGFR:ENSP00000395243.2:p.(Ala236Val)	CPSR_classification|ClinVar_classification|class	NA	introns[15];IS:introns[7,24-27],all_exons	.	.	include	variant_in_more_than_10%_of_tumor_samples_(18.57%)_with_VAF_under_0.01	.	.
CL-AcroMetrix	EGFR	ENST00000275493	NM_005228|NM_001346900	7:55233043	G>T	c.1793G>T	exon15	G598V	Gly598Val	c.1793G>T:exon15:G598V:Gly598Val	missense_variant	1274	0.199	NA	NA	NA	NA	COSV51769031|COSV51808387	rs139236063	376210	4e-06	NA	0.0000088	NA	EGFR|G598|6.32e-57	Glioblastoma_Multiforme:_3.3%_(13/393)|Brain_Lower_Grade_Glioma:_1.2%_(6/509)	NA	T:27+0+0+1=28/463|N:5+0+0+0=5/104|A:32+0+0+1=33/567	EGFR:p.G598V:ENST00000342916&ENST00000344576&ENST00000275493&ENST00000442591:CTAT_POPULATION|CTAT_CANCER|3D_STRUCTURE	RTKRAS	NA	[HC]_1.916/1.832_NA	TIER_3	Likely_Pathogenic	Likely_Pathogenic	SOM	Growth_factor_receptor_domain_IV	Afatinib|Lapatinib_Ditosylate|Cetuximab|Panitumumab|Necitumumab|Neratinib|Icotinib|Afatinib_Dimaleate|Zalutumumab|Nimotuzumab|Dacomitinib|Vandetanib|Osimertinib|Pyrotinib|Tesevatinib|Rociletinib|Brigatinib|Naquotinib|EGFR/FLT3/Abl_Inhibitor_SKLB1028|Depatuxizumab_Mafodotin|Neratinib_Maleate|Amivantamab|Abivertinib|Abivertinib_Maleate|Avitinib_Maleate|Lazertinib|Aumolertinib|Mobocertinib|Erlotinib|Lapatinib|Gefitinib	missense_variant:R:EGFR:XP_005271805.1:p.(Gly598Val)|R:EGFR:XP_005271803.1:p.(Gly553Val)|E:EGFR:ENSP00000415559.1:p.(Gly553Val)|R:EGFR:NP_001333826.1:p.(Gly553Val)|R:EGFR:NP_001333827.1:p.(Gly598Val)|R:EGFR:NP_001333870.1:p.(Gly331Val)|R:EGFR:Canonical:NP_005219.2:p.(Gly598Val)|R:EGFR:NP_001333828.1:p.(Gly553Val)|E:EGFR:ENSP00000342376.3:p.(Gly598Val)|R:EGFR:NP_958439.1:p.(Gly598Val)|R:EGFR:NP_958441.1:p.(Gly598Val)|R:EGFR:NP_005219.2:p.(Gly598Val)|E:EGFR:ENSP00000345973.2:p.(Gly598Val)|E:EGFR:Canonical:ENSP00000275493.2:p.(Gly598Val)|E:EGFR:ENSP00000410031.1:p.(Gly598Val)|R:EGFR:XP_005271804.1:p.(Gly545Val)|R:EGFR:NP_001333829.1:p.(Gly545Val)|E:EGFR:ENSP00000395243.2:p.(Gly545Val)	CPSR_classification|ClinVar_classification|class	NA	introns[15];IS:introns[7,24-27],all_exons	.	.	include	.	.	.
CL-AcroMetrix	EGFR	ENST00000275493	NM_005228|NM_001346900	7:55249077	T>C	c.2375T>C	exon20	L792P	Leu792Pro	c.2375T>C:exon20:L792P:Leu792Pro	missense_variant	1542	0.174	NA	NA	NA	NA	COSV51832111|COSV51860329	NA	NA	NA	NA	NA	NA	EGFR|L747|1.57e-10	NA	NA	T:17+0+0+0=17/463|N:3+0+0+0=3/104|A:20+0+0+0=20/567	NA	RTKRAS	NA	[HC]_1.916/1.832_NA	TIER_3	VUS	NA	SOM	Protein_tyrosine_and_serine/threonine_kinase	Afatinib|Lapatinib_Ditosylate|Cetuximab|Panitumumab|Necitumumab|Neratinib|Icotinib|Afatinib_Dimaleate|Zalutumumab|Nimotuzumab|Dacomitinib|Vandetanib|Osimertinib|Pyrotinib|Tesevatinib|Rociletinib|Brigatinib|Naquotinib|EGFR/FLT3/Abl_Inhibitor_SKLB1028|Depatuxizumab_Mafodotin|Neratinib_Maleate|Amivantamab|Abivertinib|Abivertinib_Maleate|Avitinib_Maleate|Lazertinib|Aumolertinib|Mobocertinib|Erlotinib|Lapatinib|Gefitinib	missense_variant:R:EGFR:XP_005271803.1:p.(Leu747Pro)|E:EGFR:ENSP00000415559.1:p.(Leu747Pro)|R:EGFR:NP_001333826.1:p.(Leu747Pro)|R:EGFR:NP_001333827.1:p.(Leu792Pro)|R:EGFR:NP_001333870.1:p.(Leu525Pro)|R:EGFR:Canonical:NP_005219.2:p.(Leu792Pro)|R:EGFR:NP_001333828.1:p.(Leu747Pro)|R:EGFR:NP_005219.2:p.(Leu792Pro)|E:EGFR:Canonical:ENSP00000275493.2:p.(Leu792Pro)|R:EGFR:XP_005271804.1:p.(Leu739Pro)|R:EGFR:NP_001333829.1:p.(Leu739Pro)|E:EGFR:ENSP00000395243.2:p.(Leu739Pro)	class	NA	introns[15];IS:introns[7,24-27],all_exons	.	.	include	.	.	.
CL-AcroMetrix	EGFR	ENST00000275493	NM_005228|NM_001346900	7:55259439	T>G	c.2497T>G	exon21	L833V	Leu833Val	c.2497T>G:exon21:L833V:Leu833Val	missense_variant	1285	0.147	NA	NA	NA	NA	COSV51773059|COSV51776947	rs397517126	45277	NA	NA	NA	NA	EGFR|L833|0.0102	Lung_Adenocarcinoma:_0.2%_(1/567)	NA	T:3+0+0+0=3/463|N:3+0+0+0=3/104|A:6+0+0+0=6/567	NA	RTKRAS	NA	[HC]_1.916/1.832_NA	TIER_3	Likely_Pathogenic	VUS	SOM	Protein_tyrosine_and_serine/threonine_kinase	Afatinib|Lapatinib_Ditosylate|Cetuximab|Panitumumab|Necitumumab|Neratinib|Icotinib|Afatinib_Dimaleate|Zalutumumab|Nimotuzumab|Dacomitinib|Vandetanib|Osimertinib|Pyrotinib|Tesevatinib|Rociletinib|Brigatinib|Naquotinib|EGFR/FLT3/Abl_Inhibitor_SKLB1028|Depatuxizumab_Mafodotin|Neratinib_Maleate|Amivantamab|Abivertinib|Abivertinib_Maleate|Avitinib_Maleate|Lazertinib|Aumolertinib|Mobocertinib|Erlotinib|Lapatinib|Gefitinib	missense_variant:R:EGFR:XP_005271803.1:p.(Leu788Val)|E:EGFR:ENSP00000415559.1:p.(Leu788Val)|R:EGFR:NP_001333826.1:p.(Leu788Val)|R:EGFR:NP_001333827.1:p.(Leu833Val)|R:EGFR:NP_001333870.1:p.(Leu566Val)|R:EGFR:Canonical:NP_005219.2:p.(Leu833Val)|R:EGFR:NP_001333828.1:p.(Leu788Val)|R:EGFR:NP_005219.2:p.(Leu833Val)|E:EGFR:Canonical:ENSP00000275493.2:p.(Leu833Val)|R:EGFR:XP_005271804.1:p.(Leu780Val)|R:EGFR:NP_001333829.1:p.(Leu780Val)|E:EGFR:ENSP00000395243.2:p.(Leu780Val)	CPSR_classification|class	NA	introns[15];IS:introns[7,24-27],all_exons	.	.	include	.	.	.
CL-AcroMetrix	ERBB2	ENST00000269571	NM_001382787|NM_001382784|NM_001382786|NM_001382789|NM_001382788|NM_001382785|NM_004448|NM_001382796|NM_001382798|NM_001382800|NM_001382797|NM_001382805|NM_001382792|NM_001382793|NM_001382794|NM_001382795|NM_001382801|NM_001382790|NM_001382806|NM_001382802|NM_001382799|NM_001382791	17:37880220	T>C	c.2264T>C	exon19	L755S	Leu755Ser	c.2264T>C:exon19:L755S:Leu755Ser	missense_variant	1175	0.056	NA	NA	NA	NA	COSV54062780|COSV54064269	rs121913470	376035	NA	NA	NA	NA	ERBB2|L755|1.41e-85	Cholangiocarcinoma:_2%_(1/51)|Kidney_Renal_Papillary_Cell_Carcinoma:_0.7%_(2/281)|Uterine_Corpus_Endometrial_Carcinoma:_0.6%_(3/530)|Breast_Invasive_Carcinoma:_0.4%_(4/986)|Bladder_Urothelial_Carcinoma:_0.2%_(1/412)|Stomach_Adenocarcinoma:_0.2%_(1/437)	NA	T:11+0+0+0=11/463|N:3+0+0+0=3/104|A:14+0+0+0=14/567	ERBB2:p.L755S:ENST00000584450&ENST00000269571:CTAT_POPULATION|CTAT_CANCER|3D_STRUCTURE	RTKRAS	NA	[HC]_2.156/2.312_NA	TIER_3	Likely_Pathogenic	Likely_Pathogenic	SOM	Protein_tyrosine_and_serine/threonine_kinase	Afatinib|Lapatinib_Ditosylate|Trastuzumab|Neratinib|Pertuzumab|Afatinib_Dimaleate|Dacomitinib|Margetuximab|Vandetanib|Pyrotinib|Tesevatinib|Tucatinib|Neratinib_Maleate|Trastuzumab_Deruxtecan|Lapatinib	missense_variant:E:ERBB2:ENSP00000462438.1:p.(Leu725Ser)|R:ERBB2:XP_005257196.1:p.(Leu740Ser)|R:ERBB2:NP_001276865.1:p.(Leu740Ser)|R:ERBB2:NP_001005862.1:p.(Leu725Ser)|E:ERBB2:ENSP00000385185.2:p.(Leu725Ser)|R:ERBB2:NP_001005862.1:p.(Leu725Ser)|E:ERBB2:Canonical:ENSP00000446466.1:p.(Leu740Ser)|E:ERBB2:ENSP00000404047.2:p.(Leu479Ser)|R:ERBB2:NP_001276866.1:p.(Leu755Ser)|R:ERBB2:Canonical:NP_004439.2:p.(Leu755Ser)|E:ERBB2:ENSP00000443562.1:p.(Leu725Ser)|R:ERBB2:NP_004439.2:p.(Leu755Ser)|E:ERBB2:ENSP00000463714.1:p.(Leu755Ser)|E:ERBB2:ENSP00000269571.4:p.(Leu755Ser)|R:ERBB2:XP_005257197.1:p.(Leu725Ser)|E:ERBB2:ENSP00000463002.1:p.(Leu124Ser);downstream_gene_variant:E:ERBB2:ENST00000582818.1|R:MIEN1:NM_032339.4|R:MIEN1:Canonical:NM_001330206.1	CPSR_classification|ClinVar_classification|class	NA	IS:all_exons	.	.	include	.	.	.
CL-AcroMetrix	ERBB2	ENST00000269571	NM_001382787|NM_001382784|NM_001382786|NM_001382789|NM_001382788|NM_001382785|NM_004448|NM_001382796|NM_001382798|NM_001382800|NM_001382797|NM_001382805|NM_001382792|NM_001382793|NM_001382794|NM_001382795|NM_001382801|NM_001382790|NM_001382806|NM_001382802|NM_001382799|NM_001382791	17:37881332	G>A	c.2524G>A	exon21	V842I	Val842Ile	c.2524G>A:exon21:V842I:Val842Ile	missense_variant	1232	0.059	NA	NA	NA	NA	COSV104371920|COSV54062791	rs1057519738	375994	4e-06	NA	0.0000088	NA	ERBB2|V842|2.9e-27	Rectum_Adenocarcinoma:_2.2%_(3/137)|Uterine_Carcinosarcoma:_1.8%_(1/57)|Pancreatic_Adenocarcinoma:_1.1%_(2/180)|Uterine_Corpus_Endometrial_Carcinoma:_1.1%_(6/530)|Bladder_Urothelial_Carcinoma:_0.5%_(2/412)|Colon_Adenocarcinoma:_0.3%_(1/399)|Stomach_Adenocarcinoma:_0.2%_(1/437)|Breast_Invasive_Carcinoma:_0.1%_(1/986)	ESAD-UK/Primary/3/97/0.0309	T:147+0+1+0=148/463|N:7+0+0+0=7/104|A:154+0+1+0=155/567	NA	RTKRAS	NA	[HC]_2.156/2.312_NA	TIER_3	Likely_Pathogenic	Likely_Pathogenic	SOM	Protein_tyrosine_and_serine/threonine_kinase	Afatinib|Lapatinib_Ditosylate|Trastuzumab|Neratinib|Pertuzumab|Afatinib_Dimaleate|Dacomitinib|Margetuximab|Vandetanib|Pyrotinib|Tesevatinib|Tucatinib|Neratinib_Maleate|Trastuzumab_Deruxtecan|Lapatinib	missense_variant:E:ERBB2:ENSP00000462438.1:p.(Val812Ile)|R:ERBB2:XP_005257196.1:p.(Val827Ile)|R:ERBB2:NP_001276865.1:p.(Val827Ile)|R:ERBB2:NP_001005862.1:p.(Val812Ile)|E:ERBB2:ENSP00000385185.2:p.(Val812Ile)|R:ERBB2:NP_001005862.1:p.(Val812Ile)|E:ERBB2:Canonical:ENSP00000446466.1:p.(Val827Ile)|E:ERBB2:ENSP00000404047.2:p.(Val566Ile)|R:ERBB2:NP_001276866.1:p.(Val842Ile)|R:ERBB2:Canonical:NP_004439.2:p.(Val842Ile)|E:ERBB2:ENSP00000443562.1:p.(Val812Ile)|R:ERBB2:NP_004439.2:p.(Val842Ile)|E:ERBB2:ENSP00000463714.1:p.(Val842Ile)|E:ERBB2:ENSP00000269571.4:p.(Val842Ile)|R:ERBB2:XP_005257197.1:p.(Val812Ile)|E:ERBB2:ENSP00000463002.1:p.(Val211Ile);downstream_gene_variant:E:ERBB2:ENST00000582818.1|R:MIEN1:NM_032339.4|R:MIEN1:Canonical:NM_001330206.1|R:MIEN1:NM_032339.3|R:MIEN1:XM_005257736.1|E:MIEN1:ENST00000394231.3|E:MIEN1:Canonical:ENST00000577810.1	CPSR_classification|ClinVar_classification|class	NA	IS:all_exons	.	.	include	variant_in_more_than_10%_of_tumor_samples_(31.75%)_with_VAF_under_0.01	.	.
CL-AcroMetrix	FBXW7	ENST00000281708	NM_001349798	4:153244092	G>A	c.2065C>T	exon12	R689W	Arg689Trp	c.2065C>T:exon12:R689W:Arg689Trp	missense_variant	990	0.056	NA	NA	NA	NA	COSV55895191|COSV55934968	NA	NA	NA	NA	NA	NA	FBXW7|R689|6.54e-11	Uterine_Carcinosarcoma:_3.5%_(2/57)|Uterine_Corpus_Endometrial_Carcinoma:_1.3%_(7/530)|Colon_Adenocarcinoma:_0.8%_(3/399)|Brain_Lower_Grade_Glioma:_0.2%_(1/509)	NA	T:113+4+0+0=117/463|N:10+0+0+0=10/104|A:123+4+0+0=127/567	FBXW7:p.R689W:ENST00000281708&ENST00000603548&ENST00000603841:CTAT_POPULATION|CTAT_CANCER	NOTCH	NA	[non-HC]_1.88/1.76_NA	TIER_3	Likely_Pathogenic	NA	SOM	NA	NA	missense_variant:R:FBXW7:XP_005263165.1:p.(Arg513Trp)|R:FBXW7:Canonical:NP_060785.2:p.(Arg609Trp)|R:FBXW7:NP_001013433.1:p.(Arg571Trp)|R:FBXW7:XP_005263164.1:p.(Arg689Trp)|R:FBXW7:NP_361014.1:p.(Arg689Trp)|E:FBXW7:Canonical:ENSP00000281708.3:p.(Arg689Trp)|E:FBXW7:ENSP00000296555.4:p.(Arg571Trp)|E:FBXW7:ENSP00000263981.4:p.(Arg609Trp)|E:FBXW7:ENSP00000474725.1:p.(Arg689Trp)|E:FBXW7:ENSP00000377528.3:p.(Arg513Trp)|E:FBXW7:ENSP00000474971.1:p.(Arg689Trp)	CPSR_classification|class	NA	all_exons	.	.	include	variant_in_more_than_10%_of_tumor_samples_(24.41%)_with_VAF_under_0.01	.	.
CL-AcroMetrix	FBXW7	ENST00000281708	NM_001349798	4:153247244	C>T	c.1558G>A	exon10	D520N	Asp520Asn	c.1558G>A:exon10:D520N:Asp520Asn	missense_variant	899	0.042	NA	NA	NA	NA	COSV55895090|COSV55923112|COSV55961967	NA	NA	NA	NA	NA	NA	FBXW7|D520|5.42e-05	Colon_Adenocarcinoma:_0.3%_(1/399)|Bladder_Urothelial_Carcinoma:_0.2%_(1/412)	NA	T:53+1+0+0=54/463|N:1+0+0+0=1/104|A:54+1+0+0=55/567	FBXW7:p.D520N:ENST00000281708&ENST00000603548&ENST00000603841:CTAT_POPULATION|CTAT_CANCER|3D_STRUCTURE	NOTCH	NA	[non-HC]_1.88/1.76_NA	TIER_3	Likely_Pathogenic	NA	SOM	WD_domain|G-beta_repeat	NA	missense_variant:R:FBXW7:XP_005263165.1:p.(Asp344Asn)|R:FBXW7:Canonical:NP_060785.2:p.(Asp440Asn)|R:FBXW7:NP_001013433.1:p.(Asp402Asn)|R:FBXW7:XP_005263164.1:p.(Asp520Asn)|R:FBXW7:NP_361014.1:p.(Asp520Asn)|E:FBXW7:Canonical:ENSP00000281708.3:p.(Asp520Asn)|E:FBXW7:ENSP00000296555.4:p.(Asp402Asn)|E:FBXW7:ENSP00000263981.4:p.(Asp440Asn)|E:FBXW7:ENSP00000474725.1:p.(Asp520Asn)|E:FBXW7:ENSP00000377528.3:p.(Asp344Asn)|E:FBXW7:ENSP00000474971.1:p.(Asp520Asn)	CPSR_classification|class	NA	all_exons	.	.	include	variant_in_more_than_10%_of_tumor_samples_(11.45%)_with_VAF_under_0.01	.	.
CL-AcroMetrix	FBXW7	ENST00000281708	NM_001349798	4:153247366	C>T	c.1436G>A	exon10	R479Q	Arg479Gln	c.1436G>A:exon10:R479Q:Arg479Gln	missense_variant	727	0.05	NA	NA	NA	NA	COSV55890822|COSV55894913|COSV55899054	rs866987936	376419	NA	NA	NA	NA	FBXW7|R479|4.38e-63	Uterine_Carcinosarcoma:_5.3%_(3/57)|Uveal_Melanoma:_1.2%_(1/80)|Stomach_Adenocarcinoma:_0.9%_(4/437)|Uterine_Corpus_Endometrial_Carcinoma:_0.9%_(5/530)|Head_and_Neck_Squamous_Cell_Carcinoma:_0.4%_(2/508)|Glioblastoma_Multiforme:_0.3%_(1/393)|Skin_Cutaneous_Melanoma:_0.2%_(1/468)|Breast_Invasive_Carcinoma:_0.1%_(1/986)	NA	T:125+0+0+0=125/463|N:3+0+0+0=3/104|A:128+0+0+0=128/567	FBXW7:p.R479Q:ENST00000281708&ENST00000603548&ENST00000603841:CTAT_POPULATION|CTAT_CANCER|3D_STRUCTURE	NOTCH	NA	[non-HC]_1.88/1.76_NA	TIER_3	Likely_Pathogenic	Likely_Pathogenic	SOM	WD_domain|G-beta_repeat	NA	missense_variant:R:FBXW7:XP_005263165.1:p.(Arg303Gln)|R:FBXW7:Canonical:NP_060785.2:p.(Arg399Gln)|R:FBXW7:NP_001013433.1:p.(Arg361Gln)|R:FBXW7:XP_005263164.1:p.(Arg479Gln)|R:FBXW7:NP_361014.1:p.(Arg479Gln)|E:FBXW7:Canonical:ENSP00000281708.3:p.(Arg479Gln)|E:FBXW7:ENSP00000296555.4:p.(Arg361Gln)|E:FBXW7:ENSP00000263981.4:p.(Arg399Gln)|E:FBXW7:ENSP00000474725.1:p.(Arg479Gln)|E:FBXW7:ENSP00000377528.3:p.(Arg303Gln)|E:FBXW7:ENSP00000474971.1:p.(Arg479Gln)	CPSR_classification|ClinVar_classification|class	NA	all_exons	.	.	include	variant_in_more_than_10%_of_tumor_samples_(27.0%)_with_VAF_under_0.01	.	.
CL-AcroMetrix	FBXW7	ENST00000281708	NM_001349798	4:153249384	C>T	c.1394G>A	exon9	R465H	Arg465His	c.1394G>A:exon9:R465H:Arg465His	missense_variant	919	0.063	NA	NA	NA	NA	COSV55891746|COSV55897262|COSV55941157	rs1057519895	376415	0	NA	0.0000000	NA	FBXW7|R465|1.92e-192	Uterine_Carcinosarcoma:_3.5%_(2/57)|Colon_Adenocarcinoma:_2.3%_(9/399)|Rectum_Adenocarcinoma:_2.2%_(3/137)|Uterine_Corpus_Endometrial_Carcinoma:_1.7%_(9/530)|Cervical_Squamous_Cell_Carcinoma_and_Endocervical_Adenocarcinoma:_0.7%_(2/289)|Stomach_Adenocarcinoma:_0.5%_(2/437)|Lung_Adenocarcinoma:_0.2%_(1/567)|Lung_Squamous_Cell_Carcinoma:_0.2%_(1/492)|Ovarian_Serous_Cystadenocarcinoma:_0.2%_(1/436)	NA	T:148+4+1+0=153/463|N:7+0+0+0=7/104|A:155+4+1+0=160/567	FBXW7:p.R465H:ENST00000281708&ENST00000603548&ENST00000603841:CTAT_POPULATION|CTAT_CANCER|3D_STRUCTURE	NOTCH	NA	[non-HC]_1.88/1.76_NA	TIER_3	Likely_Pathogenic	Likely_Pathogenic	SOM	WD_domain|G-beta_repeat	NA	missense_variant:R:FBXW7:XP_005263165.1:p.(Arg289His)|R:FBXW7:Canonical:NP_060785.2:p.(Arg385His)|R:FBXW7:NP_001013433.1:p.(Arg347His)|R:FBXW7:XP_005263164.1:p.(Arg465His)|R:FBXW7:NP_361014.1:p.(Arg465His)|E:FBXW7:Canonical:ENSP00000281708.3:p.(Arg465His)|E:FBXW7:ENSP00000296555.4:p.(Arg347His)|E:FBXW7:ENSP00000263981.4:p.(Arg385His)|E:FBXW7:ENSP00000474725.1:p.(Arg465His)|E:FBXW7:ENSP00000377528.3:p.(Arg289His)|E:FBXW7:ENSP00000474971.1:p.(Arg465His)	CPSR_classification|ClinVar_classification|class	NA	all_exons	.	.	include	variant_in_more_than_10%_of_tumor_samples_(31.97%)_with_VAF_under_0.01	.	.
CL-AcroMetrix	FBXW7	ENST00000281708	NM_001349798	4:153249456	C>A	c.1322G>T	exon9	R441L	Arg441Leu	c.1322G>T:exon9:R441L:Arg441Leu	missense_variant	905	0.056	NA	NA	NA	NA	COSV55898232|COSV55900020|COSV55902900	NA	NA	NA	NA	NA	NA	FBXW7|R441|0.0529	NA	NA	T:34+2+0+0=36/463|N:4+1+0+0=5/104|A:38+3+0+0=41/567	NA	NOTCH	NA	[non-HC]_1.88/1.76_NA	TIER_3	Likely_Pathogenic	NA	SOM	WD_domain|G-beta_repeat	NA	missense_variant:R:FBXW7:XP_005263165.1:p.(Arg265Leu)|R:FBXW7:Canonical:NP_060785.2:p.(Arg361Leu)|R:FBXW7:NP_001013433.1:p.(Arg323Leu)|R:FBXW7:XP_005263164.1:p.(Arg441Leu)|R:FBXW7:NP_361014.1:p.(Arg441Leu)|E:FBXW7:Canonical:ENSP00000281708.3:p.(Arg441Leu)|E:FBXW7:ENSP00000296555.4:p.(Arg323Leu)|E:FBXW7:ENSP00000263981.4:p.(Arg361Leu)|E:FBXW7:ENSP00000474725.1:p.(Arg441Leu)|E:FBXW7:ENSP00000377528.3:p.(Arg265Leu)|E:FBXW7:ENSP00000474971.1:p.(Arg441Leu)	CPSR_classification|class	NA	all_exons	.	.	include	.	.	.
CL-AcroMetrix	FGFR2	ENST00000457416	NM_022970	10:123258034	A>T	c.1650T>A	exon12	N550K	Asn550Lys	c.1650T>A:exon12:N550K:Asn550Lys	missense_variant	839	0.078	NA	NA	NA	NA	COSV60638757|COSV60639738	rs121913476	376157	NA	NA	NA	NA	FGFR2|N549|2.64e-44	Uterine_Corpus_Endometrial_Carcinoma:_1.1%_(6/530)|Bladder_Urothelial_Carcinoma:_0.2%_(1/412)|Breast_Invasive_Carcinoma:_0.2%_(2/986)|Lung_Adenocarcinoma:_0.2%_(1/567)	NA	T:6+0+0+0=6/463|N:4+0+0+0=4/104|A:10+0+0+0=10/567	NA	RTKRAS	NA	[HC]_1.816/1.632_NA	TIER_3	VUS	Likely_Pathogenic	SOM	Protein_tyrosine_and_serine/threonine_kinase	Infigratinib|Regorafenib|Regorafenib_Hydrate|Orantinib|Erdafitinib|Futibatinib|Brivanib|Pemigatinib|Nintedanib	missense_variant:R:FGFR2:NP_001307583.1:p.(Asn321Lys)|R:FGFR2:NP_001138386.1:p.(Asn437Lys)|R:FGFR2:NP_075418.1:p.(Asn460Lys)|R:FGFR2:NP_001138388.1:p.(Asn434Lys)|R:FGFR2:NP_001138387.1:p.(Asn460Lys)|R:FGFR2:Canonical:NP_075259.4:p.(Asn550Lys)|R:FGFR2:NP_000132.3:p.(Asn549Lys)|R:FGFR2:NP_001138389.1:p.(Asn433Lys)|R:FGFR2:NP_001138390.1:p.(Asn432Lys)|R:FGFR2:NP_001307587.1:p.(Asn547Lys)|E:FGFR2:ENSP00000358057.4:p.(Asn437Lys)|E:FGFR2:ENSP00000350166.5:p.(Asn460Lys)|E:FGFR2:ENSP00000351276.5:p.(Asn549Lys)|E:FGFR2:ENSP00000474011.1:p.(Asn321Lys)|E:FGFR2:ENSP00000348559.4:p.(Asn432Lys)|E:FGFR2:ENSP00000358056.4:p.(Asn433Lys)|E:FGFR2:ENSP00000358055.1:p.(Asn435Lys)|E:FGFR2:ENSP00000404219.1:p.(Asn141Lys)|E:FGFR2:ENSP00000263451.5:p.(Asn547Lys)|E:FGFR2:Canonical:ENSP00000410294.2:p.(Asn550Lys)|E:FGFR2:ENSP00000309878.8:p.(Asn547Lys)|E:FGFR2:ENSP00000353262.3:p.(Asn461Lys)|R:FGFR2:NP_001138385.1:p.(Asn550Lys)|R:FGFR2:NP_001138391.1:p.(Asn461Lys)|E:FGFR2:ENSP00000358052.1:p.(Asn550Lys)|E:FGFR2:ENSP00000358054.3:p.(Asn550Lys)|E:FGFR2:ENSP00000337665.6:p.(Asn458Lys)	ClinVar_classification|class	NA	introns[1];IS:introns[17],all_exons	.	.	include	.	.	.
CL-AcroMetrix	FGFR2	ENST00000457416	NM_022970	10:123274774	A>G	c.1147T>C	exon9	C383R	Cys383Arg	c.1147T>C:exon9:C383R:Cys383Arg	missense_variant	1236	0.066	NA	NA	NA	NA	COSV60638681|COSV60642677	rs121913474	376431	NA	NA	NA	NA	FGFR2|C382|4.77e-18	Uterine_Corpus_Endometrial_Carcinoma:_0.9%_(5/530)|Lung_Squamous_Cell_Carcinoma:_0.2%_(1/492)|Stomach_Adenocarcinoma:_0.2%_(1/437)	NA	T:10+0+0+0=10/463|N:3+0+0+0=3/104|A:13+0+0+0=13/567	FGFR2:p.C383R:ENST00000457416&ENST00000369056&ENST00000369058:CTAT_POPULATION|CTAT_CANCER	RTKRAS	NA	[HC]_1.816/1.632_NA	TIER_3	VUS	VUS	SOM	NA	Infigratinib|Regorafenib|Regorafenib_Hydrate|Orantinib|Erdafitinib|Futibatinib|Brivanib|Pemigatinib|Nintedanib	missense_variant:R:FGFR2:NP_001307583.1:p.(Cys154Arg)|R:FGFR2:NP_001138386.1:p.(Cys270Arg)|R:FGFR2:NP_075418.1:p.(Cys293Arg)|R:FGFR2:NP_001138388.1:p.(Cys267Arg)|R:FGFR2:NP_001138387.1:p.(Cys293Arg)|R:FGFR2:Canonical:NP_075259.4:p.(Cys383Arg)|R:FGFR2:NP_000132.3:p.(Cys382Arg)|R:FGFR2:NP_001138390.1:p.(Cys267Arg)|R:FGFR2:NP_001307587.1:p.(Cys382Arg)|E:FGFR2:ENSP00000358057.4:p.(Cys270Arg)|E:FGFR2:ENSP00000350166.5:p.(Cys293Arg)|E:FGFR2:ENSP00000351276.5:p.(Cys382Arg)|E:FGFR2:ENSP00000474011.1:p.(Cys154Arg)|E:FGFR2:ENSP00000348559.4:p.(Cys267Arg)|E:FGFR2:ENSP00000358055.1:p.(Cys268Arg)|E:FGFR2:ENSP00000263451.5:p.(Cys382Arg)|E:FGFR2:Canonical:ENSP00000410294.2:p.(Cys383Arg)|E:FGFR2:ENSP00000309878.8:p.(Cys382Arg)|E:FGFR2:ENSP00000353262.3:p.(Cys294Arg)|R:FGFR2:NP_001138385.1:p.(Cys383Arg)|R:FGFR2:NP_001138391.1:p.(Cys294Arg)|E:FGFR2:ENSP00000358052.1:p.(Cys383Arg)|E:FGFR2:ENSP00000358054.3:p.(Cys383Arg)|E:FGFR2:ENSP00000337665.6:p.(Cys293Arg);upstream_gene_variant:E:FGFR2:ENST00000429361.1	class	NA	introns[1];IS:introns[17],all_exons	.	.	include	.	.	.
CL-AcroMetrix	FGFR2	ENST00000457416	NM_022970	10:123274794	T>C	c.1127A>G	exon9	Y376C	Tyr376Cys	c.1127A>G:exon9:Y376C:Tyr376Cys	missense_variant	1169	0.062	NA	NA	NA	NA	COSV60640350	rs121913478	13277	NA	NA	NA	NA	FGFR2|Y375|0.000503	Cholangiocarcinoma:_2%_(1/51)|Uterine_Corpus_Endometrial_Carcinoma:_0.4%_(2/530)|Cervical_Squamous_Cell_Carcinoma_and_Endocervical_Adenocarcinoma:_0.3%_(1/289)	LIRI-JP/Primary/1/250/0.004	T:7+0+0+0=7/463|N:2+0+0+0=2/104|A:9+0+0+0=9/567	FGFR2:p.Y376C:ENST00000457416&ENST00000369056&ENST00000369058:CTAT_POPULATION|CTAT_CANCER	RTKRAS	NA	[HC]_1.816/1.632_NA	TIER_3	Pathogenic	Likely_Pathogenic	SOM	NA	Infigratinib|Regorafenib|Regorafenib_Hydrate|Orantinib|Erdafitinib|Futibatinib|Brivanib|Pemigatinib|Nintedanib	missense_variant:R:FGFR2:NP_001307583.1:p.(Tyr147Cys)|R:FGFR2:NP_001138386.1:p.(Tyr263Cys)|R:FGFR2:NP_075418.1:p.(Tyr286Cys)|R:FGFR2:NP_001138388.1:p.(Tyr260Cys)|R:FGFR2:NP_001138387.1:p.(Tyr286Cys)|R:FGFR2:Canonical:NP_075259.4:p.(Tyr376Cys)|R:FGFR2:NP_000132.3:p.(Tyr375Cys)|R:FGFR2:NP_001138390.1:p.(Tyr260Cys)|R:FGFR2:NP_001307587.1:p.(Tyr375Cys)|E:FGFR2:ENSP00000358057.4:p.(Tyr263Cys)|E:FGFR2:ENSP00000350166.5:p.(Tyr286Cys)|E:FGFR2:ENSP00000351276.5:p.(Tyr375Cys)|E:FGFR2:ENSP00000474011.1:p.(Tyr147Cys)|E:FGFR2:ENSP00000348559.4:p.(Tyr260Cys)|E:FGFR2:ENSP00000358055.1:p.(Tyr261Cys)|E:FGFR2:ENSP00000263451.5:p.(Tyr375Cys)|E:FGFR2:Canonical:ENSP00000410294.2:p.(Tyr376Cys)|E:FGFR2:ENSP00000309878.8:p.(Tyr375Cys)|E:FGFR2:ENSP00000353262.3:p.(Tyr287Cys)|R:FGFR2:NP_001138385.1:p.(Tyr376Cys)|R:FGFR2:NP_001138391.1:p.(Tyr287Cys)|E:FGFR2:ENSP00000358052.1:p.(Tyr376Cys)|E:FGFR2:ENSP00000358054.3:p.(Tyr376Cys)|E:FGFR2:ENSP00000337665.6:p.(Tyr286Cys);upstream_gene_variant:E:FGFR2:ENST00000429361.1	CPSR_classification|ClinVar_classification|class	NA	introns[1];IS:introns[17],all_exons	.	.	include	.	.	.
CL-AcroMetrix	FGFR2	ENST00000457416	NM_022970	10:123279677	G>C	c.755C>G	exon7	S252W	Ser252Trp	c.755C>G:exon7:S252W:Ser252Trp	missense_variant	1169	0.075	NA	NA	NA	NA	COSV60638319|COSV60657130	rs79184941	13272	4e-06	NA	0.0000000	NA	FGFR2|S252|4.17e-24	Uterine_Corpus_Endometrial_Carcinoma:_4.3%_(23/530)|Uterine_Carcinosarcoma:_1.8%_(1/57)	BTCA-SG/Primary/1/12/0.0833	T:14+0+0+0=14/463|N:2+0+0+0=2/104|A:16+0+0+0=16/567	FGFR2:p.S252W:ENST00000358487&ENST00000369060&ENST00000346997&ENST00000457416&ENST00000351936&ENST00000369056&ENST00000369058:CTAT_POPULATION|CTAT_CANCER|3D_STRUCTURE	RTKRAS	NA	[HC]_1.816/1.632_NA	TIER_3	Pathogenic	Pathogenic	SOM	NA	Infigratinib|Regorafenib|Regorafenib_Hydrate|Orantinib|Erdafitinib|Futibatinib|Brivanib|Pemigatinib|Nintedanib	missense_variant:R:FGFR2:NP_001307583.1:p.(Ser24Trp)|R:FGFR2:NP_075418.1:p.(Ser163Trp)|R:FGFR2:NP_001138388.1:p.(Ser137Trp)|R:FGFR2:NP_001138387.1:p.(Ser163Trp)|R:FGFR2:Canonical:NP_075259.4:p.(Ser252Trp)|R:FGFR2:NP_000132.3:p.(Ser252Trp)|R:FGFR2:NP_001138389.1:p.(Ser252Trp)|R:FGFR2:NP_001138390.1:p.(Ser137Trp)|R:FGFR2:NP_001307587.1:p.(Ser252Trp)|E:FGFR2:ENSP00000350166.5:p.(Ser163Trp)|E:FGFR2:ENSP00000351276.5:p.(Ser252Trp)|E:FGFR2:ENSP00000474011.1:p.(Ser24Trp)|E:FGFR2:ENSP00000348559.4:p.(Ser137Trp)|E:FGFR2:ENSP00000358056.4:p.(Ser252Trp)|E:FGFR2:ENSP00000358055.1:p.(Ser137Trp)|E:FGFR2:ENSP00000263451.5:p.(Ser252Trp)|E:FGFR2:Canonical:ENSP00000410294.2:p.(Ser252Trp)|E:FGFR2:ENSP00000309878.8:p.(Ser252Trp)|E:FGFR2:ENSP00000353262.3:p.(Ser163Trp)|R:FGFR2:NP_001138385.1:p.(Ser252Trp)|R:FGFR2:NP_001138391.1:p.(Ser163Trp)|E:FGFR2:ENSP00000358052.1:p.(Ser252Trp)|E:FGFR2:ENSP00000358054.3:p.(Ser252Trp)|E:FGFR2:ENSP00000337665.6:p.(Ser163Trp);upstream_gene_variant:E:FGFR2:ENST00000429361.1	CPSR_classification|ClinVar_classification|class	NA	introns[1];IS:introns[17],all_exons	.	.	include	.	.	.
CL-AcroMetrix	FGFR3	ENST00000340107	NM_001163213	4:1803568	C>G	c.746C>G	exon7	S249C	Ser249Cys	c.746C>G:exon7:S249C:Ser249Cys	missense_variant	972	0.071	NA	NA	NA	NA	COSV53390026	rs121913483	16339	0	NA	0.0000000	NA	FGFR3|S249|3.49e-229	Bladder_Urothelial_Carcinoma:_7.5%_(31/412)|Head_and_Neck_Squamous_Cell_Carcinoma:_0.8%_(4/508)|Lung_Squamous_Cell_Carcinoma:_0.6%_(3/492)	NA	T:2+0+0+0=2/462|N:0+0+0+0=0/103|A:2+0+0+0=2/565	FGFR3:p.S249C:ENST00000481110&ENST00000340107&ENST00000440486&ENST00000412135&ENST00000260795&ENST00000352904:CTAT_POPULATION|CTAT_CANCER|3D_STRUCTURE	RTKRAS	NA	[HC]_2.122/2.244_NA	TIER_3	Pathogenic	Pathogenic	SOM	NA	Pazopanib_Hydrochloride|Infigratinib|Masitinib|Orantinib|Erdafitinib|Futibatinib|Brivanib|Pemigatinib|Pazopanib|Nintedanib|Dovitinib	missense_variant:E:FGFR3:ENSP00000420533.2:p.(Ser249Cys)|E:FGFR3:Canonical:ENSP00000339824.4:p.(Ser249Cys)|E:FGFR3:ENSP00000414914.2:p.(Ser249Cys)|E:FGFR3:ENSP00000412903.2:p.(Ser249Cys)|R:FGFR3:Canonical:NP_001156685.1:p.(Ser249Cys)|R:FGFR3:NP_075254.1:p.(Ser249Cys)|R:FGFR3:NP_000133.1:p.(Ser249Cys)|E:FGFR3:ENSP00000260795.2:p.(Ser249Cys)|E:FGFR3:ENSP00000231803.1:p.(Ser249Cys)|E:FGFR3:ENSP00000427289.1:p.(Ser69Cys)	CPSR_classification|ClinVar_classification|class	NA	all_exons;IS:introns[17],exons[7,9aka10,14,18]	.	.	include	.	.	.
CL-AcroMetrix	FGFR3	ENST00000340107	NM_001163213	4:1806089	G>T	c.1114G>T	exon9	G372C	Gly372Cys	c.1114G>T:exon9:G372C:Gly372Cys	missense_variant	1283	0.049	NA	NA	NA	NA	COSV53390089|COSV99600444	rs121913479	16359	0	NA	0.0000000	NA	FGFR3|G370|4.34e-13	Bladder_Urothelial_Carcinoma:_1.2%_(5/412)	NA	T:32+1+0+0=33/463|N:4+0+0+0=4/104|A:36+1+0+0=37/567	NA	RTKRAS	NA	[HC]_2.122/2.244_NA	TIER_3	Likely_Pathogenic	Pathogenic	SOM	NA	Pazopanib_Hydrochloride|Infigratinib|Masitinib|Orantinib|Erdafitinib|Futibatinib|Brivanib|Pemigatinib|Pazopanib|Nintedanib|Dovitinib	missense_variant:E:FGFR3:ENSP00000420533.2:p.(Gly370Cys)|E:FGFR3:Canonical:ENSP00000339824.4:p.(Gly372Cys)|E:FGFR3:ENSP00000414914.2:p.(Gly370Cys)|R:FGFR3:Canonical:NP_001156685.1:p.(Gly372Cys)|R:FGFR3:NP_000133.1:p.(Gly370Cys)|E:FGFR3:ENSP00000260795.2:p.(Gly370Cys);downstream_gene_variant:E:FGFR3:ENST00000507588.1	CPSR_classification|ClinVar_classification|class	NA	all_exons;IS:introns[17],exons[7,9aka10,14,18]	.	.	include	.	.	.
CL-AcroMetrix	FGFR3	ENST00000340107	NM_001163213	4:1806119	G>A	c.1144G>A	exon9	G382R	Gly382Arg	c.1144G>A:exon9:G382R:Gly382Arg	missense_variant	1243	0.043	NA	NA	NA	NA	COSV53399372|COSV99602429	rs28931614	16327	0	NA	0.0000000	NA	FGFR3|G380|1.21e-08	Bladder_Urothelial_Carcinoma:_0.5%_(2/412)|Head_and_Neck_Squamous_Cell_Carcinoma:_0.2%_(1/508)|Stomach_Adenocarcinoma:_0.2%_(1/437)	NA	T:98+1+0+0=99/463|N:4+0+0+0=4/104|A:102+1+0+0=103/567	FGFR3:p.G382R:ENST00000340107:CTAT_POPULATION|CTAT_CANCER	RTKRAS	NA	[HC]_2.122/2.244_NA	TIER_3	Pathogenic	VUS	SOM	NA	Pazopanib_Hydrochloride|Infigratinib|Masitinib|Orantinib|Erdafitinib|Futibatinib|Brivanib|Pemigatinib|Pazopanib|Nintedanib|Dovitinib	missense_variant:E:FGFR3:ENSP00000420533.2:p.(Gly380Arg)|E:FGFR3:Canonical:ENSP00000339824.4:p.(Gly382Arg)|E:FGFR3:ENSP00000414914.2:p.(Gly380Arg)|R:FGFR3:Canonical:NP_001156685.1:p.(Gly382Arg)|R:FGFR3:NP_000133.1:p.(Gly380Arg)|E:FGFR3:ENSP00000260795.2:p.(Gly380Arg);downstream_gene_variant:E:FGFR3:ENST00000507588.1	CPSR_classification|class	NA	all_exons;IS:introns[17],exons[7,9aka10,14,18]	.	.	include	variant_in_more_than_10%_of_tumor_samples_(21.17%)_with_VAF_under_0.01	.	.
CL-AcroMetrix	FGFR3	ENST00000340107	NM_001163213	4:1807889	A>G	c.1954A>G	exon14	K652E	Lys652Glu	c.1954A>G:exon14:K652E:Lys652Glu	missense_variant	1087	0.076	NA	NA	NA	NA	COSV53390625|COSV53407424	rs78311289	16331	NA	NA	NA	NA	FGFR3|K650|2.01e-12	Bladder_Urothelial_Carcinoma:_0.5%_(2/412)|Glioblastoma_Multiforme:_0.3%_(1/393)	NA	T:6+0+0+0=6/463|N:3+0+0+0=3/104|A:9+0+0+0=9/567	FGFR3:p.K652E:ENST00000340107:CTAT_POPULATION|CTAT_CANCER	RTKRAS	NA	[HC]_2.122/2.244_NA	TIER_3	Pathogenic	Pathogenic	SOM	Protein_tyrosine_and_serine/threonine_kinase	Pazopanib_Hydrochloride|Infigratinib|Masitinib|Orantinib|Erdafitinib|Futibatinib|Brivanib|Pemigatinib|Pazopanib|Nintedanib|Dovitinib	missense_variant:E:FGFR3:ENSP00000420533.2:p.(Lys651Glu)|E:FGFR3:Canonical:ENSP00000339824.4:p.(Lys652Glu)|E:FGFR3:ENSP00000414914.2:p.(Lys650Glu)|E:FGFR3:ENSP00000412903.2:p.(Lys538Glu)|R:FGFR3:Canonical:NP_001156685.1:p.(Lys652Glu)|R:FGFR3:NP_075254.1:p.(Lys538Glu)|R:FGFR3:NP_000133.1:p.(Lys650Glu)|E:FGFR3:ENSP00000260795.2:p.(Lys650Glu)|E:FGFR3:ENSP00000231803.1:p.(Lys538Glu);downstream_gene_variant:E:FGFR3:ENST00000507588.1	CPSR_classification|ClinVar_classification|class	NA	all_exons;IS:introns[17],exons[7,9aka10,14,18]	.	.	include	.	.	.
CL-AcroMetrix	GNAQ	ENST00000286548	NM_002072	9:80412493	C>T	c.548G>A	exon4	R183Q	Arg183Gln	c.548G>A:exon4:R183Q:Arg183Gln	missense_variant	993	0.202	NA	NA	NA	NA	COSV54106047|COSV54107425	rs397514698	50853	NA	NA	NA	NA	GNAQ|R183|0.000623	Uveal_Melanoma:_1.2%_(1/80)|Colon_Adenocarcinoma:_0.3%_(1/399)	NA	T:96+1+0+1=98/463|N:4+0+0+0=4/104|A:100+1+0+1=102/567	GNAQ:p.R183Q:ENST00000286548:CTAT_POPULATION|CTAT_CANCER|3D_STRUCTURE	NA	NA	[non-HC]_1.97/1.94_NA	TIER_3	NA	NA	SOM	G-protein_alpha_subunit	NA	missense_variant:E:GNAQ:Canonical:ENSP00000286548.4:p.(Arg183Gln)|R:GNAQ:Canonical:NP_002063.2:p.(Arg183Gln)|R:GNAQ:NP_002063.2:p.(Arg183Gln)|E:GNAQ:ENSP00000391501.1:p.(Arg154Gln);5_prime_UTR_variant:E:GNAQ:ENST00000397476.3	class	NA	all_exons;IS:exons[4-5]	.	.	include	variant_in_more_than_10%_of_tumor_samples_(20.73%)_with_VAF_under_0.01	.	.
CL-AcroMetrix	GNAS	ENST00000371100	NM_080425	20:57484420	C>T	c.2530C>T	exon8	R844C	Arg844Cys	c.2530C>T:exon8:R844C:Arg844Cys	missense_variant	1088	0.072	NA	NA	NA	NA	COSV55670339|COSV55670675|COSV55677163	rs11554273	15933	0	NA	0.0000000	NA	GNAS|R201|7.47e-257	Pancreatic_Adenocarcinoma:_2.2%_(4/180)|Adrenocortical_Carcinoma:_1.1%_(1/92)|Liver_Hepatocellular_Carcinoma:_1.1%_(4/364)|Colon_Adenocarcinoma:_0.5%_(2/399)|Esophageal_Carcinoma:_0.5%_(1/184)|Stomach_Adenocarcinoma:_0.5%_(2/437)|Cervical_Squamous_Cell_Carcinoma_and_Endocervical_Adenocarcinoma:_0.3%_(1/289)|Lung_Adenocarcinoma:_0.2%_(1/567)|Skin_Cutaneous_Melanoma:_0.2%_(1/468)|Breast_Invasive_Carcinoma:_0.1%_(1/986)	BRCA-EU/Primary/1/76/0.0132|ESAD-UK/Primary/1/97/0.0103|PACA-AU/Primary/3/90/0.0333|PACA-CA/Primary/2/140/0.0143	T:137+2+2+0=141/463|N:6+0+0+0=6/104|A:143+2+2+0=147/567	GNAS:p.R844C:ENST00000371100:CTAT_POPULATION|CTAT_CANCER	NA	NA	[non-HC]_2.02/2.04_NA	TIER_3	VUS	Likely_Pathogenic	SOM	G-protein_alpha_subunit	NA	3_prime_UTR_variant:E:GNAS:ENST00000313949.7|R:GNAS:NM_016592.3|R:GNAS:NM_016592.2|E:GNAS:ENST00000371075.3|R:GNAS:NM_001077490.1|R:GNAS:NM_001077490.2;missense_variant:R:GNAS:XP_005260454.1:p.(Arg169Cys)|R:GNAS:XP_005260455.1:p.(Arg154Cys)|R:GNAS:XP_005260458.1:p.(Arg127Cys)|R:GNAS:NP_001296790.1:p.(Arg142Cys)|E:GNAS:Canonical:ENSP00000360141.3:p.(Arg844Cys)|R:GNAS:NP_536350.2:p.(Arg844Cys)|R:GNAS:Canonical:NP_536350.2:p.(Arg844Cys)|E:GNAS:ENSP00000360143.4:p.(Arg830Cys)|R:GNAS:XP_005260453.1:p.(Arg182Cys)|R:GNAS:NP_001296769.1:p.(Arg142Cys)|E:GNAS:ENSP00000474219.1:p.(Arg142Cys)|R:GNAS:XP_005260456.1:p.(Arg127Cys)|R:GNAS:XP_005260459.1:p.(Arg143Cys)|E:GNAS:ENSP00000360136.3:p.(Arg187Cys)|E:GNAS:ENSP00000360126.3:p.(Arg201Cys)|E:GNAS:ENSP00000346328.7:p.(Arg202Cys)|R:GNAS:NP_536351.1:p.(Arg187Cys)|R:GNAS:NP_001070956.1:p.(Arg202Cys)|R:GNAS:NP_001070957.1:p.(Arg186Cys)|R:GNAS:NP_000507.1:p.(Arg201Cys)|E:GNAS:ENSP00000265620.7:p.(Arg186Cys)|R:GNAS:NP_001070957.1:p.(Arg186Cys)|R:GNAS:NP_000507.1:p.(Arg201Cys)|R:GNAS:NP_001070956.1:p.(Arg202Cys)|R:GNAS:NP_536351.1:p.(Arg187Cys)|E:GNAS:ENSP00000304472.10:p.(Arg187Cys)|R:GNAS:XP_005260457.1:p.(Arg127Cys);downstream_gene_variant:E:GNAS:ENST00000419558.1|E:GNAS:ENST00000450130.1|E:GNAS:ENST00000349036.3|E:GNAS:ENST00000603546.1	ClinVar_classification|class	NA	all_exons;IS:exons[1,8]	.	.	include	variant_in_more_than_10%_of_tumor_samples_(29.59%)_with_VAF_under_0.01	.	.
CL-AcroMetrix	GNAS	ENST00000371100	NM_080425	20:57484596	A>T	c.2609A>T	exon9	Q870L	Gln870Leu	c.2609A>T:exon9:Q870L:Gln870Leu	missense_variant	1122	0.075	NA	NA	NA	NA	COSV55670795|COSV55671120	rs121913494	210047	NA	NA	NA	NA	GNAS|Q227|9.93e-10	Skin_Cutaneous_Melanoma:_0.2%_(1/468)	NA	T:7+0+0+0=7/463|N:5+0+0+0=5/104|A:12+0+0+0=12/567	GNAS:p.Q870L:ENST00000371100:CTAT_POPULATION|CTAT_CANCER	NA	NA	[non-HC]_2.02/2.04_NA	TIER_3	VUS	Likely_Pathogenic	SOM	G-protein_alpha_subunit	NA	3_prime_UTR_variant:E:GNAS:ENST00000313949.7|R:GNAS:NM_016592.3|R:GNAS:NM_016592.2|E:GNAS:ENST00000371075.3|R:GNAS:NM_001077490.1|R:GNAS:NM_001077490.2;missense_variant:R:GNAS:XP_005260454.1:p.(Gln195Leu)|R:GNAS:XP_005260455.1:p.(Gln180Leu)|R:GNAS:XP_005260458.1:p.(Gln153Leu)|R:GNAS:NP_001296790.1:p.(Gln168Leu)|E:GNAS:Canonical:ENSP00000360141.3:p.(Gln870Leu)|R:GNAS:NP_536350.2:p.(Gln870Leu)|R:GNAS:Canonical:NP_536350.2:p.(Gln870Leu)|E:GNAS:ENSP00000360143.4:p.(Gln856Leu)|R:GNAS:XP_005260453.1:p.(Gln208Leu)|R:GNAS:NP_001296769.1:p.(Gln168Leu)|R:GNAS:XP_005260456.1:p.(Gln153Leu)|R:GNAS:XP_005260459.1:p.(Gln169Leu)|E:GNAS:ENSP00000360136.3:p.(Gln213Leu)|E:GNAS:ENSP00000360126.3:p.(Gln227Leu)|E:GNAS:ENSP00000346328.7:p.(Gln228Leu)|R:GNAS:NP_536351.1:p.(Gln213Leu)|R:GNAS:NP_001070956.1:p.(Gln228Leu)|R:GNAS:NP_001070957.1:p.(Gln212Leu)|R:GNAS:NP_000507.1:p.(Gln227Leu)|E:GNAS:ENSP00000265620.7:p.(Gln212Leu)|R:GNAS:NP_001070957.1:p.(Gln212Leu)|R:GNAS:NP_000507.1:p.(Gln227Leu)|R:GNAS:NP_001070956.1:p.(Gln228Leu)|R:GNAS:NP_536351.1:p.(Gln213Leu)|E:GNAS:ENSP00000304472.10:p.(Gln213Leu)|R:GNAS:XP_005260457.1:p.(Gln153Leu);downstream_gene_variant:E:GNAS:ENST00000419558.1|E:GNAS:ENST00000450130.1|E:GNAS:ENST00000349036.3|E:GNAS:ENST00000604005.1|E:GNAS:ENST00000603546.1	ClinVar_classification|class	NA	all_exons;IS:exons[1,8]	.	.	include	.	.	.
CL-AcroMetrix	HRAS	ENST00000451590	NM_001130442	11:533874	T>C	c.182A>G	exon3	Q61R	Gln61Arg	c.182A>G:exon3:Q61R:Gln61Arg	missense_variant	1270	0.062	NA	NA	NA	NA	COSV54236656|COSV54236691|COSV54238654	rs121913233	160364	NA	NA	NA	NA	HRAS|Q61|8.15e-210	Pheochromocytoma_and_Paraganglioma:_7.3%_(13/179)|Thyroid_Carcinoma:_2.8%_(14/492)|Prostate_Adenocarcinoma:_0.4%_(2/496)	NA	T:12+0+1+1=14/462|N:1+0+0+0=1/104|A:13+0+1+1=15/566	HRAS:p.Q61R:ENST00000397594&ENST00000397596&ENST00000451590&ENST00000417302&ENST00000311189:CTAT_CANCER|3D_STRUCTURE	RTKRAS	NA	[non-HC]_2.302/2.604_NA	TIER_3	Pathogenic	Likely_Pathogenic	SOM	Ras_family	NA	downstream_gene_variant:R:LOC101059906:XM_003959933.2;missense_variant:E:HRAS:ENSP00000380722.1:p.(Gln61Arg)|E:HRAS:ENSP00000380723.2:p.(Gln61Arg)|R:HRAS:NP_005334.1:p.(Gln61Arg)|R:HRAS:NP_789765.1:p.(Gln61Arg)|R:HRAS:NP_001123914.1:p.(Gln61Arg)|R:HRAS:NP_001123914.1:p.(Gln61Arg)|R:HRAS:NP_789765.1:p.(Gln61Arg)|R:HRAS:Canonical:NP_005334.1:p.(Gln61Arg)|E:HRAS:Canonical:ENSP00000407586.1:p.(Gln61Arg)|E:HRAS:ENSP00000388246.1:p.(Gln61Arg)|E:HRAS:ENSP00000309845.7:p.(Gln61Arg)|R:HRAS:XP_005252941.1:p.(Gln61Arg);5_prime_UTR_variant:R:HRAS:NM_001318054.1;upstream_gene_variant:R:LRRC56:XM_005252777.1|R:LRRC56:XM_005252776.1|R:LRRC56:XM_005252775.1|R:LRRC56:XM_005252778.1|R:LRRC56:Canonical:NM_198075.3|E:LRRC56:Canonical:ENST00000270115.7	CPSR_classification|ClinVar_classification|class	NA	all_exons;IS:exons[2,3]	.	.	include	.	.	.
CL-AcroMetrix	HRAS	ENST00000451590	NM_001130442	11:534288	C>A	c.35G>T	exon2	G12V	Gly12Val	c.35G>T:exon2:G12V:Gly12Val	missense_variant	1062	0.056	NA	NA	NA	NA	COSV54236734|COSV54236774|COSV54238174	rs104894230	12600	NA	NA	NA	NA	HRAS|G12|4.29e-56	Head_and_Neck_Squamous_Cell_Carcinoma:_0.2%_(1/508)|Lung_Squamous_Cell_Carcinoma:_0.2%_(1/492)	ORCA-IN/Primary/1/13/0.0769	T:22+0+0+0=22/463|N:0+0+0+0=0/104|A:22+0+0+0=22/567	HRAS:p.G12V:ENST00000397594&ENST00000397596&ENST00000451590&ENST00000417302&ENST00000311189:CTAT_POPULATION|CTAT_CANCER|3D_STRUCTURE	RTKRAS	NA	[non-HC]_2.302/2.604_NA	TIER_3	Pathogenic	Pathogenic	SOM	Ras_family	NA	downstream_gene_variant:R:LOC101059906:XM_003959933.2;missense_variant:E:HRAS:ENSP00000380722.1:p.(Gly12Val)|E:HRAS:ENSP00000380723.2:p.(Gly12Val)|R:HRAS:NP_005334.1:p.(Gly12Val)|R:HRAS:NP_789765.1:p.(Gly12Val)|R:HRAS:NP_001123914.1:p.(Gly12Val)|R:HRAS:NP_001123914.1:p.(Gly12Val)|R:HRAS:NP_789765.1:p.(Gly12Val)|R:HRAS:Canonical:NP_005334.1:p.(Gly12Val)|E:HRAS:Canonical:ENSP00000407586.1:p.(Gly12Val)|E:HRAS:ENSP00000388246.1:p.(Gly12Val)|E:HRAS:ENSP00000309845.7:p.(Gly12Val)|R:HRAS:XP_005252941.1:p.(Gly12Val);5_prime_UTR_variant:R:HRAS:NM_001318054.1;upstream_gene_variant:R:LRRC56:XM_005252777.1|R:LRRC56:XM_005252776.1|R:LRRC56:XM_005252775.1|R:LRRC56:XM_005252778.1|R:LRRC56:Canonical:NM_198075.3|E:LRRC56:Canonical:ENST00000270115.7	CPSR_classification|ClinVar_classification|class	NA	all_exons;IS:exons[2,3]	.	.	include	.	.	.
CL-AcroMetrix	IDH1	ENST00000415913	NM_001282387	2:209113112	C>T	c.395G>A	exon4	R132H	Arg132His	c.395G>A:exon4:R132H:Arg132His	missense_variant	866	0.031	NA	NA	NA	NA	COSV61615239|COSV61615420	rs121913500	156444	0	NA	0.0000000	NA	IDH1|R132|0	Brain_Lower_Grade_Glioma:_69.9%_(356/509)|Glioblastoma_Multiforme:_5.9%_(23/393)|Acute_Myeloid_Leukemia:_2.1%_(3/144)|Bladder_Urothelial_Carcinoma:_0.2%_(1/412)|Prostate_Adenocarcinoma:_0.2%_(1/496)|Breast_Invasive_Carcinoma:_0.1%_(1/986)	MALY-DE/Primary/1/100/0.01|PRAD-CA/Primary/1/110/0.0091	T:129+1+1+4=135/463|N:9+0+0+0=9/104|A:138+1+1+4=144/567	IDH1:p.R132H:ENST00000345146&ENST00000446179&ENST00000415913&ENST00000415282:CTAT_POPULATION|CTAT_CANCER|3D_STRUCTURE	NA	NA	[non-HC]_2.024/2.048_NA	TIER_3	Pathogenic	Pathogenic	SOM	Isocitrate/isopropylmalate_dehydrogenase	Ivosidenib|Vorasidenib	missense_variant:R:IDH1:XP_005246581.1:p.(Arg132His)|R:IDH1:XP_005246580.1:p.(Arg132His)|R:IDH1:NP_001269316.1:p.(Arg132His)|R:IDH1:XP_005246579.1:p.(Arg132His)|R:IDH1:NP_001269315.1:p.(Arg132His)|E:IDH1:Canonical:ENSP00000260985.2:p.(Arg132His)|R:IDH1:Canonical:NP_005887.2:p.(Arg132His)|R:IDH1:XP_005246578.1:p.(Arg132His)|R:IDH1:NP_005887.2:p.(Arg132His)|E:IDH1:ENSP00000410513.1:p.(Arg132His)|E:IDH1:ENSP00000390265.1:p.(Arg132His)|E:IDH1:ENSP00000391075.1:p.(Arg132His);downstream_gene_variant:E:IDH1:ENST00000417583.1|E:IDH1:ENST00000451391.1	CPSR_classification|ClinVar_classification|class	NA	all_exons;IS:exons[4]	.	.	include	variant_in_more_than_10%_of_tumor_samples_(27.86%)_with_VAF_under_0.01	.	.
CL-AcroMetrix	KIT	ENST00000288135	NM_000222	4:55593661	T>C	c.1727T>C	exon11	L576P	Leu576Pro	c.1727T>C:exon11:L576P:Leu576Pro	missense_variant	942	0.055	NA	NA	NA	NA	COSV55386593|COSV55412340	rs121913513	375919	NA	NA	NA	NA	KIT|L576|6.1e-16	Skin_Cutaneous_Melanoma:_0.4%_(2/468)	NA	T:11+0+0+0=11/463|N:6+0+0+0=6/104|A:17+0+0+0=17/567	KIT:p.L576P:ENST00000288135:CTAT_POPULATION|CTAT_CANCER|3D_STRUCTURE	RTKRAS	NA	[HC]_2.044/2.088_NA	TIER_3	Likely_Pathogenic	Likely_Pathogenic	SOM	NA	Vatalanib|Sorafenib_Tosylate|Pazopanib_Hydrochloride|Sorafenib|Dasatinib|Masitinib|Regorafenib|Regorafenib_Hydrate|Semaxanib|Anlotinib|Famitinib|Pexidartinib|Sitravatinib|Pexidartinib_Hydrochloride|Avapritinib|Ripretinib|Pazopanib|Cediranib|Dovitinib|Sunitinib_Malate|Motesanib|Quizartinib|Midostaurin|Imatinib	missense_variant:E:KIT:ENSP00000390987.2:p.(Leu572Pro)|E:KIT:Canonical:ENSP00000288135.5:p.(Leu576Pro)|R:KIT:NP_001087241.1:p.(Leu572Pro)|R:KIT:Canonical:NP_000213.1:p.(Leu576Pro)|R:KIT:XP_005265799.1:p.(Leu573Pro)|R:KIT:XP_005265797.1:p.(Leu577Pro)|R:KIT:XP_005265798.1:p.(Leu577Pro)	CPSR_classification|ClinVar_classification|class	NA	all_exons;IS:introns[16],exons[8-9,11-13,17]	.	.	include	.	.	.
CL-AcroMetrix	KIT	ENST00000288135	NM_000222	4:55594221	A>G	c.1924A>G	exon13	K642E	Lys642Glu	c.1924A>G:exon13:K642E:Lys642Glu	missense_variant	1117	0.084	NA	NA	NA	NA	COSV55387507|COSV55411978	rs121913512	13866	NA	NA	NA	NA	KIT|K642|1.34e-19	Skin_Cutaneous_Melanoma:_1.3%_(6/468)	MELA-AU/Metastatic/1/60/0.0167	T:7+0+0+0=7/463|N:5+0+0+0=5/104|A:12+0+0+0=12/567	KIT:p.K642E:ENST00000288135:CTAT_POPULATION|CTAT_CANCER|3D_STRUCTURE	RTKRAS	NA	[HC]_2.044/2.088_NA	TIER_3	Likely_Pathogenic	Pathogenic	SOM	Protein_tyrosine_and_serine/threonine_kinase	Vatalanib|Sorafenib_Tosylate|Pazopanib_Hydrochloride|Sorafenib|Dasatinib|Masitinib|Regorafenib|Regorafenib_Hydrate|Semaxanib|Anlotinib|Famitinib|Pexidartinib|Sitravatinib|Pexidartinib_Hydrochloride|Avapritinib|Ripretinib|Pazopanib|Cediranib|Dovitinib|Sunitinib_Malate|Motesanib|Quizartinib|Midostaurin|Imatinib	missense_variant:E:KIT:ENSP00000390987.2:p.(Lys638Glu)|E:KIT:Canonical:ENSP00000288135.5:p.(Lys642Glu)|R:KIT:NP_001087241.1:p.(Lys638Glu)|R:KIT:Canonical:NP_000213.1:p.(Lys642Glu)|R:KIT:XP_005265799.1:p.(Lys639Glu)|R:KIT:XP_005265797.1:p.(Lys643Glu)|R:KIT:XP_005265798.1:p.(Lys643Glu)	CPSR_classification|ClinVar_classification|class	NA	all_exons;IS:introns[16],exons[8-9,11-13,17]	.	.	include	.	.	.
CL-AcroMetrix	KRAS	ENST00000256078	NM_001369786|NM_033360	12:25378647	T>G	c.351A>C	exon4	K117N	Lys117Asn	c.351A>C:exon4:K117N:Lys117Asn	missense_variant	858	0.07	NA	NA	NA	NA	COSV55504752|COSV55545304	rs770248150	375965	4e-06	NA	0.0000000	NA	KRAS|K117|5.41e-24	Colon_Adenocarcinoma:_0.5%_(2/399)|Skin_Cutaneous_Melanoma:_0.2%_(1/468)	NA	T:4+0+0+0=4/463|N:0+0+0+0=0/104|A:4+0+0+0=4/567	KRAS:p.K117N:ENST00000311936&ENST00000256078:CTAT_POPULATION|CTAT_CANCER|3D_STRUCTURE	RTKRAS	NA	[HC]_1.89/1.78_NA	TIER_3	Likely_Pathogenic	Pathogenic	SOM	Ras_family	Adagrasib	missense_variant:E:KRAS:ENSP00000308495.3:p.(Lys117Asn)|R:KRAS:Canonical:NP_203524.1:p.(Lys117Asn)|R:KRAS:NP_004976.2:p.(Lys117Asn)|R:KRAS:NP_203524.1:p.(Lys117Asn)|R:KRAS:NP_004976.2:p.(Lys117Asn)|E:KRAS:Canonical:ENSP00000256078.4:p.(Lys117Asn)|R:KRAS:XP_005253422.1:p.(Lys117Asn);upstream_gene_variant:E:AC087239.1:Canonical:ENST00000594112.1	CPSR_classification|ClinVar_classification|class	NA	IS:all_exons	.	.	include	.	.	.
CL-AcroMetrix	KRAS	ENST00000256078	NM_001369786|NM_033360	12:25380275	T>G	c.183A>C	exon3	Q61H	Gln61His	c.183A>C:exon3:Q61H:Gln61His	missense_variant	897	0.064	NA	NA	NA	NA	COSV55498802|COSV55499223|COSV55811221	rs17851045	177881	4e-06	NA	0.0000000	NA	KRAS|Q61|0	Pancreatic_Adenocarcinoma:_2.2%_(4/180)|Uterine_Corpus_Endometrial_Carcinoma:_0.8%_(4/530)|Rectum_Adenocarcinoma:_0.7%_(1/137)|Colon_Adenocarcinoma:_0.5%_(2/399)|Stomach_Adenocarcinoma:_0.5%_(2/437)	LIRI-JP/Primary/2/250/0.008|PACA-AU/Primary/4/90/0.0444|PACA-CA/Primary/4/140/0.0286	T:2+0+0+0=2/463|N:1+0+0+0=1/104|A:3+0+0+0=3/567	KRAS:p.Q61H:ENST00000311936&ENST00000256078:CTAT_CANCER|3D_STRUCTURE	RTKRAS	NA	[HC]_1.89/1.78_NA	TIER_3	Likely_Pathogenic	Likely_Pathogenic	SOM	Ras_family	Adagrasib	missense_variant:E:KRAS:ENSP00000308495.3:p.(Gln61His)|R:KRAS:Canonical:NP_203524.1:p.(Gln61His)|R:KRAS:NP_004976.2:p.(Gln61His)|R:KRAS:NP_203524.1:p.(Gln61His)|R:KRAS:NP_004976.2:p.(Gln61His)|E:KRAS:Canonical:ENSP00000256078.4:p.(Gln61His)|R:KRAS:XP_005253422.1:p.(Gln61His);upstream_gene_variant:E:AC087239.1:Canonical:ENST00000594112.1	CPSR_classification|ClinVar_classification|class	NA	IS:all_exons	.	.	include	.	.	.
CL-AcroMetrix	KRAS	ENST00000256078	NM_001369786|NM_033360	12:25380283	C>T	c.175G>A	exon3	A59T	Ala59Thr	c.175G>A:exon3:A59T:Ala59Thr	missense_variant	918	0.064	NA	NA	NA	NA	COSV55499283|COSV55796966	rs121913528	12581	NA	NA	NA	NA	KRAS|A59|3.18e-09	Rectum_Adenocarcinoma:_0.7%_(1/137)|Stomach_Adenocarcinoma:_0.7%_(3/437)	NA	T:68+0+0+0=68/463|N:5+0+0+0=5/104|A:73+0+0+0=73/567	KRAS:p.A59T:ENST00000311936&ENST00000256078:CTAT_POPULATION|CTAT_CANCER|3D_STRUCTURE	RTKRAS	NA	[HC]_1.89/1.78_NA	TIER_3	Likely_Pathogenic	Likely_Pathogenic	SOM	Ras_family	Adagrasib	missense_variant:E:KRAS:ENSP00000308495.3:p.(Ala59Thr)|R:KRAS:Canonical:NP_203524.1:p.(Ala59Thr)|R:KRAS:NP_004976.2:p.(Ala59Thr)|R:KRAS:NP_203524.1:p.(Ala59Thr)|R:KRAS:NP_004976.2:p.(Ala59Thr)|E:KRAS:Canonical:ENSP00000256078.4:p.(Ala59Thr)|R:KRAS:XP_005253422.1:p.(Ala59Thr);upstream_gene_variant:E:AC087239.1:Canonical:ENST00000594112.1	CPSR_classification|ClinVar_classification|class	NA	IS:all_exons	.	.	include	variant_in_more_than_10%_of_tumor_samples_(14.69%)_with_VAF_under_0.01	.	.
CL-AcroMetrix	MET	ENST00000318493	NM_001127500	7:116423474	T>C	c.3803T>C	exon19	M1268T	Met1268Thr	c.3803T>C:exon19:M1268T:Met1268Thr	missense_variant	1091	0.156	NA	NA	NA	NA	COSV59255872	rs121913245	376126	NA	NA	NA	NA	MET|M1250|5.24e-07	Kidney_Renal_Papillary_Cell_Carcinoma:_1.4%_(4/281)	NA	T:7+0+0+0=7/463|N:3+0+0+0=3/104|A:10+0+0+0=10/567	MET:p.M1268T:ENST00000318493:CTAT_POPULATION|CTAT_CANCER	RTKRAS	NA	[HC]_2.166/2.332_NA	TIER_3	VUS	Likely_Pathogenic	SOM	Protein_tyrosine_and_serine/threonine_kinase	Onartuzumab|Cabozantinib_S-malate|Tivantinib|Cabozantinib|Capmatinib|Savolitinib|Tepotinib|Sitravatinib|Capmatinib_Hydrochloride|Tepotinib_Hydrochloride|Crizotinib	missense_variant:R:MET:XP_005250410.1:p.(Met1287Thr)|R:MET:NP_001311331.1:p.(Met820Thr)|R:MET:Canonical:NP_001120972.1:p.(Met1268Thr)|R:MET:NP_000236.2:p.(Met1250Thr)|E:MET:ENSP00000380860.3:p.(Met1250Thr)|E:MET:Canonical:ENSP00000317272.6:p.(Met1268Thr)|R:MET:NP_001120972.1:p.(Met1268Thr)|R:MET:NP_000236.2:p.(Met1250Thr)|R:MET:XP_005250411.1:p.(Met820Thr)|E:MET:ENSP00000445020.1:p.(Met120Thr)	ClinVar_classification|class	NA	IS:all_exons	.	.	include	.	.	.
CL-AcroMetrix	NRAS	ENST00000369535	NM_002524	1:115256529	T>C	c.182A>G	exon3	Q61R	Gln61Arg	c.182A>G:exon3:Q61R:Gln61Arg	missense_variant	877	0.105	NA	NA	NA	NA	COSV54736340|COSV54736624|COSV54738969|COSV54747786	rs11554290	13900	NA	NA	NA	NA	NRAS|Q61|0	Skin_Cutaneous_Melanoma:_12.2%_(57/468)|Thyroid_Carcinoma:_6.3%_(31/492)|Cholangiocarcinoma:_2%_(1/51)|Testicular_Germ_Cell_Tumors:_1.4%_(2/145)|Uterine_Corpus_Endometrial_Carcinoma:_0.9%_(5/530)|Thymoma:_0.8%_(1/123)|Acute_Myeloid_Leukemia:_0.7%_(1/144)|Ovarian_Serous_Cystadenocarcinoma:_0.7%_(3/436)|Rectum_Adenocarcinoma:_0.7%_(1/137)|Bladder_Urothelial_Carcinoma:_0.5%_(2/412)|Lung_Squamous_Cell_Carcinoma:_0.4%_(2/492)|Cervical_Squamous_Cell_Carcinoma_and_Endocervical_Adenocarcinoma:_0.3%_(1/289)|Colon_Adenocarcinoma:_0.3%_(1/399)|Liver_Hepatocellular_Carcinoma:_0.3%_(1/364)|Brain_Lower_Grade_Glioma:_0.2%_(1/509)|Stomach_Adenocarcinoma:_0.2%_(1/437)	LIRI-JP/Primary/1/250/0.004|MELA-AU/Metastatic/7/60/0.1167	T:11+0+2+3=16/463|N:6+0+0+0=6/104|A:17+0+2+3=22/567	NRAS:p.Q61R:ENST00000369535:CTAT_POPULATION|CTAT_CANCER|3D_STRUCTURE	RTKRAS	NA	[HC]_1.918/1.836_NA	TIER_3	Likely_Pathogenic	Pathogenic	SOM	Ras_family	NA	missense_variant:R:NRAS:Canonical:NP_002515.1:p.(Gln61Arg)|E:NRAS:Canonical:ENSP00000358548.4:p.(Gln61Arg);downstream_gene_variant:E:CSDE1:ENST00000339438.6|R:CSDE1:NM_001242893.1|R:CSDE1:NM_001242892.1|R:CSDE1:Canonical:NM_001242891.1|R:CSDE1:NM_001130523.2|R:CSDE1:NM_007158.5|R:CSDE1:NM_001007553.2|E:CSDE1:Canonical:ENST00000438362.2|R:CSDE1:XM_005271178.1|E:CSDE1:ENST00000358528.4|E:CSDE1:ENST00000261443.5|E:CSDE1:ENST00000530886.1|E:CSDE1:ENST00000369530.1|E:CSDE1:ENST00000534699.1	CPSR_classification|ClinVar_classification|class	NA	all_exons;IS:exons[2-3]	.	.	include	.	.	.
CL-AcroMetrix	PDGFRA	ENST00000257290	NM_001347828|NM_006206|NM_001347829|NM_001347830	4:55144148	C>A	c.1977C>A	exon14	N659K	Asn659Lys	c.1977C>A:exon14:N659K:Asn659Lys	missense_variant	918	0.061	NA	NA	NA	NA	COSV57264866|COSV57265972	rs1057519700	375901	NA	NA	NA	NA	PDGFRA|N659|0.00278	NA	NA	T:17+1+0+0=18/463|N:2+0+0+0=2/104|A:19+1+0+0=20/567	NA	RTKRAS	NA	[HC]_2.056/2.112_NA	TIER_3	Likely_Pathogenic	Pathogenic	SOM	Protein_tyrosine_and_serine/threonine_kinase	Vatalanib|Pazopanib_Hydrochloride|Olaratumab|Masitinib|Regorafenib|Regorafenib_Hydrate|Crenolanib|Linifanib|Orantinib|Famitinib|Avapritinib|Ripretinib|Pazopanib|Cediranib|Nintedanib|Dovitinib|Sunitinib_Malate|Motesanib|Quizartinib|Midostaurin	missense_variant:E:FIP1L1:Canonical:ENSP00000423325.1:p.(Asn419Lys)|R:PDGFRA:NP_001334756.1:p.(Asn659Lys)|R:PDGFRA:Canonical:NP_006197.1:p.(Asn659Lys)|R:PDGFRA:NP_001334757.1:p.(Asn684Lys)|R:PDGFRA:NP_006197.1:p.(Asn659Lys)|E:PDGFRA:Canonical:ENSP00000257290.5:p.(Asn659Lys)|R:PDGFRA:XP_005265801.1:p.(Asn659Lys)|R:PDGFRA:XP_005265800.1:p.(Asn659Lys)|R:PDGFRA:NP_001334758.1:p.(Asn659Lys)|R:PDGFRA:NP_001334759.1:p.(Asn672Lys)	CPSR_classification|ClinVar_classification|class	NA	all_exons;IS:introns[7,9,11],exons[12,18]	.	.	include	.	.	.
CL-AcroMetrix	PIK3CA	ENST00000263967	NM_006218	3:178916936	G>A	c.323G>A	exon2	R108H	Arg108His	c.323G>A:exon2:R108H:Arg108His	missense_variant	617	0.032	NA	NA	NA	NA	COSV55873442|COSV55926654|COSV55949642	rs886042002	280875	NA	NA	NA	NA	PIK3CA|R108|2.18e-30	Uterine_Carcinosarcoma:_3.5%_(2/57)|Uterine_Corpus_Endometrial_Carcinoma:_1.5%_(8/530)|Colon_Adenocarcinoma:_0.8%_(3/399)|Glioblastoma_Multiforme:_0.3%_(1/393)|Stomach_Adenocarcinoma:_0.2%_(1/437)|Breast_Invasive_Carcinoma:_0.1%_(1/986)	NA	T:153+2+0+0=155/463|N:10+0+0+0=10/104|A:163+2+0+0=165/567	PIK3CA:p.R108H:ENST00000263967&ENST00000468036:CTAT_CANCER|3D_STRUCTURE	PI3K	NA	[HC]_1.812/1.624_NA	TIER_3	Likely_Pathogenic	VUS	SOM	PI3-kinase_family|p85-binding_domain	Buparlisib|Taselisib|Alpelisib|Copanlisib|Copanlisib_Hydrochloride	downstream_gene_variant:E:PIK3CA:ENST00000477735.1;missense_variant:R:PIK3CA:NP_006209.2:p.(Arg108His)|E:PIK3CA:Canonical:ENSP00000263967.3:p.(Arg108His)|R:PIK3CA:Canonical:NP_006209.2:p.(Arg108His)|E:PIK3CA:ENSP00000417479.1:p.(Arg108His)	CPSR_classification|class	NA	all_exons;IS:exons[2-3,5-8,10,14,19,21;coding:1-2,4-7,9,13,18,20]	.	.	include	variant_in_more_than_10%_of_tumor_samples_(33.05%)_with_VAF_under_0.01	.	.
CL-AcroMetrix	PIK3CA	ENST00000263967	NM_006218	3:178916944	A>G	c.331A>G	exon2	K111E	Lys111Glu	c.331A>G:exon2:K111E:Lys111Glu	missense_variant	580	0.028	NA	NA	NA	NA	COSV55878486|COSV56029794	rs1057519933	376482	NA	NA	NA	NA	PIK3CA|K111|3.94e-47	Uterine_Corpus_Endometrial_Carcinoma:_0.6%_(3/530)|Stomach_Adenocarcinoma:_0.5%_(2/437)|Brain_Lower_Grade_Glioma:_0.4%_(2/509)|Colon_Adenocarcinoma:_0.3%_(1/399)|Head_and_Neck_Squamous_Cell_Carcinoma:_0.2%_(1/508)|Breast_Invasive_Carcinoma:_0.1%_(1/986)	PACA-CA/Primary/1/140/0.0071	T:8+0+1+0=9/463|N:3+0+0+0=3/104|A:11+0+1+0=12/567	PIK3CA:p.K111E:ENST00000263967&ENST00000468036:CTAT_CANCER|3D_STRUCTURE	PI3K	NA	[HC]_1.812/1.624_NA	TIER_3	Likely_Pathogenic	Likely_Pathogenic	SOM	NA	Buparlisib|Taselisib|Alpelisib|Copanlisib|Copanlisib_Hydrochloride	downstream_gene_variant:E:PIK3CA:ENST00000477735.1;missense_variant:R:PIK3CA:NP_006209.2:p.(Lys111Glu)|E:PIK3CA:Canonical:ENSP00000263967.3:p.(Lys111Glu)|R:PIK3CA:Canonical:NP_006209.2:p.(Lys111Glu)|E:PIK3CA:ENSP00000417479.1:p.(Lys111Glu)	CPSR_classification|ClinVar_classification|class	NA	all_exons;IS:exons[2-3,5-8,10,14,19,21;coding:1-2,4-7,9,13,18,20]	.	.	include	.	.	.
CL-AcroMetrix	PIK3CA	ENST00000263967	NM_006218	3:178921553	T>A	c.1035T>A	exon5	N345K	Asn345Lys	c.1035T>A:exon5:N345K:Asn345Lys	missense_variant	628	0.056	NA	NA	NA	NA	COSV55873276	rs121913284	376050	NA	NA	NA	NA	PIK3CA|N345|3.87e-219	Breast_Invasive_Carcinoma:_1.5%_(15/986)|Stomach_Adenocarcinoma:_1.1%_(5/437)|Uterine_Corpus_Endometrial_Carcinoma:_0.8%_(4/530)|Testicular_Germ_Cell_Tumors:_0.7%_(1/145)|Sarcoma:_0.4%_(1/237)|Colon_Adenocarcinoma:_0.3%_(1/399)|Glioblastoma_Multiforme:_0.3%_(1/393)|Bladder_Urothelial_Carcinoma:_0.2%_(1/412)|Head_and_Neck_Squamous_Cell_Carcinoma:_0.2%_(1/508)|Lung_Adenocarcinoma:_0.2%_(1/567)	BRCA-EU/Primary/1/76/0.0132	T:13+0+2+0=15/463|N:4+0+0+0=4/104|A:17+0+2+0=19/567	PIK3CA:p.N345K:ENST00000263967:CTAT_CANCER|3D_STRUCTURE	PI3K	NA	[HC]_1.812/1.624_NA	TIER_3	Likely_Pathogenic	Pathogenic	SOM	NA	Buparlisib|Taselisib|Alpelisib|Copanlisib|Copanlisib_Hydrochloride	downstream_gene_variant:E:PIK3CA:ENST00000477735.1|E:PIK3CA:ENST00000468036.1;missense_variant:R:PIK3CA:NP_006209.2:p.(Asn345Lys)|E:PIK3CA:Canonical:ENSP00000263967.3:p.(Asn345Lys)|R:PIK3CA:Canonical:NP_006209.2:p.(Asn345Lys)	CPSR_classification|ClinVar_classification|class	NA	all_exons;IS:exons[2-3,5-8,10,14,19,21;coding:1-2,4-7,9,13,18,20]	.	.	include	.	.	.
CL-AcroMetrix	PIK3CA	ENST00000263967	NM_006218	3:178927980	T>C	c.1258T>C	exon8	C420R	Cys420Arg	c.1258T>C:exon8:C420R:Cys420Arg	missense_variant	581	0.064	NA	NA	NA	NA	COSV55874020	rs121913272	31945	NA	NA	NA	NA	PIK3CA|C420|2.6e-80	Uterine_Corpus_Endometrial_Carcinoma:_1.3%_(7/530)|Colon_Adenocarcinoma:_0.8%_(3/399)|Cervical_Squamous_Cell_Carcinoma_and_Endocervical_Adenocarcinoma:_0.7%_(2/289)|Stomach_Adenocarcinoma:_0.7%_(3/437)|Breast_Invasive_Carcinoma:_0.5%_(5/986)|Head_and_Neck_Squamous_Cell_Carcinoma:_0.2%_(1/508)|Brain_Lower_Grade_Glioma:_0.2%_(1/509)|Lung_Squamous_Cell_Carcinoma:_0.2%_(1/492)	PBCA-DE/Primary/1/230/0.0043	T:7+0+2+0=9/463|N:6+0+0+0=6/104|A:13+0+2+0=15/567	PIK3CA:p.C420R:ENST00000263967:CTAT_POPULATION|CTAT_CANCER|3D_STRUCTURE	PI3K	NA	[HC]_1.812/1.624_NA	TIER_3	Pathogenic	Pathogenic	SOM	Phosphoinositide_3-kinase_C2	Buparlisib|Taselisib|Alpelisib|Copanlisib|Copanlisib_Hydrochloride	missense_variant:R:PIK3CA:NP_006209.2:p.(Cys420Arg)|E:PIK3CA:Canonical:ENSP00000263967.3:p.(Cys420Arg)|R:PIK3CA:Canonical:NP_006209.2:p.(Cys420Arg)	CPSR_classification|ClinVar_classification|class	NA	all_exons;IS:exons[2-3,5-8,10,14,19,21;coding:1-2,4-7,9,13,18,20]	.	.	include	.	.	.
CL-AcroMetrix	PIK3CA	ENST00000263967	NM_006218	3:178947827	G>T	c.2702G>T	exon19	C901F	Cys901Phe	c.2702G>T:exon19:C901F:Cys901Phe	missense_variant	808	0.08	NA	NA	NA	NA	COSV55881149	NA	NA	NA	NA	NA	NA	PIK3CA|C901|1.63e-14	Uterine_Corpus_Endometrial_Carcinoma:_0.4%_(2/530)|Head_and_Neck_Squamous_Cell_Carcinoma:_0.2%_(1/508)|Brain_Lower_Grade_Glioma:_0.2%_(1/509)|Breast_Invasive_Carcinoma:_0.1%_(1/986)	NA	T:22+0+2+1=25/463|N:1+0+0+0=1/104|A:23+0+2+1=26/567	PIK3CA:p.C901F:ENST00000263967:CTAT_POPULATION|CTAT_CANCER	PI3K	NA	[HC]_1.812/1.624_NA	TIER_3	Likely_Pathogenic	NA	SOM	Phosphatidylinositol_3-_and_4-kinase	Buparlisib|Taselisib|Alpelisib|Copanlisib|Copanlisib_Hydrochloride	missense_variant:R:PIK3CA:NP_006209.2:p.(Cys901Phe)|E:PIK3CA:Canonical:ENSP00000263967.3:p.(Cys901Phe)|R:PIK3CA:Canonical:NP_006209.2:p.(Cys901Phe)	CPSR_classification|class	NA	all_exons;IS:exons[2-3,5-8,10,14,19,21;coding:1-2,4-7,9,13,18,20]	.	.	include	.	.	.
CL-AcroMetrix	PTEN	ENST00000371953	NM_000314	10:89624297	A>G	c.71A>G	exon1	D24G	Asp24Gly	c.71A>G:exon1:D24G:Asp24Gly	missense_variant	1388	0.089	NA	NA	NA	NA	COSV64293188|COSV64296384|COSV64307484	rs797044910	208723	NA	NA	NA	NA	PTEN|D24|0.00531	Uterine_Corpus_Endometrial_Carcinoma:_0.4%_(2/530)|Lung_Squamous_Cell_Carcinoma:_0.2%_(1/492)	NA	T:9+0+0+0=9/463|N:4+0+0+0=4/104|A:13+0+0+0=13/567	PTEN:p.D24G:ENST00000371953:CTAT_CANCER|3D_STRUCTURE	PI3K	NA	[HC]_1.964/1.928_NA	TIER_3	Pathogenic	Likely_Pathogenic	SOM	NA	NA	upstream_gene_variant:E:KLLN:Canonical:ENST00000445946.3|R:KLLN:Canonical:NM_001126049.1;missense_variant:E:PTEN:Canonical:ENSP00000361021.3:p.(Asp24Gly)|R:PTEN:NP_000305.3:p.(Asp24Gly)|R:PTEN:Canonical:NP_000305.3:p.(Asp24Gly)|R:PTEN:NP_001291646.2:p.(Asp197Gly);5_prime_UTR_variant:R:PTEN:NM_001304718.1	CPSR_classification|ClinVar_classification|class	NA	IS:all_exons	.	.	include	.	.	.
CL-AcroMetrix	PTEN	ENST00000371953	NM_000314	10:89653814	C>T	c.112C>T	exon2	P38S	Pro38Ser	c.112C>T:exon2:P38S:Pro38Ser	missense_variant	688	0.122	NA	NA	NA	NA	COSV100911304|COSV64289791	rs587780004	127688	NA	NA	NA	NA	PTEN|P38|0.00565	Skin_Cutaneous_Melanoma:_0.6%_(3/468)|Uterine_Corpus_Endometrial_Carcinoma:_0.2%_(1/530)	NA	T:35+1+0+0=36/462|N:1+0+0+0=1/104|A:36+1+0+0=37/566	PTEN:p.P38S:ENST00000371953:CTAT_CANCER|3D_STRUCTURE	PI3K	NA	[HC]_1.964/1.928_NA	TIER_3	Likely_Pathogenic	VUS	SOM	NA	NA	missense_variant:E:PTEN:Canonical:ENSP00000361021.3:p.(Pro38Ser)|R:PTEN:NP_000305.3:p.(Pro38Ser)|R:PTEN:Canonical:NP_000305.3:p.(Pro38Ser)|R:PTEN:NP_001291646.2:p.(Pro211Ser);5_prime_UTR_variant:R:PTEN:NM_001304718.1	CPSR_classification|class	NA	IS:all_exons	.	.	include	.	.	.
CL-AcroMetrix	PTEN	ENST00000371953	NM_000314	10:89685307	T>C	c.202T>C	exon3	Y68H	Tyr68His	c.202T>C:exon3:Y68H:Tyr68His	missense_variant	286	0.066	NA	NA	NA	NA	COSV64289561|COSV64292590	rs398123317	189474	NA	NA	NA	NA	PTEN|Y68|5.28e-09	NA	PRAD-UK/Primary/1/24/0.0417	T:5+0+0+0=5/457|N:1+0+0+0=1/103|A:6+0+0+0=6/560	NA	PI3K	NA	[HC]_1.964/1.928_NA	TIER_3	Pathogenic	Likely_Pathogenic	SOM	NA	NA	missense_variant:E:PTEN:Canonical:ENSP00000361021.3:p.(Tyr68His)|R:PTEN:NP_000305.3:p.(Tyr68His)|R:PTEN:Canonical:NP_000305.3:p.(Tyr68His)|R:PTEN:NP_001291646.2:p.(Tyr241His)	CPSR_classification|ClinVar_classification|class	NA	IS:all_exons	.	.	include	.	.	.
CL-AcroMetrix	PTEN	ENST00000371953	NM_000314	10:89692818	T>C	c.302T>C	exon5	I101T	Ile101Thr	c.302T>C:exon5:I101T:Ile101Thr	missense_variant	603	0.056	NA	NA	NA	NA	COSV64289692|COSV64297668|COSV64311547	rs1339631701	822660	NA	NA	NA	NA	PTEN|I101|0.0833	Sarcoma:_0.4%_(1/237)|Glioblastoma_Multiforme:_0.3%_(1/393)|Uterine_Corpus_Endometrial_Carcinoma:_0.2%_(1/530)	MALY-DE/Primary/1/100/0.01	T:5+0+0+0=5/459|N:2+0+0+0=2/104|A:7+0+0+0=7/563	PTEN:p.I101T:ENST00000371953:CTAT_CANCER|3D_STRUCTURE	PI3K	NA	[HC]_1.964/1.928_NA	TIER_3	Likely_Pathogenic	Likely_Pathogenic	SOM	Dual_specificity_phosphatase|catalytic_domain	NA	missense_variant:E:PTEN:Canonical:ENSP00000361021.3:p.(Ile101Thr)|R:PTEN:NP_000305.3:p.(Ile101Thr)|R:PTEN:Canonical:NP_000305.3:p.(Ile101Thr)|R:PTEN:NP_001291646.2:p.(Ile274Thr);5_prime_UTR_variant:R:PTEN:NM_001304718.1	CPSR_classification|ClinVar_classification|class	NA	IS:all_exons	.	.	include	.	.	.
CL-AcroMetrix	PTEN	ENST00000371953	NM_000314	10:89692911	G>A	c.395G>A	exon5	G132D	Gly132Asp	c.395G>A:exon5:G132D:Gly132Asp	missense_variant	820	0.135	NA	NA	NA	NA	COSV64288421|COSV64288528|COSV64293854	rs121909241	92822	NA	NA	NA	NA	PTEN|G132|1.53e-11	Glioblastoma_Multiforme:_1%_(4/393)|Uterine_Corpus_Endometrial_Carcinoma:_0.6%_(3/530)|Brain_Lower_Grade_Glioma:_0.2%_(1/509)	NA	T:25+2+0+0=27/462|N:3+0+0+0=3/104|A:28+2+0+0=30/566	PTEN:p.G132D:ENST00000371953:CTAT_CANCER|3D_STRUCTURE	PI3K	NA	[HC]_1.964/1.928_NA	TIER_3	Likely_Pathogenic	Likely_Pathogenic	SOM	Dual_specificity_phosphatase|catalytic_domain	NA	missense_variant:E:PTEN:Canonical:ENSP00000361021.3:p.(Gly132Asp)|R:PTEN:NP_000305.3:p.(Gly132Asp)|R:PTEN:Canonical:NP_000305.3:p.(Gly132Asp)|R:PTEN:NP_001291646.2:p.(Gly305Asp);5_prime_UTR_variant:R:PTEN:NM_001304718.1	CPSR_classification|ClinVar_classification|class	NA	IS:all_exons	.	.	include	.	.	.
CL-AcroMetrix	PTEN	ENST00000371953	NM_000314	10:89692980	A>G	c.464A>G	exon5	Y155C	Tyr155Cys	c.464A>G:exon5:Y155C:Tyr155Cys	missense_variant	776	0.125	NA	NA	NA	NA	COSV64291751|COSV64292375	rs1060500126	404168	NA	NA	NA	NA	PTEN|Y155|0.001	Uterine_Carcinosarcoma:_1.8%_(1/57)|Uterine_Corpus_Endometrial_Carcinoma:_0.2%_(1/530)	NA	T:6+0+0+0=6/461|N:5+0+0+0=5/104|A:11+0+0+0=11/565	PTEN:p.Y155C:ENST00000371953:CTAT_CANCER|3D_STRUCTURE	PI3K	NA	[HC]_1.964/1.928_NA	TIER_3	Likely_Pathogenic	Pathogenic	SOM	Dual_specificity_phosphatase|catalytic_domain	NA	missense_variant:E:PTEN:Canonical:ENSP00000361021.3:p.(Tyr155Cys)|R:PTEN:NP_000305.3:p.(Tyr155Cys)|R:PTEN:Canonical:NP_000305.3:p.(Tyr155Cys)|R:PTEN:NP_001291646.2:p.(Tyr328Cys);5_prime_UTR_variant:R:PTEN:NM_001304718.1	CPSR_classification|ClinVar_classification|class	NA	IS:all_exons	.	.	include	.	.	.
CL-AcroMetrix	PTPN11	ENST00000351677	NM_002834|NM_001374625	12:112888165	G>T	c.181G>T	exon3	D61Y	Asp61Tyr	c.181G>T:exon3:D61Y:Asp61Tyr	missense_variant	1002	0.052	NA	NA	NA	NA	COSV61004841|COSV61006072|COSV61006164	rs397507510	228392	NA	NA	NA	NA	PTPN11|D61|0.0319	NA	NA	T:44+0+0+0=44/463|N:6+1+0+0=7/104|A:50+1+0+0=51/567	NA	RTKRAS	NA	[non-HC]_2.096/2.192_NA	TIER_3	Pathogenic	Pathogenic	SOM	SH2_domain	NA	missense_variant:R:PTPN11:NP_542168.1:p.(Asp61Tyr)|R:PTPN11:Canonical:NP_002825.3:p.(Asp61Tyr)|R:PTPN11:NP_542168.1:p.(Asp61Tyr)|R:PTPN11:NP_002825.3:p.(Asp61Tyr)|R:PTPN11:NP_001317366.1:p.(Asp61Tyr)|E:PTPN11:ENSP00000376376.1:p.(Asp61Tyr)|E:PTPN11:Canonical:ENSP00000340944.2:p.(Asp61Tyr);upstream_gene_variant:E:PTPN11:ENST00000530818.1	CPSR_classification|ClinVar_classification|class	NA	IS:all_exons	.	.	include	.	.	.
CL-AcroMetrix	PTPN11	ENST00000351677	NM_002834|NM_001374625	12:112888189	G>A	c.205G>A	exon3	E69K	Glu69Lys	c.205G>A:exon3:E69K:Glu69Lys	missense_variant	981	0.031	NA	NA	NA	NA	COSV61004768|COSV61009351	rs397507511	224414	NA	NA	NA	NA	PTPN11|E69|1.81e-06	Colon_Adenocarcinoma:_0.3%_(1/399)|Glioblastoma_Multiforme:_0.3%_(1/393)	PBCA-DE/Primary/1/230/0.0043	T:45+3+0+0=48/463|N:7+0+0+0=7/104|A:52+3+0+0=55/567	NA	RTKRAS	NA	[non-HC]_2.096/2.192_NA	TIER_3	Pathogenic	Likely_Pathogenic	SOM	SH2_domain	NA	missense_variant:R:PTPN11:NP_542168.1:p.(Glu69Lys)|R:PTPN11:Canonical:NP_002825.3:p.(Glu69Lys)|R:PTPN11:NP_542168.1:p.(Glu69Lys)|R:PTPN11:NP_002825.3:p.(Glu69Lys)|R:PTPN11:NP_001317366.1:p.(Glu69Lys)|E:PTPN11:ENSP00000376376.1:p.(Glu69Lys)|E:PTPN11:Canonical:ENSP00000340944.2:p.(Glu69Lys);upstream_gene_variant:E:PTPN11:ENST00000530818.1	CPSR_classification|ClinVar_classification|class	NA	IS:all_exons	.	.	include	.	.	.
CL-AcroMetrix	PTPN11	ENST00000351677	NM_002834|NM_001374625	12:112888199	C>T	c.215C>T	exon3	A72V	Ala72Val	c.215C>T:exon3:A72V:Ala72Val	missense_variant	967	0.03	NA	NA	NA	NA	COSV61005613|COSV61008344|COSV61012146	rs121918454	41443	NA	NA	NA	NA	PTPN11|A72|3.59e-21	Acute_Myeloid_Leukemia:_0.7%_(1/144)|Glioblastoma_Multiforme:_0.3%_(1/393)	NA	T:45+1+0+0=46/463|N:5+0+0+0=5/104|A:50+1+0+0=51/567	NA	RTKRAS	NA	[non-HC]_2.096/2.192_NA	TIER_3	Pathogenic	VUS	SOM	SH2_domain	NA	missense_variant:R:PTPN11:NP_542168.1:p.(Ala72Val)|R:PTPN11:Canonical:NP_002825.3:p.(Ala72Val)|R:PTPN11:NP_542168.1:p.(Ala72Val)|R:PTPN11:NP_002825.3:p.(Ala72Val)|R:PTPN11:NP_001317366.1:p.(Ala72Val)|E:PTPN11:ENSP00000376376.1:p.(Ala72Val)|E:PTPN11:Canonical:ENSP00000340944.2:p.(Ala72Val);upstream_gene_variant:E:PTPN11:ENST00000530818.1	CPSR_classification|class	NA	IS:all_exons	.	.	include	.	.	.
CL-AcroMetrix	PTPN11	ENST00000351677	NM_002834|NM_001374625	12:112888210	G>A	c.226G>A	exon3	E76K	Glu76Lys	c.226G>A:exon3:E76K:Glu76Lys	missense_variant	970	0.036	NA	NA	NA	NA	COSV61004751|COSV61004889	rs121918464	13336	NA	NA	NA	NA	PTPN11|E76|1.05e-10	Colon_Adenocarcinoma:_0.3%_(1/399)|Lung_Squamous_Cell_Carcinoma:_0.2%_(1/492)	CLLE-ES/Primary/1/90/0.0111	T:49+0+0+0=49/463|N:3+0+0+0=3/104|A:52+0+0+0=52/567	PTPN11:p.E76K:ENST00000392597&ENST00000351677:CTAT_POPULATION|CTAT_CANCER|3D_STRUCTURE	RTKRAS	NA	[non-HC]_2.096/2.192_NA	TIER_3	Pathogenic	VUS	SOM	SH2_domain	NA	missense_variant:R:PTPN11:NP_542168.1:p.(Glu76Lys)|R:PTPN11:Canonical:NP_002825.3:p.(Glu76Lys)|R:PTPN11:NP_542168.1:p.(Glu76Lys)|R:PTPN11:NP_002825.3:p.(Glu76Lys)|R:PTPN11:NP_001317366.1:p.(Glu76Lys)|E:PTPN11:ENSP00000376376.1:p.(Glu76Lys)|E:PTPN11:Canonical:ENSP00000340944.2:p.(Glu76Lys);upstream_gene_variant:E:PTPN11:ENST00000530818.1	CPSR_classification|class	NA	IS:all_exons	.	.	include	variant_in_more_than_10%_of_tumor_samples_(10.58%)_with_VAF_under_0.01	.	.
CL-AcroMetrix	SMAD4	ENST00000342988	NM_005359	18:48593405	G>C	c.1156G>C	exon10	G386R	Gly386Arg	c.1156G>C:exon10:G386R:Gly386Arg	missense_variant	723	0.073	NA	NA	NA	NA	COSV61689171|COSV61689611|COSV61697840	NA	NA	NA	NA	NA	NA	SMAD4|G386|8.22e-22	NA	NA	T:4+0+0+0=4/463|N:0+0+0+0=0/104|A:4+0+0+0=4/567	NA	TFGBETA	NA	[non-HC]_2.106/2.212_NA	TIER_3	Likely_Pathogenic	NA	SOM	MH2_domain	NA	missense_variant:E:SMAD4:Canonical:ENSP00000381452.1:p.(Gly386Arg)|E:SMAD4:ENSP00000341551.3:p.(Gly386Arg)|R:SMAD4:Canonical:NP_005350.1:p.(Gly386Arg)|E:SMAD4:ENSP00000464901.1:p.(Gly290Arg);upstream_gene_variant:E:SMAD4:ENST00000593223.1	CPSR_classification|class	NA	all_exons	.	.	include	.	.	.
CL-AcroMetrix	SMO	ENST00000249373	NM_005631	7:128846398	C>T	c.1234C>T	exon6	L412F	Leu412Phe	c.1234C>T:exon6:L412F:Leu412Phe	missense_variant	1120	0.196	NA	NA	NA	NA	COSV50824425	rs879255280	245609	NA	NA	NA	NA	SMO|L412|8.71e-06	NA	PBCA-DE/Primary/4/230/0.0174	T:50+1+0+0=51/463|N:4+0+0+0=4/104|A:54+1+0+0=55/567	NA	NA	NA	[non-HC]_2.032/2.064_NA	TIER_3	Likely_Pathogenic	Pathogenic	SOM	Frizzled/Smoothened_family_membrane_region	Glasdegib|Sonidegib|Glasdegib_Maleate|Vismodegib|Patidegib	missense_variant:E:SMO:Canonical:ENSP00000249373.3:p.(Leu412Phe)|R:SMO:Canonical:NP_005622.1:p.(Leu412Phe)	CPSR_classification|ClinVar_classification|class	NA	IS:all_exons	.	.	include	variant_in_more_than_10%_of_tumor_samples_(10.8%)_with_VAF_under_0.01	.	.
CL-AcroMetrix	SMO	ENST00000249373	NM_005631	7:128850341	G>T	c.1604G>T	exon9	W535L	Trp535Leu	c.1604G>T:exon9:W535L:Trp535Leu	missense_variant	1247	0.196	NA	NA	NA	NA	COSV50824509	rs121918347	8117	NA	NA	NA	NA	SMO|W535|0.0117	NA	PBCA-DE/Primary/1/230/0.0043	T:19+0+0+0=19/463|N:2+0+0+0=2/104|A:21+0+0+0=21/567	NA	NA	NA	[non-HC]_2.032/2.064_NA	TIER_3	Likely_Pathogenic	Pathogenic	SOM	Frizzled/Smoothened_family_membrane_region	Glasdegib|Sonidegib|Glasdegib_Maleate|Vismodegib|Patidegib	missense_variant:E:SMO:Canonical:ENSP00000249373.3:p.(Trp535Leu)|R:SMO:Canonical:NP_005622.1:p.(Trp535Leu)	CPSR_classification|ClinVar_classification|class	NA	IS:all_exons	.	.	include	.	.	.
CL-AcroMetrix	STK11	ENST00000326873	NM_000455	19:1220487	G>T	c.580G>T	exon4	D194Y	Asp194Tyr	c.580G>T:exon4:D194Y:Asp194Tyr	missense_variant	1197	0.06	NA	NA	NA	NA	COSV58820621|COSV58820976|COSV99045288	rs121913315	7450	NA	NA	NA	NA	STK11|D194|3.49e-11	Lung_Adenocarcinoma:_0.2%_(1/567)	NA	T:23+0+0+0=23/463|N:4+1+0+0=5/104|A:27+1+0+0=28/567	NA	PI3K	NA	[non-HC]_2.366/2.732_NA	TIER_3	Pathogenic	Likely_Pathogenic	SOM	Protein_kinase_domain	NA	missense_variant:E:STK11:Canonical:ENSP00000324856.6:p.(Asp194Tyr)|R:STK11:Canonical:NP_000446.1:p.(Asp194Tyr)|R:STK11:XP_005259675.1:p.(Asp194Tyr)|R:STK11:XP_005259674.1:p.(Asp194Tyr)|E:STK11:ENSP00000467912.1:p.(Asp136Tyr);upstream_gene_variant:E:STK11:ENST00000586243.1	CPSR_classification|ClinVar_classification|class	NA	IS:all_exons	.	.	include	.	.	.
CL-AcroMetrix	TP53	ENST00000269305	NM_000546	17:7574018	G>A	c.1009C>T	exon10	R337C	Arg337Cys	c.1009C>T:exon10:R337C:Arg337Cys	missense_variant	986	0.024	NA	NA	NA	NA	COSV52669243|COSV52718762|COSV52810068|COSV52816817	rs587782529	142536	0	NA	0.0000000	NA	TP53|R337|8.7e-22	Acute_Myeloid_Leukemia:_0.7%_(1/144)|Head_and_Neck_Squamous_Cell_Carcinoma:_0.6%_(3/508)|Pancreatic_Adenocarcinoma:_0.6%_(1/180)|Stomach_Adenocarcinoma:_0.5%_(2/437)|Lung_Adenocarcinoma:_0.4%_(2/567)|Colon_Adenocarcinoma:_0.3%_(1/399)|Brain_Lower_Grade_Glioma:_0.2%_(1/509)|Lung_Squamous_Cell_Carcinoma:_0.2%_(1/492)|Prostate_Adenocarcinoma:_0.2%_(1/496)	BOCA-UK/Primary/1/61/0.0164|BRCA-EU/Primary/1/76/0.0132|LIRI-JP/Primary/1/250/0.004|PACA-AU/Primary/1/90/0.0111|PACA-CA/Primary/1/140/0.0071	T:92+1+3+0=96/462|N:11+0+0+0=11/104|A:103+1+3+0=107/566	TP53:p.R337C:ENST00000269305&ENST00000445888:CTAT_CANCER|3D_STRUCTURE	TP53	4_c_NS	[non-HC]_2.45/2.9_NA	TIER_3	Pathogenic	Likely_Pathogenic	SOM	P53_tetramerisation_motif	NA	missense_variant:R:TP53:NP_001119587.1:p.(Arg205Cys)|R:TP53:NP_001263626.1:p.(Arg178Cys)|E:TP53:Canonical:ENSP00000269305.4:p.(Arg337Cys)|R:TP53:NP_001119590.1:p.(Arg298Cys)|R:TP53:Canonical:NP_000537.3:p.(Arg337Cys)|R:TP53:NP_001263689.1:p.(Arg298Cys)|R:TP53:NP_001263690.1:p.(Arg298Cys)|R:TP53:NP_001119584.1:p.(Arg337Cys)|E:TP53:ENSP00000391478.2:p.(Arg337Cys)|R:TP53:XP_005256835.1:p.(Arg317Cys);3_prime_UTR_variant:R:TP53:NM_001276699.1|R:TP53:NM_001126117.1|R:TP53:NM_001276698.1|R:TP53:NM_001126116.1|R:TP53:NM_001276696.1|R:TP53:NM_001126113.2|R:TP53:NM_001276695.1|R:TP53:NM_001126114.2|E:TP53:ENST00000455263.2|E:TP53:ENST00000420246.2;downstream_gene_variant:E:TP53:ENST00000509690.1|E:TP53:ENST00000514944.1|E:TP53:ENST00000508793.1|E:TP53:ENST00000604348.1|E:TP53:ENST00000503591.1	CPSR_classification|ClinVar_classification|class	NA	IS:all_exons	.	.	include	variant_in_more_than_10%_of_tumor_samples_(19.91%)_with_VAF_under_0.01	.	.
CL-AcroMetrix	TP53	ENST00000269305	NM_000546	17:7577105	G>A	c.833C>T	exon8	P278L	Pro278Leu	c.833C>T:exon8:P278L:Pro278Leu	missense_variant	1144	0.035	NA	NA	NA	NA	COSV52661225|COSV52665769|COSV52678063	rs876659802	232497	NA	NA	NA	NA	TP53|P278|5.75e-50	Ovarian_Serous_Cystadenocarcinoma:_0.5%_(2/436)|Bladder_Urothelial_Carcinoma:_0.2%_(1/412)|Brain_Lower_Grade_Glioma:_0.2%_(1/509)|Skin_Cutaneous_Melanoma:_0.2%_(1/468)|Breast_Invasive_Carcinoma:_0.1%_(1/986)	NA	T:26+0+1+0=27/461|N:3+0+0+0=3/104|A:29+0+1+0=30/565	TP53:p.P278L:ENST00000359597&ENST00000269305&ENST00000455263&ENST00000420246&ENST00000445888:CTAT_CANCER|3D_STRUCTURE	TP53	4_c_NS	[non-HC]_2.45/2.9_NA	TIER_3	Likely_Pathogenic	VUS	SOM	P53_DNA-binding_domain	NA	missense_variant:E:TP53:ENSP00000352610.4:p.(Pro278Leu)|R:TP53:NP_001119587.1:p.(Pro146Leu)|R:TP53:NP_001263626.1:p.(Pro119Leu)|R:TP53:NP_001263628.1:p.(Pro119Leu)|R:TP53:NP_001119589.1:p.(Pro146Leu)|R:TP53:NP_001263627.1:p.(Pro119Leu)|R:TP53:NP_001119588.1:p.(Pro146Leu)|E:TP53:Canonical:ENSP00000269305.4:p.(Pro278Leu)|R:TP53:NP_001263625.1:p.(Pro239Leu)|R:TP53:NP_001119590.1:p.(Pro239Leu)|R:TP53:NP_001119585.1:p.(Pro278Leu)|R:TP53:Canonical:NP_000537.3:p.(Pro278Leu)|R:TP53:NP_001263689.1:p.(Pro239Leu)|R:TP53:NP_001263690.1:p.(Pro239Leu)|R:TP53:NP_001263624.1:p.(Pro239Leu)|R:TP53:NP_001119586.1:p.(Pro278Leu)|R:TP53:NP_001119584.1:p.(Pro278Leu)|E:TP53:ENSP00000398846.2:p.(Pro278Leu)|E:TP53:ENSP00000391127.2:p.(Pro278Leu)|E:TP53:ENSP00000391478.2:p.(Pro278Leu)|R:TP53:XP_005256835.1:p.(Pro258Leu)|E:TP53:ENSP00000425104.1:p.(Pro146Leu);upstream_gene_variant:E:TP53:ENST00000576024.1;downstream_gene_variant:E:TP53:ENST00000514944.1|E:TP53:ENST00000508793.1|E:TP53:ENST00000604348.1|E:TP53:ENST00000503591.1	CPSR_classification|class	NA	IS:all_exons	.	.	include	.	.	.
CL-AcroMetrix	TP53	ENST00000269305	NM_000546	17:7577548	C>T	c.733G>A	exon7	G245S	Gly245Ser	c.733G>A:exon7:G245S:Gly245Ser	missense_variant	1144	0.037	NA	NA	NA	NA	COSV52661744|COSV52661877|COSV52713951|COSV52839866	rs28934575	12365	0	NA	0.0000000	NA	TP53|G245|8.55e-208	Head_and_Neck_Squamous_Cell_Carcinoma:_1.6%_(8/508)|Rectum_Adenocarcinoma:_1.5%_(2/137)|Colon_Adenocarcinoma:_1.3%_(5/399)|Mesothelioma:_1.2%_(1/82)|Esophageal_Carcinoma:_1.1%_(2/184)|Pancreatic_Adenocarcinoma:_1.1%_(2/180)|Glioblastoma_Multiforme:_0.8%_(3/393)|Brain_Lower_Grade_Glioma:_0.8%_(4/509)|Prostate_Adenocarcinoma:_0.6%_(3/496)|Bladder_Urothelial_Carcinoma:_0.5%_(2/412)|Ovarian_Serous_Cystadenocarcinoma:_0.5%_(2/436)|Stomach_Adenocarcinoma:_0.5%_(2/437)|Uterine_Corpus_Endometrial_Carcinoma:_0.4%_(2/530)|Breast_Invasive_Carcinoma:_0.2%_(2/986)|Lung_Adenocarcinoma:_0.2%_(1/567)|Lung_Squamous_Cell_Carcinoma:_0.2%_(1/492)	EOPC-DE/Primary/1/41/0.0244|ESAD-UK/Primary/4/97/0.0412|MALY-DE/Primary/1/100/0.01|PACA-CA/Primary/3/140/0.0214	T:86+3+2+7=98/461|N:5+0+0+0=5/104|A:91+3+2+7=103/565	TP53:p.G245S:ENST00000413465&ENST00000359597&ENST00000269305&ENST00000455263&ENST00000420246&ENST00000445888:CTAT_POPULATION|CTAT_CANCER|3D_STRUCTURE	TP53	4_c_NS	[non-HC]_2.45/2.9_NA	TIER_3	Likely_Pathogenic	Pathogenic	SOM	P53_DNA-binding_domain	NA	missense_variant:E:TP53:ENSP00000410739.2:p.(Gly245Ser)|E:TP53:ENSP00000352610.4:p.(Gly245Ser)|R:TP53:NP_001119587.1:p.(Gly113Ser)|R:TP53:NP_001263626.1:p.(Gly86Ser)|R:TP53:NP_001263628.1:p.(Gly86Ser)|R:TP53:NP_001119589.1:p.(Gly113Ser)|R:TP53:NP_001263627.1:p.(Gly86Ser)|R:TP53:NP_001119588.1:p.(Gly113Ser)|E:TP53:Canonical:ENSP00000269305.4:p.(Gly245Ser)|R:TP53:NP_001263625.1:p.(Gly206Ser)|R:TP53:NP_001119590.1:p.(Gly206Ser)|R:TP53:NP_001119585.1:p.(Gly245Ser)|R:TP53:Canonical:NP_000537.3:p.(Gly245Ser)|R:TP53:NP_001263689.1:p.(Gly206Ser)|R:TP53:NP_001263690.1:p.(Gly206Ser)|R:TP53:NP_001263624.1:p.(Gly206Ser)|R:TP53:NP_001119586.1:p.(Gly245Ser)|R:TP53:NP_001119584.1:p.(Gly245Ser)|E:TP53:ENSP00000398846.2:p.(Gly245Ser)|E:TP53:ENSP00000391127.2:p.(Gly245Ser)|E:TP53:ENSP00000391478.2:p.(Gly245Ser)|R:TP53:XP_005256835.1:p.(Gly225Ser)|E:TP53:ENSP00000425104.1:p.(Gly113Ser)|E:TP53:ENSP00000423862.1:p.(Gly152Ser);upstream_gene_variant:E:TP53:ENST00000576024.1;downstream_gene_variant:E:TP53:ENST00000508793.1|E:TP53:ENST00000604348.1|E:TP53:ENST00000503591.1	CPSR_classification|ClinVar_classification|class	NA	IS:all_exons	.	.	include	variant_in_more_than_10%_of_tumor_samples_(18.66%)_with_VAF_under_0.01	.	.
CL-AcroMetrix	TP53	ENST00000269305	NM_000546	17:7577559	G>A	c.722C>T	exon7	S241F	Ser241Phe	c.722C>T:exon7:S241F:Ser241Phe	missense_variant	1081	0.037	NA	NA	NA	NA	COSV52661688|COSV52662386|COSV52713934|COSV52760886	rs28934573	12359	4e-06	NA	0.0000088	NA	TP53|S241|7.18e-46	Cholangiocarcinoma:_2%_(1/51)|Ovarian_Serous_Cystadenocarcinoma:_1.4%_(6/436)|Bladder_Urothelial_Carcinoma:_1.2%_(5/412)|Pancreatic_Adenocarcinoma:_0.6%_(1/180)|Skin_Cutaneous_Melanoma:_0.6%_(3/468)|Uterine_Corpus_Endometrial_Carcinoma:_0.6%_(3/530)|Esophageal_Carcinoma:_0.5%_(1/184)|Sarcoma:_0.4%_(1/237)|Cervical_Squamous_Cell_Carcinoma_and_Endocervical_Adenocarcinoma:_0.3%_(1/289)|Lung_Adenocarcinoma:_0.2%_(1/567)|Breast_Invasive_Carcinoma:_0.1%_(1/986)	ESAD-UK/Primary/1/97/0.0103|MELA-AU/Metastatic/1/60/0.0167|OV-AU/Primary/1/60/0.0167|PACA-CA/Primary/1/140/0.0071	T:64+2+0+1=67/461|N:1+0+0+0=1/104|A:65+2+0+1=68/565	TP53:p.S241F:ENST00000413465&ENST00000359597&ENST00000269305&ENST00000455263&ENST00000420246&ENST00000445888:CTAT_POPULATION|CTAT_CANCER|3D_STRUCTURE	TP53	4_c_NS	[non-HC]_2.45/2.9_NA	TIER_3	Likely_Pathogenic	Likely_Pathogenic	SOM	P53_DNA-binding_domain	NA	missense_variant:E:TP53:ENSP00000410739.2:p.(Ser241Phe)|E:TP53:ENSP00000352610.4:p.(Ser241Phe)|R:TP53:NP_001119587.1:p.(Ser109Phe)|R:TP53:NP_001263626.1:p.(Ser82Phe)|R:TP53:NP_001263628.1:p.(Ser82Phe)|R:TP53:NP_001119589.1:p.(Ser109Phe)|R:TP53:NP_001263627.1:p.(Ser82Phe)|R:TP53:NP_001119588.1:p.(Ser109Phe)|E:TP53:Canonical:ENSP00000269305.4:p.(Ser241Phe)|R:TP53:NP_001263625.1:p.(Ser202Phe)|R:TP53:NP_001119590.1:p.(Ser202Phe)|R:TP53:NP_001119585.1:p.(Ser241Phe)|R:TP53:Canonical:NP_000537.3:p.(Ser241Phe)|R:TP53:NP_001263689.1:p.(Ser202Phe)|R:TP53:NP_001263690.1:p.(Ser202Phe)|R:TP53:NP_001263624.1:p.(Ser202Phe)|R:TP53:NP_001119586.1:p.(Ser241Phe)|R:TP53:NP_001119584.1:p.(Ser241Phe)|E:TP53:ENSP00000398846.2:p.(Ser241Phe)|E:TP53:ENSP00000391127.2:p.(Ser241Phe)|E:TP53:ENSP00000391478.2:p.(Ser241Phe)|R:TP53:XP_005256835.1:p.(Ser221Phe)|E:TP53:ENSP00000425104.1:p.(Ser109Phe)|E:TP53:ENSP00000423862.1:p.(Ser148Phe);upstream_gene_variant:E:TP53:ENST00000576024.1;downstream_gene_variant:E:TP53:ENST00000508793.1|E:TP53:ENST00000604348.1|E:TP53:ENST00000503591.1	CPSR_classification|ClinVar_classification|class	NA	IS:all_exons	.	.	include	variant_in_more_than_10%_of_tumor_samples_(13.88%)_with_VAF_under_0.01	.	.
CL-AcroMetrix	TP53	ENST00000269305	NM_000546	17:7577580	T>C	c.701A>G	exon7	Y234C	Tyr234Cys	c.701A>G:exon7:Y234C:Tyr234Cys	missense_variant	1010	0.04	NA	NA	NA	NA	COSV52661201|COSV52686167|COSV53142556	rs587780073	127820	4e-06	NA	0.0000088	NA	TP53|Y234|4.21e-68	Lung_Squamous_Cell_Carcinoma:_1.4%_(7/492)|Mesothelioma:_1.2%_(1/82)|Adrenocortical_Carcinoma:_1.1%_(1/92)|Ovarian_Serous_Cystadenocarcinoma:_0.7%_(3/436)|Glioblastoma_Multiforme:_0.5%_(2/393)|Head_and_Neck_Squamous_Cell_Carcinoma:_0.4%_(2/508)|Sarcoma:_0.4%_(1/237)|Breast_Invasive_Carcinoma:_0.2%_(2/986)|Brain_Lower_Grade_Glioma:_0.2%_(1/509)	BRCA-EU/Primary/1/76/0.0132|LIRI-JP/Primary/1/250/0.004	T:9+0+0+0=9/461|N:5+0+0+0=5/104|A:14+0+0+0=14/565	TP53:p.Y234C:ENST00000413465&ENST00000359597&ENST00000269305&ENST00000455263&ENST00000420246&ENST00000445888:CTAT_POPULATION|CTAT_CANCER|3D_STRUCTURE	TP53	4_c_NS	[non-HC]_2.45/2.9_NA	TIER_3	Likely_Pathogenic	Likely_Pathogenic	SOM	P53_DNA-binding_domain	NA	missense_variant:E:TP53:ENSP00000410739.2:p.(Tyr234Cys)|E:TP53:ENSP00000352610.4:p.(Tyr234Cys)|R:TP53:NP_001119587.1:p.(Tyr102Cys)|R:TP53:NP_001263626.1:p.(Tyr75Cys)|R:TP53:NP_001263628.1:p.(Tyr75Cys)|R:TP53:NP_001119589.1:p.(Tyr102Cys)|R:TP53:NP_001263627.1:p.(Tyr75Cys)|R:TP53:NP_001119588.1:p.(Tyr102Cys)|E:TP53:Canonical:ENSP00000269305.4:p.(Tyr234Cys)|R:TP53:NP_001263625.1:p.(Tyr195Cys)|R:TP53:NP_001119590.1:p.(Tyr195Cys)|R:TP53:NP_001119585.1:p.(Tyr234Cys)|R:TP53:Canonical:NP_000537.3:p.(Tyr234Cys)|R:TP53:NP_001263689.1:p.(Tyr195Cys)|R:TP53:NP_001263690.1:p.(Tyr195Cys)|R:TP53:NP_001263624.1:p.(Tyr195Cys)|R:TP53:NP_001119586.1:p.(Tyr234Cys)|R:TP53:NP_001119584.1:p.(Tyr234Cys)|E:TP53:ENSP00000398846.2:p.(Tyr234Cys)|E:TP53:ENSP00000391127.2:p.(Tyr234Cys)|E:TP53:ENSP00000391478.2:p.(Tyr234Cys)|R:TP53:XP_005256835.1:p.(Tyr214Cys)|E:TP53:ENSP00000425104.1:p.(Tyr102Cys)|E:TP53:ENSP00000423862.1:p.(Tyr141Cys);upstream_gene_variant:E:TP53:ENST00000576024.1;downstream_gene_variant:E:TP53:ENST00000508793.1|E:TP53:ENST00000604348.1|E:TP53:ENST00000503591.1	CPSR_classification|ClinVar_classification|class	NA	IS:all_exons	.	.	include	.	.	.
CL-AcroMetrix	TP53	ENST00000269305	NM_000546	17:7578190	T>C	c.659A>G	exon6	Y220C	Tyr220Cys	c.659A>G:exon6:Y220C:Tyr220Cys	missense_variant	1215	0.029	NA	NA	NA	NA	COSV52661282|COSV52677517	rs121912666	127819	8e-06	NA	0.0000176	NA	TP53|Y220|4.54e-208	Ovarian_Serous_Cystadenocarcinoma:_2.1%_(9/436)|Brain_Lower_Grade_Glioma:_2%_(10/509)|Esophageal_Carcinoma:_1.6%_(3/184)|Head_and_Neck_Squamous_Cell_Carcinoma:_1.4%_(7/508)|Glioblastoma_Multiforme:_1.3%_(5/393)|Pancreatic_Adenocarcinoma:_1.1%_(2/180)|Uterine_Corpus_Endometrial_Carcinoma:_1.1%_(6/530)|Stomach_Adenocarcinoma:_0.9%_(4/437)|Lung_Squamous_Cell_Carcinoma:_0.8%_(4/492)|Breast_Invasive_Carcinoma:_0.7%_(7/986)|Colon_Adenocarcinoma:_0.5%_(2/399)|Liver_Hepatocellular_Carcinoma:_0.5%_(2/364)|Lung_Adenocarcinoma:_0.5%_(3/567)|Sarcoma:_0.4%_(1/237)|Bladder_Urothelial_Carcinoma:_0.2%_(1/412)|Skin_Cutaneous_Melanoma:_0.2%_(1/468)	BRCA-UK/Primary/1/44/0.0227|CLLE-ES/Primary/2/90/0.0222|ESAD-UK/Primary/1/97/0.0103|LINC-JP/Primary/1/28/0.0357|LIRI-JP/Primary/1/250/0.004|OV-AU/Primary/3/60/0.05|PACA-AU/Primary/2/90/0.0222|PACA-CA/Primary/3/140/0.0214	T:12+0+0+1=13/462|N:5+0+0+0=5/104|A:17+0+0+1=18/566	TP53:p.Y220C:ENST00000413465&ENST00000359597&ENST00000269305&ENST00000455263&ENST00000420246&ENST00000445888:CTAT_POPULATION|CTAT_CANCER|3D_STRUCTURE	TP53	4_c_NS	[non-HC]_2.45/2.9_NA	TIER_3	Likely_Pathogenic	Pathogenic	SOM	P53_DNA-binding_domain	NA	missense_variant:E:TP53:ENSP00000410739.2:p.(Tyr220Cys)|E:TP53:ENSP00000352610.4:p.(Tyr220Cys)|R:TP53:NP_001119587.1:p.(Tyr88Cys)|R:TP53:NP_001263626.1:p.(Tyr61Cys)|R:TP53:NP_001263628.1:p.(Tyr61Cys)|R:TP53:NP_001119589.1:p.(Tyr88Cys)|R:TP53:NP_001263627.1:p.(Tyr61Cys)|R:TP53:NP_001119588.1:p.(Tyr88Cys)|E:TP53:Canonical:ENSP00000269305.4:p.(Tyr220Cys)|R:TP53:NP_001263625.1:p.(Tyr181Cys)|R:TP53:NP_001119590.1:p.(Tyr181Cys)|R:TP53:NP_001119585.1:p.(Tyr220Cys)|R:TP53:Canonical:NP_000537.3:p.(Tyr220Cys)|R:TP53:NP_001263689.1:p.(Tyr181Cys)|R:TP53:NP_001263690.1:p.(Tyr181Cys)|R:TP53:NP_001263624.1:p.(Tyr181Cys)|R:TP53:NP_001119586.1:p.(Tyr220Cys)|R:TP53:NP_001119584.1:p.(Tyr220Cys)|E:TP53:ENSP00000398846.2:p.(Tyr220Cys)|E:TP53:ENSP00000391127.2:p.(Tyr220Cys)|E:TP53:ENSP00000391478.2:p.(Tyr220Cys)|R:TP53:XP_005256835.1:p.(Tyr200Cys)|E:TP53:ENSP00000425104.1:p.(Tyr88Cys)|E:TP53:ENSP00000423862.1:p.(Tyr127Cys);upstream_gene_variant:E:TP53:ENST00000576024.1;downstream_gene_variant:E:TP53:ENST00000508793.1|E:TP53:ENST00000604348.1|E:TP53:ENST00000503591.1	CPSR_classification|ClinVar_classification|class	NA	IS:all_exons	.	.	include	.	.	.
CL-AcroMetrix	TP53	ENST00000269305	NM_000546	17:7578196	A>T	c.653T>A	exon6	V218E	Val218Glu	c.653T>A:exon6:V218E:Val218Glu	missense_variant	1181	0.028	NA	NA	NA	NA	COSV52690974|COSV52712839|COSV52761003	NA	NA	NA	NA	NA	NA	TP53|V218|0.0644	NA	NA	T:11+0+0+0=11/462|N:6+0+0+0=6/104|A:17+0+0+0=17/566	TP53:p.V218E:ENST00000413465&ENST00000359597&ENST00000269305&ENST00000455263&ENST00000420246&ENST00000445888:CTAT_POPULATION|CTAT_CANCER|3D_STRUCTURE	TP53	4_c_NS	[non-HC]_2.45/2.9_NA	TIER_3	Likely_Pathogenic	NA	SOM	P53_DNA-binding_domain	NA	missense_variant:E:TP53:ENSP00000410739.2:p.(Val218Glu)|E:TP53:ENSP00000352610.4:p.(Val218Glu)|R:TP53:NP_001119587.1:p.(Val86Glu)|R:TP53:NP_001263626.1:p.(Val59Glu)|R:TP53:NP_001263628.1:p.(Val59Glu)|R:TP53:NP_001119589.1:p.(Val86Glu)|R:TP53:NP_001263627.1:p.(Val59Glu)|R:TP53:NP_001119588.1:p.(Val86Glu)|E:TP53:Canonical:ENSP00000269305.4:p.(Val218Glu)|R:TP53:NP_001263625.1:p.(Val179Glu)|R:TP53:NP_001119590.1:p.(Val179Glu)|R:TP53:NP_001119585.1:p.(Val218Glu)|R:TP53:Canonical:NP_000537.3:p.(Val218Glu)|R:TP53:NP_001263689.1:p.(Val179Glu)|R:TP53:NP_001263690.1:p.(Val179Glu)|R:TP53:NP_001263624.1:p.(Val179Glu)|R:TP53:NP_001119586.1:p.(Val218Glu)|R:TP53:NP_001119584.1:p.(Val218Glu)|E:TP53:ENSP00000398846.2:p.(Val218Glu)|E:TP53:ENSP00000391127.2:p.(Val218Glu)|E:TP53:ENSP00000391478.2:p.(Val218Glu)|R:TP53:XP_005256835.1:p.(Val198Glu)|E:TP53:ENSP00000425104.1:p.(Val86Glu)|E:TP53:ENSP00000423862.1:p.(Val125Glu);upstream_gene_variant:E:TP53:ENST00000576024.1;downstream_gene_variant:E:TP53:ENST00000508793.1|E:TP53:ENST00000604348.1|E:TP53:ENST00000503591.1	CPSR_classification|class	NA	IS:all_exons	.	.	include	.	.	.
CL-AcroMetrix	TP53	ENST00000269305	NM_000546	17:7578203	C>T	c.646G>A	exon6	V216M	Val216Met	c.646G>A:exon6:V216M:Val216Met	missense_variant	1262	0.025	NA	NA	NA	NA	COSV52671096|COSV52751864|COSV53384298	rs730882025	182965	NA	NA	NA	NA	TP53|V216|7.06e-22	Ovarian_Serous_Cystadenocarcinoma:_0.7%_(3/436)|Glioblastoma_Multiforme:_0.5%_(2/393)|Brain_Lower_Grade_Glioma:_0.4%_(2/509)|Breast_Invasive_Carcinoma:_0.3%_(3/986)|Head_and_Neck_Squamous_Cell_Carcinoma:_0.2%_(1/508)|Uterine_Corpus_Endometrial_Carcinoma:_0.2%_(1/530)	LIRI-JP/Primary/1/250/0.004	T:45+1+2+0=48/462|N:3+0+0+0=3/104|A:48+1+2+0=51/566	TP53:p.V216M:ENST00000413465&ENST00000359597&ENST00000269305&ENST00000455263&ENST00000420246&ENST00000445888:CTAT_CANCER|3D_STRUCTURE	TP53	4_c_NS	[non-HC]_2.45/2.9_NA	TIER_3	Likely_Pathogenic	VUS	SOM	P53_DNA-binding_domain	NA	missense_variant:E:TP53:ENSP00000410739.2:p.(Val216Met)|E:TP53:ENSP00000352610.4:p.(Val216Met)|R:TP53:NP_001119587.1:p.(Val84Met)|R:TP53:NP_001263626.1:p.(Val57Met)|R:TP53:NP_001263628.1:p.(Val57Met)|R:TP53:NP_001119589.1:p.(Val84Met)|R:TP53:NP_001263627.1:p.(Val57Met)|R:TP53:NP_001119588.1:p.(Val84Met)|E:TP53:Canonical:ENSP00000269305.4:p.(Val216Met)|R:TP53:NP_001263625.1:p.(Val177Met)|R:TP53:NP_001119590.1:p.(Val177Met)|R:TP53:NP_001119585.1:p.(Val216Met)|R:TP53:Canonical:NP_000537.3:p.(Val216Met)|R:TP53:NP_001263689.1:p.(Val177Met)|R:TP53:NP_001263690.1:p.(Val177Met)|R:TP53:NP_001263624.1:p.(Val177Met)|R:TP53:NP_001119586.1:p.(Val216Met)|R:TP53:NP_001119584.1:p.(Val216Met)|E:TP53:ENSP00000398846.2:p.(Val216Met)|E:TP53:ENSP00000391127.2:p.(Val216Met)|E:TP53:ENSP00000391478.2:p.(Val216Met)|R:TP53:XP_005256835.1:p.(Val196Met)|E:TP53:ENSP00000425104.1:p.(Val84Met)|E:TP53:ENSP00000423862.1:p.(Val123Met);upstream_gene_variant:E:TP53:ENST00000576024.1;downstream_gene_variant:E:TP53:ENST00000508793.1|E:TP53:ENST00000604348.1|E:TP53:ENST00000503591.1	CPSR_classification|class	NA	IS:all_exons	.	.	include	.	.	.
CL-AcroMetrix	TP53	ENST00000269305	NM_000546	17:7578235	T>C	c.614A>G	exon6	Y205C	Tyr205Cys	c.614A>G:exon6:Y205C:Tyr205Cys	missense_variant	1290	0.038	NA	NA	NA	NA	COSV52665440|COSV52677268|COSV52688506	rs1057520007	376681	NA	NA	NA	NA	TP53|Y205|7.47e-58	Uterine_Corpus_Endometrial_Carcinoma:_0.6%_(3/530)|Colon_Adenocarcinoma:_0.5%_(2/399)|Esophageal_Carcinoma:_0.5%_(1/184)|Liver_Hepatocellular_Carcinoma:_0.5%_(2/364)|Lung_Adenocarcinoma:_0.5%_(3/567)|Sarcoma:_0.4%_(1/237)|Glioblastoma_Multiforme:_0.3%_(1/393)|Head_and_Neck_Squamous_Cell_Carcinoma:_0.2%_(1/508)|Lung_Squamous_Cell_Carcinoma:_0.2%_(1/492)|Ovarian_Serous_Cystadenocarcinoma:_0.2%_(1/436)|Stomach_Adenocarcinoma:_0.2%_(1/437)|Breast_Invasive_Carcinoma:_0.1%_(1/986)	LIRI-JP/Primary/2/250/0.008|MELA-AU/Metastatic/1/60/0.0167	T:12+0+0+0=12/461|N:2+0+0+0=2/104|A:14+0+0+0=14/565	TP53:p.Y205C:ENST00000413465&ENST00000359597&ENST00000269305&ENST00000455263&ENST00000420246&ENST00000445888:CTAT_CANCER|3D_STRUCTURE	TP53	4_c_NS	[non-HC]_2.45/2.9_NA	TIER_3	Likely_Pathogenic	Likely_Pathogenic	SOM	P53_DNA-binding_domain	NA	missense_variant:E:TP53:ENSP00000410739.2:p.(Tyr205Cys)|E:TP53:ENSP00000352610.4:p.(Tyr205Cys)|R:TP53:NP_001119587.1:p.(Tyr73Cys)|R:TP53:NP_001263626.1:p.(Tyr46Cys)|R:TP53:NP_001263628.1:p.(Tyr46Cys)|R:TP53:NP_001119589.1:p.(Tyr73Cys)|R:TP53:NP_001263627.1:p.(Tyr46Cys)|R:TP53:NP_001119588.1:p.(Tyr73Cys)|E:TP53:Canonical:ENSP00000269305.4:p.(Tyr205Cys)|R:TP53:NP_001263625.1:p.(Tyr166Cys)|R:TP53:NP_001119590.1:p.(Tyr166Cys)|R:TP53:NP_001119585.1:p.(Tyr205Cys)|R:TP53:Canonical:NP_000537.3:p.(Tyr205Cys)|R:TP53:NP_001263689.1:p.(Tyr166Cys)|R:TP53:NP_001263690.1:p.(Tyr166Cys)|R:TP53:NP_001263624.1:p.(Tyr166Cys)|R:TP53:NP_001119586.1:p.(Tyr205Cys)|R:TP53:NP_001119584.1:p.(Tyr205Cys)|E:TP53:ENSP00000398846.2:p.(Tyr205Cys)|E:TP53:ENSP00000391127.2:p.(Tyr205Cys)|E:TP53:ENSP00000391478.2:p.(Tyr205Cys)|R:TP53:XP_005256835.1:p.(Tyr185Cys)|E:TP53:ENSP00000425104.1:p.(Tyr73Cys)|E:TP53:ENSP00000423862.1:p.(Tyr112Cys);upstream_gene_variant:E:TP53:ENST00000576024.1;downstream_gene_variant:E:TP53:ENST00000508793.1|E:TP53:ENST00000604348.1|E:TP53:ENST00000503591.1	CPSR_classification|ClinVar_classification|class	NA	IS:all_exons	.	.	include	.	.	.
CL-AcroMetrix	TP53	ENST00000269305	NM_000546	17:7578388	C>T	c.542G>A	exon5	R181H	Arg181His	c.542G>A:exon5:R181H:Arg181His	missense_variant	1228	0.064	NA	NA	NA	NA	COSV52675795|COSV52676870|COSV52730435|COSV53567603	rs397514495	142320	1.19e-05	NA	0.0000264	NA	TP53|R181|0.0142	Colon_Adenocarcinoma:_0.3%_(1/399)|Bladder_Urothelial_Carcinoma:_0.2%_(1/412)|Brain_Lower_Grade_Glioma:_0.2%_(1/509)|Uterine_Corpus_Endometrial_Carcinoma:_0.2%_(1/530)	PACA-AU/Primary/1/90/0.0111|PACA-CA/Primary/1/140/0.0071	T:81+0+0+0=81/461|N:5+0+0+0=5/104|A:86+0+0+0=86/565	TP53:p.R181H:ENST00000413465&ENST00000359597&ENST00000269305&ENST00000455263&ENST00000420246&ENST00000445888:CTAT_POPULATION|CTAT_CANCER|3D_STRUCTURE	TP53	4_c_NS	[non-HC]_2.45/2.9_NA	TIER_3	Likely_Pathogenic	Likely_Pathogenic	SOM	P53_DNA-binding_domain	NA	missense_variant:E:TP53:ENSP00000410739.2:p.(Arg181His)|E:TP53:ENSP00000352610.4:p.(Arg181His)|R:TP53:NP_001119587.1:p.(Arg49His)|R:TP53:NP_001263626.1:p.(Arg22His)|R:TP53:NP_001263628.1:p.(Arg22His)|R:TP53:NP_001119589.1:p.(Arg49His)|R:TP53:NP_001263627.1:p.(Arg22His)|R:TP53:NP_001119588.1:p.(Arg49His)|E:TP53:Canonical:ENSP00000269305.4:p.(Arg181His)|R:TP53:NP_001263625.1:p.(Arg142His)|R:TP53:NP_001119590.1:p.(Arg142His)|R:TP53:NP_001119585.1:p.(Arg181His)|R:TP53:Canonical:NP_000537.3:p.(Arg181His)|R:TP53:NP_001263689.1:p.(Arg142His)|R:TP53:NP_001263690.1:p.(Arg142His)|R:TP53:NP_001263624.1:p.(Arg142His)|R:TP53:NP_001119586.1:p.(Arg181His)|R:TP53:NP_001119584.1:p.(Arg181His)|E:TP53:ENSP00000398846.2:p.(Arg181His)|E:TP53:ENSP00000391127.2:p.(Arg181His)|E:TP53:ENSP00000391478.2:p.(Arg181His)|R:TP53:XP_005256835.1:p.(Arg161His)|E:TP53:ENSP00000425104.1:p.(Arg49His)|E:TP53:ENSP00000423862.1:p.(Arg88His);upstream_gene_variant:E:TP53:ENST00000576024.1;downstream_gene_variant:E:TP53:ENST00000508793.1|E:TP53:ENST00000604348.1|E:TP53:ENST00000503591.1	CPSR_classification|ClinVar_classification|class	NA	IS:all_exons	.	.	include	variant_in_more_than_10%_of_tumor_samples_(17.57%)_with_VAF_under_0.01	.	.
CL-AcroMetrix	TP53	ENST00000269305	NM_000546	17:7578442	T>C	c.488A>G	exon5	Y163C	Tyr163Cys	c.488A>G:exon5:Y163C:Tyr163Cys	missense_variant	1382	0.04	NA	NA	NA	NA	COSV52663142|COSV52676381	rs148924904	127814	NA	NA	NA	NA	TP53|Y163|6.76e-86	Lung_Squamous_Cell_Carcinoma:_1.4%_(7/492)|Ovarian_Serous_Cystadenocarcinoma:_1.4%_(6/436)|Head_and_Neck_Squamous_Cell_Carcinoma:_1%_(5/508)|Esophageal_Carcinoma:_0.5%_(1/184)|Brain_Lower_Grade_Glioma:_0.4%_(2/509)|Lung_Adenocarcinoma:_0.4%_(2/567)|Colon_Adenocarcinoma:_0.3%_(1/399)|Breast_Invasive_Carcinoma:_0.1%_(1/986)	BRCA-EU/Primary/1/76/0.0132|LIRI-JP/Primary/1/250/0.004|OV-AU/Primary/1/60/0.0167	T:13+0+1+0=14/462|N:5+0+0+0=5/104|A:18+0+1+0=19/566	TP53:p.Y163C:ENST00000413465&ENST00000359597&ENST00000269305&ENST00000455263&ENST00000420246&ENST00000445888&ENST00000508793:CTAT_POPULATION|CTAT_CANCER|3D_STRUCTURE	TP53	4_c_NS	[non-HC]_2.45/2.9_NA	TIER_3	Likely_Pathogenic	Pathogenic	SOM	P53_DNA-binding_domain	NA	missense_variant:E:TP53:ENSP00000410739.2:p.(Tyr163Cys)|E:TP53:ENSP00000352610.4:p.(Tyr163Cys)|R:TP53:NP_001119587.1:p.(Tyr31Cys)|R:TP53:NP_001263626.1:p.(Tyr4Cys)|R:TP53:NP_001263628.1:p.(Tyr4Cys)|R:TP53:NP_001119589.1:p.(Tyr31Cys)|R:TP53:NP_001263627.1:p.(Tyr4Cys)|R:TP53:NP_001119588.1:p.(Tyr31Cys)|E:TP53:Canonical:ENSP00000269305.4:p.(Tyr163Cys)|R:TP53:NP_001263625.1:p.(Tyr124Cys)|R:TP53:NP_001119590.1:p.(Tyr124Cys)|R:TP53:NP_001119585.1:p.(Tyr163Cys)|R:TP53:Canonical:NP_000537.3:p.(Tyr163Cys)|R:TP53:NP_001263689.1:p.(Tyr124Cys)|R:TP53:NP_001263690.1:p.(Tyr124Cys)|R:TP53:NP_001263624.1:p.(Tyr124Cys)|R:TP53:NP_001119586.1:p.(Tyr163Cys)|R:TP53:NP_001119584.1:p.(Tyr163Cys)|E:TP53:ENSP00000398846.2:p.(Tyr163Cys)|E:TP53:ENSP00000391127.2:p.(Tyr163Cys)|E:TP53:ENSP00000391478.2:p.(Tyr163Cys)|R:TP53:XP_005256835.1:p.(Tyr143Cys)|E:TP53:ENSP00000425104.1:p.(Tyr31Cys)|E:TP53:ENSP00000423862.1:p.(Tyr70Cys)|E:TP53:ENSP00000424104.1:p.(Tyr163Cys);upstream_gene_variant:E:TP53:ENST00000576024.1;downstream_gene_variant:E:TP53:ENST00000604348.1|E:TP53:ENST00000503591.1	CPSR_classification|ClinVar_classification|class	NA	IS:all_exons	.	.	include	.	.	.
CL-AcroMetrix	TP53	ENST00000269305	NM_000546	17:7578449	C>T	c.481G>A	exon5	A161T	Ala161Thr	c.481G>A:exon5:A161T:Ala161Thr	missense_variant	1356	0.036	NA	NA	NA	NA	COSV52660939|COSV52789715|COSV53470581	rs193920817	161518	NA	NA	NA	NA	TP53|A161|8.66e-06	Bladder_Urothelial_Carcinoma:_0.5%_(2/412)|Colon_Adenocarcinoma:_0.3%_(1/399)|Head_and_Neck_Squamous_Cell_Carcinoma:_0.2%_(1/508)|Brain_Lower_Grade_Glioma:_0.2%_(1/509)|Lung_Squamous_Cell_Carcinoma:_0.2%_(1/492)	OV-AU/Primary/1/60/0.0167|PACA-CA/Primary/1/140/0.0071	T:67+1+1+1=70/462|N:5+0+0+0=5/104|A:72+1+1+1=75/566	TP53:p.A161T:ENST00000413465&ENST00000359597&ENST00000269305&ENST00000455263&ENST00000420246&ENST00000445888&ENST00000508793:CTAT_POPULATION|CTAT_CANCER|3D_STRUCTURE	TP53	4_c_NS	[non-HC]_2.45/2.9_NA	TIER_3	Likely_Pathogenic	VUS	SOM	P53_DNA-binding_domain	NA	missense_variant:E:TP53:ENSP00000410739.2:p.(Ala161Thr)|E:TP53:ENSP00000352610.4:p.(Ala161Thr)|R:TP53:NP_001119587.1:p.(Ala29Thr)|R:TP53:NP_001263626.1:p.(Ala2Thr)|R:TP53:NP_001263628.1:p.(Ala2Thr)|R:TP53:NP_001119589.1:p.(Ala29Thr)|R:TP53:NP_001263627.1:p.(Ala2Thr)|R:TP53:NP_001119588.1:p.(Ala29Thr)|E:TP53:Canonical:ENSP00000269305.4:p.(Ala161Thr)|R:TP53:NP_001263625.1:p.(Ala122Thr)|R:TP53:NP_001119590.1:p.(Ala122Thr)|R:TP53:NP_001119585.1:p.(Ala161Thr)|R:TP53:Canonical:NP_000537.3:p.(Ala161Thr)|R:TP53:NP_001263689.1:p.(Ala122Thr)|R:TP53:NP_001263690.1:p.(Ala122Thr)|R:TP53:NP_001263624.1:p.(Ala122Thr)|R:TP53:NP_001119586.1:p.(Ala161Thr)|R:TP53:NP_001119584.1:p.(Ala161Thr)|E:TP53:ENSP00000398846.2:p.(Ala161Thr)|E:TP53:ENSP00000391127.2:p.(Ala161Thr)|E:TP53:ENSP00000391478.2:p.(Ala161Thr)|R:TP53:XP_005256835.1:p.(Ala141Thr)|E:TP53:ENSP00000425104.1:p.(Ala29Thr)|E:TP53:ENSP00000423862.1:p.(Ala68Thr)|E:TP53:ENSP00000424104.1:p.(Ala161Thr);upstream_gene_variant:E:TP53:ENST00000576024.1;downstream_gene_variant:E:TP53:ENST00000604348.1|E:TP53:ENST00000503591.1	CPSR_classification|class	NA	IS:all_exons	.	.	include	variant_in_more_than_10%_of_tumor_samples_(14.5%)_with_VAF_under_0.01	.	.
CL-AcroMetrix	TP53	ENST00000269305	NM_000546	17:7578461	C>A	c.469G>T	exon5	V157F	Val157Phe	c.469G>T:exon5:V157F:Val157Phe	missense_variant	1360	0.04	NA	NA	NA	NA	COSV52667015|COSV52676009|COSV52752314|COSV53205488	rs121912654	12353	NA	NA	NA	NA	TP53|V157|1.04e-43	Lung_Squamous_Cell_Carcinoma:_2.6%_(13/492)|Ovarian_Serous_Cystadenocarcinoma:_1.1%_(5/436)|Head_and_Neck_Squamous_Cell_Carcinoma:_1%_(5/508)|Liver_Hepatocellular_Carcinoma:_0.8%_(3/364)|Esophageal_Carcinoma:_0.5%_(1/184)|Lung_Adenocarcinoma:_0.5%_(3/567)|Colon_Adenocarcinoma:_0.3%_(1/399)|Prostate_Adenocarcinoma:_0.2%_(1/496)|Breast_Invasive_Carcinoma:_0.1%_(1/986)	LIRI-JP/Primary/1/250/0.004|PACA-AU/Primary/1/90/0.0111	T:35+0+0+0=35/462|N:1+0+0+0=1/104|A:36+0+0+0=36/566	TP53:p.V157F:ENST00000413465&ENST00000359597&ENST00000269305&ENST00000455263&ENST00000420246&ENST00000445888&ENST00000508793:CTAT_CANCER|3D_STRUCTURE	TP53	4_c_NS	[non-HC]_2.45/2.9_NA	TIER_3	Likely_Pathogenic	VUS	SOM	P53_DNA-binding_domain	NA	missense_variant:E:TP53:ENSP00000410739.2:p.(Val157Phe)|E:TP53:ENSP00000352610.4:p.(Val157Phe)|R:TP53:NP_001119587.1:p.(Val25Phe)|R:TP53:NP_001119589.1:p.(Val25Phe)|R:TP53:NP_001119588.1:p.(Val25Phe)|E:TP53:Canonical:ENSP00000269305.4:p.(Val157Phe)|R:TP53:NP_001263625.1:p.(Val118Phe)|R:TP53:NP_001119590.1:p.(Val118Phe)|R:TP53:NP_001119585.1:p.(Val157Phe)|R:TP53:Canonical:NP_000537.3:p.(Val157Phe)|R:TP53:NP_001263689.1:p.(Val118Phe)|R:TP53:NP_001263690.1:p.(Val118Phe)|R:TP53:NP_001263624.1:p.(Val118Phe)|R:TP53:NP_001119586.1:p.(Val157Phe)|R:TP53:NP_001119584.1:p.(Val157Phe)|E:TP53:ENSP00000398846.2:p.(Val157Phe)|E:TP53:ENSP00000391127.2:p.(Val157Phe)|E:TP53:ENSP00000391478.2:p.(Val157Phe)|R:TP53:XP_005256835.1:p.(Val137Phe)|E:TP53:ENSP00000425104.1:p.(Val25Phe)|E:TP53:ENSP00000423862.1:p.(Val64Phe)|E:TP53:ENSP00000424104.1:p.(Val157Phe);5_prime_UTR_variant:R:TP53:NM_001276697.1|R:TP53:NM_001276699.1|R:TP53:NM_001276698.1;upstream_gene_variant:E:TP53:ENST00000576024.1;downstream_gene_variant:E:TP53:ENST00000604348.1|E:TP53:ENST00000503591.1	CPSR_classification|class	NA	IS:all_exons	.	.	include	.	.	.
CL-AcroMetrix	TP53	ENST00000269305	NM_000546	17:7578526	C>T	c.404G>A	exon5	C135Y	Cys135Tyr	c.404G>A:exon5:C135Y:Cys135Tyr	missense_variant	1290	0.043	NA	NA	NA	NA	COSV52675774|COSV52680475|COSV52702460|COSV53452020	rs587781991	141762	0	NA	0.0000000	NA	TP53|C135|3.53e-50	Adrenocortical_Carcinoma:_1.1%_(1/92)|Pancreatic_Adenocarcinoma:_0.6%_(1/180)|Esophageal_Carcinoma:_0.5%_(1/184)|Colon_Adenocarcinoma:_0.3%_(1/399)|Bladder_Urothelial_Carcinoma:_0.2%_(1/412)|Lung_Squamous_Cell_Carcinoma:_0.2%_(1/492)|Ovarian_Serous_Cystadenocarcinoma:_0.2%_(1/436)|Prostate_Adenocarcinoma:_0.2%_(1/496)|Breast_Invasive_Carcinoma:_0.1%_(1/986)	BOCA-UK/Primary/1/61/0.0164|ESAD-UK/Primary/1/97/0.0103	T:33+0+0+3=36/462|N:2+0+0+0=2/104|A:35+0+0+3=38/566	TP53:p.C135Y:ENST00000413465&ENST00000359597&ENST00000269305&ENST00000455263&ENST00000420246&ENST00000445888&ENST00000508793:CTAT_POPULATION|CTAT_CANCER|3D_STRUCTURE	TP53	4_c_NS	[non-HC]_2.45/2.9_NA	TIER_3	Likely_Pathogenic	VUS	SOM	P53_DNA-binding_domain	NA	missense_variant:E:TP53:ENSP00000410739.2:p.(Cys135Tyr)|E:TP53:ENSP00000352610.4:p.(Cys135Tyr)|R:TP53:NP_001119587.1:p.(Cys3Tyr)|R:TP53:NP_001119589.1:p.(Cys3Tyr)|R:TP53:NP_001119588.1:p.(Cys3Tyr)|E:TP53:Canonical:ENSP00000269305.4:p.(Cys135Tyr)|R:TP53:NP_001263625.1:p.(Cys96Tyr)|R:TP53:NP_001119590.1:p.(Cys96Tyr)|R:TP53:NP_001119585.1:p.(Cys135Tyr)|R:TP53:Canonical:NP_000537.3:p.(Cys135Tyr)|R:TP53:NP_001263689.1:p.(Cys96Tyr)|R:TP53:NP_001263690.1:p.(Cys96Tyr)|R:TP53:NP_001263624.1:p.(Cys96Tyr)|R:TP53:NP_001119586.1:p.(Cys135Tyr)|R:TP53:NP_001119584.1:p.(Cys135Tyr)|E:TP53:ENSP00000398846.2:p.(Cys135Tyr)|E:TP53:ENSP00000391127.2:p.(Cys135Tyr)|E:TP53:ENSP00000391478.2:p.(Cys135Tyr)|R:TP53:XP_005256835.1:p.(Cys115Tyr)|E:TP53:ENSP00000425104.1:p.(Cys3Tyr)|E:TP53:ENSP00000423862.1:p.(Cys42Tyr)|E:TP53:ENSP00000424104.1:p.(Cys135Tyr)|E:TP53:ENSP00000473895.1:p.(Cys128Tyr);5_prime_UTR_variant:R:TP53:NM_001276697.1|R:TP53:NM_001276699.1|R:TP53:NM_001276698.1;upstream_gene_variant:E:TP53:ENST00000576024.1;downstream_gene_variant:E:TP53:ENST00000503591.1	CPSR_classification|class	NA	IS:all_exons	.	.	include	.	.	.
CL-AcroMetrix	TP53	ENST00000269305	NM_000546	17:7578535	T>C	c.395A>G	exon5	K132R	Lys132Arg	c.395A>G:exon5:K132R:Lys132Arg	missense_variant	1314	0.043	NA	NA	NA	NA	COSV52666637|COSV52701687|COSV52759171	rs1057519996	376625	0	NA	0.0000000	NA	TP53|K132|1.67e-40	Sarcoma:_0.8%_(2/237)|Colon_Adenocarcinoma:_0.3%_(1/399)|Brain_Lower_Grade_Glioma:_0.2%_(1/509)|Lung_Adenocarcinoma:_0.2%_(1/567)|Lung_Squamous_Cell_Carcinoma:_0.2%_(1/492)|Ovarian_Serous_Cystadenocarcinoma:_0.2%_(1/436)	OV-AU/Primary/1/60/0.0167|PACA-CA/Primary/1/140/0.0071	T:11+0+0+0=11/462|N:2+0+0+0=2/104|A:13+0+0+0=13/566	TP53:p.K132R:ENST00000413465&ENST00000359597&ENST00000269305&ENST00000455263&ENST00000420246&ENST00000445888&ENST00000508793:CTAT_POPULATION|CTAT_CANCER|3D_STRUCTURE	TP53	4_c_NS	[non-HC]_2.45/2.9_NA	TIER_3	Likely_Pathogenic	VUS	SOM	P53_DNA-binding_domain	NA	missense_variant:E:TP53:ENSP00000410739.2:p.(Lys132Arg)|E:TP53:ENSP00000352610.4:p.(Lys132Arg)|E:TP53:Canonical:ENSP00000269305.4:p.(Lys132Arg)|R:TP53:NP_001263625.1:p.(Lys93Arg)|R:TP53:NP_001119590.1:p.(Lys93Arg)|R:TP53:NP_001119585.1:p.(Lys132Arg)|R:TP53:Canonical:NP_000537.3:p.(Lys132Arg)|R:TP53:NP_001263689.1:p.(Lys93Arg)|R:TP53:NP_001263690.1:p.(Lys93Arg)|R:TP53:NP_001263624.1:p.(Lys93Arg)|R:TP53:NP_001119586.1:p.(Lys132Arg)|R:TP53:NP_001119584.1:p.(Lys132Arg)|E:TP53:ENSP00000398846.2:p.(Lys132Arg)|E:TP53:ENSP00000391127.2:p.(Lys132Arg)|E:TP53:ENSP00000391478.2:p.(Lys132Arg)|R:TP53:XP_005256835.1:p.(Lys112Arg)|E:TP53:ENSP00000423862.1:p.(Lys39Arg)|E:TP53:ENSP00000424104.1:p.(Lys132Arg);5_prime_UTR_variant:R:TP53:NM_001126115.1|R:TP53:NM_001276697.1|R:TP53:NM_001276699.1|R:TP53:NM_001126117.1|R:TP53:NM_001276698.1|R:TP53:NM_001126116.1|E:TP53:ENST00000509690.1;upstream_gene_variant:E:TP53:ENST00000576024.1;splice_acceptor_variant:E:TP53:ENST00000604348.1;downstream_gene_variant:E:TP53:ENST00000503591.1	CPSR_classification|protein_changes:splice_acceptor_variant|class	NA	IS:all_exons	.	.	include	.	.	.
CL-AcroMetrix	TP53	ENST00000269305	NM_000546	17:7578542	G>C	c.388C>G	exon5	L130V	Leu130Val	c.388C>G:exon5:L130V:Leu130Val	missense_variant	1265	0.046	NA	NA	NA	NA	COSV52686543|COSV52692226|COSV99368721	rs863224683	458543	NA	NA	NA	NA	TP53|L130|2.06e-07	Esophageal_Carcinoma:_0.5%_(1/184)|Brain_Lower_Grade_Glioma:_0.2%_(1/509)|Lung_Squamous_Cell_Carcinoma:_0.2%_(1/492)|Ovarian_Serous_Cystadenocarcinoma:_0.2%_(1/436)|Stomach_Adenocarcinoma:_0.2%_(1/437)|Breast_Invasive_Carcinoma:_0.1%_(1/986)	NA	T:8+0+0+0=8/462|N:1+0+0+0=1/104|A:9+0+0+0=9/566	TP53:p.L130V:ENST00000413465&ENST00000359597&ENST00000269305&ENST00000455263&ENST00000420246&ENST00000445888&ENST00000508793:CTAT_POPULATION|CTAT_CANCER|3D_STRUCTURE	TP53	4_c_NS	[non-HC]_2.45/2.9_NA	TIER_3	Likely_Pathogenic	VUS	SOM	P53_DNA-binding_domain	NA	missense_variant:E:TP53:ENSP00000410739.2:p.(Leu130Val)|E:TP53:ENSP00000352610.4:p.(Leu130Val)|E:TP53:Canonical:ENSP00000269305.4:p.(Leu130Val)|R:TP53:NP_001263625.1:p.(Leu91Val)|R:TP53:NP_001119590.1:p.(Leu91Val)|R:TP53:NP_001119585.1:p.(Leu130Val)|R:TP53:Canonical:NP_000537.3:p.(Leu130Val)|R:TP53:NP_001263689.1:p.(Leu91Val)|R:TP53:NP_001263690.1:p.(Leu91Val)|R:TP53:NP_001263624.1:p.(Leu91Val)|R:TP53:NP_001119586.1:p.(Leu130Val)|R:TP53:NP_001119584.1:p.(Leu130Val)|E:TP53:ENSP00000398846.2:p.(Leu130Val)|E:TP53:ENSP00000391127.2:p.(Leu130Val)|E:TP53:ENSP00000391478.2:p.(Leu130Val)|R:TP53:XP_005256835.1:p.(Leu110Val)|E:TP53:ENSP00000423862.1:p.(Leu37Val)|E:TP53:ENSP00000424104.1:p.(Leu130Val);5_prime_UTR_variant:R:TP53:NM_001126115.1|R:TP53:NM_001276697.1|R:TP53:NM_001276699.1|R:TP53:NM_001126117.1|R:TP53:NM_001276698.1|R:TP53:NM_001126116.1|E:TP53:ENST00000509690.1;upstream_gene_variant:E:TP53:ENST00000576024.1;downstream_gene_variant:E:TP53:ENST00000503591.1	CPSR_classification|class	NA	IS:all_exons	.	.	include	.	.	.
CL-AcroMetrix	TP53	ENST00000269305	NM_000546	17:7578550	G>A	c.380C>T	exon5	S127F	Ser127Phe	c.380C>T:exon5:S127F:Ser127Phe	missense_variant	1273	0.047	NA	NA	NA	NA	COSV52666031|COSV52675881|COSV52731113|COSV52828604	rs730881999	182928	NA	NA	NA	NA	TP53|S127|3.33e-10	Pancreatic_Adenocarcinoma:_0.6%_(1/180)|Ovarian_Serous_Cystadenocarcinoma:_0.5%_(2/436)|Lung_Adenocarcinoma:_0.4%_(2/567)|Colon_Adenocarcinoma:_0.3%_(1/399)|Head_and_Neck_Squamous_Cell_Carcinoma:_0.2%_(1/508)|Brain_Lower_Grade_Glioma:_0.2%_(1/509)|Skin_Cutaneous_Melanoma:_0.2%_(1/468)|Uterine_Corpus_Endometrial_Carcinoma:_0.2%_(1/530)	NA	T:61+0+0+0=61/462|N:7+0+0+0=7/104|A:68+0+0+0=68/566	TP53:p.S127F:ENST00000413465&ENST00000359597&ENST00000269305&ENST00000455263&ENST00000420246&ENST00000445888&ENST00000508793&ENST00000503591:CTAT_CANCER|3D_STRUCTURE	TP53	4_c_NS	[non-HC]_2.45/2.9_NA	TIER_3	Likely_Pathogenic	VUS	SOM	P53_DNA-binding_domain	NA	missense_variant:E:TP53:ENSP00000410739.2:p.(Ser127Phe)|E:TP53:ENSP00000352610.4:p.(Ser127Phe)|E:TP53:Canonical:ENSP00000269305.4:p.(Ser127Phe)|R:TP53:NP_001263625.1:p.(Ser88Phe)|R:TP53:NP_001119590.1:p.(Ser88Phe)|R:TP53:NP_001119585.1:p.(Ser127Phe)|R:TP53:Canonical:NP_000537.3:p.(Ser127Phe)|R:TP53:NP_001263689.1:p.(Ser88Phe)|R:TP53:NP_001263690.1:p.(Ser88Phe)|R:TP53:NP_001263624.1:p.(Ser88Phe)|R:TP53:NP_001119586.1:p.(Ser127Phe)|R:TP53:NP_001119584.1:p.(Ser127Phe)|E:TP53:ENSP00000398846.2:p.(Ser127Phe)|E:TP53:ENSP00000391127.2:p.(Ser127Phe)|E:TP53:ENSP00000391478.2:p.(Ser127Phe)|R:TP53:XP_005256835.1:p.(Ser107Phe)|E:TP53:ENSP00000423862.1:p.(Ser34Phe)|E:TP53:ENSP00000424104.1:p.(Ser127Phe)|E:TP53:ENSP00000426252.1:p.(Ser127Phe);5_prime_UTR_variant:R:TP53:NM_001126115.1|R:TP53:NM_001276697.1|R:TP53:NM_001276699.1|R:TP53:NM_001126117.1|R:TP53:NM_001276698.1|R:TP53:NM_001126116.1|E:TP53:ENST00000509690.1;upstream_gene_variant:E:TP53:ENST00000576024.1	CPSR_classification|class	NA	IS:all_exons	.	.	include	variant_in_more_than_10%_of_tumor_samples_(13.2%)_with_VAF_under_0.01	.	.
CL-AcroMetrix	TP53	ENST00000269305	NM_000546	17:7579358	C>A	c.329G>T	exon4	R110L	Arg110Leu	c.329G>T:exon4:R110L:Arg110Leu	missense_variant	1032	0.057	NA	NA	NA	NA	COSV52662399|COSV52668419|COSV52680444|COSV53132492	rs11540654	406597	0	NA	0.0000000	NA	TP53|R110|1.13e-11	Head_and_Neck_Squamous_Cell_Carcinoma:_0.8%_(4/508)|Pancreatic_Adenocarcinoma:_0.6%_(1/180)|Esophageal_Carcinoma:_0.5%_(1/184)|Lung_Adenocarcinoma:_0.5%_(3/567)|Bladder_Urothelial_Carcinoma:_0.2%_(1/412)|Lung_Squamous_Cell_Carcinoma:_0.2%_(1/492)|Ovarian_Serous_Cystadenocarcinoma:_0.2%_(1/436)	NA	T:21+0+0+0=21/460|N:2+0+0+0=2/104|A:23+0+0+0=23/564	TP53:p.R110L:ENST00000413465&ENST00000359597&ENST00000269305&ENST00000455263&ENST00000420246&ENST00000445888&ENST00000508793&ENST00000604348&ENST00000503591:CTAT_CANCER|3D_STRUCTURE	TP53	4_c_NS	[non-HC]_2.45/2.9_NA	TIER_3	Likely_Pathogenic	Likely_Pathogenic	SOM	P53_DNA-binding_domain	NA	missense_variant:E:TP53:ENSP00000410739.2:p.(Arg110Leu)|E:TP53:ENSP00000352610.4:p.(Arg110Leu)|E:TP53:Canonical:ENSP00000269305.4:p.(Arg110Leu)|R:TP53:NP_001263625.1:p.(Arg71Leu)|R:TP53:NP_001119590.1:p.(Arg71Leu)|R:TP53:NP_001119585.1:p.(Arg110Leu)|R:TP53:Canonical:NP_000537.3:p.(Arg110Leu)|R:TP53:NP_001263689.1:p.(Arg71Leu)|R:TP53:NP_001263690.1:p.(Arg71Leu)|R:TP53:NP_001263624.1:p.(Arg71Leu)|R:TP53:NP_001119586.1:p.(Arg110Leu)|R:TP53:NP_001119584.1:p.(Arg110Leu)|E:TP53:ENSP00000398846.2:p.(Arg110Leu)|E:TP53:ENSP00000391127.2:p.(Arg110Leu)|E:TP53:ENSP00000391478.2:p.(Arg110Leu)|R:TP53:XP_005256835.1:p.(Arg90Leu)|E:TP53:ENSP00000424104.1:p.(Arg110Leu)|E:TP53:ENSP00000473895.1:p.(Arg110Leu)|E:TP53:ENSP00000426252.1:p.(Arg110Leu);upstream_gene_variant:R:TP53:NM_001126115.1|R:TP53:NM_001276697.1|R:TP53:NM_001276699.1|R:TP53:NM_001126117.1|R:TP53:NM_001276698.1|R:TP53:NM_001126116.1|E:TP53:ENST00000576024.1	CPSR_classification|ClinVar_classification|class	NA	IS:all_exons	.	.	include	.	.	.
CL-AcroMetrix	TP53	ENST00000269305	NM_000546	17:7579368	A>C	c.319T>G	exon4	Y107D	Tyr107Asp	c.319T>G:exon4:Y107D:Tyr107Asp	missense_variant	1051	0.053	NA	NA	NA	NA	COSV52679423|COSV53179040	rs368771578	641482	NA	NA	NA	NA	TP53|Y107|0.015	Stomach_Adenocarcinoma:_0.2%_(1/437)|Breast_Invasive_Carcinoma:_0.1%_(1/986)	NA	T:1+0+0+0=1/460|N:0+0+0+0=0/104|A:1+0+0+0=1/564	TP53:p.Y107D:ENST00000413465&ENST00000359597&ENST00000269305&ENST00000455263&ENST00000420246&ENST00000445888&ENST00000508793&ENST00000604348&ENST00000503591:CTAT_POPULATION|CTAT_CANCER|3D_STRUCTURE	TP53	4_c_NS	[non-HC]_2.45/2.9_NA	TIER_3	Likely_Pathogenic	VUS	SOM	P53_DNA-binding_domain	NA	missense_variant:E:TP53:ENSP00000410739.2:p.(Tyr107Asp)|E:TP53:ENSP00000352610.4:p.(Tyr107Asp)|E:TP53:Canonical:ENSP00000269305.4:p.(Tyr107Asp)|R:TP53:NP_001263625.1:p.(Tyr68Asp)|R:TP53:NP_001119590.1:p.(Tyr68Asp)|R:TP53:NP_001119585.1:p.(Tyr107Asp)|R:TP53:Canonical:NP_000537.3:p.(Tyr107Asp)|R:TP53:NP_001263689.1:p.(Tyr68Asp)|R:TP53:NP_001263690.1:p.(Tyr68Asp)|R:TP53:NP_001263624.1:p.(Tyr68Asp)|R:TP53:NP_001119586.1:p.(Tyr107Asp)|R:TP53:NP_001119584.1:p.(Tyr107Asp)|E:TP53:ENSP00000398846.2:p.(Tyr107Asp)|E:TP53:ENSP00000391127.2:p.(Tyr107Asp)|E:TP53:ENSP00000391478.2:p.(Tyr107Asp)|R:TP53:XP_005256835.1:p.(Tyr87Asp)|E:TP53:ENSP00000424104.1:p.(Tyr107Asp)|E:TP53:ENSP00000473895.1:p.(Tyr107Asp)|E:TP53:ENSP00000426252.1:p.(Tyr107Asp);upstream_gene_variant:R:TP53:NM_001126115.1|R:TP53:NM_001276697.1|R:TP53:NM_001276699.1|R:TP53:NM_001126117.1|R:TP53:NM_001276698.1|R:TP53:NM_001126116.1|E:TP53:ENST00000576024.1	CPSR_classification|class	NA	IS:all_exons	.	.	include	.	.	.
CL-AcroMetrix	VHL	ENST00000256474	NM_000551	3:10183797	T>A	c.266T>A	exon1	L89H	Leu89His	c.266T>A:exon1:L89H:Leu89His	missense_variant	1362	0.043	NA	NA	NA	NA	COSV56543066|COSV56543312|COSV56543561	rs5030807	376047	NA	NA	NA	NA	VHL|L89|2.85e-10	NA	RECA-EU/Primary/2/74/0.027	T:8+0+0+0=8/463|N:3+0+0+0=3/104|A:11+0+0+0=11/567	VHL:p.L89H:ENST00000256474&ENST00000345392:CTAT_POPULATION|CTAT_CANCER|3D_STRUCTURE	NA	1_a_NA	[non-HC]_2.198/2.396_NA	TIER_3	Pathogenic	Likely_Pathogenic	SOM	VHL_beta_domain	NA	missense_variant:E:VHL:Canonical:ENSP00000256474.2:p.(Leu89His)|R:VHL:NP_937799.1:p.(Leu89His)|R:VHL:Canonical:NP_000542.1:p.(Leu89His)|E:VHL:ENSP00000344757.2:p.(Leu89His)	CPSR_classification|ClinVar_classification|class	NA	all_exons	.	.	include	.	.	.
CL-AcroMetrix	VHL	ENST00000256474	NM_000551	3:10191479	C>G	c.472C>G	exon3	L158V	Leu158Val	c.472C>G:exon3:L158V:Leu158Val	missense_variant	544	0.037	NA	NA	NA	NA	COSV56544074|COSV56552085	rs1559429613	567944	NA	NA	NA	NA	VHL|L158|8.09e-05	Kidney_Renal_Clear_Cell_Carcinoma:_0.6%_(2/336)	NA	T:1+0+0+0=1/462|N:1+0+0+0=1/104|A:2+0+0+0=2/566	VHL:p.L158V:ENST00000256474:CTAT_POPULATION|CTAT_CANCER|3D_STRUCTURE	NA	1_a_NA	[non-HC]_2.198/2.396_NA	TIER_3	Pathogenic	Pathogenic	SOM	VHL_beta_domain	NA	missense_variant:E:VHL:Canonical:ENSP00000256474.2:p.(Leu158Val)|R:VHL:NP_937799.1:p.(Leu117Val)|R:VHL:Canonical:NP_000542.1:p.(Leu158Val)|E:VHL:ENSP00000344757.2:p.(Leu117Val)	CPSR_classification|ClinVar_classification|class	NA	all_exons	.	.	include	.	.	.
CL-AcroMetrix	VHL	ENST00000256474	NM_000551	3:10191513	T>C	c.506T>C	exon3	L169P	Leu169Pro	c.506T>C:exon3:L169P:Leu169Pro	missense_variant	841	0.033	NA	NA	NA	NA	COSV104374386|COSV56542402|COSV56545166	rs1131690962	428809	NA	NA	NA	NA	VHL|L169|0.0449	Kidney_Renal_Clear_Cell_Carcinoma:_0.6%_(2/336)	NA	T:7+0+0+0=7/463|N:7+0+0+0=7/104|A:14+0+0+0=14/567	VHL:p.L169P:ENST00000256474:CTAT_POPULATION|CTAT_CANCER	NA	1_a_NA	[non-HC]_2.198/2.396_NA	TIER_3	Likely_Pathogenic	Likely_Pathogenic	SOM	VHL_beta_domain	NA	missense_variant:E:VHL:Canonical:ENSP00000256474.2:p.(Leu169Pro)|R:VHL:NP_937799.1:p.(Leu128Pro)|R:VHL:Canonical:NP_000542.1:p.(Leu169Pro)|E:VHL:ENSP00000344757.2:p.(Leu128Pro)	CPSR_classification|ClinVar_classification|class	NA	all_exons	.	.	include	.	.	.
CL-AcroMetrix	BRAF	ENST00000288602	NA	7:140453193	T>C	c.1742A>G	exon15	N581S	Asn581Ser	c.1742A>G:exon15:N581S:Asn581Ser	missense_variant,splice_region_variant	437	0.146	NA	NA	NA	NA	COSV56058108|COSV56106422|COSV56110832	rs121913370	177776	NA	NA	NA	NA	BRAF|N581|3.87e-36	Kidney_Renal_Papillary_Cell_Carcinoma:_0.4%_(1/281)|Lung_Adenocarcinoma:_0.2%_(1/567)|Ovarian_Serous_Cystadenocarcinoma:_0.2%_(1/436)|Skin_Cutaneous_Melanoma:_0.2%_(1/468)	NA	T:7+0+1+0=8/463|N:2+0+0+0=2/104|A:9+0+1+0=10/567	BRAF:p.N581S:ENST00000288602:CTAT_CANCER|3D_STRUCTURE	RTKRAS	NA	[HC]_1.804/1.608_NA	TIER_3	VUS	Likely_Pathogenic	SOM	Protein_tyrosine_and_serine/threonine_kinase	Sorafenib_Tosylate|Vemurafenib|Sorafenib|Regorafenib|Regorafenib_Hydrate|Dabrafenib|Dabrafenib_Mesylate|Encorafenib	missense_variant,splice_region_variant:R:BRAF:XP_005250104.1:p.(Asn581Ser)|E:BRAF:ENSP00000419060.1:p.(Asn189Ser)|R:BRAF:XP_005250103.1:p.(Asn581Ser)|R:BRAF:XP_005250102.1:p.(Asn581Ser)|R:BRAF:Canonical:NP_004324.2:p.(Asn581Ser)|E:BRAF:Canonical:ENSP00000288602.6:p.(Asn581Ser)	ClinVar_classification|class	NA	all_exons,introns[7-10];IS:exons[11-18]	.	.	include	.	.	.
CL-AcroMetrix	ERBB2	ENST00000269571	NM_001382787|NM_001382784|NM_001382786|NM_001382789|NM_001382788|NM_001382785|NM_004448|NM_001382796|NM_001382798|NM_001382800|NM_001382797|NM_001382805|NM_001382792|NM_001382793|NM_001382794|NM_001382795|NM_001382801|NM_001382790|NM_001382806|NM_001382802|NM_001382799|NM_001382791	17:37880261	G>T	c.2305G>T	exon19	D769Y	Asp769Tyr	c.2305G>T:exon19:D769Y:Asp769Tyr	missense_variant,splice_region_variant	919	0.048	NA	NA	NA	NA	COSV54062373|COSV54062425|COSV54063143	rs121913468	375992	NA	NA	NA	NA	ERBB2|D769|4.15e-12	Bladder_Urothelial_Carcinoma:_0.2%_(1/412)|Breast_Invasive_Carcinoma:_0.2%_(2/986)|Stomach_Adenocarcinoma:_0.2%_(1/437)	BRCA-EU/Primary/1/76/0.0132	T:10+0+0+0=10/463|N:3+0+0+0=3/104|A:13+0+0+0=13/567	NA	RTKRAS	NA	[HC]_2.156/2.312_NA	TIER_3	VUS	Likely_Pathogenic	SOM	Protein_tyrosine_and_serine/threonine_kinase	Afatinib|Lapatinib_Ditosylate|Trastuzumab|Neratinib|Pertuzumab|Afatinib_Dimaleate|Dacomitinib|Margetuximab|Vandetanib|Pyrotinib|Tesevatinib|Tucatinib|Neratinib_Maleate|Trastuzumab_Deruxtecan|Lapatinib	missense_variant,splice_region_variant:E:ERBB2:ENSP00000462438.1:p.(Asp739Tyr)|R:ERBB2:XP_005257196.1:p.(Asp754Tyr)|R:ERBB2:NP_001276865.1:p.(Asp754Tyr)|R:ERBB2:NP_001005862.1:p.(Asp739Tyr)|E:ERBB2:ENSP00000385185.2:p.(Asp739Tyr)|R:ERBB2:NP_001005862.1:p.(Asp739Tyr)|E:ERBB2:Canonical:ENSP00000446466.1:p.(Asp754Tyr)|E:ERBB2:ENSP00000404047.2:p.(Asp493Tyr)|R:ERBB2:NP_001276866.1:p.(Asp769Tyr)|R:ERBB2:Canonical:NP_004439.2:p.(Asp769Tyr)|E:ERBB2:ENSP00000443562.1:p.(Asp739Tyr)|R:ERBB2:NP_004439.2:p.(Asp769Tyr)|E:ERBB2:ENSP00000463714.1:p.(Asp769Tyr)|E:ERBB2:ENSP00000269571.4:p.(Asp769Tyr)|R:ERBB2:XP_005257197.1:p.(Asp739Tyr)|E:ERBB2:ENSP00000463002.1:p.(Asp138Tyr);downstream_gene_variant:E:ERBB2:ENST00000582818.1|R:MIEN1:NM_032339.4|R:MIEN1:Canonical:NM_001330206.1	ClinVar_classification|class	NA	IS:all_exons	.	.	include	.	.	.
CL-AcroMetrix	PTEN	ENST00000371953	NM_000314	10:89653782	A>G	c.80A>G	exon2	Y27C	Tyr27Cys	c.80A>G:exon2:Y27C:Tyr27Cys	missense_variant,splice_region_variant	547	0.137	NA	NA	NA	NA	COSV64294406|COSV64304704	rs886041877	404160	NA	NA	NA	NA	PTEN|Y27|2.97e-06	Glioblastoma_Multiforme:_0.3%_(1/393)	NA	T:4+0+0+0=4/461|N:1+0+0+0=1/104|A:5+0+0+0=5/565	PTEN:p.Y27C:ENST00000371953:CTAT_CANCER|3D_STRUCTURE	PI3K	NA	[HC]_1.964/1.928_NA	TIER_3	Pathogenic	Likely_Pathogenic	SOM	NA	NA	missense_variant,splice_region_variant:E:PTEN:Canonical:ENSP00000361021.3:p.(Tyr27Cys)|R:PTEN:NP_000305.3:p.(Tyr27Cys)|R:PTEN:Canonical:NP_000305.3:p.(Tyr27Cys)|R:PTEN:NP_001291646.2:p.(Tyr200Cys);5_prime_UTR_variant,splice_region_variant:R:PTEN:NM_001304718.1	CPSR_classification|ClinVar_classification|class	NA	IS:all_exons	.	.	include	.	.	.
CL-AcroMetrix	VHL	ENST00000256474	NM_000551	3:10188200	C>A	c.343C>A	exon2	H115N	His115Asn	c.343C>A:exon2:H115N:His115Asn	missense_variant,splice_region_variant	975	0.043	NA	NA	NA	NA	COSV56545369|COSV56546151|COSV56556158|COSV56571206	NA	NA	NA	NA	NA	NA	VHL|H115|0.00743	Kidney_Renal_Clear_Cell_Carcinoma:_0.9%_(3/336)	NA	T:33+0+0+0=33/463|N:3+1+0+0=4/104|A:36+1+0+0=37/567	VHL:p.H115N:ENST00000256474:CTAT_POPULATION|CTAT_CANCER|3D_STRUCTURE	NA	1_a_NA	[non-HC]_2.198/2.396_NA	TIER_3	VUS	NA	SOM	VHL_beta_domain	NA	missense_variant,splice_region_variant:E:VHL:Canonical:ENSP00000256474.2:p.(His115Asn)|R:VHL:Canonical:NP_000542.1:p.(His115Asn)	class	NA	all_exons	.	.	include	.	.	.
CL-AcroMetrix	APC	ENST00000457016	NA	5:112175171	C>T	c.3880C>T	exon16	Q1294X	Gln1294Ter	c.3880C>T:exon16:Q1294X:Gln1294Ter	stop_gained	992	0.16	NA	NA	NA	NA	COSV104567789|COSV57323524	rs1554085373	469942	NA	NA	NA	NA	APC|Q1294|0.00829	Colon_Adenocarcinoma:_0.8%_(3/399)|Rectum_Adenocarcinoma:_0.7%_(1/137)	NA	T:34+0+0+0=34/463|N:4+0+0+0=4/104|A:38+0+0+0=38/567	NA	WNT	3_NA_NA	[non-HC]_2.012/2.024_NA	TIER_3	Pathogenic	Pathogenic	SOM	NA	NA	stop_gained:R:APC:NP_001120983.2:p.(Gln1276Ter)|R:APC:XP_005272032.1:p.(Gln1294Ter)|E:APC:Canonical:ENSP00000413133.1:p.(Gln1294Ter)|R:APC:XP_005272034.1:p.(Gln1193Ter)|R:APC:Canonical:NP_000029.2:p.(Gln1294Ter)|R:APC:NP_001120982.1:p.(Gln1294Ter)|E:APC:ENSP00000257430.4:p.(Gln1294Ter)|E:APC:ENSP00000427089.2:p.(Gln1294Ter)|E:APC:ENSP00000423828.2:p.(Gln1294Ter)|R:APC:XP_005272031.1:p.(Gln1294Ter)|R:APC:XP_005272033.1:p.(Gln1235Ter);downstream_gene_variant:E:APC:ENST00000507379.1|E:APC:ENST00000504915.2	CPSR_classification|ClinVar_classification|protein_changes:stop_gained|class	NA	IS:all_exons	.	.	include	.	.	.
CL-AcroMetrix	APC	ENST00000457016	NA	5:112175348	G>T	c.4057G>T	exon16	E1353X	Glu1353Ter	c.4057G>T:exon16:E1353X:Glu1353Ter	stop_gained	1284	0.191	NA	NA	NA	NA	COSV57321750|COSV57332693	rs1114167568	428122	NA	NA	NA	NA	APC|E1353|0.000103	Rectum_Adenocarcinoma:_2.9%_(4/137)|Colon_Adenocarcinoma:_0.3%_(1/399)	NA	T:26+1+0+0=27/463|N:5+0+0+0=5/104|A:31+1+0+0=32/567	NA	WNT	3_NA_NA	[non-HC]_2.012/2.024_NA	TIER_3	Pathogenic	Pathogenic	SOM	NA	NA	stop_gained:R:APC:NP_001120983.2:p.(Glu1335Ter)|R:APC:XP_005272032.1:p.(Glu1353Ter)|E:APC:Canonical:ENSP00000413133.1:p.(Glu1353Ter)|R:APC:XP_005272034.1:p.(Glu1252Ter)|R:APC:Canonical:NP_000029.2:p.(Glu1353Ter)|R:APC:NP_001120982.1:p.(Glu1353Ter)|E:APC:ENSP00000257430.4:p.(Glu1353Ter)|E:APC:ENSP00000427089.2:p.(Glu1353Ter)|R:APC:XP_005272031.1:p.(Glu1353Ter)|R:APC:XP_005272033.1:p.(Glu1294Ter);downstream_gene_variant:E:APC:ENST00000507379.1|E:APC:ENST00000512211.2|E:APC:ENST00000504915.2	CPSR_classification|ClinVar_classification|protein_changes:stop_gained|class	NA	IS:all_exons	.	.	include	.	.	.
CL-AcroMetrix	APC	ENST00000457016	NA	5:112175423	C>T	c.4132C>T	exon16	Q1378X	Gln1378Ter	c.4132C>T:exon16:Q1378X:Gln1378Ter	stop_gained	1255	0.178	NA	NA	NA	NA	COSV57322261	rs121913329	376061	NA	NA	NA	NA	APC|Q1378|6.88e-08	Rectum_Adenocarcinoma:_3.6%_(5/137)|Colon_Adenocarcinoma:_1.5%_(6/399)	NA	T:42+2+0+0=44/463|N:4+0+0+0=4/104|A:46+2+0+0=48/567	NA	WNT	3_NA_NA	[non-HC]_2.012/2.024_NA	TIER_3	Pathogenic	Pathogenic	SOM	APC_repeat	NA	stop_gained:R:APC:NP_001120983.2:p.(Gln1360Ter)|R:APC:XP_005272032.1:p.(Gln1378Ter)|E:APC:Canonical:ENSP00000413133.1:p.(Gln1378Ter)|R:APC:XP_005272034.1:p.(Gln1277Ter)|R:APC:Canonical:NP_000029.2:p.(Gln1378Ter)|R:APC:NP_001120982.1:p.(Gln1378Ter)|E:APC:ENSP00000257430.4:p.(Gln1378Ter)|E:APC:ENSP00000427089.2:p.(Gln1378Ter)|R:APC:XP_005272031.1:p.(Gln1378Ter)|R:APC:XP_005272033.1:p.(Gln1319Ter);downstream_gene_variant:E:APC:ENST00000507379.1|E:APC:ENST00000512211.2|E:APC:ENST00000504915.2	CPSR_classification|ClinVar_classification|protein_changes:stop_gained|class	NA	IS:all_exons	.	.	include	.	.	.
CL-AcroMetrix	APC	ENST00000457016	NA	5:112175507	C>T	c.4216C>T	exon16	Q1406X	Gln1406Ter	c.4216C>T:exon16:Q1406X:Gln1406Ter	stop_gained	1251	0.183	NA	NA	NA	NA	COSV57321535	rs587782518	142519	NA	NA	NA	NA	APC|Q1406|1.71e-05	Rectum_Adenocarcinoma:_2.2%_(3/137)|Colon_Adenocarcinoma:_0.5%_(2/399)	NA	T:38+0+1+0=39/463|N:4+0+0+0=4/104|A:42+0+1+0=43/567	NA	WNT	3_NA_NA	[non-HC]_2.012/2.024_NA	TIER_3	Pathogenic	Pathogenic	SOM	NA	NA	stop_gained:R:APC:NP_001120983.2:p.(Gln1388Ter)|R:APC:XP_005272032.1:p.(Gln1406Ter)|E:APC:Canonical:ENSP00000413133.1:p.(Gln1406Ter)|R:APC:XP_005272034.1:p.(Gln1305Ter)|R:APC:Canonical:NP_000029.2:p.(Gln1406Ter)|R:APC:NP_001120982.1:p.(Gln1406Ter)|E:APC:ENSP00000257430.4:p.(Gln1406Ter)|E:APC:ENSP00000427089.2:p.(Gln1406Ter)|R:APC:XP_005272031.1:p.(Gln1406Ter)|R:APC:XP_005272033.1:p.(Gln1347Ter);downstream_gene_variant:E:APC:ENST00000507379.1|E:APC:ENST00000512211.2|E:APC:ENST00000504915.2	CPSR_classification|ClinVar_classification|protein_changes:stop_gained|class	NA	IS:all_exons	.	.	include	.	.	.
CL-AcroMetrix	APC	ENST00000457016	NA	5:112175576	C>T	c.4285C>T	exon16	Q1429X	Gln1429Ter	c.4285C>T:exon16:Q1429X:Gln1429Ter	stop_gained	1282	0.19	NA	NA	NA	NA	COSV57322632|COSV57333893	rs74535574	376063	NA	NA	NA	NA	APC|Q1429|1.21e-11	Rectum_Adenocarcinoma:_2.2%_(3/137)|Colon_Adenocarcinoma:_0.8%_(3/399)	NA	T:57+0+0+0=57/463|N:3+0+0+0=3/104|A:60+0+0+0=60/567	NA	WNT	3_NA_NA	[non-HC]_2.012/2.024_NA	TIER_3	Pathogenic	Likely_Pathogenic	SOM	NA	NA	stop_gained:R:APC:NP_001120983.2:p.(Gln1411Ter)|R:APC:XP_005272032.1:p.(Gln1429Ter)|E:APC:Canonical:ENSP00000413133.1:p.(Gln1429Ter)|R:APC:XP_005272034.1:p.(Gln1328Ter)|R:APC:Canonical:NP_000029.2:p.(Gln1429Ter)|R:APC:NP_001120982.1:p.(Gln1429Ter)|E:APC:ENSP00000257430.4:p.(Gln1429Ter)|E:APC:ENSP00000427089.2:p.(Gln1429Ter)|R:APC:XP_005272031.1:p.(Gln1429Ter)|R:APC:XP_005272033.1:p.(Gln1370Ter);downstream_gene_variant:E:APC:ENST00000507379.1|E:APC:ENST00000512211.2|E:APC:ENST00000504915.2	CPSR_classification|ClinVar_classification|protein_changes:stop_gained|class	NA	IS:all_exons	.	.	include	variant_in_more_than_10%_of_tumor_samples_(12.31%)_with_VAF_under_0.01	.	.
CL-AcroMetrix	CDKN2A	ENST00000498124	NM_001195132	9:21971000	C>A	c.358G>T	exon2	E120X	Glu120Ter	c.358G>T:exon2:E120X:Glu120Ter	stop_gained	1397	0.185	NA	NA	NA	NA	COSV58683444|COSV58717600	NA	NA	NA	NA	NA	NA	CDKN2A|E120|3.49e-07	Head_and_Neck_Squamous_Cell_Carcinoma:_1%_(5/508)|Pancreatic_Adenocarcinoma:_0.6%_(1/180)|Lung_Squamous_Cell_Carcinoma:_0.4%_(2/492)|Stomach_Adenocarcinoma:_0.2%_(1/437)	PACA-AU/Primary/1/90/0.0111	T:17+0+0+0=17/459|N:3+0+0+0=3/104|A:20+0+0+0=20/563	NA	CC	NA	[non-HC]_2.044/2.088_NA	TIER_3	Pathogenic	NA	SOM	Ankyrin_repeats_(3_copies)	NA	downstream_gene_variant:E:CDKN2A-AS1:Canonical:ENST00000441769.2;stop_gained:R:CDKN2A:XP_005251400.1:p.(Glu69Ter)|R:CDKN2A:NP_001182061.1:p.(Glu120Ter)|R:CDKN2A:Canonical:NP_000068.1:p.(Glu120Ter)|E:CDKN2A:ENSP00000307101.5:p.(Glu120Ter)|E:CDKN2A:ENSP00000464202.1:p.(Glu120Ter)|E:CDKN2A:ENSP00000467390.1:p.(Glu69Ter)|E:CDKN2A:ENSP00000418915.1:p.(Glu120Ter)|E:CDKN2A:ENSP00000467857.1:p.(Glu69Ter)|E:CDKN2A:ENSP00000464952.1:p.(Glu69Ter)|R:CDKN2A:XP_005251398.1:p.(Glu120Ter)|E:CDKN2A:ENSP00000394932.1:p.(Glu120Ter)|E:CDKN2A:ENSP00000466887.1:p.(Glu69Ter)|E:CDKN2A:ENSP00000468510.1:p.(Glu69Ter);3_prime_UTR_variant:R:CDKN2A:NM_058197.4|E:CDKN2A:Canonical:ENST00000361570.3|R:CDKN2A:NM_058195.3|E:CDKN2A:ENST00000579755.1|E:CDKN2A:ENST00000530628.2	CPSR_classification|protein_changes:stop_gained|class	NA	IS:all_exons	.	.	include	.	.	.
CL-AcroMetrix	CDKN2A	ENST00000498124	NM_001195132	9:21971028	C>T	c.330G>A	exon2	W110X	Trp110Ter	c.330G>A:exon2:W110X:Trp110Ter	stop_gained	1275	0.176	NA	NA	NA	NA	COSV58682827|COSV58708986	rs121913389	376303	NA	NA	NA	NA	CDKN2A|W110|5.2e-39	Head_and_Neck_Squamous_Cell_Carcinoma:_1.2%_(6/508)|Skin_Cutaneous_Melanoma:_0.6%_(3/468)|Glioblastoma_Multiforme:_0.3%_(1/393)	MELA-AU/Metastatic/1/60/0.0167|PACA-AU/Primary/2/90/0.0222	T:20+1+0+0=21/455|N:1+0+0+0=1/103|A:21+1+0+0=22/558	NA	CC	NA	[non-HC]_2.044/2.088_NA	TIER_3	Pathogenic	Likely_Pathogenic	SOM	Ankyrin_repeats_(3_copies)	NA	downstream_gene_variant:E:CDKN2A-AS1:Canonical:ENST00000441769.2;stop_gained:R:CDKN2A:XP_005251400.1:p.(Trp59Ter)|R:CDKN2A:NP_001182061.1:p.(Trp110Ter)|R:CDKN2A:Canonical:NP_000068.1:p.(Trp110Ter)|E:CDKN2A:ENSP00000307101.5:p.(Trp110Ter)|E:CDKN2A:ENSP00000464202.1:p.(Trp110Ter)|E:CDKN2A:ENSP00000467390.1:p.(Trp59Ter)|E:CDKN2A:ENSP00000418915.1:p.(Trp110Ter)|E:CDKN2A:ENSP00000467857.1:p.(Trp59Ter)|E:CDKN2A:ENSP00000464952.1:p.(Trp59Ter)|R:CDKN2A:XP_005251398.1:p.(Trp110Ter)|E:CDKN2A:ENSP00000394932.1:p.(Trp110Ter)|E:CDKN2A:ENSP00000466887.1:p.(Trp59Ter)|E:CDKN2A:ENSP00000468510.1:p.(Trp59Ter);3_prime_UTR_variant:R:CDKN2A:NM_058197.4;missense_variant:E:CDKN2A:Canonical:ENSP00000355153.3:p.(Gly166Arg)|R:CDKN2A:NP_478102.2:p.(Gly125Arg)|E:CDKN2A:ENSP00000462950.1:p.(Gly125Arg)|E:CDKN2A:ENSP00000432664.2:p.(Gly125Arg)	CPSR_classification|ClinVar_classification|protein_changes:stop_gained|class	NA	IS:all_exons	.	.	include	.	.	.
CL-AcroMetrix	CDKN2A	ENST00000498124	NM_001195132	9:21971120	G>A	c.238C>T	exon2	R80X	Arg80Ter	c.238C>T:exon2:R80X:Arg80Ter	stop_gained	1198	0.204	NA	NA	NA	NA	COSV58682746|COSV58721651	rs121913388	9409	0	NA	0.0000000	NA	CDKN2A|R80|1.18e-111	Head_and_Neck_Squamous_Cell_Carcinoma:_4.3%_(22/508)|Pancreatic_Adenocarcinoma:_3.3%_(6/180)|Skin_Cutaneous_Melanoma:_1.1%_(5/468)|Bladder_Urothelial_Carcinoma:_0.7%_(3/412)|Kidney_Renal_Papillary_Cell_Carcinoma:_0.4%_(1/281)|Lung_Squamous_Cell_Carcinoma:_0.4%_(2/492)|Prostate_Adenocarcinoma:_0.2%_(1/496)|Stomach_Adenocarcinoma:_0.2%_(1/437)|Thyroid_Carcinoma:_0.2%_(1/492)	LIRI-JP/Primary/1/250/0.004|MELA-AU/Metastatic/2/60/0.0333|ORCA-IN/Primary/2/13/0.1538|PACA-AU/Primary/3/90/0.0333|PACA-CA/Primary/1/140/0.0071	T:46+3+2+2=53/456|N:2+0+0+0=2/103|A:48+3+2+2=55/559	NA	CC	NA	[non-HC]_2.044/2.088_NA	TIER_3	Pathogenic	Pathogenic	SOM	Ankyrin_repeats_(3_copies)	NA	downstream_gene_variant:E:CDKN2A-AS1:Canonical:ENST00000441769.2;stop_gained:R:CDKN2A:XP_005251400.1:p.(Arg29Ter)|R:CDKN2A:NP_001182061.1:p.(Arg80Ter)|R:CDKN2A:Canonical:NP_000068.1:p.(Arg80Ter)|E:CDKN2A:ENSP00000307101.5:p.(Arg80Ter)|E:CDKN2A:ENSP00000464202.1:p.(Arg80Ter)|E:CDKN2A:ENSP00000467390.1:p.(Arg29Ter)|E:CDKN2A:ENSP00000418915.1:p.(Arg80Ter)|E:CDKN2A:ENSP00000467857.1:p.(Arg29Ter)|E:CDKN2A:ENSP00000464952.1:p.(Arg29Ter)|R:CDKN2A:XP_005251398.1:p.(Arg80Ter)|E:CDKN2A:ENSP00000394932.1:p.(Arg80Ter)|E:CDKN2A:ENSP00000466887.1:p.(Arg29Ter)|E:CDKN2A:ENSP00000468510.1:p.(Arg29Ter);3_prime_UTR_variant:R:CDKN2A:NM_058197.4;missense_variant:E:CDKN2A:Canonical:ENSP00000355153.3:p.(Pro135Leu)|R:CDKN2A:NP_478102.2:p.(Pro94Leu)|E:CDKN2A:ENSP00000462950.1:p.(Pro94Leu)|E:CDKN2A:ENSP00000432664.2:p.(Pro94Leu)	CPSR_classification|ClinVar_classification|protein_changes:stop_gained|class	NA	IS:all_exons	.	.	include	variant_in_more_than_10%_of_tumor_samples_(10.09%)_with_VAF_under_0.01	.	.
CL-AcroMetrix	CDKN2A	ENST00000498124	NM_001195132	9:21971186	G>A	c.172C>T	exon2	R58X	Arg58Ter	c.172C>T:exon2:R58X:Arg58Ter	stop_gained	1237	0.226	NA	NA	NA	NA	COSV58682666|COSV58721549|COSV99053472	rs121913387	376310	0	NA	0.0000000	NA	CDKN2A|R58|2.56e-57	Head_and_Neck_Squamous_Cell_Carcinoma:_1.8%_(9/508)|Skin_Cutaneous_Melanoma:_1.1%_(5/468)|Pancreatic_Adenocarcinoma:_0.6%_(1/180)|Lung_Squamous_Cell_Carcinoma:_0.4%_(2/492)|Lung_Adenocarcinoma:_0.2%_(1/567)	ESAD-UK/Primary/3/97/0.0309|PAEN-AU/Primary/1/47/0.0213	T:67+1+0+0=68/460|N:5+0+0+0=5/104|A:72+1+0+0=73/564	NA	CC	NA	[non-HC]_2.044/2.088_NA	TIER_3	Pathogenic	Pathogenic	SOM	Ankyrin_repeats_(3_copies)	NA	downstream_gene_variant:E:CDKN2A-AS1:Canonical:ENST00000441769.2;stop_gained:R:CDKN2A:XP_005251400.1:p.(Arg7Ter)|R:CDKN2A:NP_001182061.1:p.(Arg58Ter)|R:CDKN2A:Canonical:NP_000068.1:p.(Arg58Ter)|E:CDKN2A:ENSP00000307101.5:p.(Arg58Ter)|E:CDKN2A:ENSP00000464202.1:p.(Arg58Ter)|E:CDKN2A:ENSP00000467390.1:p.(Arg7Ter)|E:CDKN2A:ENSP00000418915.1:p.(Arg58Ter)|E:CDKN2A:ENSP00000467857.1:p.(Arg7Ter)|E:CDKN2A:ENSP00000464952.1:p.(Arg7Ter)|R:CDKN2A:XP_005251398.1:p.(Arg58Ter)|E:CDKN2A:ENSP00000394932.1:p.(Arg58Ter)|E:CDKN2A:ENSP00000466887.1:p.(Arg7Ter)|E:CDKN2A:ENSP00000468510.1:p.(Arg7Ter);3_prime_UTR_variant:R:CDKN2A:NM_058197.4;missense_variant:E:CDKN2A:Canonical:ENSP00000355153.3:p.(Pro113Leu)|R:CDKN2A:NP_478102.2:p.(Pro72Leu)|E:CDKN2A:ENSP00000462950.1:p.(Pro72Leu)|E:CDKN2A:ENSP00000432664.2:p.(Pro72Leu)	CPSR_classification|ClinVar_classification|protein_changes:stop_gained|class	NA	IS:all_exons	.	.	include	variant_in_more_than_10%_of_tumor_samples_(14.57%)_with_VAF_under_0.01	.	.
CL-AcroMetrix	FBXW7	ENST00000281708	NM_001349798	4:153250883	G>A	c.1177C>T	exon8	R393X	Arg393Ter	c.1177C>T:exon8:R393X:Arg393Ter	stop_gained	747	0.067	NA	NA	NA	NA	COSV55892695	NA	NA	NA	NA	NA	NA	FBXW7|R393|0.1	Esophageal_Carcinoma:_0.5%_(1/184)|Head_and_Neck_Squamous_Cell_Carcinoma:_0.2%_(1/508)|Uterine_Corpus_Endometrial_Carcinoma:_0.2%_(1/530)	NA	T:134+1+0+0=135/463|N:6+0+0+0=6/104|A:140+1+0+0=141/567	NA	NOTCH	NA	[non-HC]_1.88/1.76_NA	TIER_3	VUS	NA	SOM	WD_domain|G-beta_repeat	NA	stop_gained:R:FBXW7:XP_005263165.1:p.(Arg217Ter)|R:FBXW7:Canonical:NP_060785.2:p.(Arg313Ter)|R:FBXW7:NP_001013433.1:p.(Arg275Ter)|R:FBXW7:XP_005263164.1:p.(Arg393Ter)|R:FBXW7:NP_361014.1:p.(Arg393Ter)|E:FBXW7:Canonical:ENSP00000281708.3:p.(Arg393Ter)|E:FBXW7:ENSP00000296555.4:p.(Arg275Ter)|E:FBXW7:ENSP00000263981.4:p.(Arg313Ter)|E:FBXW7:ENSP00000474725.1:p.(Arg393Ter)|E:FBXW7:ENSP00000377528.3:p.(Arg217Ter)|E:FBXW7:ENSP00000474971.1:p.(Arg393Ter)	protein_changes:stop_gained|class	NA	all_exons	.	.	include	variant_in_more_than_10%_of_tumor_samples_(28.94%)_with_VAF_under_0.01	.	.
CL-AcroMetrix	FBXW7	ENST00000281708	NM_001349798	4:153258983	G>A	c.832C>T	exon5	R278X	Arg278Ter	c.832C>T:exon5:R278X:Arg278Ter	stop_gained	801	0.064	NA	NA	NA	NA	COSV55891638	NA	NA	NA	NA	NA	NA	FBXW7|R278|0.000883	Cervical_Squamous_Cell_Carcinoma_and_Endocervical_Adenocarcinoma:_0.3%_(1/289)|Bladder_Urothelial_Carcinoma:_0.2%_(1/412)|Stomach_Adenocarcinoma:_0.2%_(1/437)|Uterine_Corpus_Endometrial_Carcinoma:_0.2%_(1/530)	PBCA-DE/Primary/1/230/0.0043	T:150+1+0+0=151/463|N:7+0+0+0=7/104|A:157+1+0+0=158/567	NA	NOTCH	NA	[non-HC]_1.88/1.76_NA	TIER_3	VUS	NA	SOM	NA	NA	stop_gained:R:FBXW7:XP_005263165.1:p.(Arg102Ter)|R:FBXW7:Canonical:NP_060785.2:p.(Arg198Ter)|R:FBXW7:NP_001013433.1:p.(Arg160Ter)|R:FBXW7:XP_005263164.1:p.(Arg278Ter)|R:FBXW7:NP_361014.1:p.(Arg278Ter)|E:FBXW7:Canonical:ENSP00000281708.3:p.(Arg278Ter)|E:FBXW7:ENSP00000296555.4:p.(Arg160Ter)|E:FBXW7:ENSP00000263981.4:p.(Arg198Ter)|E:FBXW7:ENSP00000474725.1:p.(Arg278Ter)|E:FBXW7:ENSP00000377528.3:p.(Arg102Ter)|E:FBXW7:ENSP00000474971.1:p.(Arg278Ter)	protein_changes:stop_gained|class	NA	all_exons	.	.	include	variant_in_more_than_10%_of_tumor_samples_(32.4%)_with_VAF_under_0.01	.	.
CL-AcroMetrix	PTEN	ENST00000371953	NM_000314	10:89717672	C>T	c.697C>T	exon7	R233X	Arg233Ter	c.697C>T:exon7:R233X:Arg233Ter	stop_gained	1143	0.122	NA	NA	NA	NA	COSV104677036|COSV104677073|COSV64288653|COSV64291717|COSV64302607|COSV64306399|COSV64306519|COSV64311585|COSV99058021	rs121909219	7813	NA	NA	NA	NA	PTEN|R233|1.42e-34	Uterine_Corpus_Endometrial_Carcinoma:_5.1%_(27/530)|Uterine_Carcinosarcoma:_1.8%_(1/57)|Glioblastoma_Multiforme:_1.3%_(5/393)|Stomach_Adenocarcinoma:_0.7%_(3/437)|Cervical_Squamous_Cell_Carcinoma_and_Endocervical_Adenocarcinoma:_0.3%_(1/289)|Colon_Adenocarcinoma:_0.3%_(1/399)	MALY-DE/Primary/1/100/0.01	T:121+2+0+1=124/463|N:9+0+0+0=9/104|A:130+2+0+1=133/567	NA	PI3K	NA	[HC]_1.964/1.928_NA	TIER_3	Pathogenic	Pathogenic	SOM	C2_domain_of_PTEN_tumour-suppressor_protein	NA	stop_gained:E:PTEN:Canonical:ENSP00000361021.3:p.(Arg233Ter)|R:PTEN:NP_000305.3:p.(Arg233Ter)|R:PTEN:Canonical:NP_000305.3:p.(Arg233Ter)|R:PTEN:NP_001291647.1:p.(Arg36Ter)|R:PTEN:NP_001291646.2:p.(Arg406Ter)	CPSR_classification|ClinVar_classification|protein_changes:stop_gained|class	NA	IS:all_exons	.	.	include	variant_in_more_than_10%_of_tumor_samples_(26.13%)_with_VAF_under_0.01	.	.
CL-AcroMetrix	RB1	ENST00000267163	NM_000321	13:48941648	C>T	c.958C>T	exon10	R320X	Arg320Ter	c.958C>T:exon10:R320X:Arg320Ter	stop_gained	405	0.03	NA	NA	NA	NA	COSV57297576|COSV57321266	rs121913300	126824	NA	NA	NA	NA	RB1|R320|5.88e-08	Bladder_Urothelial_Carcinoma:_0.2%_(1/412)|Lung_Adenocarcinoma:_0.2%_(1/567)|Lung_Squamous_Cell_Carcinoma:_0.2%_(1/492)|Ovarian_Serous_Cystadenocarcinoma:_0.2%_(1/436)|Stomach_Adenocarcinoma:_0.2%_(1/437)|Uterine_Corpus_Endometrial_Carcinoma:_0.2%_(1/530)	NA	T:92+4+0+0=96/459|N:0+0+0+0=0/103|A:92+4+0+0=96/562	NA	CC	3_NA_NA	[non-HC]_2.194/2.388_NA	TIER_3	Pathogenic	Pathogenic	SOM	NA	NA	stop_gained:R:RB1:Canonical:NP_000312.2:p.(Arg320Ter)|E:RB1:Canonical:ENSP00000267163.4:p.(Arg320Ter)	CPSR_classification|ClinVar_classification|protein_changes:stop_gained|class	NA	IS:all_exons	.	.	include	variant_in_more_than_10%_of_tumor_samples_(20.04%)_with_VAF_under_0.01	.	.
CL-AcroMetrix	RB1	ENST00000267163	NM_000321	13:48953760	C>T	c.1363C>T	exon14	R455X	Arg455Ter	c.1363C>T:exon14:R455X:Arg455Ter	stop_gained	486	0.039	NA	NA	NA	NA	COSV57297545	rs121913302	126837	NA	NA	NA	NA	RB1|R455|0.00379	Bladder_Urothelial_Carcinoma:_0.2%_(1/412)|Skin_Cutaneous_Melanoma:_0.2%_(1/468)|Breast_Invasive_Carcinoma:_0.1%_(1/986)	LIRI-JP/Primary/1/250/0.004	T:116+6+0+0=122/462|N:6+0+0+0=6/104|A:122+6+0+0=128/566	NA	CC	3_NA_NA	[non-HC]_2.194/2.388_NA	TIER_3	Pathogenic	Pathogenic	SOM	Retinoblastoma-associated_protein_A_domain	NA	stop_gained:R:RB1:Canonical:NP_000312.2:p.(Arg455Ter)|E:RB1:Canonical:ENSP00000267163.4:p.(Arg455Ter)	CPSR_classification|ClinVar_classification|protein_changes:stop_gained|class	NA	IS:all_exons	.	.	include	variant_in_more_than_10%_of_tumor_samples_(25.11%)_with_VAF_under_0.01	.	.
CL-AcroMetrix	RB1	ENST00000267163	NM_000321	13:48955538	C>T	c.1654C>T	exon17	R552X	Arg552Ter	c.1654C>T:exon17:R552X:Arg552Ter	stop_gained	625	0.048	NA	NA	NA	NA	COSV57297124	rs121913303	126840	NA	NA	NA	NA	RB1|R552|4.65e-06	Esophageal_Carcinoma:_0.5%_(1/184)|Sarcoma:_0.4%_(1/237)|Glioblastoma_Multiforme:_0.3%_(1/393)|Bladder_Urothelial_Carcinoma:_0.2%_(1/412)|Lung_Adenocarcinoma:_0.2%_(1/567)|Stomach_Adenocarcinoma:_0.2%_(1/437)|Breast_Invasive_Carcinoma:_0.1%_(1/986)	NA	T:114+4+0+0=118/462|N:7+0+0+0=7/104|A:121+4+0+0=125/566	NA	CC	3_NA_NA	[non-HC]_2.194/2.388_NA	TIER_3	Pathogenic	Pathogenic	SOM	Retinoblastoma-associated_protein_A_domain	NA	stop_gained:R:RB1:Canonical:NP_000312.2:p.(Arg552Ter)|E:RB1:Canonical:ENSP00000267163.4:p.(Arg552Ter)	CPSR_classification|ClinVar_classification|protein_changes:stop_gained|class	NA	IS:all_exons	.	.	include	variant_in_more_than_10%_of_tumor_samples_(24.68%)_with_VAF_under_0.01	.	.
CL-AcroMetrix	RB1	ENST00000267163	NM_000321	13:49027168	C>T	c.1735C>T	exon18	R579X	Arg579Ter	c.1735C>T:exon18:R579X:Arg579Ter	stop_gained	766	0.063	NA	NA	NA	NA	COSV57294317|COSV99923811	rs121913305	126785	NA	NA	NA	NA	RB1|R579|0.00017	Skin_Cutaneous_Melanoma:_0.4%_(2/468)|Head_and_Neck_Squamous_Cell_Carcinoma:_0.2%_(1/508)	NA	T:138+2+0+0=140/463|N:2+0+0+0=2/104|A:140+2+0+0=142/567	NA	CC	3_NA_NA	[non-HC]_2.194/2.388_NA	TIER_3	Pathogenic	Pathogenic	SOM	NA	NA	stop_gained:R:RB1:Canonical:NP_000312.2:p.(Arg579Ter)|E:RB1:Canonical:ENSP00000267163.4:p.(Arg579Ter)	CPSR_classification|ClinVar_classification|protein_changes:stop_gained|class	NA	IS:all_exons	.	.	include	variant_in_more_than_10%_of_tumor_samples_(29.81%)_with_VAF_under_0.01	.	.
CL-AcroMetrix	SMAD4	ENST00000342988	NM_005359	18:48581229	C>A	c.533C>A	exon5	S178X	Ser178Ter	c.533C>A:exon5:S178X:Ser178Ter	stop_gained	959	0.053	NA	NA	NA	NA	COSV61686156|COSV61688610|COSV61689431	NA	836290	NA	NA	NA	NA	SMAD4|S178|0.0947	Pancreatic_Adenocarcinoma:_0.6%_(1/180)|Colon_Adenocarcinoma:_0.3%_(1/399)	NA	T:36+1+0+0=37/463|N:6+0+0+0=6/104|A:42+1+0+0=43/567	NA	TFGBETA	NA	[non-HC]_2.106/2.212_NA	TIER_3	Pathogenic	Pathogenic	SOM	NA	NA	3_prime_UTR_variant:E:SMAD4:ENST00000452201.2;stop_gained:E:SMAD4:Canonical:ENSP00000381452.1:p.(Ser178Ter)|E:SMAD4:ENSP00000341551.3:p.(Ser178Ter)|R:SMAD4:Canonical:NP_005350.1:p.(Ser178Ter)|E:SMAD4:ENSP00000464901.1:p.(Ser178Ter)	CPSR_classification|ClinVar_classification|protein_changes:stop_gained|class	NA	all_exons	.	.	include	.	.	.
CL-AcroMetrix	SMAD4	ENST00000342988	NM_005359	18:48603032	C>T	c.1333C>T	exon11	R445X	Arg445Ter	c.1333C>T:exon11:R445X:Arg445Ter	stop_gained	896	0.065	NA	NA	NA	NA	COSV61685033	rs377767360	24850	4e-06	NA	0.0000088	NA	SMAD4|R445|1.11e-07	Esophageal_Carcinoma:_1.1%_(2/184)|Cervical_Squamous_Cell_Carcinoma_and_Endocervical_Adenocarcinoma:_0.3%_(1/289)	PACA-AU/Primary/1/90/0.0111|PACA-CA/Primary/3/140/0.0214	T:94+4+1+0=99/463|N:8+0+0+0=8/104|A:102+4+1+0=107/567	NA	TFGBETA	NA	[non-HC]_2.106/2.212_NA	TIER_3	Pathogenic	Pathogenic	SOM	MH2_domain	NA	stop_gained:E:SMAD4:Canonical:ENSP00000381452.1:p.(Arg445Ter)|E:SMAD4:ENSP00000341551.3:p.(Arg445Ter)|R:SMAD4:Canonical:NP_005350.1:p.(Arg445Ter)|E:SMAD4:ENSP00000464901.1:p.(Arg349Ter)|E:SMAD4:ENSP00000466118.1:p.(Arg34Ter)	CPSR_classification|ClinVar_classification|protein_changes:stop_gained|class	NA	all_exons	.	.	include	variant_in_more_than_10%_of_tumor_samples_(20.3%)_with_VAF_under_0.01	.	.
CL-AcroMetrix	SMAD4	ENST00000342988	NM_005359	18:48604754	G>T	c.1576G>T	exon12	E526X	Glu526Ter	c.1576G>T:exon12:E526X:Glu526Ter	stop_gained	1055	0.065	NA	NA	NA	NA	COSV61685158|COSV61687482|COSV61687686	NA	NA	NA	NA	NA	NA	SMAD4|E526|0.000221	Lung_Squamous_Cell_Carcinoma:_0.2%_(1/492)|Breast_Invasive_Carcinoma:_0.1%_(1/986)	NA	T:22+1+0+0=23/463|N:2+1+0+0=3/104|A:24+2+0+0=26/567	NA	TFGBETA	NA	[non-HC]_2.106/2.212_NA	TIER_3	Pathogenic	NA	SOM	MH2_domain	NA	stop_gained:E:SMAD4:Canonical:ENSP00000381452.1:p.(Glu526Ter)|E:SMAD4:ENSP00000341551.3:p.(Glu526Ter)|R:SMAD4:Canonical:NP_005350.1:p.(Glu526Ter)|E:SMAD4:ENSP00000464901.1:p.(Glu430Ter);downstream_gene_variant:E:SMAD4:ENST00000593223.1	CPSR_classification|protein_changes:stop_gained|class	NA	all_exons	.	.	include	.	.	.
CL-AcroMetrix	TP53	ENST00000269305	NM_000546	17:7574003	G>A	c.1024C>T	exon10	R342X	Arg342Ter	c.1024C>T:exon10:R342X:Arg342Ter	stop_gained	1028	0.033	NA	NA	NA	NA	COSV52665487	rs730882029	182970	NA	NA	NA	NA	TP53|R342|1.47e-85	Esophageal_Carcinoma:_1.6%_(3/184)|Breast_Invasive_Carcinoma:_0.7%_(7/986)|Ovarian_Serous_Cystadenocarcinoma:_0.7%_(3/436)|Rectum_Adenocarcinoma:_0.7%_(1/137)|Skin_Cutaneous_Melanoma:_0.6%_(3/468)|Colon_Adenocarcinoma:_0.5%_(2/399)|Glioblastoma_Multiforme:_0.5%_(2/393)|Stomach_Adenocarcinoma:_0.5%_(2/437)|Head_and_Neck_Squamous_Cell_Carcinoma:_0.4%_(2/508)|Sarcoma:_0.4%_(1/237)|Uterine_Corpus_Endometrial_Carcinoma:_0.4%_(2/530)|Brain_Lower_Grade_Glioma:_0.2%_(1/509)|Lung_Adenocarcinoma:_0.2%_(1/567)|Lung_Squamous_Cell_Carcinoma:_0.2%_(1/492)|Prostate_Adenocarcinoma:_0.2%_(1/496)	ESAD-UK/Primary/3/97/0.0309|OV-AU/Primary/1/60/0.0167|PACA-CA/Primary/3/140/0.0214	T:106+3+0+0=109/462|N:2+0+0+0=2/104|A:108+3+0+0=111/566	NA	TP53	4_c_NS	[non-HC]_2.45/2.9_NA	TIER_3	Pathogenic	Pathogenic	SOM	P53_tetramerisation_motif	NA	stop_gained:R:TP53:NP_001119587.1:p.(Arg210Ter)|R:TP53:NP_001263626.1:p.(Arg183Ter)|E:TP53:Canonical:ENSP00000269305.4:p.(Arg342Ter)|R:TP53:NP_001119590.1:p.(Arg303Ter)|R:TP53:Canonical:NP_000537.3:p.(Arg342Ter)|R:TP53:NP_001263689.1:p.(Arg303Ter)|R:TP53:NP_001263690.1:p.(Arg303Ter)|R:TP53:NP_001119584.1:p.(Arg342Ter)|E:TP53:ENSP00000391478.2:p.(Arg342Ter)|R:TP53:XP_005256835.1:p.(Arg322Ter);3_prime_UTR_variant:R:TP53:NM_001276699.1|R:TP53:NM_001126117.1|R:TP53:NM_001276698.1|R:TP53:NM_001126116.1|R:TP53:NM_001276696.1|R:TP53:NM_001126113.2|R:TP53:NM_001276695.1|R:TP53:NM_001126114.2|E:TP53:ENST00000455263.2|E:TP53:ENST00000420246.2;downstream_gene_variant:E:TP53:ENST00000509690.1|E:TP53:ENST00000514944.1|E:TP53:ENST00000508793.1|E:TP53:ENST00000604348.1|E:TP53:ENST00000503591.1	CPSR_classification|ClinVar_classification|protein_changes:stop_gained|class	NA	IS:all_exons	.	.	include	variant_in_more_than_10%_of_tumor_samples_(22.94%)_with_VAF_under_0.01	.	.
CL-AcroMetrix	TP53	ENST00000269305	NM_000546	17:7576897	G>A	c.949C>T	exon9	Q317X	Gln317Ter	c.949C>T:exon9:Q317X:Gln317Ter	stop_gained	1267	0.051	NA	NA	NA	NA	COSV52685086|COSV53209009	rs764735889	450344	NA	NA	NA	NA	TP53|Q317|3.1e-07	Acute_Myeloid_Leukemia:_0.7%_(1/144)|Esophageal_Carcinoma:_0.5%_(1/184)|Lung_Adenocarcinoma:_0.5%_(3/567)|Sarcoma:_0.4%_(1/237)|Skin_Cutaneous_Melanoma:_0.4%_(2/468)|Liver_Hepatocellular_Carcinoma:_0.3%_(1/364)|Bladder_Urothelial_Carcinoma:_0.2%_(1/412)|Brain_Lower_Grade_Glioma:_0.2%_(1/509)|Lung_Squamous_Cell_Carcinoma:_0.2%_(1/492)|Ovarian_Serous_Cystadenocarcinoma:_0.2%_(1/436)|Stomach_Adenocarcinoma:_0.2%_(1/437)|Uterine_Corpus_Endometrial_Carcinoma:_0.2%_(1/530)	MELA-AU/Metastatic/1/60/0.0167|PACA-CA/Primary/2/140/0.0143	T:66+3+1+1=71/461|N:11+0+0+0=11/104|A:77+3+1+1=82/565	NA	TP53	4_c_NS	[non-HC]_2.45/2.9_NA	TIER_3	Pathogenic	Likely_Pathogenic	SOM	NA	NA	stop_gained:E:TP53:ENSP00000352610.4:p.(Gln317Ter)|R:TP53:NP_001119587.1:p.(Gln185Ter)|R:TP53:NP_001263626.1:p.(Gln158Ter)|R:TP53:NP_001263628.1:p.(Gln158Ter)|R:TP53:NP_001119589.1:p.(Gln185Ter)|R:TP53:NP_001263627.1:p.(Gln158Ter)|R:TP53:NP_001119588.1:p.(Gln185Ter)|E:TP53:Canonical:ENSP00000269305.4:p.(Gln317Ter)|R:TP53:NP_001263625.1:p.(Gln278Ter)|R:TP53:NP_001119590.1:p.(Gln278Ter)|R:TP53:NP_001119585.1:p.(Gln317Ter)|R:TP53:Canonical:NP_000537.3:p.(Gln317Ter)|R:TP53:NP_001263689.1:p.(Gln278Ter)|R:TP53:NP_001263690.1:p.(Gln278Ter)|R:TP53:NP_001263624.1:p.(Gln278Ter)|R:TP53:NP_001119586.1:p.(Gln317Ter)|R:TP53:NP_001119584.1:p.(Gln317Ter)|E:TP53:ENSP00000398846.2:p.(Gln317Ter)|E:TP53:ENSP00000391127.2:p.(Gln317Ter)|E:TP53:ENSP00000391478.2:p.(Gln317Ter)|R:TP53:XP_005256835.1:p.(Gln297Ter)|E:TP53:ENSP00000458393.1:p.(Gln4Ter)|E:TP53:ENSP00000425104.1:p.(Gln185Ter);downstream_gene_variant:E:TP53:ENST00000514944.1|E:TP53:ENST00000508793.1|E:TP53:ENST00000604348.1|E:TP53:ENST00000503591.1	CPSR_classification|ClinVar_classification|protein_changes:stop_gained|class	NA	IS:all_exons	.	.	include	variant_in_more_than_10%_of_tumor_samples_(14.32%)_with_VAF_under_0.01	.	.
CL-AcroMetrix	TP53	ENST00000269305	NM_000546	17:7577022	G>A	c.916C>T	exon8	R306X	Arg306Ter	c.916C>T:exon8:R306X:Arg306Ter	stop_gained	1255	0.045	NA	NA	NA	NA	COSV52662281|COSV52987117|COSV53852813	rs121913344	142144	NA	NA	NA	NA	TP53|R306|1.86e-26	Esophageal_Carcinoma:_1.6%_(3/184)|Rectum_Adenocarcinoma:_1.5%_(2/137)|Head_and_Neck_Squamous_Cell_Carcinoma:_1.2%_(6/508)|Ovarian_Serous_Cystadenocarcinoma:_0.9%_(4/436)|Colon_Adenocarcinoma:_0.8%_(3/399)|Stomach_Adenocarcinoma:_0.7%_(3/437)|Brain_Lower_Grade_Glioma:_0.6%_(3/509)|Pancreatic_Adenocarcinoma:_0.6%_(1/180)|Lung_Squamous_Cell_Carcinoma:_0.4%_(2/492)|Glioblastoma_Multiforme:_0.3%_(1/393)|Liver_Hepatocellular_Carcinoma:_0.3%_(1/364)|Breast_Invasive_Carcinoma:_0.2%_(2/986)|Uterine_Corpus_Endometrial_Carcinoma:_0.2%_(1/530)	ESAD-UK/Primary/3/97/0.0309|ORCA-IN/Primary/1/13/0.0769|PACA-CA/Primary/1/140/0.0071	T:71+0+1+1=73/460|N:4+0+0+0=4/104|A:75+0+1+1=77/564	NA	TP53	4_c_NS	[non-HC]_2.45/2.9_NA	TIER_3	Pathogenic	Pathogenic	SOM	NA	NA	stop_gained:E:TP53:ENSP00000352610.4:p.(Arg306Ter)|R:TP53:NP_001119587.1:p.(Arg174Ter)|R:TP53:NP_001263626.1:p.(Arg147Ter)|R:TP53:NP_001263628.1:p.(Arg147Ter)|R:TP53:NP_001119589.1:p.(Arg174Ter)|R:TP53:NP_001263627.1:p.(Arg147Ter)|R:TP53:NP_001119588.1:p.(Arg174Ter)|E:TP53:Canonical:ENSP00000269305.4:p.(Arg306Ter)|R:TP53:NP_001263625.1:p.(Arg267Ter)|R:TP53:NP_001119590.1:p.(Arg267Ter)|R:TP53:NP_001119585.1:p.(Arg306Ter)|R:TP53:Canonical:NP_000537.3:p.(Arg306Ter)|R:TP53:NP_001263689.1:p.(Arg267Ter)|R:TP53:NP_001263690.1:p.(Arg267Ter)|R:TP53:NP_001263624.1:p.(Arg267Ter)|R:TP53:NP_001119586.1:p.(Arg306Ter)|R:TP53:NP_001119584.1:p.(Arg306Ter)|E:TP53:ENSP00000398846.2:p.(Arg306Ter)|E:TP53:ENSP00000391127.2:p.(Arg306Ter)|E:TP53:ENSP00000391478.2:p.(Arg306Ter)|R:TP53:XP_005256835.1:p.(Arg286Ter)|E:TP53:ENSP00000425104.1:p.(Arg174Ter);upstream_gene_variant:E:TP53:ENST00000576024.1;downstream_gene_variant:E:TP53:ENST00000514944.1|E:TP53:ENST00000508793.1|E:TP53:ENST00000604348.1|E:TP53:ENST00000503591.1	CPSR_classification|ClinVar_classification|protein_changes:stop_gained|class	NA	IS:all_exons	.	.	include	variant_in_more_than_10%_of_tumor_samples_(15.43%)_with_VAF_under_0.01	.	.
CL-AcroMetrix	TP53	ENST00000269305	NM_000546	17:7577046	C>A	c.892G>T	exon8	E298X	Glu298Ter	c.892G>T:exon8:E298X:Glu298Ter	stop_gained	1257	0.044	NA	NA	NA	NA	COSV52661551|COSV52761493|COSV53353479|COSV53790595	rs201744589	93323	NA	NA	NA	NA	TP53|E298|1.5e-09	Head_and_Neck_Squamous_Cell_Carcinoma:_1.2%_(6/508)|Lung_Squamous_Cell_Carcinoma:_1.2%_(6/492)|Pancreatic_Adenocarcinoma:_0.6%_(1/180)|Lung_Adenocarcinoma:_0.5%_(3/567)|Sarcoma:_0.4%_(1/237)|Prostate_Adenocarcinoma:_0.2%_(1/496)	NA	T:25+2+0+0=27/460|N:2+1+0+0=3/104|A:27+3+0+0=30/564	NA	TP53	4_c_NS	[non-HC]_2.45/2.9_NA	TIER_3	Pathogenic	Pathogenic	SOM	NA	NA	stop_gained:E:TP53:ENSP00000352610.4:p.(Glu298Ter)|R:TP53:NP_001119587.1:p.(Glu166Ter)|R:TP53:NP_001263626.1:p.(Glu139Ter)|R:TP53:NP_001263628.1:p.(Glu139Ter)|R:TP53:NP_001119589.1:p.(Glu166Ter)|R:TP53:NP_001263627.1:p.(Glu139Ter)|R:TP53:NP_001119588.1:p.(Glu166Ter)|E:TP53:Canonical:ENSP00000269305.4:p.(Glu298Ter)|R:TP53:NP_001263625.1:p.(Glu259Ter)|R:TP53:NP_001119590.1:p.(Glu259Ter)|R:TP53:NP_001119585.1:p.(Glu298Ter)|R:TP53:Canonical:NP_000537.3:p.(Glu298Ter)|R:TP53:NP_001263689.1:p.(Glu259Ter)|R:TP53:NP_001263690.1:p.(Glu259Ter)|R:TP53:NP_001263624.1:p.(Glu259Ter)|R:TP53:NP_001119586.1:p.(Glu298Ter)|R:TP53:NP_001119584.1:p.(Glu298Ter)|E:TP53:ENSP00000398846.2:p.(Glu298Ter)|E:TP53:ENSP00000391127.2:p.(Glu298Ter)|E:TP53:ENSP00000391478.2:p.(Glu298Ter)|R:TP53:XP_005256835.1:p.(Glu278Ter)|E:TP53:ENSP00000425104.1:p.(Glu166Ter);upstream_gene_variant:E:TP53:ENST00000576024.1;downstream_gene_variant:E:TP53:ENST00000514944.1|E:TP53:ENST00000508793.1|E:TP53:ENST00000604348.1|E:TP53:ENST00000503591.1	CPSR_classification|ClinVar_classification|protein_changes:stop_gained|class	NA	IS:all_exons	.	.	include	.	.	.
CL-AcroMetrix	TP53	ENST00000269305	NM_000546	17:7579414	C>T	c.273G>A	exon4	W91X	Trp91Ter	c.273G>A:exon4:W91X:Trp91Ter	stop_gained	1158	0.037	NA	NA	NA	NA	COSV52673580	rs876660548	233650	NA	NA	NA	NA	TP53|W91|7.29e-10	Esophageal_Carcinoma:_1.1%_(2/184)|Lung_Squamous_Cell_Carcinoma:_0.4%_(2/492)|Sarcoma:_0.4%_(1/237)|Lung_Adenocarcinoma:_0.2%_(1/567)|Stomach_Adenocarcinoma:_0.2%_(1/437)|Breast_Invasive_Carcinoma:_0.1%_(1/986)	OV-AU/Primary/1/60/0.0167	T:46+0+0+0=46/460|N:5+0+0+0=5/104|A:51+0+0+0=51/564	NA	TP53	4_c_NS	[non-HC]_2.45/2.9_NA	TIER_3	Pathogenic	Pathogenic	SOM	NA	NA	stop_gained:E:TP53:ENSP00000410739.2:p.(Trp91Ter)|E:TP53:ENSP00000352610.4:p.(Trp91Ter)|E:TP53:Canonical:ENSP00000269305.4:p.(Trp91Ter)|R:TP53:NP_001263625.1:p.(Trp52Ter)|R:TP53:NP_001119590.1:p.(Trp52Ter)|R:TP53:NP_001119585.1:p.(Trp91Ter)|R:TP53:Canonical:NP_000537.3:p.(Trp91Ter)|R:TP53:NP_001263689.1:p.(Trp52Ter)|R:TP53:NP_001263690.1:p.(Trp52Ter)|R:TP53:NP_001263624.1:p.(Trp52Ter)|R:TP53:NP_001119586.1:p.(Trp91Ter)|R:TP53:NP_001119584.1:p.(Trp91Ter)|E:TP53:ENSP00000398846.2:p.(Trp91Ter)|E:TP53:ENSP00000391127.2:p.(Trp91Ter)|E:TP53:ENSP00000391478.2:p.(Trp91Ter)|R:TP53:XP_005256835.1:p.(Trp71Ter)|E:TP53:ENSP00000424104.1:p.(Trp91Ter)|E:TP53:ENSP00000473895.1:p.(Trp91Ter)|E:TP53:ENSP00000426252.1:p.(Trp91Ter);upstream_gene_variant:R:TP53:NM_001126115.1|R:TP53:NM_001276697.1|R:TP53:NM_001276699.1|R:TP53:NM_001126117.1|R:TP53:NM_001276698.1|R:TP53:NM_001126116.1|E:TP53:ENST00000576024.1	CPSR_classification|ClinVar_classification|protein_changes:stop_gained|class	NA	IS:all_exons	.	.	include	variant_in_more_than_10%_of_tumor_samples_(10.0%)_with_VAF_under_0.01	.	.
CL-AcroMetrix	VHL	ENST00000256474	NM_000551	3:10191488	C>T	c.481C>T	exon3	R161X	Arg161Ter	c.481C>T:exon3:R161X:Arg161Ter	stop_gained	634	0.035	NA	NA	NA	NA	COSV56542817|COSV56554019|COSV56564848	rs5030818	2217	NA	NA	NA	NA	VHL|R161|0.000555	Kidney_Renal_Clear_Cell_Carcinoma:_0.6%_(2/336)	NA	T:86+3+0+1=90/463|N:7+0+0+0=7/104|A:93+3+0+1=97/567	NA	NA	1_a_NA	[non-HC]_2.198/2.396_NA	TIER_3	Pathogenic	Pathogenic	SOM	VHL_beta_domain	NA	stop_gained:E:VHL:Canonical:ENSP00000256474.2:p.(Arg161Ter)|R:VHL:NP_937799.1:p.(Arg120Ter)|R:VHL:Canonical:NP_000542.1:p.(Arg161Ter)|E:VHL:ENSP00000344757.2:p.(Arg120Ter)	CPSR_classification|ClinVar_classification|protein_changes:stop_gained|class	NA	all_exons	.	.	include	variant_in_more_than_10%_of_tumor_samples_(18.57%)_with_VAF_under_0.01	.	.
CL-AcroMetrix	TP53	ENST00000269305	NM_000546	17:7576855	G>A	c.991C>T	exon9	Q331X	Gln331Ter	c.991C>T:exon9:Q331X:Gln331Ter	stop_gained,splice_region_variant	1067	0.036	NA	NA	NA	NA	COSV52664188	NA	922893	NA	NA	NA	NA	TP53|Q331|0.000393	Bladder_Urothelial_Carcinoma:_1.7%_(7/412)|Mesothelioma:_1.2%_(1/82)|Rectum_Adenocarcinoma:_0.7%_(1/137)|Lung_Adenocarcinoma:_0.4%_(2/567)|Skin_Cutaneous_Melanoma:_0.4%_(2/468)|Breast_Invasive_Carcinoma:_0.3%_(3/986)|Cervical_Squamous_Cell_Carcinoma_and_Endocervical_Adenocarcinoma:_0.3%_(1/289)|Head_and_Neck_Squamous_Cell_Carcinoma:_0.2%_(1/508)|Brain_Lower_Grade_Glioma:_0.2%_(1/509)|Ovarian_Serous_Cystadenocarcinoma:_0.2%_(1/436)|Uterine_Corpus_Endometrial_Carcinoma:_0.2%_(1/530)	BRCA-EU/Primary/1/76/0.0132|ESAD-UK/Primary/1/97/0.0103|PACA-CA/Primary/1/140/0.0071	T:19+1+1+2=23/461|N:3+0+0+0=3/104|A:22+1+1+2=26/565	NA	TP53	4_c_NS	[non-HC]_2.45/2.9_NA	TIER_3	Pathogenic	Pathogenic	SOM	P53_tetramerisation_motif	NA	splice_region_variant,stop_gained:E:TP53:ENSP00000352610.4:p.(Gln331Ter)|R:TP53:NP_001119587.1:p.(Gln199Ter)|R:TP53:NP_001263626.1:p.(Gln172Ter)|R:TP53:NP_001263628.1:p.(Gln172Ter)|R:TP53:NP_001119589.1:p.(Gln199Ter)|R:TP53:NP_001263627.1:p.(Gln172Ter)|R:TP53:NP_001119588.1:p.(Gln199Ter)|E:TP53:Canonical:ENSP00000269305.4:p.(Gln331Ter)|R:TP53:NP_001263625.1:p.(Gln292Ter)|R:TP53:NP_001119590.1:p.(Gln292Ter)|R:TP53:NP_001119585.1:p.(Gln331Ter)|R:TP53:Canonical:NP_000537.3:p.(Gln331Ter)|R:TP53:NP_001263689.1:p.(Gln292Ter)|R:TP53:NP_001263690.1:p.(Gln292Ter)|R:TP53:NP_001263624.1:p.(Gln292Ter)|R:TP53:NP_001119586.1:p.(Gln331Ter)|R:TP53:NP_001119584.1:p.(Gln331Ter)|E:TP53:ENSP00000398846.2:p.(Gln331Ter)|E:TP53:ENSP00000391127.2:p.(Gln331Ter)|E:TP53:ENSP00000391478.2:p.(Gln331Ter)|R:TP53:XP_005256835.1:p.(Gln311Ter)|E:TP53:ENSP00000458393.1:p.(Gln18Ter);stop_gained:E:TP53:ENSP00000425104.1:p.(Gln199Ter);downstream_gene_variant:E:TP53:ENST00000514944.1|E:TP53:ENST00000508793.1|E:TP53:ENST00000604348.1|E:TP53:ENST00000503591.1	CPSR_classification|ClinVar_classification|protein_changes:stop_gained|class	NA	IS:all_exons	.	.	include	.	.	.
CL-AcroMetrix	GNA11	ENST00000078429	NM_002067	19:3115012	C>T	c.547C>T	exon4	R183C	Arg183Cys	c.547C>T:exon4:R183C:Arg183Cys	missense_variant	1235	0.079	NA	NA	NA	NA	COSV50017316	rs1555702147	548668	NA	NA	NA	NA	GNA11|R183|0.00596	Uveal_Melanoma:_1.2%_(1/80)|Lung_Adenocarcinoma:_0.2%_(1/567)|Skin_Cutaneous_Melanoma:_0.2%_(1/468)	NA	T:119+3+0+0=122/463|N:10+0+0+0=10/104|A:129+3+0+0=132/567	GNA11:p.R183C:ENST00000078429:CTAT_POPULATION|CTAT_CANCER|3D_STRUCTURE	NA	NA	[non-HC]_1.968/1.936_NA	TIER_4	NA	NA	SOM	G-protein_alpha_subunit	NA	missense_variant:R:GNA11:NP_002058.2:p.(Arg183Cys)|R:GNA11:Canonical:NP_002058.2:p.(Arg183Cys)|E:GNA11:Canonical:ENSP00000078429.3:p.(Arg183Cys)|E:GNA11:ENSP00000465935.1:p.(Arg32Cys)	class	NA	all_exons;IS:exons[4-5]	.	.	include	variant_in_more_than_10%_of_tumor_samples_(25.7%)_with_VAF_under_0.01	.	.
CL-AcroMetrix	GNA11	ENST00000078429	NM_002067	19:3118942	A>T	c.626A>T	exon5	Q209L	Gln209Leu	c.626A>T:exon5:Q209L:Gln209Leu	missense_variant	1085	0.052	NA	NA	NA	NA	COSV50017277|COSV50017623|COSV50017882	rs1057519742	376002	NA	NA	NA	NA	GNA11|Q209|3.54e-183	Uveal_Melanoma:_42.5%_(34/80)|Skin_Cutaneous_Melanoma:_0.6%_(3/468)	NA	T:9+0+3+1=13/463|N:2+0+0+0=2/104|A:11+0+3+1=15/567	GNA11:p.Q209L:ENST00000078429:CTAT_POPULATION|CTAT_CANCER|3D_STRUCTURE	NA	NA	[non-HC]_1.968/1.936_NA	TIER_4	NA	NA	SOM	G-protein_alpha_subunit	NA	missense_variant:R:GNA11:NP_002058.2:p.(Gln209Leu)|R:GNA11:Canonical:NP_002058.2:p.(Gln209Leu)|E:GNA11:Canonical:ENSP00000078429.3:p.(Gln209Leu)|E:GNA11:ENSP00000465935.1:p.(Gln58Leu)	class	NA	all_exons;IS:exons[4-5]	.	.	include	.	.	.
CL-AcroMetrix	PIK3CA	ENST00000263967	NM_006218	3:178952149	C>CA	c.3204_3205insA	exon21	X1069fs	Ter1069MetfsTer4	c.3204_3205insA:exon21:X1069fs:Ter1069MetfsTer4	frameshift_variant	664	0.068	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	PI3K	NA	[HC]_1.812/1.624_NA	TIER_2	VUS	NA	SOM	NA	Buparlisib|Taselisib|Alpelisib|Copanlisib|Copanlisib_Hydrochloride	frameshift_variant:R:PIK3CA:NP_006209.2:p.(Ter1069MetfsTer4)|E:PIK3CA:Canonical:ENSP00000263967.3:p.(Ter1069MetfsTer4)|R:PIK3CA:Canonical:NP_006209.2:p.(Ter1069MetfsTer4)	tier|protein_changes:frameshift_variant|class	NA	all_exons;IS:exons[2-3,5-8,10,14,19,21;coding:1-2,4-7,9,13,18,20]	.	.	include	no_recurrence_data	.	.
CL-AcroMetrix	ERBB2	ENST00000269571	NM_001382787|NM_001382784|NM_001382786|NM_001382789|NM_001382788|NM_001382785|NM_004448|NM_001382796|NM_001382798|NM_001382800|NM_001382797|NM_001382805|NM_001382792|NM_001382793|NM_001382794|NM_001382795|NM_001382801|NM_001382790|NM_001382806|NM_001382802|NM_001382799|NM_001382791	17:37880981	A>AGCATACGTGATG	c.2313_2324dup	exon20	Y772_A775dup	Tyr772_Ala775dup	c.2313_2324dup:exon20:Y772_A775dup:Tyr772_Ala775dup	inframe_insertion	1383	0.054	NA	NA	NA	NA	NA	rs397516975	13875	NA	NA	NA	NA	NA	Lung_Adenocarcinoma:_0.9%_(5/567)	NA	T:0+0+3+1=4/463|N:0+0+0+0=0/104|A:0+0+3+1=4/567	NA	RTKRAS	NA	[HC]_2.156/2.312_NA	TIER_2	VUS	Likely_Pathogenic	SOM	Protein_tyrosine_and_serine/threonine_kinase	Afatinib|Lapatinib_Ditosylate|Trastuzumab|Neratinib|Pertuzumab|Afatinib_Dimaleate|Dacomitinib|Margetuximab|Vandetanib|Pyrotinib|Tesevatinib|Tucatinib|Neratinib_Maleate|Trastuzumab_Deruxtecan|Lapatinib	inframe_insertion:E:ERBB2:ENSP00000462438.1:p.(Tyr742_Ala745dup)|R:ERBB2:XP_005257196.1:p.(Tyr757_Ala760dup)|R:ERBB2:NP_001276865.1:p.(Tyr757_Ala760dup)|R:ERBB2:NP_001005862.1:p.(Tyr742_Ala745dup)|E:ERBB2:ENSP00000385185.2:p.(Tyr742_Ala745dup)|R:ERBB2:NP_001005862.1:p.(Tyr742_Ala745dup)|E:ERBB2:Canonical:ENSP00000446466.1:p.(Tyr757_Ala760dup)|E:ERBB2:ENSP00000404047.2:p.(Tyr496_Ala499dup)|R:ERBB2:NP_001276866.1:p.(Tyr772_Ala775dup)|R:ERBB2:Canonical:NP_004439.2:p.(Tyr772_Ala775dup)|E:ERBB2:ENSP00000443562.1:p.(Tyr742_Ala745dup)|R:ERBB2:NP_004439.2:p.(Tyr772_Ala775dup)|E:ERBB2:ENSP00000463714.1:p.(Tyr772_Ala775dup)|E:ERBB2:ENSP00000269571.4:p.(Tyr772_Ala775dup)|R:ERBB2:XP_005257197.1:p.(Tyr742_Ala745dup)|E:ERBB2:ENSP00000463002.1:p.(Tyr141_Ala144dup);downstream_gene_variant:E:ERBB2:ENST00000582818.1|R:MIEN1:NM_032339.4|R:MIEN1:Canonical:NM_001330206.1|R:MIEN1:NM_032339.3|R:MIEN1:XM_005257736.1|E:MIEN1:ENST00000394231.3|E:MIEN1:Canonical:ENST00000577810.1	tier|ClinVar_classification|class	NA	IS:all_exons	.	.	include	.	.	.
CL-AcroMetrix	KIT	ENST00000288135	NM_000222	4:55592178	C>CTGCCTA	c.1504_1509dup	exon9	A502_Y503dup	Ala502_Tyr503dup	c.1504_1509dup:exon9:A502_Y503dup:Ala502_Tyr503dup	inframe_insertion	1025	0.042	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	T:0+0+0+1=1/463|N:0+0+0+0=0/104|A:0+0+0+1=1/567	NA	RTKRAS	NA	[HC]_2.044/2.088_NA	TIER_2	VUS	NA	SOM	NA	Vatalanib|Sorafenib_Tosylate|Pazopanib_Hydrochloride|Sorafenib|Dasatinib|Masitinib|Regorafenib|Regorafenib_Hydrate|Semaxanib|Anlotinib|Famitinib|Pexidartinib|Sitravatinib|Pexidartinib_Hydrochloride|Avapritinib|Ripretinib|Pazopanib|Cediranib|Dovitinib|Sunitinib_Malate|Motesanib|Quizartinib|Midostaurin|Imatinib	inframe_insertion:E:KIT:ENSP00000390987.2:p.(Ala502_Tyr503dup)|E:KIT:Canonical:ENSP00000288135.5:p.(Ala502_Tyr503dup)|R:KIT:NP_001087241.1:p.(Ala502_Tyr503dup)|R:KIT:Canonical:NP_000213.1:p.(Ala502_Tyr503dup)|R:KIT:XP_005265799.1:p.(Ala503_Tyr504dup)|R:KIT:XP_005265797.1:p.(Ala503_Tyr504dup)|R:KIT:XP_005265798.1:p.(Ala503_Tyr504dup)	tier|class	NA	all_exons;IS:introns[16],exons[8-9,11-13,17]	.	.	include	.	.	.
CL-AcroMetrix	ABL1	ENST00000318560	NM_005157	9:133738342	C>G	c.742C>G	exon4	L248V	Leu248Val	c.742C>G:exon4:L248V:Leu248Val	missense_variant	1376	0.121	NA	NA	NA	NA	COSV59325261	rs121913455	376085	NA	NA	NA	NA	NA	NA	NA	T:13+0+0+0=13/463|N:0+0+0+0=0/104|A:13+0+0+0=13/567	NA	RTKRAS	NA	[non-HC]_1.942/1.884_NA	TIER_2	VUS	Likely_Pathogenic	SOM	Protein_tyrosine_and_serine/threonine_kinase	Ponatinib|Nilotinib_Hydrochloride_Monohydrate|Dasatinib|Regorafenib|Regorafenib_Hydrate|Ponatinib_Hydrochloride|Nilotinib|Bosutinib|Flumbatinib|EGFR/FLT3/Abl_Inhibitor_SKLB1028|Asciminib|Radotinib|Imatinib	missense_variant:R:ABL1:XP_005272234.1:p.(Leu266Val)|R:ABL1:Canonical:NP_009297.2:p.(Leu267Val)|E:ABL1:Canonical:ENSP00000361423.2:p.(Leu267Val)|E:ABL1:ENSP00000323315.5:p.(Leu248Val)|R:ABL1:NP_005148.2:p.(Leu248Val)|R:ABL1:NP_005148.2:p.(Leu248Val)	tier|ClinVar_classification|class	NA	all_exons;IS:exons[4-9]	.	.	include	.	.	.
CL-AcroMetrix	ABL1	ENST00000318560	NM_005157	9:133738349	G>A	c.749G>A	exon4	G250E	Gly250Glu	c.749G>A:exon4:G250E:Gly250Glu	missense_variant	1353	0.105	NA	NA	NA	NA	COSV59324360	rs121913453	376086	NA	NA	NA	NA	NA	NA	NA	T:110+0+0+0=110/463|N:12+0+0+0=12/104|A:122+0+0+0=122/567	NA	RTKRAS	NA	[non-HC]_1.942/1.884_NA	TIER_2	VUS	Likely_Pathogenic	SOM	Protein_tyrosine_and_serine/threonine_kinase	Ponatinib|Nilotinib_Hydrochloride_Monohydrate|Dasatinib|Regorafenib|Regorafenib_Hydrate|Ponatinib_Hydrochloride|Nilotinib|Bosutinib|Flumbatinib|EGFR/FLT3/Abl_Inhibitor_SKLB1028|Asciminib|Radotinib|Imatinib	missense_variant:R:ABL1:XP_005272234.1:p.(Gly268Glu)|R:ABL1:Canonical:NP_009297.2:p.(Gly269Glu)|E:ABL1:Canonical:ENSP00000361423.2:p.(Gly269Glu)|E:ABL1:ENSP00000323315.5:p.(Gly250Glu)|R:ABL1:NP_005148.2:p.(Gly250Glu)|R:ABL1:NP_005148.2:p.(Gly250Glu)	tier|ClinVar_classification|class	NA	all_exons;IS:exons[4-9]	.	.	include	variant_in_more_than_10%_of_tumor_samples_(23.76%)_with_VAF_under_0.01	.	.
CL-AcroMetrix	ABL1	ENST00000318560	NM_005157	9:133738357	T>C	c.757T>C	exon4	Y253H	Tyr253His	c.757T>C:exon4:Y253H:Tyr253His	missense_variant	1355	0.106	NA	NA	NA	NA	COSV100584395|COSV59325175	rs121913461	12627	NA	NA	NA	NA	NA	NA	NA	T:9+0+0+0=9/463|N:4+0+0+0=4/104|A:13+0+0+0=13/567	NA	RTKRAS	NA	[non-HC]_1.942/1.884_NA	TIER_2	VUS	Likely_Pathogenic	SOM	Protein_tyrosine_and_serine/threonine_kinase	Ponatinib|Nilotinib_Hydrochloride_Monohydrate|Dasatinib|Regorafenib|Regorafenib_Hydrate|Ponatinib_Hydrochloride|Nilotinib|Bosutinib|Flumbatinib|EGFR/FLT3/Abl_Inhibitor_SKLB1028|Asciminib|Radotinib|Imatinib	missense_variant:R:ABL1:XP_005272234.1:p.(Tyr271His)|R:ABL1:Canonical:NP_009297.2:p.(Tyr272His)|E:ABL1:Canonical:ENSP00000361423.2:p.(Tyr272His)|E:ABL1:ENSP00000323315.5:p.(Tyr253His)|R:ABL1:NP_005148.2:p.(Tyr253His)|R:ABL1:NP_005148.2:p.(Tyr253His)	tier|ClinVar_classification|class	NA	all_exons;IS:exons[4-9]	.	.	include	.	.	.
CL-AcroMetrix	ABL1	ENST00000318560	NM_005157	9:133738363	G>A	c.763G>A	exon4	E255K	Glu255Lys	c.763G>A:exon4:E255K:Glu255Lys	missense_variant	1378	0.114	NA	NA	NA	NA	COSV59325418	rs121913448	376090	NA	NA	NA	NA	NA	NA	NA	T:71+0+0+0=71/463|N:3+0+0+0=3/104|A:74+0+0+0=74/567	NA	RTKRAS	NA	[non-HC]_1.942/1.884_NA	TIER_2	VUS	Likely_Pathogenic	SOM	Protein_tyrosine_and_serine/threonine_kinase	Ponatinib|Nilotinib_Hydrochloride_Monohydrate|Dasatinib|Regorafenib|Regorafenib_Hydrate|Ponatinib_Hydrochloride|Nilotinib|Bosutinib|Flumbatinib|EGFR/FLT3/Abl_Inhibitor_SKLB1028|Asciminib|Radotinib|Imatinib	missense_variant:R:ABL1:XP_005272234.1:p.(Glu273Lys)|R:ABL1:Canonical:NP_009297.2:p.(Glu274Lys)|E:ABL1:Canonical:ENSP00000361423.2:p.(Glu274Lys)|E:ABL1:ENSP00000323315.5:p.(Glu255Lys)|R:ABL1:NP_005148.2:p.(Glu255Lys)|R:ABL1:NP_005148.2:p.(Glu255Lys)	tier|ClinVar_classification|class	NA	all_exons;IS:exons[4-9]	.	.	include	variant_in_more_than_10%_of_tumor_samples_(15.33%)_with_VAF_under_0.01	.	.
CL-AcroMetrix	ABL1	ENST00000318560	NM_005157	9:133747520	A>G	c.827A>G	exon5	D276G	Asp276Gly	c.827A>G:exon5:D276G:Asp276Gly	missense_variant	1002	0.138	NA	NA	NA	NA	COSV59323752	rs121913447	NA	NA	NA	NA	NA	NA	NA	NA	T:10+0+0+0=10/463|N:3+0+0+0=3/104|A:13+0+0+0=13/567	NA	RTKRAS	NA	[non-HC]_1.942/1.884_NA	TIER_2	VUS	NA	SOM	Protein_tyrosine_and_serine/threonine_kinase	Ponatinib|Nilotinib_Hydrochloride_Monohydrate|Dasatinib|Regorafenib|Regorafenib_Hydrate|Ponatinib_Hydrochloride|Nilotinib|Bosutinib|Flumbatinib|EGFR/FLT3/Abl_Inhibitor_SKLB1028|Asciminib|Radotinib|Imatinib	missense_variant:R:ABL1:XP_005272234.1:p.(Asp294Gly)|R:ABL1:Canonical:NP_009297.2:p.(Asp295Gly)|E:ABL1:Canonical:ENSP00000361423.2:p.(Asp295Gly)|E:ABL1:ENSP00000323315.5:p.(Asp276Gly)|R:ABL1:NP_005148.2:p.(Asp276Gly)|R:ABL1:NP_005148.2:p.(Asp276Gly)	tier|class	NA	all_exons;IS:exons[4-9]	.	.	include	.	.	.
CL-AcroMetrix	ABL1	ENST00000318560	NM_005157	9:133748391	T>C	c.1052T>C	exon6	M351T	Met351Thr	c.1052T>C:exon6:M351T:Met351Thr	missense_variant	904	0.11	NA	NA	NA	NA	COSV59325906	rs121913457	12629	NA	NA	NA	NA	NA	NA	NA	T:9+0+0+0=9/463|N:1+0+0+0=1/104|A:10+0+0+0=10/567	NA	RTKRAS	NA	[non-HC]_1.942/1.884_NA	TIER_2	VUS	Likely_Pathogenic	SOM	Protein_tyrosine_and_serine/threonine_kinase	Ponatinib|Nilotinib_Hydrochloride_Monohydrate|Dasatinib|Regorafenib|Regorafenib_Hydrate|Ponatinib_Hydrochloride|Nilotinib|Bosutinib|Flumbatinib|EGFR/FLT3/Abl_Inhibitor_SKLB1028|Asciminib|Radotinib|Imatinib	missense_variant:R:ABL1:XP_005272234.1:p.(Met369Thr)|R:ABL1:Canonical:NP_009297.2:p.(Met370Thr)|E:ABL1:Canonical:ENSP00000361423.2:p.(Met370Thr)|E:ABL1:ENSP00000323315.5:p.(Met351Thr)|R:ABL1:NP_005148.2:p.(Met351Thr)|R:ABL1:NP_005148.2:p.(Met351Thr)	tier|ClinVar_classification|class	NA	all_exons;IS:exons[4-9]	.	.	include	.	.	.
CL-AcroMetrix	ABL1	ENST00000318560	NM_005157	9:133748403	A>G	c.1064A>G	exon6	E355G	Glu355Gly	c.1064A>G:exon6:E355G:Glu355Gly	missense_variant	734	0.086	NA	NA	NA	NA	COSV59325892	rs121913450	376095	NA	NA	NA	NA	NA	NA	NA	T:11+0+0+0=11/463|N:3+0+0+0=3/104|A:14+0+0+0=14/567	NA	RTKRAS	NA	[non-HC]_1.942/1.884_NA	TIER_2	VUS	Likely_Pathogenic	SOM	Protein_tyrosine_and_serine/threonine_kinase	Ponatinib|Nilotinib_Hydrochloride_Monohydrate|Dasatinib|Regorafenib|Regorafenib_Hydrate|Ponatinib_Hydrochloride|Nilotinib|Bosutinib|Flumbatinib|EGFR/FLT3/Abl_Inhibitor_SKLB1028|Asciminib|Radotinib|Imatinib	missense_variant:R:ABL1:XP_005272234.1:p.(Glu373Gly)|R:ABL1:Canonical:NP_009297.2:p.(Glu374Gly)|E:ABL1:Canonical:ENSP00000361423.2:p.(Glu374Gly)|E:ABL1:ENSP00000323315.5:p.(Glu355Gly)|R:ABL1:NP_005148.2:p.(Glu355Gly)|R:ABL1:NP_005148.2:p.(Glu355Gly)	tier|ClinVar_classification|class	NA	all_exons;IS:exons[4-9]	.	.	include	.	.	.
CL-AcroMetrix	ABL1	ENST00000318560	NM_005157	9:133748414	T>G	c.1075T>G	exon6	F359V	Phe359Val	c.1075T>G:exon6:F359V:Phe359Val	missense_variant	653	0.086	NA	NA	NA	NA	COSV59324514|COSV59324758	rs121913452	376096	NA	NA	NA	NA	NA	NA	NA	T:1+0+0+0=1/461|N:0+0+0+0=0/104|A:1+0+0+0=1/565	NA	RTKRAS	NA	[non-HC]_1.942/1.884_NA	TIER_2	VUS	Likely_Pathogenic	SOM	Protein_tyrosine_and_serine/threonine_kinase	Ponatinib|Nilotinib_Hydrochloride_Monohydrate|Dasatinib|Regorafenib|Regorafenib_Hydrate|Ponatinib_Hydrochloride|Nilotinib|Bosutinib|Flumbatinib|EGFR/FLT3/Abl_Inhibitor_SKLB1028|Asciminib|Radotinib|Imatinib	missense_variant:R:ABL1:XP_005272234.1:p.(Phe377Val)|R:ABL1:Canonical:NP_009297.2:p.(Phe378Val)|E:ABL1:Canonical:ENSP00000361423.2:p.(Phe378Val)|E:ABL1:ENSP00000323315.5:p.(Phe359Val)|R:ABL1:NP_005148.2:p.(Phe359Val)|R:ABL1:NP_005148.2:p.(Phe359Val)	tier|ClinVar_classification|class	NA	all_exons;IS:exons[4-9]	.	.	include	.	.	.
CL-AcroMetrix	ABL1	ENST00000318560	NM_005157	9:133750319	C>A	c.1150C>A	exon7	L384M	Leu384Met	c.1150C>A:exon7:L384M:Leu384Met	missense_variant	1342	0.171	NA	NA	NA	NA	COSV59327217|COSV59331853	NA	NA	NA	NA	NA	NA	NA	NA	NA	T:37+2+0+0=39/463|N:5+0+0+0=5/104|A:42+2+0+0=44/567	NA	RTKRAS	NA	[non-HC]_1.942/1.884_NA	TIER_2	VUS	NA	SOM	Protein_tyrosine_and_serine/threonine_kinase	Ponatinib|Nilotinib_Hydrochloride_Monohydrate|Dasatinib|Regorafenib|Regorafenib_Hydrate|Ponatinib_Hydrochloride|Nilotinib|Bosutinib|Flumbatinib|EGFR/FLT3/Abl_Inhibitor_SKLB1028|Asciminib|Radotinib|Imatinib	missense_variant:R:ABL1:XP_005272234.1:p.(Leu402Met)|R:ABL1:Canonical:NP_009297.2:p.(Leu403Met)|E:ABL1:Canonical:ENSP00000361423.2:p.(Leu403Met)|E:ABL1:ENSP00000323315.5:p.(Leu384Met)|R:ABL1:NP_005148.2:p.(Leu384Met)|R:ABL1:NP_005148.2:p.(Leu384Met)	tier|class	NA	all_exons;IS:exons[4-9]	.	.	include	.	.	.
CL-AcroMetrix	ABL1	ENST00000318560	NM_005157	9:133750356	A>G	c.1187A>G	exon7	H396R	His396Arg	c.1187A>G:exon7:H396R:His396Arg	missense_variant	1504	0.173	NA	NA	NA	NA	COSV59323744|COSV59324877	rs121913454	376097	NA	NA	NA	NA	NA	NA	NA	T:5+0+0+0=5/463|N:3+0+0+0=3/104|A:8+0+0+0=8/567	NA	RTKRAS	NA	[non-HC]_1.942/1.884_NA	TIER_2	VUS	Likely_Pathogenic	SOM	Protein_tyrosine_and_serine/threonine_kinase	Ponatinib|Nilotinib_Hydrochloride_Monohydrate|Dasatinib|Regorafenib|Regorafenib_Hydrate|Ponatinib_Hydrochloride|Nilotinib|Bosutinib|Flumbatinib|EGFR/FLT3/Abl_Inhibitor_SKLB1028|Asciminib|Radotinib|Imatinib	missense_variant:R:ABL1:XP_005272234.1:p.(His414Arg)|R:ABL1:Canonical:NP_009297.2:p.(His415Arg)|E:ABL1:Canonical:ENSP00000361423.2:p.(His415Arg)|E:ABL1:ENSP00000323315.5:p.(His396Arg)|R:ABL1:NP_005148.2:p.(His396Arg)|R:ABL1:NP_005148.2:p.(His396Arg)	tier|ClinVar_classification|class	NA	all_exons;IS:exons[4-9]	.	.	include	.	.	.
CL-AcroMetrix	KIT	ENST00000288135	NM_000222	4:55592081	T>C	c.1405T>C	exon9	F469L	Phe469Leu	c.1405T>C:exon9:F469L:Phe469Leu	missense_variant	1043	0.066	NA	NA	NA	NA	COSV55415544|COSV55423557	NA	NA	NA	NA	NA	NA	NA	NA	NA	T:6+0+0+0=6/463|N:1+0+0+0=1/104|A:7+0+0+0=7/567	NA	RTKRAS	NA	[HC]_2.044/2.088_NA	TIER_2	VUS	NA	SOM	Immunoglobulin_domain	Vatalanib|Sorafenib_Tosylate|Pazopanib_Hydrochloride|Sorafenib|Dasatinib|Masitinib|Regorafenib|Regorafenib_Hydrate|Semaxanib|Anlotinib|Famitinib|Pexidartinib|Sitravatinib|Pexidartinib_Hydrochloride|Avapritinib|Ripretinib|Pazopanib|Cediranib|Dovitinib|Sunitinib_Malate|Motesanib|Quizartinib|Midostaurin|Imatinib	missense_variant:E:KIT:ENSP00000390987.2:p.(Phe469Leu)|E:KIT:Canonical:ENSP00000288135.5:p.(Phe469Leu)|R:KIT:NP_001087241.1:p.(Phe469Leu)|R:KIT:Canonical:NP_000213.1:p.(Phe469Leu)|R:KIT:XP_005265799.1:p.(Phe470Leu)|R:KIT:XP_005265797.1:p.(Phe470Leu)|R:KIT:XP_005265798.1:p.(Phe470Leu)	tier|class	NA	all_exons;IS:introns[16],exons[8-9,11-13,17]	.	.	include	.	.	.
CL-AcroMetrix	KIT	ENST00000288135	NM_000222	4:55592192	T>C	c.1516T>C	exon9	F506L	Phe506Leu	c.1516T>C:exon9:F506L:Phe506Leu	missense_variant	937	0.03	NA	NA	NA	NA	COSV55412302	NA	NA	NA	NA	NA	NA	NA	NA	NA	T:12+1+0+0=13/463|N:2+0+0+0=2/104|A:14+1+0+0=15/567	NA	RTKRAS	NA	[HC]_2.044/2.088_NA	TIER_2	VUS	NA	SOM	NA	Vatalanib|Sorafenib_Tosylate|Pazopanib_Hydrochloride|Sorafenib|Dasatinib|Masitinib|Regorafenib|Regorafenib_Hydrate|Semaxanib|Anlotinib|Famitinib|Pexidartinib|Sitravatinib|Pexidartinib_Hydrochloride|Avapritinib|Ripretinib|Pazopanib|Cediranib|Dovitinib|Sunitinib_Malate|Motesanib|Quizartinib|Midostaurin|Imatinib	missense_variant:E:KIT:ENSP00000390987.2:p.(Phe506Leu)|E:KIT:Canonical:ENSP00000288135.5:p.(Phe506Leu)|R:KIT:NP_001087241.1:p.(Phe506Leu)|R:KIT:Canonical:NP_000213.1:p.(Phe506Leu)|R:KIT:XP_005265799.1:p.(Phe507Leu)|R:KIT:XP_005265797.1:p.(Phe507Leu)|R:KIT:XP_005265798.1:p.(Phe507Leu)	tier|class	NA	all_exons;IS:introns[16],exons[8-9,11-13,17]	.	.	include	.	.	.
CL-AcroMetrix	KIT	ENST00000288135	NM_000222	4:55592202	A>T	c.1526A>T	exon9	K509I	Lys509Ile	c.1526A>T:exon9:K509I:Lys509Ile	missense_variant	911	0.033	NA	NA	NA	NA	COSV55394709	rs1577992594	651292	NA	NA	NA	NA	NA	NA	NA	T:9+1+0+0=10/463|N:0+0+0+0=0/104|A:9+1+0+0=10/567	NA	RTKRAS	NA	[HC]_2.044/2.088_NA	TIER_2	VUS	Pathogenic	SOM	NA	Vatalanib|Sorafenib_Tosylate|Pazopanib_Hydrochloride|Sorafenib|Dasatinib|Masitinib|Regorafenib|Regorafenib_Hydrate|Semaxanib|Anlotinib|Famitinib|Pexidartinib|Sitravatinib|Pexidartinib_Hydrochloride|Avapritinib|Ripretinib|Pazopanib|Cediranib|Dovitinib|Sunitinib_Malate|Motesanib|Quizartinib|Midostaurin|Imatinib	missense_variant,splice_region_variant:E:KIT:ENSP00000390987.2:p.(Lys509Ile)|R:KIT:NP_001087241.1:p.(Lys509Ile)|R:KIT:XP_005265799.1:p.(Lys510Ile);missense_variant:E:KIT:Canonical:ENSP00000288135.5:p.(Lys509Ile)|R:KIT:Canonical:NP_000213.1:p.(Lys509Ile)|R:KIT:XP_005265797.1:p.(Lys510Ile)|R:KIT:XP_005265798.1:p.(Lys510Ile)	tier|ClinVar_classification|class	NA	all_exons;IS:introns[16],exons[8-9,11-13,17]	.	.	include	.	.	.
CL-AcroMetrix	KIT	ENST00000288135	NM_000222	4:55592211	A>G	c.1535A>G	exon9	N512S	Asn512Ser	c.1535A>G:exon9:N512S:Asn512Ser	missense_variant	943	0.04	NA	NA	NA	NA	COSV55397408	rs1354751133	NA	NA	NA	NA	NA	NA	NA	NA	T:8+0+0+0=8/463|N:2+0+0+0=2/104|A:10+0+0+0=10/567	NA	RTKRAS	NA	[HC]_2.044/2.088_NA	TIER_2	VUS	NA	SOM	NA	Vatalanib|Sorafenib_Tosylate|Pazopanib_Hydrochloride|Sorafenib|Dasatinib|Masitinib|Regorafenib|Regorafenib_Hydrate|Semaxanib|Anlotinib|Famitinib|Pexidartinib|Sitravatinib|Pexidartinib_Hydrochloride|Avapritinib|Ripretinib|Pazopanib|Cediranib|Dovitinib|Sunitinib_Malate|Motesanib|Quizartinib|Midostaurin|Imatinib	intron_variant,splice_region_variant:E:KIT:ENST00000412167.2|R:KIT:NM_001093772.1|R:KIT:XM_005265742.1;missense_variant:E:KIT:Canonical:ENSP00000288135.5:p.(Asn512Ser)|R:KIT:Canonical:NP_000213.1:p.(Asn512Ser)|R:KIT:XP_005265797.1:p.(Asn513Ser)|R:KIT:XP_005265798.1:p.(Asn513Ser)	tier|class	NA	all_exons;IS:introns[16],exons[8-9,11-13,17]	.	.	include	.	.	.
CL-AcroMetrix	KRAS	ENST00000256078	NM_001369786|NM_033360	12:25398215	G>A	c.104C>T	exon2	T35I	Thr35Ile	c.104C>T:exon2:T35I:Thr35Ile	missense_variant	628	0.067	NA	NA	NA	NA	COSV55909186	NA	NA	NA	NA	NA	NA	NA	NA	NA	T:11+0+0+0=11/463|N:2+0+0+0=2/104|A:13+0+0+0=13/567	NA	RTKRAS	NA	[HC]_1.89/1.78_NA	TIER_2	VUS	NA	SOM	Ras_family	Adagrasib	missense_variant:E:KRAS:ENSP00000308495.3:p.(Thr35Ile)|R:KRAS:Canonical:NP_203524.1:p.(Thr35Ile)|R:KRAS:NP_004976.2:p.(Thr35Ile)|R:KRAS:NP_203524.1:p.(Thr35Ile)|R:KRAS:NP_004976.2:p.(Thr35Ile)|E:KRAS:ENSP00000452512.1:p.(Thr35Ile)|E:KRAS:Canonical:ENSP00000256078.4:p.(Thr35Ile)|R:KRAS:XP_005253422.1:p.(Thr35Ile)|E:KRAS:ENSP00000451856.1:p.(Thr35Ile)	tier|class	NA	IS:all_exons	.	.	include	.	.	.
CL-AcroMetrix	PIK3CA	ENST00000263967	NM_006218	3:178936098	A>G	c.1640A>G	exon10	E547G	Glu547Gly	c.1640A>G:exon10:E547G:Glu547Gly	missense_variant	650	0.035	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	T:15+0+0+0=15/463|N:2+0+0+0=2/104|A:17+0+0+0=17/567	NA	PI3K	NA	[HC]_1.812/1.624_NA	TIER_2	VUS	NA	SOM	Phosphoinositide_3-kinase_family|accessory_domain_(PIK_domain)	Buparlisib|Taselisib|Alpelisib|Copanlisib|Copanlisib_Hydrochloride	missense_variant:R:PIK3CA:NP_006209.2:p.(Glu547Gly)|E:PIK3CA:Canonical:ENSP00000263967.3:p.(Glu547Gly)|R:PIK3CA:Canonical:NP_006209.2:p.(Glu547Gly)	tier|class	NA	all_exons;IS:exons[2-3,5-8,10,14,19,21;coding:1-2,4-7,9,13,18,20]	.	.	include	.	.	.
CL-AcroMetrix	PIK3CA	ENST00000263967	NM_006218	3:178952055	A>G	c.3110A>G	exon21	E1037G	Glu1037Gly	c.3110A>G:exon21:E1037G:Glu1037Gly	missense_variant	853	0.074	NA	NA	NA	NA	COSV55940420	NA	NA	NA	NA	NA	NA	NA	NA	NA	T:19+1+0+0=20/463|N:4+0+0+0=4/104|A:23+1+0+0=24/567	NA	PI3K	NA	[HC]_1.812/1.624_NA	TIER_2	VUS	NA	SOM	NA	Buparlisib|Taselisib|Alpelisib|Copanlisib|Copanlisib_Hydrochloride	missense_variant:R:PIK3CA:NP_006209.2:p.(Glu1037Gly)|E:PIK3CA:Canonical:ENSP00000263967.3:p.(Glu1037Gly)|R:PIK3CA:Canonical:NP_006209.2:p.(Glu1037Gly)	tier|class	NA	all_exons;IS:exons[2-3,5-8,10,14,19,21;coding:1-2,4-7,9,13,18,20]	.	.	include	.	.	.
CL-AcroMetrix	JAK2	ENST00000381652	NM_001322194|NM_001322195|NM_004972|NM_001322198|NM_001322196|NM_001322199|NM_001322204	9:5073770	G>T	c.1849G>T	exon14	V617F	Val617Phe	c.1849G>T:exon14:V617F:Val617Phe	missense_variant	1002	0.135	NA	NA	NA	NA	COSV67569051|COSV67571909	rs77375493	14662	0.0003516	NA	0.0003974	NA	NA	Liver_Hepatocellular_Carcinoma:_0.3%_(1/364)	NA	T:21+1+0+0=22/463|N:2+0+0+0=2/104|A:23+1+0+0=24/567	NA	RTKRAS	NA	[HC]_2.226/2.452_NA	TIER_2	Pathogenic	Pathogenic	GL_DB	Protein_tyrosine_and_serine/threonine_kinase	Momelotinib|Fedratinib|Ruxolitinib|Ruxolitinib_Phosphate	missense_variant:E:JAK2:ENSP00000440387.1:p.(Val617Phe)|R:JAK2:NP_001309124.1:p.(Val617Phe)|R:JAK2:NP_001309123.1:p.(Val617Phe)|R:JAK2:NP_001309125.1:p.(Val617Phe)|R:JAK2:NP_001309127.1:p.(Val212Phe)|R:JAK2:NP_001309128.1:p.(Val212Phe)|E:JAK2:Canonical:ENSP00000371067.3:p.(Val617Phe)|R:JAK2:Canonical:NP_004963.1:p.(Val617Phe)|R:JAK2:XP_005251512.1:p.(Val617Phe)|E:JAK2:ENSP00000443103.1:p.(Val468Phe)|R:JAK2:NP_001309133.1:p.(Val468Phe);downstream_gene_variant:E:AL161450.1:Canonical:ENST00000601793.1	CPSR_classification|ClinVar_classification|tier	NA	all_exons;IS:exons[14]	.	.	include	.	.	.
CL-AcroMetrix	CDKN2A	ENST00000498124	NM_001195132	9:21975017	C>T	NA	NA	NA	NA	NA	x:noncoding_variant	1254	0.473	NA	NA	NA	NA	COSV58720858	rs3814960	873184	NA	0.4878	NA	GLOBAL_AF_1KG:0.4878000|AFR_AF_1KG:0.1793000|AMR_AF_1KG:0.4424000|EAS_AF_1KG:0.6657000|EUR_AF_1KG:0.6243000|SAS_AF_1KG:0.6135000	NA	NA	NA	T:5+3+18+387=413/461|N:2+0+0+91=93/104|A:7+3+18+478=506/565	NA	CC	NA	[non-HC]_2.044/2.088_NA	TIER_2	Likely_Benign	Benign	GL_DB	NA	NA	upstream_gene_variant:R:CDKN2A:XM_005251343.1|R:CDKN2A:NM_058197.4|E:CDKN2A:ENST00000579122.1|E:CDKN2A:ENST00000578845.2|E:CDKN2A:ENST00000498124.1|E:CDKN2A:ENST00000479692.2|E:CDKN2A:ENST00000497750.1;5_prime_UTR_variant:R:CDKN2A:NM_001195132.1|R:CDKN2A:Canonical:NM_000077.4|E:CDKN2A:ENST00000304494.5|R:CDKN2A:XM_005251341.1|E:CDKN2A:ENST00000446177.1	tier	recurrent_germline|HET_VAF_RANGE|germline_population	IS:all_exons	.	.	exclude	germline_population,recurrent_germline	.	.
CL-AcroMetrix	FGFR1	ENST00000425967	NA	8:38285864	G>A	NA	NA	NA	NA	NA	coding	1234	0.152	NA	NA	NA	NA	COSV58334457	rs746094709	1311567	8.1e-06	NA	0.0000090	NA	NA	Colon_Adenocarcinoma:_0.8%_(3/399)	NA	T:123+1+0+0=124/463|N:6+0+0+0=6/104|A:129+1+0+0=130/567	NA	RTKRAS	NA	[HC]_2.034/2.068_NA	TIER_3	VUS	VUS	SOM	NA	Pazopanib_Hydrochloride|Infigratinib|Regorafenib|Regorafenib_Hydrate|Orantinib|Erdafitinib|Futibatinib|Brivanib|Sulfatinib|Pemigatinib|Pazopanib|Nintedanib	intron_variant,splice_region_variant:E:FGFR1:Canonical:ENST00000425967.3|R:FGFR1:NM_001174065.1|R:FGFR1:NM_001174067.1|E:FGFR1:ENST00000397091.5|R:FGFR1:NM_023106.2|R:FGFR1:NM_015850.3|E:FGFR1:ENST00000341462.5|E:FGFR1:ENST00000397113.2|E:FGFR1:ENST00000326324.6|E:FGFR1:ENST00000397103.1|E:FGFR1:ENST00000397108.4|E:FGFR1:ENST00000533668.1|E:FGFR1:ENST00000526742.1|E:FGFR1:ENST00000530568.1;missense_variant,splice_region_variant:R:FGFR1:NP_001167537.1:p.(Pro61Ser)|R:FGFR1:NP_075593.1:p.(Pro61Ser)|R:FGFR1:Canonical:NP_075598.2:p.(Pro150Ser)|R:FGFR1:NP_001167534.1:p.(Pro150Ser)|R:FGFR1:NP_001167535.1:p.(Pro142Ser)|E:FGFR1:ENSP00000400162.2:p.(Pro150Ser)|E:FGFR1:ENSP00000432972.1:p.(Pro150Ser)|R:FGFR1:XP_005273506.1:p.(Pro142Ser)|E:FGFR1:ENSP00000348537.5:p.(Pro61Ser)|E:FGFR1:ENSP00000337247.5:p.(Pro142Ser)|E:FGFR1:ENSP00000434712.1:p.(Pro150Ser)|E:FGFR1:ENSP00000435283.1:p.(Pro61Ser);downstream_gene_variant:E:FGFR1:ENST00000434187.1|E:FGFR1:ENST00000413133.2	class	NA	introns[1,5];IS:introns[17],all_exons	.	.	include	variant_in_more_than_10%_of_tumor_samples_(26.57%)_with_VAF_under_0.01	.	.
CL-AcroMetrix	APC	ENST00000457016	NA	5:112173830	G>GA	c.2544dup	exon16	D849fs	Asp849ArgfsTer2	c.2544dup:exon16:D849fs:Asp849ArgfsTer2	frameshift_variant	998	0.166	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Rectum_Adenocarcinoma:_0.7%_(1/137)|Colon_Adenocarcinoma:_0.3%_(1/399)	NA	T:3+0+0+0=3/463|N:0+0+0+0=0/104|A:3+0+0+0=3/567	NA	WNT	3_NA_NA	[non-HC]_2.012/2.024_NA	TIER_3	Pathogenic	NA	SOM	NA	NA	frameshift_variant:R:APC:NP_001120983.2:p.(Asp831ArgfsTer2)|R:APC:XP_005272032.1:p.(Asp849ArgfsTer2)|E:APC:Canonical:ENSP00000413133.1:p.(Asp849ArgfsTer2)|E:APC:ENSP00000423224.1:p.(Asp831ArgfsTer2)|R:APC:XP_005272034.1:p.(Asp748ArgfsTer2)|R:APC:Canonical:NP_000029.2:p.(Asp849ArgfsTer2)|R:APC:NP_001120982.1:p.(Asp849ArgfsTer2)|E:APC:ENSP00000257430.4:p.(Asp849ArgfsTer2)|E:APC:ENSP00000427089.2:p.(Asp849ArgfsTer2)|E:APC:ENSP00000423828.2:p.(Asp849ArgfsTer2)|R:APC:XP_005272031.1:p.(Asp849ArgfsTer2)|R:APC:XP_005272033.1:p.(Asp790ArgfsTer2);downstream_gene_variant:E:APC:ENST00000504915.2	CPSR_classification|protein_changes:frameshift_variant|class	NA	IS:all_exons	.	.	include	.	.	.
CL-AcroMetrix	APC	ENST00000457016	NA	5:112174989	CA>C	c.3700del	exon16	S1234fs	Ser1234ValfsTer31	c.3700del:exon16:S1234fs:Ser1234ValfsTer31	frameshift_variant	1154	0.205	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	T:1+0+0+0=1/463|N:0+0+0+0=0/104|A:1+0+0+0=1/567	NA	WNT	3_NA_NA	[non-HC]_2.012/2.024_NA	TIER_3	Pathogenic	NA	SOM	NA	NA	frameshift_variant:R:APC:NP_001120983.2:p.(Ser1216ValfsTer31)|R:APC:XP_005272032.1:p.(Ser1234ValfsTer31)|E:APC:Canonical:ENSP00000413133.1:p.(Ser1234ValfsTer31)|R:APC:XP_005272034.1:p.(Ser1133ValfsTer31)|R:APC:Canonical:NP_000029.2:p.(Ser1234ValfsTer31)|R:APC:NP_001120982.1:p.(Ser1234ValfsTer31)|E:APC:ENSP00000257430.4:p.(Ser1234ValfsTer31)|E:APC:ENSP00000427089.2:p.(Ser1234ValfsTer31)|E:APC:ENSP00000423828.2:p.(Ser1234ValfsTer31)|R:APC:XP_005272031.1:p.(Ser1234ValfsTer31)|R:APC:XP_005272033.1:p.(Ser1175ValfsTer31);downstream_gene_variant:E:APC:ENST00000507379.1|E:APC:ENST00000504915.2	CPSR_classification|protein_changes:frameshift_variant|class	NA	IS:all_exons	.	.	include	.	.	.
CL-AcroMetrix	APC	ENST00000457016	NA	5:112175211	T>TA	c.3924dup	exon16	E1309fs	Glu1309ArgfsTer6	c.3924dup:exon16:E1309fs:Glu1309ArgfsTer6	frameshift_variant	964	0.18	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	WNT	3_NA_NA	[non-HC]_2.012/2.024_NA	TIER_3	Pathogenic	NA	SOM	NA	NA	frameshift_variant:R:APC:NP_001120983.2:p.(Glu1291ArgfsTer6)|R:APC:XP_005272032.1:p.(Glu1309ArgfsTer6)|E:APC:Canonical:ENSP00000413133.1:p.(Glu1309ArgfsTer6)|R:APC:XP_005272034.1:p.(Glu1208ArgfsTer6)|R:APC:Canonical:NP_000029.2:p.(Glu1309ArgfsTer6)|R:APC:NP_001120982.1:p.(Glu1309ArgfsTer6)|E:APC:ENSP00000257430.4:p.(Glu1309ArgfsTer6)|E:APC:ENSP00000427089.2:p.(Glu1309ArgfsTer6)|R:APC:XP_005272031.1:p.(Glu1309ArgfsTer6)|R:APC:XP_005272033.1:p.(Glu1250ArgfsTer6);downstream_gene_variant:E:APC:ENST00000507379.1|E:APC:ENST00000512211.2|E:APC:ENST00000504915.2	CPSR_classification|protein_changes:frameshift_variant|class	NA	IS:all_exons	.	.	include	no_recurrence_data	.	.
CL-AcroMetrix	APC	ENST00000457016	NA	5:112175479	TGA>T	c.4192_4193del	exon16	R1399fs	Arg1399PhefsTer9	c.4192_4193del:exon16:R1399fs:Arg1399PhefsTer9	frameshift_variant	1281	0.173	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Rectum_Adenocarcinoma:_0.7%_(1/137)	NA	NA	NA	WNT	3_NA_NA	[non-HC]_2.012/2.024_NA	TIER_3	Pathogenic	NA	SOM	NA	NA	frameshift_variant:R:APC:NP_001120983.2:p.(Arg1381PhefsTer9)|R:APC:XP_005272032.1:p.(Arg1399PhefsTer9)|E:APC:Canonical:ENSP00000413133.1:p.(Arg1399PhefsTer9)|R:APC:XP_005272034.1:p.(Arg1298PhefsTer9)|R:APC:Canonical:NP_000029.2:p.(Arg1399PhefsTer9)|R:APC:NP_001120982.1:p.(Arg1399PhefsTer9)|E:APC:ENSP00000257430.4:p.(Arg1399PhefsTer9)|E:APC:ENSP00000427089.2:p.(Arg1399PhefsTer9)|R:APC:XP_005272031.1:p.(Arg1399PhefsTer9)|R:APC:XP_005272033.1:p.(Arg1340PhefsTer9);downstream_gene_variant:E:APC:ENST00000507379.1|E:APC:ENST00000512211.2|E:APC:ENST00000504915.2	CPSR_classification|protein_changes:frameshift_variant|class	NA	IS:all_exons	.	.	include	no_recurrence_data	.	.
CL-AcroMetrix	APC	ENST00000457016	NA	5:112175675	AAG>A	c.4393_4394del	exon16	S1465fs	Ser1465TrpfsTer3	c.4393_4394del:exon16:S1465fs:Ser1465TrpfsTer3	frameshift_variant	1271	0.172	NA	NA	NA	NA	NA	rs387906234	811	NA	NA	NA	NA	NA	Colon_Adenocarcinoma:_2.8%_(11/399)|Adrenocortical_Carcinoma:_1.1%_(1/92)|Uterine_Corpus_Endometrial_Carcinoma:_0.4%_(2/530)|Stomach_Adenocarcinoma:_0.2%_(1/437)	NA	T:81+0+0+0=81/463|N:26+0+0+0=26/104|A:107+0+0+0=107/567	NA	WNT	3_NA_NA	[non-HC]_2.012/2.024_NA	TIER_3	Pathogenic	Pathogenic	SOM	NA	NA	frameshift_variant:R:APC:NP_001120983.2:p.(Ser1447TrpfsTer3)|R:APC:XP_005272032.1:p.(Ser1465TrpfsTer3)|E:APC:Canonical:ENSP00000413133.1:p.(Ser1465TrpfsTer3)|R:APC:XP_005272034.1:p.(Ser1364TrpfsTer3)|R:APC:Canonical:NP_000029.2:p.(Ser1465TrpfsTer3)|R:APC:NP_001120982.1:p.(Ser1465TrpfsTer3)|E:APC:ENSP00000257430.4:p.(Ser1465TrpfsTer3)|E:APC:ENSP00000427089.2:p.(Ser1465TrpfsTer3)|R:APC:XP_005272031.1:p.(Ser1465TrpfsTer3)|R:APC:XP_005272033.1:p.(Ser1406TrpfsTer3);downstream_gene_variant:E:APC:ENST00000507379.1|E:APC:ENST00000512211.2|E:APC:ENST00000504915.2	CPSR_classification|protein_changes:frameshift_variant|ClinVar_classification|class	NA	IS:all_exons	.	.	include	variant_in_more_than_10%_of_tumor_samples_(17.49%)_with_VAF_under_0.01	.	.
CL-AcroMetrix	APC	ENST00000457016	NA	5:112175830	GC>G	c.4541del	exon16	P1514fs	Pro1514HisfsTer9	c.4541del:exon16:P1514fs:Pro1514HisfsTer9	frameshift_variant	1167	0.194	NA	NA	NA	NA	COSV57373528	NA	NA	NA	NA	NA	NA	NA	NA	NA	T:4+0+0+0=4/463|N:1+0+0+0=1/104|A:5+0+0+0=5/567	NA	WNT	3_NA_NA	[non-HC]_2.012/2.024_NA	TIER_3	Pathogenic	NA	SOM	NA	NA	frameshift_variant:R:APC:NP_001120983.2:p.(Pro1496HisfsTer9)|R:APC:XP_005272032.1:p.(Pro1514HisfsTer9)|E:APC:Canonical:ENSP00000413133.1:p.(Pro1514HisfsTer9)|R:APC:XP_005272034.1:p.(Pro1413HisfsTer9)|R:APC:Canonical:NP_000029.2:p.(Pro1514HisfsTer9)|R:APC:NP_001120982.1:p.(Pro1514HisfsTer9)|E:APC:ENSP00000257430.4:p.(Pro1514HisfsTer9)|E:APC:ENSP00000427089.2:p.(Pro1514HisfsTer9)|R:APC:XP_005272031.1:p.(Pro1514HisfsTer9)|R:APC:XP_005272033.1:p.(Pro1455HisfsTer9);downstream_gene_variant:E:APC:ENST00000507379.1|E:APC:ENST00000512211.2|E:APC:ENST00000504915.2	CPSR_classification|protein_changes:frameshift_variant|class	NA	IS:all_exons	.	.	include	.	.	.
CL-AcroMetrix	APC	ENST00000457016	NA	5:112175951	G>GA	c.4666dup	exon16	T1556fs	Thr1556AsnfsTer3	c.4666dup:exon16:T1556fs:Thr1556AsnfsTer3	frameshift_variant	861	0.137	NA	NA	NA	NA	COSV57351096	rs587783031	428112	NA	NA	NA	NA	NA	Colon_Adenocarcinoma:_3%_(12/399)|Rectum_Adenocarcinoma:_2.2%_(3/137)|Esophageal_Carcinoma:_1.1%_(2/184)|Stomach_Adenocarcinoma:_0.7%_(3/437)|Uterine_Corpus_Endometrial_Carcinoma:_0.6%_(3/530)|Liver_Hepatocellular_Carcinoma:_0.3%_(1/364)|Head_and_Neck_Squamous_Cell_Carcinoma:_0.2%_(1/508)|Lung_Squamous_Cell_Carcinoma:_0.2%_(1/492)|Skin_Cutaneous_Melanoma:_0.2%_(1/468)	ESAD-UK/Primary/5/97/0.0515	T:10+0+5+0=15/463|N:2+0+0+0=2/104|A:12+0+5+0=17/567	NA	WNT	3_NA_NA	[non-HC]_2.012/2.024_NA	TIER_3	Pathogenic	Pathogenic	SOM	NA	NA	frameshift_variant:R:APC:NP_001120983.2:p.(Thr1538AsnfsTer3)|R:APC:XP_005272032.1:p.(Thr1556AsnfsTer3)|E:APC:Canonical:ENSP00000413133.1:p.(Thr1556AsnfsTer3)|R:APC:XP_005272034.1:p.(Thr1455AsnfsTer3)|R:APC:Canonical:NP_000029.2:p.(Thr1556AsnfsTer3)|R:APC:NP_001120982.1:p.(Thr1556AsnfsTer3)|E:APC:ENSP00000257430.4:p.(Thr1556AsnfsTer3)|E:APC:ENSP00000427089.2:p.(Thr1556AsnfsTer3)|R:APC:XP_005272031.1:p.(Thr1556AsnfsTer3)|R:APC:XP_005272033.1:p.(Thr1497AsnfsTer3);downstream_gene_variant:E:APC:ENST00000507379.1|E:APC:ENST00000512211.2|E:APC:ENST00000504915.2	CPSR_classification|protein_changes:frameshift_variant|ClinVar_classification|class	NA	IS:all_exons	.	.	include	.	.	.
CL-AcroMetrix	APC	ENST00000457016	NA	5:112176063	C>CA	c.4778dup	exon16	P1594fs	Pro1594AlafsTer38	c.4778dup:exon16:P1594fs:Pro1594AlafsTer38	frameshift_variant	1056	0.178	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Uterine_Corpus_Endometrial_Carcinoma:_0.2%_(1/530)	ESAD-UK/Primary/1/97/0.0103	T:23+0+0+0=23/463|N:9+0+0+0=9/104|A:32+0+0+0=32/567	NA	WNT	3_NA_NA	[non-HC]_2.012/2.024_NA	TIER_3	Pathogenic	NA	SOM	NA	NA	frameshift_variant:R:APC:NP_001120983.2:p.(Pro1576AlafsTer38)|R:APC:XP_005272032.1:p.(Pro1594AlafsTer38)|E:APC:Canonical:ENSP00000413133.1:p.(Pro1594AlafsTer38)|R:APC:XP_005272034.1:p.(Pro1493AlafsTer38)|R:APC:Canonical:NP_000029.2:p.(Pro1594AlafsTer38)|R:APC:NP_001120982.1:p.(Pro1594AlafsTer38)|E:APC:ENSP00000257430.4:p.(Pro1594AlafsTer38)|E:APC:ENSP00000427089.2:p.(Pro1594AlafsTer38)|R:APC:XP_005272031.1:p.(Pro1594AlafsTer38)|R:APC:XP_005272033.1:p.(Pro1535AlafsTer38);downstream_gene_variant:E:APC:ENST00000507379.1|E:APC:ENST00000512211.2|E:APC:ENST00000504915.2	CPSR_classification|protein_changes:frameshift_variant|class	NA	IS:all_exons	.	.	include	.	.	.
CL-AcroMetrix	CDH1	ENST00000261769	NM_004360	16:68855924	A>AC	c.1733dup	exon12	G579fs	Gly579ArgfsTer9	c.1733dup:exon12:G579fs:Gly579ArgfsTer9	frameshift_variant	1124	0.058	NA	NA	NA	NA	NA	rs1555516821	545756	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	[non-HC]_2.096/2.192_NA	TIER_3	Pathogenic	Pathogenic	SOM	Cadherin_domain	NA	frameshift_variant:R:CDH1:XP_005256329.1:p.(Gly518ArgfsTer9)|E:CDH1:Canonical:ENSP00000261769.4:p.(Gly579ArgfsTer9)|R:CDH1:NP_001304113.1:p.(Gly518ArgfsTer9)|R:CDH1:NP_001304114.1:p.(Gly63ArgfsTer9)|R:CDH1:Canonical:NP_004351.1:p.(Gly579ArgfsTer9)|R:CDH1:NP_004351.1:p.(Gly579ArgfsTer9)|E:CDH1:ENSP00000414946.2:p.(Gly518ArgfsTer9);5_prime_UTR_variant:R:CDH1:NM_001317186.1	CPSR_classification|protein_changes:frameshift_variant|ClinVar_classification|class	NA	IS:all_exons	.	.	include	no_recurrence_data	.	.
CL-AcroMetrix	FBXW7	ENST00000281708	NM_001349798	4:153244155	TC>T	c.2001del	exon12	S668fs	Ser668ValfsTer39	c.2001del:exon12:S668fs:Ser668ValfsTer39	frameshift_variant	1093	0.066	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Colon_Adenocarcinoma:_1.3%_(5/399)|Esophageal_Carcinoma:_0.5%_(1/184)|Stomach_Adenocarcinoma:_0.5%_(2/437)|Cervical_Squamous_Cell_Carcinoma_and_Endocervical_Adenocarcinoma:_0.3%_(1/289)|Uterine_Corpus_Endometrial_Carcinoma:_0.2%_(1/530)|Breast_Invasive_Carcinoma:_0.1%_(1/986)	NA	T:191+2+0+0=193/463|N:48+0+0+0=48/104|A:239+2+0+0=241/567	NA	NOTCH	NA	[non-HC]_1.88/1.76_NA	TIER_3	VUS	NA	SOM	NA	NA	frameshift_variant:R:FBXW7:XP_005263165.1:p.(Ser492ValfsTer39)|R:FBXW7:Canonical:NP_060785.2:p.(Ser588ValfsTer39)|R:FBXW7:NP_001013433.1:p.(Ser550ValfsTer39)|R:FBXW7:XP_005263164.1:p.(Ser668ValfsTer39)|R:FBXW7:NP_361014.1:p.(Ser668ValfsTer39)|E:FBXW7:Canonical:ENSP00000281708.3:p.(Ser668ValfsTer39)|E:FBXW7:ENSP00000296555.4:p.(Ser550ValfsTer39)|E:FBXW7:ENSP00000263981.4:p.(Ser588ValfsTer39)|E:FBXW7:ENSP00000474725.1:p.(Ser668ValfsTer39)|E:FBXW7:ENSP00000377528.3:p.(Ser492ValfsTer39)|E:FBXW7:ENSP00000474971.1:p.(Ser668ValfsTer39)	protein_changes:frameshift_variant|class	NA	all_exons	.	.	include	variant_in_more_than_10%_of_tumor_samples_(41.25%)_with_VAF_under_0.01	.	.
CL-AcroMetrix	FGFR3	ENST00000340107	NM_001163213	4:1803668	GC>G	c.850del	exon7	H284fs	His284ThrfsTer10	c.850del:exon7:H284fs:His284ThrfsTer10	frameshift_variant	1236	0.057	NA	NA	NA	NA	COSV53394291	rs587776836	16352	NA	NA	NA	NA	NA	NA	NA	T:15+0+0+0=15/463|N:5+0+0+0=5/104|A:20+0+0+0=20/567	NA	RTKRAS	NA	[HC]_2.122/2.244_NA	TIER_3	VUS	Pathogenic	SOM	Immunoglobulin_I-set_domain	Pazopanib_Hydrochloride|Infigratinib|Masitinib|Orantinib|Erdafitinib|Futibatinib|Brivanib|Pemigatinib|Pazopanib|Nintedanib|Dovitinib	frameshift_variant:E:FGFR3:ENSP00000420533.2:p.(His284ThrfsTer10)|E:FGFR3:Canonical:ENSP00000339824.4:p.(His284ThrfsTer10)|E:FGFR3:ENSP00000414914.2:p.(His284ThrfsTer10)|E:FGFR3:ENSP00000412903.2:p.(His284ThrfsTer10)|R:FGFR3:Canonical:NP_001156685.1:p.(His284ThrfsTer10)|R:FGFR3:NP_075254.1:p.(His284ThrfsTer10)|R:FGFR3:NP_000133.1:p.(His284ThrfsTer10)|E:FGFR3:ENSP00000260795.2:p.(His284ThrfsTer10)|E:FGFR3:ENSP00000231803.1:p.(His284ThrfsTer10)	protein_changes:frameshift_variant|ClinVar_classification|class	NA	all_exons;IS:introns[17],exons[7,9aka10,14,18]	.	.	include	.	.	.
CL-AcroMetrix	GNAQ	ENST00000286548	NM_002072	9:80343489	T>TGTAC	c.829_830insGTAC	exon6	D277fs	Asp277GlyfsTer21	c.829_830insGTAC:exon6:D277fs:Asp277GlyfsTer21	frameshift_variant	823	0.203	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	[non-HC]_1.97/1.94_NA	TIER_3	NA	NA	SOM	G-protein_alpha_subunit	NA	frameshift_variant:E:GNAQ:Canonical:ENSP00000286548.4:p.(Asp277GlyfsTer21)|R:GNAQ:Canonical:NP_002063.2:p.(Asp277GlyfsTer21)|R:GNAQ:NP_002063.2:p.(Asp277GlyfsTer21)|E:GNAQ:ENSP00000443197.1:p.(Asp75GlyfsTer21)	protein_changes:frameshift_variant|class	NA	all_exons;IS:exons[4-5]	.	.	include	no_recurrence_data	.	.
CL-AcroMetrix	KDR	ENST00000263923	NM_002253	4:55953816	ACTTCCTCCTCCTCCATACAGGAAAC>A	c.3595_3619del	exon27	V1199fs	Val1199TyrfsTer28	c.3595_3619del:exon27:V1199fs:Val1199TyrfsTer28	frameshift_variant	1121	0.068	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	[non-HC]_2.116/2.232_NA	TIER_3	VUS	NA	SOM	NA	Vatalanib|Sorafenib_Tosylate|Pazopanib_Hydrochloride|Tivozanib|Lenvatinib|Axitinib|Sorafenib|Ramucirumab|Regorafenib|Regorafenib_Hydrate|Cabozantinib_S-malate|Lenvatinib_Mesylate|Cabozantinib|Linifanib|Vandetanib|Orantinib|Semaxanib|Rivoceranib|Anlotinib|Famitinib|Rivoceranib_Mesylate|Brivanib|Sitravatinib|Sulfatinib|Fruquintinib|Pazopanib|Cediranib|Nintedanib|Dovitinib|Sunitinib_Malate|Motesanib|Midostaurin	frameshift_variant:R:KDR:Canonical:NP_002244.1:p.(Val1199TyrfsTer28)|E:KDR:Canonical:ENSP00000263923.4:p.(Val1199TyrfsTer28)	protein_changes:frameshift_variant|class	NA	all_exons	.	.	include	no_recurrence_data	.	.
CL-AcroMetrix	NOTCH1	ENST00000277541	NA	9:139390804	CG>C	c.7386del	exon34	A2463fs	Ala2463ProfsTer14	c.7386del:exon34:A2463fs:Ala2463ProfsTer14	frameshift_variant	1658	0.143	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Breast_Invasive_Carcinoma:_0.1%_(1/986)	NA	T:21+0+0+0=21/463|N:8+0+0+0=8/104|A:29+0+0+0=29/567	NA	NOTCH	NA	[non-HC]_2.294/2.588_NA	TIER_3	VUS	NA	SOM	NA	NA	frameshift_variant:R:NOTCH1:Canonical:NP_060087.3:p.(Ala2463ProfsTer14)|R:NOTCH1:NP_060087.3:p.(Ala2463ProfsTer14)|E:NOTCH1:Canonical:ENSP00000277541.6:p.(Ala2463ProfsTer14)	protein_changes:frameshift_variant|class	NA	all_exons	.	.	include	.	.	.
CL-AcroMetrix	NPM1	ENST00000296930	NM_002520	5:170837543	C>CTCTG	c.860_863dup	exon11	W288fs	Trp288CysfsTer12	c.860_863dup:exon11:W288fs:Trp288CysfsTer12	frameshift_variant	513	0.172	NA	NA	NA	NA	COSV51548899|COSV51555098|COSV51559390|COSV51564309	rs587776806	13998	NA	NA	NA	NA	NA	Acute_Myeloid_Leukemia:_8.3%_(12/144)	NA	NA	NA	NA	NA	[non-HC]_2.328/2.656_NA	TIER_3	NA	NA	SOM	NA	Ceritinib|Crizotinib	frameshift_variant:E:NPM1:Canonical:ENSP00000428755.1:p.(Trp288CysfsTer12)|E:NPM1:ENSP00000296930.5:p.(Trp288CysfsTer12)|R:NPM1:NP_954654.1:p.(Trp259CysfsTer12)|R:NPM1:Canonical:NP_002511.1:p.(Trp288CysfsTer12)|E:NPM1:ENSP00000341168.6:p.(Trp259CysfsTer12)|R:NPM1:XP_005265976.1:p.(Trp280CysfsTer12);downstream_gene_variant:R:NPM1:XM_005265920.1|R:NPM1:NM_001037738.2|E:NPM1:ENST00000393820.2	protein_changes:frameshift_variant|class	NA	all_exons;IS:exons[4-6,8,10]	.	.	include	no_recurrence_data	.	.
CL-AcroMetrix	PTEN	ENST00000371953	NM_000314	10:89717769	TA>T	c.800del	exon7	K267fs	Lys267ArgfsTer9	c.800del:exon7:K267fs:Lys267ArgfsTer9	frameshift_variant	792	0.155	NA	NA	NA	NA	NA	rs121913289	92828	NA	NA	NA	NA	NA	Colon_Adenocarcinoma:_1.8%_(7/399)|Stomach_Adenocarcinoma:_1.8%_(8/437)|Uterine_Corpus_Endometrial_Carcinoma:_1.7%_(9/530)|Cervical_Squamous_Cell_Carcinoma_and_Endocervical_Adenocarcinoma:_0.3%_(1/289)|Breast_Invasive_Carcinoma:_0.2%_(2/986)	MELA-AU/Metastatic/1/60/0.0167	T:69+2+1+0=72/461|N:23+0+0+0=23/104|A:92+2+1+0=95/565	NA	PI3K	NA	[HC]_1.964/1.928_NA	TIER_3	Pathogenic	Pathogenic	SOM	C2_domain_of_PTEN_tumour-suppressor_protein	NA	frameshift_variant:E:PTEN:Canonical:ENSP00000361021.3:p.(Lys267ArgfsTer9)|R:PTEN:NP_000305.3:p.(Lys267ArgfsTer9)|R:PTEN:Canonical:NP_000305.3:p.(Lys267ArgfsTer9)|R:PTEN:NP_001291647.1:p.(Lys70ArgfsTer9)|R:PTEN:NP_001291646.2:p.(Lys440ArgfsTer9)	CPSR_classification|protein_changes:frameshift_variant|ClinVar_classification|class	NA	IS:all_exons	.	.	include	variant_in_more_than_10%_of_tumor_samples_(14.97%)_with_VAF_under_0.01	.	.
CL-AcroMetrix	PTEN	ENST00000371953	NM_000314	10:89720798	GTACT>G	c.955_958del	exon8	T319X	Thr319Ter	c.955_958del:exon8:T319X:Thr319Ter	frameshift_variant	780	0.199	NA	NA	NA	NA	NA	rs146650273	71118	NA	NA	NA	NA	NA	Uterine_Corpus_Endometrial_Carcinoma:_2.6%_(14/530)|Glioblastoma_Multiforme:_1%_(4/393)|Esophageal_Carcinoma:_0.5%_(1/184)|Stomach_Adenocarcinoma:_0.5%_(2/437)|Breast_Invasive_Carcinoma:_0.3%_(3/986)|Cervical_Squamous_Cell_Carcinoma_and_Endocervical_Adenocarcinoma:_0.3%_(1/289)|Kidney_Renal_Clear_Cell_Carcinoma:_0.3%_(1/336)	BRCA-EU/Primary/2/76/0.0263	T:0+0+1+0=1/462|N:0+0+0+0=0/104|A:0+0+1+0=1/566	NA	PI3K	NA	[HC]_1.964/1.928_NA	TIER_3	Pathogenic	Pathogenic	SOM	C2_domain_of_PTEN_tumour-suppressor_protein	NA	frameshift_variant:E:PTEN:Canonical:ENSP00000361021.3:p.(Thr319Ter)|R:PTEN:NP_000305.3:p.(Thr319Ter)|R:PTEN:Canonical:NP_000305.3:p.(Thr319Ter)|R:PTEN:NP_001291647.1:p.(Thr122Ter)|R:PTEN:NP_001291646.2:p.(Thr492Ter)	CPSR_classification|protein_changes:frameshift_variant|ClinVar_classification|class	NA	IS:all_exons	.	.	include	.	.	.
CL-AcroMetrix	PTEN	ENST00000371953	NM_000314	10:89725056	TTC>T	c.1040_1041del	exon9	F347fs	Phe347TyrfsTer13	c.1040_1041del:exon9:F347fs:Phe347TyrfsTer13	frameshift_variant	638	0.114	NA	NA	NA	NA	COSV64307084	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	PI3K	NA	[HC]_1.964/1.928_NA	TIER_3	Pathogenic	NA	SOM	C2_domain_of_PTEN_tumour-suppressor_protein	NA	frameshift_variant:E:PTEN:Canonical:ENSP00000361021.3:p.(Phe347TyrfsTer13)|R:PTEN:NP_000305.3:p.(Phe347TyrfsTer13)|R:PTEN:Canonical:NP_000305.3:p.(Phe347TyrfsTer13)|R:PTEN:NP_001291647.1:p.(Phe150TyrfsTer13)|R:PTEN:NP_001291646.2:p.(Phe520TyrfsTer13)	CPSR_classification|protein_changes:frameshift_variant|class	NA	IS:all_exons	.	.	include	no_recurrence_data	.	.
CL-AcroMetrix	RB1	ENST00000267163	NM_000321	13:49033890	TAGAACATATCATC>T	c.2028_2040del	exon20	L676fs	Leu676PhefsTer16	c.2028_2040del:exon20:L676fs:Leu676PhefsTer16	frameshift_variant	1060	0.047	NA	NA	NA	NA	COSV57316145	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	CC	3_NA_NA	[non-HC]_2.194/2.388_NA	TIER_3	Pathogenic	NA	SOM	Retinoblastoma-associated_protein_B_domain	NA	frameshift_variant:R:RB1:Canonical:NP_000312.2:p.(Leu676PhefsTer16)|E:RB1:Canonical:ENSP00000267163.4:p.(Leu676PhefsTer16)	CPSR_classification|protein_changes:frameshift_variant|class	NA	IS:all_exons	.	.	include	no_recurrence_data	.	.
CL-AcroMetrix	RET	ENST00000355710	NM_020975	10:43609941	CG>C	c.1894del	exon11	E632fs	Glu632SerfsTer6	c.1894del:exon11:E632fs:Glu632SerfsTer6	frameshift_variant	1579	0.174	NA	NA	NA	NA	COSV60688897|COSV60703538|COSV60707687	NA	NA	NA	NA	NA	NA	NA	NA	NA	T:2+0+0+0=2/463|N:1+0+0+0=1/104|A:3+0+0+0=3/567	NA	RTKRAS	1_NA_NA	[HC]_2.206/2.412_NA	TIER_3	VUS	NA	SOM	NA	Sorafenib_Tosylate|Sorafenib|Alectinib|Regorafenib|Regorafenib_Hydrate|Vandetanib|Sitravatinib|Selpercatinib|Sunitinib_Malate|Motesanib|Quizartinib	frameshift_variant:E:RET:Canonical:ENSP00000347942.3:p.(Glu632SerfsTer6)|R:RET:NP_065681.1:p.(Glu632SerfsTer6)|R:RET:Canonical:NP_066124.1:p.(Glu632SerfsTer6)|E:RET:ENSP00000419080.1:p.(Glu149SerfsTer6)|E:RET:ENSP00000344798.4:p.(Glu632SerfsTer6)	protein_changes:frameshift_variant|class	NA	introns[7-8],all_exons;IS:introns[9-11],exons[11,13-16]	.	.	include	.	.	.
CL-AcroMetrix	RET	ENST00000355710	NM_020975	10:43609946	TGTGCCGCA>T	c.1899_1906del	exon11	C634fs	Cys634GlyfsTer37	c.1899_1906del:exon11:C634fs:Cys634GlyfsTer37	frameshift_variant	1587	0.163	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	RTKRAS	1_NA_NA	[HC]_2.206/2.412_NA	TIER_3	VUS	NA	SOM	NA	Sorafenib_Tosylate|Sorafenib|Alectinib|Regorafenib|Regorafenib_Hydrate|Vandetanib|Sitravatinib|Selpercatinib|Sunitinib_Malate|Motesanib|Quizartinib	frameshift_variant:E:RET:Canonical:ENSP00000347942.3:p.(Cys634GlyfsTer37)|R:RET:NP_065681.1:p.(Cys634GlyfsTer37)|R:RET:Canonical:NP_066124.1:p.(Cys634GlyfsTer37)|E:RET:ENSP00000419080.1:p.(Cys151GlyfsTer?)|E:RET:ENSP00000344798.4:p.(Cys634GlyfsTer37)	protein_changes:frameshift_variant|class	NA	introns[7-8],all_exons;IS:introns[9-11],exons[11,13-16]	.	.	include	no_recurrence_data	.	.
CL-AcroMetrix	SMAD4	ENST00000342988	NM_005359	18:48584602	ACT>A	c.776_777del	exon6	T259fs	Thr259IlefsTer4	c.776_777del:exon6:T259fs:Thr259IlefsTer4	frameshift_variant	871	0.055	NA	NA	NA	NA	COSV61685259	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	TFGBETA	NA	[non-HC]_2.106/2.212_NA	TIER_3	Pathogenic	NA	SOM	NA	NA	downstream_gene_variant:E:SMAD4:ENST00000452201.2;frameshift_variant:E:SMAD4:Canonical:ENSP00000381452.1:p.(Thr259IlefsTer4)|E:SMAD4:ENSP00000341551.3:p.(Thr259IlefsTer4)|R:SMAD4:Canonical:NP_005350.1:p.(Thr259IlefsTer4)	CPSR_classification|protein_changes:frameshift_variant|class	NA	all_exons	.	.	include	no_recurrence_data	.	.
CL-AcroMetrix	SMAD4	ENST00000342988	NM_005359	18:48593475	T>TAC	c.1228_1229dup	exon10	Q410fs	Gln410HisfsTer6	c.1228_1229dup:exon10:Q410fs:Gln410HisfsTer6	frameshift_variant	880	0.073	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	TFGBETA	NA	[non-HC]_2.106/2.212_NA	TIER_3	Pathogenic	NA	SOM	MH2_domain	NA	frameshift_variant:E:SMAD4:Canonical:ENSP00000381452.1:p.(Gln410HisfsTer6)|E:SMAD4:ENSP00000341551.3:p.(Gln410HisfsTer6)|R:SMAD4:Canonical:NP_005350.1:p.(Gln410HisfsTer6)|E:SMAD4:ENSP00000464901.1:p.(Gln314HisfsTer6);upstream_gene_variant:E:SMAD4:ENST00000593223.1	CPSR_classification|protein_changes:frameshift_variant|class	NA	all_exons	.	.	include	no_recurrence_data	.	.
CL-AcroMetrix	SMARCB1	ENST00000263121	NA	22:24145528	C>CCCGAGGTGCTGGTCCCCAT	c.551_569dup	exon5	L191fs	Leu191GlyfsTer26	c.551_569dup:exon5:L191fs:Leu191GlyfsTer26	frameshift_variant	1383	0.038	NA	NA	NA	NA	COSV54094941	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	[non-HC]_2.142/2.284_NA	TIER_3	Pathogenic	NA	SOM	SNF5_/_SMARCB1_/_INI1	NA	frameshift_variant:R:SMARCB1:NP_001304875.1:p.(Leu200GlyfsTer26)|R:SMARCB1:Canonical:NP_003064.2:p.(Leu191GlyfsTer26)|R:SMARCB1:NP_001007469.1:p.(Leu182GlyfsTer26)|E:SMARCB1:ENSP00000388489.1:p.(Leu209GlyfsTer?)|E:SMARCB1:Canonical:ENSP00000340883.6:p.(Leu200GlyfsTer26)|R:SMARCB1:NP_003064.2:p.(Leu191GlyfsTer26)|R:SMARCB1:NP_001007469.1:p.(Leu182GlyfsTer26)|E:SMARCB1:ENSP00000263121.7:p.(Leu191GlyfsTer26)|R:SMARCB1:XP_005261775.1:p.(Leu200GlyfsTer26)|E:SMARCB1:ENSP00000383984.3:p.(Leu182GlyfsTer26)|E:SMARCB1:ENSP00000385226.3:p.(Leu145GlyfsTer26)	CPSR_classification|protein_changes:frameshift_variant|class	NA	all_exons	.	.	include	no_recurrence_data	.	.
CL-AcroMetrix	SMARCB1	ENST00000263121	NA	22:24176353	GC>G	c.1148del	exon9	P383fs	Pro383ArgfsTer100	c.1148del:exon9:P383fs:Pro383ArgfsTer100	frameshift_variant	778	0.072	NA	NA	NA	NA	COSV51955921	NA	NA	NA	NA	NA	NA	NA	NA	NA	T:20+0+0+0=20/462|N:7+0+0+0=7/104|A:27+0+0+0=27/566	NA	NA	NA	[non-HC]_2.142/2.284_NA	TIER_3	Likely_Pathogenic	NA	SOM	NA	NA	frameshift_variant:R:SMARCB1:NP_001304875.1:p.(Pro392ArgfsTer100)|R:SMARCB1:Canonical:NP_003064.2:p.(Pro383ArgfsTer100)|R:SMARCB1:NP_001007469.1:p.(Pro374ArgfsTer100)|E:SMARCB1:Canonical:ENSP00000340883.6:p.(Pro392ArgfsTer100)|R:SMARCB1:NP_003064.2:p.(Pro383ArgfsTer100)|R:SMARCB1:NP_001007469.1:p.(Pro374ArgfsTer100)|E:SMARCB1:ENSP00000263121.7:p.(Pro383ArgfsTer100)|R:SMARCB1:XP_005261775.1:p.(Pro392ArgfsTer100)|E:SMARCB1:ENSP00000383984.3:p.(Pro374ArgfsTer100)|E:SMARCB1:ENSP00000385226.3:p.(Pro337ArgfsTer?);downstream_gene_variant:E:DERL3:Canonical:ENST00000406855.3|E:DERL3:ENST00000404056.1|R:DERL3:Canonical:NM_001135751.1|R:DERL3:NM_001002862.2|R:DERL3:NM_198440.3|R:DERL3:XM_005261823.1|E:DERL3:ENST00000318109.7|E:DERL3:ENST00000476077.1|R:DERL3:XM_005261824.1|R:DERL3:XM_005261822.1|R:DERL3:XM_005261820.1|R:DERL3:XM_005261821.1	CPSR_classification|protein_changes:frameshift_variant|class	NA	all_exons	.	.	include	.	.	.
CL-AcroMetrix	STK11	ENST00000326873	NM_000455	19:1207076	TG>T	c.169del	exon1	E57fs	Glu57LysfsTer7	c.169del:exon1:E57fs:Glu57LysfsTer7	frameshift_variant	1488	0.06	NA	NA	NA	NA	NA	rs121913319	NA	NA	NA	NA	NA	NA	Lung_Adenocarcinoma:_0.4%_(2/567)|Stomach_Adenocarcinoma:_0.2%_(1/437)	NA	T:73+0+0+1=74/463|N:31+0+0+0=31/104|A:104+0+0+1=105/567	NA	PI3K	NA	[non-HC]_2.366/2.732_NA	TIER_3	Pathogenic	NA	SOM	Protein_kinase_domain	NA	frameshift_variant:E:STK11:Canonical:ENSP00000324856.6:p.(Glu57LysfsTer7)|R:STK11:Canonical:NP_000446.1:p.(Glu57LysfsTer7)|R:STK11:XP_005259675.1:p.(Glu57LysfsTer7)|R:STK11:XP_005259674.1:p.(Glu57LysfsTer7)|E:STK11:ENSP00000467912.1:p.(Glu57LysfsTer7)	CPSR_classification|protein_changes:frameshift_variant|class	NA	IS:all_exons	.	.	include	variant_in_more_than_10%_of_tumor_samples_(15.77%)_with_VAF_under_0.01	.	.
CL-AcroMetrix	TP53	ENST00000269305	NM_000546	17:7572962	GT>G	c.1146del	exon11	K382fs	Lys382AsnfsTer40	c.1146del:exon11:K382fs:Lys382AsnfsTer40	frameshift_variant	1187	0.052	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Uterine_Corpus_Endometrial_Carcinoma:_0.6%_(3/530)|Bladder_Urothelial_Carcinoma:_0.2%_(1/412)|Brain_Lower_Grade_Glioma:_0.2%_(1/509)|Stomach_Adenocarcinoma:_0.2%_(1/437)	NA	T:30+2+0+0=32/462|N:20+0+0+0=20/104|A:50+2+0+0=52/566	NA	TP53	4_c_NS	[non-HC]_2.45/2.9_NA	TIER_3	Likely_Pathogenic	NA	SOM	NA	NA	frameshift_variant:R:TP53:NP_001119587.1:p.(Lys250AsnfsTer40)|R:TP53:NP_001263626.1:p.(Lys223AsnfsTer40)|E:TP53:Canonical:ENSP00000269305.4:p.(Lys382AsnfsTer40)|R:TP53:NP_001119590.1:p.(Lys343AsnfsTer40)|R:TP53:Canonical:NP_000537.3:p.(Lys382AsnfsTer40)|R:TP53:NP_001263689.1:p.(Lys343AsnfsTer40)|R:TP53:NP_001263690.1:p.(Lys343AsnfsTer40)|R:TP53:NP_001119584.1:p.(Lys382AsnfsTer40)|E:TP53:ENSP00000391478.2:p.(Lys382AsnfsTer40)|R:TP53:XP_005256835.1:p.(Lys362AsnfsTer40);3_prime_UTR_variant:R:TP53:NM_001276699.1|R:TP53:NM_001126117.1|R:TP53:NM_001276698.1|R:TP53:NM_001126116.1|R:TP53:NM_001276696.1|R:TP53:NM_001126113.2|R:TP53:NM_001276695.1|R:TP53:NM_001126114.2|E:TP53:ENST00000455263.2|E:TP53:ENST00000420246.2|E:TP53:ENST00000576024.1;downstream_gene_variant:E:TP53:ENST00000509690.1|E:TP53:ENST00000514944.1	CPSR_classification|protein_changes:frameshift_variant|class	NA	IS:all_exons	.	.	include	.	.	.
CL-AcroMetrix	TP53	ENST00000269305	NM_000546	17:7579715	AG>A	c.80del	exon3	P27fs	Pro27LeufsTer17	c.80del:exon3:P27fs:Pro27LeufsTer17	frameshift_variant	1056	0.052	NA	NA	NA	NA	COSV52837004|COSV53662521	rs1192416464	NA	0	NA	0.0000000	NA	NA	Kidney_Chromophobe:_1.5%_(1/66)|Adrenocortical_Carcinoma:_1.1%_(1/92)|Pancreatic_Adenocarcinoma:_0.6%_(1/180)|Ovarian_Serous_Cystadenocarcinoma:_0.5%_(2/436)|Cervical_Squamous_Cell_Carcinoma_and_Endocervical_Adenocarcinoma:_0.3%_(1/289)|Colon_Adenocarcinoma:_0.3%_(1/399)|Brain_Lower_Grade_Glioma:_0.2%_(1/509)	NA	T:1+0+0+0=1/460|N:1+0+0+0=1/104|A:2+0+0+0=2/564	NA	TP53	4_c_NS	[non-HC]_2.45/2.9_NA	TIER_3	Pathogenic	NA	SOM	P53_transactivation_motif	NA	frameshift_variant:E:TP53:ENSP00000410739.2:p.(Pro27LeufsTer17)|E:TP53:ENSP00000352610.4:p.(Pro27LeufsTer17)|E:TP53:Canonical:ENSP00000269305.4:p.(Pro27LeufsTer17)|R:TP53:NP_001119585.1:p.(Pro27LeufsTer17)|R:TP53:Canonical:NP_000537.3:p.(Pro27LeufsTer17)|R:TP53:NP_001119586.1:p.(Pro27LeufsTer17)|R:TP53:NP_001119584.1:p.(Pro27LeufsTer17)|E:TP53:ENSP00000398846.2:p.(Pro27LeufsTer17)|E:TP53:ENSP00000391127.2:p.(Pro27LeufsTer17)|E:TP53:ENSP00000391478.2:p.(Pro27LeufsTer17)|R:TP53:XP_005256835.1:p.(Pro27LeufsTer17)|E:TP53:ENSP00000423862.1:p.(Pro27LeufsTer50)|E:TP53:ENSP00000424104.1:p.(Pro27LeufsTer17)|E:TP53:ENSP00000473895.1:p.(Pro27LeufsTer17)|E:TP53:ENSP00000426252.1:p.(Pro27LeufsTer17);upstream_gene_variant:R:TP53:NM_001126115.1|R:TP53:NM_001276697.1|R:TP53:NM_001276699.1|R:TP53:NM_001126117.1|R:TP53:NM_001276698.1|R:TP53:NM_001126116.1|E:TP53:ENST00000576024.1;5_prime_UTR_variant:R:TP53:NM_001276696.1|R:TP53:NM_001126118.1|R:TP53:NM_001276760.1|R:TP53:NM_001276761.1|R:TP53:NM_001276695.1	CPSR_classification|protein_changes:frameshift_variant|class	NA	IS:all_exons	.	.	include	.	.	.
CL-AcroMetrix	VHL	ENST00000256474	NM_000551	3:10183824	AC>A	c.296del	exon1	P99fs	Pro99GlnfsTer60	c.296del:exon1:P99fs:Pro99GlnfsTer60	frameshift_variant	1175	0.046	NA	NA	NA	NA	COSV56542810|COSV56543017	NA	NA	NA	NA	NA	NA	NA	NA	RECA-EU/Primary/1/74/0.0135	T:11+0+0+0=11/462|N:2+0+0+0=2/103|A:13+0+0+0=13/565	NA	NA	1_a_NA	[non-HC]_2.198/2.396_NA	TIER_3	Pathogenic	NA	SOM	VHL_beta_domain	NA	frameshift_variant:E:VHL:Canonical:ENSP00000256474.2:p.(Pro99GlnfsTer60)|R:VHL:NP_937799.1:p.(Pro99GlnfsTer19)|R:VHL:Canonical:NP_000542.1:p.(Pro99GlnfsTer60)|E:VHL:ENSP00000344757.2:p.(Pro99GlnfsTer19)	CPSR_classification|protein_changes:frameshift_variant|class	NA	all_exons	.	.	include	.	.	.
CL-AcroMetrix	VHL	ENST00000256474	NM_000551	3:10188286	CG>C	c.431del	exon2	G144fs	Gly144AspfsTer15	c.431del:exon2:G144fs:Gly144AspfsTer15	frameshift_variant	1018	0.061	NA	NA	NA	NA	COSV56544477|COSV56545017	rs869025651	223209	NA	NA	NA	NA	NA	Kidney_Renal_Clear_Cell_Carcinoma:_0.3%_(1/336)	RECA-EU/Primary/1/74/0.0135	T:1+0+0+0=1/463|N:0+0+0+0=0/104|A:1+0+0+0=1/567	NA	NA	1_a_NA	[non-HC]_2.198/2.396_NA	TIER_3	Pathogenic	Pathogenic	SOM	VHL_beta_domain	NA	frameshift_variant:E:VHL:Canonical:ENSP00000256474.2:p.(Gly144AspfsTer15)|R:VHL:Canonical:NP_000542.1:p.(Gly144AspfsTer15)	CPSR_classification|protein_changes:frameshift_variant|ClinVar_classification|class	NA	all_exons	.	.	include	.	.	.
CL-AcroMetrix	ASXL1	ENST00000375687	NM_015338	20:31022441	AG>A	c.1934del	exon13	G645fs	Gly645ValfsTer58	c.1934del:exon13:G645fs:Gly645ValfsTer58	frameshift_variant	1070	0.025	NA	NA	NA	NA	NA	rs750318549	NA	0.0002859	NA	0.0003429	NA	NA	Stomach_Adenocarcinoma:_1.1%_(5/437)|Colon_Adenocarcinoma:_0.8%_(3/399)|Thymoma:_0.8%_(1/123)|Uterine_Corpus_Endometrial_Carcinoma:_0.8%_(4/530)|Cervical_Squamous_Cell_Carcinoma_and_Endocervical_Adenocarcinoma:_0.7%_(2/289)|Esophageal_Carcinoma:_0.5%_(1/184)	LIRI-JP/Primary/1/250/0.004	T:70+369+2+0=441/463|N:6+95+0+0=101/103|A:76+464+2+0=542/566	NA	NA	NA	[non-HC]_1.99/1.98_NA	TIER_3	VUS	NA	BL	NA	NA	frameshift_variant:R:ASXL1:Canonical:NP_056153.2:p.(Gly645ValfsTer58)|E:ASXL1:Canonical:ENSP00000364839.4:p.(Gly645ValfsTer58)|E:ASXL1:ENSP00000305119.5:p.(Gly640ValfsTer58);downstream_gene_variant:E:ASXL1:ENST00000553345.1	protein_changes:frameshift_variant	recurrent_artifact	all_exons	.	.	exclude	recurrent_artifact,variant_in_more_than_10%_of_tumor_samples_(15.12%)_with_VAF_under_0.01,BL_class	.	.
CL-AcroMetrix	CDH1	ENST00000261769	NM_004360	16:68835650	GGTGTGATTACAGTCAAAAGGCCTCTACGGT>G	c.242_271del	exon3	G81_F91delinsV	Gly81_Phe91delinsVal	c.242_271del:exon3:G81_F91delinsV:Gly81_Phe91delinsVal	inframe_deletion	1211	0.053	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	[non-HC]_2.096/2.192_NA	TIER_3	VUS	NA	SOM	Cadherin_prodomain_like	NA	inframe_deletion:R:CDH1:XP_005256329.1:p.(Gly81_Phe91delinsVal)|E:CDH1:Canonical:ENSP00000261769.4:p.(Gly81_Phe91delinsVal)|R:CDH1:NP_001304113.1:p.(Gly81_Phe91delinsVal)|R:CDH1:Canonical:NP_004351.1:p.(Gly81_Phe91delinsVal)|R:CDH1:NP_004351.1:p.(Gly81_Phe91delinsVal)|E:CDH1:ENSP00000414946.2:p.(Gly81_Phe91delinsVal);5_prime_UTR_variant:R:CDH1:NM_001317185.1|R:CDH1:NM_001317186.1	class	NA	IS:all_exons	.	.	include	no_recurrence_data	.	.
CL-AcroMetrix	EGFR	ENST00000275493	NM_005228|NM_001346900	7:55242464	AGGAATTAAGAGAAGC>A	c.2235_2249del	exon19	E746_A750del	Glu746_Ala750del	c.2235_2249del:exon19:E746_A750del:Glu746_Ala750del	inframe_deletion	1281	0.145	NA	NA	NA	NA	COSV51765119	rs121913421	163343	NA	NA	NA	NA	NA	Lung_Adenocarcinoma:_2.1%_(12/567)|Lung_Squamous_Cell_Carcinoma:_0.2%_(1/492)	NA	T:0+0+1+0=1/463|N:0+0+0+0=0/104|A:0+0+1+0=1/567	NA	RTKRAS	NA	[HC]_1.916/1.832_NA	TIER_3	VUS	VUS	SOM	Protein_tyrosine_and_serine/threonine_kinase	Afatinib|Lapatinib_Ditosylate|Cetuximab|Panitumumab|Necitumumab|Neratinib|Icotinib|Afatinib_Dimaleate|Zalutumumab|Nimotuzumab|Dacomitinib|Vandetanib|Osimertinib|Pyrotinib|Tesevatinib|Rociletinib|Brigatinib|Naquotinib|EGFR/FLT3/Abl_Inhibitor_SKLB1028|Depatuxizumab_Mafodotin|Neratinib_Maleate|Amivantamab|Abivertinib|Abivertinib_Maleate|Avitinib_Maleate|Lazertinib|Aumolertinib|Mobocertinib|Erlotinib|Lapatinib|Gefitinib	downstream_gene_variant:R:EGFR:XM_005271748.1|R:EGFR:NM_201284.1|E:EGFR:ENST00000344576.2;inframe_deletion:R:EGFR:XP_005271803.1:p.(Glu701_Ala705del)|E:EGFR:ENSP00000415559.1:p.(Glu701_Ala705del)|R:EGFR:NP_001333826.1:p.(Glu701_Ala705del)|R:EGFR:NP_001333827.1:p.(Glu746_Ala750del)|R:EGFR:NP_001333870.1:p.(Glu479_Ala483del)|R:EGFR:Canonical:NP_005219.2:p.(Glu746_Ala750del)|R:EGFR:NP_001333828.1:p.(Glu701_Ala705del)|R:EGFR:NP_005219.2:p.(Glu746_Ala750del)|E:EGFR:Canonical:ENSP00000275493.2:p.(Glu746_Ala750del)|R:EGFR:XP_005271804.1:p.(Glu693_Ala697del)|R:EGFR:NP_001333829.1:p.(Glu693_Ala697del)|E:EGFR:ENSP00000395243.2:p.(Glu693_Ala697del)	class	NA	introns[15];IS:introns[7,24-27],all_exons	.	.	include	.	.	.
CL-AcroMetrix	PDGFRA	ENST00000257290	NM_001347828|NM_006206|NM_001347829|NM_001347830	4:55141051	GCCCAGATGGACATGA>G	c.1698_1712del	exon12	S566_E571delinsR	Ser566_Glu571delinsArg	c.1698_1712del:exon12:S566_E571delinsR:Ser566_Glu571delinsArg	inframe_deletion	1077	0.077	NA	NA	NA	NA	COSV57264414	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	RTKRAS	NA	[HC]_2.056/2.112_NA	TIER_3	VUS	NA	SOM	NA	Vatalanib|Pazopanib_Hydrochloride|Olaratumab|Masitinib|Regorafenib|Regorafenib_Hydrate|Crenolanib|Linifanib|Orantinib|Famitinib|Avapritinib|Ripretinib|Pazopanib|Cediranib|Nintedanib|Dovitinib|Sunitinib_Malate|Motesanib|Quizartinib|Midostaurin	inframe_deletion:R:PDGFRA:NP_001334756.1:p.(Ser566_Glu571delinsArg)|R:PDGFRA:Canonical:NP_006197.1:p.(Ser566_Glu571delinsArg)|R:PDGFRA:NP_001334757.1:p.(Ser591_Glu596delinsArg)|R:PDGFRA:NP_006197.1:p.(Ser566_Glu571delinsArg)|E:PDGFRA:Canonical:ENSP00000257290.5:p.(Ser566_Glu571delinsArg)|R:PDGFRA:XP_005265801.1:p.(Ser566_Glu571delinsArg)|R:PDGFRA:XP_005265800.1:p.(Ser566_Glu571delinsArg)|R:PDGFRA:NP_001334758.1:p.(Ser566_Glu571delinsArg)|R:PDGFRA:NP_001334759.1:p.(Ser579_Glu584delinsArg)	class	NA	all_exons;IS:introns[7,9,11],exons[12,18]	.	.	include	no_recurrence_data	.	.
CL-AcroMetrix	PTEN	ENST00000371953	NM_000314	10:89711972	AGAT>A	c.595_597del	exon6	M199del	Met199del	c.595_597del:exon6:M199del:Met199del	inframe_deletion	938	0.061	NA	NA	NA	NA	NA	rs1064793244	418437	NA	NA	NA	NA	NA	NA	NA	NA	NA	PI3K	NA	[HC]_1.964/1.928_NA	TIER_3	VUS	VUS	SOM	C2_domain_of_PTEN_tumour-suppressor_protein	NA	inframe_deletion:E:PTEN:Canonical:ENSP00000361021.3:p.(Met199del)|R:PTEN:NP_000305.3:p.(Met199del)|R:PTEN:Canonical:NP_000305.3:p.(Met199del)|R:PTEN:NP_001291646.2:p.(Met372del);5_prime_UTR_variant,coding_sequence_variant:R:PTEN:NP_001291647.1:p.(Met2del)	class	NA	IS:all_exons	.	.	include	no_recurrence_data	.	.
CL-AcroMetrix	FLT3	ENST00000241453	NM_004119	13:28608255	G>GATCATATTCATATTCTCTGAA	c.1780_1800dup	exon14	F594_D600dup	Phe594_Asp600dup	c.1780_1800dup:exon14:F594_D600dup:Phe594_Asp600dup	inframe_insertion	903	0.019	NA	NA	NA	NA	COSV54056313|COSV54065206|COSV54069334|COSV54070989	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	RTKRAS	NA	[non-HC]_2.368/2.736_NA	TIER_3	VUS	NA	SOM	NA	Sorafenib_Tosylate|Fedratinib|Sorafenib|Crenolanib|Linifanib|Gilteritinib_Fumarate|Gilteritinib|Famitinib|EGFR/FLT3/Abl_Inhibitor_SKLB1028|Pexidartinib|Pexidartinib_Hydrochloride|Dovitinib|Sunitinib_Malate|Quizartinib|Midostaurin	inframe_insertion:E:FLT3:ENSP00000241453.7:p.(Phe594_Asp600dup)|R:FLT3:Canonical:NP_004110.2:p.(Phe594_Asp600dup)|R:FLT3:XP_005266375.1:p.(Phe594_Asp600dup)|E:FLT3:Canonical:ENSP00000370369.4:p.(Phe594_Asp600dup)|R:FLT3:XP_005266376.1:p.(Phe594_Asp600dup)|E:FLT3:ENSP00000438139.1:p.(Phe594_Asp600dup)	class	LOW_TUMOR_VAF	all_exons;IS:exons[14-15,20]	.	.	exclude	LOW_TUMOR_VAF,no_recurrence_data	.	.
CL-AcroMetrix	APC	ENST00000457016	NA	5:112173930	T>C	c.2639T>C	exon16	I880T	Ile880Thr	c.2639T>C:exon16:I880T:Ile880Thr	missense_variant	1191	0.166	NA	NA	NA	NA	COSV57395661	rs1400295986	860400	0	NA	0.0000000	NA	NA	NA	NA	T:10+0+0+0=10/463|N:2+0+0+0=2/104|A:12+0+0+0=12/567	NA	WNT	3_NA_NA	[non-HC]_2.012/2.024_NA	TIER_3	VUS	VUS	SOM	NA	NA	missense_variant:R:APC:NP_001120983.2:p.(Ile862Thr)|R:APC:XP_005272032.1:p.(Ile880Thr)|E:APC:Canonical:ENSP00000413133.1:p.(Ile880Thr)|E:APC:ENSP00000423224.1:p.(Ile862Thr)|R:APC:XP_005272034.1:p.(Ile779Thr)|R:APC:Canonical:NP_000029.2:p.(Ile880Thr)|R:APC:NP_001120982.1:p.(Ile880Thr)|E:APC:ENSP00000257430.4:p.(Ile880Thr)|E:APC:ENSP00000427089.2:p.(Ile880Thr)|E:APC:ENSP00000423828.2:p.(Ile880Thr)|R:APC:XP_005272031.1:p.(Ile880Thr)|R:APC:XP_005272033.1:p.(Ile821Thr);downstream_gene_variant:E:APC:ENST00000504915.2	class	NA	IS:all_exons	.	.	include	.	.	.
CL-AcroMetrix	APC	ENST00000457016	NA	5:112174596	A>G	c.3305A>G	exon16	Y1102C	Tyr1102Cys	c.3305A>G:exon16:Y1102C:Tyr1102Cys	missense_variant	1237	0.179	NA	NA	NA	NA	NA	rs769608546	420808	4e-06	NA	0.0000000	NA	NA	NA	NA	T:6+0+0+0=6/463|N:1+0+0+0=1/104|A:7+0+0+0=7/567	NA	WNT	3_NA_NA	[non-HC]_2.012/2.024_NA	TIER_3	VUS	VUS	SOM	NA	NA	missense_variant:R:APC:NP_001120983.2:p.(Tyr1084Cys)|R:APC:XP_005272032.1:p.(Tyr1102Cys)|E:APC:Canonical:ENSP00000413133.1:p.(Tyr1102Cys)|E:APC:ENSP00000423224.1:p.(Tyr1084Cys)|R:APC:XP_005272034.1:p.(Tyr1001Cys)|R:APC:Canonical:NP_000029.2:p.(Tyr1102Cys)|R:APC:NP_001120982.1:p.(Tyr1102Cys)|E:APC:ENSP00000257430.4:p.(Tyr1102Cys)|E:APC:ENSP00000427089.2:p.(Tyr1102Cys)|E:APC:ENSP00000423828.2:p.(Tyr1102Cys)|R:APC:XP_005272031.1:p.(Tyr1102Cys)|R:APC:XP_005272033.1:p.(Tyr1043Cys);downstream_gene_variant:E:APC:ENST00000504915.2	class	NA	IS:all_exons	.	.	include	.	.	.
CL-AcroMetrix	APC	ENST00000457016	NA	5:112175354	T>C	c.4063T>C	exon16	S1355P	Ser1355Pro	c.4063T>C:exon16:S1355P:Ser1355Pro	missense_variant	1281	0.189	NA	NA	NA	NA	COSV57326400|COSV57369995	rs730881248	181804	NA	NA	NA	NA	NA	NA	NA	T:5+0+0+0=5/463|N:4+0+0+0=4/104|A:9+0+0+0=9/567	NA	WNT	3_NA_NA	[non-HC]_2.012/2.024_NA	TIER_3	VUS	VUS	SOM	NA	NA	missense_variant:R:APC:NP_001120983.2:p.(Ser1337Pro)|R:APC:XP_005272032.1:p.(Ser1355Pro)|E:APC:Canonical:ENSP00000413133.1:p.(Ser1355Pro)|R:APC:XP_005272034.1:p.(Ser1254Pro)|R:APC:Canonical:NP_000029.2:p.(Ser1355Pro)|R:APC:NP_001120982.1:p.(Ser1355Pro)|E:APC:ENSP00000257430.4:p.(Ser1355Pro)|E:APC:ENSP00000427089.2:p.(Ser1355Pro)|R:APC:XP_005272031.1:p.(Ser1355Pro)|R:APC:XP_005272033.1:p.(Ser1296Pro);downstream_gene_variant:E:APC:ENST00000507379.1|E:APC:ENST00000512211.2|E:APC:ENST00000504915.2	class	NA	IS:all_exons	.	.	include	.	.	.
CL-AcroMetrix	APC	ENST00000457016	NA	5:112175432	C>T	c.4141C>T	exon16	P1381S	Pro1381Ser	c.4141C>T:exon16:P1381S:Pro1381Ser	missense_variant	1298	0.18	NA	NA	NA	NA	COSV57324510|COSV99970014	NA	1019943	NA	NA	NA	NA	NA	NA	NA	T:49+0+0+0=49/463|N:4+0+0+0=4/104|A:53+0+0+0=53/567	NA	WNT	3_NA_NA	[non-HC]_2.012/2.024_NA	TIER_3	VUS	VUS	SOM	APC_repeat	NA	missense_variant:R:APC:NP_001120983.2:p.(Pro1363Ser)|R:APC:XP_005272032.1:p.(Pro1381Ser)|E:APC:Canonical:ENSP00000413133.1:p.(Pro1381Ser)|R:APC:XP_005272034.1:p.(Pro1280Ser)|R:APC:Canonical:NP_000029.2:p.(Pro1381Ser)|R:APC:NP_001120982.1:p.(Pro1381Ser)|E:APC:ENSP00000257430.4:p.(Pro1381Ser)|E:APC:ENSP00000427089.2:p.(Pro1381Ser)|R:APC:XP_005272031.1:p.(Pro1381Ser)|R:APC:XP_005272033.1:p.(Pro1322Ser);downstream_gene_variant:E:APC:ENST00000507379.1|E:APC:ENST00000512211.2|E:APC:ENST00000504915.2	class	NA	IS:all_exons	.	.	include	variant_in_more_than_10%_of_tumor_samples_(10.58%)_with_VAF_under_0.01	.	.
CL-AcroMetrix	APC	ENST00000457016	NA	5:112176117	C>T	c.4826C>T	exon16	P1609L	Pro1609Leu	c.4826C>T:exon16:P1609L:Pro1609Leu	missense_variant	1179	0.161	NA	NA	NA	NA	COSV57360712	NA	NA	NA	NA	NA	NA	NA	NA	NA	T:38+0+0+0=38/463|N:1+0+0+0=1/104|A:39+0+0+0=39/567	NA	WNT	3_NA_NA	[non-HC]_2.012/2.024_NA	TIER_3	VUS	NA	SOM	NA	NA	missense_variant:R:APC:NP_001120983.2:p.(Pro1591Leu)|R:APC:XP_005272032.1:p.(Pro1609Leu)|E:APC:Canonical:ENSP00000413133.1:p.(Pro1609Leu)|R:APC:XP_005272034.1:p.(Pro1508Leu)|R:APC:Canonical:NP_000029.2:p.(Pro1609Leu)|R:APC:NP_001120982.1:p.(Pro1609Leu)|E:APC:ENSP00000257430.4:p.(Pro1609Leu)|E:APC:ENSP00000427089.2:p.(Pro1609Leu)|R:APC:XP_005272031.1:p.(Pro1609Leu)|R:APC:XP_005272033.1:p.(Pro1550Leu);downstream_gene_variant:E:APC:ENST00000507379.1|E:APC:ENST00000512211.2|E:APC:ENST00000504915.2	class	NA	IS:all_exons	.	.	include	.	.	.
CL-AcroMetrix	ATM	ENST00000278616	NA	11:108170479	G>T	c.5044G>T	exon34	D1682Y	Asp1682Tyr	c.5044G>T:exon34:D1682Y:Asp1682Tyr	missense_variant	816	0.077	NA	NA	NA	NA	COSV53728454|COSV53735978	NA	NA	NA	NA	NA	NA	NA	Rectum_Adenocarcinoma:_0.7%_(1/137)	NA	T:21+0+0+0=21/463|N:3+0+0+0=3/104|A:24+0+0+0=24/567	NA	TP53	NA	[HC]_2.122/2.244_NA	TIER_3	VUS	NA	SOM	NA	Iniparib	missense_variant:E:ATM:Canonical:ENSP00000278616.4:p.(Asp1682Tyr)|R:ATM:Canonical:NP_000042.3:p.(Asp1682Tyr)|E:ATM:ENSP00000388058.2:p.(Asp1682Tyr)|R:ATM:XP_005271619.1:p.(Asp1682Tyr)|R:ATM:XP_005271618.1:p.(Asp1682Tyr)|R:ATM:XP_005271620.1:p.(Asp1682Tyr)|R:ATM:XP_005271621.1:p.(Asp1334Tyr);downstream_gene_variant:E:ATM:ENST00000531525.2	class	NA	IS:all_exons	.	.	include	.	.	.
CL-AcroMetrix	ATM	ENST00000278616	NA	11:108170587	C>G	c.5152C>G	exon34	L1718V	Leu1718Val	c.5152C>G:exon34:L1718V:Leu1718Val	missense_variant	762	0.081	NA	NA	NA	NA	COSV53751724	NA	NA	NA	NA	NA	NA	NA	NA	NA	T:7+0+0+0=7/463|N:2+0+0+0=2/104|A:9+0+0+0=9/567	NA	TP53	NA	[HC]_2.122/2.244_NA	TIER_3	VUS	NA	SOM	NA	Iniparib	missense_variant:E:ATM:Canonical:ENSP00000278616.4:p.(Leu1718Val)|R:ATM:Canonical:NP_000042.3:p.(Leu1718Val)|E:ATM:ENSP00000388058.2:p.(Leu1718Val)|R:ATM:XP_005271619.1:p.(Leu1718Val)|R:ATM:XP_005271618.1:p.(Leu1718Val)|R:ATM:XP_005271620.1:p.(Leu1718Val)|R:ATM:XP_005271621.1:p.(Leu1370Val);downstream_gene_variant:E:ATM:ENST00000531525.2	class	NA	IS:all_exons	.	.	include	.	.	.
CL-AcroMetrix	ATM	ENST00000278616	NA	11:108172421	G>C	c.5224G>C	exon35	A1742P	Ala1742Pro	c.5224G>C:exon35:A1742P:Ala1742Pro	missense_variant	824	0.062	NA	NA	NA	NA	COSV53744526	NA	NA	NA	NA	NA	NA	NA	NA	NA	T:7+0+0+0=7/463|N:4+0+0+0=4/104|A:11+0+0+0=11/567	NA	TP53	NA	[HC]_2.122/2.244_NA	TIER_3	VUS	NA	SOM	NA	Iniparib	missense_variant:E:ATM:Canonical:ENSP00000278616.4:p.(Ala1742Pro)|R:ATM:Canonical:NP_000042.3:p.(Ala1742Pro)|E:ATM:ENSP00000388058.2:p.(Ala1742Pro)|R:ATM:XP_005271619.1:p.(Ala1742Pro)|R:ATM:XP_005271618.1:p.(Ala1742Pro)|R:ATM:XP_005271620.1:p.(Ala1742Pro)|R:ATM:XP_005271621.1:p.(Ala1394Pro)	class	NA	IS:all_exons	.	.	include	.	.	.
CL-AcroMetrix	ATM	ENST00000278616	NA	11:108173736	T>G	c.5476T>G	exon36	L1826V	Leu1826Val	c.5476T>G:exon36:L1826V:Leu1826Val	missense_variant	671	0.061	NA	NA	NA	NA	COSV53758822	rs1555106563	576923	NA	NA	NA	NA	NA	NA	NA	T:1+0+0+0=1/463|N:1+0+0+0=1/104|A:2+0+0+0=2/567	NA	TP53	NA	[HC]_2.122/2.244_NA	TIER_3	VUS	VUS	SOM	NA	Iniparib	missense_variant:E:ATM:Canonical:ENSP00000278616.4:p.(Leu1826Val)|R:ATM:Canonical:NP_000042.3:p.(Leu1826Val)|E:ATM:ENSP00000388058.2:p.(Leu1826Val)|R:ATM:XP_005271619.1:p.(Leu1826Val)|R:ATM:XP_005271618.1:p.(Leu1826Val)|R:ATM:XP_005271620.1:p.(Leu1826Val)|R:ATM:XP_005271621.1:p.(Leu1478Val)	class	NA	IS:all_exons	.	.	include	.	.	.
CL-AcroMetrix	ATM	ENST00000278616	NA	11:108200958	A>C	c.7325A>C	exon50	Q2442P	Gln2442Pro	c.7325A>C:exon50:Q2442P:Gln2442Pro	missense_variant	734	0.082	NA	NA	NA	NA	COSV53725662|COSV53766264	NA	NA	NA	NA	NA	NA	NA	NA	LIRI-JP/Primary/1/250/0.004	T:1+0+0+0=1/463|N:0+0+0+0=0/104|A:1+0+0+0=1/567	NA	TP53	NA	[HC]_2.122/2.244_NA	TIER_3	VUS	NA	SOM	FAT_domain	Iniparib	missense_variant:E:ATM:Canonical:ENSP00000278616.4:p.(Gln2442Pro)|R:ATM:Canonical:NP_000042.3:p.(Gln2442Pro)|E:ATM:ENSP00000388058.2:p.(Gln2442Pro)|R:ATM:XP_005271619.1:p.(Gln2442Pro)|R:ATM:XP_005271618.1:p.(Gln2442Pro)|R:ATM:XP_005271620.1:p.(Gln2442Pro)|R:ATM:XP_005271621.1:p.(Gln2094Pro);downstream_gene_variant:R:C11orf65:XM_005271415.1|E:C11orf65:ENST00000524755.1|R:C11orf65:XM_005271414.1	class	NA	IS:all_exons	.	.	include	.	.	.
CL-AcroMetrix	ATM	ENST00000278616	NA	11:108204681	A>G	c.7996A>G	exon54	T2666A	Thr2666Ala	c.7996A>G:exon54:T2666A:Thr2666Ala	missense_variant	662	0.074	NA	NA	NA	NA	COSV53768095	rs745775382	219594	8e-06	NA	0.0000176	NA	NA	NA	NA	T:2+0+0+0=2/461|N:1+0+0+0=1/104|A:3+0+0+0=3/565	NA	TP53	NA	[HC]_2.122/2.244_NA	TIER_3	VUS	VUS	SOM	NA	Iniparib	missense_variant:E:ATM:Canonical:ENSP00000278616.4:p.(Thr2666Ala)|R:ATM:Canonical:NP_000042.3:p.(Thr2666Ala)|E:ATM:ENSP00000388058.2:p.(Thr2666Ala)|R:ATM:XP_005271619.1:p.(Thr2666Ala)|R:ATM:XP_005271618.1:p.(Thr2666Ala)|R:ATM:XP_005271620.1:p.(Thr2666Ala)|R:ATM:XP_005271621.1:p.(Thr2318Ala)	class	NA	IS:all_exons	.	.	include	.	.	.
CL-AcroMetrix	ATM	ENST00000278616	NA	11:108205769	G>C	c.8084G>C	exon55	G2695A	Gly2695Ala	c.8084G>C:exon55:G2695A:Gly2695Ala	missense_variant	849	0.066	NA	NA	NA	NA	COSV53725384|COSV53751353	rs1060501680	636708	NA	NA	NA	NA	NA	NA	NA	T:8+0+0+0=8/463|N:1+0+0+0=1/104|A:9+0+0+0=9/567	NA	TP53	NA	[HC]_2.122/2.244_NA	TIER_3	VUS	VUS	SOM	NA	Iniparib	missense_variant:E:ATM:Canonical:ENSP00000278616.4:p.(Gly2695Ala)|R:ATM:Canonical:NP_000042.3:p.(Gly2695Ala)|E:ATM:ENSP00000388058.2:p.(Gly2695Ala)|R:ATM:XP_005271619.1:p.(Gly2695Ala)|R:ATM:XP_005271618.1:p.(Gly2695Ala)|R:ATM:XP_005271620.1:p.(Gly2695Ala)|R:ATM:XP_005271621.1:p.(Gly2347Ala)	class	NA	IS:all_exons	.	.	include	.	.	.
CL-AcroMetrix	ATM	ENST00000278616	NA	11:108205780	C>A	c.8095C>A	exon55	P2699T	Pro2699Thr	c.8095C>A:exon55:P2699T:Pro2699Thr	missense_variant	817	0.06	NA	NA	NA	NA	COSV53743560|COSV53753572	NA	NA	NA	NA	NA	NA	NA	NA	NA	T:23+1+0+0=24/463|N:4+0+0+0=4/104|A:27+1+0+0=28/567	NA	TP53	NA	[HC]_2.122/2.244_NA	TIER_3	VUS	NA	SOM	NA	Iniparib	missense_variant:E:ATM:Canonical:ENSP00000278616.4:p.(Pro2699Thr)|R:ATM:Canonical:NP_000042.3:p.(Pro2699Thr)|E:ATM:ENSP00000388058.2:p.(Pro2699Thr)|R:ATM:XP_005271619.1:p.(Pro2699Thr)|R:ATM:XP_005271618.1:p.(Pro2699Thr)|R:ATM:XP_005271620.1:p.(Pro2699Thr)|R:ATM:XP_005271621.1:p.(Pro2351Thr)	class	NA	IS:all_exons	.	.	include	.	.	.
CL-AcroMetrix	ATM	ENST00000278616	NA	11:108206594	A>T	c.8174A>T	exon56	D2725V	Asp2725Val	c.8174A>T:exon56:D2725V:Asp2725Val	missense_variant	796	0.083	NA	NA	NA	NA	COSV53728899|COSV53751109	NA	1043376	NA	NA	NA	NA	NA	NA	NA	T:10+0+0+0=10/463|N:4+0+0+0=4/104|A:14+0+0+0=14/567	NA	TP53	NA	[HC]_2.122/2.244_NA	TIER_3	VUS	VUS	SOM	Phosphatidylinositol_3-_and_4-kinase	Iniparib	missense_variant:E:ATM:Canonical:ENSP00000278616.4:p.(Asp2725Val)|R:ATM:Canonical:NP_000042.3:p.(Asp2725Val)|E:ATM:ENSP00000388058.2:p.(Asp2725Val)|R:ATM:XP_005271619.1:p.(Asp2725Val)|R:ATM:XP_005271618.1:p.(Asp2725Val)|R:ATM:XP_005271620.1:p.(Asp2725Val)|R:ATM:XP_005271621.1:p.(Asp2377Val)	class	NA	IS:all_exons	.	.	include	.	.	.
CL-AcroMetrix	ATM	ENST00000278616	NA	11:108225590	A>T	c.8839A>T	exon61	T2947S	Thr2947Ser	c.8839A>T:exon61:T2947S:Thr2947Ser	missense_variant	736	0.096	NA	NA	NA	NA	COSV53724756|COSV53741956	rs760950400	941310	0	NA	0.0000000	NA	NA	NA	NA	T:9+0+0+0=9/463|N:3+0+0+0=3/104|A:12+0+0+0=12/567	NA	TP53	NA	[HC]_2.122/2.244_NA	TIER_3	VUS	VUS	SOM	Phosphatidylinositol_3-_and_4-kinase	Iniparib	missense_variant:E:ATM:Canonical:ENSP00000278616.4:p.(Thr2947Ser)|R:ATM:Canonical:NP_000042.3:p.(Thr2947Ser)|E:ATM:ENSP00000388058.2:p.(Thr2947Ser)|R:ATM:XP_005271619.1:p.(Thr2947Ser)|R:ATM:XP_005271618.1:p.(Thr2947Ser)|R:ATM:XP_005271620.1:p.(Thr2947Ser)|R:ATM:XP_005271621.1:p.(Thr2599Ser)	class	NA	IS:all_exons	.	.	include	.	.	.
CL-AcroMetrix	BRAF	ENST00000288602	NA	7:140481417	C>A	c.1391G>T	exon11	G464V	Gly464Val	c.1391G>T:exon11:G464V:Gly464Val	missense_variant	1030	0.13	NA	NA	NA	NA	COSV56066746|COSV56075378	rs121913348	40364	NA	NA	NA	NA	NA	Lung_Adenocarcinoma:_0.2%_(1/567)	NA	T:31+0+0+0=31/463|N:6+0+0+0=6/104|A:37+0+0+0=37/567	BRAF:p.G464V:ENST00000288602:CTAT_POPULATION|CTAT_CANCER|3D_STRUCTURE	RTKRAS	NA	[HC]_1.804/1.608_NA	TIER_3	VUS	Likely_Pathogenic	SOM	Protein_tyrosine_and_serine/threonine_kinase	Sorafenib_Tosylate|Vemurafenib|Sorafenib|Regorafenib|Regorafenib_Hydrate|Dabrafenib|Dabrafenib_Mesylate|Encorafenib	missense_variant:R:BRAF:XP_005250104.1:p.(Gly464Val)|E:BRAF:ENSP00000419060.1:p.(Gly72Val)|R:BRAF:XP_005250103.1:p.(Gly464Val)|R:BRAF:XP_005250102.1:p.(Gly464Val)|R:BRAF:Canonical:NP_004324.2:p.(Gly464Val)|E:BRAF:Canonical:ENSP00000288602.6:p.(Gly464Val)	ClinVar_classification|class	NA	all_exons,introns[7-10];IS:exons[11-18]	.	.	include	.	.	.
CL-AcroMetrix	BRAF	ENST00000288602	NA	7:140481478	G>A	c.1330C>T	exon11	R444W	Arg444Trp	c.1330C>T:exon11:R444W:Arg444Trp	missense_variant	874	0.129	NA	NA	NA	NA	COSV56083156	rs121913371	376074	4e-06	NA	0.0000000	NA	NA	NA	NA	T:135+1+0+0=136/463|N:2+0+0+0=2/104|A:137+1+0+0=138/567	NA	RTKRAS	NA	[HC]_1.804/1.608_NA	TIER_3	VUS	Likely_Pathogenic	SOM	NA	Sorafenib_Tosylate|Vemurafenib|Sorafenib|Regorafenib|Regorafenib_Hydrate|Dabrafenib|Dabrafenib_Mesylate|Encorafenib	missense_variant:R:BRAF:XP_005250104.1:p.(Arg444Trp)|E:BRAF:ENSP00000419060.1:p.(Arg52Trp)|R:BRAF:XP_005250103.1:p.(Arg444Trp)|R:BRAF:XP_005250102.1:p.(Arg444Trp)|R:BRAF:Canonical:NP_004324.2:p.(Arg444Trp)|E:BRAF:Canonical:ENSP00000288602.6:p.(Arg444Trp)	ClinVar_classification|class	NA	all_exons,introns[7-10];IS:exons[11-18]	.	.	include	variant_in_more_than_10%_of_tumor_samples_(29.16%)_with_VAF_under_0.01	.	.
CL-AcroMetrix	CDH1	ENST00000261769	NM_004360	16:68846087	A>G	c.1058A>G	exon8	E353G	Glu353Gly	c.1058A>G:exon8:E353G:Glu353Gly	missense_variant	1158	0.048	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	T:14+0+0+0=14/463|N:2+0+0+0=2/104|A:16+0+0+0=16/567	NA	NA	NA	[non-HC]_2.096/2.192_NA	TIER_3	VUS	NA	SOM	Cadherin_domain	NA	missense_variant:R:CDH1:XP_005256329.1:p.(Glu353Gly)|E:CDH1:Canonical:ENSP00000261769.4:p.(Glu353Gly)|R:CDH1:NP_001304113.1:p.(Glu353Gly)|R:CDH1:Canonical:NP_004351.1:p.(Glu353Gly)|R:CDH1:NP_004351.1:p.(Glu353Gly)|E:CDH1:ENSP00000414946.2:p.(Glu353Gly);5_prime_UTR_variant:R:CDH1:NM_001317185.1|R:CDH1:NM_001317186.1	class	NA	IS:all_exons	.	.	include	.	.	.
CL-AcroMetrix	CDH1	ENST00000261769	NM_004360	16:68846137	G>C	c.1108G>C	exon8	D370H	Asp370His	c.1108G>C:exon8:D370H:Asp370His	missense_variant	1101	0.05	NA	NA	NA	NA	COSV55736502|COSV55745161	NA	NA	NA	NA	NA	NA	NA	NA	NA	T:15+0+0+0=15/463|N:2+0+0+0=2/104|A:17+0+0+0=17/567	NA	NA	NA	[non-HC]_2.096/2.192_NA	TIER_3	VUS	NA	SOM	NA	NA	missense_variant:R:CDH1:XP_005256329.1:p.(Asp370His)|E:CDH1:Canonical:ENSP00000261769.4:p.(Asp370His)|R:CDH1:NP_001304113.1:p.(Asp370His)|R:CDH1:Canonical:NP_004351.1:p.(Asp370His)|R:CDH1:NP_004351.1:p.(Asp370His)|E:CDH1:ENSP00000414946.2:p.(Asp370His);5_prime_UTR_variant:R:CDH1:NM_001317185.1|R:CDH1:NM_001317186.1	class	NA	IS:all_exons	.	.	include	.	.	.
CL-AcroMetrix	CDH1	ENST00000261769	NM_004360	16:68847282	G>A	c.1204G>A	exon9	D402N	Asp402Asn	c.1204G>A:exon9:D402N:Asp402Asn	missense_variant	1155	0.061	NA	NA	NA	NA	COSV55731369|COSV55732870|COSV55741714	NA	NA	NA	NA	NA	NA	NA	NA	NA	T:49+0+0+0=49/463|N:1+0+0+0=1/104|A:50+0+0+0=50/567	NA	NA	NA	[non-HC]_2.096/2.192_NA	TIER_3	VUS	NA	SOM	Cadherin_domain	NA	missense_variant:E:CDH1:Canonical:ENSP00000261769.4:p.(Asp402Asn)|R:CDH1:Canonical:NP_004351.1:p.(Asp402Asn)|R:CDH1:NP_004351.1:p.(Asp402Asn);5_prime_UTR_variant:R:CDH1:NM_001317185.1|R:CDH1:NM_001317186.1	class	NA	IS:all_exons	.	.	include	variant_in_more_than_10%_of_tumor_samples_(10.58%)_with_VAF_under_0.01	.	.
CL-AcroMetrix	CDH1	ENST00000261769	NM_004360	16:68855934	T>C	c.1742T>C	exon12	L581P	Leu581Pro	c.1742T>C:exon12:L581P:Leu581Pro	missense_variant	1166	0.063	NA	NA	NA	NA	COSV55745760	NA	NA	NA	NA	NA	NA	NA	NA	NA	T:7+0+0+0=7/463|N:5+0+0+0=5/104|A:12+0+0+0=12/567	NA	NA	NA	[non-HC]_2.096/2.192_NA	TIER_3	VUS	NA	SOM	Cadherin_domain	NA	missense_variant:R:CDH1:XP_005256329.1:p.(Leu520Pro)|E:CDH1:Canonical:ENSP00000261769.4:p.(Leu581Pro)|R:CDH1:NP_001304113.1:p.(Leu520Pro)|R:CDH1:NP_001304114.1:p.(Leu65Pro)|R:CDH1:Canonical:NP_004351.1:p.(Leu581Pro)|R:CDH1:NP_004351.1:p.(Leu581Pro)|E:CDH1:ENSP00000414946.2:p.(Leu520Pro);5_prime_UTR_variant:R:CDH1:NM_001317186.1	class	NA	IS:all_exons	.	.	include	.	.	.
CL-AcroMetrix	CDH1	ENST00000261769	NM_004360	16:68856093	C>T	c.1901C>T	exon12	A634V	Ala634Val	c.1901C>T:exon12:A634V:Ala634Val	missense_variant	1066	0.044	NA	NA	NA	NA	COSV55730231	rs121964878	12244	NA	NA	NA	NA	NA	Glioblastoma_Multiforme:_0.3%_(1/393)|Uterine_Corpus_Endometrial_Carcinoma:_0.2%_(1/530)	NA	T:106+2+0+0=108/463|N:13+0+0+0=13/104|A:119+2+0+0=121/567	NA	NA	NA	[non-HC]_2.096/2.192_NA	TIER_3	Likely_Pathogenic	Likely_Pathogenic	SOM	Cadherin_domain	NA	missense_variant:R:CDH1:XP_005256329.1:p.(Ala573Val)|E:CDH1:Canonical:ENSP00000261769.4:p.(Ala634Val)|R:CDH1:NP_001304113.1:p.(Ala573Val)|R:CDH1:NP_001304114.1:p.(Ala118Val)|R:CDH1:Canonical:NP_004351.1:p.(Ala634Val)|R:CDH1:NP_004351.1:p.(Ala634Val)|E:CDH1:ENSP00000414946.2:p.(Ala573Val);5_prime_UTR_variant:R:CDH1:NM_001317186.1	CPSR_classification|ClinVar_classification|class	NA	IS:all_exons	.	.	include	variant_in_more_than_10%_of_tumor_samples_(22.89%)_with_VAF_under_0.01	.	.
CL-AcroMetrix	CSF1R	ENST00000286301	NM_001375321|NM_005211|NM_001375320	5:149433645	T>C	c.2906A>G	exon22	Y969C	Tyr969Cys	c.2906A>G:exon22:Y969C:Tyr969Cys	missense_variant	1190	0.18	NA	NA	NA	NA	COSV53829431|COSV53829466	rs1801271	376271	NA	NA	NA	NA	NA	NA	NA	T:10+0+0+0=10/463|N:3+0+0+0=3/104|A:13+0+0+0=13/567	NA	NA	NA	[non-HC]_2.128/2.256_NA	TIER_3	NA	NA	SOM	NA	Vatalanib|Pazopanib_Hydrochloride|Linifanib|Pexidartinib|Pexidartinib_Hydrochloride|Pazopanib|Sunitinib_Malate|Quizartinib	downstream_gene_variant:E:HMGXB3:ENST00000503427.1|R:HMGXB3:Canonical:NM_014983.2|E:HMGXB3:Canonical:ENST00000502717.1;missense_variant:R:CSF1R:NP_001275634.1:p.(Tyr969Cys)|E:CSF1R:Canonical:ENSP00000286301.3:p.(Tyr969Cys)|R:CSF1R:Canonical:NP_005202.2:p.(Tyr969Cys)|R:CSF1R:XP_005268432.1:p.(Tyr969Cys)	class	NA	all_exons	.	.	include	.	.	.
CL-AcroMetrix	CSF1R	ENST00000286301	NM_001375321|NM_005211|NM_001375320	5:149433673	C>T	c.2878G>A	exon22	A960T	Ala960Thr	c.2878G>A:exon22:A960T:Ala960Thr	missense_variant	1242	0.181	NA	NA	NA	NA	COSV53835075	rs1467770819	NA	4e-06	NA	0.0000000	NA	NA	NA	LIRI-JP/Primary/1/250/0.004	T:101+1+0+0=102/463|N:8+0+0+0=8/104|A:109+1+0+0=110/567	NA	NA	NA	[non-HC]_2.128/2.256_NA	TIER_3	NA	NA	SOM	NA	Vatalanib|Pazopanib_Hydrochloride|Linifanib|Pexidartinib|Pexidartinib_Hydrochloride|Pazopanib|Sunitinib_Malate|Quizartinib	downstream_gene_variant:E:HMGXB3:ENST00000503427.1|R:HMGXB3:Canonical:NM_014983.2|E:HMGXB3:Canonical:ENST00000502717.1;missense_variant:R:CSF1R:NP_001275634.1:p.(Ala960Thr)|E:CSF1R:Canonical:ENSP00000286301.3:p.(Ala960Thr)|R:CSF1R:Canonical:NP_005202.2:p.(Ala960Thr)|R:CSF1R:XP_005268432.1:p.(Ala960Thr)	class	NA	all_exons	.	.	include	variant_in_more_than_10%_of_tumor_samples_(21.81%)_with_VAF_under_0.01	.	.
CL-AcroMetrix	DNMT3A	ENST00000264709	NM_175629	2:25457155	C>T	c.2732G>A	exon23	C911Y	Cys911Tyr	c.2732G>A:exon23:C911Y:Cys911Tyr	missense_variant	974	0.316	NA	NA	NA	NA	COSV104585302	rs906113912	NA	NA	NA	NA	NA	NA	NA	NA	T:53+2+0+0=55/463|N:3+0+0+0=3/104|A:56+2+0+0=58/567	NA	NA	NA	[non-HC]_2.044/2.088_NA	TIER_3	NA	NA	SOM	NA	Decitabine|Azacitidine	missense_variant:R:DNMT3A:XP_005264234.1:p.(Cys688Tyr)|R:DNMT3A:XP_005264232.1:p.(Cys911Tyr)|R:DNMT3A:XP_005264233.1:p.(Cys911Tyr)|R:DNMT3A:NP_001307822.1:p.(Cys759Tyr)|R:DNMT3A:NP_715640.2:p.(Cys722Tyr)|R:DNMT3A:NP_072046.2:p.(Cys911Tyr)|R:DNMT3A:Canonical:NP_783328.1:p.(Cys911Tyr)|E:DNMT3A:ENSP00000370122.4:p.(Cys722Tyr)|E:DNMT3A:ENSP00000324375.5:p.(Cys911Tyr)|E:DNMT3A:Canonical:ENSP00000264709.3:p.(Cys911Tyr)|E:DNMT3A:ENSP00000384237.1:p.(Cys688Tyr)	class	NA	all_exons	.	.	include	variant_in_more_than_10%_of_tumor_samples_(11.45%)_with_VAF_under_0.01	.	.
CL-AcroMetrix	EGFR	ENST00000275493	NM_005228|NM_001346900	7:55211097	G>A	c.340G>A	exon3	E114K	Glu114Lys	c.340G>A:exon3:E114K:Glu114Lys	missense_variant	1109	0.162	NA	NA	NA	NA	COSV51781835	rs1219568637	1059673	NA	NA	NA	NA	NA	Rectum_Adenocarcinoma:_0.7%_(1/137)|Breast_Invasive_Carcinoma:_0.2%_(2/986)|Ovarian_Serous_Cystadenocarcinoma:_0.2%_(1/436)|Skin_Cutaneous_Melanoma:_0.2%_(1/468)	NA	T:175+2+0+0=177/463|N:4+0+0+0=4/104|A:179+2+0+0=181/567	NA	RTKRAS	NA	[HC]_1.916/1.832_NA	TIER_3	VUS	VUS	SOM	Receptor_L_domain	Afatinib|Lapatinib_Ditosylate|Cetuximab|Panitumumab|Necitumumab|Neratinib|Icotinib|Afatinib_Dimaleate|Zalutumumab|Nimotuzumab|Dacomitinib|Vandetanib|Osimertinib|Pyrotinib|Tesevatinib|Rociletinib|Brigatinib|Naquotinib|EGFR/FLT3/Abl_Inhibitor_SKLB1028|Depatuxizumab_Mafodotin|Neratinib_Maleate|Amivantamab|Abivertinib|Abivertinib_Maleate|Avitinib_Maleate|Lazertinib|Aumolertinib|Mobocertinib|Erlotinib|Lapatinib|Gefitinib	missense_variant:R:EGFR:XP_005271805.1:p.(Glu114Lys)|R:EGFR:XP_005271803.1:p.(Glu114Lys)|E:EGFR:ENSP00000415559.1:p.(Glu114Lys)|R:EGFR:NP_001333826.1:p.(Glu114Lys)|R:EGFR:NP_001333827.1:p.(Glu114Lys)|R:EGFR:Canonical:NP_005219.2:p.(Glu114Lys)|R:EGFR:NP_001333828.1:p.(Glu114Lys)|R:EGFR:NP_958440.1:p.(Glu114Lys)|E:EGFR:ENSP00000342376.3:p.(Glu114Lys)|R:EGFR:NP_958439.1:p.(Glu114Lys)|R:EGFR:NP_958441.1:p.(Glu114Lys)|R:EGFR:NP_005219.2:p.(Glu114Lys)|E:EGFR:ENSP00000345973.2:p.(Glu114Lys)|E:EGFR:ENSP00000413843.2:p.(Glu114Lys)|E:EGFR:Canonical:ENSP00000275493.2:p.(Glu114Lys)|E:EGFR:ENSP00000410031.1:p.(Glu114Lys)|E:EGFR:ENSP00000413354.1:p.(Glu61Lys)|R:EGFR:XP_005271804.1:p.(Glu61Lys)|R:EGFR:NP_001333829.1:p.(Glu61Lys)|E:EGFR:ENSP00000395243.2:p.(Glu61Lys)	class	NA	introns[15];IS:introns[7,24-27],all_exons	.	.	include	variant_in_more_than_10%_of_tumor_samples_(37.8%)_with_VAF_under_0.01	.	.
CL-AcroMetrix	EGFR	ENST00000275493	NM_005228|NM_001346900	7:55221830	G>T	c.874G>T	exon7	V292L	Val292Leu	c.874G>T:exon7:V292L:Val292Leu	missense_variant	1405	0.177	NA	NA	NA	NA	COSV51766389|COSV51769145	NA	NA	NA	NA	NA	NA	NA	NA	NA	T:31+1+0+0=32/463|N:2+0+0+0=2/104|A:33+1+0+0=34/567	NA	RTKRAS	NA	[HC]_1.916/1.832_NA	TIER_3	VUS	NA	SOM	Furin-like_cysteine_rich_region	Afatinib|Lapatinib_Ditosylate|Cetuximab|Panitumumab|Necitumumab|Neratinib|Icotinib|Afatinib_Dimaleate|Zalutumumab|Nimotuzumab|Dacomitinib|Vandetanib|Osimertinib|Pyrotinib|Tesevatinib|Rociletinib|Brigatinib|Naquotinib|EGFR/FLT3/Abl_Inhibitor_SKLB1028|Depatuxizumab_Mafodotin|Neratinib_Maleate|Amivantamab|Abivertinib|Abivertinib_Maleate|Avitinib_Maleate|Lazertinib|Aumolertinib|Mobocertinib|Erlotinib|Lapatinib|Gefitinib	missense_variant:R:EGFR:XP_005271805.1:p.(Val292Leu)|R:EGFR:XP_005271803.1:p.(Val247Leu)|E:EGFR:ENSP00000415559.1:p.(Val247Leu)|R:EGFR:NP_001333826.1:p.(Val247Leu)|R:EGFR:NP_001333827.1:p.(Val292Leu)|R:EGFR:Canonical:NP_005219.2:p.(Val292Leu)|R:EGFR:NP_001333828.1:p.(Val247Leu)|R:EGFR:NP_958440.1:p.(Val292Leu)|E:EGFR:ENSP00000342376.3:p.(Val292Leu)|R:EGFR:NP_958439.1:p.(Val292Leu)|R:EGFR:NP_958441.1:p.(Val292Leu)|R:EGFR:NP_005219.2:p.(Val292Leu)|E:EGFR:ENSP00000345973.2:p.(Val292Leu)|E:EGFR:ENSP00000413843.2:p.(Val292Leu)|E:EGFR:Canonical:ENSP00000275493.2:p.(Val292Leu)|E:EGFR:ENSP00000410031.1:p.(Val292Leu)|R:EGFR:XP_005271804.1:p.(Val239Leu)|R:EGFR:NP_001333829.1:p.(Val239Leu)|E:EGFR:ENSP00000395243.2:p.(Val239Leu)	class	NA	introns[15];IS:introns[7,24-27],all_exons	.	.	include	.	.	.
CL-AcroMetrix	EGFR	ENST00000275493	NM_005228|NM_001346900	7:55233109	G>A	c.1859G>A	exon15	C620Y	Cys620Tyr	c.1859G>A:exon15:C620Y:Cys620Tyr	missense_variant	1505	0.201	NA	NA	NA	NA	COSV51809225	rs150899403	NA	NA	NA	NA	NA	NA	Glioblastoma_Multiforme:_0.3%_(1/393)	NA	T:49+0+0+0=49/463|N:12+0+0+0=12/104|A:61+0+0+0=61/567	EGFR:p.C620Y:ENST00000342916&ENST00000344576&ENST00000275493&ENST00000442591:CTAT_POPULATION|CTAT_CANCER	RTKRAS	NA	[HC]_1.916/1.832_NA	TIER_3	VUS	NA	SOM	Growth_factor_receptor_domain_IV	Afatinib|Lapatinib_Ditosylate|Cetuximab|Panitumumab|Necitumumab|Neratinib|Icotinib|Afatinib_Dimaleate|Zalutumumab|Nimotuzumab|Dacomitinib|Vandetanib|Osimertinib|Pyrotinib|Tesevatinib|Rociletinib|Brigatinib|Naquotinib|EGFR/FLT3/Abl_Inhibitor_SKLB1028|Depatuxizumab_Mafodotin|Neratinib_Maleate|Amivantamab|Abivertinib|Abivertinib_Maleate|Avitinib_Maleate|Lazertinib|Aumolertinib|Mobocertinib|Erlotinib|Lapatinib|Gefitinib	missense_variant:R:EGFR:XP_005271805.1:p.(Cys620Tyr)|R:EGFR:XP_005271803.1:p.(Cys575Tyr)|E:EGFR:ENSP00000415559.1:p.(Cys575Tyr)|R:EGFR:NP_001333826.1:p.(Cys575Tyr)|R:EGFR:NP_001333827.1:p.(Cys620Tyr)|R:EGFR:NP_001333870.1:p.(Cys353Tyr)|R:EGFR:Canonical:NP_005219.2:p.(Cys620Tyr)|R:EGFR:NP_001333828.1:p.(Cys575Tyr)|E:EGFR:ENSP00000342376.3:p.(Cys620Tyr)|R:EGFR:NP_958439.1:p.(Cys620Tyr)|R:EGFR:NP_958441.1:p.(Cys620Tyr)|R:EGFR:NP_005219.2:p.(Cys620Tyr)|E:EGFR:ENSP00000345973.2:p.(Cys620Tyr)|E:EGFR:Canonical:ENSP00000275493.2:p.(Cys620Tyr)|E:EGFR:ENSP00000410031.1:p.(Cys620Tyr)|R:EGFR:XP_005271804.1:p.(Cys567Tyr)|R:EGFR:NP_001333829.1:p.(Cys567Tyr)|E:EGFR:ENSP00000395243.2:p.(Cys567Tyr)	class	NA	introns[15];IS:introns[7,24-27],all_exons	.	.	include	variant_in_more_than_10%_of_tumor_samples_(10.58%)_with_VAF_under_0.01	.	.
CL-AcroMetrix	EGFR	ENST00000275493	NM_005228|NM_001346900	7:55241644	G>A	c.2092G>A	exon18	A698T	Ala698Thr	c.2092G>A:exon18:A698T:Ala698Thr	missense_variant	1101	0.195	NA	NA	NA	NA	COSV51807024	NA	NA	NA	NA	NA	NA	NA	NA	NA	T:49+0+0+0=49/463|N:3+0+0+0=3/104|A:52+0+0+0=52/567	NA	RTKRAS	NA	[HC]_1.916/1.832_NA	TIER_3	VUS	NA	SOM	NA	Afatinib|Lapatinib_Ditosylate|Cetuximab|Panitumumab|Necitumumab|Neratinib|Icotinib|Afatinib_Dimaleate|Zalutumumab|Nimotuzumab|Dacomitinib|Vandetanib|Osimertinib|Pyrotinib|Tesevatinib|Rociletinib|Brigatinib|Naquotinib|EGFR/FLT3/Abl_Inhibitor_SKLB1028|Depatuxizumab_Mafodotin|Neratinib_Maleate|Amivantamab|Abivertinib|Abivertinib_Maleate|Avitinib_Maleate|Lazertinib|Aumolertinib|Mobocertinib|Erlotinib|Lapatinib|Gefitinib	downstream_gene_variant:R:EGFR:XM_005271748.1|R:EGFR:NM_201284.1|E:EGFR:ENST00000344576.2;missense_variant:R:EGFR:XP_005271803.1:p.(Ala653Thr)|E:EGFR:ENSP00000415559.1:p.(Ala653Thr)|R:EGFR:NP_001333826.1:p.(Ala653Thr)|R:EGFR:NP_001333827.1:p.(Ala698Thr)|R:EGFR:NP_001333870.1:p.(Ala431Thr)|R:EGFR:Canonical:NP_005219.2:p.(Ala698Thr)|R:EGFR:NP_001333828.1:p.(Ala653Thr)|R:EGFR:NP_005219.2:p.(Ala698Thr)|E:EGFR:Canonical:ENSP00000275493.2:p.(Ala698Thr)|R:EGFR:XP_005271804.1:p.(Ala645Thr)|R:EGFR:NP_001333829.1:p.(Ala645Thr)|E:EGFR:ENSP00000395243.2:p.(Ala645Thr)	class	NA	introns[15];IS:introns[7,24-27],all_exons	.	.	include	variant_in_more_than_10%_of_tumor_samples_(10.58%)_with_VAF_under_0.01	.	.
CL-AcroMetrix	EGFR	ENST00000275493	NM_005228|NM_001346900	7:55241722	G>A	c.2170G>A	exon18	G724S	Gly724Ser	c.2170G>A:exon18:G724S:Gly724Ser	missense_variant	1072	0.189	NA	NA	NA	NA	COSV51788393	rs1051753269	376360	NA	NA	NA	NA	NA	Brain_Lower_Grade_Glioma:_0.2%_(1/509)	NA	T:119+1+1+0=121/463|N:4+0+0+0=4/104|A:123+1+1+0=125/567	EGFR:p.G724S:ENST00000275493:CTAT_POPULATION|CTAT_CANCER|3D_STRUCTURE	RTKRAS	NA	[HC]_1.916/1.832_NA	TIER_3	VUS	VUS	SOM	Protein_tyrosine_and_serine/threonine_kinase	Afatinib|Lapatinib_Ditosylate|Cetuximab|Panitumumab|Necitumumab|Neratinib|Icotinib|Afatinib_Dimaleate|Zalutumumab|Nimotuzumab|Dacomitinib|Vandetanib|Osimertinib|Pyrotinib|Tesevatinib|Rociletinib|Brigatinib|Naquotinib|EGFR/FLT3/Abl_Inhibitor_SKLB1028|Depatuxizumab_Mafodotin|Neratinib_Maleate|Amivantamab|Abivertinib|Abivertinib_Maleate|Avitinib_Maleate|Lazertinib|Aumolertinib|Mobocertinib|Erlotinib|Lapatinib|Gefitinib	downstream_gene_variant:R:EGFR:XM_005271748.1|R:EGFR:NM_201284.1|E:EGFR:ENST00000344576.2;missense_variant:R:EGFR:XP_005271803.1:p.(Gly679Ser)|E:EGFR:ENSP00000415559.1:p.(Gly679Ser)|R:EGFR:NP_001333826.1:p.(Gly679Ser)|R:EGFR:NP_001333827.1:p.(Gly724Ser)|R:EGFR:NP_001333870.1:p.(Gly457Ser)|R:EGFR:Canonical:NP_005219.2:p.(Gly724Ser)|R:EGFR:NP_001333828.1:p.(Gly679Ser)|R:EGFR:NP_005219.2:p.(Gly724Ser)|E:EGFR:Canonical:ENSP00000275493.2:p.(Gly724Ser)|R:EGFR:XP_005271804.1:p.(Gly671Ser)|R:EGFR:NP_001333829.1:p.(Gly671Ser)|E:EGFR:ENSP00000395243.2:p.(Gly671Ser)	class	NA	introns[15];IS:introns[7,24-27],all_exons	.	.	include	variant_in_more_than_10%_of_tumor_samples_(25.7%)_with_VAF_under_0.01	.	.
CL-AcroMetrix	EGFR	ENST00000275493	NM_005228|NM_001346900	7:55242427	C>T	c.2197C>T	exon19	P733S	Pro733Ser	c.2197C>T:exon19:P733S:Pro733Ser	missense_variant	950	0.078	NA	NA	NA	NA	COSV51774667	NA	NA	NA	NA	NA	NA	NA	NA	NA	T:47+0+0+0=47/463|N:1+0+0+0=1/104|A:48+0+0+0=48/567	NA	RTKRAS	NA	[HC]_1.916/1.832_NA	TIER_3	VUS	NA	SOM	Protein_tyrosine_and_serine/threonine_kinase	Afatinib|Lapatinib_Ditosylate|Cetuximab|Panitumumab|Necitumumab|Neratinib|Icotinib|Afatinib_Dimaleate|Zalutumumab|Nimotuzumab|Dacomitinib|Vandetanib|Osimertinib|Pyrotinib|Tesevatinib|Rociletinib|Brigatinib|Naquotinib|EGFR/FLT3/Abl_Inhibitor_SKLB1028|Depatuxizumab_Mafodotin|Neratinib_Maleate|Amivantamab|Abivertinib|Abivertinib_Maleate|Avitinib_Maleate|Lazertinib|Aumolertinib|Mobocertinib|Erlotinib|Lapatinib|Gefitinib	downstream_gene_variant:R:EGFR:XM_005271748.1|R:EGFR:NM_201284.1|E:EGFR:ENST00000344576.2;missense_variant:R:EGFR:XP_005271803.1:p.(Pro688Ser)|E:EGFR:ENSP00000415559.1:p.(Pro688Ser)|R:EGFR:NP_001333826.1:p.(Pro688Ser)|R:EGFR:NP_001333827.1:p.(Pro733Ser)|R:EGFR:NP_001333870.1:p.(Pro466Ser)|R:EGFR:Canonical:NP_005219.2:p.(Pro733Ser)|R:EGFR:NP_001333828.1:p.(Pro688Ser)|R:EGFR:NP_005219.2:p.(Pro733Ser)|E:EGFR:Canonical:ENSP00000275493.2:p.(Pro733Ser)|R:EGFR:XP_005271804.1:p.(Pro680Ser)|R:EGFR:NP_001333829.1:p.(Pro680Ser)|E:EGFR:ENSP00000395243.2:p.(Pro680Ser)	class	NA	introns[15];IS:introns[7,24-27],all_exons	.	.	include	variant_in_more_than_10%_of_tumor_samples_(10.15%)_with_VAF_under_0.01	.	.
CL-AcroMetrix	EGFR	ENST00000275493	NM_005228|NM_001346900	7:55242433	G>A	c.2203G>A	exon19	G735S	Gly735Ser	c.2203G>A:exon19:G735S:Gly735Ser	missense_variant	1007	0.087	NA	NA	NA	NA	COSV51794784	rs121913430	376078	NA	NA	NA	NA	NA	NA	NA	T:78+0+0+0=78/463|N:2+0+0+0=2/104|A:80+0+0+0=80/567	NA	RTKRAS	NA	[HC]_1.916/1.832_NA	TIER_3	VUS	Likely_Pathogenic	SOM	Protein_tyrosine_and_serine/threonine_kinase	Afatinib|Lapatinib_Ditosylate|Cetuximab|Panitumumab|Necitumumab|Neratinib|Icotinib|Afatinib_Dimaleate|Zalutumumab|Nimotuzumab|Dacomitinib|Vandetanib|Osimertinib|Pyrotinib|Tesevatinib|Rociletinib|Brigatinib|Naquotinib|EGFR/FLT3/Abl_Inhibitor_SKLB1028|Depatuxizumab_Mafodotin|Neratinib_Maleate|Amivantamab|Abivertinib|Abivertinib_Maleate|Avitinib_Maleate|Lazertinib|Aumolertinib|Mobocertinib|Erlotinib|Lapatinib|Gefitinib	downstream_gene_variant:R:EGFR:XM_005271748.1|R:EGFR:NM_201284.1|E:EGFR:ENST00000344576.2;missense_variant:R:EGFR:XP_005271803.1:p.(Gly690Ser)|E:EGFR:ENSP00000415559.1:p.(Gly690Ser)|R:EGFR:NP_001333826.1:p.(Gly690Ser)|R:EGFR:NP_001333827.1:p.(Gly735Ser)|R:EGFR:NP_001333870.1:p.(Gly468Ser)|R:EGFR:Canonical:NP_005219.2:p.(Gly735Ser)|R:EGFR:NP_001333828.1:p.(Gly690Ser)|R:EGFR:NP_005219.2:p.(Gly735Ser)|E:EGFR:Canonical:ENSP00000275493.2:p.(Gly735Ser)|R:EGFR:XP_005271804.1:p.(Gly682Ser)|R:EGFR:NP_001333829.1:p.(Gly682Ser)|E:EGFR:ENSP00000395243.2:p.(Gly682Ser)	ClinVar_classification|class	NA	introns[15];IS:introns[7,24-27],all_exons	.	.	include	variant_in_more_than_10%_of_tumor_samples_(16.85%)_with_VAF_under_0.01	.	.
CL-AcroMetrix	EGFR	ENST00000275493	NM_005228|NM_001346900	7:55242452	C>T	c.2222C>T	exon19	P741L	Pro741Leu	c.2222C>T:exon19:P741L:Pro741Leu	missense_variant	1143	0.097	NA	NA	NA	NA	COSV51772347	NA	NA	NA	NA	NA	NA	NA	Sarcoma:_0.4%_(1/237)	NA	T:67+0+0+0=67/463|N:1+0+0+0=1/104|A:68+0+0+0=68/567	NA	RTKRAS	NA	[HC]_1.916/1.832_NA	TIER_3	VUS	NA	SOM	Protein_tyrosine_and_serine/threonine_kinase	Afatinib|Lapatinib_Ditosylate|Cetuximab|Panitumumab|Necitumumab|Neratinib|Icotinib|Afatinib_Dimaleate|Zalutumumab|Nimotuzumab|Dacomitinib|Vandetanib|Osimertinib|Pyrotinib|Tesevatinib|Rociletinib|Brigatinib|Naquotinib|EGFR/FLT3/Abl_Inhibitor_SKLB1028|Depatuxizumab_Mafodotin|Neratinib_Maleate|Amivantamab|Abivertinib|Abivertinib_Maleate|Avitinib_Maleate|Lazertinib|Aumolertinib|Mobocertinib|Erlotinib|Lapatinib|Gefitinib	downstream_gene_variant:R:EGFR:XM_005271748.1|R:EGFR:NM_201284.1|E:EGFR:ENST00000344576.2;missense_variant:R:EGFR:XP_005271803.1:p.(Pro696Leu)|E:EGFR:ENSP00000415559.1:p.(Pro696Leu)|R:EGFR:NP_001333826.1:p.(Pro696Leu)|R:EGFR:NP_001333827.1:p.(Pro741Leu)|R:EGFR:NP_001333870.1:p.(Pro474Leu)|R:EGFR:Canonical:NP_005219.2:p.(Pro741Leu)|R:EGFR:NP_001333828.1:p.(Pro696Leu)|R:EGFR:NP_005219.2:p.(Pro741Leu)|E:EGFR:Canonical:ENSP00000275493.2:p.(Pro741Leu)|R:EGFR:XP_005271804.1:p.(Pro688Leu)|R:EGFR:NP_001333829.1:p.(Pro688Leu)|E:EGFR:ENSP00000395243.2:p.(Pro688Leu)	class	NA	introns[15];IS:introns[7,24-27],all_exons	.	.	include	variant_in_more_than_10%_of_tumor_samples_(14.47%)_with_VAF_under_0.01	.	.
CL-AcroMetrix	EGFR	ENST00000275493	NM_005228|NM_001346900	7:55249131	G>A	c.2429G>A	exon20	G810D	Gly810Asp	c.2429G>A:exon20:G810D:Gly810Asp	missense_variant	1379	0.154	NA	NA	NA	NA	COSV51789261|COSV51836903	rs121913431	376279	NA	NA	NA	NA	NA	NA	NA	T:59+0+0+0=59/463|N:3+0+0+0=3/104|A:62+0+0+0=62/567	NA	RTKRAS	NA	[HC]_1.916/1.832_NA	TIER_3	VUS	Likely_Pathogenic	SOM	Protein_tyrosine_and_serine/threonine_kinase	Afatinib|Lapatinib_Ditosylate|Cetuximab|Panitumumab|Necitumumab|Neratinib|Icotinib|Afatinib_Dimaleate|Zalutumumab|Nimotuzumab|Dacomitinib|Vandetanib|Osimertinib|Pyrotinib|Tesevatinib|Rociletinib|Brigatinib|Naquotinib|EGFR/FLT3/Abl_Inhibitor_SKLB1028|Depatuxizumab_Mafodotin|Neratinib_Maleate|Amivantamab|Abivertinib|Abivertinib_Maleate|Avitinib_Maleate|Lazertinib|Aumolertinib|Mobocertinib|Erlotinib|Lapatinib|Gefitinib	missense_variant:R:EGFR:XP_005271803.1:p.(Gly765Asp)|E:EGFR:ENSP00000415559.1:p.(Gly765Asp)|R:EGFR:NP_001333826.1:p.(Gly765Asp)|R:EGFR:NP_001333827.1:p.(Gly810Asp)|R:EGFR:NP_001333870.1:p.(Gly543Asp)|R:EGFR:Canonical:NP_005219.2:p.(Gly810Asp)|R:EGFR:NP_001333828.1:p.(Gly765Asp)|R:EGFR:NP_005219.2:p.(Gly810Asp)|E:EGFR:Canonical:ENSP00000275493.2:p.(Gly810Asp)|R:EGFR:XP_005271804.1:p.(Gly757Asp)|R:EGFR:NP_001333829.1:p.(Gly757Asp)|E:EGFR:ENSP00000395243.2:p.(Gly757Asp)	ClinVar_classification|class	NA	introns[15];IS:introns[7,24-27],all_exons	.	.	include	variant_in_more_than_10%_of_tumor_samples_(12.74%)_with_VAF_under_0.01	.	.
CL-AcroMetrix	EGFR	ENST00000275493	NM_005228|NM_001346900	7:55249143	T>C	c.2441T>C	exon20	L814P	Leu814Pro	c.2441T>C:exon20:L814P:Leu814Pro	missense_variant	1389	0.156	NA	NA	NA	NA	COSV51773249	NA	943799	NA	NA	NA	NA	NA	NA	NA	T:16+0+0+0=16/463|N:4+0+0+0=4/104|A:20+0+0+0=20/567	NA	RTKRAS	NA	[HC]_1.916/1.832_NA	TIER_3	VUS	VUS	SOM	Protein_tyrosine_and_serine/threonine_kinase	Afatinib|Lapatinib_Ditosylate|Cetuximab|Panitumumab|Necitumumab|Neratinib|Icotinib|Afatinib_Dimaleate|Zalutumumab|Nimotuzumab|Dacomitinib|Vandetanib|Osimertinib|Pyrotinib|Tesevatinib|Rociletinib|Brigatinib|Naquotinib|EGFR/FLT3/Abl_Inhibitor_SKLB1028|Depatuxizumab_Mafodotin|Neratinib_Maleate|Amivantamab|Abivertinib|Abivertinib_Maleate|Avitinib_Maleate|Lazertinib|Aumolertinib|Mobocertinib|Erlotinib|Lapatinib|Gefitinib	missense_variant:R:EGFR:XP_005271803.1:p.(Leu769Pro)|E:EGFR:ENSP00000415559.1:p.(Leu769Pro)|R:EGFR:NP_001333826.1:p.(Leu769Pro)|R:EGFR:NP_001333827.1:p.(Leu814Pro)|R:EGFR:NP_001333870.1:p.(Leu547Pro)|R:EGFR:Canonical:NP_005219.2:p.(Leu814Pro)|R:EGFR:NP_001333828.1:p.(Leu769Pro)|R:EGFR:NP_005219.2:p.(Leu814Pro)|E:EGFR:Canonical:ENSP00000275493.2:p.(Leu814Pro)|R:EGFR:XP_005271804.1:p.(Leu761Pro)|R:EGFR:NP_001333829.1:p.(Leu761Pro)|E:EGFR:ENSP00000395243.2:p.(Leu761Pro)	class	NA	introns[15];IS:introns[7,24-27],all_exons	.	.	include	.	.	.
CL-AcroMetrix	EGFR	ENST00000275493	NM_005228|NM_001346900	7:55259427	G>A	c.2485G>A	exon21	E829K	Glu829Lys	c.2485G>A:exon21:E829K:Glu829Lys	missense_variant	1178	0.144	NA	NA	NA	NA	COSV51774325|COSV51803719	NA	NA	NA	NA	NA	NA	NA	NA	NA	T:17+0+0+0=17/463|N:2+0+0+0=2/104|A:19+0+0+0=19/567	NA	RTKRAS	NA	[HC]_1.916/1.832_NA	TIER_3	VUS	NA	SOM	Protein_tyrosine_and_serine/threonine_kinase	Afatinib|Lapatinib_Ditosylate|Cetuximab|Panitumumab|Necitumumab|Neratinib|Icotinib|Afatinib_Dimaleate|Zalutumumab|Nimotuzumab|Dacomitinib|Vandetanib|Osimertinib|Pyrotinib|Tesevatinib|Rociletinib|Brigatinib|Naquotinib|EGFR/FLT3/Abl_Inhibitor_SKLB1028|Depatuxizumab_Mafodotin|Neratinib_Maleate|Amivantamab|Abivertinib|Abivertinib_Maleate|Avitinib_Maleate|Lazertinib|Aumolertinib|Mobocertinib|Erlotinib|Lapatinib|Gefitinib	missense_variant:R:EGFR:XP_005271803.1:p.(Glu784Lys)|E:EGFR:ENSP00000415559.1:p.(Glu784Lys)|R:EGFR:NP_001333826.1:p.(Glu784Lys)|R:EGFR:NP_001333827.1:p.(Glu829Lys)|R:EGFR:NP_001333870.1:p.(Glu562Lys)|R:EGFR:Canonical:NP_005219.2:p.(Glu829Lys)|R:EGFR:NP_001333828.1:p.(Glu784Lys)|R:EGFR:NP_005219.2:p.(Glu829Lys)|E:EGFR:Canonical:ENSP00000275493.2:p.(Glu829Lys)|R:EGFR:XP_005271804.1:p.(Glu776Lys)|R:EGFR:NP_001333829.1:p.(Glu776Lys)|E:EGFR:ENSP00000395243.2:p.(Glu776Lys)	class	NA	introns[15];IS:introns[7,24-27],all_exons	.	.	include	.	.	.
CL-AcroMetrix	EGFR	ENST00000275493	NM_005228|NM_001346900	7:55259446	A>T	c.2504A>T	exon21	H835L	His835Leu	c.2504A>T:exon21:H835L:His835Leu	missense_variant	1302	0.154	NA	NA	NA	NA	COSV51777782	rs397517128	45280	NA	NA	NA	NA	NA	NA	NA	T:6+0+0+0=6/463|N:1+0+0+0=1/104|A:7+0+0+0=7/567	NA	RTKRAS	NA	[HC]_1.916/1.832_NA	TIER_3	VUS	VUS	SOM	Protein_tyrosine_and_serine/threonine_kinase	Afatinib|Lapatinib_Ditosylate|Cetuximab|Panitumumab|Necitumumab|Neratinib|Icotinib|Afatinib_Dimaleate|Zalutumumab|Nimotuzumab|Dacomitinib|Vandetanib|Osimertinib|Pyrotinib|Tesevatinib|Rociletinib|Brigatinib|Naquotinib|EGFR/FLT3/Abl_Inhibitor_SKLB1028|Depatuxizumab_Mafodotin|Neratinib_Maleate|Amivantamab|Abivertinib|Abivertinib_Maleate|Avitinib_Maleate|Lazertinib|Aumolertinib|Mobocertinib|Erlotinib|Lapatinib|Gefitinib	missense_variant:R:EGFR:XP_005271803.1:p.(His790Leu)|E:EGFR:ENSP00000415559.1:p.(His790Leu)|R:EGFR:NP_001333826.1:p.(His790Leu)|R:EGFR:NP_001333827.1:p.(His835Leu)|R:EGFR:NP_001333870.1:p.(His568Leu)|R:EGFR:Canonical:NP_005219.2:p.(His835Leu)|R:EGFR:NP_001333828.1:p.(His790Leu)|R:EGFR:NP_005219.2:p.(His835Leu)|E:EGFR:Canonical:ENSP00000275493.2:p.(His835Leu)|R:EGFR:XP_005271804.1:p.(His782Leu)|R:EGFR:NP_001333829.1:p.(His782Leu)|E:EGFR:ENSP00000395243.2:p.(His782Leu)	class	NA	introns[15];IS:introns[7,24-27],all_exons	.	.	include	.	.	.
CL-AcroMetrix	EGFR	ENST00000275493	NM_005228|NM_001346900	7:55259457	G>A	c.2515G>A	exon21	A839T	Ala839Thr	c.2515G>A:exon21:A839T:Ala839Thr	missense_variant	1377	0.149	NA	NA	NA	NA	COSV51816100	NA	NA	NA	NA	NA	NA	NA	NA	NA	T:60+0+0+0=60/463|N:4+0+0+0=4/104|A:64+0+0+0=64/567	NA	RTKRAS	NA	[HC]_1.916/1.832_NA	TIER_3	VUS	NA	SOM	Protein_tyrosine_and_serine/threonine_kinase	Afatinib|Lapatinib_Ditosylate|Cetuximab|Panitumumab|Necitumumab|Neratinib|Icotinib|Afatinib_Dimaleate|Zalutumumab|Nimotuzumab|Dacomitinib|Vandetanib|Osimertinib|Pyrotinib|Tesevatinib|Rociletinib|Brigatinib|Naquotinib|EGFR/FLT3/Abl_Inhibitor_SKLB1028|Depatuxizumab_Mafodotin|Neratinib_Maleate|Amivantamab|Abivertinib|Abivertinib_Maleate|Avitinib_Maleate|Lazertinib|Aumolertinib|Mobocertinib|Erlotinib|Lapatinib|Gefitinib	missense_variant:R:EGFR:XP_005271803.1:p.(Ala794Thr)|E:EGFR:ENSP00000415559.1:p.(Ala794Thr)|R:EGFR:NP_001333826.1:p.(Ala794Thr)|R:EGFR:NP_001333827.1:p.(Ala839Thr)|R:EGFR:NP_001333870.1:p.(Ala572Thr)|R:EGFR:Canonical:NP_005219.2:p.(Ala839Thr)|R:EGFR:NP_001333828.1:p.(Ala794Thr)|R:EGFR:NP_005219.2:p.(Ala839Thr)|E:EGFR:Canonical:ENSP00000275493.2:p.(Ala839Thr)|R:EGFR:XP_005271804.1:p.(Ala786Thr)|R:EGFR:NP_001333829.1:p.(Ala786Thr)|E:EGFR:ENSP00000395243.2:p.(Ala786Thr)	class	NA	introns[15];IS:introns[7,24-27],all_exons	.	.	include	variant_in_more_than_10%_of_tumor_samples_(12.96%)_with_VAF_under_0.01	.	.
CL-AcroMetrix	EGFR	ENST00000275493	NM_005228|NM_001346900	7:55259530	G>A	c.2588G>A	exon21	G863D	Gly863Asp	c.2588G>A:exon21:G863D:Gly863Asp	missense_variant	1343	0.137	NA	NA	NA	NA	COSV51778659|COSV51788909	rs909797662	1063910	NA	NA	NA	NA	NA	NA	NA	T:80+0+0+0=80/463|N:6+0+0+0=6/104|A:86+0+0+0=86/567	NA	RTKRAS	NA	[HC]_1.916/1.832_NA	TIER_3	VUS	VUS	SOM	Protein_tyrosine_and_serine/threonine_kinase	Afatinib|Lapatinib_Ditosylate|Cetuximab|Panitumumab|Necitumumab|Neratinib|Icotinib|Afatinib_Dimaleate|Zalutumumab|Nimotuzumab|Dacomitinib|Vandetanib|Osimertinib|Pyrotinib|Tesevatinib|Rociletinib|Brigatinib|Naquotinib|EGFR/FLT3/Abl_Inhibitor_SKLB1028|Depatuxizumab_Mafodotin|Neratinib_Maleate|Amivantamab|Abivertinib|Abivertinib_Maleate|Avitinib_Maleate|Lazertinib|Aumolertinib|Mobocertinib|Erlotinib|Lapatinib|Gefitinib	missense_variant:R:EGFR:XP_005271803.1:p.(Gly818Asp)|E:EGFR:ENSP00000415559.1:p.(Gly818Asp)|R:EGFR:NP_001333826.1:p.(Gly818Asp)|R:EGFR:NP_001333827.1:p.(Gly863Asp)|R:EGFR:NP_001333870.1:p.(Gly596Asp)|R:EGFR:Canonical:NP_005219.2:p.(Gly863Asp)|R:EGFR:NP_001333828.1:p.(Gly818Asp)|R:EGFR:NP_005219.2:p.(Gly863Asp)|E:EGFR:Canonical:ENSP00000275493.2:p.(Gly863Asp)|R:EGFR:XP_005271804.1:p.(Gly810Asp)|R:EGFR:NP_001333829.1:p.(Gly810Asp)|E:EGFR:ENSP00000395243.2:p.(Gly810Asp)	class	NA	introns[15];IS:introns[7,24-27],all_exons	.	.	include	variant_in_more_than_10%_of_tumor_samples_(17.28%)_with_VAF_under_0.01	.	.
CL-AcroMetrix	EGFR	ENST00000275493	NM_005228|NM_001346900	7:55259554	C>G	c.2612C>G	exon21	A871G	Ala871Gly	c.2612C>G:exon21:A871G:Ala871Gly	missense_variant	1128	0.146	NA	NA	NA	NA	COSV51774247|COSV51780429|COSV99292321	rs397517134	45291	NA	NA	NA	NA	NA	NA	NA	T:15+0+0+0=15/463|N:2+0+0+0=2/104|A:17+0+0+0=17/567	NA	RTKRAS	NA	[HC]_1.916/1.832_NA	TIER_3	VUS	VUS	SOM	Protein_tyrosine_and_serine/threonine_kinase	Afatinib|Lapatinib_Ditosylate|Cetuximab|Panitumumab|Necitumumab|Neratinib|Icotinib|Afatinib_Dimaleate|Zalutumumab|Nimotuzumab|Dacomitinib|Vandetanib|Osimertinib|Pyrotinib|Tesevatinib|Rociletinib|Brigatinib|Naquotinib|EGFR/FLT3/Abl_Inhibitor_SKLB1028|Depatuxizumab_Mafodotin|Neratinib_Maleate|Amivantamab|Abivertinib|Abivertinib_Maleate|Avitinib_Maleate|Lazertinib|Aumolertinib|Mobocertinib|Erlotinib|Lapatinib|Gefitinib	missense_variant:R:EGFR:XP_005271803.1:p.(Ala826Gly)|E:EGFR:ENSP00000415559.1:p.(Ala826Gly)|R:EGFR:NP_001333826.1:p.(Ala826Gly)|R:EGFR:NP_001333827.1:p.(Ala871Gly)|R:EGFR:NP_001333870.1:p.(Ala604Gly)|R:EGFR:Canonical:NP_005219.2:p.(Ala871Gly)|R:EGFR:NP_001333828.1:p.(Ala826Gly)|R:EGFR:NP_005219.2:p.(Ala871Gly)|E:EGFR:Canonical:ENSP00000275493.2:p.(Ala871Gly)|R:EGFR:XP_005271804.1:p.(Ala818Gly)|R:EGFR:NP_001333829.1:p.(Ala818Gly)|E:EGFR:ENSP00000395243.2:p.(Ala818Gly)	class	NA	introns[15];IS:introns[7,24-27],all_exons	.	.	include	.	.	.
CL-AcroMetrix	ERBB2	ENST00000269571	NM_001382787|NM_001382784|NM_001382786|NM_001382789|NM_001382788|NM_001382785|NM_004448|NM_001382796|NM_001382798|NM_001382800|NM_001382797|NM_001382805|NM_001382792|NM_001382793|NM_001382794|NM_001382795|NM_001382801|NM_001382790|NM_001382806|NM_001382802|NM_001382799|NM_001382791	17:37881378	A>G	c.2570A>G	exon21	N857S	Asn857Ser	c.2570A>G:exon21:N857S:Asn857Ser	missense_variant	1212	0.073	NA	NA	NA	NA	COSV54087177	rs28933370	13880	NA	NA	NA	NA	NA	NA	NA	T:5+0+0+0=5/463|N:2+0+0+0=2/104|A:7+0+0+0=7/567	NA	RTKRAS	NA	[HC]_2.156/2.312_NA	TIER_3	VUS	Likely_Pathogenic	SOM	Protein_tyrosine_and_serine/threonine_kinase	Afatinib|Lapatinib_Ditosylate|Trastuzumab|Neratinib|Pertuzumab|Afatinib_Dimaleate|Dacomitinib|Margetuximab|Vandetanib|Pyrotinib|Tesevatinib|Tucatinib|Neratinib_Maleate|Trastuzumab_Deruxtecan|Lapatinib	missense_variant:E:ERBB2:ENSP00000462438.1:p.(Asn827Ser)|R:ERBB2:XP_005257196.1:p.(Asn842Ser)|R:ERBB2:NP_001276865.1:p.(Asn842Ser)|R:ERBB2:NP_001005862.1:p.(Asn827Ser)|E:ERBB2:ENSP00000385185.2:p.(Asn827Ser)|R:ERBB2:NP_001005862.1:p.(Asn827Ser)|E:ERBB2:Canonical:ENSP00000446466.1:p.(Asn842Ser)|E:ERBB2:ENSP00000404047.2:p.(Asn581Ser)|R:ERBB2:NP_001276866.1:p.(Asn857Ser)|R:ERBB2:Canonical:NP_004439.2:p.(Asn857Ser)|E:ERBB2:ENSP00000443562.1:p.(Asn827Ser)|R:ERBB2:NP_004439.2:p.(Asn857Ser)|E:ERBB2:ENSP00000463714.1:p.(Asn857Ser)|E:ERBB2:ENSP00000269571.4:p.(Asn857Ser)|R:ERBB2:XP_005257197.1:p.(Asn827Ser)|E:ERBB2:ENSP00000463002.1:p.(Asn226Ser);downstream_gene_variant:E:ERBB2:ENST00000582818.1|R:MIEN1:NM_032339.4|R:MIEN1:Canonical:NM_001330206.1|R:MIEN1:NM_032339.3|R:MIEN1:XM_005257736.1|E:MIEN1:ENST00000394231.3|E:MIEN1:Canonical:ENST00000577810.1	ClinVar_classification|class	NA	IS:all_exons	.	.	include	.	.	.
CL-AcroMetrix	ERBB2	ENST00000269571	NM_001382787|NM_001382784|NM_001382786|NM_001382789|NM_001382788|NM_001382785|NM_004448|NM_001382796|NM_001382798|NM_001382800|NM_001382797|NM_001382805|NM_001382792|NM_001382793|NM_001382794|NM_001382795|NM_001382801|NM_001382790|NM_001382806|NM_001382802|NM_001382799|NM_001382791	17:37881440	C>T	c.2632C>T	exon21	H878Y	His878Tyr	c.2632C>T:exon21:H878Y:His878Tyr	missense_variant	1232	0.072	NA	NA	NA	NA	COSV54066178	NA	NA	NA	NA	NA	NA	NA	NA	NA	T:34+0+0+0=34/463|N:1+0+0+0=1/104|A:35+0+0+0=35/567	NA	RTKRAS	NA	[HC]_2.156/2.312_NA	TIER_3	VUS	NA	SOM	Protein_tyrosine_and_serine/threonine_kinase	Afatinib|Lapatinib_Ditosylate|Trastuzumab|Neratinib|Pertuzumab|Afatinib_Dimaleate|Dacomitinib|Margetuximab|Vandetanib|Pyrotinib|Tesevatinib|Tucatinib|Neratinib_Maleate|Trastuzumab_Deruxtecan|Lapatinib	missense_variant:E:ERBB2:ENSP00000462438.1:p.(His848Tyr)|R:ERBB2:XP_005257196.1:p.(His863Tyr)|R:ERBB2:NP_001276865.1:p.(His863Tyr)|R:ERBB2:NP_001005862.1:p.(His848Tyr)|E:ERBB2:ENSP00000385185.2:p.(His848Tyr)|R:ERBB2:NP_001005862.1:p.(His848Tyr)|E:ERBB2:Canonical:ENSP00000446466.1:p.(His863Tyr)|E:ERBB2:ENSP00000404047.2:p.(His602Tyr)|R:ERBB2:NP_001276866.1:p.(His878Tyr)|R:ERBB2:Canonical:NP_004439.2:p.(His878Tyr)|E:ERBB2:ENSP00000443562.1:p.(His848Tyr)|R:ERBB2:NP_004439.2:p.(His878Tyr)|E:ERBB2:ENSP00000463714.1:p.(His878Tyr)|E:ERBB2:ENSP00000269571.4:p.(His878Tyr)|R:ERBB2:XP_005257197.1:p.(His848Tyr)|E:ERBB2:ENSP00000463002.1:p.(His247Tyr);downstream_gene_variant:E:ERBB2:ENST00000582818.1|R:MIEN1:NM_032339.4|R:MIEN1:Canonical:NM_001330206.1|R:MIEN1:NM_032339.3|R:MIEN1:XM_005257736.1|E:MIEN1:ENST00000394231.3|E:MIEN1:Canonical:ENST00000577810.1	class	NA	IS:all_exons	.	.	include	.	.	.
CL-AcroMetrix	ERBB4	ENST00000342788	NM_005235	2:212288955	C>A	c.2791G>T	exon23	D931Y	Asp931Tyr	c.2791G>T:exon23:D931Y:Asp931Tyr	missense_variant	766	0.078	NA	NA	NA	NA	COSV61471929|COSV61484615	NA	NA	NA	NA	NA	NA	NA	NA	NA	T:37+0+0+0=37/463|N:4+1+0+0=5/104|A:41+1+0+0=42/567	NA	RTKRAS	NA	[non-HC]_1.798/1.596_NA	TIER_3	VUS	NA	SOM	Protein_tyrosine_and_serine/threonine_kinase	Afatinib|Neratinib|Afatinib_Dimaleate|Dacomitinib|Vandetanib|Neratinib_Maleate	missense_variant:R:ERBB4:Canonical:NP_005226.1:p.(Asp931Tyr)|R:ERBB4:NP_001036064.1:p.(Asp931Tyr)|R:ERBB4:XP_005246433.1:p.(Asp921Tyr)|R:ERBB4:XP_005246434.1:p.(Asp921Tyr)|R:ERBB4:XP_005246432.1:p.(Asp946Tyr)|E:ERBB4:Canonical:ENSP00000342235.4:p.(Asp931Tyr)|E:ERBB4:ENSP00000403204.1:p.(Asp931Tyr)|E:ERBB4:ENSP00000385565.1:p.(Asp921Tyr)	class	NA	all_exons	.	.	include	.	.	.
CL-AcroMetrix	ERBB4	ENST00000342788	NM_005235	2:212530091	G>T	c.1828C>A	exon15	P610T	Pro610Thr	c.1828C>A:exon15:P610T:Pro610Thr	missense_variant	903	0.072	NA	NA	NA	NA	COSV53520038|COSV53578775	NA	NA	NA	NA	NA	NA	NA	Lung_Adenocarcinoma:_0.2%_(1/567)	NA	T:39+1+0+0=40/463|N:6+0+0+0=6/104|A:45+1+0+0=46/567	NA	RTKRAS	NA	[non-HC]_1.798/1.596_NA	TIER_3	VUS	NA	SOM	Growth_factor_receptor_domain_IV	Afatinib|Neratinib|Afatinib_Dimaleate|Dacomitinib|Vandetanib|Neratinib_Maleate	missense_variant:R:ERBB4:Canonical:NP_005226.1:p.(Pro610Thr)|R:ERBB4:NP_001036064.1:p.(Pro610Thr)|R:ERBB4:XP_005246433.1:p.(Pro610Thr)|R:ERBB4:XP_005246434.1:p.(Pro610Thr)|R:ERBB4:XP_005246432.1:p.(Pro610Thr)|E:ERBB4:Canonical:ENSP00000342235.4:p.(Pro610Thr)|E:ERBB4:ENSP00000403204.1:p.(Pro610Thr)|E:ERBB4:ENSP00000385565.1:p.(Pro610Thr)|E:ERBB4:ENSP00000260943.6:p.(Pro610Thr)	class	NA	all_exons	.	.	include	.	.	.
CL-AcroMetrix	ERBB4	ENST00000342788	NM_005235	2:212530135	T>C	c.1784A>G	exon15	D595G	Asp595Gly	c.1784A>G:exon15:D595G:Asp595Gly	missense_variant	867	0.078	NA	NA	NA	NA	COSV53572508	NA	NA	NA	NA	NA	NA	NA	NA	NA	T:3+0+0+0=3/463|N:1+0+0+0=1/104|A:4+0+0+0=4/567	NA	RTKRAS	NA	[non-HC]_1.798/1.596_NA	TIER_3	VUS	NA	SOM	Growth_factor_receptor_domain_IV	Afatinib|Neratinib|Afatinib_Dimaleate|Dacomitinib|Vandetanib|Neratinib_Maleate	missense_variant:R:ERBB4:Canonical:NP_005226.1:p.(Asp595Gly)|R:ERBB4:NP_001036064.1:p.(Asp595Gly)|R:ERBB4:XP_005246433.1:p.(Asp595Gly)|R:ERBB4:XP_005246434.1:p.(Asp595Gly)|R:ERBB4:XP_005246432.1:p.(Asp595Gly)|E:ERBB4:Canonical:ENSP00000342235.4:p.(Asp595Gly)|E:ERBB4:ENSP00000403204.1:p.(Asp595Gly)|E:ERBB4:ENSP00000385565.1:p.(Asp595Gly)|E:ERBB4:ENSP00000260943.6:p.(Asp595Gly)	class	NA	all_exons	.	.	include	.	.	.
CL-AcroMetrix	ERBB4	ENST00000342788	NM_005235	2:212576877	G>A	c.1022C>T	exon9	S341L	Ser341Leu	c.1022C>T:exon9:S341L:Ser341Leu	missense_variant	842	0.075	NA	NA	NA	NA	COSV53544457	rs148183215	NA	NA	NA	NA	NA	NA	NA	NA	T:52+0+0+0=52/463|N:2+0+0+0=2/104|A:54+0+0+0=54/567	NA	RTKRAS	NA	[non-HC]_1.798/1.596_NA	TIER_3	VUS	NA	SOM	NA	Afatinib|Neratinib|Afatinib_Dimaleate|Dacomitinib|Vandetanib|Neratinib_Maleate	missense_variant:R:ERBB4:Canonical:NP_005226.1:p.(Ser341Leu)|R:ERBB4:NP_001036064.1:p.(Ser341Leu)|R:ERBB4:XP_005246433.1:p.(Ser341Leu)|R:ERBB4:XP_005246434.1:p.(Ser341Leu)|R:ERBB4:XP_005246432.1:p.(Ser341Leu)|E:ERBB4:Canonical:ENSP00000342235.4:p.(Ser341Leu)|E:ERBB4:ENSP00000403204.1:p.(Ser341Leu)|E:ERBB4:ENSP00000385565.1:p.(Ser341Leu)|E:ERBB4:ENSP00000260943.6:p.(Ser341Leu)	class	NA	all_exons	.	.	include	variant_in_more_than_10%_of_tumor_samples_(11.23%)_with_VAF_under_0.01	.	.
CL-AcroMetrix	ERBB4	ENST00000342788	NM_005235	2:212576896	C>A	c.1003G>T	exon9	D335Y	Asp335Tyr	c.1003G>T:exon9:D335Y:Asp335Tyr	missense_variant	793	0.063	NA	NA	NA	NA	COSV53559616	NA	NA	NA	NA	NA	NA	NA	NA	NA	T:28+3+0+0=31/463|N:4+0+0+0=4/104|A:32+3+0+0=35/567	NA	RTKRAS	NA	[non-HC]_1.798/1.596_NA	TIER_3	VUS	NA	SOM	NA	Afatinib|Neratinib|Afatinib_Dimaleate|Dacomitinib|Vandetanib|Neratinib_Maleate	missense_variant:R:ERBB4:Canonical:NP_005226.1:p.(Asp335Tyr)|R:ERBB4:NP_001036064.1:p.(Asp335Tyr)|R:ERBB4:XP_005246433.1:p.(Asp335Tyr)|R:ERBB4:XP_005246434.1:p.(Asp335Tyr)|R:ERBB4:XP_005246432.1:p.(Asp335Tyr)|E:ERBB4:Canonical:ENSP00000342235.4:p.(Asp335Tyr)|E:ERBB4:ENSP00000403204.1:p.(Asp335Tyr)|E:ERBB4:ENSP00000385565.1:p.(Asp335Tyr)|E:ERBB4:ENSP00000260943.6:p.(Asp335Tyr)	class	NA	all_exons	.	.	include	.	.	.
CL-AcroMetrix	ERBB4	ENST00000342788	NM_005235	2:212587172	G>T	c.829C>A	exon7	H277N	His277Asn	c.829C>A:exon7:H277N:His277Asn	missense_variant	773	0.107	NA	NA	NA	NA	COSV53560501	NA	NA	NA	NA	NA	NA	NA	NA	NA	T:31+0+0+0=31/463|N:3+0+0+0=3/104|A:34+0+0+0=34/567	NA	RTKRAS	NA	[non-HC]_1.798/1.596_NA	TIER_3	VUS	NA	SOM	Furin-like_cysteine_rich_region	Afatinib|Neratinib|Afatinib_Dimaleate|Dacomitinib|Vandetanib|Neratinib_Maleate	missense_variant:R:ERBB4:Canonical:NP_005226.1:p.(His277Asn)|R:ERBB4:NP_001036064.1:p.(His277Asn)|R:ERBB4:XP_005246433.1:p.(His277Asn)|R:ERBB4:XP_005246434.1:p.(His277Asn)|R:ERBB4:XP_005246432.1:p.(His277Asn)|E:ERBB4:Canonical:ENSP00000342235.4:p.(His277Asn)|E:ERBB4:ENSP00000403204.1:p.(His277Asn)|E:ERBB4:ENSP00000385565.1:p.(His277Asn)|E:ERBB4:ENSP00000260943.6:p.(His277Asn)	class	NA	all_exons	.	.	include	.	.	.
CL-AcroMetrix	ERBB4	ENST00000342788	NM_005235	2:212589812	T>C	c.730A>G	exon6	T244A	Thr244Ala	c.730A>G:exon6:T244A:Thr244Ala	missense_variant	699	0.07	NA	NA	NA	NA	NA	rs376200174	NA	4e-06	NA	0.0000088	NA	NA	NA	NA	T:7+0+0+0=7/463|N:1+0+0+0=1/104|A:8+0+0+0=8/567	NA	RTKRAS	NA	[non-HC]_1.798/1.596_NA	TIER_3	VUS	NA	SOM	Furin-like_cysteine_rich_region	Afatinib|Neratinib|Afatinib_Dimaleate|Dacomitinib|Vandetanib|Neratinib_Maleate	missense_variant:R:ERBB4:Canonical:NP_005226.1:p.(Thr244Ala)|R:ERBB4:NP_001036064.1:p.(Thr244Ala)|R:ERBB4:XP_005246433.1:p.(Thr244Ala)|R:ERBB4:XP_005246434.1:p.(Thr244Ala)|R:ERBB4:XP_005246432.1:p.(Thr244Ala)|E:ERBB4:Canonical:ENSP00000342235.4:p.(Thr244Ala)|E:ERBB4:ENSP00000403204.1:p.(Thr244Ala)|E:ERBB4:ENSP00000385565.1:p.(Thr244Ala)|E:ERBB4:ENSP00000260943.6:p.(Thr244Ala)	class	NA	all_exons	.	.	include	.	.	.
CL-AcroMetrix	ERBB4	ENST00000342788	NM_005235	2:212589838	G>A	c.704C>T	exon6	A235V	Ala235Val	c.704C>T:exon6:A235V:Ala235Val	missense_variant	907	0.076	NA	NA	NA	NA	COSV53546049	NA	NA	NA	NA	NA	NA	NA	Lung_Adenocarcinoma:_0.2%_(1/567)	NA	T:30+0+0+0=30/463|N:6+0+0+0=6/104|A:36+0+0+0=36/567	NA	RTKRAS	NA	[non-HC]_1.798/1.596_NA	TIER_3	VUS	NA	SOM	Furin-like_cysteine_rich_region	Afatinib|Neratinib|Afatinib_Dimaleate|Dacomitinib|Vandetanib|Neratinib_Maleate	missense_variant:R:ERBB4:Canonical:NP_005226.1:p.(Ala235Val)|R:ERBB4:NP_001036064.1:p.(Ala235Val)|R:ERBB4:XP_005246433.1:p.(Ala235Val)|R:ERBB4:XP_005246434.1:p.(Ala235Val)|R:ERBB4:XP_005246432.1:p.(Ala235Val)|E:ERBB4:Canonical:ENSP00000342235.4:p.(Ala235Val)|E:ERBB4:ENSP00000403204.1:p.(Ala235Val)|E:ERBB4:ENSP00000385565.1:p.(Ala235Val)|E:ERBB4:ENSP00000260943.6:p.(Ala235Val)	class	NA	all_exons	.	.	include	.	.	.
CL-AcroMetrix	ERBB4	ENST00000342788	NM_005235	2:212652764	T>C	c.542A>G	exon4	N181S	Asn181Ser	c.542A>G:exon4:N181S:Asn181Ser	missense_variant	661	0.062	NA	NA	NA	NA	COSV53497699	NA	NA	NA	NA	NA	NA	NA	NA	NA	T:6+0+0+0=6/463|N:3+0+0+0=3/104|A:9+0+0+0=9/567	NA	RTKRAS	NA	[non-HC]_1.798/1.596_NA	TIER_3	VUS	NA	SOM	NA	Afatinib|Neratinib|Afatinib_Dimaleate|Dacomitinib|Vandetanib|Neratinib_Maleate	missense_variant:R:ERBB4:Canonical:NP_005226.1:p.(Asn181Ser)|R:ERBB4:NP_001036064.1:p.(Asn181Ser)|R:ERBB4:XP_005246433.1:p.(Asn181Ser)|R:ERBB4:XP_005246434.1:p.(Asn181Ser)|R:ERBB4:XP_005246432.1:p.(Asn181Ser)|E:ERBB4:Canonical:ENSP00000342235.4:p.(Asn181Ser)|E:ERBB4:ENSP00000403204.1:p.(Asn181Ser)|E:ERBB4:ENSP00000385565.1:p.(Asn181Ser)|E:ERBB4:ENSP00000260943.6:p.(Asn181Ser)|E:ERBB4:ENSP00000405564.1:p.(Asn122Ser)	class	NA	all_exons	.	.	include	.	.	.
CL-AcroMetrix	ERBB4	ENST00000342788	NM_005235	2:212652791	G>C	c.515C>G	exon4	P172R	Pro172Arg	c.515C>G:exon4:P172R:Pro172Arg	missense_variant	786	0.08	NA	NA	NA	NA	COSV53512801|COSV53563942	NA	NA	NA	NA	NA	NA	NA	Breast_Invasive_Carcinoma:_0.1%_(1/986)	NA	T:8+0+0+0=8/463|N:1+0+0+0=1/104|A:9+0+0+0=9/567	NA	RTKRAS	NA	[non-HC]_1.798/1.596_NA	TIER_3	VUS	NA	SOM	NA	Afatinib|Neratinib|Afatinib_Dimaleate|Dacomitinib|Vandetanib|Neratinib_Maleate	missense_variant:R:ERBB4:Canonical:NP_005226.1:p.(Pro172Arg)|R:ERBB4:NP_001036064.1:p.(Pro172Arg)|R:ERBB4:XP_005246433.1:p.(Pro172Arg)|R:ERBB4:XP_005246434.1:p.(Pro172Arg)|R:ERBB4:XP_005246432.1:p.(Pro172Arg)|E:ERBB4:Canonical:ENSP00000342235.4:p.(Pro172Arg)|E:ERBB4:ENSP00000403204.1:p.(Pro172Arg)|E:ERBB4:ENSP00000385565.1:p.(Pro172Arg)|E:ERBB4:ENSP00000260943.6:p.(Pro172Arg)|E:ERBB4:ENSP00000405564.1:p.(Pro113Arg)	class	NA	all_exons	.	.	include	.	.	.
CL-AcroMetrix	FBXW7	ENST00000281708	NM_001349798	4:153247222	T>C	c.1580A>G	exon10	D527G	Asp527Gly	c.1580A>G:exon10:D527G:Asp527Gly	missense_variant	840	0.04	NA	NA	NA	NA	COSV55954646	NA	NA	NA	NA	NA	NA	NA	NA	NA	T:6+1+0+0=7/463|N:5+0+0+0=5/104|A:11+1+0+0=12/567	NA	NOTCH	NA	[non-HC]_1.88/1.76_NA	TIER_3	VUS	NA	SOM	WD_domain|G-beta_repeat	NA	missense_variant:R:FBXW7:XP_005263165.1:p.(Asp351Gly)|R:FBXW7:Canonical:NP_060785.2:p.(Asp447Gly)|R:FBXW7:NP_001013433.1:p.(Asp409Gly)|R:FBXW7:XP_005263164.1:p.(Asp527Gly)|R:FBXW7:NP_361014.1:p.(Asp527Gly)|E:FBXW7:Canonical:ENSP00000281708.3:p.(Asp527Gly)|E:FBXW7:ENSP00000296555.4:p.(Asp409Gly)|E:FBXW7:ENSP00000263981.4:p.(Asp447Gly)|E:FBXW7:ENSP00000474725.1:p.(Asp527Gly)|E:FBXW7:ENSP00000377528.3:p.(Asp351Gly)|E:FBXW7:ENSP00000474971.1:p.(Asp527Gly)	class	NA	all_exons	.	.	include	.	.	.
CL-AcroMetrix	FBXW7	ENST00000281708	NM_001349798	4:153247226	A>G	c.1576T>C	exon10	W526R	Trp526Arg	c.1576T>C:exon10:W526R:Trp526Arg	missense_variant	846	0.037	NA	NA	NA	NA	COSV55922932	NA	NA	NA	NA	NA	NA	NA	Head_and_Neck_Squamous_Cell_Carcinoma:_0.2%_(1/508)	NA	T:3+0+0+0=3/463|N:0+0+0+0=0/104|A:3+0+0+0=3/567	FBXW7:p.W526R:ENST00000281708&ENST00000603548&ENST00000603841:CTAT_POPULATION|CTAT_CANCER	NOTCH	NA	[non-HC]_1.88/1.76_NA	TIER_3	VUS	NA	SOM	WD_domain|G-beta_repeat	NA	missense_variant:R:FBXW7:XP_005263165.1:p.(Trp350Arg)|R:FBXW7:Canonical:NP_060785.2:p.(Trp446Arg)|R:FBXW7:NP_001013433.1:p.(Trp408Arg)|R:FBXW7:XP_005263164.1:p.(Trp526Arg)|R:FBXW7:NP_361014.1:p.(Trp526Arg)|E:FBXW7:Canonical:ENSP00000281708.3:p.(Trp526Arg)|E:FBXW7:ENSP00000296555.4:p.(Trp408Arg)|E:FBXW7:ENSP00000263981.4:p.(Trp446Arg)|E:FBXW7:ENSP00000474725.1:p.(Trp526Arg)|E:FBXW7:ENSP00000377528.3:p.(Trp350Arg)|E:FBXW7:ENSP00000474971.1:p.(Trp526Arg)	class	NA	all_exons	.	.	include	.	.	.
CL-AcroMetrix	FBXW7	ENST00000281708	NM_001349798	4:153247351	C>A	c.1451G>T	exon10	R484M	Arg484Met	c.1451G>T:exon10:R484M:Arg484Met	missense_variant	778	0.058	NA	NA	NA	NA	COSV55900396|COSV55903386	NA	NA	NA	NA	NA	NA	NA	NA	NA	T:23+0+0+0=23/463|N:4+0+0+0=4/104|A:27+0+0+0=27/567	NA	NOTCH	NA	[non-HC]_1.88/1.76_NA	TIER_3	VUS	NA	SOM	WD_domain|G-beta_repeat	NA	missense_variant:R:FBXW7:XP_005263165.1:p.(Arg308Met)|R:FBXW7:Canonical:NP_060785.2:p.(Arg404Met)|R:FBXW7:NP_001013433.1:p.(Arg366Met)|R:FBXW7:XP_005263164.1:p.(Arg484Met)|R:FBXW7:NP_361014.1:p.(Arg484Met)|E:FBXW7:Canonical:ENSP00000281708.3:p.(Arg484Met)|E:FBXW7:ENSP00000296555.4:p.(Arg366Met)|E:FBXW7:ENSP00000263981.4:p.(Arg404Met)|E:FBXW7:ENSP00000474725.1:p.(Arg484Met)|E:FBXW7:ENSP00000377528.3:p.(Arg308Met)|E:FBXW7:ENSP00000474971.1:p.(Arg484Met)	class	NA	all_exons	.	.	include	.	.	.
CL-AcroMetrix	FBXW7	ENST00000281708	NM_001349798	4:153259071	C>A	c.744G>T	exon5	E248D	Glu248Asp	c.744G>T:exon5:E248D:Glu248Asp	missense_variant	660	0.052	NA	NA	NA	NA	COSV55921179	NA	NA	NA	NA	NA	NA	NA	Uterine_Corpus_Endometrial_Carcinoma:_0.4%_(2/530)	NA	T:14+0+0+0=14/463|N:2+0+0+0=2/104|A:16+0+0+0=16/567	NA	NOTCH	NA	[non-HC]_1.88/1.76_NA	TIER_3	VUS	NA	SOM	NA	NA	missense_variant:R:FBXW7:XP_005263165.1:p.(Glu72Asp)|R:FBXW7:Canonical:NP_060785.2:p.(Glu168Asp)|R:FBXW7:NP_001013433.1:p.(Glu130Asp)|R:FBXW7:XP_005263164.1:p.(Glu248Asp)|R:FBXW7:NP_361014.1:p.(Glu248Asp)|E:FBXW7:Canonical:ENSP00000281708.3:p.(Glu248Asp)|E:FBXW7:ENSP00000296555.4:p.(Glu130Asp)|E:FBXW7:ENSP00000263981.4:p.(Glu168Asp)|E:FBXW7:ENSP00000474725.1:p.(Glu248Asp)|E:FBXW7:ENSP00000377528.3:p.(Glu72Asp)|E:FBXW7:ENSP00000474971.1:p.(Glu248Asp)	class	NA	all_exons	.	.	include	.	.	.
CL-AcroMetrix	FGFR1	ENST00000425967	NA	8:38285891	T>C	c.520A>G	exon5	T174A	Thr174Ala	c.520A>G:exon5:T174A:Thr174Ala	missense_variant	1343	0.159	NA	NA	NA	NA	NA	rs1315551279	NA	4e-06	NA	0.0000090	NA	NA	NA	NA	T:9+0+0+0=9/463|N:8+0+0+0=8/104|A:17+0+0+0=17/567	NA	RTKRAS	NA	[HC]_2.034/2.068_NA	TIER_3	VUS	NA	SOM	NA	Pazopanib_Hydrochloride|Infigratinib|Regorafenib|Regorafenib_Hydrate|Orantinib|Erdafitinib|Futibatinib|Brivanib|Sulfatinib|Pemigatinib|Pazopanib|Nintedanib	missense_variant:E:FGFR1:Canonical:ENSP00000393312.3:p.(Thr174Ala)|R:FGFR1:NP_001167536.1:p.(Thr141Ala)|R:FGFR1:NP_001167538.1:p.(Thr174Ala)|R:FGFR1:NP_001167537.1:p.(Thr52Ala)|E:FGFR1:ENSP00000380280.5:p.(Thr141Ala)|R:FGFR1:NP_075593.1:p.(Thr52Ala)|R:FGFR1:NP_075594.1:p.(Thr52Ala)|R:FGFR1:NP_056934.2:p.(Thr141Ala)|R:FGFR1:Canonical:NP_075598.2:p.(Thr141Ala)|R:FGFR1:NP_001167534.1:p.(Thr141Ala)|R:FGFR1:NP_001167535.1:p.(Thr133Ala)|E:FGFR1:ENSP00000400162.2:p.(Thr141Ala)|E:FGFR1:ENSP00000340636.5:p.(Thr144Ala)|E:FGFR1:ENSP00000432972.1:p.(Thr141Ala)|R:FGFR1:XP_005273506.1:p.(Thr133Ala)|E:FGFR1:ENSP00000380302.2:p.(Thr141Ala)|E:FGFR1:ENSP00000348537.5:p.(Thr52Ala)|E:FGFR1:ENSP00000337247.5:p.(Thr133Ala)|E:FGFR1:ENSP00000327229.6:p.(Thr52Ala)|E:FGFR1:ENSP00000380292.1:p.(Thr52Ala)|E:FGFR1:ENSP00000380297.4:p.(Thr141Ala)|E:FGFR1:ENSP00000434712.1:p.(Thr141Ala)|E:FGFR1:ENSP00000433569.1:p.(Thr52Ala)|E:FGFR1:ENSP00000435283.1:p.(Thr52Ala)|E:FGFR1:ENSP00000434473.1:p.(Thr52Ala)|E:FGFR1:ENSP00000392645.1:p.(Thr52Ala);5_prime_UTR_variant:E:FGFR1:ENST00000533668.1;downstream_gene_variant:E:FGFR1:ENST00000413133.2	class	NA	introns[1,5];IS:introns[17],all_exons	.	.	include	.	.	.
CL-AcroMetrix	FGFR1	ENST00000425967	NA	8:38285938	G>A	c.473C>T	exon5	S158L	Ser158Leu	c.473C>T:exon5:S158L:Ser158Leu	missense_variant	1367	0.185	NA	NA	NA	NA	COSV58332163	rs121913473	376297	1.22e-05	NA	0.0000000	NA	NA	NA	NA	T:115+2+0+0=117/463|N:6+0+0+0=6/104|A:121+2+0+0=123/567	NA	RTKRAS	NA	[HC]_2.034/2.068_NA	TIER_3	VUS	Likely_Pathogenic	SOM	NA	Pazopanib_Hydrochloride|Infigratinib|Regorafenib|Regorafenib_Hydrate|Orantinib|Erdafitinib|Futibatinib|Brivanib|Sulfatinib|Pemigatinib|Pazopanib|Nintedanib	missense_variant:E:FGFR1:Canonical:ENSP00000393312.3:p.(Ser158Leu)|R:FGFR1:NP_001167536.1:p.(Ser125Leu)|R:FGFR1:NP_001167538.1:p.(Ser158Leu)|R:FGFR1:NP_001167537.1:p.(Ser36Leu)|E:FGFR1:ENSP00000380280.5:p.(Ser125Leu)|R:FGFR1:NP_075593.1:p.(Ser36Leu)|R:FGFR1:NP_075594.1:p.(Ser36Leu)|R:FGFR1:NP_056934.2:p.(Ser125Leu)|R:FGFR1:Canonical:NP_075598.2:p.(Ser125Leu)|R:FGFR1:NP_001167534.1:p.(Ser125Leu)|R:FGFR1:NP_001167535.1:p.(Ser117Leu)|E:FGFR1:ENSP00000400162.2:p.(Ser125Leu)|E:FGFR1:ENSP00000340636.5:p.(Ser128Leu)|E:FGFR1:ENSP00000432972.1:p.(Ser125Leu)|R:FGFR1:XP_005273506.1:p.(Ser117Leu)|E:FGFR1:ENSP00000380302.2:p.(Ser125Leu)|E:FGFR1:ENSP00000348537.5:p.(Ser36Leu)|E:FGFR1:ENSP00000337247.5:p.(Ser117Leu)|E:FGFR1:ENSP00000327229.6:p.(Ser36Leu)|E:FGFR1:ENSP00000380292.1:p.(Ser36Leu)|E:FGFR1:ENSP00000380297.4:p.(Ser125Leu)|E:FGFR1:ENSP00000434712.1:p.(Ser125Leu)|E:FGFR1:ENSP00000433569.1:p.(Ser36Leu)|E:FGFR1:ENSP00000435283.1:p.(Ser36Leu)|E:FGFR1:ENSP00000434473.1:p.(Ser36Leu)|E:FGFR1:ENSP00000392645.1:p.(Ser36Leu);5_prime_UTR_variant:E:FGFR1:ENST00000533668.1;downstream_gene_variant:E:FGFR1:ENST00000413133.2	ClinVar_classification|class	NA	introns[1,5];IS:introns[17],all_exons	.	.	include	variant_in_more_than_10%_of_tumor_samples_(24.84%)_with_VAF_under_0.01	.	.
CL-AcroMetrix	FGFR2	ENST00000457416	NM_022970	10:123274810	T>C	c.1111A>G	exon9	T371A	Thr371Ala	c.1111A>G:exon9:T371A:Thr371Ala	missense_variant	1139	0.069	NA	NA	NA	NA	COSV100336196	NA	NA	NA	NA	NA	NA	NA	Stomach_Adenocarcinoma:_0.2%_(1/437)	NA	T:7+0+0+0=7/463|N:3+0+0+0=3/104|A:10+0+0+0=10/567	NA	RTKRAS	NA	[HC]_1.816/1.632_NA	TIER_3	VUS	NA	SOM	NA	Infigratinib|Regorafenib|Regorafenib_Hydrate|Orantinib|Erdafitinib|Futibatinib|Brivanib|Pemigatinib|Nintedanib	missense_variant:R:FGFR2:NP_001307583.1:p.(Thr142Ala)|R:FGFR2:NP_001138386.1:p.(Thr258Ala)|R:FGFR2:NP_075418.1:p.(Thr281Ala)|R:FGFR2:NP_001138388.1:p.(Thr255Ala)|R:FGFR2:NP_001138387.1:p.(Thr281Ala)|R:FGFR2:Canonical:NP_075259.4:p.(Thr371Ala)|R:FGFR2:NP_000132.3:p.(Thr370Ala)|R:FGFR2:NP_001138390.1:p.(Thr255Ala)|R:FGFR2:NP_001307587.1:p.(Thr370Ala)|E:FGFR2:ENSP00000358057.4:p.(Thr258Ala)|E:FGFR2:ENSP00000350166.5:p.(Thr281Ala)|E:FGFR2:ENSP00000351276.5:p.(Thr370Ala)|E:FGFR2:ENSP00000474011.1:p.(Thr142Ala)|E:FGFR2:ENSP00000348559.4:p.(Thr255Ala)|E:FGFR2:ENSP00000358055.1:p.(Thr256Ala)|E:FGFR2:ENSP00000263451.5:p.(Thr370Ala)|E:FGFR2:Canonical:ENSP00000410294.2:p.(Thr371Ala)|E:FGFR2:ENSP00000309878.8:p.(Thr370Ala)|E:FGFR2:ENSP00000353262.3:p.(Thr282Ala)|R:FGFR2:NP_001138385.1:p.(Thr371Ala)|R:FGFR2:NP_001138391.1:p.(Thr282Ala)|E:FGFR2:ENSP00000358052.1:p.(Thr371Ala)|E:FGFR2:ENSP00000358054.3:p.(Thr371Ala)|E:FGFR2:ENSP00000337665.6:p.(Thr281Ala);upstream_gene_variant:E:FGFR2:ENST00000429361.1	class	NA	introns[1];IS:introns[17],all_exons	.	.	include	.	.	.
CL-AcroMetrix	FGFR2	ENST00000457416	NM_022970	10:123279503	T>C	c.929A>G	exon7	K310R	Lys310Arg	c.929A>G:exon7:K310R:Lys310Arg	missense_variant	1012	0.077	NA	NA	NA	NA	COSV60641086	rs121913475	376317	NA	NA	NA	NA	NA	NA	NA	T:17+0+0+0=17/463|N:2+0+0+0=2/104|A:19+0+0+0=19/567	NA	RTKRAS	NA	[HC]_1.816/1.632_NA	TIER_3	VUS	Likely_Pathogenic	SOM	Immunoglobulin_I-set_domain	Infigratinib|Regorafenib|Regorafenib_Hydrate|Orantinib|Erdafitinib|Futibatinib|Brivanib|Pemigatinib|Nintedanib	missense_variant:R:FGFR2:NP_001307583.1:p.(Lys82Arg)|R:FGFR2:NP_075418.1:p.(Lys221Arg)|R:FGFR2:NP_001138388.1:p.(Lys195Arg)|R:FGFR2:NP_001138387.1:p.(Lys221Arg)|R:FGFR2:Canonical:NP_075259.4:p.(Lys310Arg)|R:FGFR2:NP_000132.3:p.(Lys310Arg)|R:FGFR2:NP_001138389.1:p.(Lys310Arg)|R:FGFR2:NP_001138390.1:p.(Lys195Arg)|R:FGFR2:NP_001307587.1:p.(Lys310Arg)|E:FGFR2:ENSP00000350166.5:p.(Lys221Arg)|E:FGFR2:ENSP00000351276.5:p.(Lys310Arg)|E:FGFR2:ENSP00000474011.1:p.(Lys82Arg)|E:FGFR2:ENSP00000348559.4:p.(Lys195Arg)|E:FGFR2:ENSP00000358056.4:p.(Lys310Arg)|E:FGFR2:ENSP00000358055.1:p.(Lys195Arg)|E:FGFR2:ENSP00000263451.5:p.(Lys310Arg)|E:FGFR2:Canonical:ENSP00000410294.2:p.(Lys310Arg)|E:FGFR2:ENSP00000309878.8:p.(Lys310Arg)|E:FGFR2:ENSP00000353262.3:p.(Lys221Arg)|R:FGFR2:NP_001138385.1:p.(Lys310Arg)|R:FGFR2:NP_001138391.1:p.(Lys221Arg)|E:FGFR2:ENSP00000358052.1:p.(Lys310Arg)|E:FGFR2:ENSP00000358054.3:p.(Lys310Arg)|E:FGFR2:ENSP00000337665.6:p.(Lys221Arg);upstream_gene_variant:E:FGFR2:ENST00000429361.1	ClinVar_classification|class	NA	introns[1];IS:introns[17],all_exons	.	.	include	.	.	.
CL-AcroMetrix	FGFR2	ENST00000457416	NM_022970	10:123279519	C>T	c.913G>A	exon7	G305R	Gly305Arg	c.913G>A:exon7:G305R:Gly305Arg	missense_variant	1066	0.084	NA	NA	NA	NA	COSV60646034|COSV60661962	NA	NA	NA	NA	NA	NA	NA	NA	NA	T:113+0+0+0=113/463|N:3+0+0+0=3/104|A:116+0+0+0=116/567	NA	RTKRAS	NA	[HC]_1.816/1.632_NA	TIER_3	VUS	NA	SOM	Immunoglobulin_I-set_domain	Infigratinib|Regorafenib|Regorafenib_Hydrate|Orantinib|Erdafitinib|Futibatinib|Brivanib|Pemigatinib|Nintedanib	missense_variant:R:FGFR2:NP_001307583.1:p.(Gly77Arg)|R:FGFR2:NP_075418.1:p.(Gly216Arg)|R:FGFR2:NP_001138388.1:p.(Gly190Arg)|R:FGFR2:NP_001138387.1:p.(Gly216Arg)|R:FGFR2:Canonical:NP_075259.4:p.(Gly305Arg)|R:FGFR2:NP_000132.3:p.(Gly305Arg)|R:FGFR2:NP_001138389.1:p.(Gly305Arg)|R:FGFR2:NP_001138390.1:p.(Gly190Arg)|R:FGFR2:NP_001307587.1:p.(Gly305Arg)|E:FGFR2:ENSP00000350166.5:p.(Gly216Arg)|E:FGFR2:ENSP00000351276.5:p.(Gly305Arg)|E:FGFR2:ENSP00000474011.1:p.(Gly77Arg)|E:FGFR2:ENSP00000348559.4:p.(Gly190Arg)|E:FGFR2:ENSP00000358056.4:p.(Gly305Arg)|E:FGFR2:ENSP00000358055.1:p.(Gly190Arg)|E:FGFR2:ENSP00000263451.5:p.(Gly305Arg)|E:FGFR2:Canonical:ENSP00000410294.2:p.(Gly305Arg)|E:FGFR2:ENSP00000309878.8:p.(Gly305Arg)|E:FGFR2:ENSP00000353262.3:p.(Gly216Arg)|R:FGFR2:NP_001138385.1:p.(Gly305Arg)|R:FGFR2:NP_001138391.1:p.(Gly216Arg)|E:FGFR2:ENSP00000358052.1:p.(Gly305Arg)|E:FGFR2:ENSP00000358054.3:p.(Gly305Arg)|E:FGFR2:ENSP00000337665.6:p.(Gly216Arg);upstream_gene_variant:E:FGFR2:ENST00000429361.1	class	NA	introns[1];IS:introns[17],all_exons	.	.	include	variant_in_more_than_10%_of_tumor_samples_(24.41%)_with_VAF_under_0.01	.	.
CL-AcroMetrix	FGFR3	ENST00000340107	NM_001163213	4:1806153	C>A	c.1178C>A	exon9	A393E	Ala393Glu	c.1178C>A:exon9:A393E:Ala393Glu	missense_variant	1060	0.05	NA	NA	NA	NA	COSV53391630|COSV53400539	rs28931615	16329	NA	NA	NA	NA	NA	NA	NA	T:39+2+0+0=41/462|N:6+0+0+0=6/104|A:45+2+0+0=47/566	NA	RTKRAS	NA	[HC]_2.122/2.244_NA	TIER_3	Pathogenic	Pathogenic	SOM	NA	Pazopanib_Hydrochloride|Infigratinib|Masitinib|Orantinib|Erdafitinib|Futibatinib|Brivanib|Pemigatinib|Pazopanib|Nintedanib|Dovitinib	missense_variant:E:FGFR3:ENSP00000420533.2:p.(Ala391Glu)|E:FGFR3:Canonical:ENSP00000339824.4:p.(Ala393Glu)|E:FGFR3:ENSP00000414914.2:p.(Ala391Glu)|R:FGFR3:Canonical:NP_001156685.1:p.(Ala393Glu)|R:FGFR3:NP_000133.1:p.(Ala391Glu)|E:FGFR3:ENSP00000260795.2:p.(Ala391Glu);downstream_gene_variant:E:FGFR3:ENST00000507588.1	CPSR_classification|ClinVar_classification|class	NA	all_exons;IS:introns[17],exons[7,9aka10,14,18]	.	.	include	.	.	.
CL-AcroMetrix	FGFR3	ENST00000340107	NM_001163213	4:1807869	A>G	c.1934A>G	exon14	H645R	His645Arg	c.1934A>G:exon14:H645R:His645Arg	missense_variant	1176	0.071	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	T:9+0+0+0=9/463|N:8+0+0+0=8/104|A:17+0+0+0=17/567	NA	RTKRAS	NA	[HC]_2.122/2.244_NA	TIER_3	VUS	NA	SOM	Protein_tyrosine_and_serine/threonine_kinase	Pazopanib_Hydrochloride|Infigratinib|Masitinib|Orantinib|Erdafitinib|Futibatinib|Brivanib|Pemigatinib|Pazopanib|Nintedanib|Dovitinib	missense_variant:E:FGFR3:ENSP00000420533.2:p.(His644Arg)|E:FGFR3:Canonical:ENSP00000339824.4:p.(His645Arg)|E:FGFR3:ENSP00000414914.2:p.(His643Arg)|E:FGFR3:ENSP00000412903.2:p.(His531Arg)|R:FGFR3:Canonical:NP_001156685.1:p.(His645Arg)|R:FGFR3:NP_075254.1:p.(His531Arg)|R:FGFR3:NP_000133.1:p.(His643Arg)|E:FGFR3:ENSP00000260795.2:p.(His643Arg)|E:FGFR3:ENSP00000231803.1:p.(His531Arg);downstream_gene_variant:E:FGFR3:ENST00000507588.1	class	NA	all_exons;IS:introns[17],exons[7,9aka10,14,18]	.	.	include	.	.	.
CL-AcroMetrix	FGFR3	ENST00000340107	NM_001163213	4:1808331	G>T	c.2095G>T	exon16	G699C	Gly699Cys	c.2095G>T:exon16:G699C:Gly699Cys	missense_variant	1106	0.07	NA	NA	NA	NA	COSV53390947|COSV53400997	rs121913480	376248	NA	NA	NA	NA	NA	NA	NA	T:30+1+0+0=31/463|N:6+0+0+0=6/104|A:36+1+0+0=37/567	NA	RTKRAS	NA	[HC]_2.122/2.244_NA	TIER_3	VUS	Likely_Pathogenic	SOM	Protein_tyrosine_and_serine/threonine_kinase	Pazopanib_Hydrochloride|Infigratinib|Masitinib|Orantinib|Erdafitinib|Futibatinib|Brivanib|Pemigatinib|Pazopanib|Nintedanib|Dovitinib	missense_variant:E:FGFR3:ENSP00000420533.2:p.(Arg674Leu)|E:FGFR3:Canonical:ENSP00000339824.4:p.(Gly699Cys)|E:FGFR3:ENSP00000414914.2:p.(Gly697Cys)|E:FGFR3:ENSP00000412903.2:p.(Gly585Cys)|R:FGFR3:Canonical:NP_001156685.1:p.(Gly699Cys)|R:FGFR3:NP_075254.1:p.(Gly585Cys)|R:FGFR3:NP_000133.1:p.(Gly697Cys)|E:FGFR3:ENSP00000260795.2:p.(Gly697Cys)|E:FGFR3:ENSP00000231803.1:p.(Gly585Cys);downstream_gene_variant:E:FGFR3:ENST00000507588.1|R:LETM1:XM_005247970.1|R:LETM1:XM_005247969.1|E:LETM1:Canonical:ENST00000302787.2|R:LETM1:Canonical:NM_012318.2	ClinVar_classification|class	NA	all_exons;IS:introns[17],exons[7,9aka10,14,18]	.	.	include	.	.	.
CL-AcroMetrix	FLT3	ENST00000241453	NM_004119	13:28592629	T>C	c.2516A>G	exon20	D839G	Asp839Gly	c.2516A>G:exon20:D839G:Asp839Gly	missense_variant	1078	0.041	NA	NA	NA	NA	COSV54045448	rs991132188	376014	NA	NA	NA	NA	NA	Acute_Myeloid_Leukemia:_0.7%_(1/144)	NA	T:5+0+0+0=5/463|N:1+0+0+0=1/104|A:6+0+0+0=6/567	NA	RTKRAS	NA	[non-HC]_2.368/2.736_NA	TIER_3	VUS	Likely_Pathogenic	SOM	Protein_tyrosine_and_serine/threonine_kinase	Sorafenib_Tosylate|Fedratinib|Sorafenib|Crenolanib|Linifanib|Gilteritinib_Fumarate|Gilteritinib|Famitinib|EGFR/FLT3/Abl_Inhibitor_SKLB1028|Pexidartinib|Pexidartinib_Hydrochloride|Dovitinib|Sunitinib_Malate|Quizartinib|Midostaurin	missense_variant:E:FLT3:ENSP00000241453.7:p.(Asp839Gly)|R:FLT3:Canonical:NP_004110.2:p.(Asp839Gly)|R:FLT3:XP_005266375.1:p.(Asp839Gly)|E:FLT3:Canonical:ENSP00000370369.4:p.(Asp839Gly)	ClinVar_classification|class	NA	all_exons;IS:exons[14-15,20]	.	.	include	.	.	.
CL-AcroMetrix	FLT3	ENST00000241453	NM_004119	13:28592653	C>T	c.2492G>A	exon20	G831E	Gly831Glu	c.2492G>A:exon20:G831E:Gly831Glu	missense_variant	1097	0.045	NA	NA	NA	NA	COSV54042783	NA	NA	NA	NA	NA	NA	NA	NA	NA	T:38+0+0+0=38/463|N:0+0+0+0=0/104|A:38+0+0+0=38/567	NA	RTKRAS	NA	[non-HC]_2.368/2.736_NA	TIER_3	VUS	NA	SOM	Protein_tyrosine_and_serine/threonine_kinase	Sorafenib_Tosylate|Fedratinib|Sorafenib|Crenolanib|Linifanib|Gilteritinib_Fumarate|Gilteritinib|Famitinib|EGFR/FLT3/Abl_Inhibitor_SKLB1028|Pexidartinib|Pexidartinib_Hydrochloride|Dovitinib|Sunitinib_Malate|Quizartinib|Midostaurin	missense_variant:E:FLT3:ENSP00000241453.7:p.(Gly831Glu)|R:FLT3:Canonical:NP_004110.2:p.(Gly831Glu)|R:FLT3:XP_005266375.1:p.(Gly831Glu)|E:FLT3:Canonical:ENSP00000370369.4:p.(Gly831Glu)	class	NA	all_exons;IS:exons[14-15,20]	.	.	include	.	.	.
CL-AcroMetrix	FLT3	ENST00000241453	NM_004119	13:28608281	A>G	c.1775T>C	exon14	V592A	Val592Ala	c.1775T>C:exon14:V592A:Val592Ala	missense_variant	933	0.041	NA	NA	NA	NA	COSV54051432|COSV54058572|COSV54074139	rs1057520025	376721	NA	NA	NA	NA	NA	NA	NA	T:9+0+0+0=9/463|N:3+0+0+0=3/104|A:12+0+0+0=12/567	NA	RTKRAS	NA	[non-HC]_2.368/2.736_NA	TIER_3	VUS	Likely_Pathogenic	SOM	NA	Sorafenib_Tosylate|Fedratinib|Sorafenib|Crenolanib|Linifanib|Gilteritinib_Fumarate|Gilteritinib|Famitinib|EGFR/FLT3/Abl_Inhibitor_SKLB1028|Pexidartinib|Pexidartinib_Hydrochloride|Dovitinib|Sunitinib_Malate|Quizartinib|Midostaurin	missense_variant:E:FLT3:ENSP00000241453.7:p.(Val592Ala)|R:FLT3:Canonical:NP_004110.2:p.(Val592Ala)|R:FLT3:XP_005266375.1:p.(Val592Ala)|E:FLT3:Canonical:ENSP00000370369.4:p.(Val592Ala)|R:FLT3:XP_005266376.1:p.(Val592Ala)|E:FLT3:ENSP00000438139.1:p.(Val592Ala)	ClinVar_classification|class	NA	all_exons;IS:exons[14-15,20]	.	.	include	.	.	.
CL-AcroMetrix	FLT3	ENST00000241453	NM_004119	13:28610138	G>A	c.1352C>T	exon11	S451F	Ser451Phe	c.1352C>T:exon11:S451F:Ser451Phe	missense_variant	1011	0.062	NA	NA	NA	NA	COSV54046796	NA	NA	NA	NA	NA	NA	NA	NA	NA	T:41+1+0+0=42/463|N:2+0+0+0=2/104|A:43+1+0+0=44/567	NA	RTKRAS	NA	[non-HC]_2.368/2.736_NA	TIER_3	VUS	NA	SOM	NA	Sorafenib_Tosylate|Fedratinib|Sorafenib|Crenolanib|Linifanib|Gilteritinib_Fumarate|Gilteritinib|Famitinib|EGFR/FLT3/Abl_Inhibitor_SKLB1028|Pexidartinib|Pexidartinib_Hydrochloride|Dovitinib|Sunitinib_Malate|Quizartinib|Midostaurin	missense_variant:E:FLT3:ENSP00000241453.7:p.(Ser451Phe)|R:FLT3:Canonical:NP_004110.2:p.(Ser451Phe)|R:FLT3:XP_005266375.1:p.(Ser451Phe)|E:FLT3:Canonical:ENSP00000370369.4:p.(Ser451Phe)|R:FLT3:XP_005266376.1:p.(Ser451Phe)|E:FLT3:ENSP00000438139.1:p.(Ser451Phe)	class	NA	all_exons;IS:exons[14-15,20]	.	.	include	.	.	.
CL-AcroMetrix	GNAQ	ENST00000286548	NM_002072	9:80409432	ACA>TGC	c.680_682delinsGCA	exon5	M227_F228delinsSI	Met227_Phe228delinsSerIle	c.680_682delinsGCA:exon5:M227_F228delinsSI:Met227_Phe228delinsSerIle	missense_variant	698	0.046	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	[non-HC]_1.97/1.94_NA	TIER_3	NA	NA	SOM	G-protein_alpha_subunit	NA	missense_variant:E:GNAQ:Canonical:ENSP00000286548.4:p.(Met227_Phe228delinsSerIle)|R:GNAQ:Canonical:NP_002063.2:p.(Met227_Phe228delinsSerIle)|R:GNAQ:NP_002063.2:p.(Met227_Phe228delinsSerIle)|E:GNAQ:ENSP00000443197.1:p.(Met25_Phe26delinsSerIle);downstream_gene_variant:E:GNAQ:ENST00000411677.1	class	NA	all_exons;IS:exons[4-5]	.	.	include	no_recurrence_data	.	.
CL-AcroMetrix	GNAQ	ENST00000286548	NM_002072	9:80412518	T>A	c.523A>T	exon4	T175S	Thr175Ser	c.523A>T:exon4:T175S:Thr175Ser	missense_variant	1055	0.193	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	T:6+0+0+0=6/463|N:1+0+0+0=1/104|A:7+0+0+0=7/567	NA	NA	NA	[non-HC]_1.97/1.94_NA	TIER_3	NA	NA	SOM	G-protein_alpha_subunit	NA	missense_variant:E:GNAQ:Canonical:ENSP00000286548.4:p.(Thr175Ser)|R:GNAQ:Canonical:NP_002063.2:p.(Thr175Ser)|R:GNAQ:NP_002063.2:p.(Thr175Ser)|E:GNAQ:ENSP00000391501.1:p.(Thr146Ser);5_prime_UTR_variant:E:GNAQ:ENST00000397476.3	class	NA	all_exons;IS:exons[4-5]	.	.	include	.	.	.
CL-AcroMetrix	HRAS	ENST00000451590	NM_001130442	11:533881	C>T	c.175G>A	exon3	A59T	Ala59Thr	c.175G>A:exon3:A59T:Ala59Thr	missense_variant	1234	0.059	NA	NA	NA	NA	COSV54244375	rs727503093	40435	NA	NA	NA	NA	NA	Uterine_Corpus_Endometrial_Carcinoma:_0.4%_(2/530)	NA	T:114+2+0+0=116/462|N:15+0+0+0=15/104|A:129+2+0+0=131/566	HRAS:p.A59T:ENST00000397594&ENST00000397596&ENST00000451590&ENST00000417302&ENST00000311189:CTAT_POPULATION|CTAT_CANCER|3D_STRUCTURE	RTKRAS	NA	[non-HC]_2.302/2.604_NA	TIER_3	Pathogenic	Likely_Pathogenic	SOM	Ras_family	NA	downstream_gene_variant:R:LOC101059906:XM_003959933.2;missense_variant:E:HRAS:ENSP00000380722.1:p.(Ala59Thr)|E:HRAS:ENSP00000380723.2:p.(Ala59Thr)|R:HRAS:NP_005334.1:p.(Ala59Thr)|R:HRAS:NP_789765.1:p.(Ala59Thr)|R:HRAS:NP_001123914.1:p.(Ala59Thr)|R:HRAS:NP_001123914.1:p.(Ala59Thr)|R:HRAS:NP_789765.1:p.(Ala59Thr)|R:HRAS:Canonical:NP_005334.1:p.(Ala59Thr)|E:HRAS:Canonical:ENSP00000407586.1:p.(Ala59Thr)|E:HRAS:ENSP00000388246.1:p.(Ala59Thr)|E:HRAS:ENSP00000309845.7:p.(Ala59Thr)|R:HRAS:XP_005252941.1:p.(Ala59Thr);5_prime_UTR_variant:R:HRAS:NM_001318054.1;upstream_gene_variant:R:LRRC56:XM_005252777.1|R:LRRC56:XM_005252776.1|R:LRRC56:XM_005252775.1|R:LRRC56:XM_005252778.1|R:LRRC56:Canonical:NM_198075.3|E:LRRC56:Canonical:ENST00000270115.7	CPSR_classification|ClinVar_classification|class	NA	all_exons;IS:exons[2,3]	.	.	include	variant_in_more_than_10%_of_tumor_samples_(24.68%)_with_VAF_under_0.01	.	.
CL-AcroMetrix	IDH1	ENST00000415913	NM_001282387	2:209113119	T>C	c.388A>G	exon4	I130V	Ile130Val	c.388A>G:exon4:I130V:Ile130Val	missense_variant	966	0.034	NA	NA	NA	NA	COSV61644989	rs762479277	NA	1.59e-05	NA	0.0000176	NA	NA	NA	NA	T:10+0+0+0=10/463|N:2+0+0+0=2/104|A:12+0+0+0=12/567	NA	NA	NA	[non-HC]_2.024/2.048_NA	TIER_3	VUS	NA	SOM	Isocitrate/isopropylmalate_dehydrogenase	Ivosidenib|Vorasidenib	missense_variant:R:IDH1:XP_005246581.1:p.(Ile130Val)|R:IDH1:XP_005246580.1:p.(Ile130Val)|R:IDH1:NP_001269316.1:p.(Ile130Val)|R:IDH1:XP_005246579.1:p.(Ile130Val)|R:IDH1:NP_001269315.1:p.(Ile130Val)|E:IDH1:Canonical:ENSP00000260985.2:p.(Ile130Val)|R:IDH1:Canonical:NP_005887.2:p.(Ile130Val)|R:IDH1:XP_005246578.1:p.(Ile130Val)|R:IDH1:NP_005887.2:p.(Ile130Val)|E:IDH1:ENSP00000410513.1:p.(Ile130Val)|E:IDH1:ENSP00000390265.1:p.(Ile130Val)|E:IDH1:ENSP00000391075.1:p.(Ile130Val);downstream_gene_variant:E:IDH1:ENST00000417583.1|E:IDH1:ENST00000451391.1	class	NA	all_exons;IS:exons[4]	.	.	include	.	.	.
CL-AcroMetrix	IDH1	ENST00000415913	NM_001282387	2:209113140	C>T	c.367G>A	exon4	G123R	Gly123Arg	c.367G>A:exon4:G123R:Gly123Arg	missense_variant	1087	0.052	NA	NA	NA	NA	COSV61626145	rs781531255	NA	8e-06	NA	0.0000000	NA	NA	NA	NA	T:86+0+0+0=86/463|N:5+0+0+0=5/104|A:91+0+0+0=91/567	NA	NA	NA	[non-HC]_2.024/2.048_NA	TIER_3	VUS	NA	SOM	Isocitrate/isopropylmalate_dehydrogenase	Ivosidenib|Vorasidenib	missense_variant:R:IDH1:XP_005246581.1:p.(Gly123Arg)|R:IDH1:XP_005246580.1:p.(Gly123Arg)|R:IDH1:NP_001269316.1:p.(Gly123Arg)|R:IDH1:XP_005246579.1:p.(Gly123Arg)|R:IDH1:NP_001269315.1:p.(Gly123Arg)|E:IDH1:Canonical:ENSP00000260985.2:p.(Gly123Arg)|R:IDH1:Canonical:NP_005887.2:p.(Gly123Arg)|R:IDH1:XP_005246578.1:p.(Gly123Arg)|R:IDH1:NP_005887.2:p.(Gly123Arg)|E:IDH1:ENSP00000410513.1:p.(Gly123Arg)|E:IDH1:ENSP00000390265.1:p.(Gly123Arg)|E:IDH1:ENSP00000391075.1:p.(Gly123Arg);downstream_gene_variant:E:IDH1:ENST00000417583.1|E:IDH1:ENST00000451391.1	class	NA	all_exons;IS:exons[4]	.	.	include	variant_in_more_than_10%_of_tumor_samples_(18.57%)_with_VAF_under_0.01	.	.
CL-AcroMetrix	JAK2	ENST00000381652	NM_001322194|NM_001322195|NM_004972|NM_001322198|NM_001322196|NM_001322199|NM_001322204	9:5073781	C>A	c.1860C>A	exon14	D620E	Asp620Glu	c.1860C>A:exon14:D620E:Asp620Glu	missense_variant	889	0.126	NA	NA	NA	NA	COSV67578238	NA	NA	NA	NA	NA	NA	NA	NA	NA	T:14+1+0+0=15/463|N:1+0+0+0=1/104|A:15+1+0+0=16/567	NA	RTKRAS	NA	[HC]_2.226/2.452_NA	TIER_3	VUS	NA	SOM	Protein_tyrosine_and_serine/threonine_kinase	Momelotinib|Fedratinib|Ruxolitinib|Ruxolitinib_Phosphate	missense_variant:E:JAK2:ENSP00000440387.1:p.(Asp620Glu)|R:JAK2:NP_001309124.1:p.(Asp620Glu)|R:JAK2:NP_001309123.1:p.(Asp620Glu)|R:JAK2:NP_001309125.1:p.(Asp620Glu)|R:JAK2:NP_001309127.1:p.(Asp215Glu)|R:JAK2:NP_001309128.1:p.(Asp215Glu)|E:JAK2:Canonical:ENSP00000371067.3:p.(Asp620Glu)|R:JAK2:Canonical:NP_004963.1:p.(Asp620Glu)|R:JAK2:XP_005251512.1:p.(Asp620Glu)|E:JAK2:ENSP00000443103.1:p.(Asp471Glu)|R:JAK2:NP_001309133.1:p.(Asp471Glu);downstream_gene_variant:E:AL161450.1:Canonical:ENST00000601793.1	class	NA	all_exons;IS:exons[14]	.	.	include	.	.	.
CL-AcroMetrix	KDR	ENST00000263923	NM_002253	4:55955112	C>T	c.3433G>A	exon26	G1145R	Gly1145Arg	c.3433G>A:exon26:G1145R:Gly1145Arg	missense_variant	1083	0.071	NA	NA	NA	NA	COSV55759250	rs776671822	NA	1.99e-05	NA	0.0000264	NA	NA	NA	NA	T:99+2+0+0=101/463|N:5+0+0+0=5/104|A:104+2+0+0=106/567	NA	NA	NA	[non-HC]_2.116/2.232_NA	TIER_3	VUS	NA	SOM	Protein_tyrosine_and_serine/threonine_kinase	Vatalanib|Sorafenib_Tosylate|Pazopanib_Hydrochloride|Tivozanib|Lenvatinib|Axitinib|Sorafenib|Ramucirumab|Regorafenib|Regorafenib_Hydrate|Cabozantinib_S-malate|Lenvatinib_Mesylate|Cabozantinib|Linifanib|Vandetanib|Orantinib|Semaxanib|Rivoceranib|Anlotinib|Famitinib|Rivoceranib_Mesylate|Brivanib|Sitravatinib|Sulfatinib|Fruquintinib|Pazopanib|Cediranib|Nintedanib|Dovitinib|Sunitinib_Malate|Motesanib|Midostaurin	missense_variant:R:KDR:Canonical:NP_002244.1:p.(Gly1145Arg)|E:KDR:Canonical:ENSP00000263923.4:p.(Gly1145Arg)	class	NA	all_exons	.	.	include	variant_in_more_than_10%_of_tumor_samples_(21.38%)_with_VAF_under_0.01	.	.
CL-AcroMetrix	KDR	ENST00000263923	NM_002253	4:55961023	C>A	c.2917G>T	exon21	A973S	Ala973Ser	c.2917G>T:exon21:A973S:Ala973Ser	missense_variant	1180	0.067	NA	NA	NA	NA	COSV55765443|COSV55773180	NA	NA	NA	NA	NA	NA	NA	Colon_Adenocarcinoma:_0.3%_(1/399)|Lung_Squamous_Cell_Carcinoma:_0.2%_(1/492)	NA	T:25+1+0+0=26/462|N:0+0+0+0=0/104|A:25+1+0+0=26/566	NA	NA	NA	[non-HC]_2.116/2.232_NA	TIER_3	VUS	NA	SOM	Protein_tyrosine_and_serine/threonine_kinase	Vatalanib|Sorafenib_Tosylate|Pazopanib_Hydrochloride|Tivozanib|Lenvatinib|Axitinib|Sorafenib|Ramucirumab|Regorafenib|Regorafenib_Hydrate|Cabozantinib_S-malate|Lenvatinib_Mesylate|Cabozantinib|Linifanib|Vandetanib|Orantinib|Semaxanib|Rivoceranib|Anlotinib|Famitinib|Rivoceranib_Mesylate|Brivanib|Sitravatinib|Sulfatinib|Fruquintinib|Pazopanib|Cediranib|Nintedanib|Dovitinib|Sunitinib_Malate|Motesanib|Midostaurin	missense_variant:R:KDR:Canonical:NP_002244.1:p.(Ala973Ser)|E:KDR:Canonical:ENSP00000263923.4:p.(Ala973Ser)	class	NA	all_exons	.	.	include	.	.	.
CL-AcroMetrix	KDR	ENST00000263923	NM_002253	4:55979623	C>A	c.824G>T	exon7	R275L	Arg275Leu	c.824G>T:exon7:R275L:Arg275Leu	missense_variant	769	0.07	NA	NA	NA	NA	COSV55763741|COSV55773353	NA	NA	NA	NA	NA	NA	NA	NA	NA	T:14+0+0+0=14/462|N:2+1+0+0=3/104|A:16+1+0+0=17/566	NA	NA	NA	[non-HC]_2.116/2.232_NA	TIER_3	VUS	NA	SOM	Immunoglobulin_V-set_domain	Vatalanib|Sorafenib_Tosylate|Pazopanib_Hydrochloride|Tivozanib|Lenvatinib|Axitinib|Sorafenib|Ramucirumab|Regorafenib|Regorafenib_Hydrate|Cabozantinib_S-malate|Lenvatinib_Mesylate|Cabozantinib|Linifanib|Vandetanib|Orantinib|Semaxanib|Rivoceranib|Anlotinib|Famitinib|Rivoceranib_Mesylate|Brivanib|Sitravatinib|Sulfatinib|Fruquintinib|Pazopanib|Cediranib|Nintedanib|Dovitinib|Sunitinib_Malate|Motesanib|Midostaurin	missense_variant:R:KDR:Canonical:NP_002244.1:p.(Arg275Leu)|E:KDR:Canonical:ENSP00000263923.4:p.(Arg275Leu)	class	NA	all_exons	.	.	include	.	.	.
CL-AcroMetrix	KIT	ENST00000288135	NM_000222	4:55561702	C>T	c.92C>T	exon2	P31L	Pro31Leu	c.92C>T:exon2:P31L:Pro31Leu	missense_variant	1057	0.059	NA	NA	NA	NA	COSV55396705	NA	NA	NA	NA	NA	NA	NA	NA	NA	T:41+0+0+0=41/463|N:4+0+0+0=4/104|A:45+0+0+0=45/567	NA	RTKRAS	NA	[HC]_2.044/2.088_NA	TIER_3	VUS	NA	SOM	NA	Vatalanib|Sorafenib_Tosylate|Pazopanib_Hydrochloride|Sorafenib|Dasatinib|Masitinib|Regorafenib|Regorafenib_Hydrate|Semaxanib|Anlotinib|Famitinib|Pexidartinib|Sitravatinib|Pexidartinib_Hydrochloride|Avapritinib|Ripretinib|Pazopanib|Cediranib|Dovitinib|Sunitinib_Malate|Motesanib|Quizartinib|Midostaurin|Imatinib	missense_variant:E:KIT:ENSP00000390987.2:p.(Pro31Leu)|E:KIT:Canonical:ENSP00000288135.5:p.(Pro31Leu)|R:KIT:NP_001087241.1:p.(Pro31Leu)|R:KIT:Canonical:NP_000213.1:p.(Pro31Leu)|R:KIT:XP_005265799.1:p.(Pro31Leu)|R:KIT:XP_005265797.1:p.(Pro31Leu)|R:KIT:XP_005265798.1:p.(Pro31Leu)	class	NA	all_exons;IS:introns[16],exons[8-9,11-13,17]	.	.	include	.	.	.
CL-AcroMetrix	KIT	ENST00000288135	NM_000222	4:55561764	G>A	c.154G>A	exon2	D52N	Asp52Asn	c.154G>A:exon2:D52N:Asp52Asn	missense_variant	1166	0.072	NA	NA	NA	NA	COSV55391210	rs121913505	376254	1.99e-05	NA	0.0000088	NA	NA	NA	NA	T:112+3+0+0=115/463|N:6+0+0+0=6/104|A:118+3+0+0=121/567	NA	RTKRAS	NA	[HC]_2.044/2.088_NA	TIER_3	VUS	VUS	SOM	Immunoglobulin_domain	Vatalanib|Sorafenib_Tosylate|Pazopanib_Hydrochloride|Sorafenib|Dasatinib|Masitinib|Regorafenib|Regorafenib_Hydrate|Semaxanib|Anlotinib|Famitinib|Pexidartinib|Sitravatinib|Pexidartinib_Hydrochloride|Avapritinib|Ripretinib|Pazopanib|Cediranib|Dovitinib|Sunitinib_Malate|Motesanib|Quizartinib|Midostaurin|Imatinib	missense_variant:E:KIT:ENSP00000390987.2:p.(Asp52Asn)|E:KIT:Canonical:ENSP00000288135.5:p.(Asp52Asn)|R:KIT:NP_001087241.1:p.(Asp52Asn)|R:KIT:Canonical:NP_000213.1:p.(Asp52Asn)|R:KIT:XP_005265799.1:p.(Asp52Asn)|R:KIT:XP_005265797.1:p.(Asp52Asn)|R:KIT:XP_005265798.1:p.(Asp52Asn)	class	NA	all_exons;IS:introns[16],exons[8-9,11-13,17]	.	.	include	variant_in_more_than_10%_of_tumor_samples_(24.19%)_with_VAF_under_0.01	.	.
CL-AcroMetrix	KIT	ENST00000288135	NM_000222	4:55561828	A>G	c.218A>G	exon2	E73G	Glu73Gly	c.218A>G:exon2:E73G:Glu73Gly	missense_variant	1100	0.082	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	T:10+0+0+0=10/463|N:3+0+0+0=3/104|A:13+0+0+0=13/567	NA	RTKRAS	NA	[HC]_2.044/2.088_NA	TIER_3	VUS	NA	SOM	Immunoglobulin_domain	Vatalanib|Sorafenib_Tosylate|Pazopanib_Hydrochloride|Sorafenib|Dasatinib|Masitinib|Regorafenib|Regorafenib_Hydrate|Semaxanib|Anlotinib|Famitinib|Pexidartinib|Sitravatinib|Pexidartinib_Hydrochloride|Avapritinib|Ripretinib|Pazopanib|Cediranib|Dovitinib|Sunitinib_Malate|Motesanib|Quizartinib|Midostaurin|Imatinib	missense_variant:E:KIT:ENSP00000390987.2:p.(Glu73Gly)|E:KIT:Canonical:ENSP00000288135.5:p.(Glu73Gly)|R:KIT:NP_001087241.1:p.(Glu73Gly)|R:KIT:Canonical:NP_000213.1:p.(Glu73Gly)|R:KIT:XP_005265799.1:p.(Glu73Gly)|R:KIT:XP_005265797.1:p.(Glu73Gly)|R:KIT:XP_005265798.1:p.(Glu73Gly)	class	NA	all_exons;IS:introns[16],exons[8-9,11-13,17]	.	.	include	.	.	.
CL-AcroMetrix	KIT	ENST00000288135	NM_000222	4:55595599	C>T	c.2089C>T	exon14	H697Y	His697Tyr	c.2089C>T:exon14:H697Y:His697Tyr	missense_variant	824	0.076	NA	NA	NA	NA	COSV55412612|COSV55419237	rs763308199	375925	1.6e-05	NA	0.0000353	NA	NA	NA	NA	T:31+0+0+0=31/463|N:4+0+0+0=4/104|A:35+0+0+0=35/567	NA	RTKRAS	NA	[HC]_2.044/2.088_NA	TIER_3	VUS	VUS	SOM	Protein_tyrosine_and_serine/threonine_kinase	Vatalanib|Sorafenib_Tosylate|Pazopanib_Hydrochloride|Sorafenib|Dasatinib|Masitinib|Regorafenib|Regorafenib_Hydrate|Semaxanib|Anlotinib|Famitinib|Pexidartinib|Sitravatinib|Pexidartinib_Hydrochloride|Avapritinib|Ripretinib|Pazopanib|Cediranib|Dovitinib|Sunitinib_Malate|Motesanib|Quizartinib|Midostaurin|Imatinib	missense_variant:E:KIT:ENSP00000390987.2:p.(His693Tyr)|E:KIT:Canonical:ENSP00000288135.5:p.(His697Tyr)|R:KIT:NP_001087241.1:p.(His693Tyr)|R:KIT:Canonical:NP_000213.1:p.(His697Tyr)|R:KIT:XP_005265799.1:p.(His694Tyr)|R:KIT:XP_005265797.1:p.(His698Tyr)|R:KIT:XP_005265798.1:p.(His698Tyr)	class	NA	all_exons;IS:introns[16],exons[8-9,11-13,17]	.	.	include	.	.	.
CL-AcroMetrix	KIT	ENST00000288135	NM_000222	4:55597561	G>A	c.2209G>A	exon15	D737N	Asp737Asn	c.2209G>A:exon15:D737N:Asp737Asn	missense_variant	980	0.056	NA	NA	NA	NA	COSV55388246|COSV99853506	rs751005114	237256	8e-06	NA	0.0000000	NA	NA	Uterine_Corpus_Endometrial_Carcinoma:_0.2%_(1/530)	NA	T:138+0+0+0=138/463|N:15+0+0+0=15/104|A:153+0+0+0=153/567	NA	RTKRAS	NA	[HC]_2.044/2.088_NA	TIER_3	VUS	VUS	SOM	Protein_tyrosine_and_serine/threonine_kinase	Vatalanib|Sorafenib_Tosylate|Pazopanib_Hydrochloride|Sorafenib|Dasatinib|Masitinib|Regorafenib|Regorafenib_Hydrate|Semaxanib|Anlotinib|Famitinib|Pexidartinib|Sitravatinib|Pexidartinib_Hydrochloride|Avapritinib|Ripretinib|Pazopanib|Cediranib|Dovitinib|Sunitinib_Malate|Motesanib|Quizartinib|Midostaurin|Imatinib	missense_variant:E:KIT:ENSP00000390987.2:p.(Asp733Asn)|E:KIT:Canonical:ENSP00000288135.5:p.(Asp737Asn)|R:KIT:NP_001087241.1:p.(Asp733Asn)|R:KIT:Canonical:NP_000213.1:p.(Asp737Asn)|R:KIT:XP_005265799.1:p.(Asp734Asn)|R:KIT:XP_005265797.1:p.(Asp738Asn)|R:KIT:XP_005265798.1:p.(Asp737Asn)	class	NA	all_exons;IS:introns[16],exons[8-9,11-13,17]	.	.	include	variant_in_more_than_10%_of_tumor_samples_(29.81%)_with_VAF_under_0.01	.	.
CL-AcroMetrix	KIT	ENST00000288135	NM_000222	4:55599284	C>T	c.2410C>T	exon17	R804W	Arg804Trp	c.2410C>T:exon17:R804W:Arg804Trp	missense_variant	863	0.085	NA	NA	NA	NA	COSV55388252	rs145602440	458919	1.2e-05	2e-04	0.0000176	SAS_AF_1KG:0.0010000	NA	Uterine_Corpus_Endometrial_Carcinoma:_0.2%_(1/530)	NA	T:136+3+0+0=139/463|N:3+0+0+0=3/104|A:139+3+0+0=142/567	NA	RTKRAS	NA	[HC]_2.044/2.088_NA	TIER_3	VUS	VUS	SOM	Protein_tyrosine_and_serine/threonine_kinase	Vatalanib|Sorafenib_Tosylate|Pazopanib_Hydrochloride|Sorafenib|Dasatinib|Masitinib|Regorafenib|Regorafenib_Hydrate|Semaxanib|Anlotinib|Famitinib|Pexidartinib|Sitravatinib|Pexidartinib_Hydrochloride|Avapritinib|Ripretinib|Pazopanib|Cediranib|Dovitinib|Sunitinib_Malate|Motesanib|Quizartinib|Midostaurin|Imatinib	missense_variant:E:KIT:ENSP00000390987.2:p.(Arg800Trp)|E:KIT:Canonical:ENSP00000288135.5:p.(Arg804Trp)|R:KIT:NP_001087241.1:p.(Arg800Trp)|R:KIT:Canonical:NP_000213.1:p.(Arg804Trp)|R:KIT:XP_005265799.1:p.(Arg801Trp)|R:KIT:XP_005265797.1:p.(Arg805Trp)|R:KIT:XP_005265798.1:p.(Arg804Trp)	class	germline_population	all_exons;IS:introns[16],exons[8-9,11-13,17]	.	.	exclude	germline_population,variant_in_more_than_10%_of_tumor_samples_(29.37%)_with_VAF_under_0.01	.	.
CL-AcroMetrix	MET	ENST00000318493	NM_001127500	7:116417499	C>G	c.3370C>G	exon16	H1124D	His1124Asp	c.3370C>G:exon16:H1124D:His1124Asp	missense_variant	1108	0.188	NA	NA	NA	NA	COSV59259344|COSV59263269	NA	NA	NA	NA	NA	NA	NA	NA	NA	T:9+0+0+0=9/463|N:0+0+0+0=0/104|A:9+0+0+0=9/567	NA	RTKRAS	NA	[HC]_2.166/2.332_NA	TIER_3	VUS	NA	SOM	Protein_tyrosine_and_serine/threonine_kinase	Onartuzumab|Cabozantinib_S-malate|Tivantinib|Cabozantinib|Capmatinib|Savolitinib|Tepotinib|Sitravatinib|Capmatinib_Hydrochloride|Tepotinib_Hydrochloride|Crizotinib	missense_variant:R:MET:XP_005250410.1:p.(His1143Asp)|R:MET:NP_001311331.1:p.(His676Asp)|R:MET:Canonical:NP_001120972.1:p.(His1124Asp)|R:MET:NP_000236.2:p.(His1106Asp)|E:MET:ENSP00000380860.3:p.(His1106Asp)|E:MET:Canonical:ENSP00000317272.6:p.(His1124Asp)|R:MET:NP_001120972.1:p.(His1124Asp)|R:MET:NP_000236.2:p.(His1106Asp)|R:MET:XP_005250411.1:p.(His676Asp);downstream_gene_variant:E:MET:ENST00000454623.1;5_prime_UTR_variant:E:MET:ENST00000539704.1	class	NA	IS:all_exons	.	.	include	.	.	.
CL-AcroMetrix	MET	ENST00000318493	NM_001127500	7:116418969	G>C	c.3534G>C	exon17	M1178I	Met1178Ile	c.3534G>C:exon17:M1178I:Met1178Ile	missense_variant	1257	0.158	NA	NA	NA	NA	COSV100577294|COSV59257974|COSV59264777	NA	NA	NA	NA	NA	NA	NA	NA	NA	T:6+0+0+0=6/463|N:2+0+0+0=2/104|A:8+0+0+0=8/567	NA	RTKRAS	NA	[HC]_2.166/2.332_NA	TIER_3	VUS	NA	SOM	Protein_tyrosine_and_serine/threonine_kinase	Onartuzumab|Cabozantinib_S-malate|Tivantinib|Cabozantinib|Capmatinib|Savolitinib|Tepotinib|Sitravatinib|Capmatinib_Hydrochloride|Tepotinib_Hydrochloride|Crizotinib	missense_variant:R:MET:XP_005250410.1:p.(Met1197Ile)|R:MET:NP_001311331.1:p.(Met730Ile)|R:MET:Canonical:NP_001120972.1:p.(Met1178Ile)|R:MET:NP_000236.2:p.(Met1160Ile)|E:MET:ENSP00000380860.3:p.(Met1160Ile)|E:MET:Canonical:ENSP00000317272.6:p.(Met1178Ile)|R:MET:NP_001120972.1:p.(Met1178Ile)|R:MET:NP_000236.2:p.(Met1160Ile)|R:MET:XP_005250411.1:p.(Met730Ile)|E:MET:ENSP00000445020.1:p.(Met30Ile);downstream_gene_variant:E:MET:ENST00000454623.1	class	NA	IS:all_exons	.	.	include	.	.	.
CL-AcroMetrix	MET	ENST00000318493	NM_001127500	7:116422133	T>G	c.3668T>G	exon18	L1223W	Leu1223Trp	c.3668T>G:exon18:L1223W:Leu1223Trp	missense_variant	882	0.172	NA	NA	NA	NA	COSV59261459	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	RTKRAS	NA	[HC]_2.166/2.332_NA	TIER_3	VUS	NA	SOM	Protein_tyrosine_and_serine/threonine_kinase	Onartuzumab|Cabozantinib_S-malate|Tivantinib|Cabozantinib|Capmatinib|Savolitinib|Tepotinib|Sitravatinib|Capmatinib_Hydrochloride|Tepotinib_Hydrochloride|Crizotinib	missense_variant:R:MET:XP_005250410.1:p.(Leu1242Trp)|R:MET:NP_001311331.1:p.(Leu775Trp)|R:MET:Canonical:NP_001120972.1:p.(Leu1223Trp)|R:MET:NP_000236.2:p.(Leu1205Trp)|E:MET:ENSP00000380860.3:p.(Leu1205Trp)|E:MET:Canonical:ENSP00000317272.6:p.(Leu1223Trp)|R:MET:NP_001120972.1:p.(Leu1223Trp)|R:MET:NP_000236.2:p.(Leu1205Trp)|R:MET:XP_005250411.1:p.(Leu775Trp)|E:MET:ENSP00000445020.1:p.(Leu75Trp)	class	NA	IS:all_exons	.	.	include	no_recurrence_data	.	.
CL-AcroMetrix	MET	ENST00000318493	NM_001127500	7:116423428	T>G	c.3757T>G	exon19	Y1253D	Tyr1253Asp	c.3757T>G:exon19:Y1253D:Tyr1253Asp	missense_variant	989	0.151	NA	NA	NA	NA	COSV59257036|COSV59270155	rs1057519824	376200	NA	NA	NA	NA	NA	NA	NA	T:4+0+0+0=4/463|N:1+0+0+0=1/104|A:5+0+0+0=5/567	NA	RTKRAS	NA	[HC]_2.166/2.332_NA	TIER_3	VUS	Likely_Pathogenic	SOM	Protein_tyrosine_and_serine/threonine_kinase	Onartuzumab|Cabozantinib_S-malate|Tivantinib|Cabozantinib|Capmatinib|Savolitinib|Tepotinib|Sitravatinib|Capmatinib_Hydrochloride|Tepotinib_Hydrochloride|Crizotinib	missense_variant:R:MET:XP_005250410.1:p.(Tyr1272Asp)|R:MET:NP_001311331.1:p.(Tyr805Asp)|R:MET:Canonical:NP_001120972.1:p.(Tyr1253Asp)|R:MET:NP_000236.2:p.(Tyr1235Asp)|E:MET:ENSP00000380860.3:p.(Tyr1235Asp)|E:MET:Canonical:ENSP00000317272.6:p.(Tyr1253Asp)|R:MET:NP_001120972.1:p.(Tyr1253Asp)|R:MET:NP_000236.2:p.(Tyr1235Asp)|R:MET:XP_005250411.1:p.(Tyr805Asp)|E:MET:ENSP00000445020.1:p.(Tyr105Asp)	ClinVar_classification|class	NA	IS:all_exons	.	.	include	.	.	.
CL-AcroMetrix	MET	ENST00000318493	NM_001127500	7:116423449	G>T	c.3778G>T	exon19	G1260C	Gly1260Cys	c.3778G>T:exon19:G1260C:Gly1260Cys	missense_variant	1010	0.123	NA	NA	NA	NA	COSV59267588	NA	NA	NA	NA	NA	NA	NA	NA	NA	T:35+0+0+0=35/463|N:6+0+0+0=6/104|A:41+0+0+0=41/567	NA	RTKRAS	NA	[HC]_2.166/2.332_NA	TIER_3	VUS	NA	SOM	Protein_tyrosine_and_serine/threonine_kinase	Onartuzumab|Cabozantinib_S-malate|Tivantinib|Cabozantinib|Capmatinib|Savolitinib|Tepotinib|Sitravatinib|Capmatinib_Hydrochloride|Tepotinib_Hydrochloride|Crizotinib	missense_variant:R:MET:XP_005250410.1:p.(Gly1279Cys)|R:MET:NP_001311331.1:p.(Gly812Cys)|R:MET:Canonical:NP_001120972.1:p.(Gly1260Cys)|R:MET:NP_000236.2:p.(Gly1242Cys)|E:MET:ENSP00000380860.3:p.(Gly1242Cys)|E:MET:Canonical:ENSP00000317272.6:p.(Gly1260Cys)|R:MET:NP_001120972.1:p.(Gly1260Cys)|R:MET:NP_000236.2:p.(Gly1242Cys)|R:MET:XP_005250411.1:p.(Gly812Cys)|E:MET:ENSP00000445020.1:p.(Gly112Cys)	class	NA	IS:all_exons	.	.	include	.	.	.
CL-AcroMetrix	MET	ENST00000318493	NM_001127500	7:116423456	A>G	c.3785A>G	exon19	K1262R	Lys1262Arg	c.3785A>G:exon19:K1262R:Lys1262Arg	missense_variant	1025	0.123	NA	NA	NA	NA	COSV59272813	rs121913677	13890	NA	NA	NA	NA	NA	NA	NA	T:9+0+0+0=9/463|N:2+0+0+0=2/104|A:11+0+0+0=11/567	NA	RTKRAS	NA	[HC]_2.166/2.332_NA	TIER_3	VUS	Pathogenic	SOM	Protein_tyrosine_and_serine/threonine_kinase	Onartuzumab|Cabozantinib_S-malate|Tivantinib|Cabozantinib|Capmatinib|Savolitinib|Tepotinib|Sitravatinib|Capmatinib_Hydrochloride|Tepotinib_Hydrochloride|Crizotinib	missense_variant:R:MET:XP_005250410.1:p.(Lys1281Arg)|R:MET:NP_001311331.1:p.(Lys814Arg)|R:MET:Canonical:NP_001120972.1:p.(Lys1262Arg)|R:MET:NP_000236.2:p.(Lys1244Arg)|E:MET:ENSP00000380860.3:p.(Lys1244Arg)|E:MET:Canonical:ENSP00000317272.6:p.(Lys1262Arg)|R:MET:NP_001120972.1:p.(Lys1262Arg)|R:MET:NP_000236.2:p.(Lys1244Arg)|R:MET:XP_005250411.1:p.(Lys814Arg)|E:MET:ENSP00000445020.1:p.(Lys114Arg)	ClinVar_classification|class	NA	IS:all_exons	.	.	include	.	.	.
CL-AcroMetrix	MPL	ENST00000372470	NM_005373	1:43814979	G>A	c.1514G>A	exon10	S505N	Ser505Asn	c.1514G>A:exon10:S505N:Ser505Asn	missense_variant	1460	0.051	NA	NA	NA	NA	COSV65244631	rs121913614	14163	NA	NA	NA	NA	NA	NA	NA	T:34+1+0+0=35/463|N:2+0+0+0=2/104|A:36+1+0+0=37/567	NA	NA	NA	[non-HC]_1.882/1.764_NA	TIER_3	VUS	Pathogenic	SOM	NA	NA	missense_variant:R:MPL:Canonical:NP_005364.1:p.(Ser505Asn)|E:MPL:Canonical:ENSP00000361548.3:p.(Ser505Asn)|E:MPL:ENSP00000414004.2:p.(Ser505Asn)|R:MPL:XP_005270931.1:p.(Ser498Asn)	ClinVar_classification|class	NA	all_exons;IS:exons[10]	.	.	include	.	.	.
CL-AcroMetrix	MPL	ENST00000372470	NM_005373	1:43815009	G>T	c.1544G>T	exon10	W515L	Trp515Leu	c.1544G>T:exon10:W515L:Trp515Leu	missense_variant	1446	0.046	NA	NA	NA	NA	COSV65243776|COSV65245195	rs121913615	14164	8e-06	NA	0.0000000	NA	NA	NA	NA	T:28+0+0+0=28/463|N:2+1+0+0=3/104|A:30+1+0+0=31/567	NA	NA	NA	[non-HC]_1.882/1.764_NA	TIER_3	VUS	VUS	SOM	NA	NA	missense_variant:R:MPL:Canonical:NP_005364.1:p.(Trp515Leu)|E:MPL:Canonical:ENSP00000361548.3:p.(Trp515Leu)|E:MPL:ENSP00000414004.2:p.(Trp515Leu)|R:MPL:XP_005270931.1:p.(Trp508Leu)	class	NA	all_exons;IS:exons[10]	.	.	include	.	.	.
CL-AcroMetrix	MPL	ENST00000372470	NM_005373	1:43815020	G>A	c.1555G>A	exon10	A519T	Ala519Thr	c.1555G>A:exon10:A519T:Ala519Thr	missense_variant	1409	0.048	NA	NA	NA	NA	COSV65245624	NA	NA	NA	NA	NA	NA	NA	NA	NA	T:52+0+0+0=52/463|N:5+0+0+0=5/104|A:57+0+0+0=57/567	NA	NA	NA	[non-HC]_1.882/1.764_NA	TIER_3	VUS	NA	SOM	NA	NA	missense_variant:R:MPL:Canonical:NP_005364.1:p.(Ala519Thr)|E:MPL:Canonical:ENSP00000361548.3:p.(Ala519Thr)|E:MPL:ENSP00000414004.2:p.(Ala519Thr)|R:MPL:XP_005270931.1:p.(Ala512Thr)	class	NA	all_exons;IS:exons[10]	.	.	include	variant_in_more_than_10%_of_tumor_samples_(11.23%)_with_VAF_under_0.01	.	.
CL-AcroMetrix	NOTCH1	ENST00000277541	NA	9:139397768	A>G	c.5033T>C	exon27	L1678P	Leu1678Pro	c.5033T>C:exon27:L1678P:Leu1678Pro	missense_variant	1372	0.144	NA	NA	NA	NA	COSV53024869|COSV53029241	NA	NA	NA	NA	NA	NA	NA	NA	NA	T:17+0+0+0=17/463|N:8+0+0+0=8/104|A:25+0+0+0=25/567	NA	NOTCH	NA	[non-HC]_2.294/2.588_NA	TIER_3	VUS	NA	SOM	NOTCH_protein	NA	missense_variant:R:NOTCH1:Canonical:NP_060087.3:p.(Leu1678Pro)|R:NOTCH1:NP_060087.3:p.(Leu1678Pro)|E:NOTCH1:Canonical:ENSP00000277541.6:p.(Leu1678Pro)	class	NA	all_exons	.	.	include	.	.	.
CL-AcroMetrix	NOTCH1	ENST00000277541	NA	9:139399344	A>G	c.4799T>C	exon26	L1600P	Leu1600Pro	c.4799T>C:exon26:L1600P:Leu1600Pro	missense_variant	1683	0.122	NA	NA	NA	NA	COSV53025622|COSV53031185	NA	NA	NA	NA	NA	NA	NA	NA	NA	T:9+0+0+0=9/463|N:0+0+0+0=0/104|A:9+0+0+0=9/567	NA	NOTCH	NA	[non-HC]_2.294/2.588_NA	TIER_3	VUS	NA	SOM	NOTCH_protein	NA	missense_variant:R:NOTCH1:Canonical:NP_060087.3:p.(Leu1600Pro)|R:NOTCH1:NP_060087.3:p.(Leu1600Pro)|E:NOTCH1:Canonical:ENSP00000277541.6:p.(Leu1600Pro)	class	NA	all_exons	.	.	include	.	.	.
CL-AcroMetrix	NOTCH1	ENST00000277541	NA	9:139399350	C>G	c.4793G>C	exon26	R1598P	Arg1598Pro	c.4793G>C:exon26:R1598P:Arg1598Pro	missense_variant	1656	0.117	NA	NA	NA	NA	COSV53027279|COSV53097635	NA	NA	NA	NA	NA	NA	NA	NA	NA	T:12+0+0+0=12/463|N:2+0+0+0=2/104|A:14+0+0+0=14/567	NA	NOTCH	NA	[non-HC]_2.294/2.588_NA	TIER_3	VUS	NA	SOM	NOTCH_protein	NA	missense_variant:R:NOTCH1:Canonical:NP_060087.3:p.(Arg1598Pro)|R:NOTCH1:NP_060087.3:p.(Arg1598Pro)|E:NOTCH1:Canonical:ENSP00000277541.6:p.(Arg1598Pro)	class	NA	all_exons	.	.	include	.	.	.
CL-AcroMetrix	NOTCH1	ENST00000277541	NA	9:139399365	A>G	c.4778T>C	exon26	L1593P	Leu1593Pro	c.4778T>C:exon26:L1593P:Leu1593Pro	missense_variant	1653	0.114	NA	NA	NA	NA	COSV53024711	NA	NA	NA	NA	NA	NA	NA	NA	NA	T:13+0+0+0=13/463|N:9+0+0+0=9/104|A:22+0+0+0=22/567	NA	NOTCH	NA	[non-HC]_2.294/2.588_NA	TIER_3	VUS	NA	SOM	NOTCH_protein	NA	missense_variant:R:NOTCH1:Canonical:NP_060087.3:p.(Leu1593Pro)|R:NOTCH1:NP_060087.3:p.(Leu1593Pro)|E:NOTCH1:Canonical:ENSP00000277541.6:p.(Leu1593Pro)	class	NA	all_exons	.	.	include	.	.	.
CL-AcroMetrix	NOTCH1	ENST00000277541	NA	9:139399422	A>G	c.4721T>C	exon26	L1574P	Leu1574Pro	c.4721T>C:exon26:L1574P:Leu1574Pro	missense_variant	1897	0.157	NA	NA	NA	NA	COSV53024760|COSV53072929	NA	NA	NA	NA	NA	NA	NA	NA	NA	T:14+0+0+0=14/463|N:7+0+0+0=7/104|A:21+0+0+0=21/567	NA	NOTCH	NA	[non-HC]_2.294/2.588_NA	TIER_3	VUS	NA	SOM	NOTCH_protein	NA	missense_variant:R:NOTCH1:Canonical:NP_060087.3:p.(Leu1574Pro)|R:NOTCH1:NP_060087.3:p.(Leu1574Pro)|E:NOTCH1:Canonical:ENSP00000277541.6:p.(Leu1574Pro)	class	NA	all_exons	.	.	include	.	.	.
CL-AcroMetrix	NRAS	ENST00000369535	NM_002524	1:115258730	C>T	c.52G>A	exon2	A18T	Ala18Thr	c.52G>A:exon2:A18T:Ala18Thr	missense_variant	1155	0.042	NA	NA	NA	NA	COSV54738309	rs121913248	376028	NA	NA	NA	NA	NA	NA	NA	T:101+1+0+0=102/463|N:8+0+0+0=8/104|A:109+1+0+0=110/567	NA	RTKRAS	NA	[HC]_1.918/1.836_NA	TIER_3	VUS	Likely_Pathogenic	SOM	Ras_family	NA	missense_variant:R:NRAS:Canonical:NP_002515.1:p.(Ala18Thr)|E:NRAS:Canonical:ENSP00000358548.4:p.(Ala18Thr);downstream_gene_variant:E:CSDE1:ENST00000339438.6|R:CSDE1:NM_001242893.1|R:CSDE1:NM_001242892.1|R:CSDE1:Canonical:NM_001242891.1|R:CSDE1:NM_001130523.2|R:CSDE1:NM_007158.5|R:CSDE1:NM_001007553.2|E:CSDE1:Canonical:ENST00000438362.2|R:CSDE1:XM_005271178.1|E:CSDE1:ENST00000358528.4|E:CSDE1:ENST00000261443.5|E:CSDE1:ENST00000530886.1|E:CSDE1:ENST00000369530.1|E:CSDE1:ENST00000534699.1	ClinVar_classification|class	NA	all_exons;IS:exons[2-3]	.	.	include	variant_in_more_than_10%_of_tumor_samples_(21.81%)_with_VAF_under_0.01	.	.
CL-AcroMetrix	NRAS	ENST00000369535	NM_002524	1:115258753	C>T	c.29G>A	exon2	G10E	Gly10Glu	c.29G>A:exon2:G10E:Gly10Glu	missense_variant	1204	0.042	NA	NA	NA	NA	COSV104538716|COSV54739076	NA	NA	NA	NA	NA	NA	NA	NA	NA	T:29+0+0+0=29/463|N:4+0+0+0=4/104|A:33+0+0+0=33/567	NA	RTKRAS	NA	[HC]_1.918/1.836_NA	TIER_3	VUS	NA	SOM	Ras_family	NA	missense_variant:R:NRAS:Canonical:NP_002515.1:p.(Gly10Glu)|E:NRAS:Canonical:ENSP00000358548.4:p.(Gly10Glu);downstream_gene_variant:E:CSDE1:ENST00000339438.6|R:CSDE1:NM_001242893.1|R:CSDE1:NM_001242892.1|R:CSDE1:Canonical:NM_001242891.1|R:CSDE1:NM_001130523.2|R:CSDE1:NM_007158.5|R:CSDE1:NM_001007553.2|E:CSDE1:Canonical:ENST00000438362.2|R:CSDE1:XM_005271178.1|E:CSDE1:ENST00000358528.4|E:CSDE1:ENST00000261443.5|E:CSDE1:ENST00000530886.1|E:CSDE1:ENST00000369530.1|E:CSDE1:ENST00000534699.1	class	NA	all_exons;IS:exons[2-3]	.	.	include	.	.	.
CL-AcroMetrix	PDGFRA	ENST00000257290	NM_001347828|NM_006206|NM_001347829|NM_001347830	4:55144547	C>T	c.2021C>T	exon15	T674I	Thr674Ile	c.2021C>T:exon15:T674I:Thr674Ile	missense_variant	771	0.074	NA	NA	NA	NA	COSV57267767	rs121908587	13550	NA	NA	NA	NA	NA	NA	NA	T:43+2+0+0=45/462|N:3+0+0+0=3/104|A:46+2+0+0=48/566	NA	RTKRAS	NA	[HC]_2.056/2.112_NA	TIER_3	VUS	Pathogenic	SOM	Protein_tyrosine_and_serine/threonine_kinase	Vatalanib|Pazopanib_Hydrochloride|Olaratumab|Masitinib|Regorafenib|Regorafenib_Hydrate|Crenolanib|Linifanib|Orantinib|Famitinib|Avapritinib|Ripretinib|Pazopanib|Cediranib|Nintedanib|Dovitinib|Sunitinib_Malate|Motesanib|Quizartinib|Midostaurin	missense_variant:E:FIP1L1:Canonical:ENSP00000423325.1:p.(Thr434Ile)|R:PDGFRA:NP_001334756.1:p.(Thr674Ile)|R:PDGFRA:Canonical:NP_006197.1:p.(Thr674Ile)|R:PDGFRA:NP_001334757.1:p.(Thr699Ile)|R:PDGFRA:NP_006197.1:p.(Thr674Ile)|E:PDGFRA:Canonical:ENSP00000257290.5:p.(Thr674Ile)|R:PDGFRA:XP_005265801.1:p.(Thr674Ile)|R:PDGFRA:XP_005265800.1:p.(Thr674Ile)|R:PDGFRA:NP_001334758.1:p.(Thr674Ile)|R:PDGFRA:NP_001334759.1:p.(Thr687Ile)	ClinVar_classification|class	NA	all_exons;IS:introns[7,9,11],exons[12,18]	.	.	include	.	.	.
CL-AcroMetrix	PDGFRA	ENST00000257290	NM_001347828|NM_006206|NM_001347829|NM_001347830	4:55152112	C>A	c.2544C>A	exon18	N848K	Asn848Lys	c.2544C>A:exon18:N848K:Asn848Lys	missense_variant	1132	0.044	NA	NA	NA	NA	COSV57271156	NA	NA	NA	NA	NA	NA	NA	NA	NA	T:33+0+0+0=33/463|N:2+0+0+0=2/104|A:35+0+0+0=35/567	NA	RTKRAS	NA	[HC]_2.056/2.112_NA	TIER_3	VUS	NA	SOM	Protein_tyrosine_and_serine/threonine_kinase	Vatalanib|Pazopanib_Hydrochloride|Olaratumab|Masitinib|Regorafenib|Regorafenib_Hydrate|Crenolanib|Linifanib|Orantinib|Famitinib|Avapritinib|Ripretinib|Pazopanib|Cediranib|Nintedanib|Dovitinib|Sunitinib_Malate|Motesanib|Quizartinib|Midostaurin	missense_variant:E:FIP1L1:Canonical:ENSP00000423325.1:p.(Asn608Lys)|R:PDGFRA:Canonical:NP_006197.1:p.(Asn848Lys)|R:PDGFRA:NP_001334757.1:p.(Asn873Lys)|R:PDGFRA:NP_006197.1:p.(Asn848Lys)|E:PDGFRA:Canonical:ENSP00000257290.5:p.(Asn848Lys)|R:PDGFRA:XP_005265800.1:p.(Asn848Lys)|R:PDGFRA:NP_001334758.1:p.(Asn848Lys)|R:PDGFRA:NP_001334759.1:p.(Asn861Lys);downstream_gene_variant:R:PDGFRA:NM_001347827.1|R:PDGFRA:XM_005265744.1	class	NA	all_exons;IS:introns[7,9,11],exons[12,18]	.	.	include	.	.	.
CL-AcroMetrix	PIK3CA	ENST00000263967	NM_006218	3:178916648	G>A	c.35G>A	exon2	G12D	Gly12Asp	c.35G>A:exon2:G12D:Gly12Asp	missense_variant	797	0.094	NA	NA	NA	NA	COSV55899130|COSV55899468	NA	NA	NA	NA	NA	NA	NA	Uterine_Corpus_Endometrial_Carcinoma:_0.2%_(1/530)	NA	T:95+3+0+0=98/463|N:7+0+0+0=7/104|A:102+3+0+0=105/567	NA	PI3K	NA	[HC]_1.812/1.624_NA	TIER_3	VUS	NA	SOM	NA	Buparlisib|Taselisib|Alpelisib|Copanlisib|Copanlisib_Hydrochloride	missense_variant:E:PIK3CA:ENSP00000418145.1:p.(Gly12Asp)|R:PIK3CA:NP_006209.2:p.(Gly12Asp)|E:PIK3CA:Canonical:ENSP00000263967.3:p.(Gly12Asp)|R:PIK3CA:Canonical:NP_006209.2:p.(Gly12Asp)|E:PIK3CA:ENSP00000417479.1:p.(Gly12Asp)	class	NA	all_exons;IS:exons[2-3,5-8,10,14,19,21;coding:1-2,4-7,9,13,18,20]	.	.	include	variant_in_more_than_10%_of_tumor_samples_(20.52%)_with_VAF_under_0.01	.	.
CL-AcroMetrix	PIK3CA	ENST00000263967	NM_006218	3:178916706	A>G	c.93A>G	exon2	I31M	Ile31Met	c.93A>G:exon2:I31M:Ile31Met	missense_variant	877	0.083	NA	NA	NA	NA	COSV55898376	NA	1296992	NA	NA	NA	NA	NA	NA	NA	T:9+1+0+0=10/463|N:5+0+0+0=5/104|A:14+1+0+0=15/567	NA	PI3K	NA	[HC]_1.812/1.624_NA	TIER_3	VUS	VUS	SOM	NA	Buparlisib|Taselisib|Alpelisib|Copanlisib|Copanlisib_Hydrochloride	downstream_gene_variant:E:PIK3CA:ENST00000477735.1;missense_variant:R:PIK3CA:NP_006209.2:p.(Ile31Met)|E:PIK3CA:Canonical:ENSP00000263967.3:p.(Ile31Met)|R:PIK3CA:Canonical:NP_006209.2:p.(Ile31Met)|E:PIK3CA:ENSP00000417479.1:p.(Ile31Met)	class	NA	all_exons;IS:exons[2-3,5-8,10,14,19,21;coding:1-2,4-7,9,13,18,20]	.	.	include	.	.	.
CL-AcroMetrix	PIK3CA	ENST00000263967	NM_006218	3:178917661	A>G	c.536A>G	exon3	K179R	Lys179Arg	c.536A>G:exon3:K179R:Lys179Arg	missense_variant	590	0.083	NA	NA	NA	NA	COSV55997547	NA	NA	NA	NA	NA	NA	NA	NA	NA	T:10+0+0+0=10/463|N:2+0+0+0=2/104|A:12+0+0+0=12/567	NA	PI3K	NA	[HC]_1.812/1.624_NA	TIER_3	VUS	NA	SOM	PI3-kinase_family|ras-binding_domain	Buparlisib|Taselisib|Alpelisib|Copanlisib|Copanlisib_Hydrochloride	downstream_gene_variant:E:PIK3CA:ENST00000477735.1|E:PIK3CA:ENST00000468036.1;missense_variant:R:PIK3CA:NP_006209.2:p.(Lys179Arg)|E:PIK3CA:Canonical:ENSP00000263967.3:p.(Lys179Arg)|R:PIK3CA:Canonical:NP_006209.2:p.(Lys179Arg)	class	NA	all_exons;IS:exons[2-3,5-8,10,14,19,21;coding:1-2,4-7,9,13,18,20]	.	.	include	.	.	.
CL-AcroMetrix	PIK3CA	ENST00000263967	NM_006218	3:178921489	C>T	c.971C>T	exon5	T324I	Thr324Ile	c.971C>T:exon5:T324I:Thr324Ile	missense_variant	828	0.054	NA	NA	NA	NA	COSV55949812	NA	NA	NA	NA	NA	NA	NA	NA	NA	T:37+1+0+0=38/463|N:5+0+0+0=5/104|A:42+1+0+0=43/567	NA	PI3K	NA	[HC]_1.812/1.624_NA	TIER_3	VUS	NA	SOM	NA	Buparlisib|Taselisib|Alpelisib|Copanlisib|Copanlisib_Hydrochloride	downstream_gene_variant:E:PIK3CA:ENST00000477735.1|E:PIK3CA:ENST00000468036.1;missense_variant:R:PIK3CA:NP_006209.2:p.(Thr324Ile)|E:PIK3CA:Canonical:ENSP00000263967.3:p.(Thr324Ile)|R:PIK3CA:Canonical:NP_006209.2:p.(Thr324Ile)	class	NA	all_exons;IS:exons[2-3,5-8,10,14,19,21;coding:1-2,4-7,9,13,18,20]	.	.	include	.	.	.
CL-AcroMetrix	PIK3CA	ENST00000263967	NM_006218	3:178927450	T>C	c.1213T>C	exon7	S405P	Ser405Pro	c.1213T>C:exon7:S405P:Ser405Pro	missense_variant	841	0.068	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	T:18+0+0+0=18/463|N:6+0+0+0=6/104|A:24+0+0+0=24/567	NA	PI3K	NA	[HC]_1.812/1.624_NA	TIER_3	VUS	NA	SOM	Phosphoinositide_3-kinase_C2	Buparlisib|Taselisib|Alpelisib|Copanlisib|Copanlisib_Hydrochloride	missense_variant:R:PIK3CA:NP_006209.2:p.(Ser405Pro)|E:PIK3CA:Canonical:ENSP00000263967.3:p.(Ser405Pro)|R:PIK3CA:Canonical:NP_006209.2:p.(Ser405Pro)	class	NA	all_exons;IS:exons[2-3,5-8,10,14,19,21;coding:1-2,4-7,9,13,18,20]	.	.	include	.	.	.
CL-AcroMetrix	PIK3CA	ENST00000263967	NM_006218	3:178928092	A>G	c.1370A>G	exon8	N457S	Asn457Ser	c.1370A>G:exon8:N457S:Asn457Ser	missense_variant	895	0.088	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	T:7+0+0+0=7/463|N:3+0+0+0=3/104|A:10+0+0+0=10/567	NA	PI3K	NA	[HC]_1.812/1.624_NA	TIER_3	VUS	NA	SOM	Phosphoinositide_3-kinase_C2	Buparlisib|Taselisib|Alpelisib|Copanlisib|Copanlisib_Hydrochloride	missense_variant:R:PIK3CA:NP_006209.2:p.(Asn457Ser)|E:PIK3CA:Canonical:ENSP00000263967.3:p.(Asn457Ser)|R:PIK3CA:Canonical:NP_006209.2:p.(Asn457Ser)	class	NA	all_exons;IS:exons[2-3,5-8,10,14,19,21;coding:1-2,4-7,9,13,18,20]	.	.	include	.	.	.
CL-AcroMetrix	PIK3CA	ENST00000263967	NM_006218	3:178938860	A>C	c.2102A>C	exon14	H701P	His701Pro	c.2102A>C:exon14:H701P:His701Pro	missense_variant	582	0.108	NA	NA	NA	NA	COSV55886031	rs121913282	376052	NA	NA	NA	NA	NA	NA	NA	T:1+0+0+0=1/460|N:1+0+0+0=1/104|A:2+0+0+0=2/564	NA	PI3K	NA	[HC]_1.812/1.624_NA	TIER_3	VUS	Likely_Pathogenic	SOM	Phosphoinositide_3-kinase_family|accessory_domain_(PIK_domain)	Buparlisib|Taselisib|Alpelisib|Copanlisib|Copanlisib_Hydrochloride	missense_variant:R:PIK3CA:NP_006209.2:p.(His701Pro)|E:PIK3CA:Canonical:ENSP00000263967.3:p.(His701Pro)|R:PIK3CA:Canonical:NP_006209.2:p.(His701Pro)	ClinVar_classification|class	NA	all_exons;IS:exons[2-3,5-8,10,14,19,21;coding:1-2,4-7,9,13,18,20]	.	.	include	.	.	.
CL-AcroMetrix	PIK3CA	ENST00000263967	NM_006218	3:178947850	T>C	c.2725T>C	exon19	F909L	Phe909Leu	c.2725T>C:exon19:F909L:Phe909Leu	missense_variant	860	0.072	NA	NA	NA	NA	COSV55882710	NA	NA	NA	NA	NA	NA	NA	NA	NA	T:6+0+1+0=7/463|N:4+0+0+0=4/104|A:10+0+1+0=11/567	NA	PI3K	NA	[HC]_1.812/1.624_NA	TIER_3	VUS	NA	SOM	Phosphatidylinositol_3-_and_4-kinase	Buparlisib|Taselisib|Alpelisib|Copanlisib|Copanlisib_Hydrochloride	missense_variant:R:PIK3CA:NP_006209.2:p.(Phe909Leu)|E:PIK3CA:Canonical:ENSP00000263967.3:p.(Phe909Leu)|R:PIK3CA:Canonical:NP_006209.2:p.(Phe909Leu)	class	NA	all_exons;IS:exons[2-3,5-8,10,14,19,21;coding:1-2,4-7,9,13,18,20]	.	.	include	.	.	.
CL-AcroMetrix	PTEN	ENST00000371953	NM_000314	10:89624266	A>G	c.40A>G	exon1	R14G	Arg14Gly	c.40A>G:exon1:R14G:Arg14Gly	missense_variant	1273	0.045	NA	NA	NA	NA	COSV64289619|COSV64304205	rs1085308047	427589	NA	NA	NA	NA	NA	NA	NA	T:21+0+0+0=21/463|N:6+0+0+0=6/104|A:27+0+0+0=27/567	NA	PI3K	NA	[HC]_1.964/1.928_NA	TIER_3	VUS	Likely_Pathogenic	SOM	NA	NA	upstream_gene_variant:E:KLLN:Canonical:ENST00000445946.3|R:KLLN:Canonical:NM_001126049.1;missense_variant:E:PTEN:Canonical:ENSP00000361021.3:p.(Arg14Gly)|R:PTEN:NP_000305.3:p.(Arg14Gly)|R:PTEN:Canonical:NP_000305.3:p.(Arg14Gly)|R:PTEN:NP_001291646.2:p.(Arg187Gly);5_prime_UTR_variant:R:PTEN:NM_001304718.1	ClinVar_classification|class	NA	IS:all_exons	.	.	include	.	.	.
CL-AcroMetrix	PTEN	ENST00000371953	NM_000314	10:89653844	A>G	c.142A>G	exon2	N48D	Asn48Asp	c.142A>G:exon2:N48D:Asn48Asp	missense_variant	677	0.109	NA	NA	NA	NA	COSV64298680	NA	918670	NA	NA	NA	NA	NA	NA	NA	T:12+0+0+0=12/462|N:3+0+0+0=3/104|A:15+0+0+0=15/566	NA	PI3K	NA	[HC]_1.964/1.928_NA	TIER_3	Likely_Pathogenic	VUS	SOM	NA	NA	missense_variant:E:PTEN:Canonical:ENSP00000361021.3:p.(Asn48Asp)|R:PTEN:NP_000305.3:p.(Asn48Asp)|R:PTEN:Canonical:NP_000305.3:p.(Asn48Asp)|R:PTEN:NP_001291646.2:p.(Asn221Asp);5_prime_UTR_variant:R:PTEN:NM_001304718.1	CPSR_classification|class	NA	IS:all_exons	.	.	include	.	.	.
CL-AcroMetrix	PTEN	ENST00000371953	NM_000314	10:89692779	A>G	c.263A>G	exon5	Y88C	Tyr88Cys	c.263A>G:exon5:Y88C:Tyr88Cys	missense_variant	725	0.114	NA	NA	NA	NA	COSV64295989|COSV64298676	NA	NA	NA	NA	NA	NA	NA	NA	NA	T:3+0+0+0=3/463|N:0+0+0+0=0/104|A:3+0+0+0=3/567	NA	PI3K	NA	[HC]_1.964/1.928_NA	TIER_3	VUS	NA	SOM	Dual_specificity_phosphatase|catalytic_domain	NA	missense_variant:E:PTEN:Canonical:ENSP00000361021.3:p.(Tyr88Cys)|R:PTEN:NP_000305.3:p.(Tyr88Cys)|R:PTEN:Canonical:NP_000305.3:p.(Tyr88Cys)|R:PTEN:NP_001291646.2:p.(Tyr261Cys);5_prime_UTR_variant:R:PTEN:NM_001304718.1	class	NA	IS:all_exons	.	.	include	.	.	.
CL-AcroMetrix	PTEN	ENST00000371953	NM_000314	10:89692830	G>T	c.314G>T	exon5	C105F	Cys105Phe	c.314G>T:exon5:C105F:Cys105Phe	missense_variant	592	0.044	NA	NA	NA	NA	COSV64290665|COSV64299259|COSV64307337	NA	NA	NA	NA	NA	NA	NA	NA	NA	T:7+1+0+0=8/457|N:2+0+0+0=2/104|A:9+1+0+0=10/561	NA	PI3K	NA	[HC]_1.964/1.928_NA	TIER_3	VUS	NA	SOM	Dual_specificity_phosphatase|catalytic_domain	NA	missense_variant:E:PTEN:Canonical:ENSP00000361021.3:p.(Cys105Phe)|R:PTEN:NP_000305.3:p.(Cys105Phe)|R:PTEN:Canonical:NP_000305.3:p.(Cys105Phe)|R:PTEN:NP_001291646.2:p.(Cys278Phe);5_prime_UTR_variant:R:PTEN:NM_001304718.1	class	NA	IS:all_exons	.	.	include	.	.	.
CL-AcroMetrix	PTEN	ENST00000371953	NM_000314	10:89692850	C>G	c.334C>G	exon5	L112V	Leu112Val	c.334C>G:exon5:L112V:Leu112Val	missense_variant	626	0.067	NA	NA	NA	NA	COSV64293200	NA	NA	NA	NA	NA	NA	NA	Uterine_Corpus_Endometrial_Carcinoma:_0.2%_(1/530)	NA	T:4+1+1+0=6/458|N:1+0+0+0=1/104|A:5+1+1+0=7/562	NA	PI3K	NA	[HC]_1.964/1.928_NA	TIER_3	VUS	NA	SOM	Dual_specificity_phosphatase|catalytic_domain	NA	missense_variant:E:PTEN:Canonical:ENSP00000361021.3:p.(Leu112Val)|R:PTEN:NP_000305.3:p.(Leu112Val)|R:PTEN:Canonical:NP_000305.3:p.(Leu112Val)|R:PTEN:NP_001291646.2:p.(Leu285Val);5_prime_UTR_variant:R:PTEN:NM_001304718.1	class	NA	IS:all_exons	.	.	include	.	.	.
CL-AcroMetrix	PTEN	ENST00000371953	NM_000314	10:89692965	A>G	c.449A>G	exon5	E150G	Glu150Gly	c.449A>G:exon5:E150G:Glu150Gly	missense_variant	764	0.105	NA	NA	NA	NA	COSV64301888	rs1554898193	468687	NA	NA	NA	NA	NA	NA	NA	T:7+0+0+0=7/461|N:3+0+0+0=3/104|A:10+0+0+0=10/565	NA	PI3K	NA	[HC]_1.964/1.928_NA	TIER_3	VUS	VUS	SOM	Dual_specificity_phosphatase|catalytic_domain	NA	missense_variant:E:PTEN:Canonical:ENSP00000361021.3:p.(Glu150Gly)|R:PTEN:NP_000305.3:p.(Glu150Gly)|R:PTEN:Canonical:NP_000305.3:p.(Glu150Gly)|R:PTEN:NP_001291646.2:p.(Glu323Gly);5_prime_UTR_variant:R:PTEN:NM_001304718.1	class	NA	IS:all_exons	.	.	include	.	.	.
CL-AcroMetrix	PTEN	ENST00000371953	NM_000314	10:89692993	G>T	c.477G>T	exon5	R159S	Arg159Ser	c.477G>T:exon5:R159S:Arg159Ser	missense_variant	760	0.136	NA	NA	NA	NA	COSV64288957|COSV64298985	rs1057519724	375959	NA	NA	NA	NA	NA	Glioblastoma_Multiforme:_0.3%_(1/393)|Stomach_Adenocarcinoma:_0.2%_(1/437)	RECA-EU/Primary/1/74/0.0135	T:20+1+0+0=21/463|N:3+1+0+0=4/104|A:23+2+0+0=25/567	PTEN:p.R159S:ENST00000371953:CTAT_CANCER|3D_STRUCTURE	PI3K	NA	[HC]_1.964/1.928_NA	TIER_3	VUS	Likely_Pathogenic	SOM	Dual_specificity_phosphatase|catalytic_domain	NA	missense_variant:E:PTEN:Canonical:ENSP00000361021.3:p.(Arg159Ser)|R:PTEN:NP_000305.3:p.(Arg159Ser)|R:PTEN:Canonical:NP_000305.3:p.(Arg159Ser)|R:PTEN:NP_001291646.2:p.(Arg332Ser);5_prime_UTR_variant:R:PTEN:NM_001304718.1	ClinVar_classification|class	NA	IS:all_exons	.	.	include	.	.	.
CL-AcroMetrix	PTEN	ENST00000371953	NM_000314	10:89711960	T>C	c.578T>C	exon6	L193P	Leu193Pro	c.578T>C:exon6:L193P:Leu193Pro	missense_variant	979	0.096	NA	NA	NA	NA	COSV64289342	rs1554900620	431875	NA	NA	NA	NA	NA	NA	NA	T:6+0+0+0=6/463|N:3+0+0+0=3/104|A:9+0+0+0=9/567	NA	PI3K	NA	[HC]_1.964/1.928_NA	TIER_3	VUS	VUS	SOM	C2_domain_of_PTEN_tumour-suppressor_protein	NA	missense_variant:E:PTEN:Canonical:ENSP00000361021.3:p.(Leu193Pro)|R:PTEN:NP_000305.3:p.(Leu193Pro)|R:PTEN:Canonical:NP_000305.3:p.(Leu193Pro)|R:PTEN:NP_001291646.2:p.(Leu366Pro);5_prime_UTR_variant:R:PTEN:NM_001304718.1	class	NA	IS:all_exons	.	.	include	.	.	.
CL-AcroMetrix	PTEN	ENST00000371953	NM_000314	10:89711992	C>A	c.610C>A	exon6	P204T	Pro204Thr	c.610C>A:exon6:P204T:Pro204Thr	missense_variant	922	0.066	NA	NA	NA	NA	COSV100909183|COSV64300197|COSV64309520	NA	NA	NA	NA	NA	NA	NA	NA	NA	T:26+3+0+0=29/463|N:5+0+0+0=5/104|A:31+3+0+0=34/567	NA	PI3K	NA	[HC]_1.964/1.928_NA	TIER_3	VUS	NA	SOM	C2_domain_of_PTEN_tumour-suppressor_protein	NA	missense_variant:E:PTEN:Canonical:ENSP00000361021.3:p.(Pro204Thr)|R:PTEN:NP_000305.3:p.(Pro204Thr)|R:PTEN:Canonical:NP_000305.3:p.(Pro204Thr)|R:PTEN:NP_001291647.1:p.(Pro7Thr)|R:PTEN:NP_001291646.2:p.(Pro377Thr)	class	NA	IS:all_exons	.	.	include	.	.	.
CL-AcroMetrix	PTEN	ENST00000371953	NM_000314	10:89711997	G>A	c.615G>A	exon6	M205I	Met205Ile	c.615G>A:exon6:M205I:Met205Ile	missense_variant	912	0.074	NA	NA	NA	NA	COSV64307327	rs1554900653	492734	NA	NA	NA	NA	NA	NA	NA	T:47+2+0+0=49/463|N:1+0+0+0=1/104|A:48+2+0+0=50/567	NA	PI3K	NA	[HC]_1.964/1.928_NA	TIER_3	VUS	VUS	SOM	C2_domain_of_PTEN_tumour-suppressor_protein	NA	missense_variant:E:PTEN:Canonical:ENSP00000361021.3:p.(Met205Ile)|R:PTEN:NP_000305.3:p.(Met205Ile)|R:PTEN:Canonical:NP_000305.3:p.(Met205Ile)|R:PTEN:NP_001291647.1:p.(Met8Ile)|R:PTEN:NP_001291646.2:p.(Met378Ile)	class	NA	IS:all_exons	.	.	include	variant_in_more_than_10%_of_tumor_samples_(10.15%)_with_VAF_under_0.01	.	.
CL-AcroMetrix	PTEN	ENST00000371953	NM_000314	10:89717696	T>C	c.721T>C	exon7	F241L	Phe241Leu	c.721T>C:exon7:F241L:Phe241Leu	missense_variant	1143	0.124	NA	NA	NA	NA	COSV64288616|COSV64291647	rs1554825207	440220	NA	NA	NA	NA	NA	NA	NA	T:11+0+0+0=11/463|N:2+0+0+0=2/104|A:13+0+0+0=13/567	NA	PI3K	NA	[HC]_1.964/1.928_NA	TIER_3	VUS	Likely_Pathogenic	SOM	C2_domain_of_PTEN_tumour-suppressor_protein	NA	missense_variant:E:PTEN:Canonical:ENSP00000361021.3:p.(Phe241Leu)|R:PTEN:NP_000305.3:p.(Phe241Leu)|R:PTEN:Canonical:NP_000305.3:p.(Phe241Leu)|R:PTEN:NP_001291647.1:p.(Phe44Leu)|R:PTEN:NP_001291646.2:p.(Phe414Leu)	ClinVar_classification|class	NA	IS:all_exons	.	.	include	.	.	.
CL-AcroMetrix	PTEN	ENST00000371953	NM_000314	10:89725072	A>G	c.1055A>G	exon9	E352G	Glu352Gly	c.1055A>G:exon9:E352G:Glu352Gly	missense_variant	559	0.114	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	T:7+0+0+0=7/460|N:0+0+0+0=0/104|A:7+0+0+0=7/564	NA	PI3K	NA	[HC]_1.964/1.928_NA	TIER_3	VUS	NA	SOM	NA	NA	missense_variant:E:PTEN:Canonical:ENSP00000361021.3:p.(Glu352Gly)|R:PTEN:NP_000305.3:p.(Glu352Gly)|R:PTEN:Canonical:NP_000305.3:p.(Glu352Gly)|R:PTEN:NP_001291647.1:p.(Glu155Gly)|R:PTEN:NP_001291646.2:p.(Glu525Gly)	class	NA	IS:all_exons	.	.	include	.	.	.
CL-AcroMetrix	PTEN	ENST00000371953	NM_000314	10:89725108	C>G	c.1091C>G	exon9	S364C	Ser364Cys	c.1091C>G:exon9:S364C:Ser364Cys	missense_variant	381	0.142	NA	NA	NA	NA	COSV64289680	rs1164665914	857491	4.2e-06	NA	0.0000000	NA	NA	NA	NA	T:0+0+0+0=0/440|N:1+0+0+0=1/103|A:1+0+0+0=1/543	NA	PI3K	NA	[HC]_1.964/1.928_NA	TIER_3	VUS	VUS	SOM	NA	NA	missense_variant:E:PTEN:Canonical:ENSP00000361021.3:p.(Ser364Cys)|R:PTEN:NP_000305.3:p.(Ser364Cys)|R:PTEN:Canonical:NP_000305.3:p.(Ser364Cys)|R:PTEN:NP_001291647.1:p.(Ser167Cys)|R:PTEN:NP_001291646.2:p.(Ser537Cys)	class	NA	IS:all_exons	.	.	include	.	.	.
CL-AcroMetrix	PTPN11	ENST00000351677	NM_002834|NM_001374625	12:112926852	C>T	c.1472C>T	exon13	P491L	Pro491Leu	c.1472C>T:exon13:P491L:Pro491Leu	missense_variant	952	0.063	NA	NA	NA	NA	COSV61004831	rs397507540	40552	NA	NA	NA	NA	NA	NA	NA	T:48+0+0+0=48/463|N:8+0+0+0=8/104|A:56+0+0+0=56/567	NA	RTKRAS	NA	[non-HC]_2.096/2.192_NA	TIER_3	VUS	Pathogenic	SOM	Protein-tyrosine_phosphatase	NA	downstream_gene_variant:R:PTPN11:NM_080601.1|R:PTPN11:NM_080601.2|E:PTPN11:ENST00000392597.1;missense_variant:R:PTPN11:Canonical:NP_002825.3:p.(Pro491Leu)|R:PTPN11:NP_002825.3:p.(Pro491Leu)|R:PTPN11:NP_001317366.1:p.(Pro495Leu)|E:PTPN11:Canonical:ENSP00000340944.2:p.(Pro491Leu)	ClinVar_classification|class	NA	IS:all_exons	.	.	include	variant_in_more_than_10%_of_tumor_samples_(10.37%)_with_VAF_under_0.01	.	.
CL-AcroMetrix	PTPN11	ENST00000351677	NM_002834|NM_001374625	12:112926888	G>C	c.1508G>C	exon13	G503A	Gly503Ala	c.1508G>C:exon13:G503A:Gly503Ala	missense_variant	891	0.045	NA	NA	NA	NA	COSV61004973|COSV61005158|COSV61008174	rs397507546	162464	NA	NA	NA	NA	NA	NA	NA	T:8+0+0+0=8/462|N:0+0+0+0=0/104|A:8+0+0+0=8/566	NA	RTKRAS	NA	[non-HC]_2.096/2.192_NA	TIER_3	VUS	Pathogenic	SOM	Protein-tyrosine_phosphatase	NA	downstream_gene_variant:R:PTPN11:NM_080601.1|R:PTPN11:NM_080601.2|E:PTPN11:ENST00000392597.1;missense_variant:R:PTPN11:Canonical:NP_002825.3:p.(Gly503Ala)|R:PTPN11:NP_002825.3:p.(Gly503Ala)|R:PTPN11:NP_001317366.1:p.(Gly507Ala)|E:PTPN11:Canonical:ENSP00000340944.2:p.(Gly503Ala)	ClinVar_classification|class	NA	IS:all_exons	.	.	include	.	.	.
CL-AcroMetrix	PTPN11	ENST00000351677	NM_002834|NM_001374625	12:112926899	A>G	c.1519A>G	exon13	T507A	Thr507Ala	c.1519A>G:exon13:T507A:Thr507Ala	missense_variant	836	0.049	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	T:6+0+0+0=6/462|N:3+0+0+0=3/104|A:9+0+0+0=9/566	NA	RTKRAS	NA	[non-HC]_2.096/2.192_NA	TIER_3	VUS	NA	SOM	Protein-tyrosine_phosphatase	NA	downstream_gene_variant:R:PTPN11:NM_080601.1|R:PTPN11:NM_080601.2|E:PTPN11:ENST00000392597.1;missense_variant:R:PTPN11:Canonical:NP_002825.3:p.(Thr507Ala)|R:PTPN11:NP_002825.3:p.(Thr507Ala)|R:PTPN11:NP_001317366.1:p.(Thr511Ala)|E:PTPN11:Canonical:ENSP00000340944.2:p.(Thr507Ala)	class	NA	IS:all_exons	.	.	include	.	.	.
CL-AcroMetrix	PTPN11	ENST00000351677	NM_002834|NM_001374625	12:112926908	C>A	c.1528C>A	exon13	Q510K	Gln510Lys	c.1528C>A:exon13:Q510K:Gln510Lys	missense_variant	807	0.048	NA	NA	NA	NA	COSV61004883|COSV61007076	rs397507549	NA	NA	NA	NA	NA	NA	NA	NA	T:18+0+0+0=18/462|N:4+0+0+0=4/104|A:22+0+0+0=22/566	NA	RTKRAS	NA	[non-HC]_2.096/2.192_NA	TIER_3	Likely_Pathogenic	NA	SOM	Protein-tyrosine_phosphatase	NA	downstream_gene_variant:R:PTPN11:NM_080601.1|R:PTPN11:NM_080601.2|E:PTPN11:ENST00000392597.1;missense_variant:R:PTPN11:Canonical:NP_002825.3:p.(Gln510Lys)|R:PTPN11:NP_002825.3:p.(Gln510Lys)|R:PTPN11:NP_001317366.1:p.(Gln514Lys)|E:PTPN11:Canonical:ENSP00000340944.2:p.(Gln510Lys)	CPSR_classification|class	NA	IS:all_exons	.	.	include	.	.	.
CL-AcroMetrix	RB1	ENST00000267163	NM_000321	13:48941658	A>G	c.968A>G	exon10	E323G	Glu323Gly	c.968A>G:exon10:E323G:Glu323Gly	missense_variant	449	0.029	NA	NA	NA	NA	NA	rs765678030	NA	8e-06	NA	0.0000177	NA	NA	NA	NA	T:6+1+0+1=8/459|N:0+0+0+1=1/103|A:6+1+0+2=9/562	NA	CC	3_NA_NA	[non-HC]_2.194/2.388_NA	TIER_3	VUS	NA	SOM	NA	NA	missense_variant:R:RB1:Canonical:NP_000312.2:p.(Glu323Gly)|E:RB1:Canonical:ENSP00000267163.4:p.(Glu323Gly)	class	NA	IS:all_exons	.	.	include	.	.	.
CL-AcroMetrix	RB1	ENST00000267163	NM_000321	13:48941672	A>G	c.982A>G	exon10	N328D	Asn328Asp	c.982A>G:exon10:N328D:Asn328Asp	missense_variant	476	0.038	NA	NA	NA	NA	COSV57297111	NA	NA	NA	NA	NA	NA	NA	NA	NA	T:5+0+0+0=5/460|N:1+0+0+0=1/103|A:6+0+0+0=6/563	NA	CC	3_NA_NA	[non-HC]_2.194/2.388_NA	TIER_3	VUS	NA	SOM	NA	NA	missense_variant:R:RB1:Canonical:NP_000312.2:p.(Asn328Asp)|E:RB1:Canonical:ENSP00000267163.4:p.(Asn328Asp)	class	NA	IS:all_exons	.	.	include	.	.	.
CL-AcroMetrix	RB1	ENST00000267163	NM_000321	13:48955571	T>C	c.1687T>C	exon17	W563R	Trp563Arg	c.1687T>C:exon17:W563R:Trp563Arg	missense_variant	736	0.045	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	T:7+0+0+0=7/463|N:1+0+0+0=1/104|A:8+0+0+0=8/567	NA	CC	3_NA_NA	[non-HC]_2.194/2.388_NA	TIER_3	VUS	NA	SOM	Retinoblastoma-associated_protein_A_domain	NA	missense_variant:R:RB1:Canonical:NP_000312.2:p.(Trp563Arg)|E:RB1:Canonical:ENSP00000267163.4:p.(Trp563Arg)	class	NA	IS:all_exons	.	.	include	.	.	.
CL-AcroMetrix	RB1	ENST00000267163	NM_000321	13:49033926	T>C	c.2063T>C	exon20	L688P	Leu688Pro	c.2063T>C:exon20:L688P:Leu688Pro	missense_variant	1029	0.065	NA	NA	NA	NA	COSV57306650	NA	NA	NA	NA	NA	NA	NA	NA	NA	T:8+0+0+0=8/463|N:9+0+0+0=9/104|A:17+0+0+0=17/567	NA	CC	3_NA_NA	[non-HC]_2.194/2.388_NA	TIER_3	VUS	NA	SOM	Retinoblastoma-associated_protein_B_domain	NA	missense_variant:R:RB1:Canonical:NP_000312.2:p.(Leu688Pro)|E:RB1:Canonical:ENSP00000267163.4:p.(Leu688Pro)	class	NA	IS:all_exons	.	.	include	.	.	.
CL-AcroMetrix	RB1	ENST00000267163	NM_000321	13:49037913	A>G	c.2153A>G	exon21	D718G	Asp718Gly	c.2153A>G:exon21:D718G:Asp718Gly	missense_variant	621	0.029	NA	NA	NA	NA	COSV104386882	NA	NA	NA	NA	NA	NA	NA	NA	NA	T:7+1+0+0=8/462|N:2+0+0+0=2/104|A:9+1+0+0=10/566	NA	CC	3_NA_NA	[non-HC]_2.194/2.388_NA	TIER_3	VUS	NA	SOM	Retinoblastoma-associated_protein_B_domain	NA	missense_variant:R:RB1:Canonical:NP_000312.2:p.(Asp718Gly)|E:RB1:Canonical:ENSP00000267163.4:p.(Asp718Gly)	class	NA	IS:all_exons	.	.	include	.	.	.
CL-AcroMetrix	RB1	ENST00000267163	NM_000321	13:49039183	T>G	c.2261T>G	exon22	V754G	Val754Gly	c.2261T>G:exon22:V754G:Val754Gly	missense_variant	524	0.042	NA	NA	NA	NA	COSV57330766	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	CC	3_NA_NA	[non-HC]_2.194/2.388_NA	TIER_3	VUS	NA	SOM	Retinoblastoma-associated_protein_B_domain	NA	missense_variant:R:RB1:Canonical:NP_000312.2:p.(Val754Gly)|E:RB1:Canonical:ENSP00000267163.4:p.(Val754Gly)	class	NA	IS:all_exons	.	.	include	no_recurrence_data	.	.
CL-AcroMetrix	RB1	ENST00000267163	NM_000321	13:49039189	A>G	c.2267A>G	exon22	Y756C	Tyr756Cys	c.2267A>G:exon22:Y756C:Tyr756Cys	missense_variant	541	0.046	NA	NA	NA	NA	COSV99923579	NA	NA	NA	NA	NA	NA	NA	Lung_Adenocarcinoma:_0.2%_(1/567)	NA	T:11+0+0+0=11/463|N:1+0+0+0=1/104|A:12+0+0+0=12/567	RB1:p.Y756C:ENST00000267163:CTAT_POPULATION|CTAT_CANCER	CC	3_NA_NA	[non-HC]_2.194/2.388_NA	TIER_3	VUS	NA	SOM	Retinoblastoma-associated_protein_B_domain	NA	missense_variant:R:RB1:Canonical:NP_000312.2:p.(Tyr756Cys)|E:RB1:Canonical:ENSP00000267163.4:p.(Tyr756Cys)	class	NA	IS:all_exons	.	.	include	.	.	.
CL-AcroMetrix	RET	ENST00000355710	NM_020975	10:43609096	T>C	c.1852T>C	exon10	C618R	Cys618Arg	c.1852T>C:exon10:C618R:Cys618Arg	missense_variant	1350	0.16	NA	NA	NA	NA	COSV104412334|COSV60699962	rs76262710	13929	4e-06	NA	0.0000000	NA	NA	NA	NA	T:8+0+0+0=8/463|N:5+0+0+0=5/104|A:13+0+0+0=13/567	NA	RTKRAS	1_NA_NA	[HC]_2.206/2.412_NA	TIER_3	Pathogenic	Pathogenic	SOM	NA	Sorafenib_Tosylate|Sorafenib|Alectinib|Regorafenib|Regorafenib_Hydrate|Vandetanib|Sitravatinib|Selpercatinib|Sunitinib_Malate|Motesanib|Quizartinib	missense_variant:E:RET:Canonical:ENSP00000347942.3:p.(Cys618Arg)|R:RET:NP_065681.1:p.(Cys618Arg)|R:RET:Canonical:NP_066124.1:p.(Cys618Arg)|E:RET:ENSP00000419080.1:p.(Cys135Arg)|E:RET:ENSP00000344798.4:p.(Cys618Arg)	CPSR_classification|ClinVar_classification|class	NA	introns[7-8],all_exons;IS:introns[9-11],exons[11,13-16]	.	.	include	.	.	.
CL-AcroMetrix	RET	ENST00000355710	NM_020975	10:43609102	T>C	c.1858T>C	exon10	C620R	Cys620Arg	c.1858T>C:exon10:C620R:Cys620Arg	missense_variant	1348	0.162	NA	NA	NA	NA	COSV60689083|COSV60691231	rs77316810	13915	NA	NA	NA	NA	NA	NA	NA	T:21+0+0+0=21/463|N:4+0+0+0=4/104|A:25+0+0+0=25/567	NA	RTKRAS	1_NA_NA	[HC]_2.206/2.412_NA	TIER_3	Pathogenic	Pathogenic	SOM	NA	Sorafenib_Tosylate|Sorafenib|Alectinib|Regorafenib|Regorafenib_Hydrate|Vandetanib|Sitravatinib|Selpercatinib|Sunitinib_Malate|Motesanib|Quizartinib	missense_variant:E:RET:Canonical:ENSP00000347942.3:p.(Cys620Arg)|R:RET:NP_065681.1:p.(Cys620Arg)|R:RET:Canonical:NP_066124.1:p.(Cys620Arg)|E:RET:ENSP00000419080.1:p.(Cys137Arg)|E:RET:ENSP00000344798.4:p.(Cys620Arg)	CPSR_classification|ClinVar_classification|class	NA	introns[7-8],all_exons;IS:introns[9-11],exons[11,13-16]	.	.	include	.	.	.
CL-AcroMetrix	RET	ENST00000355710	NM_020975	10:43610039	C>A	c.1991C>A	exon11	A664D	Ala664Asp	c.1991C>A:exon11:A664D:Ala664Asp	missense_variant	1704	0.167	NA	NA	NA	NA	COSV60686869	NA	NA	NA	NA	NA	NA	NA	NA	NA	T:40+0+0+0=40/463|N:4+0+0+0=4/104|A:44+0+0+0=44/567	NA	RTKRAS	1_NA_NA	[HC]_2.206/2.412_NA	TIER_3	VUS	NA	SOM	NA	Sorafenib_Tosylate|Sorafenib|Alectinib|Regorafenib|Regorafenib_Hydrate|Vandetanib|Sitravatinib|Selpercatinib|Sunitinib_Malate|Motesanib|Quizartinib	missense_variant:E:RET:Canonical:ENSP00000347942.3:p.(Ala664Asp)|R:RET:NP_065681.1:p.(Ala664Asp)|R:RET:Canonical:NP_066124.1:p.(Ala664Asp)|E:RET:ENSP00000419080.1:p.(Ala181Asp)|E:RET:ENSP00000344798.4:p.(Ala664Asp)	class	NA	introns[7-8],all_exons;IS:introns[9-11],exons[11,13-16]	.	.	include	.	.	.
CL-AcroMetrix	RET	ENST00000355710	NM_020975	10:43613840	G>C	c.2304G>C	exon13	E768D	Glu768Asp	c.2304G>C:exon13:E768D:Glu768Asp	missense_variant	1526	0.162	NA	NA	NA	NA	COSV60687895	rs78014899	13931	NA	NA	NA	NA	NA	NA	NA	T:7+0+0+0=7/463|N:0+0+0+0=0/104|A:7+0+0+0=7/567	NA	RTKRAS	1_NA_NA	[HC]_2.206/2.412_NA	TIER_3	Pathogenic	Likely_Pathogenic	SOM	Protein_tyrosine_and_serine/threonine_kinase	Sorafenib_Tosylate|Sorafenib|Alectinib|Regorafenib|Regorafenib_Hydrate|Vandetanib|Sitravatinib|Selpercatinib|Sunitinib_Malate|Motesanib|Quizartinib	missense_variant:E:RET:Canonical:ENSP00000347942.3:p.(Glu768Asp)|R:RET:NP_065681.1:p.(Glu768Asp)|R:RET:Canonical:NP_066124.1:p.(Glu768Asp)|E:RET:ENSP00000344798.4:p.(Glu768Asp);downstream_gene_variant:E:RET:ENST00000498820.1	CPSR_classification|ClinVar_classification|class	NA	introns[7-8],all_exons;IS:introns[9-11],exons[11,13-16]	.	.	include	.	.	.
CL-AcroMetrix	RET	ENST00000355710	NM_020975	10:43615568	GC>TT	c.2647_2648delinsTT	exon15	A883F	Ala883Phe	c.2647_2648delinsTT:exon15:A883F:Ala883Phe	missense_variant	1424	0.135	NA	NA	NA	NA	COSV60699157	rs377767429	38629	NA	NA	NA	NA	NA	NA	NA	NA	NA	RTKRAS	1_NA_NA	[HC]_2.206/2.412_NA	TIER_3	VUS	Likely_Pathogenic	SOM	Protein_tyrosine_and_serine/threonine_kinase	Sorafenib_Tosylate|Sorafenib|Alectinib|Regorafenib|Regorafenib_Hydrate|Vandetanib|Sitravatinib|Selpercatinib|Sunitinib_Malate|Motesanib|Quizartinib	missense_variant:E:RET:Canonical:ENSP00000347942.3:p.(Ala883Phe)|R:RET:NP_065681.1:p.(Ala883Phe)|R:RET:Canonical:NP_066124.1:p.(Ala883Phe)|E:RET:ENSP00000344798.4:p.(Ala883Phe)	ClinVar_classification|class	NA	introns[7-8],all_exons;IS:introns[9-11],exons[11,13-16]	.	.	include	no_recurrence_data	.	.
CL-AcroMetrix	RET	ENST00000355710	NM_020975	10:43615622	G>A	c.2701G>A	exon15	E901K	Glu901Lys	c.2701G>A:exon15:E901K:Glu901Lys	missense_variant	1344	0.177	NA	NA	NA	NA	COSV60710147	NA	NA	NA	NA	NA	NA	NA	Lung_Adenocarcinoma:_0.2%_(1/567)	NA	T:57+0+0+0=57/463|N:1+0+0+0=1/104|A:58+0+0+0=58/567	NA	RTKRAS	1_NA_NA	[HC]_2.206/2.412_NA	TIER_3	VUS	NA	SOM	Protein_tyrosine_and_serine/threonine_kinase	Sorafenib_Tosylate|Sorafenib|Alectinib|Regorafenib|Regorafenib_Hydrate|Vandetanib|Sitravatinib|Selpercatinib|Sunitinib_Malate|Motesanib|Quizartinib	missense_variant:E:RET:Canonical:ENSP00000347942.3:p.(Glu901Lys)|R:RET:NP_065681.1:p.(Glu901Lys)|R:RET:Canonical:NP_066124.1:p.(Glu901Lys)|E:RET:ENSP00000344798.4:p.(Glu901Lys)	class	NA	introns[7-8],all_exons;IS:introns[9-11],exons[11,13-16]	.	.	include	variant_in_more_than_10%_of_tumor_samples_(12.31%)_with_VAF_under_0.01	.	.
CL-AcroMetrix	SMAD4	ENST00000342988	NM_005359	18:48575183	T>C	c.377T>C	exon3	V126A	Val126Ala	c.377T>C:exon3:V126A:Val126Ala	missense_variant	783	0.02	NA	NA	NA	NA	COSV61688047|COSV61689376	NA	1002956	NA	NA	NA	NA	NA	NA	NA	T:10+0+0+0=10/463|N:2+0+0+0=2/104|A:12+0+0+0=12/567	NA	TFGBETA	NA	[non-HC]_2.106/2.212_NA	TIER_3	VUS	VUS	SOM	MH1_domain	NA	missense_variant:E:SMAD4:ENSP00000409551.2:p.(Val126Ala)|E:SMAD4:ENSP00000465878.1:p.(Val126Ala)|E:SMAD4:Canonical:ENSP00000381452.1:p.(Val126Ala)|E:SMAD4:ENSP00000464772.1:p.(Val126Ala)|E:SMAD4:ENSP00000466941.1:p.(Val126Ala)|E:SMAD4:ENSP00000341551.3:p.(Val126Ala)|R:SMAD4:Canonical:NP_005350.1:p.(Val126Ala)|E:SMAD4:ENSP00000464901.1:p.(Val126Ala);downstream_gene_variant:E:SMAD4:ENST00000589076.1|E:SMAD4:ENST00000589941.1	class	NA	all_exons	.	.	include	.	.	.
CL-AcroMetrix	SMAD4	ENST00000342988	NM_005359	18:48575195	C>T	c.389C>T	exon3	P130L	Pro130Leu	c.389C>T:exon3:P130L:Pro130Leu	missense_variant	770	0.014	NA	NA	NA	NA	COSV61685922	NA	NA	NA	NA	NA	NA	NA	NA	PACA-AU/Primary/1/90/0.0111	T:32+1+0+0=33/463|N:2+0+0+0=2/104|A:34+1+0+0=35/567	NA	TFGBETA	NA	[non-HC]_2.106/2.212_NA	TIER_3	VUS	NA	SOM	MH1_domain	NA	missense_variant:E:SMAD4:ENSP00000409551.2:p.(Pro130Leu)|E:SMAD4:Canonical:ENSP00000381452.1:p.(Pro130Leu)|E:SMAD4:ENSP00000464772.1:p.(Pro130Leu)|E:SMAD4:ENSP00000466941.1:p.(Pro130Leu)|E:SMAD4:ENSP00000341551.3:p.(Pro130Leu)|R:SMAD4:Canonical:NP_005350.1:p.(Pro130Leu)|E:SMAD4:ENSP00000464901.1:p.(Pro130Leu);downstream_gene_variant:E:SMAD4:ENST00000588860.1|E:SMAD4:ENST00000589076.1|E:SMAD4:ENST00000589941.1	class	LOW_TUMOR_VAF	all_exons	.	.	exclude	LOW_TUMOR_VAF	.	.
CL-AcroMetrix	SMAD4	ENST00000342988	NM_005359	18:48591838	A>G	c.1001A>G	exon9	Q334R	Gln334Arg	c.1001A>G:exon9:Q334R:Gln334Arg	missense_variant	843	0.044	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	T:25+0+0+0=25/462|N:14+0+0+0=14/104|A:39+0+0+0=39/566	NA	TFGBETA	NA	[non-HC]_2.106/2.212_NA	TIER_3	VUS	NA	SOM	MH2_domain	NA	missense_variant:E:SMAD4:Canonical:ENSP00000381452.1:p.(Gln334Arg)|E:SMAD4:ENSP00000341551.3:p.(Gln334Arg)|R:SMAD4:Canonical:NP_005350.1:p.(Gln334Arg)|E:SMAD4:ENSP00000464901.1:p.(Gln238Arg);upstream_gene_variant:E:SMAD4:ENST00000593223.1	class	NA	all_exons	.	.	include	.	.	.
CL-AcroMetrix	SMAD4	ENST00000342988	NM_005359	18:48591847	A>G	c.1010A>G	exon9	E337G	Glu337Gly	c.1010A>G:exon9:E337G:Glu337Gly	missense_variant	904	0.031	NA	NA	NA	NA	COSV61690645	NA	NA	NA	NA	NA	NA	NA	NA	NA	T:6+0+0+0=6/463|N:5+0+0+0=5/104|A:11+0+0+0=11/567	NA	TFGBETA	NA	[non-HC]_2.106/2.212_NA	TIER_3	VUS	NA	SOM	MH2_domain	NA	missense_variant:E:SMAD4:Canonical:ENSP00000381452.1:p.(Glu337Gly)|E:SMAD4:ENSP00000341551.3:p.(Glu337Gly)|R:SMAD4:Canonical:NP_005350.1:p.(Glu337Gly)|E:SMAD4:ENSP00000464901.1:p.(Glu241Gly);upstream_gene_variant:E:SMAD4:ENST00000593223.1	class	NA	all_exons	.	.	include	.	.	.
CL-AcroMetrix	SMAD4	ENST00000342988	NM_005359	18:48591855	A>G	c.1018A>G	exon9	K340E	Lys340Glu	c.1018A>G:exon9:K340E:Lys340Glu	missense_variant	934	0.032	NA	NA	NA	NA	COSV61689631	rs1599195392	656791	NA	NA	NA	NA	NA	Colon_Adenocarcinoma:_0.3%_(1/399)	NA	T:15+0+0+0=15/463|N:5+0+0+0=5/104|A:20+0+0+0=20/567	SMAD4:p.K340E:ENST00000398417&ENST00000342988:CTAT_POPULATION|CTAT_CANCER	TFGBETA	NA	[non-HC]_2.106/2.212_NA	TIER_3	VUS	VUS	SOM	MH2_domain	NA	missense_variant:E:SMAD4:Canonical:ENSP00000381452.1:p.(Lys340Glu)|E:SMAD4:ENSP00000341551.3:p.(Lys340Glu)|R:SMAD4:Canonical:NP_005350.1:p.(Lys340Glu)|E:SMAD4:ENSP00000464901.1:p.(Lys244Glu);upstream_gene_variant:E:SMAD4:ENST00000593223.1	class	NA	all_exons	.	.	include	.	.	.
CL-AcroMetrix	SMAD4	ENST00000342988	NM_005359	18:48593465	G>A	c.1216G>A	exon10	A406T	Ala406Thr	c.1216G>A:exon10:A406T:Ala406Thr	missense_variant	888	0.072	NA	NA	NA	NA	COSV61684489	rs794726995	193679	NA	NA	NA	NA	NA	Stomach_Adenocarcinoma:_0.2%_(1/437)|Uterine_Corpus_Endometrial_Carcinoma:_0.2%_(1/530)	NA	T:119+2+0+0=121/463|N:3+0+0+0=3/104|A:122+2+0+0=124/567	NA	TFGBETA	NA	[non-HC]_2.106/2.212_NA	TIER_3	VUS	VUS	SOM	MH2_domain	NA	missense_variant:E:SMAD4:Canonical:ENSP00000381452.1:p.(Ala406Thr)|E:SMAD4:ENSP00000341551.3:p.(Ala406Thr)|R:SMAD4:Canonical:NP_005350.1:p.(Ala406Thr)|E:SMAD4:ENSP00000464901.1:p.(Ala310Thr);upstream_gene_variant:E:SMAD4:ENST00000593223.1	class	NA	all_exons	.	.	include	variant_in_more_than_10%_of_tumor_samples_(25.7%)_with_VAF_under_0.01	.	.
CL-AcroMetrix	SMAD4	ENST00000342988	NM_005359	18:48593495	A>G	c.1246A>G	exon10	R416G	Arg416Gly	c.1246A>G:exon10:R416G:Arg416Gly	missense_variant	931	0.081	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	T:7+0+0+0=7/463|N:3+0+0+0=3/104|A:10+0+0+0=10/567	NA	TFGBETA	NA	[non-HC]_2.106/2.212_NA	TIER_3	VUS	NA	SOM	MH2_domain	NA	missense_variant:E:SMAD4:Canonical:ENSP00000381452.1:p.(Arg416Gly)|E:SMAD4:ENSP00000341551.3:p.(Arg416Gly)|R:SMAD4:Canonical:NP_005350.1:p.(Arg416Gly)|E:SMAD4:ENSP00000464901.1:p.(Arg320Gly)|E:SMAD4:ENSP00000466118.1:p.(Arg5Gly)	class	NA	all_exons	.	.	include	.	.	.
CL-AcroMetrix	SMAD4	ENST00000342988	NM_005359	18:48604682	A>G	c.1504A>G	exon12	R502G	Arg502Gly	c.1504A>G:exon12:R502G:Arg502Gly	missense_variant	1009	0.067	NA	NA	NA	NA	COSV61698007	NA	NA	NA	NA	NA	NA	NA	NA	NA	T:22+0+0+0=22/462|N:5+0+0+0=5/104|A:27+0+0+0=27/566	NA	TFGBETA	NA	[non-HC]_2.106/2.212_NA	TIER_3	VUS	NA	SOM	MH2_domain	NA	missense_variant:E:SMAD4:Canonical:ENSP00000381452.1:p.(Arg502Gly)|E:SMAD4:ENSP00000341551.3:p.(Arg502Gly)|R:SMAD4:Canonical:NP_005350.1:p.(Arg502Gly)|E:SMAD4:ENSP00000464901.1:p.(Arg406Gly);downstream_gene_variant:E:SMAD4:ENST00000593223.1	class	NA	all_exons	.	.	include	.	.	.
CL-AcroMetrix	SMAD4	ENST00000342988	NM_005359	18:48604697	A>G	c.1519A>G	exon12	K507E	Lys507Glu	c.1519A>G:exon12:K507E:Lys507Glu	missense_variant	1039	0.068	NA	NA	NA	NA	COSV61691735|COSV61696728	NA	NA	NA	NA	NA	NA	NA	NA	NA	T:13+0+0+0=13/463|N:3+0+0+0=3/104|A:16+0+0+0=16/567	NA	TFGBETA	NA	[non-HC]_2.106/2.212_NA	TIER_3	VUS	NA	SOM	MH2_domain	NA	missense_variant:E:SMAD4:Canonical:ENSP00000381452.1:p.(Lys507Glu)|E:SMAD4:ENSP00000341551.3:p.(Lys507Glu)|R:SMAD4:Canonical:NP_005350.1:p.(Lys507Glu)|E:SMAD4:ENSP00000464901.1:p.(Lys411Glu);downstream_gene_variant:E:SMAD4:ENST00000593223.1	class	NA	all_exons	.	.	include	.	.	.
CL-AcroMetrix	SMARCB1	ENST00000263121	NA	22:24145588	G>A	c.607G>A	exon5	A203T	Ala203Thr	c.607G>A:exon5:A203T:Ala203Thr	missense_variant	1291	0.05	NA	NA	NA	NA	COSV54098356	rs762962010	340912	1.59e-05	NA	0.0000352	NA	NA	NA	NA	T:109+2+0+0=111/462|N:3+0+0+0=3/104|A:112+2+0+0=114/566	NA	NA	NA	[non-HC]_2.142/2.284_NA	TIER_3	VUS	VUS	SOM	SNF5_/_SMARCB1_/_INI1	NA	missense_variant:R:SMARCB1:NP_001304875.1:p.(Ala212Thr)|R:SMARCB1:Canonical:NP_003064.2:p.(Ala203Thr)|R:SMARCB1:NP_001007469.1:p.(Ala194Thr)|E:SMARCB1:ENSP00000388489.1:p.(Ala221Thr)|E:SMARCB1:Canonical:ENSP00000340883.6:p.(Ala212Thr)|R:SMARCB1:NP_003064.2:p.(Ala203Thr)|R:SMARCB1:NP_001007469.1:p.(Ala194Thr)|E:SMARCB1:ENSP00000263121.7:p.(Ala203Thr)|R:SMARCB1:XP_005261775.1:p.(Ala212Thr)|E:SMARCB1:ENSP00000383984.3:p.(Ala194Thr)|E:SMARCB1:ENSP00000385226.3:p.(Ala157Thr)	class	NA	all_exons	.	.	include	variant_in_more_than_10%_of_tumor_samples_(23.59%)_with_VAF_under_0.01	.	.
CL-AcroMetrix	SMO	ENST00000249373	NM_005631	7:128846040	G>A	c.970G>A	exon5	A324T	Ala324Thr	c.970G>A:exon5:A324T:Ala324Thr	missense_variant	1603	0.223	NA	NA	NA	NA	COSV50824218	NA	NA	NA	NA	NA	NA	NA	NA	NA	T:98+2+1+0=101/463|N:9+0+0+0=9/104|A:107+2+1+0=110/567	NA	NA	NA	[non-HC]_2.032/2.064_NA	TIER_3	VUS	NA	SOM	Frizzled/Smoothened_family_membrane_region	Glasdegib|Sonidegib|Glasdegib_Maleate|Vismodegib|Patidegib	missense_variant:E:SMO:Canonical:ENSP00000249373.3:p.(Ala324Thr)|R:SMO:Canonical:NP_005622.1:p.(Ala324Thr)	class	NA	IS:all_exons	.	.	include	variant_in_more_than_10%_of_tumor_samples_(21.17%)_with_VAF_under_0.01	.	.
CL-AcroMetrix	SMO	ENST00000249373	NM_005631	7:128851593	A>G	c.1918A>G	exon11	T640A	Thr640Ala	c.1918A>G:exon11:T640A:Thr640Ala	missense_variant	1244	0.196	NA	NA	NA	NA	COSV50824212	NA	NA	NA	NA	NA	NA	NA	NA	NA	T:9+0+0+0=9/463|N:3+0+0+0=3/104|A:12+0+0+0=12/567	NA	NA	NA	[non-HC]_2.032/2.064_NA	TIER_3	VUS	NA	SOM	NA	Glasdegib|Sonidegib|Glasdegib_Maleate|Vismodegib|Patidegib	missense_variant:E:SMO:Canonical:ENSP00000249373.3:p.(Thr640Ala)|R:SMO:Canonical:NP_005622.1:p.(Thr640Ala)	class	NA	IS:all_exons	.	.	include	.	.	.
CL-AcroMetrix	SRC	ENST00000373578	NM_005417|NM_198291	20:36031631	C>T	c.1460C>T	exon14	P487L	Pro487Leu	c.1460C>T:exon14:P487L:Pro487Leu	missense_variant	1139	0.059	NA	NA	NA	NA	COSV62439404	rs756665933	NA	2.56e-05	NA	0.0000117	NA	NA	NA	NA	T:116+1+0+0=117/463|N:3+0+0+0=3/104|A:119+1+0+0=120/567	NA	NA	NA	[non-HC]_2.004/2.008_NA	TIER_3	VUS	NA	SOM	Protein_tyrosine_and_serine/threonine_kinase	Dasatinib|Vandetanib|Bosutinib|Tirbanibulin	missense_variant:E:SRC:ENSP00000408503.1:p.(Pro487Leu)|R:SRC:NP_005408.1:p.(Pro487Leu)|R:SRC:Canonical:NP_938033.1:p.(Pro487Leu)|E:SRC:Canonical:ENSP00000362680.2:p.(Pro487Leu)|E:SRC:ENSP00000353950.4:p.(Pro493Leu)|E:SRC:ENSP00000350941.4:p.(Pro487Leu)|E:SRC:ENSP00000362668.2:p.(Pro487Leu)|E:SRC:ENSP00000362659.2:p.(Pro493Leu)	class	NA	all_exons	.	.	include	variant_in_more_than_10%_of_tumor_samples_(25.05%)_with_VAF_under_0.01	.	.
CL-AcroMetrix	TP53	ENST00000269305	NM_000546	17:7574026	C>A	c.1001G>T	exon10	G334V	Gly334Val	c.1001G>T:exon10:G334V:Gly334Val	missense_variant	921	0.025	NA	NA	NA	NA	COSV52689817|COSV52759537|COSV52925149	NA	NA	NA	NA	NA	NA	NA	Lung_Adenocarcinoma:_0.4%_(2/567)|Lung_Squamous_Cell_Carcinoma:_0.4%_(2/492)|Uterine_Corpus_Endometrial_Carcinoma:_0.2%_(1/530)	NA	T:22+0+0+0=22/462|N:4+0+0+0=4/104|A:26+0+0+0=26/566	TP53:p.G334V:ENST00000269305&ENST00000445888:CTAT_POPULATION|CTAT_CANCER|3D_STRUCTURE	TP53	4_c_NS	[non-HC]_2.45/2.9_NA	TIER_3	Likely_Pathogenic	NA	SOM	P53_tetramerisation_motif	NA	missense_variant:R:TP53:NP_001119587.1:p.(Gly202Val)|R:TP53:NP_001263626.1:p.(Gly175Val)|E:TP53:Canonical:ENSP00000269305.4:p.(Gly334Val)|R:TP53:NP_001119590.1:p.(Gly295Val)|R:TP53:Canonical:NP_000537.3:p.(Gly334Val)|R:TP53:NP_001263689.1:p.(Gly295Val)|R:TP53:NP_001263690.1:p.(Gly295Val)|R:TP53:NP_001119584.1:p.(Gly334Val)|E:TP53:ENSP00000391478.2:p.(Gly334Val)|R:TP53:XP_005256835.1:p.(Gly314Val);3_prime_UTR_variant:R:TP53:NM_001276699.1|R:TP53:NM_001126117.1|R:TP53:NM_001276698.1|R:TP53:NM_001126116.1|R:TP53:NM_001276696.1|R:TP53:NM_001126113.2|R:TP53:NM_001276695.1|R:TP53:NM_001126114.2|E:TP53:ENST00000455263.2|E:TP53:ENST00000420246.2;downstream_gene_variant:E:TP53:ENST00000509690.1|E:TP53:ENST00000514944.1|E:TP53:ENST00000508793.1|E:TP53:ENST00000604348.1|E:TP53:ENST00000503591.1	CPSR_classification|class	NA	IS:all_exons	.	.	include	.	.	.
CL-AcroMetrix	TP53	ENST00000269305	NM_000546	17:7579442	G>A	c.245C>T	exon4	P82L	Pro82Leu	c.245C>T:exon4:P82L:Pro82Leu	missense_variant	1201	0.046	NA	NA	NA	NA	COSV53209087	rs534447939	182946	2e-05	NA	0.0000265	NA	NA	NA	NA	T:134+4+0+0=138/461|N:7+0+0+0=7/103|A:141+4+0+0=145/564	NA	TP53	4_c_NS	[non-HC]_2.45/2.9_NA	TIER_3	Likely_Benign	Likely_Benign	SOM	NA	NA	missense_variant:E:TP53:ENSP00000410739.2:p.(Pro82Leu)|E:TP53:ENSP00000352610.4:p.(Pro82Leu)|E:TP53:Canonical:ENSP00000269305.4:p.(Pro82Leu)|R:TP53:NP_001263625.1:p.(Pro43Leu)|R:TP53:NP_001119590.1:p.(Pro43Leu)|R:TP53:NP_001119585.1:p.(Pro82Leu)|R:TP53:Canonical:NP_000537.3:p.(Pro82Leu)|R:TP53:NP_001263689.1:p.(Pro43Leu)|R:TP53:NP_001263690.1:p.(Pro43Leu)|R:TP53:NP_001263624.1:p.(Pro43Leu)|R:TP53:NP_001119586.1:p.(Pro82Leu)|R:TP53:NP_001119584.1:p.(Pro82Leu)|E:TP53:ENSP00000398846.2:p.(Pro82Leu)|E:TP53:ENSP00000391127.2:p.(Pro82Leu)|E:TP53:ENSP00000391478.2:p.(Pro82Leu)|R:TP53:XP_005256835.1:p.(Pro62Leu)|E:TP53:ENSP00000424104.1:p.(Pro82Leu)|E:TP53:ENSP00000473895.1:p.(Pro82Leu)|E:TP53:ENSP00000426252.1:p.(Pro82Leu);upstream_gene_variant:R:TP53:NM_001126115.1|R:TP53:NM_001276697.1|R:TP53:NM_001276699.1|R:TP53:NM_001126117.1|R:TP53:NM_001276698.1|R:TP53:NM_001126116.1|E:TP53:ENST00000576024.1	class	NA	IS:all_exons	.	.	include	variant_in_more_than_10%_of_tumor_samples_(29.07%)_with_VAF_under_0.01	.	.
CL-AcroMetrix	TP53	ENST00000269305	NM_000546	17:7579553	A>G	c.134T>C	exon4	L45P	Leu45Pro	c.134T>C:exon4:L45P:Leu45Pro	missense_variant	1318	0.047	NA	NA	NA	NA	COSV53509736	rs879254066	246049	NA	NA	NA	NA	NA	NA	NA	T:13+0+0+0=13/462|N:3+0+0+0=3/104|A:16+0+0+0=16/566	NA	TP53	4_c_NS	[non-HC]_2.45/2.9_NA	TIER_3	VUS	VUS	SOM	NA	NA	missense_variant:E:TP53:ENSP00000410739.2:p.(Leu45Pro)|E:TP53:ENSP00000352610.4:p.(Leu45Pro)|E:TP53:Canonical:ENSP00000269305.4:p.(Leu45Pro)|R:TP53:NP_001263625.1:p.(Leu6Pro)|R:TP53:NP_001119590.1:p.(Leu6Pro)|R:TP53:NP_001119585.1:p.(Leu45Pro)|R:TP53:Canonical:NP_000537.3:p.(Leu45Pro)|R:TP53:NP_001263689.1:p.(Leu6Pro)|R:TP53:NP_001263690.1:p.(Leu6Pro)|R:TP53:NP_001263624.1:p.(Leu6Pro)|R:TP53:NP_001119586.1:p.(Leu45Pro)|R:TP53:NP_001119584.1:p.(Leu45Pro)|E:TP53:ENSP00000398846.2:p.(Leu45Pro)|E:TP53:ENSP00000391127.2:p.(Leu45Pro)|E:TP53:ENSP00000391478.2:p.(Leu45Pro)|R:TP53:XP_005256835.1:p.(Leu45Pro)|E:TP53:ENSP00000424104.1:p.(Leu45Pro)|E:TP53:ENSP00000473895.1:p.(Leu45Pro)|E:TP53:ENSP00000426252.1:p.(Leu45Pro);upstream_gene_variant:R:TP53:NM_001126115.1|R:TP53:NM_001276697.1|R:TP53:NM_001276699.1|R:TP53:NM_001126117.1|R:TP53:NM_001276698.1|R:TP53:NM_001126116.1|E:TP53:ENST00000576024.1	class	NA	IS:all_exons	.	.	include	.	.	.
CL-AcroMetrix	VHL	ENST00000256474	NM_000551	3:10183808	G>C	c.277G>C	exon1	G93R	Gly93Arg	c.277G>C:exon1:G93R:Gly93Arg	missense_variant	1267	0.04	NA	NA	NA	NA	COSV56545729|COSV56558995	rs5030808	223174	NA	NA	NA	NA	NA	NA	NA	T:8+0+0+0=8/463|N:0+0+0+0=0/104|A:8+0+0+0=8/567	NA	NA	1_a_NA	[non-HC]_2.198/2.396_NA	TIER_3	Likely_Pathogenic	VUS	SOM	VHL_beta_domain	NA	missense_variant:E:VHL:Canonical:ENSP00000256474.2:p.(Gly93Arg)|R:VHL:NP_937799.1:p.(Gly93Arg)|R:VHL:Canonical:NP_000542.1:p.(Gly93Arg)|E:VHL:ENSP00000344757.2:p.(Gly93Arg)	CPSR_classification|class	NA	all_exons	.	.	include	.	.	.
CL-AcroMetrix	VHL	ENST00000256474	NM_000551	3:10188210	T>C	c.353T>C	exon2	L118P	Leu118Pro	c.353T>C:exon2:L118P:Leu118Pro	missense_variant	1025	0.044	NA	NA	NA	NA	COSV56544274|COSV56546980|COSV56570311	rs5030830	428807	NA	NA	NA	NA	NA	Kidney_Renal_Clear_Cell_Carcinoma:_0.3%_(1/336)	NA	T:14+0+0+0=14/463|N:2+0+0+0=2/104|A:16+0+0+0=16/567	VHL:p.L118P:ENST00000256474:CTAT_POPULATION|CTAT_CANCER|3D_STRUCTURE	NA	1_a_NA	[non-HC]_2.198/2.396_NA	TIER_3	Pathogenic	Pathogenic	SOM	VHL_beta_domain	NA	missense_variant:E:VHL:Canonical:ENSP00000256474.2:p.(Leu118Pro)|R:VHL:Canonical:NP_000542.1:p.(Leu118Pro)	CPSR_classification|ClinVar_classification|class	NA	all_exons	.	.	include	.	.	.
CL-AcroMetrix	VHL	ENST00000256474	NM_000551	3:10188245	G>C	c.388G>C	exon2	V130L	Val130Leu	c.388G>C:exon2:V130L:Val130Leu	missense_variant	1069	0.059	NA	NA	NA	NA	COSV56543368|COSV56544519|COSV56551325|COSV56566091	rs104893830	2229	NA	NA	NA	NA	NA	Kidney_Renal_Clear_Cell_Carcinoma:_0.3%_(1/336)	NA	T:12+0+0+0=12/463|N:4+0+0+0=4/104|A:16+0+0+0=16/567	VHL:p.V130L:ENST00000256474:CTAT_CANCER|3D_STRUCTURE	NA	1_a_NA	[non-HC]_2.198/2.396_NA	TIER_3	Pathogenic	Pathogenic	SOM	VHL_beta_domain	NA	missense_variant:E:VHL:Canonical:ENSP00000256474.2:p.(Val130Leu)|R:VHL:Canonical:NP_000542.1:p.(Val130Leu)	CPSR_classification|ClinVar_classification|class	NA	all_exons	.	.	include	.	.	.
CL-AcroMetrix	VHL	ENST00000256474	NM_000551	3:10191506	C>T	c.499C>T	exon3	R167W	Arg167Trp	c.499C>T:exon3:R167W:Arg167Trp	missense_variant	787	0.03	NA	NA	NA	NA	COSV56545406|COSV56546550|COSV56572034	rs5030820	2218	8e-06	NA	0.0000176	NA	NA	Uterine_Corpus_Endometrial_Carcinoma:_0.2%_(1/530)	NA	T:83+1+0+0=84/463|N:8+0+0+0=8/104|A:91+1+0+0=92/567	NA	NA	1_a_NA	[non-HC]_2.198/2.396_NA	TIER_3	Pathogenic	Pathogenic	SOM	VHL_beta_domain	NA	missense_variant:E:VHL:Canonical:ENSP00000256474.2:p.(Arg167Trp)|R:VHL:NP_937799.1:p.(Arg126Trp)|R:VHL:Canonical:NP_000542.1:p.(Arg167Trp)|E:VHL:ENSP00000344757.2:p.(Arg126Trp)	CPSR_classification|ClinVar_classification|class	NA	all_exons	.	.	include	variant_in_more_than_10%_of_tumor_samples_(17.93%)_with_VAF_under_0.01	.	.
CL-AcroMetrix	ARID1A	ENST00000324856	NM_006015	1:27023503	C>A	c.609C>A	exon1	H203Q	His203Gln	c.609C>A:exon1:H203Q:His203Gln	missense_variant	899	0.457	NA	NA	NA	NA	NA	rs558792709	NA	4.48e-05	2e-04	0.0000286	NA	NA	NA	NA	T:24+0+0+0=24/463|N:2+0+0+0=2/104|A:26+0+0+0=26/567	NA	NA	NA	[non-HC]_1.754/1.508_NA	TIER_3	VUS	NA	GL_P	NA	NA	upstream_gene_variant:R:LOC101928728:XM_005246053.1;missense_variant:R:ARID1A:NP_624361.1:p.(His203Gln)|R:ARID1A:Canonical:NP_006006.3:p.(His203Gln)|E:ARID1A:Canonical:ENSP00000320485.7:p.(His203Gln)|R:ARID1A:XP_005246062.1:p.(His203Gln)|E:ARID1A:ENSP00000387636.2:p.(His203Gln)	class	HET_VAF_RANGE	all_exons	.	.	include	.	.	.
CL-AcroMetrix	BARD1	ENST00000260947	NM_000465	2:215632255	CA>TG	c.1518_1519inv	exon6	V507M	Val507Met	c.1518_1519inv:exon6:V507M:Val507Met	missense_variant	852	0.445	NA	NA	NA	NA	NA	rs386654966	215471	NA	NA	NA	NA	NA	NA	NA	T:47+3+31+246=327/463|N:0+0+0+73=73/104|A:47+3+31+319=400/567	NA	NA	NA	[non-HC]_2.002/2.004_NA	TIER_3	Likely_Benign	Likely_Benign	GL_P	Ankyrin_repeat	NA	missense_variant:R:BARD1:XP_005246785.1:p.(Val410Met)|R:BARD1:XP_005246784.1:p.(Val488Met)|E:BARD1:Canonical:ENSP00000260947.4:p.(Val507Met)|R:BARD1:Canonical:NP_000456.2:p.(Val507Met)|R:BARD1:NP_001269472.1:p.(Val488Met)|R:BARD1:NP_000456.2:p.(Val507Met)|E:BARD1:ENSP00000406752.2:p.(Val363Met)	class	recurrent_germline|HET_VAF_RANGE	all_exons	.	.	exclude	recurrent_germline,variant_in_more_than_10%_of_tumor_samples_(10.15%)_with_VAF_under_0.01	.	.
CL-AcroMetrix	EGFR	ENST00000275493	NM_005228|NM_001346900	7:55241615	T>C	c.2063T>C	exon18	L688P	Leu688Pro	c.2063T>C:exon18:L688P:Leu688Pro	missense_variant,splice_region_variant	993	0.193	NA	NA	NA	NA	COSV51807685	NA	NA	NA	NA	NA	NA	NA	NA	NA	T:10+0+0+0=10/463|N:2+0+0+0=2/104|A:12+0+0+0=12/567	NA	RTKRAS	NA	[HC]_1.916/1.832_NA	TIER_3	VUS	NA	SOM	NA	Afatinib|Lapatinib_Ditosylate|Cetuximab|Panitumumab|Necitumumab|Neratinib|Icotinib|Afatinib_Dimaleate|Zalutumumab|Nimotuzumab|Dacomitinib|Vandetanib|Osimertinib|Pyrotinib|Tesevatinib|Rociletinib|Brigatinib|Naquotinib|EGFR/FLT3/Abl_Inhibitor_SKLB1028|Depatuxizumab_Mafodotin|Neratinib_Maleate|Amivantamab|Abivertinib|Abivertinib_Maleate|Avitinib_Maleate|Lazertinib|Aumolertinib|Mobocertinib|Erlotinib|Lapatinib|Gefitinib	downstream_gene_variant:R:EGFR:XM_005271748.1|R:EGFR:NM_201284.1|E:EGFR:ENST00000344576.2;missense_variant,splice_region_variant:R:EGFR:XP_005271803.1:p.(Leu643Pro)|E:EGFR:ENSP00000415559.1:p.(Leu643Pro)|R:EGFR:NP_001333826.1:p.(Leu643Pro)|R:EGFR:NP_001333827.1:p.(Leu688Pro)|R:EGFR:NP_001333870.1:p.(Leu421Pro)|R:EGFR:Canonical:NP_005219.2:p.(Leu688Pro)|R:EGFR:NP_001333828.1:p.(Leu643Pro)|R:EGFR:NP_005219.2:p.(Leu688Pro)|E:EGFR:Canonical:ENSP00000275493.2:p.(Leu688Pro)|R:EGFR:XP_005271804.1:p.(Leu635Pro)|R:EGFR:NP_001333829.1:p.(Leu635Pro)|E:EGFR:ENSP00000395243.2:p.(Leu635Pro)	class	NA	introns[15];IS:introns[7,24-27],all_exons	.	.	include	.	.	.
CL-AcroMetrix	ERBB4	ENST00000342788	NM_005235	2:212578372	A>C	c.885T>G	exon8	H295Q	His295Gln	c.885T>G:exon8:H295Q:His295Gln	missense_variant,splice_region_variant	234	0.051	NA	NA	NA	NA	COSV53548659	NA	NA	NA	NA	NA	NA	NA	NA	NA	T:1+0+0+0=1/461|N:1+0+0+0=1/104|A:2+0+0+0=2/565	NA	RTKRAS	NA	[non-HC]_1.798/1.596_NA	TIER_3	VUS	NA	SOM	Furin-like_cysteine_rich_region	Afatinib|Neratinib|Afatinib_Dimaleate|Dacomitinib|Vandetanib|Neratinib_Maleate	missense_variant,splice_region_variant:R:ERBB4:Canonical:NP_005226.1:p.(His295Gln)|R:ERBB4:NP_001036064.1:p.(His295Gln)|R:ERBB4:XP_005246433.1:p.(His295Gln)|R:ERBB4:XP_005246434.1:p.(His295Gln)|R:ERBB4:XP_005246432.1:p.(His295Gln)|E:ERBB4:Canonical:ENSP00000342235.4:p.(His295Gln)|E:ERBB4:ENSP00000403204.1:p.(His295Gln)|E:ERBB4:ENSP00000385565.1:p.(His295Gln)|E:ERBB4:ENSP00000260943.6:p.(His295Gln)	class	NA	all_exons	.	.	include	.	.	.
CL-AcroMetrix	PTEN	ENST00000371953	NM_000314	10:89653865	A>G	c.163A>G	exon2	R55G	Arg55Gly	c.163A>G:exon2:R55G:Arg55Gly	missense_variant,splice_region_variant	582	0.093	NA	NA	NA	NA	COSV64297880|COSV64307047	NA	NA	NA	NA	NA	NA	NA	NA	NA	T:5+0+0+0=5/462|N:1+0+0+0=1/104|A:6+0+0+0=6/566	NA	PI3K	NA	[HC]_1.964/1.928_NA	TIER_3	VUS	NA	SOM	NA	NA	missense_variant,splice_region_variant:E:PTEN:Canonical:ENSP00000361021.3:p.(Arg55Gly)|R:PTEN:NP_000305.3:p.(Arg55Gly)|R:PTEN:Canonical:NP_000305.3:p.(Arg55Gly)|R:PTEN:NP_001291646.2:p.(Arg228Gly);5_prime_UTR_variant,splice_region_variant:R:PTEN:NM_001304718.1	class	NA	IS:all_exons	.	.	include	.	.	.
CL-AcroMetrix	PTEN	ENST00000371953	NM_000314	10:89685271	T>G	c.166T>G	exon3	F56V	Phe56Val	c.166T>G:exon3:F56V:Phe56Val	missense_variant,splice_region_variant	280	0.071	NA	NA	NA	NA	COSV64290332	NA	924880	NA	NA	NA	NA	NA	NA	NA	T:2+2+0+0=4/456|N:1+0+0+0=1/101|A:3+2+0+0=5/557	NA	PI3K	NA	[HC]_1.964/1.928_NA	TIER_3	VUS	VUS	SOM	NA	NA	missense_variant,splice_region_variant:E:PTEN:Canonical:ENSP00000361021.3:p.(Phe56Val)|R:PTEN:NP_000305.3:p.(Phe56Val)|R:PTEN:Canonical:NP_000305.3:p.(Phe56Val)|R:PTEN:NP_001291646.2:p.(Phe229Val)	class	NA	IS:all_exons	.	.	include	.	.	.
CL-AcroMetrix	PTEN	ENST00000371953	NM_000314	10:89720874	A>G	c.1025A>G	exon8	K342R	Lys342Arg	c.1025A>G:exon8:K342R:Lys342Arg	missense_variant,splice_region_variant	773	0.216	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	T:6+0+0+0=6/462|N:8+1+0+0=9/104|A:14+1+0+0=15/566	NA	PI3K	NA	[HC]_1.964/1.928_NA	TIER_3	VUS	NA	SOM	C2_domain_of_PTEN_tumour-suppressor_protein	NA	missense_variant,splice_region_variant:E:PTEN:Canonical:ENSP00000361021.3:p.(Lys342Arg)|R:PTEN:NP_000305.3:p.(Lys342Arg)|R:PTEN:Canonical:NP_000305.3:p.(Lys342Arg)|R:PTEN:NP_001291647.1:p.(Lys145Arg)|R:PTEN:NP_001291646.2:p.(Lys515Arg)	class	NA	IS:all_exons	.	.	include	.	.	.
CL-AcroMetrix	ABL1	ENST00000318560	NM_005157	9:133747571	T>TGCC	c.878_879insGCC	exon5	I293delinsMP	Ile293delinsMetPro	c.878_879insGCC:exon5:I293delinsMP:Ile293delinsMetPro	protein_altering_variant	1107	0.149	NA	NA	NA	NA	COSV59333681	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	RTKRAS	NA	[non-HC]_1.942/1.884_NA	TIER_3	VUS	NA	SOM	Protein_tyrosine_and_serine/threonine_kinase	Ponatinib|Nilotinib_Hydrochloride_Monohydrate|Dasatinib|Regorafenib|Regorafenib_Hydrate|Ponatinib_Hydrochloride|Nilotinib|Bosutinib|Flumbatinib|EGFR/FLT3/Abl_Inhibitor_SKLB1028|Asciminib|Radotinib|Imatinib	inframe_insertion:R:ABL1:XP_005272234.1:p.(Ile311delinsMetPro)|R:ABL1:Canonical:NP_009297.2:p.(Ile312delinsMetPro)|E:ABL1:Canonical:ENSP00000361423.2:p.(Ile312delinsMetPro)|E:ABL1:ENSP00000323315.5:p.(Ile293delinsMetPro)|R:ABL1:NP_005148.2:p.(Ile293delinsMetPro)|R:ABL1:NP_005148.2:p.(Ile293delinsMetPro)	class	NA	all_exons;IS:exons[4-9]	.	.	include	no_recurrence_data	.	.
CL-AcroMetrix	ATM	ENST00000278616	NA	11:108172374	G>T	c.5178-1G>T	NA	NA	NA	c.5178-1G>T:NA:NA:NA	splice_acceptor_variant	654	0.038	NA	NA	NA	NA	COSV53737155|COSV99588039	rs1555105579	825507	NA	NA	NA	NA	NA	NA	NA	T:19+0+0+0=19/463|N:2+0+0+0=2/104|A:21+0+0+0=21/567	NA	TP53	NA	[HC]_2.122/2.244_NA	TIER_3	Likely_Pathogenic	Likely_Pathogenic	SOM	NA	Iniparib	splice_acceptor_variant:E:ATM:Canonical:ENST00000278616.4|R:ATM:Canonical:NM_000051.3|E:ATM:ENST00000452508.2|R:ATM:XM_005271562.1|R:ATM:XM_005271561.1|R:ATM:XM_005271563.1|R:ATM:XM_005271564.1	CPSR_classification|ClinVar_classification|protein_changes:splice_acceptor_variant|class	NA	IS:all_exons	.	.	include	.	.	.
CL-AcroMetrix	CSF1R	ENST00000286301	NM_001375321|NM_005211|NM_001375320	5:149453057	C>CACTGCTTGA	c.890-2_890-1insTCAAGCAGT	NA	NA	NA	c.890-2_890-1insTCAAGCAGT:NA:NA:NA	splice_acceptor_variant	1490	0.18	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	[non-HC]_2.128/2.256_NA	TIER_3	NA	NA	SOM	NA	Vatalanib|Pazopanib_Hydrochloride|Linifanib|Pexidartinib|Pexidartinib_Hydrochloride|Pazopanib|Sunitinib_Malate|Quizartinib	splice_acceptor_variant:R:CSF1R:NM_001288705.2|E:CSF1R:Canonical:ENST00000286301.3|R:CSF1R:Canonical:NM_005211.3|R:CSF1R:XM_005268375.1	protein_changes:splice_acceptor_variant|class	NA	all_exons	.	.	include	no_recurrence_data	.	.
CL-AcroMetrix	PTEN	ENST00000371953	NM_000314	10:89725042	A>G	c.1027-2A>G	NA	NA	NA	c.1027-2A>G:NA:NA:NA	splice_acceptor_variant	722	0.129	NA	NA	NA	NA	COSV64293079|COSV64296375	rs1085308041	427581	NA	NA	NA	NA	NA	Glioblastoma_Multiforme:_0.3%_(1/393)|Breast_Invasive_Carcinoma:_0.1%_(1/986)	RECA-EU/Primary/1/74/0.0135	T:3+0+0+0=3/462|N:2+0+0+0=2/104|A:5+0+0+0=5/566	NA	PI3K	NA	[HC]_1.964/1.928_NA	TIER_3	Likely_Pathogenic	Pathogenic	SOM	NA	NA	splice_acceptor_variant:E:PTEN:Canonical:ENST00000371953.3|R:PTEN:NM_000314.4|R:PTEN:Canonical:NM_000314.6|R:PTEN:NM_001304718.1|R:PTEN:NM_001304717.2	CPSR_classification|ClinVar_classification|protein_changes:splice_acceptor_variant|class	NA	IS:all_exons	.	.	include	.	.	.
CL-AcroMetrix	RB1	ENST00000267163	NM_000321	13:48941628	A>T	c.940-2A>T	NA	NA	NA	c.940-2A>T:NA:NA:NA	splice_acceptor_variant	317	0.028	NA	NA	NA	NA	COSV57299272|COSV57311373|COSV57332889	NA	NA	NA	NA	NA	NA	NA	NA	NA	T:3+0+0+0=3/456|N:0+0+0+0=0/103|A:3+0+0+0=3/559	NA	CC	3_NA_NA	[non-HC]_2.194/2.388_NA	TIER_3	Likely_Pathogenic	NA	SOM	NA	NA	splice_acceptor_variant:R:RB1:Canonical:NM_000321.2|E:RB1:Canonical:ENST00000267163.4	CPSR_classification|protein_changes:splice_acceptor_variant|class	NA	IS:all_exons	.	.	include	.	.	.
CL-AcroMetrix	STK11	ENST00000326873	NM_000455	19:1220371	G>T	c.465-1G>T	NA	NA	NA	c.465-1G>T:NA:NA:NA	splice_acceptor_variant	1033	0.052	NA	NA	NA	NA	COSV58820358|COSV58822934	NA	NA	NA	NA	NA	NA	NA	Lung_Adenocarcinoma:_0.4%_(2/567)	NA	T:29+1+0+0=30/463|N:1+1+0+0=2/104|A:30+2+0+0=32/567	NA	PI3K	NA	[non-HC]_2.366/2.732_NA	TIER_3	Likely_Pathogenic	NA	SOM	NA	NA	splice_acceptor_variant:E:STK11:Canonical:ENST00000326873.7|R:STK11:Canonical:NM_000455.4|R:STK11:XM_005259618.1|R:STK11:XM_005259617.1|E:STK11:ENST00000585851.1;upstream_gene_variant:E:STK11:ENST00000586243.1	CPSR_classification|protein_changes:splice_acceptor_variant|class	NA	IS:all_exons	.	.	include	.	.	.
CL-AcroMetrix	TP53	ENST00000269305	NM_000546	17:7573010	T>C	c.1101-2A>G	NA	NA	NA	c.1101-2A>G:NA:NA:NA	splice_acceptor_variant	1033	0.052	NA	NA	NA	NA	COSV52676811|COSV52714663|COSV53348267	rs587781664	141332	NA	NA	NA	NA	NA	Bladder_Urothelial_Carcinoma:_0.2%_(1/412)	NA	T:6+0+0+0=6/462|N:3+0+0+0=3/104|A:9+0+0+0=9/566	NA	TP53	4_c_NS	[non-HC]_2.45/2.9_NA	TIER_3	Likely_Pathogenic	Likely_Pathogenic	SOM	NA	NA	splice_acceptor_variant:R:TP53:NM_001126115.1|R:TP53:NM_001276697.1|R:TP53:NM_001276699.1|R:TP53:NM_001126117.1|R:TP53:NM_001276698.1|R:TP53:NM_001126116.1|E:TP53:Canonical:ENST00000269305.4|R:TP53:NM_001276696.1|R:TP53:NM_001126118.1|R:TP53:NM_001126113.2|R:TP53:Canonical:NM_000546.5|R:TP53:NM_001276760.1|R:TP53:NM_001276761.1|R:TP53:NM_001276695.1|R:TP53:NM_001126114.2|R:TP53:NM_001126112.2|E:TP53:ENST00000455263.2|E:TP53:ENST00000420246.2|E:TP53:ENST00000445888.2|R:TP53:XM_005256778.1|E:TP53:ENST00000576024.1;downstream_gene_variant:E:TP53:ENST00000509690.1|E:TP53:ENST00000514944.1	CPSR_classification|ClinVar_classification|protein_changes:splice_acceptor_variant|class	NA	IS:all_exons	.	.	include	.	.	.
CL-AcroMetrix	KDR	ENST00000263923	NM_002253	4:55972978	CTATAAGAAAGAGATAACAGCGCATATTATGATTTAATTTTT>C	c.1413-42_1413-2del	NA	NA	NA	c.1413-42_1413-2del:NA:NA:NA	splice_acceptor_variant,splice_polypyrimidine_tract_variant,intron_variant	531	0.092	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	[non-HC]_2.116/2.232_NA	TIER_3	VUS	NA	SOM	NA	Vatalanib|Sorafenib_Tosylate|Pazopanib_Hydrochloride|Tivozanib|Lenvatinib|Axitinib|Sorafenib|Ramucirumab|Regorafenib|Regorafenib_Hydrate|Cabozantinib_S-malate|Lenvatinib_Mesylate|Cabozantinib|Linifanib|Vandetanib|Orantinib|Semaxanib|Rivoceranib|Anlotinib|Famitinib|Rivoceranib_Mesylate|Brivanib|Sitravatinib|Sulfatinib|Fruquintinib|Pazopanib|Cediranib|Nintedanib|Dovitinib|Sunitinib_Malate|Motesanib|Midostaurin	intron_variant,splice_acceptor_variant:R:KDR:Canonical:NM_002253.2|E:KDR:Canonical:ENST00000263923.4	protein_changes:splice_acceptor_variant|class	NA	all_exons	.	.	include	no_recurrence_data	.	.
CL-AcroMetrix	ATM	ENST00000278616	NA	11:108123641	T>A	c.1898+2T>A	NA	NA	NA	c.1898+2T>A:NA:NA:NA	splice_donor_variant	527	0.076	NA	NA	NA	NA	COSV53724140	NA	NA	NA	NA	NA	NA	NA	NA	PACA-AU/Primary/1/90/0.0111	T:4+0+0+0=4/463|N:1+0+0+0=1/104|A:5+0+0+0=5/567	NA	TP53	NA	[HC]_2.122/2.244_NA	TIER_3	Likely_Pathogenic	NA	SOM	NA	Iniparib	splice_donor_variant:E:ATM:ENST00000527805.1|E:ATM:Canonical:ENST00000278616.4|R:ATM:Canonical:NM_000051.3|E:ATM:ENST00000452508.2|R:ATM:XM_005271562.1|R:ATM:XM_005271561.1|R:ATM:XM_005271563.1|R:ATM:XM_005271564.1	CPSR_classification|protein_changes:splice_donor_variant|class	NA	IS:all_exons	.	.	include	.	.	.
CL-AcroMetrix	KRAS	ENST00000256078	NM_001369786|NM_033360	12:25398207	C>A	c.111+1G>T	NA	NA	NA	c.111+1G>T:NA:NA:NA	splice_donor_variant	565	0.062	NA	NA	NA	NA	COSV55883992	NA	NA	NA	NA	NA	NA	NA	NA	NA	T:13+0+0+0=13/463|N:3+0+0+0=3/104|A:16+0+0+0=16/567	NA	RTKRAS	NA	[HC]_1.89/1.78_NA	TIER_3	Likely_Pathogenic	NA	SOM	NA	Adagrasib	splice_donor_variant:E:KRAS:ENST00000311936.3|R:KRAS:Canonical:NM_033360.3|R:KRAS:NM_004985.4|R:KRAS:NM_033360.2|R:KRAS:NM_004985.3|E:KRAS:ENST00000557334.1|E:KRAS:Canonical:ENST00000256078.4|R:KRAS:XM_005253365.1|E:KRAS:ENST00000556131.1	CPSR_classification|protein_changes:splice_donor_variant|class	NA	IS:all_exons	.	.	include	.	.	.
CL-AcroMetrix	MET	ENST00000318493	NM_001127500	7:116412044	G>A	c.3082+1G>A	NA	NA	NA	c.3082+1G>A:NA:NA:NA	splice_donor_variant	1236	0.213	NA	NA	NA	NA	COSV59256499|COSV59256681|COSV59259384|COSV59260405	NA	976843	NA	NA	NA	NA	NA	Lung_Adenocarcinoma:_0.2%_(1/567)	NA	T:78+1+0+0=79/463|N:2+0+0+0=2/104|A:80+1+0+0=81/567	NA	RTKRAS	NA	[HC]_2.166/2.332_NA	TIER_3	Likely_Pathogenic	VUS	SOM	NA	Onartuzumab|Cabozantinib_S-malate|Tivantinib|Cabozantinib|Capmatinib|Savolitinib|Tepotinib|Sitravatinib|Capmatinib_Hydrochloride|Tepotinib_Hydrochloride|Crizotinib	splice_donor_variant:R:MET:XM_005250353.1|R:MET:NM_001324402.1|R:MET:Canonical:NM_001127500.2|R:MET:NM_000245.3|E:MET:ENST00000397752.3|E:MET:Canonical:ENST00000318493.6|R:MET:NM_001127500.1|R:MET:NM_000245.2|R:MET:XM_005250354.1;downstream_gene_variant:R:MET:NM_001324401.1|E:MET:ENST00000422097.1	CPSR_classification|protein_changes:splice_donor_variant|class	NA	IS:all_exons	.	.	include	variant_in_more_than_10%_of_tumor_samples_(16.85%)_with_VAF_under_0.01	.	.
CL-AcroMetrix	RB1	ENST00000267163	NM_000321	13:49027249	T>C	c.1814+2T>C	NA	NA	NA	c.1814+2T>C:NA:NA:NA	splice_donor_variant	565	0.055	NA	NA	NA	NA	COSV57310724|COSV57329041	NA	NA	NA	NA	NA	NA	NA	NA	NA	T:6+0+0+0=6/461|N:2+0+0+0=2/104|A:8+0+0+0=8/565	NA	CC	3_NA_NA	[non-HC]_2.194/2.388_NA	TIER_3	Likely_Pathogenic	NA	SOM	NA	NA	splice_donor_variant:R:RB1:Canonical:NM_000321.2|E:RB1:Canonical:ENST00000267163.4	CPSR_classification|protein_changes:splice_donor_variant|class	NA	IS:all_exons	.	.	include	.	.	.
CL-AcroMetrix	APC	ENST00000457016	NA	5:112173917	C>T	c.2626C>T	exon16	R876X	Arg876Ter	c.2626C>T:exon16:R876X:Arg876Ter	stop_gained	1157	0.168	NA	NA	NA	NA	COSV57320538	rs121913333	216014	NA	NA	NA	NA	NA	Rectum_Adenocarcinoma:_7.3%_(10/137)|Colon_Adenocarcinoma:_3.5%_(14/399)|Uterine_Corpus_Endometrial_Carcinoma:_0.4%_(2/530)	NA	T:109+1+1+0=111/463|N:5+0+0+0=5/104|A:114+1+1+0=116/567	NA	WNT	3_NA_NA	[non-HC]_2.012/2.024_NA	TIER_3	Pathogenic	Pathogenic	SOM	NA	NA	stop_gained:R:APC:NP_001120983.2:p.(Arg858Ter)|R:APC:XP_005272032.1:p.(Arg876Ter)|E:APC:Canonical:ENSP00000413133.1:p.(Arg876Ter)|E:APC:ENSP00000423224.1:p.(Arg858Ter)|R:APC:XP_005272034.1:p.(Arg775Ter)|R:APC:Canonical:NP_000029.2:p.(Arg876Ter)|R:APC:NP_001120982.1:p.(Arg876Ter)|E:APC:ENSP00000257430.4:p.(Arg876Ter)|E:APC:ENSP00000427089.2:p.(Arg876Ter)|E:APC:ENSP00000423828.2:p.(Arg876Ter)|R:APC:XP_005272031.1:p.(Arg876Ter)|R:APC:XP_005272033.1:p.(Arg817Ter);downstream_gene_variant:E:APC:ENST00000504915.2	CPSR_classification|ClinVar_classification|protein_changes:stop_gained|class	NA	IS:all_exons	.	.	include	variant_in_more_than_10%_of_tumor_samples_(23.54%)_with_VAF_under_0.01	.	.
CL-AcroMetrix	APC	ENST00000457016	NA	5:112173947	C>T	c.2656C>T	exon16	Q886X	Gln886Ter	c.2656C>T:exon16:Q886X:Gln886Ter	stop_gained	1188	0.173	NA	NA	NA	NA	COSV57332678	rs755806668	486755	NA	NA	NA	NA	NA	NA	NA	T:47+0+0+0=47/463|N:2+0+0+0=2/104|A:49+0+0+0=49/567	NA	WNT	3_NA_NA	[non-HC]_2.012/2.024_NA	TIER_3	Pathogenic	Pathogenic	SOM	NA	NA	stop_gained:R:APC:NP_001120983.2:p.(Gln868Ter)|R:APC:XP_005272032.1:p.(Gln886Ter)|E:APC:Canonical:ENSP00000413133.1:p.(Gln886Ter)|E:APC:ENSP00000423224.1:p.(Gln868Ter)|R:APC:XP_005272034.1:p.(Gln785Ter)|R:APC:Canonical:NP_000029.2:p.(Gln886Ter)|R:APC:NP_001120982.1:p.(Gln886Ter)|E:APC:ENSP00000257430.4:p.(Gln886Ter)|E:APC:ENSP00000427089.2:p.(Gln886Ter)|E:APC:ENSP00000423828.2:p.(Gln886Ter)|R:APC:XP_005272031.1:p.(Gln886Ter)|R:APC:XP_005272033.1:p.(Gln827Ter);downstream_gene_variant:E:APC:ENST00000504915.2	CPSR_classification|ClinVar_classification|protein_changes:stop_gained|class	NA	IS:all_exons	.	.	include	variant_in_more_than_10%_of_tumor_samples_(10.15%)_with_VAF_under_0.01	.	.
CL-AcroMetrix	APC	ENST00000457016	NA	5:112174043	G>T	c.2752G>T	exon16	E918X	Glu918Ter	c.2752G>T:exon16:E918X:Glu918Ter	stop_gained	1201	0.198	NA	NA	NA	NA	COSV57328628|COSV57339762|COSV99965505	NA	NA	NA	NA	NA	NA	NA	Colon_Adenocarcinoma:_0.5%_(2/399)|Lung_Squamous_Cell_Carcinoma:_0.2%_(1/492)	NA	T:43+0+0+0=43/463|N:4+1+0+0=5/104|A:47+1+0+0=48/567	NA	WNT	3_NA_NA	[non-HC]_2.012/2.024_NA	TIER_3	Pathogenic	NA	SOM	NA	NA	stop_gained:R:APC:NP_001120983.2:p.(Glu900Ter)|R:APC:XP_005272032.1:p.(Glu918Ter)|E:APC:Canonical:ENSP00000413133.1:p.(Glu918Ter)|E:APC:ENSP00000423224.1:p.(Glu900Ter)|R:APC:XP_005272034.1:p.(Glu817Ter)|R:APC:Canonical:NP_000029.2:p.(Glu918Ter)|R:APC:NP_001120982.1:p.(Glu918Ter)|E:APC:ENSP00000257430.4:p.(Glu918Ter)|E:APC:ENSP00000427089.2:p.(Glu918Ter)|E:APC:ENSP00000423828.2:p.(Glu918Ter)|R:APC:XP_005272031.1:p.(Glu918Ter)|R:APC:XP_005272033.1:p.(Glu859Ter);downstream_gene_variant:E:APC:ENST00000504915.2	CPSR_classification|protein_changes:stop_gained|class	NA	IS:all_exons	.	.	include	.	.	.
CL-AcroMetrix	APC	ENST00000457016	NA	5:112174577	C>T	c.3286C>T	exon16	Q1096X	Gln1096Ter	c.3286C>T:exon16:Q1096X:Gln1096Ter	stop_gained	1245	0.185	NA	NA	NA	NA	COSV57336639	rs587783029	156475	NA	NA	NA	NA	NA	NA	NA	T:42+0+0+0=42/463|N:7+0+0+0=7/104|A:49+0+0+0=49/567	NA	WNT	3_NA_NA	[non-HC]_2.012/2.024_NA	TIER_3	Pathogenic	Pathogenic	SOM	NA	NA	stop_gained:R:APC:NP_001120983.2:p.(Gln1078Ter)|R:APC:XP_005272032.1:p.(Gln1096Ter)|E:APC:Canonical:ENSP00000413133.1:p.(Gln1096Ter)|E:APC:ENSP00000423224.1:p.(Gln1078Ter)|R:APC:XP_005272034.1:p.(Gln995Ter)|R:APC:Canonical:NP_000029.2:p.(Gln1096Ter)|R:APC:NP_001120982.1:p.(Gln1096Ter)|E:APC:ENSP00000257430.4:p.(Gln1096Ter)|E:APC:ENSP00000427089.2:p.(Gln1096Ter)|E:APC:ENSP00000423828.2:p.(Gln1096Ter)|R:APC:XP_005272031.1:p.(Gln1096Ter)|R:APC:XP_005272033.1:p.(Gln1037Ter);downstream_gene_variant:E:APC:ENST00000504915.2	CPSR_classification|ClinVar_classification|protein_changes:stop_gained|class	NA	IS:all_exons	.	.	include	.	.	.
CL-AcroMetrix	APC	ENST00000457016	NA	5:112175162	C>T	c.3871C>T	exon16	Q1291X	Gln1291Ter	c.3871C>T:exon16:Q1291X:Gln1291Ter	stop_gained	974	0.165	NA	NA	NA	NA	COSV57321476|COSV57325789|COSV57375930	rs1561588104	575517	NA	NA	NA	NA	NA	Colon_Adenocarcinoma:_0.8%_(3/399)	NA	T:41+1+0+0=42/463|N:2+0+0+0=2/104|A:43+1+0+0=44/567	NA	WNT	3_NA_NA	[non-HC]_2.012/2.024_NA	TIER_3	Pathogenic	Pathogenic	SOM	NA	NA	stop_gained:R:APC:NP_001120983.2:p.(Gln1273Ter)|R:APC:XP_005272032.1:p.(Gln1291Ter)|E:APC:Canonical:ENSP00000413133.1:p.(Gln1291Ter)|R:APC:XP_005272034.1:p.(Gln1190Ter)|R:APC:Canonical:NP_000029.2:p.(Gln1291Ter)|R:APC:NP_001120982.1:p.(Gln1291Ter)|E:APC:ENSP00000257430.4:p.(Gln1291Ter)|E:APC:ENSP00000427089.2:p.(Gln1291Ter)|E:APC:ENSP00000423828.2:p.(Gln1291Ter)|R:APC:XP_005272031.1:p.(Gln1291Ter)|R:APC:XP_005272033.1:p.(Gln1232Ter);downstream_gene_variant:E:APC:ENST00000507379.1|E:APC:ENST00000504915.2	CPSR_classification|ClinVar_classification|protein_changes:stop_gained|class	NA	IS:all_exons	.	.	include	.	.	.
CL-AcroMetrix	APC	ENST00000457016	NA	5:112175255	G>T	c.3964G>T	exon16	E1322X	Glu1322Ter	c.3964G>T:exon16:E1322X:Glu1322Ter	stop_gained	1225	0.219	NA	NA	NA	NA	COSV57325414|COSV57354660|COSV57393116|COSV99964740	NA	NA	NA	NA	NA	NA	NA	Rectum_Adenocarcinoma:_1.5%_(2/137)|Colon_Adenocarcinoma:_0.3%_(1/399)	NA	T:32+0+0+0=32/463|N:9+0+0+0=9/104|A:41+0+0+0=41/567	NA	WNT	3_NA_NA	[non-HC]_2.012/2.024_NA	TIER_3	Pathogenic	NA	SOM	NA	NA	stop_gained:R:APC:NP_001120983.2:p.(Glu1304Ter)|R:APC:XP_005272032.1:p.(Glu1322Ter)|E:APC:Canonical:ENSP00000413133.1:p.(Glu1322Ter)|R:APC:XP_005272034.1:p.(Glu1221Ter)|R:APC:Canonical:NP_000029.2:p.(Glu1322Ter)|R:APC:NP_001120982.1:p.(Glu1322Ter)|E:APC:ENSP00000257430.4:p.(Glu1322Ter)|E:APC:ENSP00000427089.2:p.(Glu1322Ter)|R:APC:XP_005272031.1:p.(Glu1322Ter)|R:APC:XP_005272033.1:p.(Glu1263Ter);downstream_gene_variant:E:APC:ENST00000507379.1|E:APC:ENST00000512211.2|E:APC:ENST00000504915.2	CPSR_classification|protein_changes:stop_gained|class	NA	IS:all_exons	.	.	include	.	.	.
CL-AcroMetrix	APC	ENST00000457016	NA	5:112175852	G>T	c.4561G>T	exon16	E1521X	Glu1521Ter	c.4561G>T:exon16:E1521X:Glu1521Ter	stop_gained	1047	0.205	NA	NA	NA	NA	COSV57322883	NA	NA	NA	NA	NA	NA	NA	NA	NA	T:20+0+0+0=20/463|N:4+1+0+0=5/104|A:24+1+0+0=25/567	NA	WNT	3_NA_NA	[non-HC]_2.012/2.024_NA	TIER_3	Pathogenic	NA	SOM	NA	NA	stop_gained:R:APC:NP_001120983.2:p.(Glu1503Ter)|R:APC:XP_005272032.1:p.(Glu1521Ter)|E:APC:Canonical:ENSP00000413133.1:p.(Glu1521Ter)|R:APC:XP_005272034.1:p.(Glu1420Ter)|R:APC:Canonical:NP_000029.2:p.(Glu1521Ter)|R:APC:NP_001120982.1:p.(Glu1521Ter)|E:APC:ENSP00000257430.4:p.(Glu1521Ter)|E:APC:ENSP00000427089.2:p.(Glu1521Ter)|R:APC:XP_005272031.1:p.(Glu1521Ter)|R:APC:XP_005272033.1:p.(Glu1462Ter);downstream_gene_variant:E:APC:ENST00000507379.1|E:APC:ENST00000512211.2|E:APC:ENST00000504915.2	CPSR_classification|protein_changes:stop_gained|class	NA	IS:all_exons	.	.	include	.	.	.
CL-AcroMetrix	APC	ENST00000457016	NA	5:112175930	G>T	c.4639G>T	exon16	E1547X	Glu1547Ter	c.4639G>T:exon16:E1547X:Glu1547Ter	stop_gained	889	0.171	NA	NA	NA	NA	COSV57322083|COSV57329454	NA	NA	NA	NA	NA	NA	NA	NA	NA	T:17+1+1+0=19/463|N:2+0+0+0=2/104|A:19+1+1+0=21/567	NA	WNT	3_NA_NA	[non-HC]_2.012/2.024_NA	TIER_3	Pathogenic	NA	SOM	NA	NA	stop_gained:R:APC:NP_001120983.2:p.(Glu1529Ter)|R:APC:XP_005272032.1:p.(Glu1547Ter)|E:APC:Canonical:ENSP00000413133.1:p.(Glu1547Ter)|R:APC:XP_005272034.1:p.(Glu1446Ter)|R:APC:Canonical:NP_000029.2:p.(Glu1547Ter)|R:APC:NP_001120982.1:p.(Glu1547Ter)|E:APC:ENSP00000257430.4:p.(Glu1547Ter)|E:APC:ENSP00000427089.2:p.(Glu1547Ter)|R:APC:XP_005272031.1:p.(Glu1547Ter)|R:APC:XP_005272033.1:p.(Glu1488Ter);downstream_gene_variant:E:APC:ENST00000507379.1|E:APC:ENST00000512211.2|E:APC:ENST00000504915.2	CPSR_classification|protein_changes:stop_gained|class	NA	IS:all_exons	.	.	include	.	.	.
CL-AcroMetrix	APC	ENST00000457016	NA	5:112175945	G>T	c.4654G>T	exon16	E1552X	Glu1552Ter	c.4654G>T:exon16:E1552X:Glu1552Ter	stop_gained	873	0.163	NA	NA	NA	NA	COSV57325678	NA	NA	NA	NA	NA	NA	NA	NA	NA	T:6+0+0+0=6/463|N:2+0+0+0=2/104|A:8+0+0+0=8/567	NA	WNT	3_NA_NA	[non-HC]_2.012/2.024_NA	TIER_3	Pathogenic	NA	SOM	NA	NA	stop_gained:R:APC:NP_001120983.2:p.(Glu1534Ter)|R:APC:XP_005272032.1:p.(Glu1552Ter)|E:APC:Canonical:ENSP00000413133.1:p.(Glu1552Ter)|R:APC:XP_005272034.1:p.(Glu1451Ter)|R:APC:Canonical:NP_000029.2:p.(Glu1552Ter)|R:APC:NP_001120982.1:p.(Glu1552Ter)|E:APC:ENSP00000257430.4:p.(Glu1552Ter)|E:APC:ENSP00000427089.2:p.(Glu1552Ter)|R:APC:XP_005272031.1:p.(Glu1552Ter)|R:APC:XP_005272033.1:p.(Glu1493Ter);downstream_gene_variant:E:APC:ENST00000507379.1|E:APC:ENST00000512211.2|E:APC:ENST00000504915.2	CPSR_classification|protein_changes:stop_gained|class	NA	IS:all_exons	.	.	include	.	.	.
CL-AcroMetrix	ATM	ENST00000278616	NA	11:108172385	C>T	c.5188C>T	exon35	R1730X	Arg1730Ter	c.5188C>T:exon35:R1730X:Arg1730Ter	stop_gained	769	0.042	NA	NA	NA	NA	COSV53730827	rs764389018	189054	8e-06	NA	0.0000176	NA	NA	Rectum_Adenocarcinoma:_1.5%_(2/137)|Colon_Adenocarcinoma:_0.3%_(1/399)	MELA-AU/Metastatic/1/60/0.0167	T:123+2+1+0=126/463|N:3+0+0+0=3/104|A:126+2+1+0=129/567	NA	TP53	NA	[HC]_2.122/2.244_NA	TIER_3	Pathogenic	Likely_Pathogenic	SOM	NA	Iniparib	stop_gained:E:ATM:Canonical:ENSP00000278616.4:p.(Arg1730Ter)|R:ATM:Canonical:NP_000042.3:p.(Arg1730Ter)|E:ATM:ENSP00000388058.2:p.(Arg1730Ter)|R:ATM:XP_005271619.1:p.(Arg1730Ter)|R:ATM:XP_005271618.1:p.(Arg1730Ter)|R:ATM:XP_005271620.1:p.(Arg1730Ter)|R:ATM:XP_005271621.1:p.(Arg1382Ter)	CPSR_classification|ClinVar_classification|protein_changes:stop_gained|class	NA	IS:all_exons	.	.	include	variant_in_more_than_10%_of_tumor_samples_(26.57%)_with_VAF_under_0.01	.	.
CL-AcroMetrix	ATM	ENST00000278616	NA	11:108236203	C>T	c.9139C>T	exon63	R3047X	Arg3047Ter	c.9139C>T:exon63:R3047X:Arg3047Ter	stop_gained	959	0.075	NA	NA	NA	NA	COSV53724126	rs121434219	3029	1.59e-05	NA	0.0000000	NA	NA	Uterine_Corpus_Endometrial_Carcinoma:_0.2%_(1/530)|Breast_Invasive_Carcinoma:_0.1%_(1/986)	NA	T:118+5+0+0=123/463|N:4+0+0+0=4/104|A:122+5+0+0=127/567	NA	TP53	NA	[HC]_2.122/2.244_NA	TIER_3	Likely_Pathogenic	Pathogenic	SOM	FATC_domain	Iniparib	stop_gained:E:ATM:Canonical:ENSP00000278616.4:p.(Arg3047Ter)|R:ATM:Canonical:NP_000042.3:p.(Arg3047Ter)|E:ATM:ENSP00000388058.2:p.(Arg3047Ter)|R:ATM:XP_005271619.1:p.(Arg3047Ter)|R:ATM:XP_005271618.1:p.(Arg3047Ter)|R:ATM:XP_005271620.1:p.(Arg3047Ter)|R:ATM:XP_005271621.1:p.(Arg2699Ter)	CPSR_classification|ClinVar_classification|protein_changes:stop_gained|class	NA	IS:all_exons	.	.	include	variant_in_more_than_10%_of_tumor_samples_(25.49%)_with_VAF_under_0.01	.	.
CL-AcroMetrix	CDH1	ENST00000261769	NM_004360	16:68856105	G>A	c.1913G>A	exon12	W638X	Trp638Ter	c.1913G>A:exon12:W638X:Trp638Ter	stop_gained	1054	0.046	NA	NA	NA	NA	COSV55734319	rs1567512585	599651	NA	NA	NA	NA	NA	NA	NA	T:61+1+0+0=62/463|N:6+0+0+0=6/104|A:67+1+0+0=68/567	NA	NA	NA	[non-HC]_2.096/2.192_NA	TIER_3	Pathogenic	Pathogenic	SOM	Cadherin_domain	NA	stop_gained:R:CDH1:XP_005256329.1:p.(Trp577Ter)|E:CDH1:Canonical:ENSP00000261769.4:p.(Trp638Ter)|R:CDH1:NP_001304113.1:p.(Trp577Ter)|R:CDH1:NP_001304114.1:p.(Trp122Ter)|R:CDH1:Canonical:NP_004351.1:p.(Trp638Ter)|R:CDH1:NP_004351.1:p.(Trp638Ter)|E:CDH1:ENSP00000414946.2:p.(Trp577Ter);5_prime_UTR_variant:R:CDH1:NM_001317186.1	CPSR_classification|ClinVar_classification|protein_changes:stop_gained|class	NA	IS:all_exons	.	.	include	variant_in_more_than_10%_of_tumor_samples_(13.17%)_with_VAF_under_0.01	.	.
CL-AcroMetrix	CDKN2A	ENST00000498124	NM_001195132	9:21971153	C>A	c.205G>T	exon2	E69X	Glu69Ter	c.205G>T:exon2:E69X:Glu69Ter	stop_gained	1156	0.196	NA	NA	NA	NA	COSV58683264|COSV58724303|COSV58727969	rs121913383	376308	NA	NA	NA	NA	NA	Head_and_Neck_Squamous_Cell_Carcinoma:_0.4%_(2/508)|Lung_Squamous_Cell_Carcinoma:_0.2%_(1/492)	NA	T:20+3+0+0=23/459|N:2+0+0+0=2/103|A:22+3+0+0=25/562	NA	CC	NA	[non-HC]_2.044/2.088_NA	TIER_3	Pathogenic	Likely_Pathogenic	SOM	Ankyrin_repeats_(3_copies)	NA	downstream_gene_variant:E:CDKN2A-AS1:Canonical:ENST00000441769.2;stop_gained:R:CDKN2A:XP_005251400.1:p.(Glu18Ter)|R:CDKN2A:NP_001182061.1:p.(Glu69Ter)|R:CDKN2A:Canonical:NP_000068.1:p.(Glu69Ter)|E:CDKN2A:ENSP00000307101.5:p.(Glu69Ter)|E:CDKN2A:ENSP00000464202.1:p.(Glu69Ter)|E:CDKN2A:ENSP00000467390.1:p.(Glu18Ter)|E:CDKN2A:ENSP00000418915.1:p.(Glu69Ter)|E:CDKN2A:ENSP00000467857.1:p.(Glu18Ter)|E:CDKN2A:ENSP00000464952.1:p.(Glu18Ter)|R:CDKN2A:XP_005251398.1:p.(Glu69Ter)|E:CDKN2A:ENSP00000394932.1:p.(Glu69Ter)|E:CDKN2A:ENSP00000466887.1:p.(Glu18Ter)|E:CDKN2A:ENSP00000468510.1:p.(Glu18Ter);3_prime_UTR_variant:R:CDKN2A:NM_058197.4;missense_variant:E:CDKN2A:Canonical:ENSP00000355153.3:p.(Gly124Val)|R:CDKN2A:NP_478102.2:p.(Gly83Val)|E:CDKN2A:ENSP00000462950.1:p.(Gly83Val)|E:CDKN2A:ENSP00000432664.2:p.(Gly83Val)	CPSR_classification|ClinVar_classification|protein_changes:stop_gained|class	NA	IS:all_exons	.	.	include	.	.	.
CL-AcroMetrix	ERBB4	ENST00000342788	NM_005235	2:212288964	C>A	c.2782G>T	exon23	E928X	Glu928Ter	c.2782G>T:exon23:E928X:Glu928Ter	stop_gained	776	0.086	NA	NA	NA	NA	COSV61479480|COSV61530911	NA	NA	NA	NA	NA	NA	NA	Rectum_Adenocarcinoma:_0.7%_(1/137)	NA	T:14+0+0+0=14/463|N:2+0+0+0=2/104|A:16+0+0+0=16/567	NA	RTKRAS	NA	[non-HC]_1.798/1.596_NA	TIER_3	VUS	NA	SOM	Protein_tyrosine_and_serine/threonine_kinase	Afatinib|Neratinib|Afatinib_Dimaleate|Dacomitinib|Vandetanib|Neratinib_Maleate	stop_gained:R:ERBB4:Canonical:NP_005226.1:p.(Glu928Ter)|R:ERBB4:NP_001036064.1:p.(Glu928Ter)|R:ERBB4:XP_005246433.1:p.(Glu918Ter)|R:ERBB4:XP_005246434.1:p.(Glu918Ter)|R:ERBB4:XP_005246432.1:p.(Glu943Ter)|E:ERBB4:Canonical:ENSP00000342235.4:p.(Glu928Ter)|E:ERBB4:ENSP00000403204.1:p.(Glu928Ter)|E:ERBB4:ENSP00000385565.1:p.(Glu918Ter)	protein_changes:stop_gained|class	NA	all_exons	.	.	include	.	.	.
CL-AcroMetrix	ERBB4	ENST00000342788	NM_005235	2:212587197	G>T	c.804C>A	exon7	Y268X	Tyr268Ter	c.804C>A:exon7:Y268X:Tyr268Ter	stop_gained	812	0.095	NA	NA	NA	NA	COSV53549312	NA	NA	NA	NA	NA	NA	NA	NA	NA	T:26+2+0+0=28/463|N:2+0+0+0=2/104|A:28+2+0+0=30/567	NA	RTKRAS	NA	[non-HC]_1.798/1.596_NA	TIER_3	VUS	NA	SOM	Furin-like_cysteine_rich_region	Afatinib|Neratinib|Afatinib_Dimaleate|Dacomitinib|Vandetanib|Neratinib_Maleate	stop_gained:R:ERBB4:Canonical:NP_005226.1:p.(Tyr268Ter)|R:ERBB4:NP_001036064.1:p.(Tyr268Ter)|R:ERBB4:XP_005246433.1:p.(Tyr268Ter)|R:ERBB4:XP_005246434.1:p.(Tyr268Ter)|R:ERBB4:XP_005246432.1:p.(Tyr268Ter)|E:ERBB4:Canonical:ENSP00000342235.4:p.(Tyr268Ter)|E:ERBB4:ENSP00000403204.1:p.(Tyr268Ter)|E:ERBB4:ENSP00000385565.1:p.(Tyr268Ter)|E:ERBB4:ENSP00000260943.6:p.(Tyr268Ter)	protein_changes:stop_gained|class	NA	all_exons	.	.	include	.	.	.
CL-AcroMetrix	FBXW7	ENST00000281708	NM_001349798	4:153244124	G>C	c.2033C>G	exon12	S678X	Ser678Ter	c.2033C>G:exon12:S678X:Ser678Ter	stop_gained	1162	0.06	NA	NA	NA	NA	COSV55897853	NA	NA	NA	NA	NA	NA	NA	Bladder_Urothelial_Carcinoma:_0.2%_(1/412)|Lung_Squamous_Cell_Carcinoma:_0.2%_(1/492)	NA	T:13+0+0+0=13/463|N:0+0+0+0=0/104|A:13+0+0+0=13/567	NA	NOTCH	NA	[non-HC]_1.88/1.76_NA	TIER_3	VUS	NA	SOM	NA	NA	stop_gained:R:FBXW7:XP_005263165.1:p.(Ser502Ter)|R:FBXW7:Canonical:NP_060785.2:p.(Ser598Ter)|R:FBXW7:NP_001013433.1:p.(Ser560Ter)|R:FBXW7:XP_005263164.1:p.(Ser678Ter)|R:FBXW7:NP_361014.1:p.(Ser678Ter)|E:FBXW7:Canonical:ENSP00000281708.3:p.(Ser678Ter)|E:FBXW7:ENSP00000296555.4:p.(Ser560Ter)|E:FBXW7:ENSP00000263981.4:p.(Ser598Ter)|E:FBXW7:ENSP00000474725.1:p.(Ser678Ter)|E:FBXW7:ENSP00000377528.3:p.(Ser502Ter)|E:FBXW7:ENSP00000474971.1:p.(Ser678Ter)	protein_changes:stop_gained|class	NA	all_exons	.	.	include	.	.	.
CL-AcroMetrix	FBXW7	ENST00000281708	NM_001349798	4:153249440	C>T	c.1338G>A	exon9	W446X	Trp446Ter	c.1338G>A:exon9:W446X:Trp446Ter	stop_gained	955	0.051	NA	NA	NA	NA	COSV55913838|COSV55933822	NA	NA	NA	NA	NA	NA	NA	NA	NA	T:48+1+0+0=49/463|N:4+0+0+0=4/104|A:52+1+0+0=53/567	NA	NOTCH	NA	[non-HC]_1.88/1.76_NA	TIER_3	VUS	NA	SOM	WD_domain|G-beta_repeat	NA	stop_gained:R:FBXW7:XP_005263165.1:p.(Trp270Ter)|R:FBXW7:Canonical:NP_060785.2:p.(Trp366Ter)|R:FBXW7:NP_001013433.1:p.(Trp328Ter)|R:FBXW7:XP_005263164.1:p.(Trp446Ter)|R:FBXW7:NP_361014.1:p.(Trp446Ter)|E:FBXW7:Canonical:ENSP00000281708.3:p.(Trp446Ter)|E:FBXW7:ENSP00000296555.4:p.(Trp328Ter)|E:FBXW7:ENSP00000263981.4:p.(Trp366Ter)|E:FBXW7:ENSP00000474725.1:p.(Trp446Ter)|E:FBXW7:ENSP00000377528.3:p.(Trp270Ter)|E:FBXW7:ENSP00000474971.1:p.(Trp446Ter)	protein_changes:stop_gained|class	NA	all_exons	.	.	include	variant_in_more_than_10%_of_tumor_samples_(10.37%)_with_VAF_under_0.01	.	.
CL-AcroMetrix	KIT	ENST00000288135	NM_000222	4:55602737	G>A	c.2558G>A	exon18	W853X	Trp853Ter	c.2558G>A:exon18:W853X:Trp853Ter	stop_gained	938	0.071	NA	NA	NA	NA	COSV55414339	NA	NA	NA	NA	NA	NA	NA	NA	NA	T:52+1+0+0=53/463|N:3+0+0+0=3/104|A:55+1+0+0=56/567	NA	RTKRAS	NA	[HC]_2.044/2.088_NA	TIER_3	VUS	NA	SOM	Protein_tyrosine_and_serine/threonine_kinase	Vatalanib|Sorafenib_Tosylate|Pazopanib_Hydrochloride|Sorafenib|Dasatinib|Masitinib|Regorafenib|Regorafenib_Hydrate|Semaxanib|Anlotinib|Famitinib|Pexidartinib|Sitravatinib|Pexidartinib_Hydrochloride|Avapritinib|Ripretinib|Pazopanib|Cediranib|Dovitinib|Sunitinib_Malate|Motesanib|Quizartinib|Midostaurin|Imatinib	stop_gained:E:KIT:ENSP00000390987.2:p.(Trp849Ter)|E:KIT:Canonical:ENSP00000288135.5:p.(Trp853Ter)|R:KIT:NP_001087241.1:p.(Trp849Ter)|R:KIT:Canonical:NP_000213.1:p.(Trp853Ter)|R:KIT:XP_005265799.1:p.(Trp850Ter)|R:KIT:XP_005265797.1:p.(Trp854Ter)|R:KIT:XP_005265798.1:p.(Trp853Ter)	protein_changes:stop_gained|class	NA	all_exons;IS:introns[16],exons[8-9,11-13,17]	.	.	include	variant_in_more_than_10%_of_tumor_samples_(11.23%)_with_VAF_under_0.01	.	.
CL-AcroMetrix	MET	ENST00000318493	NM_001127500	7:116418997	C>T	c.3562C>T	exon17	R1188X	Arg1188Ter	c.3562C>T:exon17:R1188X:Arg1188Ter	stop_gained	1109	0.137	NA	NA	NA	NA	COSV59258293	rs200754673	546023	NA	NA	NA	NA	NA	Rectum_Adenocarcinoma:_0.7%_(1/137)|Colon_Adenocarcinoma:_0.3%_(1/399)	NA	T:157+9+0+0=166/463|N:5+0+0+0=5/104|A:162+9+0+0=171/567	NA	RTKRAS	NA	[HC]_2.166/2.332_NA	TIER_3	VUS	VUS	SOM	Protein_tyrosine_and_serine/threonine_kinase	Onartuzumab|Cabozantinib_S-malate|Tivantinib|Cabozantinib|Capmatinib|Savolitinib|Tepotinib|Sitravatinib|Capmatinib_Hydrochloride|Tepotinib_Hydrochloride|Crizotinib	stop_gained:R:MET:XP_005250410.1:p.(Arg1207Ter)|R:MET:NP_001311331.1:p.(Arg740Ter)|R:MET:Canonical:NP_001120972.1:p.(Arg1188Ter)|R:MET:NP_000236.2:p.(Arg1170Ter)|E:MET:ENSP00000380860.3:p.(Arg1170Ter)|E:MET:Canonical:ENSP00000317272.6:p.(Arg1188Ter)|R:MET:NP_001120972.1:p.(Arg1188Ter)|R:MET:NP_000236.2:p.(Arg1170Ter)|R:MET:XP_005250411.1:p.(Arg740Ter)|E:MET:ENSP00000445020.1:p.(Arg40Ter);downstream_gene_variant:E:MET:ENST00000454623.1	protein_changes:stop_gained|class	NA	IS:all_exons	.	.	include	variant_in_more_than_10%_of_tumor_samples_(33.91%)_with_VAF_under_0.01	.	.
CL-AcroMetrix	NOTCH1	ENST00000277541	NA	9:139390779	G>T	c.7412C>A	exon34	S2471X	Ser2471Ter	c.7412C>A:exon34:S2471X:Ser2471Ter	stop_gained	1724	0.151	NA	NA	NA	NA	COSV53046543|COSV53058145	NA	NA	NA	NA	NA	NA	NA	NA	NA	T:26+0+0+0=26/463|N:6+0+0+0=6/104|A:32+0+0+0=32/567	NA	NOTCH	NA	[non-HC]_2.294/2.588_NA	TIER_3	VUS	NA	SOM	NA	NA	stop_gained:R:NOTCH1:Canonical:NP_060087.3:p.(Ser2471Ter)|R:NOTCH1:NP_060087.3:p.(Ser2471Ter)|E:NOTCH1:Canonical:ENSP00000277541.6:p.(Ser2471Ter)	protein_changes:stop_gained|class	NA	all_exons	.	.	include	.	.	.
CL-AcroMetrix	NOTCH1	ENST00000277541	NA	9:139390816	G>A	c.7375C>T	exon34	Q2459X	Gln2459Ter	c.7375C>T:exon34:Q2459X:Gln2459Ter	stop_gained	1613	0.149	NA	NA	NA	NA	COSV53025731	rs1292613938	NA	4.6e-06	NA	0.0000101	NA	NA	NA	NA	T:46+1+0+0=47/463|N:1+0+0+0=1/103|A:47+1+0+0=48/566	NA	NOTCH	NA	[non-HC]_2.294/2.588_NA	TIER_3	VUS	NA	SOM	NA	NA	stop_gained:R:NOTCH1:Canonical:NP_060087.3:p.(Gln2459Ter)|R:NOTCH1:NP_060087.3:p.(Gln2459Ter)|E:NOTCH1:Canonical:ENSP00000277541.6:p.(Gln2459Ter)	protein_changes:stop_gained|class	NA	all_exons	.	.	include	.	.	.
CL-AcroMetrix	NOTCH1	ENST00000277541	NA	9:139390873	G>A	c.7318C>T	exon34	Q2440X	Gln2440Ter	c.7318C>T:exon34:Q2440X:Gln2440Ter	stop_gained	1561	0.156	NA	NA	NA	NA	COSV53024887	NA	NA	NA	NA	NA	NA	NA	NA	NA	T:34+0+0+0=34/463|N:3+0+0+0=3/104|A:37+0+0+0=37/567	NA	NOTCH	NA	[non-HC]_2.294/2.588_NA	TIER_3	VUS	NA	SOM	NA	NA	stop_gained:R:NOTCH1:Canonical:NP_060087.3:p.(Gln2440Ter)|R:NOTCH1:NP_060087.3:p.(Gln2440Ter)|E:NOTCH1:Canonical:ENSP00000277541.6:p.(Gln2440Ter)	protein_changes:stop_gained|class	NA	all_exons	.	.	include	.	.	.
CL-AcroMetrix	PTEN	ENST00000371953	NM_000314	10:89624245	G>T	c.19G>T	exon1	E7X	Glu7Ter	c.19G>T:exon1:E7X:Glu7Ter	stop_gained	1304	0.071	NA	NA	NA	NA	COSV64288471|COSV64291810	rs1554890335	493079	NA	NA	NA	NA	NA	Uterine_Corpus_Endometrial_Carcinoma:_1.7%_(9/530)|Rectum_Adenocarcinoma:_1.5%_(2/137)	NA	T:35+0+0+0=35/463|N:8+0+0+0=8/104|A:43+0+0+0=43/567	NA	PI3K	NA	[HC]_1.964/1.928_NA	TIER_3	Pathogenic	Likely_Pathogenic	SOM	NA	NA	upstream_gene_variant:E:KLLN:Canonical:ENST00000445946.3|R:KLLN:Canonical:NM_001126049.1;stop_gained:E:PTEN:Canonical:ENSP00000361021.3:p.(Glu7Ter)|R:PTEN:NP_000305.3:p.(Glu7Ter)|R:PTEN:Canonical:NP_000305.3:p.(Glu7Ter)|R:PTEN:NP_001291646.2:p.(Glu180Ter);5_prime_UTR_variant:R:PTEN:NM_001304718.1	CPSR_classification|ClinVar_classification|protein_changes:stop_gained|class	NA	IS:all_exons	.	.	include	.	.	.
CL-AcroMetrix	PTEN	ENST00000371953	NM_000314	10:89624275	C>T	c.49C>T	exon1	Q17X	Gln17Ter	c.49C>T:exon1:Q17X:Gln17Ter	stop_gained	1275	0.045	NA	NA	NA	NA	COSV64288346	rs786204910	189458	NA	NA	NA	NA	NA	Uterine_Carcinosarcoma:_1.8%_(1/57)|Bladder_Urothelial_Carcinoma:_0.5%_(2/412)|Uterine_Corpus_Endometrial_Carcinoma:_0.2%_(1/530)	NA	T:51+2+0+0=53/462|N:1+0+0+0=1/104|A:52+2+0+0=54/566	NA	PI3K	NA	[HC]_1.964/1.928_NA	TIER_3	Pathogenic	Pathogenic	SOM	NA	NA	upstream_gene_variant:E:KLLN:Canonical:ENST00000445946.3|R:KLLN:Canonical:NM_001126049.1;stop_gained:E:PTEN:Canonical:ENSP00000361021.3:p.(Gln17Ter)|R:PTEN:NP_000305.3:p.(Gln17Ter)|R:PTEN:Canonical:NP_000305.3:p.(Gln17Ter)|R:PTEN:NP_001291646.2:p.(Gln190Ter);5_prime_UTR_variant:R:PTEN:NM_001304718.1	CPSR_classification|ClinVar_classification|protein_changes:stop_gained|class	NA	IS:all_exons	.	.	include	variant_in_more_than_10%_of_tumor_samples_(11.04%)_with_VAF_under_0.01	.	.
CL-AcroMetrix	PTEN	ENST00000371953	NM_000314	10:89717678	G>T	c.703G>T	exon7	E235X	Glu235Ter	c.703G>T:exon7:E235X:Glu235Ter	stop_gained	1134	0.123	NA	NA	NA	NA	COSV64291436|COSV64298657|COSV64300002	rs1554825200	NA	NA	NA	NA	NA	NA	Lung_Squamous_Cell_Carcinoma:_0.2%_(1/492)|Uterine_Corpus_Endometrial_Carcinoma:_0.2%_(1/530)	NA	T:25+0+0+0=25/463|N:4+0+0+0=4/104|A:29+0+0+0=29/567	NA	PI3K	NA	[HC]_1.964/1.928_NA	TIER_3	Pathogenic	NA	SOM	C2_domain_of_PTEN_tumour-suppressor_protein	NA	stop_gained:E:PTEN:Canonical:ENSP00000361021.3:p.(Glu235Ter)|R:PTEN:NP_000305.3:p.(Glu235Ter)|R:PTEN:Canonical:NP_000305.3:p.(Glu235Ter)|R:PTEN:NP_001291647.1:p.(Glu38Ter)|R:PTEN:NP_001291646.2:p.(Glu408Ter)	CPSR_classification|protein_changes:stop_gained|class	NA	IS:all_exons	.	.	include	.	.	.
CL-AcroMetrix	PTEN	ENST00000371953	NM_000314	10:89717762	A>T	c.787A>T	exon7	K263X	Lys263Ter	c.787A>T:exon7:K263X:Lys263Ter	stop_gained	882	0.172	NA	NA	NA	NA	COSV64298269	rs1554825254	NA	NA	NA	NA	NA	NA	Esophageal_Carcinoma:_0.5%_(1/184)|Glioblastoma_Multiforme:_0.3%_(1/393)|Kidney_Renal_Clear_Cell_Carcinoma:_0.3%_(1/336)	NA	T:3+0+0+0=3/463|N:0+0+0+0=0/104|A:3+0+0+0=3/567	NA	PI3K	NA	[HC]_1.964/1.928_NA	TIER_3	Pathogenic	NA	SOM	C2_domain_of_PTEN_tumour-suppressor_protein	NA	stop_gained:E:PTEN:Canonical:ENSP00000361021.3:p.(Lys263Ter)|R:PTEN:NP_000305.3:p.(Lys263Ter)|R:PTEN:Canonical:NP_000305.3:p.(Lys263Ter)|R:PTEN:NP_001291647.1:p.(Lys66Ter)|R:PTEN:NP_001291646.2:p.(Lys436Ter)	CPSR_classification|protein_changes:stop_gained|class	NA	IS:all_exons	.	.	include	.	.	.
CL-AcroMetrix	PTEN	ENST00000371953	NM_000314	10:89720744	G>T	c.895G>T	exon8	E299X	Glu299Ter	c.895G>T:exon8:E299X:Glu299Ter	stop_gained	705	0.187	NA	NA	NA	NA	COSV64293312	rs1114167674	428263	NA	NA	NA	NA	NA	Rectum_Adenocarcinoma:_1.5%_(2/137)|Uterine_Corpus_Endometrial_Carcinoma:_1.5%_(8/530)|Colon_Adenocarcinoma:_0.5%_(2/399)|Glioblastoma_Multiforme:_0.3%_(1/393)	NA	T:8+1+0+1=10/463|N:2+1+0+0=3/104|A:10+2+0+1=13/567	NA	PI3K	NA	[HC]_1.964/1.928_NA	TIER_3	Pathogenic	Pathogenic	SOM	C2_domain_of_PTEN_tumour-suppressor_protein	NA	stop_gained:E:PTEN:Canonical:ENSP00000361021.3:p.(Glu299Ter)|R:PTEN:NP_000305.3:p.(Glu299Ter)|R:PTEN:Canonical:NP_000305.3:p.(Glu299Ter)|R:PTEN:NP_001291647.1:p.(Glu102Ter)|R:PTEN:NP_001291646.2:p.(Glu472Ter)	CPSR_classification|ClinVar_classification|protein_changes:stop_gained|class	NA	IS:all_exons	.	.	include	.	.	.
CL-AcroMetrix	RB1	ENST00000267163	NM_000321	13:48919244	G>T	c.409G>T	exon4	E137X	Glu137Ter	c.409G>T:exon4:E137X:Glu137Ter	stop_gained	540	0.059	NA	NA	NA	NA	COSV57300832	rs121913296	126810	NA	NA	NA	NA	NA	Uterine_Corpus_Endometrial_Carcinoma:_0.8%_(4/530)	NA	T:8+1+0+1=10/462|N:1+0+0+0=1/104|A:9+1+0+1=11/566	NA	CC	3_NA_NA	[non-HC]_2.194/2.388_NA	TIER_3	Pathogenic	Pathogenic	SOM	Domain_of_unknown_function_(DUF3452)	NA	stop_gained:R:RB1:Canonical:NP_000312.2:p.(Glu137Ter)|E:RB1:Canonical:ENSP00000267163.4:p.(Glu137Ter)	CPSR_classification|ClinVar_classification|protein_changes:stop_gained|class	NA	IS:all_exons	.	.	include	.	.	.
CL-AcroMetrix	RB1	ENST00000267163	NM_000321	13:48923148	T>A	c.596T>A	exon6	L199X	Leu199Ter	c.596T>A:exon6:L199X:Leu199Ter	stop_gained	536	0.056	NA	NA	NA	NA	COSV57298555|COSV57300700|COSV57307513	rs121913298	376329	NA	NA	NA	NA	NA	NA	NA	T:1+0+0+0=1/459|N:1+0+0+0=1/104|A:2+0+0+0=2/563	NA	CC	3_NA_NA	[non-HC]_2.194/2.388_NA	TIER_3	Pathogenic	Likely_Pathogenic	SOM	Domain_of_unknown_function_(DUF3452)	NA	stop_gained:R:RB1:Canonical:NP_000312.2:p.(Leu199Ter)|E:RB1:Canonical:ENSP00000267163.4:p.(Leu199Ter)	CPSR_classification|ClinVar_classification|protein_changes:stop_gained|class	NA	IS:all_exons	.	.	include	.	.	.
CL-AcroMetrix	RB1	ENST00000267163	NM_000321	13:48942685	C>T	c.1072C>T	exon11	R358X	Arg358Ter	c.1072C>T:exon11:R358X:Arg358Ter	stop_gained	715	0.055	NA	NA	NA	NA	COSV57296833	rs121913301	13076	NA	NA	NA	NA	NA	Cervical_Squamous_Cell_Carcinoma_and_Endocervical_Adenocarcinoma:_0.3%_(1/289)	NA	T:132+2+0+0=134/463|N:8+0+0+0=8/104|A:140+2+0+0=142/567	NA	CC	3_NA_NA	[non-HC]_2.194/2.388_NA	TIER_3	Pathogenic	Pathogenic	SOM	NA	NA	stop_gained:R:RB1:Canonical:NP_000312.2:p.(Arg358Ter)|E:RB1:Canonical:ENSP00000267163.4:p.(Arg358Ter)	CPSR_classification|ClinVar_classification|protein_changes:stop_gained|class	NA	IS:all_exons	.	.	include	variant_in_more_than_10%_of_tumor_samples_(28.51%)_with_VAF_under_0.01	.	.
CL-AcroMetrix	RB1	ENST00000267163	NM_000321	13:48955550	C>T	c.1666C>T	exon17	R556X	Arg556Ter	c.1666C>T:exon17:R556X:Arg556Ter	stop_gained	681	0.046	NA	NA	NA	NA	COSV57296489	rs121913304	13090	NA	NA	NA	NA	NA	Glioblastoma_Multiforme:_0.3%_(1/393)|Lung_Squamous_Cell_Carcinoma:_0.2%_(1/492)|Skin_Cutaneous_Melanoma:_0.2%_(1/468)	BRCA-UK/Primary/1/44/0.0227	T:132+1+0+0=133/462|N:2+0+0+0=2/104|A:134+1+0+0=135/566	NA	CC	3_NA_NA	[non-HC]_2.194/2.388_NA	TIER_3	Pathogenic	Pathogenic	SOM	Retinoblastoma-associated_protein_A_domain	NA	stop_gained:R:RB1:Canonical:NP_000312.2:p.(Arg556Ter)|E:RB1:Canonical:ENSP00000267163.4:p.(Arg556Ter)	CPSR_classification|ClinVar_classification|protein_changes:stop_gained|class	NA	IS:all_exons	.	.	include	variant_in_more_than_10%_of_tumor_samples_(28.57%)_with_VAF_under_0.01	.	.
CL-AcroMetrix	RB1	ENST00000267163	NM_000321	13:49033916	C>T	c.2053C>T	exon20	Q685X	Gln685Ter	c.2053C>T:exon20:Q685X:Gln685Ter	stop_gained	1029	0.058	NA	NA	NA	NA	COSV57323601	rs878853949	237668	NA	NA	NA	NA	NA	NA	NA	T:85+0+0+0=85/463|N:2+0+0+0=2/104|A:87+0+0+0=87/567	NA	CC	3_NA_NA	[non-HC]_2.194/2.388_NA	TIER_3	Pathogenic	Pathogenic	SOM	Retinoblastoma-associated_protein_B_domain	NA	stop_gained:R:RB1:Canonical:NP_000312.2:p.(Gln685Ter)|E:RB1:Canonical:ENSP00000267163.4:p.(Gln685Ter)	CPSR_classification|ClinVar_classification|protein_changes:stop_gained|class	NA	IS:all_exons	.	.	include	variant_in_more_than_10%_of_tumor_samples_(18.36%)_with_VAF_under_0.01	.	.
CL-AcroMetrix	RB1	ENST00000267163	NM_000321	13:49037903	A>T	c.2143A>T	exon21	K715X	Lys715Ter	c.2143A>T:exon21:K715X:Lys715Ter	stop_gained	612	0.021	NA	NA	NA	NA	COSV57309774	NA	NA	NA	NA	NA	NA	NA	NA	NA	T:4+0+0+0=4/462|N:4+0+0+0=4/104|A:8+0+0+0=8/566	NA	CC	3_NA_NA	[non-HC]_2.194/2.388_NA	TIER_3	Pathogenic	NA	SOM	Retinoblastoma-associated_protein_B_domain	NA	stop_gained:R:RB1:Canonical:NP_000312.2:p.(Lys715Ter)|E:RB1:Canonical:ENSP00000267163.4:p.(Lys715Ter)	CPSR_classification|protein_changes:stop_gained|class	NA	IS:all_exons	.	.	include	.	.	.
CL-AcroMetrix	RB1	ENST00000267163	NM_000321	13:49039164	G>T	c.2242G>T	exon22	E748X	Glu748Ter	c.2242G>T:exon22:E748X:Glu748Ter	stop_gained	437	0.055	NA	NA	NA	NA	COSV57302909	rs121913297	13078	NA	NA	NA	NA	NA	NA	NA	T:13+0+0+0=13/462|N:2+0+0+0=2/104|A:15+0+0+0=15/566	NA	CC	3_NA_NA	[non-HC]_2.194/2.388_NA	TIER_3	Pathogenic	Likely_Pathogenic	SOM	Retinoblastoma-associated_protein_B_domain	NA	stop_gained:R:RB1:Canonical:NP_000312.2:p.(Glu748Ter)|E:RB1:Canonical:ENSP00000267163.4:p.(Glu748Ter)	CPSR_classification|ClinVar_classification|protein_changes:stop_gained|class	NA	IS:all_exons	.	.	include	.	.	.
CL-AcroMetrix	RB1	ENST00000267163	NM_000321	13:49039215	A>T	c.2293A>T	exon22	K765X	Lys765Ter	c.2293A>T:exon22:K765X:Lys765Ter	stop_gained	622	0.053	NA	NA	NA	NA	COSV57303249	NA	995910	NA	NA	NA	NA	NA	Bladder_Urothelial_Carcinoma:_0.2%_(1/412)	NA	T:4+0+0+0=4/463|N:1+0+0+0=1/104|A:5+0+0+0=5/567	NA	CC	3_NA_NA	[non-HC]_2.194/2.388_NA	TIER_3	Pathogenic	Pathogenic	SOM	Retinoblastoma-associated_protein_B_domain	NA	stop_gained:R:RB1:Canonical:NP_000312.2:p.(Lys765Ter)|E:RB1:Canonical:ENSP00000267163.4:p.(Lys765Ter)	CPSR_classification|ClinVar_classification|protein_changes:stop_gained|class	NA	IS:all_exons	.	.	include	.	.	.
CL-AcroMetrix	SMAD4	ENST00000342988	NM_005359	18:48575671	C>G	c.431C>G	exon4	S144X	Ser144Ter	c.431C>G:exon4:S144X:Ser144Ter	stop_gained	536	0.048	NA	NA	NA	NA	COSV61685296|COSV61696805	NA	NA	NA	NA	NA	NA	NA	Pancreatic_Adenocarcinoma:_0.6%_(1/180)|Esophageal_Carcinoma:_0.5%_(1/184)	BRCA-UK/Primary/1/44/0.0227	T:9+0+0+0=9/461|N:1+0+0+0=1/104|A:10+0+0+0=10/565	NA	TFGBETA	NA	[non-HC]_2.106/2.212_NA	TIER_3	Pathogenic	NA	SOM	NA	NA	stop_gained:E:SMAD4:ENSP00000409551.2:p.(Ser144Ter)|E:SMAD4:Canonical:ENSP00000381452.1:p.(Ser144Ter)|E:SMAD4:ENSP00000466941.1:p.(Ser144Ter)|E:SMAD4:ENSP00000341551.3:p.(Ser144Ter)|R:SMAD4:Canonical:NP_005350.1:p.(Ser144Ter)|E:SMAD4:ENSP00000464901.1:p.(Ser144Ter);downstream_gene_variant:E:SMAD4:ENST00000588860.1|E:SMAD4:ENST00000589076.1|E:SMAD4:ENST00000590061.1|E:SMAD4:ENST00000589941.1	CPSR_classification|protein_changes:stop_gained|class	NA	all_exons	.	.	include	.	.	.
CL-AcroMetrix	SMAD4	ENST00000342988	NM_005359	18:48581198	G>T	c.502G>T	exon5	G168X	Gly168Ter	c.502G>T:exon5:G168X:Gly168Ter	stop_gained	790	0.048	NA	NA	NA	NA	COSV61697794	NA	933206	NA	NA	NA	NA	NA	Lung_Adenocarcinoma:_0.2%_(1/567)	NA	T:40+0+0+0=40/463|N:3+0+0+0=3/104|A:43+0+0+0=43/567	NA	TFGBETA	NA	[non-HC]_2.106/2.212_NA	TIER_3	Pathogenic	Likely_Pathogenic	SOM	NA	NA	3_prime_UTR_variant:E:SMAD4:ENST00000452201.2;stop_gained:E:SMAD4:Canonical:ENSP00000381452.1:p.(Gly168Ter)|E:SMAD4:ENSP00000341551.3:p.(Gly168Ter)|R:SMAD4:Canonical:NP_005350.1:p.(Gly168Ter)|E:SMAD4:ENSP00000464901.1:p.(Gly168Ter)	CPSR_classification|ClinVar_classification|protein_changes:stop_gained|class	NA	all_exons	.	.	include	.	.	.
CL-AcroMetrix	SMAD4	ENST00000342988	NM_005359	18:48581243	C>T	c.547C>T	exon5	Q183X	Gln183Ter	c.547C>T:exon5:Q183X:Gln183Ter	stop_gained	1027	0.06	NA	NA	NA	NA	COSV104419337|COSV61689260	NA	839230	NA	NA	NA	NA	NA	Lung_Squamous_Cell_Carcinoma:_0.2%_(1/492)	NA	T:68+3+0+0=71/463|N:4+0+0+0=4/104|A:72+3+0+0=75/567	NA	TFGBETA	NA	[non-HC]_2.106/2.212_NA	TIER_3	Pathogenic	Pathogenic	SOM	NA	NA	3_prime_UTR_variant:E:SMAD4:ENST00000452201.2;stop_gained:E:SMAD4:Canonical:ENSP00000381452.1:p.(Gln183Ter)|E:SMAD4:ENSP00000341551.3:p.(Gln183Ter)|R:SMAD4:Canonical:NP_005350.1:p.(Gln183Ter)|E:SMAD4:ENSP00000464901.1:p.(Gln183Ter)	CPSR_classification|ClinVar_classification|protein_changes:stop_gained|class	NA	all_exons	.	.	include	variant_in_more_than_10%_of_tumor_samples_(14.69%)_with_VAF_under_0.01	.	.
CL-AcroMetrix	SMAD4	ENST00000342988	NM_005359	18:48584560	C>T	c.733C>T	exon6	Q245X	Gln245Ter	c.733C>T:exon6:Q245X:Gln245Ter	stop_gained	980	0.076	NA	NA	NA	NA	COSV61684971|COSV61693968	NA	1050635	NA	NA	NA	NA	NA	Breast_Invasive_Carcinoma:_0.1%_(1/986)	ESAD-UK/Primary/1/97/0.0103	T:46+0+0+0=46/463|N:4+0+0+0=4/104|A:50+0+0+0=50/567	NA	TFGBETA	NA	[non-HC]_2.106/2.212_NA	TIER_3	Pathogenic	Pathogenic	SOM	NA	NA	downstream_gene_variant:E:SMAD4:ENST00000452201.2;stop_gained:E:SMAD4:Canonical:ENSP00000381452.1:p.(Gln245Ter)|E:SMAD4:ENSP00000341551.3:p.(Gln245Ter)|R:SMAD4:Canonical:NP_005350.1:p.(Gln245Ter)	CPSR_classification|ClinVar_classification|protein_changes:stop_gained|class	NA	all_exons	.	.	include	.	.	.
CL-AcroMetrix	SMAD4	ENST00000342988	NM_005359	18:48584593	C>T	c.766C>T	exon6	Q256X	Gln256Ter	c.766C>T:exon6:Q256X:Gln256Ter	stop_gained	950	0.061	NA	NA	NA	NA	COSV61686540|COSV61686776	NA	NA	NA	NA	NA	NA	NA	NA	NA	T:31+0+0+0=31/463|N:1+0+0+0=1/104|A:32+0+0+0=32/567	NA	TFGBETA	NA	[non-HC]_2.106/2.212_NA	TIER_3	Pathogenic	NA	SOM	NA	NA	downstream_gene_variant:E:SMAD4:ENST00000452201.2;stop_gained:E:SMAD4:Canonical:ENSP00000381452.1:p.(Gln256Ter)|E:SMAD4:ENSP00000341551.3:p.(Gln256Ter)|R:SMAD4:Canonical:NP_005350.1:p.(Gln256Ter)	CPSR_classification|protein_changes:stop_gained|class	NA	all_exons	.	.	include	.	.	.
CL-AcroMetrix	SMAD4	ENST00000342988	NM_005359	18:48586262	C>T	c.931C>T	exon8	Q311X	Gln311Ter	c.931C>T:exon8:Q311X:Gln311Ter	stop_gained	701	0.066	NA	NA	NA	NA	COSV61687817	rs876658694	230663	NA	NA	NA	NA	NA	NA	PACA-CA/Primary/1/140/0.0071	T:55+0+0+0=55/463|N:0+0+0+0=0/104|A:55+0+0+0=55/567	NA	TFGBETA	NA	[non-HC]_2.106/2.212_NA	TIER_3	Pathogenic	Pathogenic	SOM	NA	NA	downstream_gene_variant:E:SMAD4:ENST00000452201.2;stop_gained:E:SMAD4:Canonical:ENSP00000381452.1:p.(Gln311Ter)|E:SMAD4:ENSP00000341551.3:p.(Gln311Ter)|R:SMAD4:Canonical:NP_005350.1:p.(Gln311Ter)	CPSR_classification|ClinVar_classification|protein_changes:stop_gained|class	NA	all_exons	.	.	include	variant_in_more_than_10%_of_tumor_samples_(11.88%)_with_VAF_under_0.01	.	.
CL-AcroMetrix	SMAD4	ENST00000342988	NM_005359	18:48591865	C>G	c.1028C>G	exon9	S343X	Ser343Ter	c.1028C>G:exon9:S343X:Ser343Ter	stop_gained	953	0.036	NA	NA	NA	NA	COSV61684149|COSV61685122|COSV61693853	rs1599195400	822036	NA	NA	NA	NA	NA	NA	NA	T:6+0+0+0=6/463|N:0+0+0+0=0/104|A:6+0+0+0=6/567	NA	TFGBETA	NA	[non-HC]_2.106/2.212_NA	TIER_3	Pathogenic	Pathogenic	SOM	MH2_domain	NA	stop_gained:E:SMAD4:Canonical:ENSP00000381452.1:p.(Ser343Ter)|E:SMAD4:ENSP00000341551.3:p.(Ser343Ter)|R:SMAD4:Canonical:NP_005350.1:p.(Ser343Ter)|E:SMAD4:ENSP00000464901.1:p.(Ser247Ter);upstream_gene_variant:E:SMAD4:ENST00000593223.1	CPSR_classification|ClinVar_classification|protein_changes:stop_gained|class	NA	all_exons	.	.	include	.	.	.
CL-AcroMetrix	SMARCB1	ENST00000263121	NA	22:24133967	C>T	c.118C>T	exon2	R40X	Arg40Ter	c.118C>T:exon2:R40X:Arg40Ter	stop_gained	1080	0.065	NA	NA	NA	NA	COSV54092906|COSV54099377	rs1060503015	410698	NA	NA	NA	NA	NA	NA	NA	T:128+1+0+0=129/462|N:4+0+0+0=4/104|A:132+1+0+0=133/566	NA	NA	NA	[non-HC]_2.142/2.284_NA	TIER_3	Pathogenic	Pathogenic	SOM	NA	NA	stop_gained:R:SMARCB1:NP_001304875.1:p.(Arg40Ter)|R:SMARCB1:Canonical:NP_003064.2:p.(Arg40Ter)|R:SMARCB1:NP_001007469.1:p.(Arg40Ter)|E:SMARCB1:ENSP00000388489.1:p.(Arg40Ter)|E:SMARCB1:Canonical:ENSP00000340883.6:p.(Arg40Ter)|R:SMARCB1:NP_003064.2:p.(Arg40Ter)|R:SMARCB1:NP_001007469.1:p.(Arg40Ter)|E:SMARCB1:ENSP00000263121.7:p.(Arg40Ter)|R:SMARCB1:XP_005261775.1:p.(Arg40Ter)|E:SMARCB1:ENSP00000383984.3:p.(Arg40Ter)|E:SMARCB1:ENSP00000385226.3:p.(Arg40Ter)	CPSR_classification|ClinVar_classification|protein_changes:stop_gained|class	NA	all_exons	.	.	include	variant_in_more_than_10%_of_tumor_samples_(27.71%)_with_VAF_under_0.01	.	.
CL-AcroMetrix	SMARCB1	ENST00000263121	NA	22:24133990	C>A	c.141C>A	exon2	Y47X	Tyr47Ter	c.141C>A:exon2:Y47X:Tyr47Ter	stop_gained	1160	0.06	NA	NA	NA	NA	COSV54093088	NA	1073885	NA	NA	NA	NA	NA	NA	NA	T:32+0+0+0=32/463|N:5+0+0+0=5/104|A:37+0+0+0=37/567	NA	NA	NA	[non-HC]_2.142/2.284_NA	TIER_3	Pathogenic	Pathogenic	SOM	NA	NA	stop_gained:R:SMARCB1:NP_001304875.1:p.(Tyr47Ter)|R:SMARCB1:Canonical:NP_003064.2:p.(Tyr47Ter)|R:SMARCB1:NP_001007469.1:p.(Tyr47Ter)|E:SMARCB1:ENSP00000388489.1:p.(Tyr47Ter)|E:SMARCB1:Canonical:ENSP00000340883.6:p.(Tyr47Ter)|R:SMARCB1:NP_003064.2:p.(Tyr47Ter)|R:SMARCB1:NP_001007469.1:p.(Tyr47Ter)|E:SMARCB1:ENSP00000263121.7:p.(Tyr47Ter)|R:SMARCB1:XP_005261775.1:p.(Tyr47Ter)|E:SMARCB1:ENSP00000383984.3:p.(Tyr47Ter)|E:SMARCB1:ENSP00000385226.3:p.(Tyr47Ter)	CPSR_classification|ClinVar_classification|protein_changes:stop_gained|class	NA	all_exons	.	.	include	.	.	.
CL-AcroMetrix	SMARCB1	ENST00000263121	NA	22:24134006	C>T	c.157C>T	exon2	R53X	Arg53Ter	c.157C>T:exon2:R53X:Arg53Ter	stop_gained	1118	0.061	NA	NA	NA	NA	COSV54096035|COSV54099986	NA	944246	NA	NA	NA	NA	NA	Uterine_Corpus_Endometrial_Carcinoma:_0.2%_(1/530)	NA	T:121+2+0+0=123/463|N:7+0+0+0=7/104|A:128+2+0+0=130/567	NA	NA	NA	[non-HC]_2.142/2.284_NA	TIER_3	Pathogenic	Pathogenic	SOM	NA	NA	stop_gained:R:SMARCB1:NP_001304875.1:p.(Arg53Ter)|R:SMARCB1:Canonical:NP_003064.2:p.(Arg53Ter)|R:SMARCB1:NP_001007469.1:p.(Arg53Ter)|E:SMARCB1:ENSP00000388489.1:p.(Arg53Ter)|E:SMARCB1:Canonical:ENSP00000340883.6:p.(Arg53Ter)|R:SMARCB1:NP_003064.2:p.(Arg53Ter)|R:SMARCB1:NP_001007469.1:p.(Arg53Ter)|E:SMARCB1:ENSP00000263121.7:p.(Arg53Ter)|R:SMARCB1:XP_005261775.1:p.(Arg53Ter)|E:SMARCB1:ENSP00000383984.3:p.(Arg53Ter)|E:SMARCB1:ENSP00000385226.3:p.(Arg53Ter)	CPSR_classification|ClinVar_classification|protein_changes:stop_gained|class	NA	all_exons	.	.	include	variant_in_more_than_10%_of_tumor_samples_(26.13%)_with_VAF_under_0.01	.	.
CL-AcroMetrix	SMARCB1	ENST00000263121	NA	22:24143240	C>T	c.472C>T	exon4	R158X	Arg158Ter	c.472C>T:exon4:R158X:Arg158Ter	stop_gained	1352	0.075	NA	NA	NA	NA	COSV54093065	NA	995897	NA	NA	NA	NA	NA	Uterine_Corpus_Endometrial_Carcinoma:_0.2%_(1/530)	NA	T:102+3+0+0=105/462|N:7+0+0+0=7/104|A:109+3+0+0=112/566	NA	NA	NA	[non-HC]_2.142/2.284_NA	TIER_3	Pathogenic	Pathogenic	SOM	NA	NA	stop_gained:R:SMARCB1:NP_001304875.1:p.(Arg149Ter)|R:SMARCB1:Canonical:NP_003064.2:p.(Arg158Ter)|R:SMARCB1:NP_001007469.1:p.(Arg149Ter)|E:SMARCB1:ENSP00000388489.1:p.(Arg158Ter)|E:SMARCB1:Canonical:ENSP00000340883.6:p.(Arg149Ter)|R:SMARCB1:NP_003064.2:p.(Arg158Ter)|R:SMARCB1:NP_001007469.1:p.(Arg149Ter)|E:SMARCB1:ENSP00000263121.7:p.(Arg158Ter)|R:SMARCB1:XP_005261775.1:p.(Arg149Ter)|E:SMARCB1:ENSP00000383984.3:p.(Arg149Ter)	CPSR_classification|ClinVar_classification|protein_changes:stop_gained|class	NA	all_exons	.	.	include	variant_in_more_than_10%_of_tumor_samples_(22.08%)_with_VAF_under_0.01	.	.
CL-AcroMetrix	SMARCB1	ENST00000263121	NA	22:24145582	C>T	c.601C>T	exon5	R201X	Arg201Ter	c.601C>T:exon5:R201X:Arg201Ter	stop_gained	1294	0.046	NA	NA	NA	NA	COSV54093216	rs1555877286	532962	NA	NA	NA	NA	NA	Colon_Adenocarcinoma:_0.5%_(2/399)	NA	T:96+0+1+0=97/462|N:8+0+0+0=8/104|A:104+0+1+0=105/566	NA	NA	NA	[non-HC]_2.142/2.284_NA	TIER_3	Pathogenic	Pathogenic	SOM	SNF5_/_SMARCB1_/_INI1	NA	stop_gained:R:SMARCB1:NP_001304875.1:p.(Arg210Ter)|R:SMARCB1:Canonical:NP_003064.2:p.(Arg201Ter)|R:SMARCB1:NP_001007469.1:p.(Arg192Ter)|E:SMARCB1:ENSP00000388489.1:p.(Arg219Ter)|E:SMARCB1:Canonical:ENSP00000340883.6:p.(Arg210Ter)|R:SMARCB1:NP_003064.2:p.(Arg201Ter)|R:SMARCB1:NP_001007469.1:p.(Arg192Ter)|E:SMARCB1:ENSP00000263121.7:p.(Arg201Ter)|R:SMARCB1:XP_005261775.1:p.(Arg210Ter)|E:SMARCB1:ENSP00000383984.3:p.(Arg192Ter)|E:SMARCB1:ENSP00000385226.3:p.(Arg155Ter)	CPSR_classification|ClinVar_classification|protein_changes:stop_gained|class	NA	all_exons	.	.	include	variant_in_more_than_10%_of_tumor_samples_(20.78%)_with_VAF_under_0.01	.	.
CL-AcroMetrix	STK11	ENST00000326873	NM_000455	19:1220382	C>T	c.475C>T	exon4	Q159X	Gln159Ter	c.475C>T:exon4:Q159X:Gln159Ter	stop_gained	1108	0.055	NA	NA	NA	NA	COSV58820732|COSV58830552	NA	NA	NA	NA	NA	NA	NA	NA	NA	T:37+2+0+0=39/463|N:3+0+0+0=3/104|A:40+2+0+0=42/567	NA	PI3K	NA	[non-HC]_2.366/2.732_NA	TIER_3	Pathogenic	NA	SOM	Protein_kinase_domain	NA	stop_gained:E:STK11:Canonical:ENSP00000324856.6:p.(Gln159Ter)|R:STK11:Canonical:NP_000446.1:p.(Gln159Ter)|R:STK11:XP_005259675.1:p.(Gln159Ter)|R:STK11:XP_005259674.1:p.(Gln159Ter)|E:STK11:ENSP00000467912.1:p.(Gln101Ter);upstream_gene_variant:E:STK11:ENST00000586243.1	CPSR_classification|protein_changes:stop_gained|class	NA	IS:all_exons	.	.	include	.	.	.
CL-AcroMetrix	TP53	ENST00000269305	NM_000546	17:7572986	G>A	c.1123C>T	exon11	Q375X	Gln375Ter	c.1123C>T:exon11:Q375X:Gln375Ter	stop_gained	1204	0.059	NA	NA	NA	NA	COSV52716070|COSV52776099	rs1555524156	480739	NA	NA	NA	NA	NA	Bladder_Urothelial_Carcinoma:_0.2%_(1/412)	NA	T:34+2+0+0=36/462|N:5+0+0+0=5/104|A:39+2+0+0=41/566	NA	TP53	4_c_NS	[non-HC]_2.45/2.9_NA	TIER_3	Likely_Pathogenic	VUS	SOM	NA	NA	stop_gained:R:TP53:NP_001119587.1:p.(Gln243Ter)|R:TP53:NP_001263626.1:p.(Gln216Ter)|E:TP53:Canonical:ENSP00000269305.4:p.(Gln375Ter)|R:TP53:NP_001119590.1:p.(Gln336Ter)|R:TP53:Canonical:NP_000537.3:p.(Gln375Ter)|R:TP53:NP_001263689.1:p.(Gln336Ter)|R:TP53:NP_001263690.1:p.(Gln336Ter)|R:TP53:NP_001119584.1:p.(Gln375Ter)|E:TP53:ENSP00000391478.2:p.(Gln375Ter)|R:TP53:XP_005256835.1:p.(Gln355Ter);3_prime_UTR_variant:R:TP53:NM_001276699.1|R:TP53:NM_001126117.1|R:TP53:NM_001276698.1|R:TP53:NM_001126116.1|R:TP53:NM_001276696.1|R:TP53:NM_001126113.2|R:TP53:NM_001276695.1|R:TP53:NM_001126114.2|E:TP53:ENST00000455263.2|E:TP53:ENST00000420246.2;missense_variant:E:TP53:ENSP00000458393.1:p.(Ser26Leu);downstream_gene_variant:E:TP53:ENST00000509690.1|E:TP53:ENST00000514944.1	CPSR_classification|protein_changes:stop_gained|class	NA	IS:all_exons	.	.	include	.	.	.
CL-AcroMetrix	TP53	ENST00000269305	NM_000546	17:7574012	C>A	c.1015G>T	exon10	E339X	Glu339Ter	c.1015G>T:exon10:E339X:Glu339Ter	stop_gained	1010	0.024	NA	NA	NA	NA	COSV52705645|COSV52980241|COSV53040770|COSV53664260	rs17882252	438708	NA	NA	NA	NA	NA	Adrenocortical_Carcinoma:_1.1%_(1/92)|Lung_Adenocarcinoma:_0.4%_(2/567)|Head_and_Neck_Squamous_Cell_Carcinoma:_0.2%_(1/508)|Brain_Lower_Grade_Glioma:_0.2%_(1/509)	NA	T:26+2+0+0=28/462|N:5+1+0+0=6/104|A:31+3+0+0=34/566	NA	TP53	4_c_NS	[non-HC]_2.45/2.9_NA	TIER_3	Pathogenic	Pathogenic	SOM	P53_tetramerisation_motif	NA	stop_gained:R:TP53:NP_001119587.1:p.(Glu207Ter)|R:TP53:NP_001263626.1:p.(Glu180Ter)|E:TP53:Canonical:ENSP00000269305.4:p.(Glu339Ter)|R:TP53:NP_001119590.1:p.(Glu300Ter)|R:TP53:Canonical:NP_000537.3:p.(Glu339Ter)|R:TP53:NP_001263689.1:p.(Glu300Ter)|R:TP53:NP_001263690.1:p.(Glu300Ter)|R:TP53:NP_001119584.1:p.(Glu339Ter)|E:TP53:ENSP00000391478.2:p.(Glu339Ter)|R:TP53:XP_005256835.1:p.(Glu319Ter);3_prime_UTR_variant:R:TP53:NM_001276699.1|R:TP53:NM_001126117.1|R:TP53:NM_001276698.1|R:TP53:NM_001126116.1|R:TP53:NM_001276696.1|R:TP53:NM_001126113.2|R:TP53:NM_001276695.1|R:TP53:NM_001126114.2|E:TP53:ENST00000455263.2|E:TP53:ENST00000420246.2;downstream_gene_variant:E:TP53:ENST00000509690.1|E:TP53:ENST00000514944.1|E:TP53:ENST00000508793.1|E:TP53:ENST00000604348.1|E:TP53:ENST00000503591.1	CPSR_classification|ClinVar_classification|protein_changes:stop_gained|class	NA	IS:all_exons	.	.	include	.	.	.
CL-AcroMetrix	TP53	ENST00000269305	NM_000546	17:7576865	A>C	c.981T>G	exon9	Y327X	Tyr327Ter	c.981T>G:exon9:Y327X:Tyr327Ter	stop_gained	1164	0.04	NA	NA	NA	NA	COSV52678878|COSV52914365|COSV52993701	rs879254077	246069	NA	NA	NA	NA	NA	Glioblastoma_Multiforme:_0.3%_(1/393)|Ovarian_Serous_Cystadenocarcinoma:_0.2%_(1/436)	NA	T:1+0+0+0=1/461|N:1+0+0+0=1/104|A:2+0+0+0=2/565	NA	TP53	4_c_NS	[non-HC]_2.45/2.9_NA	TIER_3	Pathogenic	Likely_Pathogenic	SOM	P53_tetramerisation_motif	NA	stop_gained:E:TP53:ENSP00000352610.4:p.(Tyr327Ter)|R:TP53:NP_001119587.1:p.(Tyr195Ter)|R:TP53:NP_001263626.1:p.(Tyr168Ter)|R:TP53:NP_001263628.1:p.(Tyr168Ter)|R:TP53:NP_001119589.1:p.(Tyr195Ter)|R:TP53:NP_001263627.1:p.(Tyr168Ter)|R:TP53:NP_001119588.1:p.(Tyr195Ter)|E:TP53:Canonical:ENSP00000269305.4:p.(Tyr327Ter)|R:TP53:NP_001263625.1:p.(Tyr288Ter)|R:TP53:NP_001119590.1:p.(Tyr288Ter)|R:TP53:NP_001119585.1:p.(Tyr327Ter)|R:TP53:Canonical:NP_000537.3:p.(Tyr327Ter)|R:TP53:NP_001263689.1:p.(Tyr288Ter)|R:TP53:NP_001263690.1:p.(Tyr288Ter)|R:TP53:NP_001263624.1:p.(Tyr288Ter)|R:TP53:NP_001119586.1:p.(Tyr327Ter)|R:TP53:NP_001119584.1:p.(Tyr327Ter)|E:TP53:ENSP00000398846.2:p.(Tyr327Ter)|E:TP53:ENSP00000391127.2:p.(Tyr327Ter)|E:TP53:ENSP00000391478.2:p.(Tyr327Ter)|R:TP53:XP_005256835.1:p.(Tyr307Ter)|E:TP53:ENSP00000458393.1:p.(Tyr14Ter)|E:TP53:ENSP00000425104.1:p.(Tyr195Ter);downstream_gene_variant:E:TP53:ENST00000514944.1|E:TP53:ENST00000508793.1|E:TP53:ENST00000604348.1|E:TP53:ENST00000503591.1	CPSR_classification|ClinVar_classification|protein_changes:stop_gained|class	NA	IS:all_exons	.	.	include	.	.	.
CL-AcroMetrix	TP53	ENST00000269305	NM_000546	17:7579521	C>A	c.166G>T	exon4	E56X	Glu56Ter	c.166G>T:exon4:E56X:Glu56Ter	stop_gained	1358	0.044	NA	NA	NA	NA	COSV52771366|COSV52826932|COSV52883452	NA	1329425	NA	NA	NA	NA	NA	Adrenocortical_Carcinoma:_1.1%_(1/92)|Head_and_Neck_Squamous_Cell_Carcinoma:_0.4%_(2/508)|Breast_Invasive_Carcinoma:_0.1%_(1/986)	NA	T:22+0+0+0=22/461|N:1+0+0+0=1/104|A:23+0+0+0=23/565	NA	TP53	4_c_NS	[non-HC]_2.45/2.9_NA	TIER_3	Pathogenic	Likely_Pathogenic	SOM	NA	NA	stop_gained:E:TP53:ENSP00000410739.2:p.(Glu56Ter)|E:TP53:ENSP00000352610.4:p.(Glu56Ter)|E:TP53:Canonical:ENSP00000269305.4:p.(Glu56Ter)|R:TP53:NP_001263625.1:p.(Glu17Ter)|R:TP53:NP_001119590.1:p.(Glu17Ter)|R:TP53:NP_001119585.1:p.(Glu56Ter)|R:TP53:Canonical:NP_000537.3:p.(Glu56Ter)|R:TP53:NP_001263689.1:p.(Glu17Ter)|R:TP53:NP_001263690.1:p.(Glu17Ter)|R:TP53:NP_001263624.1:p.(Glu17Ter)|R:TP53:NP_001119586.1:p.(Glu56Ter)|R:TP53:NP_001119584.1:p.(Glu56Ter)|E:TP53:ENSP00000398846.2:p.(Glu56Ter)|E:TP53:ENSP00000391127.2:p.(Glu56Ter)|E:TP53:ENSP00000391478.2:p.(Glu56Ter)|R:TP53:XP_005256835.1:p.(Glu56Ter)|E:TP53:ENSP00000424104.1:p.(Glu56Ter)|E:TP53:ENSP00000473895.1:p.(Glu56Ter)|E:TP53:ENSP00000426252.1:p.(Glu56Ter);upstream_gene_variant:R:TP53:NM_001126115.1|R:TP53:NM_001276697.1|R:TP53:NM_001276699.1|R:TP53:NM_001126117.1|R:TP53:NM_001276698.1|R:TP53:NM_001126116.1|E:TP53:ENST00000576024.1	CPSR_classification|ClinVar_classification|protein_changes:stop_gained|class	NA	IS:all_exons	.	.	include	.	.	.
CL-AcroMetrix	TP53	ENST00000269305	NM_000546	17:7579536	C>A	c.151G>T	exon4	E51X	Glu51Ter	c.151G>T:exon4:E51X:Glu51Ter	stop_gained	1334	0.04	NA	NA	NA	NA	COSV52694020|COSV53536519	rs1567556930	568781	NA	NA	NA	NA	NA	Rectum_Adenocarcinoma:_0.7%_(1/137)|Esophageal_Carcinoma:_0.5%_(1/184)|Ovarian_Serous_Cystadenocarcinoma:_0.2%_(1/436)	NA	T:45+0+0+0=45/461|N:5+1+0+0=6/104|A:50+1+0+0=51/565	NA	TP53	4_c_NS	[non-HC]_2.45/2.9_NA	TIER_3	Pathogenic	Pathogenic	SOM	NA	NA	stop_gained:E:TP53:ENSP00000410739.2:p.(Glu51Ter)|E:TP53:ENSP00000352610.4:p.(Glu51Ter)|E:TP53:Canonical:ENSP00000269305.4:p.(Glu51Ter)|R:TP53:NP_001263625.1:p.(Glu12Ter)|R:TP53:NP_001119590.1:p.(Glu12Ter)|R:TP53:NP_001119585.1:p.(Glu51Ter)|R:TP53:Canonical:NP_000537.3:p.(Glu51Ter)|R:TP53:NP_001263689.1:p.(Glu12Ter)|R:TP53:NP_001263690.1:p.(Glu12Ter)|R:TP53:NP_001263624.1:p.(Glu12Ter)|R:TP53:NP_001119586.1:p.(Glu51Ter)|R:TP53:NP_001119584.1:p.(Glu51Ter)|E:TP53:ENSP00000398846.2:p.(Glu51Ter)|E:TP53:ENSP00000391127.2:p.(Glu51Ter)|E:TP53:ENSP00000391478.2:p.(Glu51Ter)|R:TP53:XP_005256835.1:p.(Glu51Ter)|E:TP53:ENSP00000424104.1:p.(Glu51Ter)|E:TP53:ENSP00000473895.1:p.(Glu51Ter)|E:TP53:ENSP00000426252.1:p.(Glu51Ter);upstream_gene_variant:R:TP53:NM_001126115.1|R:TP53:NM_001276697.1|R:TP53:NM_001276699.1|R:TP53:NM_001126117.1|R:TP53:NM_001276698.1|R:TP53:NM_001126116.1|E:TP53:ENST00000576024.1	CPSR_classification|ClinVar_classification|protein_changes:stop_gained|class	NA	IS:all_exons	.	.	include	.	.	.
CL-AcroMetrix	TP53	ENST00000269305	NM_000546	17:7579575	G>A	c.112C>T	exon4	Q38X	Gln38Ter	c.112C>T:exon4:Q38X:Gln38Ter	stop_gained	1263	0.049	NA	NA	NA	NA	COSV52689258	NA	NA	NA	NA	NA	NA	NA	Pancreatic_Adenocarcinoma:_0.6%_(1/180)|Head_and_Neck_Squamous_Cell_Carcinoma:_0.2%_(1/508)|Lung_Squamous_Cell_Carcinoma:_0.2%_(1/492)	NA	T:40+0+0+0=40/461|N:2+0+0+0=2/104|A:42+0+0+0=42/565	NA	TP53	4_c_NS	[non-HC]_2.45/2.9_NA	TIER_3	Pathogenic	NA	SOM	NA	NA	stop_gained:E:TP53:ENSP00000410739.2:p.(Gln38Ter)|E:TP53:ENSP00000352610.4:p.(Gln38Ter)|E:TP53:Canonical:ENSP00000269305.4:p.(Gln38Ter)|R:TP53:NP_001119585.1:p.(Gln38Ter)|R:TP53:Canonical:NP_000537.3:p.(Gln38Ter)|R:TP53:NP_001119586.1:p.(Gln38Ter)|R:TP53:NP_001119584.1:p.(Gln38Ter)|E:TP53:ENSP00000398846.2:p.(Gln38Ter)|E:TP53:ENSP00000391127.2:p.(Gln38Ter)|E:TP53:ENSP00000391478.2:p.(Gln38Ter)|R:TP53:XP_005256835.1:p.(Gln38Ter)|E:TP53:ENSP00000424104.1:p.(Gln38Ter)|E:TP53:ENSP00000473895.1:p.(Gln38Ter)|E:TP53:ENSP00000426252.1:p.(Gln38Ter);upstream_gene_variant:R:TP53:NM_001126115.1|R:TP53:NM_001276697.1|R:TP53:NM_001276699.1|R:TP53:NM_001126117.1|R:TP53:NM_001276698.1|R:TP53:NM_001126116.1|E:TP53:ENST00000576024.1;5_prime_UTR_variant:R:TP53:NM_001276696.1|R:TP53:NM_001126118.1|R:TP53:NM_001276760.1|R:TP53:NM_001276761.1|R:TP53:NM_001276695.1	CPSR_classification|protein_changes:stop_gained|class	NA	IS:all_exons	.	.	include	.	.	.
CL-AcroMetrix	VHL	ENST00000256474	NM_000551	3:10183817	C>T	c.286C>T	exon1	Q96X	Gln96Ter	c.286C>T:exon1:Q96X:Gln96Ter	stop_gained	1192	0.045	NA	NA	NA	NA	COSV56542588|COSV56546894	rs1131690959	428804	NA	NA	NA	NA	NA	NA	RECA-EU/Primary/1/74/0.0135	T:20+2+0+0=22/463|N:1+0+0+0=1/103|A:21+2+0+0=23/566	NA	NA	1_a_NA	[non-HC]_2.198/2.396_NA	TIER_3	Pathogenic	Pathogenic	SOM	VHL_beta_domain	NA	stop_gained:E:VHL:Canonical:ENSP00000256474.2:p.(Gln96Ter)|R:VHL:NP_937799.1:p.(Gln96Ter)|R:VHL:Canonical:NP_000542.1:p.(Gln96Ter)|E:VHL:ENSP00000344757.2:p.(Gln96Ter)	CPSR_classification|ClinVar_classification|protein_changes:stop_gained|class	NA	all_exons	.	.	include	.	.	.
CL-AcroMetrix	STK11	ENST00000326873	NM_000455	19:1220502	G>T	c.595G>T	exon4	E199X	Glu199Ter	c.595G>T:exon4:E199X:Glu199Ter	stop_gained,splice_region_variant	1140	0.062	NA	NA	NA	NA	COSV58822577|COSV58822973|COSV58827104	rs121913317	376338	NA	NA	NA	NA	NA	Lung_Adenocarcinoma:_0.2%_(1/567)	NA	T:24+2+0+0=26/463|N:3+0+0+0=3/104|A:27+2+0+0=29/567	NA	PI3K	NA	[non-HC]_2.366/2.732_NA	TIER_3	Pathogenic	Likely_Pathogenic	SOM	Protein_kinase_domain	NA	splice_region_variant,stop_gained:E:STK11:Canonical:ENSP00000324856.6:p.(Glu199Ter)|R:STK11:Canonical:NP_000446.1:p.(Glu199Ter)|R:STK11:XP_005259675.1:p.(Glu199Ter)|R:STK11:XP_005259674.1:p.(Glu199Ter)|E:STK11:ENSP00000467912.1:p.(Glu141Ter);upstream_gene_variant:E:STK11:ENST00000586243.1	CPSR_classification|ClinVar_classification|protein_changes:stop_gained|class	NA	IS:all_exons	.	.	include	.	.	.
CL-AcroMetrix	HNF1A	ENST00000257555	NM_000545	12:121432117	G>GC	c.872dup	exon4	G292fs	Gly292ArgfsTer25	c.872dup:exon4:G292fs:Gly292ArgfsTer25	frameshift_variant	929	0.061	NA	NA	NA	NA	NA	rs587776825	14927	0.0003725	NA	0.0004911	NA	NA	NA	NA	T:133+231+1+0=365/463|N:17+68+0+0=85/104|A:150+299+1+0=450/567	NA	NA	NA	[non-HC]_2.05/2.1_NA	TIER_4	Pathogenic	Pathogenic	BL	Hepatocyte_nuclear_factor_1_(HNF-1)|beta_isoform_C_terminus	NA	frameshift_variant:R:HNF1A:XP_005253989.1:p.(Gly175ArgfsTer25)|R:HNF1A:XP_005253988.1:p.(Gly292ArgfsTer25)|E:HNF1A:Canonical:ENSP00000257555.4:p.(Gly292ArgfsTer25)|E:HNF1A:ENSP00000476181.1:p.(Gly292ArgfsTer25)|R:HNF1A:NP_001293108.1:p.(Gly292ArgfsTer25)|R:HNF1A:Canonical:NP_000536.5:p.(Gly292ArgfsTer25)|E:HNF1A:ENSP00000475300.1:p.(Gly292ArgfsTer25)|E:HNF1A:ENSP00000439721.1:p.(Gly175ArgfsTer25)|E:HNF1A:ENSP00000443112.1:p.(Gly292ArgfsTer25)|R:HNF1A:NP_000536.5:p.(Gly292ArgfsTer25)|E:HNF1A:ENSP00000438804.1:p.(Gly292ArgfsTer25)	CPSR_classification|protein_changes:frameshift_variant|ClinVar_classification	NA	all_exons	.	.	include	variant_in_more_than_10%_of_tumor_samples_(28.73%)_with_VAF_under_0.01,BL_class	.	.
CL-AcroMetrix	IRS1	ENST00000305123	NM_005544	2:227661663	GC>G	c.1791del	exon1	H598fs	His598ThrfsTer38	c.1791del:exon1:H598fs:His598ThrfsTer38	frameshift_variant	1350	0.023	NA	NA	NA	NA	NA	rs761880048	NA	0.0002519	NA	0.0001212	NA	NA	Colon_Adenocarcinoma:_0.8%_(3/399)	NA	T:208+219+2+0=429/463|N:23+76+0+0=99/104|A:231+295+2+0=528/567	NA	RTKRAS	NA	[non-HC]_1.966/1.932_NA	TIER_4	NA	NA	BL	NA	NA	frameshift_variant:R:IRS1:Canonical:NP_005535.1:p.(His598ThrfsTer38)|E:IRS1:Canonical:ENSP00000304895.4:p.(His598ThrfsTer38)|R:IRS1:XP_005246591.1:p.(His598ThrfsTer38)	protein_changes:frameshift_variant	recurrent_artifact	NA	.	.	exclude	recurrent_artifact,variant_in_more_than_10%_of_tumor_samples_(44.92%)_with_VAF_under_0.01,BL_class	.	.
CL-AcroMetrix	KMT2B	ENST00000222270	NA	19:36211898	A>AC	c.1656dup	exon3	K553fs	Lys553GlnfsTer46	c.1656dup:exon3:K553fs:Lys553GlnfsTer46	frameshift_variant	740	0.024	NA	NA	NA	NA	NA	rs775294431	1207914	2.91e-05	NA	0.0000460	NA	NA	Uterine_Corpus_Endometrial_Carcinoma:_0.4%_(2/530)|Colon_Adenocarcinoma:_0.3%_(1/399)	NA	T:124+75+1+0=200/463|N:22+40+0+0=62/104|A:146+115+1+0=262/567	NA	NA	NA	[non-HC]_2.07/2.14_NA	TIER_4	NA	NA	BL	NA	NA	downstream_gene_variant:R:ZBTB32:XM_005258739.1|R:ZBTB32:XM_005258737.1|R:ZBTB32:Canonical:NM_014383.2|R:ZBTB32:NM_001316903.1|R:ZBTB32:NM_001316902.1|E:ZBTB32:Canonical:ENST00000392197.2|E:ZBTB32:ENST00000426659.2|E:ZBTB32:ENST00000262630.3|R:ZBTB32:NM_014383.1|R:ZBTB32:XM_005258738.1;frameshift_variant:E:KMT2B:ENSP00000398837.1:p.(Lys553GlnfsTer46)|E:KMT2B:Canonical:ENSP00000222270.6:p.(Lys553GlnfsTer46)|R:KMT2B:NP_055542.1:p.(Lys553GlnfsTer46)|R:KMT2B:Canonical:NP_055542.1:p.(Lys553GlnfsTer46);upstream_gene_variant:R:KMT2B:XM_005259446.1	protein_changes:frameshift_variant	recurrent_artifact	NA	.	.	exclude	recurrent_artifact,variant_in_more_than_10%_of_tumor_samples_(26.78%)_with_VAF_under_0.01,BL_class	.	.
CL-AcroMetrix	MSH6	ENST00000234420	NM_000179	2:48030639	AC>A	c.3261del	exon5	F1088fs	Phe1088SerfsTer2	c.3261del:exon5:F1088fs:Phe1088SerfsTer2	frameshift_variant	1154	0.092	NA	NA	NA	NA	COSV99029757	rs267608078	89363	1.2e-05	NA	0.0000089	NA	NA	Uterine_Carcinosarcoma:_1.8%_(1/57)	LIRI-JP/Primary/1/250/0.004	T:248+184+1+0=433/463|N:45+57+0+0=102/104|A:293+241+1+0=535/567	NA	NA	1_NA_NA	[non-HC]_2.14/2.28_NA	TIER_4	Pathogenic	Pathogenic	BL	MutS_domain_V	NA	frameshift_variant:R:MSH6:NP_001268422.1:p.(Phe786SerfsTer2)|R:MSH6:NP_001268421.1:p.(Phe958SerfsTer2)|R:MSH6:Canonical:NP_000170.1:p.(Phe1088SerfsTer2)|E:MSH6:Canonical:ENSP00000234420.4:p.(Phe1088SerfsTer2)|E:MSH6:ENSP00000446475.1:p.(Phe958SerfsTer2)|E:MSH6:ENSP00000438580.1:p.(Phe786SerfsTer2)|R:MSH6:NP_001268423.1:p.(Phe786SerfsTer2)|R:MSH6:XP_005264328.1:p.(Phe989SerfsTer2);downstream_gene_variant:E:MSH6:ENST00000455383.1|E:MSH6:ENST00000411819.1|E:FBXO11:ENST00000402508.1|R:FBXO11:NM_025133.4|R:FBXO11:XM_005264575.1|E:FBXO11:Canonical:ENST00000403359.3|R:FBXO11:Canonical:NM_001190274.1|R:FBXO11:XM_005264573.1|R:FBXO11:XM_005264572.1|R:FBXO11:XM_005264574.1|E:FBXO11:ENST00000316377.4|E:FBXO11:ENST00000434523.2	CPSR_classification|protein_changes:frameshift_variant|ClinVar_classification	NA	all_exons	.	.	include	variant_in_more_than_10%_of_tumor_samples_(53.56%)_with_VAF_under_0.01,BL_class	.	.
CL-AcroMetrix	RAD50	ENST00000265335	NA	5:131931451	TA>T	c.2165del	exon13	K722fs	Lys722ArgfsTer14	c.2165del:exon13:K722fs:Lys722ArgfsTer14	frameshift_variant	692	0.045	NA	NA	NA	NA	COSV54758496	rs397507178	408407	0.0001418	NA	0.0001472	NA	NA	NA	NA	T:20+419+11+0=450/463|N:1+91+11+0=103/104|A:21+510+22+0=553/567	NA	NA	NA	[non-HC]_1.782/1.564_NA	TIER_4	Pathogenic	Pathogenic	BL	NA	NA	frameshift_variant:E:RAD50:ENSP00000368100.3:p.(Lys583ArgfsTer14)|R:RAD50:Canonical:NP_005723.2:p.(Lys722ArgfsTer14)|E:RAD50:Canonical:ENSP00000265335.6:p.(Lys722ArgfsTer14)|E:RAD50:ENST00000453394.1:c.1982del(p.(Ter661=));downstream_gene_variant:E:RAD50:ENST00000434288.1	CPSR_classification|protein_changes:frameshift_variant|ClinVar_classification	recurrent_artifact	NA	.	.	exclude	recurrent_artifact,BL_class	.	.
CL-AcroMetrix	KMT2B	ENST00000222270	NA	19:36214632	A>AG	c.3059dup	exonNA	R1021fs	Arg1021ProfsTer14	c.3059dup:exonNA:R1021fs:Arg1021ProfsTer14	frameshift_variant,splice_region_variant	580	0.991	NA	NA	NA	NA	NA	rs11373774	NA	1	NA	1.0000000	GLOBAL_AF_GNOMAD:1.0000000|AFR_AF_1KG:1.0000000|AFR_AF_GNOMAD:1.0000000|AMR_AF_1KG:1.0000000|AMR_AF_GNOMAD:1.0000000|ASJ_AF_GNOMAD:1.0000000|EAS_AF_1KG:1.0000000|EAS_AF_GNOMAD:1.0000000|EUR_AF_1KG:1.0000000|FIN_AF_GNOMAD:0.9999000|NFE_AF_GNOMAD:1.0000000|OTH_AF_GNOMAD:1.0000000|SAS_AF_1KG:1.0000000|SAS_AF_GNOMAD:1.0000000	NA	NA	NA	T:0+0+0+463=463/463|N:0+0+0+104=104/104|A:0+0+0+567=567/567	NA	NA	NA	[non-HC]_2.07/2.14_NA	TIER_4	NA	NA	BL	NA	NA	downstream_gene_variant:E:KMT2B:ENST00000341701.1;splice_acceptor_variant:E:KMT2B:ENSP00000398837.1:p.(Arg1021ProfsTer14);frameshift_variant,splice_region_variant:E:KMT2B:Canonical:ENSP00000222270.6:p.(Arg1021ProfsTer14)|R:KMT2B:NP_055542.1:p.(Arg1021ProfsTer14)|R:KMT2B:Canonical:NP_055542.1:p.(Arg1021ProfsTer14)|R:KMT2B:XP_005259503.1:p.(Arg262ProfsTer14)	protein_changes:frameshift_variant,splice_acceptor_variant	recurrent_germline|HIGH_TUMOR_VAF|germline_population	NA	.	.	exclude	germline_population,recurrent_germline,BL_class	.	.
CL-AcroMetrix	PRKDC	ENST00000314191	NM_006904	8:48805816	A>AG	c.3729dup	exonNA	R1244fs	Arg1244ProfsTer41	c.3729dup:exonNA:R1244fs:Arg1244ProfsTer41	frameshift_variant,splice_region_variant,splice_polypyrimidine_tract_variant,intron_variant	849	0.965	NA	NA	NA	NA	NA	rs11411516	NA	1	NA	1.0000000	GLOBAL_AF_GNOMAD:1.0000000|AFR_AF_1KG:1.0000000|AFR_AF_GNOMAD:0.9999000|AMR_AF_1KG:1.0000000|AMR_AF_GNOMAD:0.9999000|ASJ_AF_GNOMAD:1.0000000|EAS_AF_1KG:1.0000000|EAS_AF_GNOMAD:1.0000000|EUR_AF_1KG:1.0000000|FIN_AF_GNOMAD:1.0000000|NFE_AF_GNOMAD:1.0000000|OTH_AF_GNOMAD:1.0000000|SAS_AF_1KG:1.0000000|SAS_AF_GNOMAD:1.0000000	NA	NA	NA	T:0+0+0+463=463/463|N:0+0+0+104=104/104|A:0+0+0+567=567/567	NA	NA	NA	[non-HC]_1.812/1.624_NA	TIER_4	NA	NA	BL	NA	NA	frameshift_variant,splice_region_variant:E:PRKDC:Canonical:ENSP00000313420.2:p.(Arg1244ProfsTer41)|E:PRKDC:ENSP00000345182.3:p.(Arg1244ProfsTer41);frameshift_variant:R:PRKDC:NM_001081640.1:c.3729dup(p.(Ter1244=))|R:PRKDC:Canonical:NM_006904.6:c.3729dup(p.(Ter1244=))	protein_changes:frameshift_variant	recurrent_germline|germline_population	NA	.	.	exclude	germline_population,recurrent_germline,BL_class	.	.
CL-AcroMetrix	HNF1A	ENST00000257555	NM_000545	12:121431413	G>T	c.617G>T	exon3	W206L	Trp206Leu	c.617G>T:exon3:W206L:Trp206Leu	missense_variant	1348	0.065	NA	NA	NA	NA	COSV57460782	NA	NA	NA	NA	NA	NA	NA	NA	NA	T:27+0+0+0=27/463|N:6+0+0+0=6/104|A:33+0+0+0=33/567	NA	NA	NA	[non-HC]_2.05/2.1_NA	TIER_4	VUS	NA	SOM	Homeodomain	NA	missense_variant:R:HNF1A:XP_005253989.1:p.(Trp89Leu)|R:HNF1A:XP_005253988.1:p.(Trp206Leu)|E:HNF1A:Canonical:ENSP00000257555.4:p.(Trp206Leu)|E:HNF1A:ENSP00000476181.1:p.(Trp206Leu)|R:HNF1A:NP_001293108.1:p.(Trp206Leu)|R:HNF1A:Canonical:NP_000536.5:p.(Trp206Leu)|E:HNF1A:ENSP00000475300.1:p.(Trp206Leu)|E:HNF1A:ENSP00000439721.1:p.(Trp89Leu)|E:HNF1A:ENSP00000443112.1:p.(Trp206Leu)|R:HNF1A:NP_000536.5:p.(Trp206Leu)|E:HNF1A:ENSP00000438804.1:p.(Trp206Leu)	class	NA	all_exons	.	.	include	.	.	.
CL-AcroMetrix	HNF1A	ENST00000257555	NM_000545	12:121431428	A>C	c.632A>C	exon3	Q211P	Gln211Pro	c.632A>C:exon3:Q211P:Gln211Pro	missense_variant	1368	0.055	NA	NA	NA	NA	COSV57462827	NA	NA	NA	NA	NA	NA	NA	NA	NA	T:2+0+0+0=2/463|N:1+0+0+0=1/104|A:3+0+0+0=3/567	NA	NA	NA	[non-HC]_2.05/2.1_NA	TIER_4	VUS	NA	SOM	Homeodomain	NA	missense_variant:R:HNF1A:XP_005253989.1:p.(Gln94Pro)|R:HNF1A:XP_005253988.1:p.(Gln211Pro)|E:HNF1A:Canonical:ENSP00000257555.4:p.(Gln211Pro)|E:HNF1A:ENSP00000476181.1:p.(Gln211Pro)|R:HNF1A:NP_001293108.1:p.(Gln211Pro)|R:HNF1A:Canonical:NP_000536.5:p.(Gln211Pro)|E:HNF1A:ENSP00000475300.1:p.(Gln211Pro)|E:HNF1A:ENSP00000439721.1:p.(Gln94Pro)|E:HNF1A:ENSP00000443112.1:p.(Gln211Pro)|R:HNF1A:NP_000536.5:p.(Gln211Pro)|E:HNF1A:ENSP00000438804.1:p.(Gln211Pro)	class	NA	all_exons	.	.	include	.	.	.
CL-AcroMetrix	HNF1A	ENST00000257555	NM_000545	12:121431506	A>G	c.710A>G	exon3	N237S	Asn237Ser	c.710A>G:exon3:N237S:Asn237Ser	missense_variant	1196	0.062	NA	NA	NA	NA	COSV57458725|COSV57462046	NA	NA	NA	NA	NA	NA	NA	Liver_Hepatocellular_Carcinoma:_0.3%_(1/364)	NA	T:17+0+0+0=17/463|N:3+0+0+0=3/104|A:20+0+0+0=20/567	NA	NA	NA	[non-HC]_2.05/2.1_NA	TIER_4	VUS	NA	SOM	Homeodomain	NA	missense_variant:R:HNF1A:XP_005253989.1:p.(Asn120Ser)|R:HNF1A:XP_005253988.1:p.(Asn237Ser)|E:HNF1A:Canonical:ENSP00000257555.4:p.(Asn237Ser)|E:HNF1A:ENSP00000476181.1:p.(Asn237Ser)|R:HNF1A:NP_001293108.1:p.(Asn237Ser)|R:HNF1A:Canonical:NP_000536.5:p.(Asn237Ser)|E:HNF1A:ENSP00000475300.1:p.(Asn237Ser)|E:HNF1A:ENSP00000439721.1:p.(Asn120Ser)|E:HNF1A:ENSP00000443112.1:p.(Asn237Ser)|R:HNF1A:NP_000536.5:p.(Asn237Ser)|E:HNF1A:ENSP00000438804.1:p.(Asn237Ser)	class	NA	all_exons	.	.	include	.	.	.
CL-AcroMetrix	HNF1A	ENST00000257555	NM_000545	12:121432032	C>T	c.779C>T	exon4	T260M	Thr260Met	c.779C>T:exon4:T260M:Thr260Met	missense_variant	1296	0.064	NA	NA	NA	NA	COSV57459458	rs886039544	265436	4e-06	NA	0.0000000	NA	NA	Cervical_Squamous_Cell_Carcinoma_and_Endocervical_Adenocarcinoma:_0.3%_(1/289)	NA	T:102+0+0+0=102/463|N:8+0+0+0=8/104|A:110+0+0+0=110/567	NA	NA	NA	[non-HC]_2.05/2.1_NA	TIER_4	Pathogenic	Likely_Pathogenic	SOM	Homeodomain	NA	missense_variant:R:HNF1A:XP_005253989.1:p.(Thr143Met)|R:HNF1A:XP_005253988.1:p.(Thr260Met)|E:HNF1A:Canonical:ENSP00000257555.4:p.(Thr260Met)|E:HNF1A:ENSP00000476181.1:p.(Thr260Met)|R:HNF1A:NP_001293108.1:p.(Thr260Met)|R:HNF1A:Canonical:NP_000536.5:p.(Thr260Met)|E:HNF1A:ENSP00000475300.1:p.(Thr260Met)|E:HNF1A:ENSP00000439721.1:p.(Thr143Met)|E:HNF1A:ENSP00000443112.1:p.(Thr260Met)|R:HNF1A:NP_000536.5:p.(Thr260Met)|E:HNF1A:ENSP00000438804.1:p.(Thr260Met)	CPSR_classification|ClinVar_classification|class	NA	all_exons	.	.	include	variant_in_more_than_10%_of_tumor_samples_(22.03%)_with_VAF_under_0.01	.	.
CL-AcroMetrix	HNF1A	ENST00000257555	NM_000545	12:121432040	C>T	c.787C>T	exon4	R263C	Arg263Cys	c.787C>T:exon4:R263C:Arg263Cys	missense_variant	1288	0.069	NA	NA	NA	NA	COSV57460808|COSV57462916	rs771108132	562367	4e-06	NA	0.0000000	NA	NA	NA	NA	T:115+1+0+0=116/463|N:5+0+0+0=5/104|A:120+1+0+0=121/567	NA	NA	NA	[non-HC]_2.05/2.1_NA	TIER_4	VUS	Pathogenic	SOM	Homeodomain	NA	missense_variant:R:HNF1A:XP_005253989.1:p.(Arg146Cys)|R:HNF1A:XP_005253988.1:p.(Arg263Cys)|E:HNF1A:Canonical:ENSP00000257555.4:p.(Arg263Cys)|E:HNF1A:ENSP00000476181.1:p.(Arg263Cys)|R:HNF1A:NP_001293108.1:p.(Arg263Cys)|R:HNF1A:Canonical:NP_000536.5:p.(Arg263Cys)|E:HNF1A:ENSP00000475300.1:p.(Arg263Cys)|E:HNF1A:ENSP00000439721.1:p.(Arg146Cys)|E:HNF1A:ENSP00000443112.1:p.(Arg263Cys)|R:HNF1A:NP_000536.5:p.(Arg263Cys)|E:HNF1A:ENSP00000438804.1:p.(Arg263Cys)	ClinVar_classification|class	NA	all_exons	.	.	include	variant_in_more_than_10%_of_tumor_samples_(24.84%)_with_VAF_under_0.01	.	.
CL-AcroMetrix	JAK3	ENST00000458235	NM_000215	19:17948009	G>A	c.1715C>T	exon13	A572V	Ala572Val	c.1715C>T:exon13:A572V:Ala572Val	missense_variant	1224	0.071	NA	NA	NA	NA	COSV71685370	rs121913504	376037	NA	NA	NA	NA	NA	NA	NA	T:56+1+0+0=57/463|N:1+0+0+0=1/104|A:57+1+0+0=58/567	NA	NA	NA	[non-HC]_2.16/2.32_NA	TIER_4	VUS	Likely_Pathogenic	SOM	Protein_tyrosine_and_serine/threonine_kinase	NA	missense_variant:R:JAK3:Canonical:NP_000206.2:p.(Ala572Val)|R:JAK3:XP_005259953.1:p.(Ala615Val)|E:JAK3:Canonical:ENSP00000391676.1:p.(Ala572Val)|E:JAK3:ENSP00000432511.1:p.(Ala572Val)|E:JAK3:ENSP00000436421.1:p.(Ala572Val)	ClinVar_classification|class	NA	all_exons;IS:exons[5,11-13,15-16]	.	.	include	variant_in_more_than_10%_of_tumor_samples_(12.1%)_with_VAF_under_0.01	.	.
CL-AcroMetrix	MAP2K1	ENST00000307102	NM_002755	15:66727483	G>A	c.199G>A	exon2	D67N	Asp67Asn	c.199G>A:exon2:D67N:Asp67Asn	missense_variant	1110	0.074	NA	NA	NA	NA	COSV61068427|COSV61072298	rs727504317	40781	NA	NA	NA	NA	NA	Rectum_Adenocarcinoma:_0.7%_(1/137)|Colon_Adenocarcinoma:_0.3%_(1/399)	NA	T:111+5+0+0=116/463|N:4+0+0+0=4/104|A:115+5+0+0=120/567	NA	RTKRAS	NA	[non-HC]_2.014/2.028_NA	TIER_4	Pathogenic	Pathogenic	SOM	NA	Selumetinib|Trametinib|Selumetinib_Sulfate|Trametinib_Dimethyl_Sulfoxide|Cobimetinib|Binimetinib	missense_variant:E:MAP2K1:Canonical:ENSP00000302486.4:p.(Asp67Asn)|R:MAP2K1:XP_005254598.1:p.(Asp67Asn)|R:MAP2K1:Canonical:NP_002746.1:p.(Asp67Asn)|R:MAP2K1:XP_005254597.1:p.(Asp45Asn)	CPSR_classification|ClinVar_classification|class	NA	aka[MEK1];all_exons;IS:exons[2,3]	.	.	include	variant_in_more_than_10%_of_tumor_samples_(23.97%)_with_VAF_under_0.01	.	.
CL-AcroMetrix	HNF1A	ENST00000257555	NM_000545	12:121431481	C>T	c.685C>T	exon3	R229X	Arg229Ter	c.685C>T:exon3:R229X:Arg229Ter	stop_gained	1196	0.05	NA	NA	NA	NA	COSV57460583|COSV57462128	rs769086289	420064	8e-06	NA	0.0000088	NA	NA	Colon_Adenocarcinoma:_0.3%_(1/399)	NA	T:98+2+0+0=100/463|N:11+0+0+0=11/104|A:109+2+0+0=111/567	NA	NA	NA	[non-HC]_2.05/2.1_NA	TIER_4	Pathogenic	Pathogenic	SOM	Homeodomain	NA	stop_gained:R:HNF1A:XP_005253989.1:p.(Arg112Ter)|R:HNF1A:XP_005253988.1:p.(Arg229Ter)|E:HNF1A:Canonical:ENSP00000257555.4:p.(Arg229Ter)|E:HNF1A:ENSP00000476181.1:p.(Arg229Ter)|R:HNF1A:NP_001293108.1:p.(Arg229Ter)|R:HNF1A:Canonical:NP_000536.5:p.(Arg229Ter)|E:HNF1A:ENSP00000475300.1:p.(Arg229Ter)|E:HNF1A:ENSP00000439721.1:p.(Arg112Ter)|E:HNF1A:ENSP00000443112.1:p.(Arg229Ter)|R:HNF1A:NP_000536.5:p.(Arg229Ter)|E:HNF1A:ENSP00000438804.1:p.(Arg229Ter)	CPSR_classification|ClinVar_classification|protein_changes:stop_gained|class	NA	all_exons	.	.	include	variant_in_more_than_10%_of_tumor_samples_(21.17%)_with_VAF_under_0.01	.	.
CL-AcroMetrix	PDGFRA	ENST00000257290	NM_001347828|NM_006206|NM_001347829|NM_001347830	4:55144172	A>G	c.2001A>G	exon14	S667S	Ser667=	c.2001A>G:exon14:S667S:Ser667=	splice_region_variant,synonymous_variant	724	0.058	NA	NA	NA	NA	NA	rs1560483194	573639	NA	NA	NA	NA	NA	NA	NA	T:12+1+0+0=13/463|N:5+0+0+0=5/104|A:17+1+0+0=18/567	NA	RTKRAS	NA	[HC]_2.056/2.112_NA	TNC	VUS	VUS	SOM	Protein_tyrosine_and_serine/threonine_kinase	Vatalanib|Pazopanib_Hydrochloride|Olaratumab|Masitinib|Regorafenib|Regorafenib_Hydrate|Crenolanib|Linifanib|Orantinib|Famitinib|Avapritinib|Ripretinib|Pazopanib|Cediranib|Nintedanib|Dovitinib|Sunitinib_Malate|Motesanib|Quizartinib|Midostaurin	splice_region_variant,synonymous_variant:E:FIP1L1:Canonical:ENST00000507166.1:c.1281A>G(p.(Ser427=))|R:PDGFRA:NM_001347827.1:c.2001A>G(p.(Ser667=))|R:PDGFRA:Canonical:NM_006206.5:c.2001A>G(p.(Ser667=))|R:PDGFRA:NM_001347828.1:c.2076A>G(p.(Ser692=))|R:PDGFRA:NM_006206.4:c.2001A>G(p.(Ser667=))|E:PDGFRA:Canonical:ENST00000257290.5:c.2001A>G(p.(Ser667=))|R:PDGFRA:XM_005265744.1:c.2001A>G(p.(Ser667=))|R:PDGFRA:XM_005265743.1:c.2001A>G(p.(Ser667=))|R:PDGFRA:NM_001347829.1:c.2001A>G(p.(Ser667=))|R:PDGFRA:NM_001347830.1:c.2040A>G(p.(Ser680=))	class	NA	all_exons;IS:introns[7,9,11],exons[12,18]	.	.	exclude	synonymous_splice_region_variant_with_no_RNA_coverage	.	.
CL-AcroMetrix	TP53	ENST00000269305	NM_000546	17:7579312	C>T	c.375G>A	exon4	T125T	Thr125=	c.375G>A:exon4:T125T:Thr125=	splice_region_variant,synonymous_variant	824	0.06	NA	NA	NA	NA	COSV52665709|COSV52718605|COSV52726641|COSV53120615	rs55863639	177825	NA	NA	NA	NA	NA	Acute_Myeloid_Leukemia:_0.7%_(1/144)|Glioblastoma_Multiforme:_0.5%_(2/393)|Colon_Adenocarcinoma:_0.3%_(1/399)|Head_and_Neck_Squamous_Cell_Carcinoma:_0.2%_(1/508)|Brain_Lower_Grade_Glioma:_0.2%_(1/509)|Lung_Squamous_Cell_Carcinoma:_0.2%_(1/492)|Skin_Cutaneous_Melanoma:_0.2%_(1/468)	CLLE-ES/Primary/1/90/0.0111	T:90+6+0+1=97/460|N:2+0+0+0=2/104|A:92+6+0+1=99/564	NA	TP53	4_c_NS	[non-HC]_2.45/2.9_NA	TNC	VUS	Pathogenic	SOM	P53_DNA-binding_domain	NA	splice_region_variant,synonymous_variant:E:TP53:ENST00000413465.2:c.375G>A(p.(Thr125=))|E:TP53:ENST00000359597.4:c.375G>A(p.(Thr125=))|E:TP53:Canonical:ENST00000269305.4:c.375G>A(p.(Thr125=))|R:TP53:NM_001276696.1:c.258G>A(p.(Thr86=))|R:TP53:NM_001126118.1:c.258G>A(p.(Thr86=))|R:TP53:NM_001126113.2:c.375G>A(p.(Thr125=))|R:TP53:Canonical:NM_000546.5:c.375G>A(p.(Thr125=))|R:TP53:NM_001276760.1:c.258G>A(p.(Thr86=))|R:TP53:NM_001276761.1:c.258G>A(p.(Thr86=))|R:TP53:NM_001276695.1:c.258G>A(p.(Thr86=))|R:TP53:NM_001126114.2:c.375G>A(p.(Thr125=))|R:TP53:NM_001126112.2:c.375G>A(p.(Thr125=))|E:TP53:ENST00000455263.2:c.375G>A(p.(Thr125=))|E:TP53:ENST00000420246.2:c.375G>A(p.(Thr125=))|E:TP53:ENST00000445888.2:c.375G>A(p.(Thr125=))|R:TP53:XM_005256778.1:c.315G>A(p.(Thr105=))|E:TP53:ENST00000508793.1:c.375G>A(p.(Thr125=))|E:TP53:ENST00000604348.1:c.375G>A(p.(Thr125=))|E:TP53:ENST00000503591.1:c.375G>A(p.(Thr125=));upstream_gene_variant:R:TP53:NM_001126115.1|R:TP53:NM_001276697.1|R:TP53:NM_001276699.1|R:TP53:NM_001126117.1|R:TP53:NM_001276698.1|R:TP53:NM_001126116.1|E:TP53:ENST00000576024.1	ClinVar_classification|class	NA	IS:all_exons	.	.	exclude	synonymous_splice_region_variant_with_no_RNA_coverage,variant_in_more_than_10%_of_tumor_samples_(19.57%)_with_VAF_under_0.01	.	.
CL-AcroMetrix	APC	ENST00000457016	NA	5:112174726	A>G	c.3435A>G	exon16	E1145E	Glu1145=	c.3435A>G:exon16:E1145E:Glu1145=	synonymous_variant	990	0.195	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	T:8+0+0+0=8/463|N:3+0+0+0=3/104|A:11+0+0+0=11/567	NA	WNT	3_NA_NA	[non-HC]_2.012/2.024_NA	TNC	Likely_Benign	NA	SOM	APC_15_residue_motif	NA	downstream_gene_variant:E:APC:ENST00000504915.2	class	NA	IS:all_exons	.	.	include	.	.	.
CL-AcroMetrix	APC	ENST00000457016	NA	5:112175086	A>G	c.3795A>G	exon16	E1265E	Glu1265=	c.3795A>G:exon16:E1265E:Glu1265=	synonymous_variant	955	0.185	NA	NA	NA	NA	COSV99967491	rs1554085311	469940	NA	NA	NA	NA	NA	NA	NA	T:9+0+0+0=9/463|N:4+0+0+0=4/104|A:13+0+0+0=13/567	NA	WNT	3_NA_NA	[non-HC]_2.012/2.024_NA	TNC	Likely_Benign	Likely_Benign	SOM	APC_repeat	NA	downstream_gene_variant:E:APC:ENST00000507379.1|E:APC:ENST00000504915.2	class	NA	IS:all_exons	.	.	include	.	.	.
CL-AcroMetrix	ATM	ENST00000278616	NA	11:108173640	C>T	c.5380C>T	exon36	L1794L	Leu1794=	c.5380C>T:exon36:L1794L:Leu1794=	synonymous_variant	691	0.071	NA	NA	NA	NA	COSV53743862|COSV53776396	NA	NA	NA	NA	NA	NA	NA	NA	NA	T:36+2+0+0=38/463|N:3+0+0+0=3/104|A:39+2+0+0=41/567	NA	TP53	NA	[HC]_2.122/2.244_NA	TNC	Likely_Benign	NA	SOM	NA	Iniparib	NA	class	NA	IS:all_exons	.	.	include	.	.	.
CL-AcroMetrix	ATM	ENST00000278616	NA	11:108236118	A>G	c.9054A>G	exon63	K3018K	Lys3018=	c.9054A>G:exon63:K3018K:Lys3018=	synonymous_variant	976	0.089	NA	NA	NA	NA	COSV53762255	NA	NA	NA	NA	NA	NA	NA	NA	NA	T:15+1+0+0=16/463|N:5+0+0+0=5/104|A:20+1+0+0=21/567	NA	TP53	NA	[HC]_2.122/2.244_NA	TNC	Likely_Benign	NA	SOM	NA	Iniparib	NA	class	NA	IS:all_exons	.	.	include	.	.	.
CL-AcroMetrix	BRAF	ENST00000288602	NA	7:140481428	T>C	c.1380A>G	exon11	G460G	Gly460=	c.1380A>G:exon11:G460G:Gly460=	synonymous_variant	1013	0.121	NA	NA	NA	NA	COSV56258682	NA	NA	NA	NA	NA	NA	NA	NA	NA	T:8+0+0+0=8/463|N:9+0+0+0=9/104|A:17+0+0+0=17/567	NA	RTKRAS	NA	[HC]_1.804/1.608_NA	TNC	Likely_Benign	NA	SOM	Protein_tyrosine_and_serine/threonine_kinase	Sorafenib_Tosylate|Vemurafenib|Sorafenib|Regorafenib|Regorafenib_Hydrate|Dabrafenib|Dabrafenib_Mesylate|Encorafenib	NA	class	NA	all_exons,introns[7-10];IS:exons[11-18]	.	.	include	.	.	.
CL-AcroMetrix	BRAF	ENST00000288602	NA	7:140481449	A>G	c.1359T>C	exon11	P453P	Pro453=	c.1359T>C:exon11:P453P:Pro453=	synonymous_variant	1019	0.117	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	T:5+0+0+0=5/463|N:1+0+0+0=1/104|A:6+0+0+0=6/567	NA	RTKRAS	NA	[HC]_1.804/1.608_NA	TNC	Likely_Benign	NA	SOM	NA	Sorafenib_Tosylate|Vemurafenib|Sorafenib|Regorafenib|Regorafenib_Hydrate|Dabrafenib|Dabrafenib_Mesylate|Encorafenib	NA	class	NA	all_exons,introns[7-10];IS:exons[11-18]	.	.	include	.	.	.
CL-AcroMetrix	EGFR	ENST00000275493	NM_005228|NM_001346900	7:55211165	C>T	c.408C>T	exon3	P136P	Pro136=	c.408C>T:exon3:P136P:Pro136=	synonymous_variant	1225	0.202	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	T:54+1+0+0=55/463|N:4+0+0+0=4/104|A:58+1+0+0=59/567	NA	RTKRAS	NA	[HC]_1.916/1.832_NA	TNC	Likely_Benign	NA	SOM	Receptor_L_domain	Afatinib|Lapatinib_Ditosylate|Cetuximab|Panitumumab|Necitumumab|Neratinib|Icotinib|Afatinib_Dimaleate|Zalutumumab|Nimotuzumab|Dacomitinib|Vandetanib|Osimertinib|Pyrotinib|Tesevatinib|Rociletinib|Brigatinib|Naquotinib|EGFR/FLT3/Abl_Inhibitor_SKLB1028|Depatuxizumab_Mafodotin|Neratinib_Maleate|Amivantamab|Abivertinib|Abivertinib_Maleate|Avitinib_Maleate|Lazertinib|Aumolertinib|Mobocertinib|Erlotinib|Lapatinib|Gefitinib	NA	class	NA	introns[15];IS:introns[7,24-27],all_exons	.	.	include	variant_in_more_than_10%_of_tumor_samples_(11.66%)_with_VAF_under_0.01	.	.
CL-AcroMetrix	ERBB4	ENST00000342788	NM_005235	2:212576810	A>G	c.1089T>C	exon9	N363N	Asn363=	c.1089T>C:exon9:N363N:Asn363=	synonymous_variant	752	0.09	NA	NA	NA	NA	COSV53506864	NA	NA	NA	NA	NA	NA	NA	NA	NA	T:9+0+0+0=9/462|N:4+0+0+0=4/104|A:13+0+0+0=13/566	NA	RTKRAS	NA	[non-HC]_1.798/1.596_NA	TNC	Likely_Benign	NA	SOM	Receptor_L_domain	Afatinib|Neratinib|Afatinib_Dimaleate|Dacomitinib|Vandetanib|Neratinib_Maleate	NA	class	NA	all_exons	.	.	include	.	.	.
CL-AcroMetrix	ERBB4	ENST00000342788	NM_005235	2:212578348	A>G	c.909T>C	exon8	S303S	Ser303=	c.909T>C:exon8:S303S:Ser303=	synonymous_variant	426	0.078	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	T:7+0+0+0=7/463|N:1+0+0+0=1/104|A:8+0+0+0=8/567	NA	RTKRAS	NA	[non-HC]_1.798/1.596_NA	TNC	Likely_Benign	NA	SOM	Furin-like_cysteine_rich_region	Afatinib|Neratinib|Afatinib_Dimaleate|Dacomitinib|Vandetanib|Neratinib_Maleate	NA	class	NA	all_exons	.	.	include	.	.	.
CL-AcroMetrix	FBXW7	ENST00000281708	NM_001349798	4:153244078	T>C	c.2079A>G	exon12	E693E	Glu693=	c.2079A>G:exon12:E693E:Glu693=	synonymous_variant	936	0.056	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	T:18+0+0+0=18/463|N:4+0+0+0=4/104|A:22+0+0+0=22/567	NA	NOTCH	NA	[non-HC]_1.88/1.76_NA	TNC	Likely_Benign	NA	SOM	NA	NA	NA	class	NA	all_exons	.	.	include	.	.	.
CL-AcroMetrix	FGFR1	ENST00000425967	NA	8:38282147	G>A	c.909C>T	exon8	N303N	Asn303=	c.909C>T:exon8:N303N:Asn303=	synonymous_variant	1414	0.154	NA	NA	NA	NA	COSV58327431	rs1370411768	NA	NA	NA	NA	NA	NA	Breast_Invasive_Carcinoma:_0.1%_(1/986)	NA	T:133+0+0+0=133/463|N:5+0+0+0=5/104|A:138+0+0+0=138/567	NA	RTKRAS	NA	[HC]_2.034/2.068_NA	TNC	Likely_Benign	NA	SOM	Immunoglobulin_I-set_domain	Pazopanib_Hydrochloride|Infigratinib|Regorafenib|Regorafenib_Hydrate|Orantinib|Erdafitinib|Futibatinib|Brivanib|Sulfatinib|Pemigatinib|Pazopanib|Nintedanib	downstream_gene_variant:E:FGFR1:ENST00000526742.1|E:FGFR1:ENST00000529552.1|E:FGFR1:ENST00000530568.1|E:FGFR1:ENST00000434187.1	class	NA	introns[1,5];IS:introns[17],all_exons	.	.	include	variant_in_more_than_10%_of_tumor_samples_(28.73%)_with_VAF_under_0.01	.	.
CL-AcroMetrix	FGFR3	ENST00000340107	NM_001163213	4:1803575	C>T	c.753C>T	exon7	H251H	His251=	c.753C>T:exon7:H251H:His251=	synonymous_variant	995	0.073	NA	NA	NA	NA	COSV53412029	rs377554120	NA	4.2e-06	NA	0.0000094	NA	NA	NA	NA	T:59+2+0+0=61/462|N:1+0+0+0=1/103|A:60+2+0+0=62/565	NA	RTKRAS	NA	[HC]_2.122/2.244_NA	TNC	Likely_Benign	NA	SOM	NA	Pazopanib_Hydrochloride|Infigratinib|Masitinib|Orantinib|Erdafitinib|Futibatinib|Brivanib|Pemigatinib|Pazopanib|Nintedanib|Dovitinib	NA	class	NA	all_exons;IS:introns[17],exons[7,9aka10,14,18]	.	.	include	variant_in_more_than_10%_of_tumor_samples_(12.77%)_with_VAF_under_0.01	.	.
CL-AcroMetrix	FGFR3	ENST00000340107	NM_001163213	4:1808962	A>C	c.2400A>C	exon18	P800P	Pro800=	c.2400A>C:exon18:P800P:Pro800=	synonymous_variant	1056	0.059	NA	NA	NA	NA	NA	rs904961491	NA	8.7e-06	NA	0.0000197	NA	NA	NA	NA	T:2+0+0+0=2/463|N:2+0+0+0=2/103|A:4+0+0+0=4/566	NA	RTKRAS	NA	[HC]_2.122/2.244_NA	TNC	Likely_Benign	NA	SOM	NA	Pazopanib_Hydrochloride|Infigratinib|Masitinib|Orantinib|Erdafitinib|Futibatinib|Brivanib|Pemigatinib|Pazopanib|Nintedanib|Dovitinib	missense_variant:E:FGFR3:ENSP00000420533.2:p.(Thr776Pro);downstream_gene_variant:E:FGFR3:ENST00000507588.1|R:LETM1:XM_005247970.1|R:LETM1:XM_005247969.1|E:LETM1:Canonical:ENST00000302787.2|R:LETM1:Canonical:NM_012318.2	class	NA	all_exons;IS:introns[17],exons[7,9aka10,14,18]	.	.	include	.	.	.
CL-AcroMetrix	GNAS	ENST00000371100	NM_080425	20:57480494	C>T	c.2418C>T	exon6	Y806Y	Tyr806=	c.2418C>T:exon6:Y806Y:Tyr806=	synonymous_variant	1088	0.085	NA	NA	NA	NA	COSV55677028|COSV55682451	rs372290095	NA	1.59e-05	NA	0.0000176	NA	NA	NA	NA	T:121+3+0+0=124/463|N:8+0+0+0=8/104|A:129+3+0+0=132/567	NA	NA	NA	[non-HC]_2.02/2.04_NA	TNC	Likely_Benign	NA	SOM	G-protein_alpha_subunit	NA	3_prime_UTR_variant:E:GNAS:ENST00000313949.7|R:GNAS:NM_016592.3|R:GNAS:NM_016592.2|E:GNAS:ENST00000371075.3|E:GNAS:ENST00000419558.1|R:GNAS:NM_001077490.1|R:GNAS:NM_001077490.2;downstream_gene_variant:E:GNAS:ENST00000453292.1|R:GNAS:NM_001309883.1|R:GNAS:NM_001309842.1	class	NA	all_exons;IS:exons[1,8]	.	.	include	variant_in_more_than_10%_of_tumor_samples_(26.13%)_with_VAF_under_0.01	.	.
CL-AcroMetrix	IDH2	ENST00000330062	NM_002168	15:90631879	T>C	c.474A>G	exon4	P158P	Pro158=	c.474A>G:exon4:P158P:Pro158=	synonymous_variant	1104	0.061	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	T:8+0+0+0=8/462|N:1+0+0+0=1/104|A:9+0+0+0=9/566	NA	NA	NA	[non-HC]_2.102/2.204_NA	TNC	NA	NA	SOM	Isocitrate/isopropylmalate_dehydrogenase	Enasidenib|Enasidenib_Mesylate|Vorasidenib	NA	class	NA	all_exons;IS:exons[4]	.	.	include	.	.	.
CL-AcroMetrix	KDR	ENST00000263923	NM_002253	4:55962505	T>C	c.2619A>G	exon19	G873G	Gly873=	c.2619A>G:exon19:G873G:Gly873=	synonymous_variant	865	0.069	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	T:7+0+0+0=7/463|N:4+0+0+0=4/104|A:11+0+0+0=11/567	NA	NA	NA	[non-HC]_2.116/2.232_NA	TNC	Likely_Benign	NA	SOM	Protein_tyrosine_and_serine/threonine_kinase	Vatalanib|Sorafenib_Tosylate|Pazopanib_Hydrochloride|Tivozanib|Lenvatinib|Axitinib|Sorafenib|Ramucirumab|Regorafenib|Regorafenib_Hydrate|Cabozantinib_S-malate|Lenvatinib_Mesylate|Cabozantinib|Linifanib|Vandetanib|Orantinib|Semaxanib|Rivoceranib|Anlotinib|Famitinib|Rivoceranib_Mesylate|Brivanib|Sitravatinib|Sulfatinib|Fruquintinib|Pazopanib|Cediranib|Nintedanib|Dovitinib|Sunitinib_Malate|Motesanib|Midostaurin	NA	class	NA	all_exons	.	.	include	.	.	.
CL-AcroMetrix	KIT	ENST00000288135	NM_000222	4:55592092	A>G	c.1416A>G	exon9	L472L	Leu472=	c.1416A>G:exon9:L472L:Leu472=	synonymous_variant	1069	0.062	NA	NA	NA	NA	COSV55410914	rs934899537	415789	NA	NA	NA	NA	NA	NA	NA	T:9+0+0+0=9/463|N:4+0+0+0=4/104|A:13+0+0+0=13/567	NA	RTKRAS	NA	[HC]_2.044/2.088_NA	TNC	Likely_Benign	Likely_Benign	SOM	Immunoglobulin_domain	Vatalanib|Sorafenib_Tosylate|Pazopanib_Hydrochloride|Sorafenib|Dasatinib|Masitinib|Regorafenib|Regorafenib_Hydrate|Semaxanib|Anlotinib|Famitinib|Pexidartinib|Sitravatinib|Pexidartinib_Hydrochloride|Avapritinib|Ripretinib|Pazopanib|Cediranib|Dovitinib|Sunitinib_Malate|Motesanib|Quizartinib|Midostaurin|Imatinib	NA	class	NA	all_exons;IS:introns[16],exons[8-9,11-13,17]	.	.	include	.	.	.
CL-AcroMetrix	KIT	ENST00000288135	NM_000222	4:55593632	C>T	c.1698C>T	exon11	N566N	Asn566=	c.1698C>T:exon11:N566N:Asn566=	synonymous_variant	933	0.064	NA	NA	NA	NA	COSV55398033	NA	NA	NA	NA	NA	NA	NA	NA	NA	T:39+0+0+0=39/463|N:2+0+0+0=2/104|A:41+0+0+0=41/567	NA	RTKRAS	NA	[HC]_2.044/2.088_NA	TNC	Likely_Benign	NA	SOM	NA	Vatalanib|Sorafenib_Tosylate|Pazopanib_Hydrochloride|Sorafenib|Dasatinib|Masitinib|Regorafenib|Regorafenib_Hydrate|Semaxanib|Anlotinib|Famitinib|Pexidartinib|Sitravatinib|Pexidartinib_Hydrochloride|Avapritinib|Ripretinib|Pazopanib|Cediranib|Dovitinib|Sunitinib_Malate|Motesanib|Quizartinib|Midostaurin|Imatinib	NA	class	NA	all_exons;IS:introns[16],exons[8-9,11-13,17]	.	.	include	.	.	.
CL-AcroMetrix	KIT	ENST00000288135	NM_000222	4:55593689	C>T	c.1755C>T	exon11	P585P	Pro585=	c.1755C>T:exon11:P585P:Pro585=	synonymous_variant	934	0.06	NA	NA	NA	NA	COSV55398046	rs121913515	NA	NA	NA	NA	NA	NA	NA	NA	T:29+0+0+0=29/463|N:4+0+0+0=4/104|A:33+0+0+0=33/567	NA	RTKRAS	NA	[HC]_2.044/2.088_NA	TNC	Likely_Benign	NA	SOM	NA	Vatalanib|Sorafenib_Tosylate|Pazopanib_Hydrochloride|Sorafenib|Dasatinib|Masitinib|Regorafenib|Regorafenib_Hydrate|Semaxanib|Anlotinib|Famitinib|Pexidartinib|Sitravatinib|Pexidartinib_Hydrochloride|Avapritinib|Ripretinib|Pazopanib|Cediranib|Dovitinib|Sunitinib_Malate|Motesanib|Quizartinib|Midostaurin|Imatinib	NA	class	NA	all_exons;IS:introns[16],exons[8-9,11-13,17]	.	.	include	.	.	.
CL-AcroMetrix	KIT	ENST00000288135	NM_000222	4:55597500	T>C	c.2148T>C	exon15	D716D	Asp716=	c.2148T>C:exon15:D716D:Asp716=	synonymous_variant	900	0.068	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	T:3+0+0+0=3/463|N:1+0+0+0=1/104|A:4+0+0+0=4/567	NA	RTKRAS	NA	[HC]_2.044/2.088_NA	TNC	Likely_Benign	NA	SOM	Protein_tyrosine_and_serine/threonine_kinase	Vatalanib|Sorafenib_Tosylate|Pazopanib_Hydrochloride|Sorafenib|Dasatinib|Masitinib|Regorafenib|Regorafenib_Hydrate|Semaxanib|Anlotinib|Famitinib|Pexidartinib|Sitravatinib|Pexidartinib_Hydrochloride|Avapritinib|Ripretinib|Pazopanib|Cediranib|Dovitinib|Sunitinib_Malate|Motesanib|Quizartinib|Midostaurin|Imatinib	NA	class	NA	all_exons;IS:introns[16],exons[8-9,11-13,17]	.	.	include	.	.	.
CL-AcroMetrix	MET	ENST00000318493	NM_001127500	7:116417465	T>C	c.3336T>C	exon16	H1112H	His1112=	c.3336T>C:exon16:H1112H:His1112=	synonymous_variant	1049	0.196	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	T:10+0+0+0=10/463|N:5+0+0+0=5/104|A:15+0+0+0=15/567	NA	RTKRAS	NA	[HC]_2.166/2.332_NA	TNC	Likely_Benign	NA	SOM	Protein_tyrosine_and_serine/threonine_kinase	Onartuzumab|Cabozantinib_S-malate|Tivantinib|Cabozantinib|Capmatinib|Savolitinib|Tepotinib|Sitravatinib|Capmatinib_Hydrochloride|Tepotinib_Hydrochloride|Crizotinib	downstream_gene_variant:E:MET:ENST00000454623.1;5_prime_UTR_variant:E:MET:ENST00000539704.1	class	NA	IS:all_exons	.	.	include	.	.	.
CL-AcroMetrix	MET	ENST00000318493	NM_001127500	7:116419008	T>C	c.3573T>C	exon17	T1191T	Thr1191=	c.3573T>C:exon17:T1191T:Thr1191=	synonymous_variant	1108	0.136	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	T:16+0+0+0=16/463|N:3+0+0+0=3/104|A:19+0+0+0=19/567	NA	RTKRAS	NA	[HC]_2.166/2.332_NA	TNC	Likely_Benign	NA	SOM	Protein_tyrosine_and_serine/threonine_kinase	Onartuzumab|Cabozantinib_S-malate|Tivantinib|Cabozantinib|Capmatinib|Savolitinib|Tepotinib|Sitravatinib|Capmatinib_Hydrochloride|Tepotinib_Hydrochloride|Crizotinib	downstream_gene_variant:E:MET:ENST00000454623.1	class	NA	IS:all_exons	.	.	include	.	.	.
CL-AcroMetrix	NOTCH1	ENST00000277541	NA	9:139397776	G>A	c.5025C>T	exon27	I1675I	Ile1675=	c.5025C>T:exon27:I1675I:Ile1675=	synonymous_variant	1231	0.147	NA	NA	NA	NA	COSV53029375	rs1352875267	NA	1.21e-05	NA	0.0000089	NA	NA	NA	NA	T:102+5+0+0=107/463|N:4+0+0+0=4/104|A:106+5+0+0=111/567	NA	NOTCH	NA	[non-HC]_2.294/2.588_NA	TNC	Likely_Benign	NA	SOM	NOTCH_protein	NA	NA	class	NA	all_exons	.	.	include	variant_in_more_than_10%_of_tumor_samples_(22.03%)_with_VAF_under_0.01	.	.
CL-AcroMetrix	NRAS	ENST00000369535	NM_002524	1:115256537	T>C	c.174A>G	exon3	T58T	Thr58=	c.174A>G:exon3:T58T:Thr58=	synonymous_variant	852	0.103	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	T:7+0+0+0=7/463|N:5+0+0+0=5/104|A:12+0+0+0=12/567	NA	RTKRAS	NA	[HC]_1.918/1.836_NA	TNC	Likely_Benign	NA	SOM	Ras_family	NA	downstream_gene_variant:E:CSDE1:ENST00000339438.6|R:CSDE1:NM_001242893.1|R:CSDE1:NM_001242892.1|R:CSDE1:Canonical:NM_001242891.1|R:CSDE1:NM_001130523.2|R:CSDE1:NM_007158.5|R:CSDE1:NM_001007553.2|E:CSDE1:Canonical:ENST00000438362.2|R:CSDE1:XM_005271178.1|E:CSDE1:ENST00000358528.4|E:CSDE1:ENST00000261443.5|E:CSDE1:ENST00000530886.1|E:CSDE1:ENST00000369530.1|E:CSDE1:ENST00000534699.1	class	NA	all_exons;IS:exons[2-3]	.	.	include	.	.	.
CL-AcroMetrix	PDGFRA	ENST00000257290	NM_001347828|NM_006206|NM_001347829|NM_001347830	4:55141097	T>C	c.1743T>C	exon12	P581P	Pro581=	c.1743T>C:exon12:P581P:Pro581=	synonymous_variant	1142	0.069	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	T:15+0+0+0=15/463|N:4+0+0+0=4/104|A:19+0+0+0=19/567	NA	RTKRAS	NA	[HC]_2.056/2.112_NA	TNC	Likely_Benign	NA	SOM	NA	Vatalanib|Pazopanib_Hydrochloride|Olaratumab|Masitinib|Regorafenib|Regorafenib_Hydrate|Crenolanib|Linifanib|Orantinib|Famitinib|Avapritinib|Ripretinib|Pazopanib|Cediranib|Nintedanib|Dovitinib|Sunitinib_Malate|Motesanib|Quizartinib|Midostaurin	NA	class	NA	all_exons;IS:introns[7,9,11],exons[12,18]	.	.	include	.	.	.
CL-AcroMetrix	PDGFRA	ENST00000257290	NM_001347828|NM_006206|NM_001347829|NM_001347830	4:55152085	G>T	c.2517G>T	exon18	L839L	Leu839=	c.2517G>T:exon18:L839L:Leu839=	synonymous_variant	1139	0.045	NA	NA	NA	NA	COSV57269465	rs1213039385	799837	4e-06	NA	0.0000000	NA	NA	Lung_Adenocarcinoma:_0.4%_(2/567)	NA	T:37+1+0+0=38/463|N:4+0+0+0=4/104|A:41+1+0+0=42/567	NA	RTKRAS	NA	[HC]_2.056/2.112_NA	TNC	Likely_Benign	Likely_Benign	SOM	Protein_tyrosine_and_serine/threonine_kinase	Vatalanib|Pazopanib_Hydrochloride|Olaratumab|Masitinib|Regorafenib|Regorafenib_Hydrate|Crenolanib|Linifanib|Orantinib|Famitinib|Avapritinib|Ripretinib|Pazopanib|Cediranib|Nintedanib|Dovitinib|Sunitinib_Malate|Motesanib|Quizartinib|Midostaurin	downstream_gene_variant:R:PDGFRA:NM_001347827.1|R:PDGFRA:XM_005265744.1	class	NA	all_exons;IS:introns[7,9,11],exons[12,18]	.	.	include	.	.	.
CL-AcroMetrix	PIK3CA	ENST00000263967	NM_006218	3:178916793	A>G	c.180A>G	exon2	Q60Q	Gln60=	c.180A>G:exon2:Q60Q:Gln60=	synonymous_variant	731	0.063	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	T:7+0+0+0=7/463|N:5+0+0+0=5/104|A:12+0+0+0=12/567	NA	PI3K	NA	[HC]_1.812/1.624_NA	TNC	Likely_Benign	NA	SOM	PI3-kinase_family|p85-binding_domain	Buparlisib|Taselisib|Alpelisib|Copanlisib|Copanlisib_Hydrochloride	downstream_gene_variant:E:PIK3CA:ENST00000477735.1	class	NA	all_exons;IS:exons[2-3,5-8,10,14,19,21;coding:1-2,4-7,9,13,18,20]	.	.	include	.	.	.
CL-AcroMetrix	PIK3CA	ENST00000263967	NM_006218	3:178916823	C>T	c.210C>T	exon2	F70F	Phe70=	c.210C>T:exon2:F70F:Phe70=	synonymous_variant	634	0.069	NA	NA	NA	NA	COSV55908704|COSV55941259	rs760094170	456535	1.61e-05	NA	0.0000177	NA	NA	Uterine_Corpus_Endometrial_Carcinoma:_0.2%_(1/530)|Breast_Invasive_Carcinoma:_0.1%_(1/986)	NA	T:147+3+0+0=150/463|N:4+0+0+0=4/104|A:151+3+0+0=154/567	NA	PI3K	NA	[HC]_1.812/1.624_NA	TNC	Likely_Benign	Likely_Benign	SOM	PI3-kinase_family|p85-binding_domain	Buparlisib|Taselisib|Alpelisib|Copanlisib|Copanlisib_Hydrochloride	downstream_gene_variant:E:PIK3CA:ENST00000477735.1	class	NA	all_exons;IS:exons[2-3,5-8,10,14,19,21;coding:1-2,4-7,9,13,18,20]	.	.	include	variant_in_more_than_10%_of_tumor_samples_(31.75%)_with_VAF_under_0.01	.	.
CL-AcroMetrix	PIK3CA	ENST00000263967	NM_006218	3:178921520	C>T	c.1002C>T	exon5	L334L	Leu334=	c.1002C>T:exon5:L334L:Leu334=	synonymous_variant	753	0.057	NA	NA	NA	NA	COSV55900595|COSV55922337	NA	NA	NA	NA	NA	NA	NA	Uterine_Corpus_Endometrial_Carcinoma:_0.2%_(1/530)	NA	T:47+0+0+0=47/463|N:3+0+0+0=3/104|A:50+0+0+0=50/567	NA	PI3K	NA	[HC]_1.812/1.624_NA	TNC	Likely_Benign	NA	SOM	NA	Buparlisib|Taselisib|Alpelisib|Copanlisib|Copanlisib_Hydrochloride	downstream_gene_variant:E:PIK3CA:ENST00000477735.1|E:PIK3CA:ENST00000468036.1	class	NA	all_exons;IS:exons[2-3,5-8,10,14,19,21;coding:1-2,4-7,9,13,18,20]	.	.	include	variant_in_more_than_10%_of_tumor_samples_(10.15%)_with_VAF_under_0.01	.	.
CL-AcroMetrix	PREX2	ENST00000288368	NM_024870	8:68993013	AT>GC	c.1818_1819delinsGC	exon17	GL606-607GL	GlyLeu606=	c.1818_1819delinsGC:exon17:GL606-607GL:GlyLeu606=	synonymous_variant	470	0.443	NA	NA	NA	NA	NA	rs368406603	NA	NA	NA	NA	NA	NA	NA	NA	T:4+2+39+327=372/462|N:1+0+1+90=92/104|A:5+2+40+417=464/566	NA	NA	NA	[non-HC]_1.966/1.932_NA	TNC	NA	NA	SOM	NA	NA	NA	class	recurrent_germline|HET_VAF_RANGE	NA	.	.	exclude	recurrent_germline	.	.
CL-AcroMetrix	PTEN	ENST00000371953	NM_000314	10:89653858	T>C	c.156T>C	exon2	D52D	Asp52=	c.156T>C:exon2:D52D:Asp52=	synonymous_variant	624	0.098	NA	NA	NA	NA	NA	rs1589617385	819569	NA	NA	NA	NA	NA	NA	NA	T:7+0+0+0=7/462|N:3+0+0+0=3/104|A:10+0+0+0=10/566	NA	PI3K	NA	[HC]_1.964/1.928_NA	TNC	Likely_Benign	Likely_Benign	SOM	NA	NA	5_prime_UTR_variant:R:PTEN:NM_001304718.1	class	NA	IS:all_exons	.	.	include	.	.	.
CL-AcroMetrix	PTEN	ENST00000371953	NM_000314	10:89720728	A>G	c.879A>G	exon8	G293G	Gly293=	c.879A>G:exon8:G293G:Gly293=	synonymous_variant	605	0.18	NA	NA	NA	NA	COSV64311358	rs1060503843	798333	NA	NA	NA	NA	NA	NA	NA	T:11+0+0+0=11/463|N:1+0+0+0=1/104|A:12+0+0+0=12/567	NA	PI3K	NA	[HC]_1.964/1.928_NA	TNC	Likely_Benign	Likely_Benign	SOM	C2_domain_of_PTEN_tumour-suppressor_protein	NA	NA	class	NA	IS:all_exons	.	.	include	.	.	.
CL-AcroMetrix	SMAD4	ENST00000342988	NM_005359	18:48575112	T>C	c.306T>C	exon3	P102P	Pro102=	c.306T>C:exon3:P102P:Pro102=	synonymous_variant	916	0.072	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	T:31+0+0+0=31/463|N:8+0+0+0=8/104|A:39+0+0+0=39/567	NA	TFGBETA	NA	[non-HC]_2.106/2.212_NA	TNC	Likely_Benign	NA	SOM	MH1_domain	NA	downstream_gene_variant:E:SMAD4:ENST00000589076.1	class	NA	all_exons	.	.	include	.	.	.
CL-AcroMetrix	SMAD4	ENST00000342988	NM_005359	18:48604769	C>A	c.1591C>A	exon12	R531R	Arg531=	c.1591C>A:exon12:R531R:Arg531=	synonymous_variant	1012	0.073	NA	NA	NA	NA	COSV61685734|COSV61686909	NA	NA	NA	NA	NA	NA	NA	NA	NA	T:47+4+0+0=51/462|N:9+1+0+0=10/104|A:56+5+0+0=61/566	NA	TFGBETA	NA	[non-HC]_2.106/2.212_NA	TNC	Likely_Benign	NA	SOM	MH2_domain	NA	downstream_gene_variant:E:SMAD4:ENST00000593223.1	class	NA	all_exons	.	.	include	variant_in_more_than_10%_of_tumor_samples_(10.17%)_with_VAF_under_0.01	.	.
CL-AcroMetrix	TP53	ENST00000269305	NM_000546	17:7576883	T>C	c.963A>G	exon9	K321K	Lys321=	c.963A>G:exon9:K321K:Lys321=	synonymous_variant	1228	0.048	NA	NA	NA	NA	COSV53339920	NA	NA	NA	NA	NA	NA	NA	NA	NA	T:7+0+0+0=7/461|N:4+0+0+0=4/104|A:11+0+0+0=11/565	NA	TP53	4_c_NS	[non-HC]_2.45/2.9_NA	TNC	Likely_Benign	NA	SOM	P53_tetramerisation_motif	NA	downstream_gene_variant:E:TP53:ENST00000514944.1|E:TP53:ENST00000508793.1|E:TP53:ENST00000604348.1|E:TP53:ENST00000503591.1	class	NA	IS:all_exons	.	.	include	.	.	.
CL-AcroMetrix	CD74	ENST00000009530	NM_001025159	5:149781815	TGG>T	NA	NA	NA	NA	NA	x:noncoding_variant	1299	0.018	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	T:1+0+0+0=1/463|N:0+0+0+0=0/104|A:1+0+0+0=1/567	NA	NA	NA	[non-HC]_2.292/2.584_NA	TNC	NA	NA	SOM	NA	NA	downstream_gene_variant:E:TCOF1:Canonical:ENST00000451292.1|E:TCOF1:ENST00000377797.3|R:TCOF1:Canonical:NM_001135243.1|R:TCOF1:NM_001195141.1|R:TCOF1:NM_001135244.1|R:TCOF1:NM_001135245.1|R:TCOF1:NM_000356.3|E:TCOF1:ENST00000445265.2|E:TCOF1:ENST00000323668.7|R:TCOF1:XM_005268506.1|R:TCOF1:XM_005268507.1|R:TCOF1:XM_005268504.1|R:TCOF1:XM_005268505.1|R:TCOF1:XM_005268503.1|R:TCOF1:XM_005268502.1|E:TCOF1:ENST00000439160.2|E:TCOF1:ENST00000427724.2|E:TCOF1:ENST00000504761.2|E:TCOF1:ENST00000513346.1|E:TCOF1:ENST00000515516.1|R:CD74:XM_005268546.1;intron_variant,splice_region_variant:E:CD74:ENST00000377795.3|R:CD74:NM_004355.3|R:CD74:Canonical:NM_001025159.2|R:CD74:NM_001025158.2|E:CD74:ENST00000353334.6|E:CD74:ENST00000009530.7;3_prime_UTR_variant:E:CD74:Canonical:ENST00000518797.1	class	LOW_TUMOR_VAF	introns[6-8]	.	.	exclude	LOW_TUMOR_VAF	.	.
CL-AcroMetrix	DNAJB1	ENST00000254322	NM_006145	19:14628497	C>G	NA	NA	NA	NA	NA	x:noncoding_variant	1055	0.014	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	T:23+45+0+0=68/463|N:3+8+0+0=11/104|A:26+53+0+0=79/567	NA	NA	NA	[non-HC]_2.092/2.184_NA	TNC	NA	NA	SOM	NA	NA	5_prime_UTR_variant:R:DNAJB1:NM_001300914.1|E:DNAJB1:ENST00000598235.1;upstream_gene_variant:E:DNAJB1:ENST00000595139.1	class	LOW_TUMOR_VAF	NA	.	.	exclude	LOW_TUMOR_VAF	.	.
CL-AcroMetrix	EGFR	ENST00000275493	NM_005228|NM_001346900	7:55243526	G>A	NA	NA	NA	NA	NA	x:noncoding_variant	699	0.04	NA	NA	NA	NA	NA	rs1562786249	NA	NA	NA	NA	NA	NA	NA	NA	T:47+1+0+0=48/463|N:3+0+0+0=3/104|A:50+1+0+0=51/567	NA	RTKRAS	NA	[HC]_1.916/1.832_NA	TNC	Likely_Benign	NA	SOM	NA	Afatinib|Lapatinib_Ditosylate|Cetuximab|Panitumumab|Necitumumab|Neratinib|Icotinib|Afatinib_Dimaleate|Zalutumumab|Nimotuzumab|Dacomitinib|Vandetanib|Osimertinib|Pyrotinib|Tesevatinib|Rociletinib|Brigatinib|Naquotinib|EGFR/FLT3/Abl_Inhibitor_SKLB1028|Depatuxizumab_Mafodotin|Neratinib_Maleate|Amivantamab|Abivertinib|Abivertinib_Maleate|Avitinib_Maleate|Lazertinib|Aumolertinib|Mobocertinib|Erlotinib|Lapatinib|Gefitinib	downstream_gene_variant:R:EGFR:XM_005271748.1|R:EGFR:NM_201284.1|E:EGFR:ENST00000344576.2	class	NA	introns[15];IS:introns[7,24-27],all_exons	.	.	include	variant_in_more_than_10%_of_tumor_samples_(10.15%)_with_VAF_under_0.01	.	.
CL-AcroMetrix	ERBB3	ENST00000267101	NM_001982	12:56480943	T>C	NA	NA	NA	NA	NA	x:noncoding_variant	239	0.059	NA	NA	NA	NA	COSV57257026	rs200428261	NA	NA	NA	NA	NA	NA	NA	NA	T:12+0+4+0=16/461|N:1+0+0+0=1/104|A:13+0+4+0=17/565	NA	RTKRAS	NA	[HC]_2.082/2.164_NA	TNC	NA	NA	SOM	NA	Patritumab|Vandetanib	downstream_gene_variant:E:ERBB3:ENST00000549282.1|E:ERBB3:ENST00000549061.1|R:ERBB3:NM_001005915.1|E:ERBB3:ENST00000411731.2|E:ERBB3:ENST00000549672.1	class	NA	all_exons;IS:exons[3,6-8,10,12,20-21,23-25]	.	.	include	.	.	.
CL-AcroMetrix	KRAS	ENST00000256078	NM_001369786|NM_033360	12:25362805	C>T	NA	NA	NA	NA	NA	x:noncoding_variant	633	0.084	NA	NA	NA	NA	COSV55790345	rs372793780	45128	1.6e-05	NA	0.0000088	NA	NA	Colon_Adenocarcinoma:_0.3%_(1/399)	MELA-AU/Metastatic/1/60/0.0167	T:118+4+0+0=122/463|N:2+0+0+0=2/104|A:120+4+0+0=124/567	NA	RTKRAS	NA	[HC]_1.89/1.78_NA	TNC	Likely_Benign	VUS	SOM	NA	Adagrasib	downstream_gene_variant:E:ETFRF1:Canonical:ENST00000381356.4|R:ETFRF1:Canonical:NM_001001660.2|E:ETFRF1:ENST00000557540.2|R:ETFRF1:XM_005253319.1|E:ETFRF1:ENST00000556885.1|E:ETFRF1:ENST00000553788.1|R:ETFRF1:XM_005253320.1;missense_variant:E:KRAS:ENSP00000308495.3:p.(Arg164Gln)|R:KRAS:NP_004976.2:p.(Arg164Gln)|R:KRAS:NP_004976.2:p.(Arg164Gln)|E:KRAS:ENSP00000452512.1:p.(Arg51Gln);3_prime_UTR_variant:R:KRAS:Canonical:NM_033360.3|R:KRAS:NM_033360.2|E:KRAS:Canonical:ENST00000256078.4	class	NA	IS:all_exons	.	.	include	variant_in_more_than_10%_of_tumor_samples_(25.49%)_with_VAF_under_0.01	.	.
CL-AcroMetrix	ETV1	ENST00000430479	NM_001370556|NM_004956	7:13979225	GA>AC	NA	NA	NA	NA	NA	x:noncoding_variant	471	0.996	NA	NA	NA	NA	NA	rs34154308	NA	NA	NA	NA	NA	NA	NA	NA	T:5+4+25+245=279/462|N:0+0+1+61=62/104|A:5+4+26+306=341/566	NA	NA	NA	[non-HC]_1.626/1.252_NA	TNC	NA	NA	GL_P	NA	NA	NA	class	recurrent_germline|HIGH_TUMOR_VAF	NA	.	.	exclude	recurrent_germline	.	.
CL-AcroMetrix	ETV1	ENST00000430479	NM_001370556|NM_004956	7:14017007	CC>TG	NA	NA	NA	NA	NA	x:noncoding_variant	491	0.44	NA	NA	NA	NA	NA	rs71523042	NA	NA	NA	NA	NA	NA	NA	NA	T:3+1+35+329=368/463|N:0+0+1+81=82/104|A:3+1+36+410=450/567	NA	NA	NA	[non-HC]_1.626/1.252_NA	TNC	NA	NA	GL_P	NA	NA	NA	class	recurrent_germline|HET_VAF_RANGE	NA	.	.	exclude	recurrent_germline	.	.
CL-AcroMetrix	ETV1	ENST00000430479	NM_001370556|NM_004956	7:14021333	TT>GC	NA	NA	NA	NA	NA	x:noncoding_variant	469	0.503	NA	NA	NA	NA	NA	rs71523043	NA	NA	NA	NA	NA	NA	NA	NA	T:1+1+23+342=367/462|N:0+0+0+82=82/104|A:1+1+23+424=449/566	NA	NA	NA	[non-HC]_1.626/1.252_NA	TNC	NA	NA	GL_P	NA	NA	NA	class	recurrent_germline|HET_VAF_RANGE	NA	.	.	exclude	recurrent_germline	.	.
CL-AcroMetrix	ETV4	ENST00000319349	NM_001079675	17:41617157	CAG>C	NA	NA	NA	NA	NA	x:noncoding_variant	1126	0.463	NA	NA	NA	NA	NA	rs750245188	NA	NA	NA	NA	NA	NA	NA	NA	T:0+0+1+0=1/463|N:0+0+0+0=0/104|A:0+0+1+0=1/567	NA	NA	NA	[non-HC]_2.024/2.048_NA	TNC	NA	NA	GL_P	NA	NA	NA	class	HET_VAF_RANGE	introns[8]	.	.	include	.	.	.
CL-AcroMetrix	ETV6	ENST00000396373	NM_001987	12:12017241	C>T	NA	NA	NA	NA	NA	x:noncoding_variant	956	0.503	NA	NA	NA	NA	NA	rs754928365	NA	NA	NA	NA	NA	NA	NA	NA	T:46+0+0+0=46/463|N:6+0+0+0=6/104|A:52+0+0+0=52/567	NA	NA	NA	[non-HC]_2.098/2.196_NA	TNC	Likely_Benign	NA	GL_P	NA	NA	NA	class	HET_VAF_RANGE	IS:introns[5-6],all_exons	.	.	include	.	.	.
CL-AcroMetrix	KIF5B	ENST00000302418	NM_004521	10:32300370	A>AG	NA	NA	NA	NA	NA	x:noncoding_variant	724	0.471	NA	NA	NA	NA	NA	rs1054637940	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	[non-HC]_2.116/2.232_NA	TNC	NA	NA	GL_P	NA	Selpercatinib	3_prime_UTR_variant:E:KIF5B:Canonical:ENST00000302418.4|R:KIF5B:Canonical:NM_004521.2	class	HET_VAF_RANGE	NA	.	.	include	no_recurrence_data	.	.
CL-AcroMetrix	NRG1	ENST00000519301	NM_001322201|NM_001160001|NM_001322202	8:32184648	C>T	NA	NA	NA	NA	NA	x:noncoding_variant	578	0.471	NA	NA	NA	NA	NA	rs779340623	NA	NA	NA	NA	NA	NA	NA	NA	T:63+1+0+0=64/463|N:3+0+0+0=3/104|A:66+1+0+0=67/567	NA	NA	NA	[HC]_1.706/1.412_NA	TNC	NA	NA	GL_P	NA	NA	NA	class	HET_VAF_RANGE	NA	.	.	include	variant_in_more_than_10%_of_tumor_samples_(13.61%)_with_VAF_under_0.01	.	.
CL-AcroMetrix	NTRK2	ENST00000376214	NA	9:87489303	C>T	NA	NA	NA	NA	NA	x:noncoding_variant	903	0.477	NA	NA	NA	NA	NA	rs567285047	NA	NA	2e-04	NA	EUR_AF_1KG:0.0010000	NA	NA	NA	T:33+1+0+0=34/463|N:2+0+0+0=2/104|A:35+1+0+0=36/567	NA	RTKRAS	NA	[non-HC]_1.968/1.936_NA	TNC	NA	NA	GL_P	NA	Entrectinib|Larotrectinib|Larotrectinib_Sulfate	3_prime_UTR_variant:R:NTRK2:XM_005252006.1|R:NTRK2:NM_001018065.2|R:NTRK2:NM_001018066.2|E:NTRK2:ENST00000376208.1|E:NTRK2:ENST00000304053.6	class	HET_VAF_RANGE|germline_population	introns[12],all_exons	.	.	exclude	germline_population	.	.
CL-AcroMetrix	PPARG	ENST00000287820	NM_015869	3:12409711	CTC>TGT	NA	NA	NA	NA	NA	x:noncoding_variant	26	1	NA	NA	NA	NA	NA	rs796734365	NA	NA	NA	NA	NA	NA	NA	NA	T:0+0+0+91=91/91|N:0+0+0+14=14/14|A:0+0+0+105=105/105	NA	NA	NA	[non-HC]_2.084/2.168_NA	TNC	NA	NA	GL_P	NA	NA	NA	class	recurrent_artifact|HIGH_TUMOR_VAF	all_exons	.	.	exclude	recurrent_artifact,too_few_(14<20)_callable_normals	.	.
CL-AcroMetrix	TFE3	ENST00000315869	NM_001282142|NM_006521	X:48894774	A>T	NA	NA	NA	NA	NA	x:noncoding_variant	111	1	NA	NA	NA	NA	NA	rs1215614737	NA	NA	NA	NA	NA	NA	NA	NA	T:3+1+0+0=4/457|N:1+0+0+0=1/104|A:4+1+0+0=5/561	NA	NA	NA	[non-HC]_0.934/0.868_NA	TNC	Likely_Benign	NA	GL_P	NA	NA	NA	class	HIGH_TUMOR_VAF	NA	.	.	include	.	.	.
CL-AcroMetrix	TP53	ENST00000269305	NM_000546	17:7574944	G>A	NA	NA	NA	NA	NA	x:noncoding_variant	558	0.47	NA	NA	NA	NA	NA	rs189071925	NA	NA	2e-04	NA	EAS_AF_1KG:0.0010000	NA	NA	NA	T:56+2+0+0=58/459|N:3+1+0+0=4/104|A:59+3+0+0=62/563	NA	TP53	4_c_NS	[non-HC]_2.45/2.9_NA	TNC	Likely_Benign	NA	GL_P	NA	NA	downstream_gene_variant:E:TP53:ENST00000509690.1|E:TP53:ENST00000514944.1|E:TP53:ENST00000508793.1|E:TP53:ENST00000604348.1|E:TP53:ENST00000503591.1	class	HET_VAF_RANGE|germline_population	IS:all_exons	.	.	exclude	germline_population,variant_in_more_than_10%_of_tumor_samples_(12.2%)_with_VAF_under_0.01	.	.
CL-AcroMetrix	NA	NA	NA	14:38054085	T>G	NA	NA	NA	NA	NA	x:noncoding_variant	640	0.477	NA	NA	NA	NA	NA	rs10149161	NA	NA	NA	NA	AFR_AF_1KG:0.9032000|AMR_AF_1KG:0.7464000|EAS_AF_1KG:0.7927000|EUR_AF_1KG:0.6690000|SAS_AF_1KG:0.6462000	NA	NA	NA	T:2+5+98+311=416/457|N:1+0+16+75=92/101|A:3+5+114+386=508/558	NA	NA	NA	NA	TNC	NA	NA	GL_DB	NA	NA	downstream_gene_variant:R:FOXA1:Canonical:NM_004496.3	intergenic_PCGR_coding_Nirvana	recurrent_germline|HET_VAF_RANGE|germline_population	NA	.	.	exclude	germline_population,recurrent_germline	.	.
CL-AcroMetrix	SPATA32	ENST00000331780	NM_152343	17:43342141	G>C	NA	NA	NA	NA	NA	x:noncoding_variant	1107	0.5	NA	NA	NA	NA	NA	rs1047833	1170667	0.7163	0.7183	0.7200000	GLOBAL_AF_1KG:0.7183000|GLOBAL_AF_GNOMAD:0.7163000|AFR_AF_1KG:0.7791000|AFR_AF_GNOMAD:0.7749000|AMR_AF_1KG:0.7651000|AMR_AF_GNOMAD:0.7508000|ASJ_AF_GNOMAD:0.6824000|EAS_AF_1KG:0.7073000|EAS_AF_GNOMAD:0.7322000|EUR_AF_1KG:0.7087000|FIN_AF_GNOMAD:0.6979000|NFE_AF_GNOMAD:0.7200000|OTH_AF_GNOMAD:0.6948000|SAS_AF_1KG:0.6237000|SAS_AF_GNOMAD:0.6536000	NA	NA	NA	T:3+1+22+399=425/463|N:1+1+0+92=94/104|A:4+2+22+491=519/567	NA	NA	NA	NA	TNC	NA	NA	GL_DB	NA	NA	upstream_gene_variant:E:SPATA32:ENST00000543122.1|E:SPATA32:Canonical:ENST00000331780.4|R:SPATA32:Canonical:NM_152343.2;stop_gained:R:MAP3K14:Canonical:NP_003945.2:p.(Ser902Ter)	protein_changes:stop_gained	recurrent_germline|HET_VAF_RANGE|germline_population	NA	.	.	exclude	germline_population,recurrent_germline	.	.
CL-AcroMetrix	LRRC14	ENST00000292524	NM_014665	8:145738767	CG>C	NA	NA	NA	NA	NA	x:noncoding_variant	1164	0.983	NA	NA	NA	NA	COSV52878080	NA	1327943	NA	NA	NA	NA	NA	NA	NA	T:0+0+0+463=463/463|N:0+0+0+104=104/104|A:0+0+0+567=567/567	NA	NA	NA	NA	TNC	Benign	Benign	BL	NA	NA	downstream_gene_variant:R:MFSD3:XM_005272311.1|R:MFSD3:Canonical:NM_138431.2|E:MFSD3:Canonical:ENST00000301327.4|R:MFSD3:NM_138431.1|E:RECQL4:ENST00000532846.2|E:RECQL4:ENST00000524998.1;frameshift_variant,splice_donor_variant:E:RECQL4:Canonical:ENSP00000475456.1:p.(Arg766GlyfsTer77);upstream_gene_variant:R:LRRC14:XM_005272361.1|R:LRRC14:NM_001272036.1|R:LRRC14:Canonical:NM_014665.3|R:LRRC14:XM_005272358.1|R:LRRC14:XM_005272360.1|R:LRRC14:XM_005272359.1|E:LRRC14:ENST00000527730.1|E:LRRC14:ENST00000529022.1|E:LRRC14:Canonical:ENST00000292524.1|E:LRRC14:ENST00000530854.1	protein_changes:frameshift_variant,splice_donor_variant	recurrent_germline|HIGH_TUMOR_VAF	NA	.	.	exclude	recurrent_germline,BL_class	.	.
CL-AcroMetrix	MAP3K14	ENST00000344686	NM_003954	17:43364293	C>CG	NA	NA	NA	NA	NA	x:noncoding_variant	1250	0.964	NA	NA	NA	NA	NA	rs56405343	NA	1	NA	1.0000000	GLOBAL_AF_GNOMAD:1.0000000|AFR_AF_1KG:1.0000000|AFR_AF_GNOMAD:0.9999000|AMR_AF_1KG:1.0000000|AMR_AF_GNOMAD:1.0000000|ASJ_AF_GNOMAD:1.0000000|EAS_AF_1KG:1.0000000|EAS_AF_GNOMAD:0.9999000|EUR_AF_1KG:1.0000000|FIN_AF_GNOMAD:1.0000000|NFE_AF_GNOMAD:1.0000000|OTH_AF_GNOMAD:1.0000000|SAS_AF_1KG:1.0000000|SAS_AF_GNOMAD:1.0000000	NA	NA	NA	T:0+0+0+463=463/463|N:0+0+0+104=104/104|A:0+0+0+567=567/567	NA	NA	NA	[non-HC]_1.862/1.724_NA	TNC	NA	NA	BL	NA	NA	frameshift_variant,splice_region_variant:R:MAP3K14:NP_003945.2:p.(Ala219GlyfsTer42);frameshift_variant:R:MAP3K14:Canonical:NP_003945.2:p.(Arg219ProfsTer730)	protein_changes:frameshift_variant	recurrent_germline|germline_population	NA	.	.	exclude	germline_population,recurrent_germline,BL_class	.	.
CL-AcroMetrix	SDHA	ENST00000264932	NM_004168	5:251703	TG>T	NA	NA	NA	NA	NA	x:noncoding_variant	901	0.336	NA	NA	NA	NA	COSV53765124|COSV53765611	rs111797600	NA	0.0714	NA	0.0531700	GLOBAL_AF_GNOMAD:0.0714000|AFR_AF_GNOMAD:0.4556000|AMR_AF_GNOMAD:0.0978100|ASJ_AF_GNOMAD:0.0448500|EAS_AF_GNOMAD:0.0361400|FIN_AF_GNOMAD:0.0426900|NFE_AF_GNOMAD:0.0531700|OTH_AF_GNOMAD:0.0822700|SAS_AF_GNOMAD:0.0271500	NA	NA	NA	T:2+4+83+25=114/463|N:0+0+22+5=27/104|A:2+4+105+30=141/567	NA	NA	1_NA_NA	[non-HC]_1.998/1.996_NA	TNC	Benign	NA	BL	NA	NA	frameshift_variant:R:SDHA:XP_005248386.1:p.(Ala639ProfsTer20)	protein_changes:frameshift_variant	recurrent_artifact|germline_population	all_exons	.	.	exclude	germline_population,recurrent_artifact,BL_class	.	.
CL-AcroMetrix	SETBP1	ENST00000282030	NA	18:42456670	C>CTCTT	NA	NA	NA	NA	NA	x:noncoding_variant	1002	0.943	NA	NA	NA	NA	COSV56311994	rs3085861	326725	0.5217	0.4938	0.5498000	GLOBAL_AF_1KG:0.4938000|GLOBAL_AF_GNOMAD:0.5217000|AFR_AF_1KG:0.5098000|AFR_AF_GNOMAD:0.5353000|AMR_AF_1KG:0.4539000|AMR_AF_GNOMAD:0.4765000|ASJ_AF_GNOMAD:0.5903000|EAS_AF_1KG:0.4762000|EAS_AF_GNOMAD:0.4998000|EUR_AF_1KG:0.5616000|FIN_AF_GNOMAD:0.5951000|NFE_AF_GNOMAD:0.5498000|OTH_AF_GNOMAD:0.5141000|SAS_AF_1KG:0.4489000|SAS_AF_GNOMAD:0.4231000	NA	NA	NA	T:3+5+37+347=392/463|N:1+0+0+91=92/104|A:4+5+37+438=484/567	NA	NA	NA	[non-HC]_1.762/1.524_NA	TNC	Benign	Benign	BL	NA	NA	frameshift_variant:E:SETBP1:ENSP00000390687.3:p.(Thr228SerfsTer8)|R:SETBP1:NP_001123582.1:p.(Thr228SerfsTer8)	protein_changes:frameshift_variant	recurrent_germline|germline_population	NA	.	.	exclude	germline_population,recurrent_germline,BL_class	.	.
